Clustering O 0 1.3217289051681291e-05
of O 0 1.1496032215063678e-07
missense O 0 0.00010718324483605102
mutations O 0 9.510643576504663e-05
in O 0 3.7601935787279217e-07
the O 0 9.017095726449043e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
gene O 0 0.00024430573103018105
in O 0 3.2580508957380516e-08
a O 0 1.589437346183331e-07
sporadic B-Disease 0 4.313316458137706e-05
T I-Disease 1 0.9735832214355469
- I-Disease 1 0.5776806473731995
cell I-Disease 1 0.9598662257194519
leukaemia I-Disease 1 0.8767430186271667
. O 0 1.2136665645812172e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
( O 0 0.03385645151138306
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
) O 0 9.974436920856533e-08
is O 0 2.8578865940431797e-09
a O 0 1.198149490733158e-08
recessive B-Disease 0 0.00011750109115382656
multi I-Disease 0 0.0007386087090708315
- I-Disease 1 0.9753755331039429
system I-Disease 0 0.009926981292665005
disorder I-Disease 0 0.21322859823703766
caused O 0 1.461773280198031e-07
by O 0 1.3569944057323369e-09
mutations O 0 6.314528633311056e-08
in O 0 4.864923464076298e-10
the O 0 1.7530995544134953e-09
ATM O 0 1.9011760741705075e-05
gene O 0 3.5612478654911683e-07
at O 0 5.593264518211072e-08
11q22 O 0 6.985447384977306e-07
- O 0 1.1786306458816398e-05
q23 O 0 2.6092866391991265e-06
( O 0 1.3774841711722274e-08
ref O 0 1.6682594150552177e-06
. O 0 5.024221039207077e-09
3 O 0 1.7987828115906268e-08
) O 0 1.8034169713132542e-08
. O 0 1.4605470255446562e-07

The O 0 8.215034767999896e-07
risk O 0 2.6406385131849675e-06
of O 0 1.3532085674228256e-08
cancer B-Disease 0 1.2117062397010159e-05
, O 0 1.891046608193392e-08
especially O 0 2.1348570911072784e-08
lymphoid B-Disease 0 5.65370010008337e-06
neoplasias I-Disease 0 3.494279008009471e-05
, O 0 2.008989063995159e-08
is O 0 4.207055592786446e-09
substantially O 0 3.0335496603584033e-07
elevated O 0 3.947591267206008e-06
in O 0 4.3492229906405555e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.03086118958890438
and O 0 9.448759641372817e-08
has O 0 4.2869345406870707e-07
long O 0 1.8452357153364574e-07
been O 0 1.3796829989587422e-07
associated O 0 1.458314500268898e-07
with O 0 8.913237365959503e-07
chromosomal O 1 1.0
instability O 1 0.999987006187439
. O 0 5.274063369142823e-06

By O 0 1.329439101027674e-06
analysing O 0 0.0002611634263303131
tumour B-Disease 1 0.9999995231628418
DNA O 0 8.69392606546171e-05
from O 0 6.953710141033298e-08
patients O 0 8.764364878288688e-08
with O 0 2.5682607152077708e-09
sporadic B-Disease 0 2.783847776299808e-06
T I-Disease 1 0.543156087398529
- I-Disease 0 0.01461371872574091
cell I-Disease 0 0.4626196026802063
prolymphocytic I-Disease 0 0.11218320578336716
leukaemia I-Disease 1 0.9540038108825684
( O 0 2.3718864383681648e-07
T B-Disease 0 0.01302733551710844
- I-Disease 0 9.417031105840579e-05
PLL I-Disease 0 3.2618296245345846e-05
) O 0 7.83454900954439e-09
, O 0 6.799504848054028e-10
a O 0 3.9339171920005356e-09
rare O 0 2.5079311072317978e-08
clonal B-Disease 0 1.1783166655732202e-06
malignancy I-Disease 0 6.635031695623184e-06
with O 0 3.2156850515718816e-09
similarities O 0 3.556590399966808e-08
to O 0 3.730345365937637e-09
a O 0 5.588007212509183e-08
mature B-Disease 0 5.9211042753304355e-06
T I-Disease 0 0.003541803453117609
- I-Disease 0 6.68817592668347e-05
cell I-Disease 0 0.013615346513688564
leukaemia I-Disease 0 0.015582586638629436
seen O 0 2.1143578123883344e-06
in O 0 1.3163972312213446e-07
A B-Disease 1 0.9999995231628418
- I-Disease 1 0.9999980926513672
T I-Disease 1 1.0
, O 0 1.5411069398396648e-07
we O 0 7.36465244344231e-09
demonstrate O 0 1.138459548855053e-09
a O 0 9.621264895898207e-10
high O 0 2.329826775948618e-09
frequency O 0 3.0375908011137653e-08
of O 0 1.6367571742392784e-09
ATM O 0 0.00018576023285277188
mutations O 0 6.675524673482869e-06
in O 0 5.533565072823876e-08
T B-Disease 0 0.029474318027496338
- I-Disease 0 0.00027895442326553166
PLL I-Disease 0 0.00033494908711872995
. O 0 8.426161457464332e-07

In O 0 5.289771820571332e-07
marked O 0 2.286273854679166e-07
contrast O 0 4.1339092149428325e-08
to O 0 4.76336481369799e-09
the O 0 1.865662735411888e-09
ATM O 0 3.367987665114924e-05
mutation O 0 4.610205053268146e-07
pattern O 0 1.3329836292541586e-06
in O 0 1.6103292921343382e-07
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
, O 0 6.058173340761641e-08
the O 0 7.678822022683107e-10
most O 0 8.00844335291373e-10
frequent O 0 8.607934809390372e-09
nucleotide O 0 1.2089597589692858e-07
changes O 0 6.698229526591604e-09
in O 0 3.5124456676527416e-09
this O 0 2.77634963907758e-08
leukaemia B-Disease 0 0.0012912576785311103
were O 0 1.5796165087067493e-07
missense O 0 4.209937105770223e-05
mutations O 0 1.9098641132586636e-05
. O 0 3.326540252146515e-07

These O 0 1.7244443029085232e-07
clustered O 0 1.3158692127035465e-06
in O 0 1.7849172806450042e-08
the O 0 6.317899536867344e-09
region O 0 1.2794295400908595e-07
corresponding O 0 3.4052899167136275e-08
to O 0 9.445945359232155e-09
the O 0 4.028421596302678e-09
kinase O 0 1.1825924275399302e-06
domain O 0 1.2764363077621965e-07
, O 0 6.417808506853362e-09
which O 0 2.025285272821975e-09
is O 0 6.708378297304307e-10
highly O 0 7.788922840035184e-10
conserved O 0 5.196446828392709e-09
in O 0 5.506325173598725e-09
ATM O 0 3.8333299016812816e-05
- O 0 9.517081593912735e-07
related O 0 2.2105203001387963e-08
proteins O 0 8.300446552311769e-09
in O 0 3.6045439966159165e-09
mouse O 0 1.6077742657216731e-06
, O 0 2.9190781347665506e-08
yeast O 0 1.714477434688888e-06
and O 0 5.9542031749515445e-08
Drosophila O 0 4.779083724315569e-07
. O 0 1.5361737837338296e-07

The O 0 1.32654221829398e-07
resulting O 0 1.263911286741859e-07
amino O 0 2.0136428702244302e-07
- O 0 4.293339316063793e-06
acid O 0 6.526602760459355e-07
substitutions O 0 5.310110395839729e-08
are O 0 1.6451703332975853e-09
predicted O 0 2.5577375595275953e-07
to O 0 6.212942160743751e-09
interfere O 0 8.934856765563381e-08
with O 0 4.531219843784129e-09
ATP O 0 4.0741673728916794e-05
binding O 0 1.0536667787164333e-06
or O 0 1.5910158879250957e-07
substrate O 0 2.954785713882302e-06
recognition O 0 4.0081289398585795e-07
. O 0 3.820573795110249e-07

Two O 0 3.7629089888469025e-07
of O 0 1.7148005682088296e-08
seventeen O 0 3.1244945830621873e-07
mutated O 0 8.288557182822842e-06
T B-Disease 0 0.0010867805685847998
- I-Disease 0 5.2407460316317156e-05
PLL I-Disease 0 3.550880865077488e-05
samples O 0 1.6750251461417065e-06
had O 0 9.767549613570736e-08
a O 0 1.4830232153428824e-08
previously O 0 9.661506510383333e-07
reported O 0 3.279161683167331e-05
A B-Disease 1 0.9995296001434326
- I-Disease 1 0.9998019337654114
T I-Disease 1 0.9999998807907104
allele O 0 5.532708382816054e-05
. O 0 5.613591724795697e-07

In O 0 9.282930477638729e-07
contrast O 0 4.282537418021093e-07
, O 0 1.697621243579306e-08
no O 0 1.6306723082948338e-08
mutations O 0 2.274100694421577e-07
were O 0 6.9108807565498864e-09
detected O 0 1.5396776120724098e-07
in O 0 6.386300932526012e-10
the O 0 6.499255023051376e-10
p53 O 0 1.792908577158414e-08
gene O 0 1.547413148728083e-07
, O 0 5.170149197653018e-09
suggesting O 0 2.5964352445839722e-08
that O 0 8.409188900770914e-09
this O 0 1.35226216002593e-07
tumour B-Disease 1 1.0
suppressor O 0 0.0002526410680729896
is O 0 1.9976600640347897e-07
not O 0 2.749311001082333e-08
frequently O 0 6.183896772427033e-08
altered O 0 5.140465418662643e-06
in O 0 2.06616128650694e-08
this O 0 8.36871194564992e-08
leukaemia B-Disease 0 0.005146723240613937
. O 0 5.536456910704146e-07

Occasional O 0 1.3450866390485317e-05
missense O 0 0.0002531259669922292
mutations O 0 8.740384510019794e-05
in O 0 1.0929313987162459e-07
ATM O 0 0.0018736663041636348
were O 0 7.67999210893322e-07
also O 0 1.4091237687807734e-07
found O 0 5.903406830043423e-08
in O 0 1.293007017011405e-07
tumour B-Disease 1 0.9999998807907104
DNA O 0 1.62439355335664e-05
from O 0 2.2671057919865234e-08
patients O 0 1.0746638245962004e-08
with O 0 3.340817622543568e-10
B B-Disease 0 1.3695329244001186e-06
- I-Disease 0 1.2883097042504232e-05
cell I-Disease 0 0.02329861745238304
non I-Disease 0 0.0002563180751167238
- I-Disease 1 0.9940599799156189
Hodgkins I-Disease 1 0.9999995231628418
lymphomas I-Disease 1 0.8450128436088562
( O 0 3.1948577117191235e-08
B B-Disease 0 8.938093287724769e-07
- I-Disease 0 2.796391299852985e-06
NHL I-Disease 0 4.980572612112155e-07
) O 0 2.2235007168802667e-09
and O 0 1.0504916936326936e-09
a O 0 2.1336481026423826e-08
B B-Disease 0 7.697069008827384e-07
- I-Disease 0 2.216208258687402e-06
NHL I-Disease 0 7.207430030575779e-07
cell O 0 1.2292229257582221e-05
line O 0 1.661102578509599e-05
. O 0 2.5125137881332194e-07

The O 0 1.235247566455655e-07
evidence O 0 3.290801942057442e-08
of O 0 4.730928981899751e-10
a O 0 5.83788839492172e-09
significant O 0 3.785333380079692e-09
proportion O 0 1.3944048582459345e-08
of O 0 1.2498692081308604e-09
loss O 0 5.001572844776092e-07
- O 0 9.789163186724181e-07
of O 0 1.5704681999295644e-08
- O 0 1.9851910110446624e-05
function O 0 1.4041244185136748e-06
mutations O 0 2.0267721083655488e-06
and O 0 1.2999192833262896e-08
a O 0 1.739533850297903e-08
complete O 0 9.480676510520425e-08
absence O 0 4.192284297488413e-09
of O 0 2.7201349506178474e-10
the O 0 3.111735535910043e-09
normal O 0 8.360159853282312e-08
copy O 0 6.934121188351128e-07
of O 0 6.522091755556403e-10
ATM O 0 2.3185244572232477e-05
in O 0 3.4877380983289186e-09
the O 0 2.6924844576114992e-09
majority O 0 1.3728520542599654e-08
of O 0 1.2548166949954975e-08
mutated O 0 0.002779383445158601
tumours B-Disease 1 1.0
establishes O 0 1.5144025837798836e-06
somatic O 0 2.6689208425523248e-06
inactivation O 0 2.850468263204675e-06
of O 0 4.779124318510242e-10
this O 0 7.784051736514641e-10
gene O 0 2.7144988479221865e-08
in O 0 1.2489563827600136e-09
the O 0 6.470254110269025e-09
pathogenesis O 0 3.4192548810096923e-06
of O 0 2.893830952643839e-09
sporadic B-Disease 0 6.3092593336477876e-06
T I-Disease 0 0.12369425594806671
- I-Disease 0 6.920347368577495e-05
PLL I-Disease 0 3.3725256798788905e-05
and O 0 6.056983181679243e-08
suggests O 0 2.4216307181745833e-08
that O 0 1.3790451003359294e-09
ATM O 0 8.092756615951657e-06
acts O 0 7.150551084578183e-08
as O 0 1.730740528671504e-08
a O 0 2.093177272399771e-06
tumour B-Disease 1 0.9999998807907104
suppressor O 0 0.0008232514373958111
. O 0 1.490156364525319e-06

As O 0 2.0360012058517896e-06
constitutional O 0 1.754449243662748e-07
DNA O 0 2.6454451926838374e-06
was O 0 1.073880980584363e-06
not O 0 6.044010181227577e-09
available O 0 3.3460292314657636e-09
, O 0 1.5189356439293533e-09
a O 0 4.7670297931290406e-08
putative O 0 2.2032601918908767e-05
hereditary O 1 0.541348934173584
predisposition O 0 0.00014437698700930923
to O 0 2.0173615666863043e-06
T B-Disease 1 0.8199748992919922
- I-Disease 0 0.0016513530863448977
PLL I-Disease 0 0.00010442650091135874
will O 0 2.3005428317901533e-07
require O 0 3.648090496355394e-09
further O 0 6.166345212221813e-09
investigation O 0 4.38306635430763e-08
. O 0 9.69454738708464e-09
. O 0 9.96224898131004e-08

Myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 1.0
protein O 0 0.0012184277875348926
kinase O 0 0.0006937604630365968
is O 0 1.7412308750408556e-07
involved O 0 1.1248082465442621e-08
in O 0 1.5527512609025962e-09
the O 0 1.1267982102936003e-09
modulation O 0 2.650717512153733e-08
of O 0 3.1031283098670315e-10
the O 0 6.25941432019772e-09
Ca2 O 0 1.5522404055445804e-06
+ O 0 6.7046885305899195e-06
homeostasis O 0 1.5988531231414527e-05
in O 0 7.556060666047415e-08
skeletal O 0 0.0004041034262627363
muscle O 0 4.6882320020813495e-05
cells O 0 1.3311136171978433e-05
. O 0 3.862093933548749e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9982361793518066
DM B-Disease 1 1.0
) O 0 1.1192908004886704e-06
, O 0 2.3173685193000892e-09
the O 0 1.3458949510436469e-09
most O 0 8.123615558019992e-09
prevalent O 0 3.961239599448163e-06
muscular B-Disease 0 0.004591435194015503
disorder I-Disease 0 0.0013098801719024777
in O 0 2.738952886716106e-08
adults O 0 4.0093181041811476e-07
, O 0 5.4749702549372614e-09
is O 0 1.0767463365368712e-08
caused O 0 1.0566942165723958e-07
by O 0 6.68982824691966e-09
( O 0 3.921857683053531e-08
CTG O 0 1.8885879399022087e-05
) O 0 1.7018486175857106e-08
n O 0 4.5597648750117514e-06
- O 0 2.4604564714536536e-06
repeat O 0 2.6684219847084023e-06
expansion O 0 1.2952613204220143e-08
in O 0 7.141426339174473e-10
a O 0 1.0319355370214112e-09
gene O 0 6.7062448927401874e-09
encoding O 0 6.702677080028252e-09
a O 0 1.1992285386952517e-08
protein O 0 6.132100338618329e-07
kinase O 0 6.807051977375522e-05
( O 0 7.613825800945051e-07
DM B-Disease 1 0.9999997615814209
protein O 0 3.0470196179521736e-06
kinase O 0 2.6158220407523913e-06
; O 0 2.8391438533503788e-08
DMPK O 0 5.7699276112543885e-06
) O 0 1.9282511143359216e-09
and O 0 3.9006370355920694e-10
involves O 0 9.776618403734005e-10
changes O 0 2.778361096744675e-09
in O 0 2.9411464375073137e-09
cytoarchitecture O 0 3.041511808987707e-05
and O 0 2.7939790925302077e-07
ion O 0 6.6320644691586494e-06
homeostasis O 0 1.3732125808019191e-05
. O 0 2.574574864411261e-07

To O 0 4.566678626360954e-07
obtain O 0 1.77874298401548e-07
clues O 0 7.688030905228516e-07
to O 0 9.398931410942168e-09
the O 0 4.7193773333731315e-09
normal O 0 9.507622422688655e-08
biological O 0 5.061716734644506e-08
role O 0 1.1893401818952043e-08
of O 0 2.006116162078797e-09
DMPK O 0 9.316542673332151e-06
in O 0 2.0185606075528995e-08
cellular O 0 6.074585598980775e-06
ion O 0 1.4553762639479828e-06
homeostasis O 0 2.8933748126291903e-06
, O 0 2.16589270962686e-08
we O 0 6.740111135883353e-09
have O 0 1.4613481535974415e-09
compared O 0 9.048350513296555e-09
the O 0 1.3869533299626369e-09
resting O 0 1.5435678335506964e-07
[ O 0 7.368333942991967e-09
Ca2 O 0 3.129116166178392e-08
+ O 0 2.4810736931613064e-07
] O 0 8.668917672594034e-08
i O 0 3.423452810125127e-08
, O 0 6.561608478783398e-10
the O 0 3.3744324001716564e-10
amplitude O 0 4.910671869140515e-09
and O 0 7.343724295338916e-09
shape O 0 2.4745563109718205e-07
of O 0 3.1708642378447394e-09
depolarization O 0 1.9486097357912513e-07
- O 0 1.0365764865127858e-05
induced O 0 5.7517431741871405e-06
Ca2 O 0 1.7705583843508066e-07
+ O 0 9.70415953815973e-07
transients O 0 7.170393473643344e-06
, O 0 2.9958964198328886e-09
and O 0 7.048512329355106e-10
the O 0 3.3773947527571124e-10
content O 0 1.0676948214438653e-08
of O 0 5.046393858343379e-10
ATP O 0 1.7944321371032856e-05
- O 0 2.7932808279729215e-06
driven O 0 9.965040135284653e-07
ion O 0 3.5045616186835105e-07
pumps O 0 3.416728020511073e-07
in O 0 2.66933608550346e-09
cultured O 0 1.668313643676811e-06
skeletal O 0 2.224117451987695e-05
muscle O 0 8.898977057469892e-07
cells O 0 8.195051748316473e-08
of O 0 5.123282353913794e-10
wild O 0 7.50419744122155e-08
- O 0 3.7026563859399175e-06
type O 0 6.913914489814488e-07
and O 0 6.575181998869084e-08
DMPK O 0 1.9126982806483284e-05
[ O 0 1.0430813546236095e-07
- O 0 1.2195513590995688e-05
/ O 0 0.0002097766409860924
- O 0 4.3063508201157674e-05
] O 0 2.0007537386845797e-06
knockout O 0 7.969716534717008e-05
mice O 0 0.00010675717203412205
. O 0 7.112647040230513e-07

In O 0 9.260364777219365e-07
vitro O 0 3.6565954360412434e-05
- O 0 4.799011003342457e-05
differentiated O 0 2.5852139515336603e-05
DMPK O 0 5.197272912482731e-05
[ O 0 2.231434592658843e-07
- O 0 8.813287422526628e-06
/ O 0 4.313189128879458e-05
- O 0 5.824333129567094e-06
] O 0 1.4756538746496517e-07
myotubes O 0 5.004359309168649e-07
exhibit O 0 2.4718151081515316e-08
a O 0 1.9757422364818922e-08
higher O 0 6.212862047050294e-08
resting O 0 3.676045992051513e-07
[ O 0 3.071363252615811e-08
Ca2 O 0 6.245273453941991e-08
+ O 0 2.1795460725115845e-07
] O 0 5.379953904594004e-08
i O 0 2.8137415952755873e-08
than O 0 2.682468469572541e-09
do O 0 4.176035961478419e-09
wild O 0 1.778019687037613e-08
- O 0 3.2348575587093364e-06
type O 0 4.4931226739208796e-07
myotubes O 0 9.487861461821012e-06
because O 0 4.354549165697108e-09
of O 0 2.4859495018070277e-10
an O 0 3.2040770037156108e-09
altered O 0 1.884574430732755e-06
open O 0 4.926041015096416e-07
probability O 0 6.718907208380642e-09
of O 0 9.077906204524311e-10
voltage O 0 2.5440856461500516e-06
- O 0 7.295822342712199e-06
dependent O 0 1.3626020063384203e-06
l O 0 1.8294305164090474e-06
- O 0 3.102226173723466e-07
type O 0 4.3445631092708936e-08
Ca2 O 0 7.910365695806831e-08
+ O 0 1.1907366115337936e-07
and O 0 3.2607552213903546e-08
Na O 0 3.0183066428435268e-06
+ O 0 6.912543994985754e-07
channels O 0 2.5414810806978494e-06
. O 0 2.8011984909426246e-07

The O 0 2.9054476158307807e-07
mutant O 0 4.734102731163148e-06
myotubes O 0 9.908269021252636e-06
exhibit O 0 1.8883385166645894e-07
smaller O 0 3.020339534032246e-08
and O 0 1.622082734797914e-08
slower O 0 8.050948849813722e-07
Ca2 O 0 3.300482944723626e-07
+ O 0 6.918637609487632e-07
responses O 0 2.4602911707916064e-08
upon O 0 4.831275823846681e-09
triggering O 0 8.401898554666332e-08
by O 0 4.165201517025707e-09
acetylcholine O 0 9.763190973899327e-06
or O 0 4.595701739162905e-07
high O 0 1.1589887094487494e-07
external O 0 2.252669901281479e-06
K O 0 6.490399755421095e-06
+ O 0 2.6901791443378897e-06
. O 0 2.40978522469959e-07

In O 0 6.001068300065526e-07
addition O 0 3.911965862357647e-08
, O 0 3.2860729248795906e-08
we O 0 1.298031282459533e-08
observed O 0 5.56140067331512e-09
that O 0 2.729333703488379e-10
these O 0 1.5487042204220813e-10
Ca2 O 0 5.409278713841559e-08
+ O 0 2.232380666100653e-06
transients O 0 1.3110743566357996e-05
partially O 0 7.653628927073441e-06
result O 0 3.11587058376972e-08
from O 0 3.764810685424891e-10
an O 0 3.787606617233763e-10
influx O 0 8.784523108928965e-10
of O 0 2.562612622103444e-10
extracellular O 0 1.5706419276284578e-08
Ca2 O 0 3.8432887095041224e-08
+ O 0 3.532482040213836e-08
through O 0 1.7184111911205946e-09
the O 0 2.5670168213309807e-09
l O 0 1.4195123867466464e-06
- O 0 3.708027236370981e-07
type O 0 1.39068163207412e-07
Ca2 O 0 4.073904733559175e-07
+ O 0 8.171558647518395e-07
channel O 0 1.3598068107967265e-05
. O 0 6.777259500267974e-07

Neither O 0 4.0566087591287214e-06
the O 0 4.756040894449143e-08
content O 0 1.5776201678363577e-07
nor O 0 5.099674993402914e-08
the O 0 2.020543510283801e-09
activity O 0 8.644954974101893e-09
of O 0 1.039434094352032e-09
Na O 0 2.6765776510728756e-06
+ O 0 6.50840320304269e-07
/ O 0 7.212738069029001e-07
K O 0 1.04152675817204e-07
+ O 0 1.5833055044822686e-07
ATPase O 0 1.52983022871922e-06
and O 0 1.9681936080928608e-08
sarcoplasmic O 0 1.426972062290588e-06
reticulum O 0 9.174764272756875e-07
Ca2 O 0 3.047962024993467e-07
+ O 0 7.256999765559158e-07
- O 0 3.5211953672842355e-06
ATPase O 0 3.2361323974328116e-05
are O 0 1.835194929356021e-08
affected O 0 1.6803284097477444e-08
by O 0 7.686503877835094e-09
DMPK O 0 8.939271356211975e-05
absence O 0 4.560520210361574e-07
. O 0 2.3744213706322626e-07

In O 0 1.3396104350249516e-06
conclusion O 0 2.428782579499966e-07
, O 0 2.6083432302925758e-08
our O 0 1.7214858871739125e-08
data O 0 1.358184249511396e-07
suggest O 0 2.1547920781017638e-08
that O 0 4.142321152755812e-09
DMPK O 0 1.0877725799218751e-05
is O 0 4.939991526953236e-09
involved O 0 1.3418656186203748e-09
in O 0 9.95414861648669e-10
modulating O 0 2.3477925026327284e-07
the O 0 9.265400002789193e-09
initial O 0 3.483505039980628e-08
events O 0 4.3329086985011145e-09
of O 0 1.7049147649217389e-09
excitation O 0 5.104565161673236e-07
- O 0 2.7727046472136863e-05
contraction O 0 5.248108573141508e-05
coupling O 0 4.003732101409696e-07
in O 0 4.460351021862152e-08
skeletal O 0 0.00011458669905550778
muscle O 0 5.4983065638225526e-06
. O 0 3.385879665529501e-08
. O 0 2.418492215383594e-07

Constitutional O 0 2.749653867795132e-05
RB1 O 0 0.0017279512248933315
- O 0 0.00017451187886763364
gene O 0 8.147085281962063e-06
mutations O 0 9.02899046195671e-06
in O 0 1.799987359163424e-08
patients O 0 3.8551280567844515e-07
with O 0 3.069108700515244e-08
isolated O 0 5.4117081162985414e-05
unilateral B-Disease 0 0.00038247526390478015
retinoblastoma I-Disease 0 0.009690861217677593
. O 0 1.967020580195822e-06

In O 0 6.531004714815936e-07
most O 0 1.4786459701099375e-07
patients O 0 2.7401765123613586e-07
with O 0 1.237621827243629e-08
isolated O 0 7.242457286338322e-06
unilateral B-Disease 0 5.502684143721126e-05
retinoblastoma I-Disease 0 0.0004018434847239405
, O 0 1.8178705829541286e-07
tumor B-Disease 0 4.895309302810347e-06
development O 0 3.63318886087427e-09
is O 0 4.693201827166149e-09
initiated O 0 5.959733595517491e-09
by O 0 1.3794712039327806e-09
somatic O 0 5.306637831381522e-07
inactivation O 0 5.38402628080803e-06
of O 0 4.754194815603796e-10
both O 0 2.4534247966556677e-09
alleles O 0 2.251793951302261e-08
of O 0 1.5475268844156176e-09
the O 0 7.637171250962638e-08
RB1 O 0 0.00021102462778799236
gene O 0 6.164081696624635e-06
. O 0 3.5702558420780406e-07

However O 0 1.2553932720038574e-06
, O 0 8.386348504529906e-09
some O 0 4.691088073549565e-10
of O 0 2.942660004556785e-10
these O 0 2.023555545349609e-09
patients O 0 6.945120389900694e-08
can O 0 2.8253900552499545e-08
transmit O 0 0.00012380542466416955
retinoblastoma B-Disease 0 0.0008699254831299186
predisposition O 0 6.347780436044559e-05
to O 0 8.864412137654654e-08
their O 0 5.210911240283167e-07
offspring O 0 1.7282523913308978e-05
. O 0 4.098463080026704e-07

To O 0 5.888629175387905e-07
determine O 0 2.0949995871433202e-07
the O 0 1.2065084042944818e-08
frequency O 0 7.212793775579485e-07
and O 0 2.6552868348517222e-08
nature O 0 2.5830294347883864e-08
of O 0 4.2491596907723306e-09
constitutional O 0 1.0339242351165012e-07
RB1 O 0 9.567886445438489e-05
- O 0 2.3643129679840058e-05
gene O 0 2.363032081120764e-06
mutations O 0 3.540959141901112e-06
in O 0 5.51389200964536e-09
patients O 0 9.897286901150437e-08
with O 0 1.9506274373526367e-09
isolated O 0 9.096309440792538e-06
unilateral B-Disease 0 1.8100003217114136e-05
retinoblastoma I-Disease 0 7.781973545206711e-05
, O 0 4.8129479068848013e-08
we O 0 1.5766989491794448e-08
analyzed O 0 4.480234849779663e-08
DNA O 0 6.526111064886209e-07
from O 0 1.5169272060688854e-08
peripheral O 0 2.5540828573866747e-05
blood O 0 8.25827464723261e-06
and O 0 5.234210220805835e-07
from O 0 3.541333626344567e-07
tumor B-Disease 0 0.0003077260626014322
tissue O 0 0.00011274521966697648
. O 0 7.144033702388697e-07

The O 0 1.9741344203794142e-07
analysis O 0 4.934433377457026e-07
of O 0 1.0948989626058392e-07
tumors B-Disease 1 0.9999998807907104
from O 0 7.608325347518985e-08
54 O 0 2.465082786784478e-07
( O 0 4.9251740463773785e-09
71 O 0 2.2920804809700712e-08
% O 0 1.006240424317184e-09
) O 0 5.04524921840499e-10
of O 0 5.967897842573677e-10
76 O 0 1.447606337023899e-07
informative O 0 1.252981974175782e-06
patients O 0 1.5970313143043313e-06
showed O 0 5.577874162554508e-07
loss O 0 1.8858388273201854e-07
of O 0 5.142032577509781e-09
constitutional O 0 8.528478474545409e-07
heterozygosity O 0 0.0001667343167355284
( O 0 7.332946097449167e-06
LOH O 1 0.9999887943267822
) O 0 2.019281311049781e-07
at O 0 3.130316486021911e-07
intragenic O 0 4.2761777876876295e-05
loci O 0 4.767703103425447e-06
. O 0 6.871844107081415e-07

Three O 0 4.21713224341147e-07
of O 0 6.081223347109699e-08
13 O 0 8.87117550973926e-07
uninformative O 0 0.000952127214986831
patients O 0 5.23593116668053e-05
had O 0 7.098383321135771e-07
constitutional O 0 2.505755958281952e-07
deletions O 0 2.2969019482843578e-05
. O 0 1.3732759498452651e-06

For O 0 3.1144455192588794e-07
39 O 0 3.6953116477889125e-07
randomly O 0 1.9545132090570405e-07
selected O 0 1.179481500912516e-06
tumors B-Disease 1 0.9999996423721313
, O 0 1.1338328675947196e-07
SSCP O 0 1.8268212443217635e-05
, O 0 1.960127704592196e-08
hetero O 0 1.5721127510914812e-06
- O 0 1.1805212807303178e-06
duplex O 0 7.507740519940853e-05
analysis O 0 5.987399731566256e-08
, O 0 1.7064958335311076e-09
sequencing O 0 2.3659531223074737e-08
, O 0 3.051130237352595e-09
and O 0 2.775987884007236e-09
Southern O 0 3.0746868162623286e-08
blot O 0 4.319215440773405e-05
analysis O 0 4.232830264072618e-08
were O 0 2.372074536793889e-09
used O 0 9.457663097123259e-09
to O 0 3.485704880290541e-08
identify O 0 1.3958159570393036e-06
mutations O 0 7.498797913285671e-06
. O 0 1.9137215190312418e-07

Mutations O 0 0.0003981292247772217
were O 0 7.108557724677667e-07
detected O 0 2.289200438099215e-06
in O 0 1.8065946960632573e-08
21 O 0 5.4240736346855556e-08
( O 0 2.2379671449357375e-09
91 O 0 9.409299117635328e-09
% O 0 1.4195082886914179e-09
) O 0 1.3967839107564828e-09
of O 0 4.123418051449335e-09
23 O 0 7.184361311374232e-05
tumors B-Disease 1 1.0
with O 0 1.1807772352767643e-05
LOH O 1 0.9999974966049194
. O 0 7.629230822203681e-06

In O 0 1.0337433877793956e-06
6 O 0 3.229082778943848e-07
( O 0 9.22130638514318e-09
38 O 0 3.5733378922486736e-08
% O 0 2.888300265624366e-09
) O 0 1.4820412674865224e-09
of O 0 5.216964638066202e-09
16 O 0 4.0342572901863605e-05
tumors B-Disease 1 1.0
without O 0 7.773443030600902e-06
LOH O 1 0.9999938011169434
, O 0 2.5701192285509933e-08
one O 0 7.918196764933327e-09
mutation O 0 4.999207448008747e-08
was O 0 1.4260400860166556e-07
detected O 0 7.81297330831876e-07
, O 0 1.7767882720676198e-09
and O 0 2.0018886548456294e-09
in O 0 2.468129700616828e-09
9 O 0 1.1451289338992865e-07
( O 0 1.561494933355334e-09
56 O 0 1.3537403198427e-08
% O 0 8.086648572991351e-10
) O 0 2.833244194810902e-10
of O 0 1.4275559623300182e-09
the O 0 1.0867088349186815e-05
tumors B-Disease 1 1.0
without O 0 2.693645001272671e-05
LOH O 1 0.999996542930603
, O 0 9.411778734147447e-08
both O 0 3.095682643561304e-08
mutations O 0 2.0094314550078707e-06
were O 0 1.600288790370996e-08
found O 0 1.1245512610003061e-07
. O 0 1.4765970490770997e-07

Thus O 0 1.3480096185958246e-06
, O 0 1.7330066270915268e-08
a O 0 2.122723774533597e-09
total O 0 2.484410233094536e-09
of O 0 8.487789915356814e-10
45 O 0 2.1783506554129417e-08
mutations O 0 2.2646818820248882e-07
were O 0 1.6438505667792924e-08
identified O 0 8.225869123634766e-07
in O 0 6.317576435321826e-07
tumors B-Disease 1 1.0
of O 0 2.3268212245852737e-08
36 O 0 8.101769140012038e-07
patients O 0 2.4644484142299916e-07
. O 0 1.618436726857908e-07

Thirty O 0 9.59463886829326e-06
- O 0 8.878912922227755e-06
nine O 0 1.1665903087987317e-07
of O 0 5.945198222612191e-10
the O 0 3.880218368834676e-09
mutations O 0 5.334779302756942e-07
- O 0 9.55146106207394e-07
including O 0 5.760692811662693e-09
34 O 0 4.560109179152505e-09
small O 0 2.6889688253817212e-09
mutations O 0 1.1123596266315872e-07
, O 0 8.105008886261089e-10
2 O 0 6.787612694125755e-09
large O 0 1.1615211015225668e-08
structural O 0 2.5655895115050953e-06
alterations O 0 3.0129892820696114e-06
, O 0 2.2980117364568287e-08
and O 0 2.1053057963626998e-08
hypermethylation O 0 4.6882669266778976e-06
in O 0 1.008677799063662e-07
3 O 0 8.556668035453185e-05
tumors O 1 1.0
- O 0 0.0021682519000023603
were O 0 1.2210956583658117e-06
not O 0 2.0254638855021767e-08
detected O 0 1.6345468623057968e-07
in O 0 5.423375082358461e-10
the O 0 2.3690271966358978e-09
corresponding O 0 1.1620954154523133e-07
peripheral O 0 1.8238757547806017e-05
blood O 0 4.0392251321463846e-06
DNA O 0 2.2719059415976517e-05
. O 0 3.6895468724651437e-07

In O 0 1.1246139592913096e-06
6 O 0 7.811341333763266e-07
( O 0 1.3706804580237986e-08
17 O 0 1.775837077389042e-08
% O 0 1.8599816131725788e-09
) O 0 5.958548099371797e-10
of O 0 1.6555130877282664e-10
the O 0 1.2767719326234328e-08
36 O 0 5.352462721930351e-07
patients O 0 1.9749096580312653e-08
, O 0 4.033755551802187e-10
a O 0 5.560573779206379e-09
mutation O 0 2.2693474477364362e-07
was O 0 3.9555891362397233e-07
detected O 0 4.4143189370515756e-07
in O 0 1.9494372782702385e-09
constitutional O 0 1.9905954662391423e-09
DNA O 0 2.2367250096522184e-07
, O 0 1.1367198737843864e-08
and O 0 5.8565130522936215e-09
1 O 0 1.1447966130617715e-08
of O 0 4.49944720370965e-10
these O 0 4.563058819684329e-09
mutations O 0 3.825127237178094e-07
is O 0 7.455772887965395e-09
known O 0 3.9575205335040664e-08
to O 0 5.6892940136776815e-08
be O 0 1.755047485119121e-08
associated O 0 1.4291450689540852e-08
with O 0 9.85273906906059e-09
reduced O 0 5.395591870183125e-06
expressivity O 0 0.0001249891211045906
. O 0 9.484173801865836e-07

The O 0 1.1645117581338127e-07
presence O 0 2.7493477716689085e-08
of O 0 1.5217485049845436e-09
a O 0 1.311054464991912e-08
constitutional O 0 2.198016524346258e-08
mutation O 0 2.760130257684068e-07
was O 0 7.74082479892968e-07
not O 0 1.0352242618694163e-08
associated O 0 4.749248549984486e-09
with O 0 1.6851547934848554e-09
an O 0 1.1181024106576842e-08
early O 0 2.692599423426145e-07
age O 0 1.5997636992892694e-08
at O 0 5.174374706484741e-08
treatment O 0 3.5565301459428156e-07
. O 0 1.7722206280268438e-07

In O 0 9.108966878557112e-07
1 O 0 1.2320538189669605e-06
patient O 0 3.301652213849593e-06
, O 0 1.9407789153547128e-08
somatic O 0 5.843973553965043e-07
mosaicism O 0 3.196180841769092e-05
was O 0 9.656661177359638e-07
demonstrated O 0 7.93847565461192e-09
by O 0 4.711568357684826e-10
molecular O 0 1.8082909392092006e-08
analysis O 0 6.3067027156193944e-09
of O 0 4.4286674327764786e-10
DNA O 0 1.1372271728760097e-06
and O 0 6.38656274531968e-08
RNA O 0 1.6542747971470817e-06
from O 0 4.665020369998274e-08
peripheral O 0 8.961872663348913e-05
blood O 0 3.693186226882972e-05
. O 0 1.0370631571277045e-06

In O 0 1.357543510493997e-06
2 O 0 2.1429282242024783e-06
patients O 0 5.289726345836243e-07
without O 0 4.894718852455071e-09
a O 0 1.772223257034966e-08
detectable O 0 3.2645878036419163e-06
mutation O 0 1.282512016587134e-06
in O 0 3.46881918744657e-08
peripheral O 0 0.00015470244397874922
blood O 0 0.00010103218664880842
, O 0 3.6622245147555077e-07
mosaicism O 0 3.251106318202801e-05
was O 0 1.6964709175226744e-06
suggested O 0 8.447630506225323e-08
because O 0 2.3629349588105697e-09
1 O 0 3.486481103820438e-09
of O 0 2.123083098215517e-10
the O 0 3.414037053062202e-08
patients O 0 9.544194199406775e-07
showed O 0 4.897363851341652e-06
multifocal O 1 0.9931094646453857
tumors B-Disease 1 1.0
and O 0 1.3004579102471325e-07
the O 0 2.938006504749069e-09
other O 0 3.5498384232113267e-09
later O 0 6.171642041863379e-08
developed O 0 5.906628075535991e-08
bilateral B-Disease 0 3.652082227745268e-07
retinoblastoma I-Disease 0 0.00011591922520892695
. O 0 7.475439360860037e-07

In O 0 7.154602030823298e-07
conclusion O 0 9.27834875597e-08
, O 0 7.55278595221398e-09
our O 0 1.2519192793547518e-08
results O 0 3.855785735140671e-08
emphasize O 0 1.5587460211463622e-08
that O 0 1.1492459206507988e-09
the O 0 1.6969597949056947e-09
manifestation O 0 4.615897708504235e-08
and O 0 1.255271531164226e-08
transmissibility O 0 3.934726748866524e-07
of O 0 2.192848125304181e-09
retinoblastoma B-Disease 0 3.002115818162565e-06
depend O 0 4.914497608865531e-08
on O 0 1.6525183355042827e-07
the O 0 7.456355533008718e-09
nature O 0 1.8006673485615465e-08
of O 0 2.6986787804439416e-10
the O 0 2.1244248582519276e-09
first O 0 4.0774800424969726e-08
mutation O 0 1.9187465838399476e-08
, O 0 4.681970366959831e-10
its O 0 5.5895603701117125e-09
time O 0 1.9946250873204008e-08
in O 0 1.3818413080457503e-09
development O 0 2.6593351964976364e-09
, O 0 8.946994256575636e-09
and O 0 3.2605547151121073e-09
the O 0 8.29895430154437e-10
number O 0 1.0089737934038112e-08
and O 0 1.2202903576508106e-08
types O 0 4.6787675955783925e-09
of O 0 1.0001175443363763e-09
cells O 0 4.743683348351624e-07
that O 0 1.1860803894592209e-08
are O 0 5.562653004886897e-09
affected O 0 1.315553355141219e-08
. O 0 6.037994992880158e-09
. O 0 1.9326751043990953e-07

Hereditary B-Disease 1 0.9999983310699463
deficiency I-Disease 1 0.9979725480079651
of I-Disease 0 3.4533453430185546e-08
the I-Disease 0 1.7335883839564303e-08
fifth I-Disease 0 1.0772453151730588e-06
component I-Disease 0 1.0778213521689395e-07
of I-Disease 0 1.3341915350295608e-09
complement I-Disease 0 2.1595111476813145e-08
in O 0 3.096993594908781e-08
man O 0 1.227349912369391e-05
. O 0 5.355618100111315e-07

I O 0 0.0007188955205492675
. O 0 7.878991709731054e-06

Clinical O 0 0.0004948670975863934
, O 0 2.659215567746287e-07
immunochemical O 0 4.727307896246202e-05
, O 0 1.6094817567591235e-07
and O 0 2.5786286883544562e-08
family O 0 1.9521363014973758e-07
studies O 0 1.0721316812123405e-07
. O 0 4.189341495930421e-07

The O 0 1.8277374635999877e-07
first O 0 1.1516166864566912e-07
recognized O 0 4.447760915127219e-08
human O 0 7.301157722849894e-08
kindred O 0 5.459667227114551e-05
with O 0 4.933247510052752e-06
hereditary B-Disease 1 0.9999873638153076
deficiency I-Disease 0 0.14278128743171692
of I-Disease 0 2.5122051106052368e-09
the I-Disease 0 1.3909065899042616e-08
fifth I-Disease 0 1.5185069059953094e-06
component I-Disease 0 1.0477592127244861e-07
of I-Disease 0 1.58885227197203e-09
complement I-Disease 0 1.7156553155928123e-07
( O 0 6.022998633170573e-08
C5 O 0 3.4239878004882485e-05
) O 0 2.5253120483625935e-08
is O 0 2.0668865730044672e-08
described O 0 8.881706321517413e-07
. O 0 3.1031140679260716e-07

The O 0 7.552355896223162e-07
proband O 0 1.6396958017139696e-05
, O 0 1.4268816350693214e-08
a O 0 6.663595009115397e-09
20 O 0 1.095631851910639e-08
- O 0 1.1683143839036347e-06
year O 0 1.8268660539888515e-07
- O 0 1.6085548395494698e-06
old O 0 1.106569470721297e-06
black O 0 2.7936835067521315e-07
female O 0 3.3121085607490386e-07
with O 0 6.211923846421996e-06
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9999986886978149
erythematosus I-Disease 1 0.9999998807907104
since O 0 1.387290808452235e-06
age O 0 3.1687196866414524e-08
11 O 0 7.2851018551034485e-09
, O 0 3.1731453020711342e-09
lacked O 0 1.477598630117427e-07
serum O 0 3.970419584220508e-07
hemolytic O 0 1.4511917470372282e-05
complement O 0 1.0202447242591006e-07
activity O 0 1.8859611827792833e-07
, O 0 8.054650280087117e-09
even O 0 1.5018189358784184e-08
during O 0 4.3822641515589567e-08
remission O 0 1.642542656554724e-06
. O 0 1.4494241895590676e-07

C5 O 0 0.0026741959154605865
was O 0 1.1312194146739785e-05
undetectable O 0 1.0570178346824832e-05
in O 0 8.627580427855719e-08
her O 0 5.161112994755968e-07
serum O 0 1.822129860329369e-07
by O 0 2.659436670882087e-09
both O 0 1.3928818098918327e-08
immunodiffusion O 0 3.995811493950896e-05
and O 0 5.140583994034387e-07
hemolytic O 0 0.0007114817854017019
assays O 0 1.2189315384603105e-05
. O 0 8.262255164481758e-07

Other O 0 1.1352209838833005e-07
complement O 0 1.8896662368206307e-07
components O 0 3.798024579282355e-07
were O 0 2.408883759130731e-08
normal O 0 5.921823031940221e-08
during O 0 1.4068835874070373e-08
remission O 0 4.1724035781953717e-07
of O 0 6.784350858879407e-09
lupus O 0 0.00021088466746732593
, O 0 8.281501706619565e-09
but O 0 8.733822554063408e-09
C1 O 0 1.8267004406880005e-06
, O 0 2.0282550750039263e-08
C4 O 0 9.336973562312778e-06
, O 0 7.816310265695847e-09
C2 O 0 9.149076163339487e-07
, O 0 7.375335897563673e-09
and O 0 9.233978914835461e-09
C3 O 0 6.43125458736904e-05
levels O 0 3.6324601637716114e-07
fell O 0 3.668110730359331e-05
during O 0 1.9345708324181032e-07
exacerbations O 0 7.908607221907005e-05
. O 0 4.289298090043303e-07

A O 0 4.172068202024093e-06
younger O 0 1.5554930996586336e-06
half O 0 8.789171488388092e-07
- O 0 0.0003110535617452115
sister O 0 0.0021783453412353992
, O 0 8.776174098557021e-08
who O 0 1.261919209127882e-07
had O 0 1.5761824556648207e-07
no O 0 7.591698647502199e-08
underlying O 0 1.2837974281865172e-05
disease O 0 0.00010270479833707213
, O 0 2.352099315316991e-08
was O 0 6.765383204765385e-07
also O 0 1.2157721585026593e-07
found O 0 2.2414328171294073e-08
to O 0 8.865930212209605e-09
lack O 0 5.0702293918902797e-08
immunochemically O 0 2.268954813189339e-05
detectable O 0 8.460709068458527e-06
C5 O 0 6.010906508890912e-05
. O 0 1.2167620297987014e-06

By O 0 1.155497216132062e-06
hemolytic O 0 0.0017736329464241862
assay O 0 0.00014219044533092529
, O 0 3.817758056356979e-07
she O 0 4.694337008004368e-07
exhibited O 0 4.993336943925897e-08
1 O 0 9.263914968471454e-09
- O 0 5.025066798225453e-07
2 O 0 6.606597224845245e-08
% O 0 6.869951829635568e-10
of O 0 9.052847360635496e-11
the O 0 5.463099750357969e-09
normal O 0 3.911369788056618e-07
serum O 0 1.2956311934431142e-07
C5 O 0 2.765510316748987e-06
level O 0 2.2352805828518285e-08
and O 0 3.982218110820668e-09
normal O 0 1.608845678902071e-08
concentrations O 0 1.4505188161706428e-08
of O 0 3.150949223762467e-10
other O 0 9.081438934188668e-10
complement O 0 4.256024155324667e-08
components O 0 9.604420938558178e-07
. O 0 2.889343875267514e-07

C5 O 0 0.002126923529431224
levels O 0 3.741175078175729e-06
of O 0 8.526346739756718e-09
other O 0 4.5740904397462145e-09
family O 0 1.7746451419498044e-08
members O 0 2.4966804179626934e-09
were O 0 2.4057555947365472e-09
either O 0 4.097725270213459e-09
normal O 0 4.273496401197008e-08
or O 0 1.29943824589418e-08
approximately O 0 1.4795170422132742e-08
half O 0 2.8539830054796766e-07
- O 0 8.171432455128524e-06
normal O 0 1.0480384844413493e-06
, O 0 4.9416595260254326e-09
consistent O 0 3.292145578370764e-08
with O 0 1.0295257091286203e-08
autosomal O 0 0.00017548870528116822
codominant O 0 9.617155228625052e-06
inheritance O 0 3.3571322433090245e-07
of O 0 3.373436863185475e-09
the O 0 3.1458242233384226e-08
gene O 0 3.742464105016552e-05
determining O 0 0.00019524885283317417
C5 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
. O 0 2.139652679034043e-06

Normal O 0 0.0014078893000259995
hemolytic O 1 0.9733707904815674
titers O 0 0.0013646438019350171
were O 0 2.5198833100148477e-06
restored O 0 6.620043109251128e-07
to O 0 2.893937356418519e-08
both O 0 7.271375324080509e-08
homozygous O 0 0.00017418107017874718
C5 B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
deficient I-Disease 1 1.0
( O 0 2.1055479010101408e-05
C5D B-Disease 1 1.0
) O 0 9.850243287701232e-08
sera O 0 5.538812501981738e-07
by O 0 2.692087663902498e-10
addition O 0 9.98788829420505e-10
of O 0 9.875236184342384e-10
highly O 0 6.645560546303386e-08
purified O 0 1.4908642924638116e-06
human O 0 2.5355930688419903e-07
C5 O 0 5.551342837861739e-05
. O 0 7.600694971188204e-07

In O 0 7.569466902168642e-07
specific O 0 2.8083056236027915e-07
C5 O 0 3.725464193848893e-05
titrations O 0 4.958021600032225e-05
, O 0 1.0102547065571343e-07
however O 0 1.2516947478502516e-08
, O 0 3.4992324593474677e-09
it O 0 5.386217338809729e-08
was O 0 7.286591312549717e-07
noted O 0 2.2741218685951026e-08
that O 0 1.2364038681766942e-09
when O 0 2.349640926269103e-09
limited O 0 7.850221583893813e-10
amounts O 0 7.760909692677842e-10
of O 0 5.947421444219003e-10
C5 O 0 6.784787728975061e-06
were O 0 3.12002157443203e-08
assayed O 0 6.811712438548057e-08
in O 0 8.60190640938896e-10
the O 0 5.830952942709189e-10
presence O 0 1.25503862857812e-09
of O 0 2.6643803829884405e-10
low O 0 4.0759402963885805e-08
dilutions O 0 8.763943810663477e-07
of O 0 6.817689079952061e-09
either O 0 8.395729196308821e-07
C5D B-Disease 1 0.9999997615814209
serum O 0 1.991017825275776e-06
, O 0 1.842004326846336e-09
curving O 0 1.0130777639005828e-07
rather O 0 4.624893357174642e-09
than O 0 1.0613228074163317e-09
linear O 0 2.8070303415006492e-08
dose O 0 5.32147112153325e-07
- O 0 1.8752447203951306e-06
response O 0 7.256952017087315e-08
plots O 0 1.4417139482247876e-06
were O 0 4.45809774873851e-07
consistently O 0 5.946814098933828e-07
obtained O 0 2.0754550078549983e-08
, O 0 2.9014415314776443e-09
suggesting O 0 1.6175411232666193e-08
some O 0 1.6297792004849043e-09
inhibitory O 0 2.909643228576897e-07
effect O 0 2.2720369940998353e-07
. O 0 1.99458384031459e-07

Further O 0 2.6990419428329915e-06
studies O 0 3.1202068839775166e-07
suggested O 0 2.3553502614959143e-07
that O 0 1.0749159784495532e-08
low O 0 1.0964286900616571e-07
dilutions O 0 1.683711525402032e-05
of O 0 6.125950591240326e-08
C5D B-Disease 1 0.9999996423721313
serum O 0 2.792489567582379e-06
contain O 0 1.0181525844643602e-08
a O 0 1.0077159551258319e-08
factor O 0 1.3490440764485356e-08
( O 0 4.477533011026935e-09
or O 0 8.64108429254884e-08
factors O 0 1.1041491276841953e-08
) O 0 5.471129327361268e-09
interfering O 0 5.316489932738477e-07
at O 0 7.730969286967593e-08
some O 0 1.9325405720138633e-09
step O 0 6.786450512663578e-08
in O 0 2.56796672815085e-09
the O 0 1.3006682841876227e-08
hemolytic O 0 4.3346022721379995e-05
assay O 0 3.7881850403209683e-06
of O 0 9.164549119589083e-09
C5 O 0 3.0256755053414963e-05
, O 0 1.4904669498605472e-08
rather O 0 3.4079523647534415e-09
than O 0 1.0477663181518437e-09
a O 0 1.1233310281966169e-08
true O 0 6.717116463050843e-08
C5 O 0 9.941908501787111e-06
inhibitor O 0 6.992545991124643e-07
or O 0 1.394438697843725e-07
inactivator O 0 4.1965489799622446e-05
. O 0 4.060879064127221e-07

Of O 0 4.0270569456879457e-07
clinical O 0 4.974874627805548e-06
interest O 0 8.874918222545602e-08
are O 0 2.4179106716815113e-08
( O 0 1.4528945158076567e-08
a O 0 1.2053793341237906e-07
) O 0 1.5934599417732898e-08
the O 0 6.040736799661772e-09
documentation O 0 7.435240689801503e-08
of O 0 3.35323768752005e-08
membranous O 0 0.026451094076037407
glomerulonephritis B-Disease 1 1.0
, O 0 4.019633342977613e-05
vasculitis B-Disease 1 0.9999998807907104
, O 0 4.890680429525673e-06
and O 0 0.00019132527813781053
arthritis B-Disease 1 1.0
in O 0 1.375646263568342e-08
an O 0 9.440596748788721e-09
individual O 0 3.7869604341267404e-08
lacking O 0 3.6416136595107673e-07
C5 O 0 1.0951723197649699e-05
( O 0 6.797718388185103e-09
and O 0 1.22157750581664e-09
its O 0 2.1553550055841697e-08
biologic O 0 9.849563866737299e-07
functions O 0 1.3107844587523232e-08
) O 0 5.6201350240314696e-09
, O 0 1.002952831896664e-08
and O 0 9.116086374660881e-08
( O 0 1.2790532188944326e-08
b O 0 1.073324469302861e-07
) O 0 1.2860881248855094e-09
a O 0 7.379894917391994e-09
remarkable O 0 3.5813414456242754e-08
propensity O 0 2.952642034870223e-06
to O 0 3.2930392990238033e-06
bacterial B-Disease 1 0.9999998807907104
infections I-Disease 1 1.0
in O 0 2.0981543613629583e-08
the O 0 3.8715853634130326e-08
proband O 0 3.608403858379461e-05
, O 0 1.195569865330981e-08
even O 0 1.8822510217120225e-09
during O 0 1.0499829894428103e-09
periods O 0 8.270605866833591e-10
of O 0 1.2031221852115692e-10
low O 0 4.027755196034377e-08
- O 0 1.6906855080378591e-06
dose O 0 8.30481155844609e-07
or O 0 8.516757077359216e-09
alternate O 0 8.954492614066112e-08
- O 0 2.1705343442590674e-06
day O 0 1.1726219781849068e-06
corticosteroid O 0 4.039677151013166e-05
therapy O 0 8.437999099442095e-07
. O 0 8.158028208526957e-08

Other O 0 4.147684080635372e-07
observations O 0 1.2038829027005704e-06
indicate O 0 1.295227320952108e-07
that O 0 1.0739936939785366e-08
the O 0 3.25324478467337e-08
C5D B-Disease 1 0.9999998807907104
state O 0 4.3631398938259736e-08
is O 0 3.2082354550766468e-09
compatible O 0 2.0431729197412096e-08
with O 0 1.6826303683714627e-09
normal O 0 1.433814418305701e-07
coagulation O 0 1.8653155109404906e-07
function O 0 1.2590028575232282e-07
and O 0 1.3289146671979779e-08
the O 0 3.8852396855304505e-09
capacity O 0 7.356607767405876e-09
to O 0 5.789983159587564e-09
mount O 0 2.2818171885319316e-07
a O 0 1.21814127851394e-06
neutrophilic O 0 0.0036895580124109983
leukocytosis O 0 0.0009594186558388174
during O 0 1.929828840729897e-06
pyogenic B-Disease 0 0.014438160695135593
infection I-Disease 0 0.001221675775013864
. O 0 6.13886399492003e-08
. O 0 2.2346588934851752e-07

Susceptibility O 1 0.5697116255760193
to O 0 0.001093670609407127
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.00013343973841983825
twins O 0 3.904893674189225e-05
: O 0 1.3182258840060967e-08
the O 0 5.856689022643025e-10
role O 0 5.0772137605292755e-09
of O 0 1.1739171856817165e-09
genes O 0 7.348729980094504e-08
, O 0 3.2856906528877516e-08
HLA O 0 1.1566765351744834e-05
, O 0 1.078121147912725e-08
and O 0 1.1703541247243265e-08
the O 0 1.8571675752809824e-08
environment O 0 6.19459854078741e-07
. O 0 2.0599802041942894e-07

OBJECTIVE O 0 1.7129497791756876e-05
To O 0 1.5249810303430422e-07
determine O 0 2.025892875678892e-08
the O 0 1.9713257692899333e-09
relative O 0 1.2344698596677972e-08
effects O 0 7.965780213226026e-08
of O 0 1.0988374654630206e-09
genetic O 0 6.0712511640304e-07
and O 0 6.024733778531299e-08
environmental O 0 3.8145731906524816e-08
factors O 0 4.6548143117775e-09
in O 0 1.5882955395341014e-08
susceptibility O 0 0.00020988188043702394
to O 0 0.05107342451810837
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 6.788227619836107e-05
AS B-Disease 1 0.9999375343322754
) O 0 4.207932136068848e-07
. O 0 4.2895106844298425e-07

METHODS O 0 2.0667072021751665e-05
Twins O 0 7.292593363672495e-05
with O 0 1.6446762174382457e-07
AS B-Disease 1 0.9998836517333984
were O 0 1.8581958727281744e-07
identified O 0 1.0537396377685582e-07
from O 0 1.2683777361743864e-09
the O 0 5.937540237255234e-09
Royal O 0 6.770172831238597e-07
National O 0 5.7735991987328816e-08
Hospital O 0 1.6799172044557054e-06
for O 0 7.61956613359871e-08
Rheumatic B-Disease 0 0.44117236137390137
Diseases I-Disease 0 0.00017275330901611596
database O 0 3.905386620317586e-06
. O 0 9.779384981811745e-07

Clinical O 0 0.00018813130736816674
and O 0 4.777606932293565e-07
radiographic O 0 2.9805329177179374e-05
examinations O 0 1.5781363345013233e-06
were O 0 1.0206827028014231e-07
performed O 0 8.748197899421939e-08
to O 0 6.119455164821375e-09
establish O 0 1.1854339732053631e-07
diagnoses O 0 0.0013154898770153522
, O 0 8.611797852609016e-08
and O 0 2.1041673790023196e-06
disease O 0 0.0007893324946053326
severity O 0 7.265868589456659e-06
was O 0 6.106603223088314e-07
assessed O 0 6.822699560871115e-08
using O 0 9.402373990496926e-09
a O 0 1.1729330395837678e-08
combination O 0 1.8674300861221127e-07
of O 0 2.924292585859689e-09
validated O 0 4.978017500434362e-07
scoring O 0 1.1590296367103292e-07
systems O 0 3.3304236239928287e-06
. O 0 5.004826562071685e-07

HLA O 0 0.0019274115329608321
typing O 0 3.903375181835145e-05
for O 0 9.949658874575107e-08
HLA O 0 8.043801062740386e-05
- O 0 1.382124173687771e-05
B27 O 0 1.17605679861299e-06
, O 0 1.9234732917539077e-08
HLA O 0 2.1689245386369294e-06
- O 0 5.773554221377708e-07
B60 O 0 3.151445753246662e-07
, O 0 1.1569044389148075e-08
and O 0 1.9444842180860178e-08
HLA O 0 7.725484465481713e-05
- O 0 9.241698717232794e-05
DR1 O 0 0.099474236369133
was O 0 6.10693575708865e-07
performed O 0 1.451792019935283e-08
by O 0 3.7761013760295725e-10
polymerase O 0 8.279515384401748e-08
chain O 0 8.803113473732083e-07
reaction O 0 7.503993870727754e-09
with O 0 5.659718804729152e-10
sequence O 0 1.0413873319237155e-08
- O 0 2.852573572909023e-07
specific O 0 6.997347146153743e-09
primers O 0 1.176220507659309e-06
, O 0 5.236334033043022e-09
and O 0 1.1022385670855783e-08
zygosity O 0 8.38214054965647e-06
was O 0 1.91010400385494e-07
assessed O 0 3.955226191010297e-08
using O 0 5.635778421719806e-08
microsatellite O 0 9.234339813701808e-06
markers O 0 1.5418392649735324e-05
. O 0 5.391581794356171e-07

Genetic O 0 0.0002503533032722771
and O 0 4.970398777004448e-07
environmental O 0 8.594813039053406e-08
variance O 0 7.064549123469988e-08
components O 0 1.1437639386713272e-06
were O 0 8.77184049841162e-08
assessed O 0 6.946658004380879e-08
with O 0 3.333276765715709e-09
the O 0 2.468988036241626e-08
program O 0 5.118755908029016e-08
Mx O 0 1.3344013893856754e-07
, O 0 7.280264169295947e-10
using O 0 1.8353690789396637e-09
data O 0 2.9870258799746807e-07
from O 0 1.083540257518223e-09
this O 0 1.4792878033631496e-09
and O 0 1.6843683781075924e-08
previous O 0 5.7493569016742185e-08
studies O 0 2.2941699651113368e-09
of O 0 6.430879717633786e-10
twins O 0 2.456076799717266e-07
with O 0 3.725405761656475e-08
AS B-Disease 1 0.9999678134918213
. O 0 1.7712688986648573e-06

RESULTS O 0 3.72105096175801e-05
Six O 0 9.513517795767257e-08
of O 0 1.109312375291438e-08
8 O 0 5.336549975254457e-07
monozygotic O 0 3.7709953630837845e-06
( O 0 4.2197069660687703e-07
MZ O 0 0.03101356141269207
) O 0 1.1829742163627088e-07
twin O 0 5.1564811656135134e-06
pairs O 0 1.4545785234076902e-06
were O 0 1.0438790241096285e-06
disease O 0 1.794353374862112e-05
concordant O 0 1.6243851632680162e-06
, O 0 1.5066646597006184e-08
compared O 0 1.1900119112340235e-08
with O 0 3.7057570900778103e-10
4 O 0 1.5127895380828704e-08
of O 0 8.460151468270283e-10
15 O 0 1.7299351284805198e-08
B27 O 0 3.7311838241294026e-07
- O 0 3.8845923882036e-06
positive O 0 1.9484164681671245e-07
dizygotic O 0 4.263515336333512e-07
( O 0 2.65312536384954e-08
DZ O 0 0.0006612412980757654
) O 0 3.942144388702218e-08
twin O 0 1.4257167322284658e-06
pairs O 0 1.3116527952661272e-07
( O 0 1.0909899650357602e-08
27 O 0 7.488755215945275e-08
% O 0 1.2045372477231808e-09
) O 0 3.9416214736576194e-10
and O 0 1.635059754256929e-09
4 O 0 7.607538599074815e-09
of O 0 1.0583068865699374e-09
32 O 0 1.577638215621846e-07
DZ O 0 0.00020747754024341702
twin O 0 2.9071902645227965e-06
pairs O 0 8.988151734001804e-08
overall O 0 8.487804166179558e-07
( O 0 4.4870569482213796e-09
12 O 0 6.742348901411788e-09
. O 0 1.1626641871487209e-09
5 O 0 9.38325772636972e-09
% O 0 2.710555113694113e-09
) O 0 6.558283693891553e-09
. O 0 7.966828974304008e-08

Nonsignificant O 0 0.0003701010427903384
increases O 0 3.6449598610488465e-06
in O 0 1.7098983562391368e-08
similarity O 0 3.021641603595526e-08
with O 0 1.482199585289834e-09
regard O 0 1.7731631274386928e-08
to O 0 5.877162223555388e-08
age O 0 7.257589373921292e-08
at O 0 8.071660317909846e-07
disease O 0 1.9514305677148513e-05
onset O 0 6.149271030153614e-07
and O 0 1.1538985766890164e-08
all O 0 8.221722191947833e-10
of O 0 1.781603531370024e-09
the O 0 3.4469002230252954e-07
disease O 0 0.00015111424727365375
severity O 0 1.3707533526030602e-06
scores O 0 4.163437381521362e-07
assessed O 0 6.759024699931615e-07
were O 0 2.278637190045174e-08
noted O 0 6.810206087948245e-08
in O 0 5.862428409386666e-08
disease O 0 8.094455552054569e-05
- O 0 0.0003451208758633584
concordant O 0 0.013559553772211075
MZ O 1 0.6893678307533264
twins O 0 9.478988431510516e-06
compared O 0 2.2962380796798243e-07
with O 0 3.459964403873528e-08
concordant O 0 0.0003697977226693183
DZ O 1 0.607184648513794
twins O 0 8.313526632264256e-05
. O 0 1.5036870308904327e-06

HLA O 0 0.03349744528532028
- O 0 0.00023354653967544436
B27 O 0 4.177411028649658e-06
and O 0 8.051826938526574e-08
B60 O 0 1.3186689784561167e-07
were O 0 5.017048554378789e-09
associated O 0 1.6286076931493199e-09
with O 0 4.6408410447895676e-10
the O 0 7.437127180764946e-08
disease O 0 1.9025488654733635e-05
in O 0 1.2219485867603908e-08
probands O 0 3.1295719963964075e-05
, O 0 1.7207012703579494e-08
and O 0 1.6327661445103558e-09
the O 0 2.110120966847262e-09
rate O 0 2.2380564246304857e-07
of O 0 3.5224152483692706e-09
disease O 0 2.7086189220426604e-06
concordance O 0 7.436914017944218e-08
was O 0 2.640998388869775e-07
significantly O 0 1.1696984358877671e-07
increased O 0 1.5386158125352267e-08
among O 0 6.59780496903295e-09
DZ O 0 0.00037406847695820034
twin O 0 5.397197583079105e-06
pairs O 0 8.927157324478685e-08
in O 0 5.450100371007238e-09
which O 0 1.2259874004882931e-08
the O 0 1.2506591318128812e-08
co O 0 0.00012808704923372716
- O 0 0.00021907118207309395
twin O 0 3.1506358936894685e-05
was O 0 6.46485318611667e-07
positive O 0 1.960833495573411e-09
for O 0 3.0924335314708173e-10
both O 0 4.031434741591511e-09
B27 O 0 6.890467716402782e-07
and O 0 2.9157320113881724e-07
DR1 O 0 0.0029316882137209177
. O 0 7.18464605142799e-07

Additive O 0 2.9029792131041177e-05
genetic O 0 8.588256605435163e-05
effects O 0 1.2852932741225231e-05
were O 0 1.0722951770958389e-07
estimated O 0 5.060336505380292e-08
to O 0 8.09731837136951e-09
contribute O 0 6.997653567708539e-09
97 O 0 6.3687144447044375e-09
% O 0 8.830956521599376e-10
of O 0 1.407083338733628e-10
the O 0 4.947638743146854e-09
population O 0 9.906102604873013e-09
variance O 0 1.5567263744742377e-07
. O 0 2.44920016712058e-07

CONCLUSION O 0 4.7553244257869665e-06
Susceptibility O 0 3.196104444214143e-05
to O 0 1.1050487955799326e-06
AS B-Disease 1 0.985421359539032
is O 0 6.287380216463134e-08
largely O 0 4.356412475203797e-08
genetically O 0 8.882129804987926e-07
determined O 0 5.463357410917524e-07
, O 0 5.865366858870402e-09
and O 0 8.533114659314833e-09
the O 0 6.871776481176539e-09
environmental O 0 6.699433185985981e-08
trigger O 0 4.5629391820511955e-07
for O 0 6.534085716936033e-09
the O 0 1.491396233177511e-07
disease O 0 2.4294886316056363e-05
is O 0 1.804676408312389e-08
probably O 0 1.0765249669475452e-07
ubiquitous O 0 2.8574031603056937e-06
. O 0 3.419551148908795e-07

HLA O 0 0.0728292390704155
- O 0 0.0002345668472116813
B27 O 0 3.349755388626363e-06
accounts O 0 2.1249330472983274e-07
for O 0 1.4438271689343196e-09
a O 0 2.9870355078287503e-09
minority O 0 1.5341848680350267e-08
of O 0 4.108672013725112e-10
the O 0 3.1423803559249563e-09
overall O 0 2.8663553166552447e-06
genetic O 0 4.073814125149511e-06
susceptibility O 0 4.570544206217164e-06
to O 0 3.740115062100813e-07
AS B-Disease 1 0.9996824264526367
. O 0 1.3723201846005395e-06

Cell O 0 0.0006103735649958253
cycle O 0 6.562784255947918e-05
- O 0 0.0001010112973744981
dependent O 0 3.1255306112143444e-06
colocalization O 0 5.050297659181524e-06
of O 0 7.419158620791677e-09
BARD1 O 0 1.861498094513081e-05
and O 0 4.880784132410554e-08
BRCA1 O 0 8.257686090473726e-07
proteins O 0 1.7538562602226193e-08
in O 0 2.7309077221815414e-09
discrete O 0 7.187332471403352e-07
nuclear O 0 2.8540742277982645e-05
domains O 0 3.2293803542415844e-06
. O 0 4.0867811890166195e-07

Germ O 0 0.003674742765724659
- O 0 0.00031244478304870427
line O 0 2.485386903572362e-05
mutations O 0 5.870663812856947e-07
of O 0 5.351579179802002e-10
the O 0 4.658971430870906e-09
BRCA1 O 0 5.031597538618371e-06
gene O 0 5.910757749916229e-07
predispose O 0 7.596419209221494e-07
women O 0 1.5761367322397746e-08
to O 0 5.500384148149351e-09
early O 0 3.3798215781644103e-07
- O 1 0.9147777557373047
onset O 1 0.8716018199920654
breast B-Disease 1 0.9999932050704956
and I-Disease 1 0.999581515789032
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
by O 0 7.112312960799727e-09
compromising O 0 1.9125716335111065e-06
the O 0 1.4907740819580795e-08
genes O 0 4.004503182386543e-07
presumptive O 0 2.987755578942597e-05
function O 0 9.766376507513996e-08
as O 0 2.419502287409614e-08
a O 0 4.666404436193261e-07
tumor B-Disease 0 0.00014875874330755323
suppressor O 0 0.00010735661635408178
. O 0 1.6296747844535275e-06

Although O 0 3.540864099704777e-07
the O 0 1.7222708592612435e-08
biochemical O 0 1.861452290086163e-07
properties O 0 4.2405878275530995e-07
of O 0 7.6011854588387e-09
BRCA1 O 0 4.3144151277374476e-05
polypeptides O 0 7.176331564551219e-06
are O 0 3.153525796051326e-08
not O 0 2.0346174522956062e-08
understood O 0 1.3083067074148858e-08
, O 0 1.216552747429489e-09
their O 0 3.3594582671270246e-09
expression O 0 4.961410127179988e-08
pattern O 0 9.082258429771173e-07
and O 0 1.8116740108098384e-08
subcellular O 0 2.4705955183890183e-06
localization O 0 9.319413720731973e-07
suggest O 0 1.588595566204276e-08
a O 0 8.948599194980034e-09
role O 0 1.5688454979567723e-08
in O 0 6.618854353490633e-09
cell O 0 4.011361670563929e-05
- O 0 8.318029722431675e-05
cycle O 0 7.141846435843036e-05
regulation O 0 1.0806872978719184e-06
. O 0 4.470367400699615e-07

When O 0 2.1747030132246437e-06
resting O 0 4.006511062470963e-06
cells O 0 6.96810161571193e-07
are O 0 6.0463158924051186e-09
induced O 0 3.0201559297893255e-07
to O 0 1.8987158512118185e-08
proliferate O 0 1.723005652820575e-06
, O 0 3.387641500651739e-09
the O 0 1.5130197095203357e-09
steady O 0 8.485756666232191e-07
- O 0 3.2638794777994917e-07
state O 0 4.14149914362838e-09
levels O 0 2.4955757460531913e-09
of O 0 2.587977887547055e-10
BRCA1 O 0 3.6757796806341503e-07
increase O 0 8.912725668608346e-09
in O 0 3.0272244710971563e-09
late O 0 1.7425631426704058e-07
G1 O 0 7.287873813766055e-06
and O 0 7.678591096293985e-09
reach O 0 2.9387128286373354e-09
a O 0 2.843271840191619e-09
maximum O 0 6.5046030783832975e-09
during O 0 3.8959790060744126e-08
S O 0 4.3379186536185443e-05
phase O 0 5.356997121452878e-07
. O 0 2.3115389069516823e-07

Moreover O 0 1.1652303328446578e-05
, O 0 9.264219613669411e-08
in O 0 1.9233485915037818e-08
S O 0 0.0001375951833324507
phase O 0 4.974182843398012e-07
cells O 0 1.150550133388606e-06
, O 0 8.528688866249468e-09
BRCA1 O 0 1.390415377500176e-06
polypeptides O 0 2.8589411726898106e-07
are O 0 6.38289421317495e-09
hyperphosphorylated O 0 1.0560529517533723e-06
and O 0 2.5937723080460273e-08
accumulate O 0 1.7787802164548339e-07
into O 0 7.354727937780581e-09
discrete O 0 8.102510946628172e-07
subnuclear O 0 5.519754995475523e-05
foci O 0 3.045697303605266e-05
termed O 0 7.14557290848461e-06
" O 0 9.494643791185808e-07
BRCA1 O 0 2.440595744701568e-05
nuclear O 0 9.630096428736579e-06
dots O 0 9.407822653884068e-05
. O 0 1.2121801091780071e-06

" O 0 4.584799171425402e-05
BRCA1 O 0 0.0006519280141219497
associates O 0 0.0006540037575177848
in O 0 7.519570743852455e-08
vivo O 0 3.941828981623985e-05
with O 0 5.101034261656423e-09
a O 0 1.7178361133574072e-07
structurally O 0 4.2501302232267335e-05
related O 0 4.987730903849297e-07
protein O 0 2.5385838853253517e-06
termed O 0 1.0824513992702123e-05
BARD1 O 0 0.0006102196639403701
. O 0 1.0100155805048416e-06

Here O 0 2.6658985916583333e-06
we O 0 9.157877656207347e-08
show O 0 2.467942650241639e-08
that O 0 7.45583983441378e-10
the O 0 1.1301861668755464e-09
steady O 0 2.437809598632157e-07
- O 0 4.100566286524554e-07
state O 0 7.104109744915377e-09
levels O 0 3.532116377158445e-09
of O 0 5.674267722355353e-10
BARD1 O 0 3.688295009851572e-06
, O 0 2.547224653426383e-09
unlike O 0 1.1711798197922008e-09
those O 0 3.0613359069953106e-10
of O 0 1.1936598376394159e-09
BRCA1 O 0 1.8328815713175572e-05
, O 0 2.1064465727249626e-08
remain O 0 1.9073583601425526e-08
relatively O 0 5.513051348771114e-09
constant O 0 3.00468805392029e-08
during O 0 7.695499704141184e-08
cell O 0 4.8565594624960795e-05
cycle O 0 7.589122105855495e-05
progression O 0 7.723973976681009e-05
. O 0 1.190105876958114e-06

However O 0 4.929856459057191e-06
, O 0 2.2082072348439397e-07
immunostaining O 0 1.3386370483203791e-05
revealed O 0 2.7813798624265473e-06
that O 0 1.1915495257142084e-08
BARD1 O 0 6.316007784334943e-06
resides O 0 1.3866053905076114e-07
within O 0 1.7132542495801317e-08
BRCA1 O 0 8.317259926116094e-06
nuclear O 0 4.5150131882110145e-06
dots O 0 2.2524276573676616e-05
during O 0 5.995336209707602e-07
S O 0 3.906603524228558e-05
phase O 0 3.318048413802899e-08
of O 0 6.289761489419732e-10
the O 0 5.493234311870765e-09
cell O 0 1.4187304259394296e-05
cycle O 0 4.656780220102519e-06
, O 0 3.102568868484923e-08
but O 0 5.934279734276515e-09
not O 0 1.6168925087711727e-09
during O 0 1.3742400550853517e-09
the O 0 4.3072501121343976e-09
G1 O 0 1.208070716529619e-05
phase O 0 3.2916972259044996e-07
. O 0 1.412571037917587e-07

Nevertheless O 0 2.9510561944334768e-05
, O 0 1.56779762505721e-07
BARD1 O 0 1.2619215340237133e-05
polypeptides O 0 9.540317478240468e-07
are O 0 5.993464391451653e-09
found O 0 4.004214293473751e-09
exclusively O 0 3.077354593372661e-09
in O 0 1.2648939673454151e-09
the O 0 1.6517542889005199e-09
nuclear O 0 8.229088166444853e-08
fractions O 0 4.687404686620766e-09
of O 0 1.3365392126374331e-10
both O 0 1.9986723387432903e-09
G1 O 0 7.3209071160817984e-06
- O 0 2.0617856080207275e-06
and O 0 3.985062448919052e-07
S O 0 6.819929694756866e-05
- O 0 1.5751412547615473e-06
phase O 0 2.777595113911957e-07
cells O 0 1.6476431028422667e-06
. O 0 1.7742668489972857e-07

Therefore O 0 4.6877303248038515e-06
, O 0 1.0998280686180806e-07
progression O 0 1.9837434592773207e-06
to O 0 1.4154271354982484e-07
S O 0 0.0007067055557854474
phase O 0 3.7185412793405703e-07
is O 0 8.527061723384577e-09
accompanied O 0 8.744990509512718e-09
by O 0 6.087507720131669e-10
the O 0 2.8037541177639014e-09
aggregation O 0 3.438852047565888e-08
of O 0 2.4665200992757264e-09
nuclear O 0 1.4386866951099364e-06
BARD1 O 0 1.0347748684580438e-05
polypeptides O 0 4.4649439701061056e-07
into O 0 7.260607048920065e-08
BRCA1 O 0 3.9701386413071305e-05
nuclear O 0 6.376536020979984e-06
dots O 0 5.0367143558105454e-05
. O 0 1.3016829143452924e-06

This O 0 2.610170213301899e-07
cell O 0 8.17944783193525e-06
cycle O 0 5.070344286650652e-06
- O 0 2.042764208454173e-05
dependent O 0 1.2127432000852423e-06
colocalization O 0 2.2479291601484874e-06
of O 0 3.9206216051468346e-09
BARD1 O 0 1.3440863767755218e-05
and O 0 7.770886156777124e-08
BRCA1 O 0 2.9794432521157432e-06
indicates O 0 2.2661893694930768e-08
a O 0 3.012593952078646e-09
role O 0 5.543143721808974e-09
for O 0 4.6227062178161304e-09
BARD1 O 0 1.4349104276334401e-05
in O 0 6.801404595080385e-08
BRCA1 O 0 0.0003392587532289326
- O 0 0.0031774488743394613
mediated O 0 0.05631003528833389
tumor B-Disease 0 0.007252357434481382
suppression O 0 3.5683842725120485e-06
. O 0 4.026895510378381e-07

Ethnic O 0 1.0960269719362259e-05
differences O 0 5.040117230237229e-06
in O 0 3.905502410361805e-08
the O 0 3.9302296528376246e-08
HFE O 0 0.00011884665582329035
codon O 0 1.4673444638901856e-05
282 O 0 2.6969860300596338e-06
( O 0 3.96995744722517e-07
Cys O 0 0.010769113898277283
/ O 0 0.0003228567074984312
Tyr O 0 7.945449033286422e-05
) O 0 1.6777352129793144e-07
polymorphism O 0 5.225519544183044e-06
. O 0 8.457745366285963e-07

Recent O 0 8.495817382936366e-06
studies O 0 8.409431870859407e-07
have O 0 1.2023221529489092e-07
shown O 0 8.646382525512308e-07
that O 0 4.969296423951164e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.0470367856323719
HH B-Disease 1 0.9956804513931274
) O 0 2.7816881242870295e-07
is O 0 6.102381888695163e-08
likely O 0 1.4794726155287208e-07
to O 0 4.4759470796407186e-08
be O 0 1.3964096012841765e-07
caused O 0 3.452205987741763e-08
by O 0 1.6187563511849135e-09
homozygosity O 0 8.650877703075821e-07
for O 0 2.3721378195062925e-09
a O 0 2.370302887300113e-08
Cys282Tyr O 0 3.0175754091033014e-06
mutation O 0 1.348566058823053e-07
in O 0 2.360025286307632e-09
the O 0 5.596622720815958e-09
HFE O 0 2.415145718259737e-05
gene O 0 9.219426146955811e-07
located O 0 2.986444940233923e-07
4 O 0 3.2680156891728984e-07
. O 0 3.371850141320465e-07

5 O 0 5.446171599032823e-06
Mb O 0 9.96172966551967e-05
telomeric O 0 9.510778909316286e-05
to O 0 6.571032145075151e-07
HLA O 0 0.00018465687753632665
- O 0 1.3354685506783426e-05
A O 0 3.0867820441926597e-06
. O 0 5.970306347080623e-07

Population O 0 2.408611862847465e-06
studies O 0 8.065060796980106e-08
of O 0 1.2631412582564394e-09
this O 0 2.607083438022073e-09
polymorphism O 0 2.564537737725914e-07
are O 0 2.4836948053774677e-09
facilitated O 0 5.665016544753598e-08
by O 0 5.8632423360904795e-09
the O 0 5.026645766292859e-09
fact O 0 6.1018328167961045e-09
that O 0 1.418009043518964e-09
the O 0 3.378904045447939e-09
Cys282Tyr O 0 5.534511274163378e-06
mutation O 0 2.3434394336163678e-07
creates O 0 2.667179721527191e-08
a O 0 2.3672125593066085e-08
Rsal O 0 3.38871791427664e-06
restriction O 0 1.1866985261121954e-07
site O 0 9.645488034948357e-07
. O 0 2.865328099233011e-07

We O 0 3.292094106654986e-06
have O 0 1.4167959250244166e-08
studied O 0 2.4081625582539345e-08
the O 0 1.7203337421278775e-08
codon O 0 2.2591129891225137e-06
282 O 0 1.4403574368770933e-06
( O 0 1.4909909396010335e-07
Cys O 0 0.0030296635814011097
/ O 0 0.00023406461696140468
Tyr O 0 1.263501417270163e-05
) O 0 9.134393685883424e-09
polymorphism O 0 4.899550631876082e-08
in O 0 1.1193564963818403e-09
different O 0 4.235396033891448e-09
ethnic O 0 7.641528299018319e-08
groups O 0 4.4993399228587805e-08
. O 0 1.9140317419896746e-07

In O 0 5.60851844966237e-07
agreement O 0 5.387789414612598e-08
with O 0 4.16004075631804e-09
previous O 0 1.362696480100567e-07
observations O 0 1.5780234718931752e-07
the O 0 9.737355810557347e-09
Tyr O 0 1.2590464848472038e-06
allele O 0 4.7016533244459424e-07
appeared O 0 2.0621520491204137e-07
to O 0 4.6758503735588874e-09
be O 0 3.992926878026992e-09
rare O 0 8.319355870867184e-09
or O 0 1.0444371412177134e-07
absent O 0 2.655682749264088e-07
in O 0 5.740105724072464e-09
Asiatic O 0 3.4926702596749237e-07
( O 0 2.027867429532648e-09
Indian O 0 1.0784928505813696e-09
, O 0 5.873335151562742e-10
Chinese O 0 6.729061197141561e-10
) O 0 4.594813862723868e-09
populations O 0 4.0561875636058176e-08
. O 0 1.6044826622874098e-07

The O 0 2.8613658287213184e-07
highest O 0 2.129129939021368e-07
allele O 0 1.206520778396225e-06
frequency O 0 8.417005687988421e-07
( O 0 9.141539969448331e-09
7 O 0 3.009436966294743e-08
. O 0 1.2588482478648189e-09
5 O 0 8.078559154967024e-09
% O 0 2.9376254762070175e-09
) O 0 2.7079507525229474e-09
was O 0 1.6728718321701308e-07
found O 0 1.865838150649779e-08
in O 0 1.1863924953559035e-08
Swedes O 0 1.2614209481398575e-05
. O 0 2.634016027514008e-07

Saamis O 0 0.00024315518385265023
( O 0 2.300692045764663e-07
2 O 0 5.466094066264304e-08
% O 0 6.904214089331617e-09
) O 0 1.5375616335688846e-09
and O 0 1.3931050091287034e-08
Mordvinians O 0 1.9336534933245275e-06
( O 0 1.934768345535076e-09
1 O 0 3.0653746208031407e-09
. O 0 1.891695022848694e-09
8 O 0 3.270715254188872e-08
% O 0 2.5190856067780487e-09
) O 0 2.188920156243057e-09
had O 0 1.5060908253872185e-07
significantly O 0 3.160897108500649e-07
lower O 0 1.459285670080135e-07
frequencies O 0 8.688284935942647e-08
of O 0 4.547323850800922e-09
the O 0 4.714746637546341e-08
Tyr O 0 3.109823592239991e-05
allele O 0 3.907781774614705e-06
. O 0 1.6508376177171158e-07

Comparisons O 0 3.665855274448404e-06
with O 0 7.158738668522346e-08
allele O 0 1.5602653320456739e-06
frequencies O 0 7.544351774413371e-07
based O 0 1.5806833175702195e-07
on O 0 5.76259651552391e-07
prevalence O 0 1.6129793948493898e-05
estimates O 0 8.051056283875369e-06
of O 0 6.631923810118678e-08
HH B-Disease 1 0.815828800201416
showed O 0 1.3414549357548822e-05
some O 0 3.920793911760256e-09
disagreements O 0 9.21369789352866e-08
with O 0 1.5051044854885731e-09
the O 0 1.3782122110228556e-08
RFLP O 0 1.4060986359254457e-05
data O 0 1.0722865226853173e-06
, O 0 1.7525577655774782e-09
particularly O 0 1.2176345487446838e-09
in O 0 4.3797383497690134e-09
Finns O 0 1.0567719073151238e-05
. O 0 3.5602189996097877e-07

The O 0 8.634549999442243e-07
newly O 0 2.0465133729885565e-06
described O 0 1.4983988876338117e-06
HFE O 0 2.8779342756024562e-05
marker O 0 1.2659418189286953e-06
provides O 0 9.485286334154353e-09
a O 0 5.48184608817337e-09
new O 0 7.238701194012265e-09
approach O 0 3.051702179845961e-08
to O 0 3.3259861531576007e-09
the O 0 2.7887141484939093e-09
screening O 0 4.7434660643830284e-08
of O 0 3.8767118404337e-09
HH B-Disease 0 0.00012065792543580756
as O 0 6.274501629377482e-08
well O 0 1.0325502231012251e-08
as O 0 1.0508951042709214e-08
studies O 0 6.319366141482874e-10
of O 0 1.419967754490159e-10
the O 0 4.190286340133298e-09
relationship O 0 3.96222574750027e-08
between O 0 1.0027386920796744e-08
the O 0 5.985926776475026e-08
HFE O 0 8.682790212333202e-05
Tyr O 0 8.7426342361141e-06
allele O 0 1.4090016975387698e-06
and O 0 4.8866432678096317e-08
different O 0 5.53033672190395e-08
disorders O 0 0.0011425496777519584
including O 0 6.393070748345053e-07
cancer B-Disease 0 0.0006266165291890502

Autosomal B-Disease 1 0.999983549118042
dominant I-Disease 1 0.9980006814002991
neurohypophyseal I-Disease 1 0.999975323677063
diabetes I-Disease 1 0.9999990463256836
insipidus I-Disease 1 0.9090611338615417
associated O 0 1.1999810567431268e-06
with O 0 8.663277206721887e-09
a O 0 8.73780905408239e-08
missense O 0 2.158350071113091e-05
mutation O 0 1.0877110980800353e-06
encoding O 0 7.9875195524437e-07
Gly23 O 0 6.012632366036996e-05
- O 0 0.0001148422306869179
- O 0 0.0010837751906365156
> O 0 2.1756782189186197e-06
Val O 0 0.00018436025129631162
in O 0 2.277447350707007e-07
neurophysin O 0 7.67413730500266e-05
II O 0 1.7631253285799176e-05
. O 0 3.6707564277094207e-07

Autosomal B-Disease 1 0.9999496936798096
dominant I-Disease 1 0.9768622517585754
neurohypophyseal I-Disease 1 0.9999692440032959
diabetes I-Disease 1 0.9999991655349731
insipidus I-Disease 1 0.9996433258056641
( O 0 7.885486411396414e-06
ADNDI B-Disease 0 0.002364112064242363
) O 0 2.5098648848143057e-07
is O 0 1.3555444411395e-07
an O 0 2.42134938162053e-05
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 2.877687438740395e-05
by O 0 9.913232901226365e-08
progressive O 0 0.0001005265221465379
degeneration O 0 0.0035028939601033926
of O 0 2.9728770556403106e-09
the O 0 3.043192720042498e-08
magnocellular O 0 5.55351834918838e-06
neurons O 0 3.923761596524855e-06
of O 0 2.1264963123712732e-09
the O 0 1.957874395941417e-08
hypothalamus O 0 2.28735643759137e-06
leading O 0 5.066348762738926e-07
to O 0 3.5133314923996295e-08
decreased O 0 5.339874178389437e-07
ability O 0 1.871376653639345e-08
to O 0 7.296435455828032e-09
produce O 0 9.858156602149393e-08
the O 0 1.1464380378356509e-07
hormone O 0 1.295204128837213e-06
arginine O 0 1.2469455441532773e-06
vasopressin O 0 1.1254691116846516e-06
( O 0 2.8015852748808356e-08
AVP O 0 7.074620953062549e-06
) O 0 5.00346182263911e-08
. O 0 1.074401865253094e-07

Affected O 0 1.8419812477077357e-05
individuals O 0 5.1987495197636235e-08
are O 0 3.932656866822981e-09
not O 0 1.3136803644897554e-08
symptomatic O 0 6.090580200179829e-07
at O 0 4.31506407494453e-07
birth O 0 1.454615812690463e-06
, O 0 2.280494015849399e-08
but O 0 1.3108419238960778e-08
usually O 0 1.2600119703165547e-07
develop O 0 1.2221359611430671e-05
diabetes B-Disease 0 0.02152824215590954
insipidus I-Disease 0 7.680317503400147e-05
at O 0 4.928112957713893e-07
1 O 0 8.567101872358762e-07
- O 0 9.493871039012447e-05
6 O 0 4.774951776198577e-06
yr O 0 7.676487439312041e-05
of O 0 1.9405792528459642e-08
age O 0 1.4428374583985715e-07
. O 0 1.6146350390044972e-07

The O 0 4.965036168869119e-07
genetic O 0 1.2784504406226915e-06
locus O 0 1.1246772828599205e-06
of O 0 8.367079473714512e-09
the O 0 1.649559919769672e-07
disease O 0 3.965892756241374e-05
is O 0 8.663855410873111e-09
the O 0 1.8902388987385166e-08
AVP O 0 0.0014018821530044079
- O 0 0.0007029936532489955
neurophysin O 0 0.0001946068659890443
II O 0 1.7588057744433172e-05
( O 0 1.3867397896660805e-08
NPII O 0 2.533572569518583e-06
) O 0 1.2484133726786695e-09
gene O 0 2.2236378072193475e-08
, O 0 1.8782666533212478e-09
and O 0 2.040730961994086e-08
mutations O 0 1.1473977110654232e-06
that O 0 4.009841703123129e-08
cause O 0 3.8955337799961853e-07
ADNDI B-Disease 0 0.0013353346148505807
have O 0 2.718427083436836e-07
been O 0 5.886046849923332e-08
found O 0 1.9213318935840107e-08
in O 0 8.652819571963732e-10
both O 0 1.005444172363923e-09
the O 0 1.1144269951302022e-09
signal O 0 5.980916739645181e-08
peptide O 0 3.2444438247125618e-09
of O 0 1.0994070931413802e-10
the O 0 2.3373978308427468e-09
prepro O 0 6.25838220003061e-06
- O 0 6.818875590397511e-06
AVP O 0 2.917717029049527e-05
- O 0 2.9822490432707127e-06
NPII O 0 4.774164153786842e-06
precursor O 0 1.3173014679068729e-07
and O 0 2.92229085374629e-09
within O 0 5.304317873822129e-09
NPII O 0 1.864336991275195e-05
itself O 0 1.8824836161002168e-06
. O 0 1.2733262622077746e-07

An O 0 1.1759558447010932e-06
affected O 0 1.8009528730544844e-06
girl O 0 3.7267222069203854e-05
who O 0 4.675549689636682e-07
presented O 0 9.031042935703226e-08
at O 0 1.4542536064254818e-07
9 O 0 3.3051256309590826e-07
months O 0 4.275820231214311e-08
of O 0 5.693152616004227e-10
age O 0 1.3011844046673104e-08
and O 0 2.0642785258928598e-08
her O 0 4.203560592941358e-07
similarly O 0 2.8069456448065466e-07
affected O 0 4.707531076064697e-08
younger O 0 6.228000870578398e-08
brother O 0 4.959840111951053e-07
and O 0 1.5881569481734914e-07
father O 0 6.221565627129166e-07
were O 0 2.0104531373021928e-08
all O 0 7.567130255736743e-10
found O 0 1.5313871060129713e-08
to O 0 9.621490271172206e-09
have O 0 1.9418631147516408e-09
a O 0 8.514905225354141e-09
novel O 0 1.299007550414899e-07
missense O 0 8.929155228543095e-06
mutation O 0 5.348794047677075e-07
( O 0 6.06988770357475e-09
G1758 O 0 3.742377430171473e-07
- O 0 2.823601425916422e-05
- O 0 0.00036449081380851567
> O 0 1.2707826044788817e-06
T O 0 1.599060487933457e-05
) O 0 9.585034987935614e-10
encoding O 0 2.515177621731368e-09
the O 0 3.539674942043547e-10
amino O 0 6.086698256524414e-09
acid O 0 1.1342768502231593e-08
substitution O 0 6.876851088577496e-09
Gly23 O 0 5.902882662667253e-07
- O 0 2.9741770504188025e-06
- O 0 4.6117231249809265e-05
> O 0 1.1128513506264426e-06
Val O 0 4.615911893779412e-05
within O 0 2.4682586285962316e-07
NPII O 0 0.0002125107275787741
. O 0 9.504165632279182e-07

The O 0 1.028799374580558e-06
mutation O 0 1.5228319171001203e-05
was O 0 2.6640002488420578e-06
confirmed O 0 3.3291806289525994e-07
by O 0 4.854358692796268e-09
restriction O 0 5.6577384555112076e-08
endonuclease O 0 4.255100975569803e-06
analysis O 0 5.650006187352119e-07
. O 0 4.378483424716251e-07

A O 0 4.797559995495249e-06
T1 O 0 0.0012782076373696327
- O 0 1.9012775737792253e-05
weighted O 0 1.5741350125608733e-06
magnetic O 0 7.994705697456084e-07
resonance O 0 7.188552899606293e-07
imaging O 0 5.550972491619177e-05
of O 0 5.752151199800437e-09
the O 0 7.484114661338026e-08
fathers O 0 6.481165655713994e-06
pituitary O 0 7.414931314997375e-05
gland O 0 2.5960744096664712e-05
demonstrates O 0 2.0521486021607416e-07
an O 0 2.1445622166993417e-08
attenuated O 0 0.00010609255696181208
posterior O 0 0.0006813256186433136
pituitary O 0 0.0012923397589474916
bright O 0 8.558448826079257e-06
spot O 0 8.11546269687824e-05
. O 0 1.3646020988744567e-06

This O 0 1.8845695137770235e-07
mutation O 0 4.2893657337117475e-06
may O 0 7.540079423051793e-07
be O 0 1.8214231234381373e-09
valuable O 0 2.5266981840132985e-09
for O 0 6.157503951165211e-10
developing O 0 5.384571011290973e-09
models O 0 9.059768757424536e-08
of O 0 5.4163376006499675e-09
dominantly B-Disease 0 0.0004139989032410085
inherited I-Disease 1 0.7055172920227051
neurodegeneration I-Disease 1 1.0
, O 0 2.2914296948783885e-07
as O 0 1.949310934890036e-09
the O 0 7.759015652197832e-10
early O 0 3.0726816646620136e-08
age O 0 3.1586049331622235e-09
of O 0 6.952470266163857e-10
onset O 0 5.014754833609913e-07
of O 0 2.116240338523312e-08
symptoms O 0 6.3315374063677154e-06
suggests O 0 7.588670136726705e-09
that O 0 1.9364074788086327e-09
this O 0 4.056332603141755e-09
mutation O 0 7.012112632764911e-07
may O 0 5.848992259416264e-07
be O 0 9.60231361091246e-09
particularly O 0 9.096872588543192e-09
deleterious O 0 1.2171379921710468e-06
to O 0 3.438392681687219e-08
the O 0 2.9724024130928228e-08
magnocellular O 0 2.2433578124037012e-05
neuron O 0 2.565991599112749e-05
. O 0 4.8871651614490474e-08
. O 0 1.6147335202276736e-07

Frequent O 0 0.00015342934057116508
inactivation O 0 0.0005759202176705003
of O 0 1.342145736771272e-07
PTEN O 0 0.002069934969767928
/ O 0 0.0009736421634443104
MMAC1 O 0 0.0005363794043660164
in O 0 3.793803216467495e-06
primary O 0 0.3107549548149109
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 2.6408904432173586e-06

Sporadic B-Disease 1 0.9822664856910706
prostate I-Disease 1 0.9999995231628418
carcinoma I-Disease 1 1.0
is O 0 1.52538382280909e-06
the O 0 2.5344693010964647e-09
most O 0 4.4726506942538435e-09
common O 0 2.6801069807902422e-08
male B-Disease 0 4.620125935161923e-07
cancer I-Disease 0 7.193298188212793e-07
in O 0 8.501123693882562e-10
the O 0 1.986135478304618e-09
Western O 0 1.4129172143384494e-07
world O 0 5.200599844101816e-07
, O 0 7.608394803071405e-09
yet O 0 9.139547452186036e-10
many O 0 3.558403571801705e-11
of O 0 3.7937576691238206e-11
the O 0 1.5789793916809458e-09
major O 0 1.1059406723745724e-08
genetic O 0 1.5184330948159186e-07
events O 0 8.380848015576703e-09
involved O 0 5.395725644063987e-09
in O 0 2.1556747498152617e-09
the O 0 7.817472891247235e-09
progression O 0 1.2762138794641942e-06
of O 0 2.3851316477419005e-09
this O 0 3.582666963097836e-08
often O 0 3.379967893124558e-06
fatal O 1 0.551884114742279
cancer B-Disease 0 0.00021742934768553823
remain O 0 1.516839631676703e-07
to O 0 3.097147427411073e-08
be O 0 7.553322944886531e-08
elucidated O 0 1.620213151909411e-05
. O 0 4.4556921352523204e-07

Numerous O 0 2.7354765279596904e-06
cytogenetic O 0 0.0008949204348027706
and O 0 4.131531113671372e-06
allelotype O 0 0.00014639973232988268
studies O 0 2.789450093132473e-07
have O 0 1.5851759371798835e-07
reported O 0 7.978605026437435e-06
frequent O 0 6.761061968063586e-07
loss O 0 2.038196498688194e-06
of O 0 1.0433356401051697e-08
heterozygosity O 0 2.6873462047660723e-05
on O 0 2.3569626137032174e-05
chromosomal O 1 0.6157217025756836
arm O 0 0.004062945954501629
10q O 0 2.9614649974973872e-05
in O 0 1.1654333320620935e-06
sporadic B-Disease 1 0.8841067552566528
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 4.11349355999846e-06

Deletion O 0 0.0003583424841053784
mapping O 0 6.120255420682952e-05
studies O 0 1.9931494534830563e-06
have O 0 1.9337886669745785e-07
unambiguously O 0 1.828721178753767e-05
identified O 0 6.588476253455156e-07
a O 0 2.877392546452029e-08
region O 0 5.218360570324876e-07
of O 0 6.953561726419366e-09
chromosome O 0 2.507405588403344e-05
10q23 O 0 7.139552167245711e-07
to O 0 8.100781911934973e-08
be O 0 7.928292689030059e-09
the O 0 2.9421451941402665e-09
minimal O 0 3.1150864998608085e-08
area O 0 1.4953283766772074e-07
of O 0 2.3020170658583083e-08
loss O 0 4.530506885203067e-06
. O 0 6.781364731978101e-07

A O 0 1.2783115153069957e-06
new O 0 3.0111425530776614e-07
tumor B-Disease 0 1.6108611816889606e-05
suppressor O 0 6.959402071515797e-06
gene O 0 3.021146085302462e-06
, O 0 6.180665934607532e-08
PTEN O 0 0.0005387460696510971
/ O 0 0.005419700872153044
MMAC1 O 0 0.0011814506724476814
, O 0 2.7563186222323566e-07
was O 0 3.014935430201149e-07
isolated O 0 2.4053400693446747e-07
recently O 0 4.1657287397356413e-07
at O 0 3.965817185758169e-08
this O 0 3.471299026003294e-09
region O 0 9.802581502071916e-08
of O 0 3.6072813625054323e-09
chromosome O 0 1.7529670003568754e-05
10q23 O 0 2.8824717901443364e-07
and O 0 3.521180858001571e-08
found O 0 1.6390634627327927e-08
to O 0 3.1380500420397084e-09
be O 0 5.0348210045569886e-09
inactivated O 0 1.2665074322626424e-08
by O 0 3.6155728411202404e-10
mutation O 0 2.3035894969325454e-08
in O 0 2.4111683316618837e-08
three O 0 0.00040679716039448977
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
cell O 0 0.00013054069131612778
lines O 0 9.814656368689612e-05
. O 0 7.774872301524738e-07

We O 0 3.8256339394138195e-06
screened O 0 1.8873744920711033e-05
80 O 0 1.0477804607944563e-05
prostate B-Disease 1 0.9320841431617737
tumors I-Disease 1 0.9999998807907104
by O 0 2.490479644734478e-08
microsatellite O 0 3.079331463595736e-06
analysis O 0 4.264641688678239e-07
and O 0 6.29829060017073e-08
found O 0 2.2618348793912446e-07
chromosome O 0 2.6195761165581644e-05
10q23 O 0 8.501584147779795e-07
to O 0 7.629338938386354e-08
be O 0 1.5968645072916843e-08
deleted O 0 1.1094541605416453e-06
in O 0 2.2375413522013332e-08
23 O 0 1.7247567996037105e-07
cases O 0 3.333557785367702e-08
. O 0 1.2807089433408692e-07

We O 0 2.11130327443243e-06
then O 0 2.592357795094813e-08
proceeded O 0 1.7064122559418138e-08
with O 0 5.693326365907581e-10
sequence O 0 4.6917967289061835e-09
analysis O 0 1.989441500427347e-09
of O 0 2.560340828239305e-10
the O 0 4.853979440611056e-09
entire O 0 4.5020743755230797e-07
PTEN O 0 0.0003146571689285338
/ O 0 1.9127184714307077e-05
MMAC1 O 0 1.4631384146923665e-05
coding O 0 9.439990208193194e-06
region O 0 1.0757014479167992e-06
and O 0 7.388334921643036e-08
tested O 0 6.180606959560464e-08
for O 0 7.555476799758765e-10
homozygous O 0 4.9814843805506825e-08
deletion O 0 8.952000030149065e-08
with O 0 1.3241344687386913e-09
new O 0 4.812590148617346e-08
intragenic O 0 4.68309190182481e-06
markers O 0 9.758832675288431e-07
in O 0 4.8439074973316565e-09
these O 0 3.860670005906286e-09
23 O 0 2.683211697274146e-08
cases O 0 8.149342312080421e-10
with O 0 1.8153363257056299e-09
10q23 O 0 1.9148365026921965e-06
loss O 0 5.648336127705988e-07
of O 0 2.5842220807703598e-08
heterozygosity O 0 4.0348189941141754e-05
. O 0 1.0386062285761e-06

The O 0 1.0040518816367694e-07
identification O 0 5.940432146189778e-08
of O 0 2.0827546354240667e-09
the O 0 3.582050212003196e-09
second O 0 1.8066054963128408e-07
mutational O 0 1.0596212405289407e-06
event O 0 3.8538519930853e-08
in O 0 5.197249741684118e-09
10 O 0 4.628714300736192e-09
( O 0 1.3737001536284765e-09
43 O 0 2.160137491102887e-08
% O 0 1.527454784877591e-08
) O 0 8.052001589931024e-07
tumors B-Disease 1 1.0
establishes O 0 2.9952927434351295e-05
PTEN O 0 0.0009808933828026056
/ O 0 6.890984514029697e-05
MMAC1 O 0 2.0295814465498552e-05
as O 0 9.775094511610405e-09
a O 0 6.259939677732973e-09
main O 0 2.9944760626676725e-07
inactivation O 0 3.725548367583542e-06
target O 0 1.4146120008717844e-07
of O 0 2.7796438484273267e-09
10q O 0 9.746062232807162e-07
loss O 0 1.6646549738652539e-06
in O 0 2.459498773532687e-07
sporadic B-Disease 1 0.6323787569999695
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.396378420144174e-07
. O 0 3.6096855637879344e-07

Risk O 0 0.00022465035726781934
reversals O 0 3.322290285723284e-05
in O 0 5.397395952400075e-08
predictive O 0 6.217690497578587e-06
testing O 0 2.9791760880470974e-06
for O 0 5.283995960780885e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999997615814209
. O 0 1.11398117041972e-06

The O 0 1.981894968139386e-07
first O 0 8.453690725218621e-08
predictive O 0 9.443189696867194e-07
testing O 0 2.78411363296982e-07
for O 0 4.067897407367127e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 6.799341463192832e-07
HD B-Disease 0 0.2517012059688568
) O 0 1.2721949360638973e-07
was O 0 8.81087373727496e-07
based O 0 3.5132782016944475e-08
on O 0 3.182044565619435e-07
analysis O 0 2.3077452837583223e-08
of O 0 7.052600170531775e-10
linked O 0 3.1282741019822424e-06
polymorphic O 0 1.5942587197059765e-06
DNA O 0 3.173012828483479e-06
markers O 0 8.722004167793784e-07
to O 0 7.939599555584209e-08
estimate O 0 1.451329126211931e-06
the O 0 1.0766703084641449e-08
likelihood O 0 5.234959132849326e-08
of O 0 1.665954374452383e-09
inheriting O 0 8.978690289040969e-07
the O 0 2.863267667407854e-08
mutation O 0 3.56320128958032e-07
for O 0 4.061358538365312e-08
HD B-Disease 0 0.0006869353237561882
. O 0 8.793899723968934e-07

Limits O 0 1.2520955579020665e-06
to O 0 9.758592511843744e-08
accuracy O 0 3.385673892353225e-07
included O 0 5.019527460348172e-09
recombination O 0 2.8047931976971086e-08
between O 0 3.937671078091398e-09
the O 0 3.4680565086375736e-09
DNA O 0 3.2546293482482724e-07
markers O 0 5.334901516107493e-07
and O 0 9.730765526683172e-09
the O 0 2.862032388861735e-09
mutation O 0 1.7883051839362452e-07
, O 0 4.0109102705798705e-09
pedigree O 0 8.765601933191647e-08
structure O 0 2.516432004995295e-07
, O 0 2.073314497863521e-08
and O 0 8.231596737573454e-09
whether O 0 1.7522571171824097e-09
DNA O 0 5.84401860237449e-08
samples O 0 2.2842463920369482e-08
were O 0 2.656653341759352e-09
available O 0 2.525532227792837e-09
from O 0 1.0684214624134825e-09
family O 0 1.874463073647803e-08
members O 0 2.781055918887887e-08
. O 0 6.335121582878855e-08

With O 0 6.804310714869644e-08
direct O 0 1.0974036968036671e-07
tests O 0 1.832292007009073e-08
for O 0 1.556707096561638e-09
the O 0 5.880792297574544e-09
HD B-Disease 0 0.00024247798137366772
mutation O 0 2.8685434472208726e-07
, O 0 6.107514494146926e-09
we O 0 9.837209269392133e-09
have O 0 2.3967421380888254e-09
assessed O 0 1.983478981060216e-08
the O 0 2.74711342562739e-09
accuracy O 0 1.2567588782985695e-06
of O 0 9.845900983407319e-09
results O 0 5.119757133797975e-07
obtained O 0 1.3323409042698131e-08
by O 0 9.202554274168051e-10
linkage O 0 1.1119926313085671e-07
approaches O 0 1.2255061676569312e-07
when O 0 1.474935640288777e-08
requested O 0 6.758468451550925e-09
to O 0 1.0528552252253576e-08
do O 0 8.87210482858336e-09
so O 0 1.1545584488459326e-09
by O 0 1.72573164092249e-10
the O 0 1.9721984045872887e-09
test O 0 1.3749800409357249e-08
individuals O 0 2.918374875093832e-09
. O 0 4.794101826632868e-08

For O 0 1.259132602626778e-07
six O 0 6.065955204803686e-08
such O 0 2.227380502262122e-09
individuals O 0 2.7482662812161607e-09
, O 0 8.556959585348523e-09
there O 0 5.1785971066919956e-09
was O 0 1.9441974075107282e-07
significant O 0 9.346979190638649e-09
disparity O 0 1.9089851477360753e-08
between O 0 3.6424796512335433e-09
the O 0 2.5495102917716395e-08
tests O 0 8.632419934428981e-08
. O 0 1.1644883812778062e-07

Three O 0 1.5335842817876255e-06
went O 0 7.066084322104871e-07
from O 0 7.671564716815737e-09
a O 0 2.687944800072728e-08
decreased O 0 5.905202215217287e-06
risk O 0 6.152050247010266e-08
to O 0 4.67824090577551e-09
an O 0 6.420428633191477e-09
increased O 0 2.610892124721431e-07
risk O 0 4.2393182297928433e-07
, O 0 9.630707786811854e-09
while O 0 1.3275566423942564e-08
in O 0 1.2702637830486196e-09
another O 0 1.1707493641210931e-08
three O 0 1.283417816466681e-08
the O 0 6.669573338058399e-08
risk O 0 4.988368118574726e-07
was O 0 4.753075302232901e-07
decreased O 0 1.343533199360536e-06
. O 0 1.1638078234454952e-07

Knowledge O 0 5.428217377811961e-07
of O 0 1.05867083988187e-08
the O 0 3.2215294876181133e-09
potential O 0 1.3207980487095483e-08
reasons O 0 2.1279529249795814e-09
for O 0 5.821384485571457e-10
these O 0 2.622853045863849e-10
changes O 0 5.045029727313022e-09
in O 0 3.369740753100814e-08
results O 0 2.3647048692509998e-06
and O 0 9.835843428618318e-08
impact O 0 1.6580585793235514e-08
of O 0 1.0172552800113976e-09
these O 0 3.732153253110937e-09
risk O 0 8.312094479379084e-08
reversals O 0 2.354070289811716e-07
on O 0 7.695021508880018e-07
both O 0 1.428208236120554e-07
patients O 0 6.262724383532259e-08
and O 0 3.984930607714432e-09
the O 0 3.5454674751633775e-09
counseling O 0 4.947129372823156e-09
team O 0 6.052277568002751e-10
can O 0 5.12592190915484e-10
assist O 0 4.381139617759544e-10
in O 0 4.3051368026070236e-10
the O 0 3.025525663336026e-10
development O 0 1.0002777495188298e-09
of O 0 1.4599015052407793e-10
strategies O 0 1.209718281103278e-08
for O 0 1.020288520336976e-09
the O 0 6.110742134524116e-09
prevention O 0 9.490012331525577e-08
and O 0 5.613763320866383e-08
, O 0 3.733391817917209e-09
where O 0 3.902410394829303e-09
necessary O 0 4.166099021318814e-09
, O 0 4.083844373781176e-09
management O 0 2.8145789698896806e-08
of O 0 4.1121214766626224e-10
a O 0 1.778971920884942e-07
risk O 0 6.119212798694207e-07
reversal O 0 4.2780638409567473e-07
in O 0 2.5482158605427685e-09
any O 0 5.84040504847394e-09
predictive O 0 2.9365969567152206e-07
testing O 0 3.9276439878221936e-08
program O 0 1.5518164531158618e-08
. O 0 5.39476863181676e-09
. O 0 5.660728419343286e-08

A O 0 1.971270194189856e-06
novel O 0 4.5803088255524926e-07
common O 0 1.3736699600030988e-07
missense O 0 1.110579523810884e-05
mutation O 0 1.1582875458771014e-06
G301C O 0 4.328095997152559e-07
in O 0 9.509251164274701e-09
the O 0 7.51852091696037e-09
N O 0 1.9658298697322607e-05
- O 0 1.1442535651440267e-05
acetylgalactosamine O 0 6.368717731675133e-05
- O 0 6.435243903979426e-06
6 O 0 6.351975798679632e-07
- O 0 1.5127170627238229e-05
sulfate O 0 1.7404087202521623e-06
sulfatase O 0 1.4825247944827424e-06
gene O 0 1.769224837744332e-07
in O 0 1.1463391125232647e-08
mucopolysaccharidosis B-Disease 0 7.114887557690963e-05
IVA I-Disease 0 0.001410823198966682
. O 0 9.75560283222876e-07

Mucopolysaccharidosis B-Disease 0 0.4325125813484192
IVA I-Disease 1 0.9996263980865479
( O 0 0.0013721117284148932
MPS B-Disease 1 0.9999986886978149
IVA I-Disease 1 1.0
) O 0 3.903053027443093e-07
is O 0 7.664719525735109e-09
an O 0 6.713349876008579e-08
autosomal B-Disease 1 0.9998767375946045
recessive I-Disease 1 0.9999598264694214
lysosomal I-Disease 1 0.9999926090240479
storage I-Disease 1 0.9999929666519165
disorder I-Disease 1 0.9999047517776489
caused O 0 1.5831092241569422e-06
by O 0 5.886616527561728e-09
a O 0 5.064385732111987e-06
genetic B-Disease 1 1.0
defect I-Disease 1 0.999996542930603
in O 0 3.621166655420893e-08
N O 0 0.00036040754639543593
- O 0 5.9980113292112947e-05
acetylgalactosamine O 0 0.00020602387667167932
- O 0 3.989639299106784e-05
6 O 0 5.788291218777886e-06
- O 0 0.0004862553905695677
sulfate O 0 1.6159294318640605e-05
sulfatase O 0 1.38642253659782e-05
( O 0 1.3595210290873183e-08
GALNS O 0 5.416461590357358e-06
) O 0 4.5213372601438095e-08
. O 0 1.2828677142806555e-07

In O 0 1.05267247363372e-06
previous O 0 1.6200286836465239e-06
studies O 0 1.3466024029185064e-07
, O 0 2.278480870643307e-08
we O 0 2.4149333199829925e-08
have O 0 2.150680744605893e-09
found O 0 1.8064939544260028e-09
two O 0 1.0382213977422339e-09
common O 0 5.865523622361479e-09
mutations O 0 6.23605984628739e-08
in O 0 1.2674756799668785e-09
Caucasians O 0 3.6539981351779716e-07
and O 0 1.664824367253459e-08
Japanese O 0 3.3895950934947905e-08
, O 0 9.92198678773093e-09
respectively O 0 1.5601075631366257e-07
. O 0 1.676233551961559e-07

To O 0 1.7187288676723256e-06
characterize O 0 1.2666950169659685e-05
the O 0 5.229838961895439e-08
mutational O 0 4.340142368164379e-06
spectrum O 0 2.340370741649167e-07
in O 0 1.3032676049462566e-09
various O 0 4.4190062720161905e-10
ethnic O 0 8.993223943321027e-09
groups O 0 1.5827605892582142e-09
, O 0 3.0792570715476586e-09
mutations O 0 2.039108437656978e-08
in O 0 5.32031363409402e-10
the O 0 2.5763264854816725e-09
GALNS O 0 5.907601462240564e-06
gene O 0 2.2751332551251835e-07
in O 0 1.4762106204102565e-08
Colombian O 0 2.7980506274616346e-05
MPS B-Disease 1 0.9999964237213135
IVA I-Disease 1 1.0
patients O 0 2.6622945370036177e-05
were O 0 1.3338614657243397e-08
investigated O 0 1.6484258935633989e-07
, O 0 7.856186812205124e-09
and O 0 8.496864545293192e-09
genetic O 0 8.629621817135558e-08
backgrounds O 0 3.179581042900281e-08
were O 0 2.381087327307796e-08
extensively O 0 9.347338902898628e-08
analyzed O 0 5.23995424828172e-07
to O 0 1.2039337526914551e-08
identify O 0 8.25612858079694e-08
racial O 0 1.161618534695208e-08
origin O 0 1.4765879186029451e-08
, O 0 5.6092654965311795e-09
based O 0 1.6057310148198667e-08
on O 0 1.7276113339903532e-07
mitochondrial O 0 1.9734070519916713e-06
DNA O 0 2.2353789972839877e-05
( O 0 3.7205555969421766e-08
mtDNA O 0 3.04787505456261e-07
) O 0 3.438733742200384e-08
lineages O 0 1.0352143817726756e-06
. O 0 1.887497802499638e-07

Three O 0 1.3995068002259359e-06
novel O 0 2.815432935676654e-06
missense O 0 0.00013401648902799934
mutations O 0 0.0001399962930008769
never O 0 6.918427061464172e-06
identified O 0 2.4607024329270644e-07
previously O 0 1.302441177131186e-07
in O 0 2.084356243159391e-09
other O 0 2.9161881798245304e-09
populations O 0 1.8219452613266185e-08
and O 0 2.5743238651898537e-08
found O 0 4.0726998662421465e-08
in O 0 2.141152144474745e-09
16 O 0 6.711760036637315e-09
out O 0 2.826073153272546e-09
of O 0 8.808448415109638e-10
19 O 0 4.5254788005877344e-07
Colombian O 0 1.2580186194099952e-05
MPS B-Disease 1 0.9994421601295471
IVA I-Disease 1 0.9999827146530151
unrelated O 0 3.0522468819071946e-07
alleles O 0 9.509145826314125e-08
account O 0 9.057246330712587e-08
for O 0 1.744035316164627e-08
84 O 0 3.78770494080527e-07
. O 0 4.2173655856458936e-07

2 O 0 1.8396268615106237e-06
% O 0 3.126998038283091e-08
of O 0 8.951991925520986e-10
the O 0 3.1073821293858828e-09
alleles O 0 4.741973924637932e-08
in O 0 4.669219677566616e-09
this O 0 9.342755014074555e-09
study O 0 3.990614061422093e-08
. O 0 1.245204117594767e-07

The O 0 3.3077617445087526e-07
G301C O 0 2.393946488155052e-06
and O 0 7.783687294704578e-08
S162F O 0 9.710520316730253e-07
mutations O 0 1.8321159132028697e-06
account O 0 1.0343305945070824e-07
for O 0 2.2233832552842614e-08
68 O 0 1.0241943755318061e-06
. O 0 2.6552143594926747e-07

4 O 0 5.776854322903091e-06
% O 0 1.431680090036025e-07
and O 0 1.0528456328984248e-07
10 O 0 1.7927209228219e-07
. O 0 3.9769150816937326e-07

5 O 0 9.808319418880274e-07
% O 0 5.8034196115386294e-08
of O 0 3.86599019464029e-09
mutations O 0 1.0783966217786656e-06
, O 0 2.5604606435081223e-08
respectively O 0 3.264390215917956e-07
, O 0 2.806236798491568e-09
whereas O 0 3.188117769781229e-09
the O 0 2.405599497379285e-09
remaining O 0 1.7844823219093087e-07
F69V O 0 2.6118084861082025e-05
is O 0 9.061113637187646e-09
limited O 0 1.884571609878094e-09
to O 0 1.7208744429453304e-09
a O 0 6.646015293654273e-09
single O 0 8.474757464682625e-07
allele O 0 7.289424047485227e-06
. O 0 3.2001705108086753e-07

The O 0 2.0660922928072978e-06
skewed O 0 2.074156691378448e-05
prevalence O 0 8.651350071886554e-06
of O 0 1.207772371003557e-08
G301C O 0 2.890319308335165e-07
in O 0 9.041501769502247e-09
only O 0 3.284297722672136e-09
Colombian O 0 5.602210535471386e-07
patients O 0 1.2077796895937354e-07
and O 0 3.503680234828721e-09
haplotype O 0 1.6911918692130712e-06
analysis O 0 1.7801710328058107e-08
by O 0 1.0276652862017954e-09
restriction O 0 1.3942586640780519e-08
fragment O 0 6.363514444274188e-07
length O 0 3.722756787283288e-07
polymorphisms O 0 5.8710616031021345e-06
in O 0 7.964667148030458e-09
the O 0 1.2033436469494063e-08
GALNS O 0 2.143378515029326e-05
gene O 0 5.071013902124832e-07
suggest O 0 3.3439381041944216e-08
that O 0 1.2217755696042332e-09
G301C O 0 4.394610186864156e-08
originated O 0 8.083245184309362e-09
from O 0 1.2619347788955793e-09
a O 0 1.1448445746964353e-08
common O 0 1.0610708756075837e-07
ancestor O 0 1.890579710561724e-06
. O 0 5.673206828760158e-07

Investigation O 0 2.732900156843243e-06
of O 0 1.184362208306311e-08
the O 0 3.6179752527232267e-09
genetic O 0 1.9768549464060925e-07
background O 0 2.994829628732987e-08
by O 0 2.0614603357671513e-09
means O 0 8.030013987081475e-09
of O 0 3.447451490945497e-10
mtDNA O 0 8.631860026753202e-08
lineages O 0 1.2718287223378866e-07
indicate O 0 1.022863500566018e-07
that O 0 3.29302318746727e-09
all O 0 3.214691846054052e-09
our O 0 2.5623910460126353e-07
patients O 0 5.613025066963928e-08
are O 0 4.2634701324928415e-10
probably O 0 6.060910440197631e-09
of O 0 7.674224589138134e-10
native O 0 1.2419711481470586e-07
American O 0 9.336716288999014e-07
descent O 0 0.00012974004494026303

Low O 0 6.452106390497647e-06
frequency O 0 4.149466349190334e-06
of O 0 1.0515451265291631e-07
BRCA1 O 0 5.46035407751333e-05
germline O 0 7.336565613513812e-05
mutations O 0 8.004700248420704e-06
in O 0 1.98686773700274e-08
45 O 0 4.801853492608643e-07
German O 1 0.9951110482215881
breast B-Disease 1 0.9999995231628418
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
families O 0 1.049903289640497e-06
. O 0 3.584458454497508e-07

In O 0 3.1933717536958284e-07
this O 0 9.159027314353807e-09
study O 0 1.1800463717293042e-08
we O 0 1.587701881078374e-08
investigated O 0 2.9393262934718223e-07
45 O 0 1.507726210547844e-07
German O 0 0.24083173274993896
breast B-Disease 1 0.9999879598617554
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 4.04814137766607e-08
for O 0 1.09536228976026e-08
germline O 0 2.0315197616582736e-05
mutations O 0 4.2459237192815635e-06
in O 0 5.826097382310991e-09
the O 0 4.985647450439501e-08
BRCA1 O 0 0.0001600456889718771
gene O 0 1.7343912986689247e-05
. O 0 1.113603047997458e-06

We O 0 1.8096454823535169e-06
identified O 0 2.61810043866717e-07
four O 0 2.073796956381102e-08
germline O 0 3.788004278248991e-06
mutations O 0 1.3457771501634852e-06
in O 0 1.3526718412038008e-08
three O 0 2.012910726989503e-06
breast B-Disease 0 0.47047916054725647
cancer I-Disease 0 0.00011484659626148641
families O 0 3.8330671969788455e-09
and O 0 6.8550853882243246e-09
in O 0 3.305427753730328e-08
one O 0 0.0022408340591937304
breast B-Disease 1 0.9999996423721313
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 5.958940505479404e-07
. O 0 4.050464408322796e-09
among O 0 1.0005525297174245e-09
these O 0 3.096080891662467e-10
were O 0 3.6638778677655637e-09
one O 0 2.3825318606895962e-08
frameshift O 0 3.0847084417473525e-05
mutation O 0 2.0398832134560507e-07
, O 0 2.6093718297204305e-09
one O 0 1.4087147448549331e-08
nonsense O 0 1.0910803212027531e-06
mutation O 0 1.777230522748141e-07
, O 0 1.662329496276982e-09
one O 0 2.7762530052655165e-09
novel O 0 2.9306985283028553e-08
splice O 0 0.00011993684893241152
site O 0 1.1375567737559322e-05
mutation O 0 1.3932000229033292e-06
, O 0 2.5176349893740735e-09
and O 0 4.8912847105953006e-09
one O 0 8.62144489133243e-08
missense O 0 3.291464599897154e-05
mutation O 0 5.68650602872367e-06
. O 0 5.437264007923659e-07

The O 0 1.0898937716774526e-06
missense O 0 0.0002686759107746184
mutation O 0 5.525042797671631e-05
was O 0 3.360426489962265e-06
also O 0 8.443200982810595e-08
found O 0 3.5847175894332395e-08
in O 0 6.344708314287573e-09
2 O 0 7.923803195808432e-07
. O 0 3.03573187920847e-07

8 O 0 1.257473286386812e-06
% O 0 1.7460925150203366e-08
of O 0 1.1496668061994342e-09
the O 0 3.0976419207462413e-09
general O 0 8.343540969235619e-09
population O 0 4.618273319323407e-09
, O 0 5.788879153811877e-09
suggesting O 0 3.5130437225916467e-08
that O 0 3.958122718472623e-09
it O 0 4.7992251950290665e-08
is O 0 6.461377211053332e-08
not O 0 3.7909137517999625e-07
disease O 0 9.511677490081638e-06
associated O 0 1.4489044986021327e-07
. O 0 2.479455929460528e-07

The O 0 2.1054388810171076e-07
average O 0 4.1831211206044827e-07
age O 0 5.04776629384196e-08
of O 0 7.50234807611605e-09
disease O 0 2.8740232664858922e-05
onset O 0 8.29961720683059e-07
in O 0 1.3672599941116914e-08
those O 0 1.6818065162738094e-08
families O 0 2.2589908610370912e-08
harbouring O 0 1.0318540262233e-05
causative O 0 2.0693752958322875e-05
mutations O 0 6.672625750070438e-05
was O 0 2.87446397351232e-07
between O 0 2.7064393393061437e-08
32 O 0 7.338196041928313e-07
. O 0 2.243238270693837e-07

3 O 0 1.2803764548152685e-05
and O 0 5.847675765835447e-07
37 O 0 1.7516784964755061e-06
. O 0 3.4004358440142823e-07

4 O 0 1.3222697816672735e-05
years O 0 1.6656221646371705e-07
, O 0 6.055525858528199e-09
whereas O 0 9.68530677880608e-09
the O 0 4.84206008621868e-09
family O 0 1.3025456269133429e-07
harbouring O 0 6.699204277538229e-06
the O 0 1.401230242947804e-08
missense O 0 6.351894171530148e-06
mutation O 0 9.582664688423392e-07
had O 0 1.2484490241604362e-07
an O 0 2.5390367586197726e-09
average O 0 7.119291467461153e-08
age O 0 9.557546754024315e-09
of O 0 2.2325610249396277e-09
onset O 0 6.961180361031438e-07
of O 0 2.1000602146159508e-08
51 O 0 2.7255082386545837e-06
. O 0 4.463560117073939e-07

2 O 0 1.2864789823652245e-05
years O 0 1.5907837678241776e-06
. O 0 6.826917342550587e-07

These O 0 7.697319119870372e-07
findings O 0 8.420136623499275e-07
show O 0 6.870900506328326e-07
that O 0 1.187069376129557e-08
BRCA1 O 0 1.0532355190662201e-05
is O 0 4.609299608659967e-08
implicated O 0 3.824824261755566e-07
in O 0 1.1161075397225773e-09
a O 0 2.440063706643514e-09
small O 0 5.059320518085997e-09
fraction O 0 1.2719013398054813e-07
of O 0 7.950310987325793e-07
breast B-Disease 1 0.9999995231628418
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.033551803672708e-08
suggesting O 0 9.710355186598463e-08
the O 0 6.154782461464947e-09
involvement O 0 4.515631957247024e-08
of O 0 2.0826036450927177e-09
another O 0 1.7214389913533523e-07
susceptibility O 0 9.967007827071939e-06
gene O 0 3.8080779631854966e-06
( O 0 3.295390911262075e-07
s O 0 0.0005407175049185753
) O 0 1.979483840841567e-06

Paternal O 0 0.0605262890458107
transmission O 1 0.6058791875839233
of O 0 0.0001511502923676744
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.00024837948149070144

We O 0 8.623665962659288e-06
report O 0 1.8234615595247305e-07
a O 0 6.124312612598715e-09
rare O 0 9.154625502105773e-09
case O 0 3.55542368879469e-08
of O 0 5.87437156696069e-08
paternally O 1 0.995116114616394
transmitted O 1 0.9999995231628418
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.6199690699577332
DM B-Disease 1 1.0
) O 0 4.530022579274373e-06
. O 0 8.400806450481468e-07

The O 0 3.002551238751039e-07
proband O 0 1.9346502085682005e-05
is O 0 1.0573671715974342e-08
a O 0 1.07002096072506e-08
23 O 0 4.653786689345907e-08
year O 0 1.8181717464926805e-08
old O 0 5.2874388529744465e-06
, O 0 2.9500211894628592e-05
mentally B-Disease 1 1.0
retarded I-Disease 1 0.9999998807907104
male O 0 0.00013113341992720962
who O 0 0.0001265289611183107
suffers O 1 0.9828041791915894
severe O 0 0.0004850161203648895
muscular B-Disease 0 0.006514711305499077
weakness I-Disease 0 0.0017326748929917812
. O 0 7.854270052121137e-07

He O 0 3.924876637029229e-06
presented O 0 3.7388312534858414e-07
with O 0 2.745167080320243e-07
respiratory O 0 0.20477072894573212
and O 0 1.0984462051055743e-06
feeding O 0 1.2490147128119133e-05
difficulties O 0 7.187359756244405e-07
at O 0 3.127156844584533e-07
birth O 0 2.5861800168058835e-06
. O 0 4.379181177682767e-07

His O 0 5.860047622263664e-06
two O 0 5.565717856370611e-06
sibs O 1 0.8578488826751709
suffer O 0 0.00403538579121232
from O 0 4.796854682354024e-07
childhood O 0 9.947357466444373e-05
onset O 0 0.04542528837919235
DM B-Disease 1 0.9999998807907104
. O 0 2.3642116502742283e-05

Their O 0 2.8130980354035273e-06
late O 0 4.971203452441841e-06
father O 0 8.400069191338844e-07
had O 0 4.9334030194359e-08
the O 0 7.117750833174341e-10
adult O 0 1.1404508448720208e-08
type O 0 5.3310458270061645e-08
of O 0 6.78906602047391e-08
DM B-Disease 1 1.0
, O 0 1.1328719295988776e-07
with O 0 7.92242627056794e-09
onset O 0 5.525654387383838e-07
around O 0 3.010366711464485e-08
30 O 0 8.346362534439322e-08
years O 0 5.506853284487079e-08
. O 0 1.3037808344051882e-07

Only O 0 2.4713395418984874e-07
six O 0 4.167523925957539e-08
other O 0 1.3058130132748147e-09
cases O 0 2.2233566099316704e-09
of O 0 1.5565201350042912e-09
paternal O 0 1.6757659977884032e-05
transmission O 0 0.32426926493644714
of O 0 7.871949492255226e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.0002634319243952632
been O 0 3.1679514904681128e-06
reported O 0 1.8319782611797564e-05
recently O 0 2.1374132757046027e-06
. O 0 2.709078898988082e-07

We O 0 2.35338848142419e-06
review O 0 5.040329398298127e-08
the O 0 4.381802032327187e-09
sex O 0 4.01038455777325e-08
related O 0 3.826173511356501e-08
effects O 0 5.417434749688255e-07
on O 0 4.093270490557188e-06
transmission O 0 0.10803065448999405
of O 0 2.4766844944679178e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 3.372538412804715e-05

Decreased O 0 0.0004922659136354923
fertility O 0 1.1142713447043207e-05
of O 0 1.3057688263984346e-08
males O 0 2.9283405922342354e-08
with O 0 6.388424012016003e-09
adult O 0 9.970801329473034e-06
onset O 0 0.0004933716845698655
DM B-Disease 1 1.0
and O 0 2.0038244201714406e-06
contraction O 0 4.200745479465695e-06
of O 0 7.405455137998729e-10
the O 0 7.243341482165988e-09
repeat O 0 1.1133948873975896e-06
upon O 0 8.570697040966024e-09
male O 0 5.930379032292876e-08
transmission O 0 1.011317749544105e-06
contribute O 0 1.3118249597710019e-08
to O 0 8.201522128103989e-09
the O 0 2.643965046900121e-09
almost O 0 4.1968068131836844e-08
absent O 0 1.262877447061328e-07
occurrence O 0 8.296714781863557e-08
of O 0 3.817817617601804e-09
paternal O 0 1.6016794688766822e-05
transmission O 0 0.03150487691164017
of O 0 3.077947621932253e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 4.861772686126642e-05

Also O 0 2.310995341758826e-06
the O 0 3.0963438035769286e-08
fathers O 0 9.477567175508739e-08
of O 0 1.9496007030994633e-09
the O 0 4.5462076769808846e-08
reported O 0 0.0002579274878371507
congenitally O 0 0.002094492083415389
affected O 0 1.5127138794923667e-06
children O 0 1.799514279809955e-07
showed O 0 6.749485805812583e-07
, O 0 1.9438899379053964e-09
on O 0 9.590035432438526e-08
average O 0 9.335152384437606e-08
, O 0 1.7844033806113657e-08
shorter O 0 2.6592281301418552e-06
CTG O 0 2.3182657969300635e-05
repeat O 0 3.1567508358421037e-06
lengths O 0 4.021187578473473e-06
and O 0 5.597063790219181e-08
hence O 0 5.4545544969641924e-08
less O 0 2.0139310663580545e-07
severe O 0 6.457437393692089e-06
clinical O 0 2.170323341488256e-06
symptoms O 0 4.5739716370007955e-06
than O 0 3.330493214548369e-09
the O 0 1.2190829679070703e-08
mothers O 0 2.3817466399123077e-07
of O 0 1.9798116479563532e-09
children O 0 3.5862979075318435e-07
with O 0 1.3937348740000743e-05
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
. O 0 2.385341031185817e-05

We O 0 7.547138920926955e-06
conclude O 0 9.099060775952239e-07
that O 0 1.2063817500518326e-08
paternal O 0 1.803240365916281e-06
transmission O 0 0.0020915381610393524
of O 0 1.6094456441351213e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 3.947000550397206e-06
rare O 0 9.620979568580879e-08
and O 0 1.4837731043826352e-08
preferentially O 0 1.6830331617256888e-07
occurs O 0 5.102026801040438e-09
with O 0 3.470028264729308e-09
onset O 0 1.0145525948246359e-06
of O 0 1.0391297422529533e-07
DM B-Disease 1 1.0
past O 0 1.95636475837091e-05
30 O 0 2.605733016025624e-07
years O 0 3.1413736056862263e-09
in O 0 1.3097991580224289e-09
the O 0 8.313248756053326e-09
father O 0 2.8497782977865427e-07
. O 0 1.7389732320793883e-08
. O 0 1.6091594545741827e-07

The O 0 1.3160799881006824e-06
RB1 O 0 0.00020951339683961123
gene O 0 7.495752470276784e-06
mutation O 0 3.0859607704769587e-06
in O 0 1.6736944274953203e-08
a O 0 1.7153476505882281e-07
child O 0 2.2229727619560435e-05
with O 0 1.0299891073373146e-05
ectopic B-Disease 1 0.9999973773956299
intracranial I-Disease 1 0.999858021736145
retinoblastoma I-Disease 1 0.957240879535675
. O 0 2.204567499575205e-05

The O 0 1.5695675301685696e-06
RB1 O 0 0.0002930706541519612
gene O 0 8.083237844402902e-06
mutation O 0 4.959526449965779e-06
was O 0 6.048844625183847e-07
investigated O 0 5.669816118825111e-07
in O 0 3.8629384135902e-09
a O 0 8.308655452538005e-08
child O 0 3.6036842629982857e-06
with O 0 1.2780297993231216e-06
ectopic B-Disease 1 0.9999891519546509
intracranial I-Disease 1 0.5416441559791565
retinoblastoma I-Disease 0 0.00011985989840468392
using O 0 2.9476856866494927e-07
DNA O 0 3.3700064250297146e-06
obtained O 0 8.575654675269107e-08
from O 0 5.811336745153994e-09
both O 0 4.759677540988605e-09
the O 0 3.648023039204418e-08
pineal B-Disease 0 0.0005415749619714916
and I-Disease 0 3.152063436573371e-05
retinal I-Disease 1 0.9919829964637756
tumours I-Disease 1 1.0
of O 0 2.344511784713177e-08
the O 0 1.1242403274991375e-07
patient O 0 4.10321308663697e-06
. O 0 2.791872191210132e-07

A O 0 4.61504896520637e-06
nonsense O 0 8.195375812647399e-06
mutation O 0 9.552444453220232e-07
in O 0 2.9443526727845892e-08
exon O 0 3.389516223251121e-06
17 O 0 3.71436982504747e-07
( O 0 8.664169826033685e-09
codon O 0 1.7451876033192093e-07
556 O 0 3.147852822849018e-08
) O 0 2.5725652719188474e-09
of O 0 4.59232346594618e-10
the O 0 1.6831512184012354e-08
RB1 O 0 1.636557499296032e-05
gene O 0 1.0941532764263684e-06
was O 0 2.106459078277112e-07
found O 0 1.2828451190216583e-08
to O 0 4.89830531691382e-09
be O 0 6.328126911370191e-09
present O 0 4.750046134205377e-09
homozygously O 0 7.062540703373088e-07
in O 0 1.941711236241872e-09
both O 0 2.2731361237759984e-09
the O 0 1.9689707642100984e-08
retinal B-Disease 0 0.00011323470971547067
and I-Disease 0 3.277135078860738e-07
the I-Disease 0 7.892497251305031e-07
pineal I-Disease 1 0.9019842743873596
tumours I-Disease 1 1.0
. O 0 2.3825218704587314e-06

The O 0 1.8943720192510227e-07
same O 0 4.870387115829544e-08
mutation O 0 3.216705692921096e-07
was O 0 1.321186573477462e-07
present O 0 5.879704723099621e-09
heterozygously O 0 6.485843186965212e-07
in O 0 1.7964538745474101e-09
the O 0 1.5018353227702619e-09
DNA O 0 3.797770773417142e-07
from O 0 3.947175919449819e-09
the O 0 2.4356092698241127e-09
constitutional O 0 2.8617375136263945e-09
cells O 0 1.663148552211169e-08
of O 0 1.6466951413551811e-10
the O 0 3.297021677894918e-08
patient O 0 1.1252844842601917e-06
, O 0 7.66160646037406e-09
proving O 0 6.201579338949159e-08
it O 0 1.4501092771013191e-08
to O 0 6.335191482520486e-09
be O 0 7.3560046942589e-09
of O 0 2.5545130455384424e-09
germline O 0 4.91326045448659e-06
origin O 0 3.2793363402561226e-07
. O 0 2.9283498292898e-07

The O 0 1.5574391909467522e-07
initial O 0 3.051015937671764e-07
mutation O 0 5.767665811617917e-07
was O 0 2.7405317837292387e-07
shown O 0 1.9821099428440903e-08
to O 0 8.178964172600445e-09
have O 0 6.415409536941752e-09
occurred O 0 2.856449121679816e-08
in O 0 3.3112188546624566e-09
the O 0 9.971846459677636e-09
paternally O 0 2.5291499241575366e-06
derived O 0 5.219196737016318e-07
RB1 O 0 4.984931001672521e-05
allele O 0 7.694178748351987e-06
. O 0 4.114217233563977e-07

The O 0 3.6433957006920537e-07
mutation O 0 1.1317548569422797e-06
is O 0 1.4703628536949509e-08
in O 0 2.7262758717228053e-09
an O 0 2.658412157074963e-09
area O 0 4.213047688494953e-08
of O 0 6.406858932272996e-10
the O 0 2.1159245466861876e-09
gene O 0 1.9710411081064194e-08
that O 0 5.781814471639279e-10
encodes O 0 8.662665251790713e-09
the O 0 1.514186109830007e-09
protein O 0 2.1864431687390606e-07
- O 0 2.517514985811431e-06
binding O 0 5.102798468215042e-07
region O 0 2.3357374345778226e-07
known O 0 3.859832276020825e-08
as O 0 7.220802178409258e-09
the O 0 1.5865001756765196e-08
pocket O 0 0.02137400396168232
region O 0 1.5861220163060352e-05
and O 0 9.150166420113237e-07
has O 0 3.9619618519282085e-07
been O 0 6.732173574164335e-08
detected O 0 2.471730908837344e-07
in O 0 4.1858505550607106e-10
other O 0 1.747637590199247e-09
cases O 0 1.1857674842019605e-09
of O 0 8.33254798493499e-10
retinoblastoma B-Disease 0 8.178573807526845e-06
. O 0 5.994861851377209e-08
. O 0 1.79465047267513e-07

Low O 0 5.757834969699616e-06
levels O 0 8.86803093180788e-08
of O 0 2.1896633395357412e-09
beta O 0 3.566835005130997e-08
hexosaminidase O 0 4.304698109081073e-07
A O 0 1.45398175277478e-07
in O 0 1.0785632831300518e-08
healthy O 0 1.3418181765700865e-07
individuals O 0 1.117151149365725e-09
with O 0 1.531760851491981e-08
apparent O 0 5.680196773028001e-05
deficiency O 0 3.807611938100308e-05
of O 0 1.0231668845506192e-09
this O 0 6.30070262630511e-09
enzyme O 0 1.7094521354010794e-06
. O 0 3.264421195581235e-07

Appreciable O 0 0.0001408019888913259
beta O 0 5.828067060065223e-06
hexosaminidase O 0 2.0480580133153126e-05
A O 0 1.0092605862155324e-06
( O 0 3.739023668458685e-08
hex O 0 6.8591821218433324e-06
A O 0 7.892655276009464e-07
) O 0 1.979219810266386e-08
activity O 0 3.926999880832227e-08
has O 0 3.769492096239446e-08
been O 0 1.5494030947138526e-08
detected O 0 1.2846183494730212e-07
in O 0 3.617188992777187e-09
cultured O 0 5.8061359595740214e-05
skin O 1 0.7361469268798828
fibroblasts O 0 2.915558434324339e-05
and O 0 3.1656741157348733e-06
melanoma B-Disease 1 0.9741089344024658
tissue O 0 5.667558070854284e-05
from O 0 5.806309388844966e-08
healthy O 0 4.1240423342969734e-07
individuals O 0 1.4822052474272596e-09
previously O 0 6.290330816227652e-07
reported O 0 1.6324282114510424e-05
as O 0 1.644318530225064e-07
having O 0 5.619116109301103e-06
deficiency B-Disease 0 9.438486813451163e-06
of I-Disease 0 1.3494552142390148e-09
hex I-Disease 0 1.0928435585810803e-05
A I-Disease 0 2.4858010760908655e-07
activity O 0 2.8854495681684966e-08
indistinguishable O 0 7.644749899782255e-08
from O 0 5.853115769838269e-10
that O 0 4.942788400796871e-10
of O 0 6.506200578293431e-10
patients O 0 1.883337006347574e-07
with O 0 1.6813980892038671e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9968948364257812
( O 0 1.3651367680722615e-07
TSD B-Disease 0 3.135391671094112e-05
) O 0 8.5745597289133e-08
. O 0 2.608497879919014e-07

Identification O 0 6.4978621594491415e-06
and O 0 6.54391612897598e-07
quantitation O 0 2.1094147086841986e-05
of O 0 2.520394204452714e-08
hex O 0 2.780892828013748e-05
A O 0 1.2321808071646956e-06
, O 0 1.8931036294134174e-08
amounting O 0 4.9370743937515726e-08
to O 0 1.5130551034303608e-08
3 O 0 2.3491274703246745e-07
. O 0 3.188971220424719e-07

5 O 0 2.683340198927908e-06
% O 0 4.805060029866581e-07
- O 0 1.7225051124114543e-05
6 O 0 2.4580690478614997e-06
. O 0 7.252274940583447e-07

9 O 0 2.591686097730417e-06
% O 0 2.8156742715168548e-08
of O 0 1.285421213914617e-09
total O 0 5.341679543136024e-09
beta O 0 3.35403704809778e-08
hexosaminidase O 0 1.1441851484050858e-06
activity O 0 9.370652520601652e-08
, O 0 1.1550920220315675e-08
has O 0 1.8229219023169208e-08
been O 0 4.556796717736233e-09
obtained O 0 6.51996856504411e-09
by O 0 2.1001471672832395e-09
cellulose O 0 3.21231855195947e-05
acetate O 0 4.2702640712377615e-06
gel O 0 9.731242244015448e-06
electrophoresis O 0 3.0072996537455765e-07
, O 0 4.579756129885482e-09
DEAE O 0 2.203866188210668e-06
- O 0 3.872324214171385e-06
cellulose O 0 1.338458514510421e-05
ion O 0 4.88858688640903e-07
- O 0 4.0739783457865997e-07
exchange O 0 1.692610425152452e-07
chromatography O 0 1.5670278230572876e-07
, O 0 5.697283089745042e-09
radial O 0 2.9825675937900087e-06
immunodiffusion O 0 6.755739377695136e-06
, O 0 1.530697879559284e-08
and O 0 3.0737663081481514e-08
radioimmunoassay O 0 1.8115526472683996e-05
. O 0 2.2678783295759786e-07

Previous O 0 9.81798984867055e-06
family O 0 1.1324921160849044e-06
studies O 0 9.340779882904826e-08
suggested O 0 1.2397983084611042e-07
that O 0 6.71109434691175e-09
these O 0 2.0985295723363606e-09
individuals O 0 1.6537340385980315e-09
may O 0 2.0209996876019432e-07
be O 0 7.430474013858657e-09
compound O 0 1.1580440428815564e-07
heterozygotes O 0 1.248652523599958e-07
for O 0 6.76713352021352e-10
the O 0 6.853382861216062e-10
common O 0 2.034695079089488e-08
mutant O 0 3.531155527980445e-07
TSD B-Disease 0 3.0066657927818596e-06
gene O 0 2.838248747139005e-07
and O 0 1.3666004328172221e-08
a O 0 6.351127979087323e-08
rare O 0 2.3571367080421624e-07
( O 0 2.9680400359666237e-08
allelic O 0 4.808053404303791e-07
) O 0 9.178438453716353e-09
mutant O 0 6.889633823448094e-07
gene O 0 2.6882121346716303e-06
. O 0 3.6091623201173206e-07

Thus O 0 8.631840842099336e-07
, O 0 1.4327449449069718e-08
the O 0 2.028045287261193e-09
postulated O 0 5.488220367055874e-08
rate O 0 5.25404466600321e-08
mutant O 0 3.9577923161004946e-08
gene O 0 1.216941427628626e-07
appears O 0 1.7349620407003385e-07
to O 0 4.343483794855274e-09
code O 0 2.3380801739136814e-09
for O 0 1.3902905493523576e-09
the O 0 1.4639035539332212e-09
expression O 0 7.676219659913386e-09
of O 0 3.070194654064551e-10
low O 0 3.839361895074944e-08
amounts O 0 9.457699512438467e-09
of O 0 3.173036278170116e-09
hex O 0 1.5341402104240842e-05
A O 0 2.2656115561403567e-06
. O 0 3.798868704052438e-07

Heterozygotes O 0 0.00015937168791424483
for O 0 1.3760063666268252e-07
the O 0 1.0220556845297324e-08
rare O 0 3.196058528942558e-08
mutant O 0 3.20971776091028e-06
may O 0 2.0994668830098817e-06
be O 0 1.0138582418051101e-08
indistinguishable O 0 2.859652852293948e-07
from O 0 5.866161334466824e-09
heterozygotes O 0 2.008974178124845e-07
for O 0 2.188644598888345e-09
the O 0 6.185923329127263e-09
common O 0 3.695963641803246e-07
TSD B-Disease 0 5.894797868677415e-05
mutant O 0 6.456217761297012e-06
. O 0 5.582573407991731e-07

However O 0 3.363734322192613e-07
, O 0 7.252189071493831e-09
direct O 0 2.013630862052196e-08
visualization O 0 1.7081076748581836e-06
and O 0 1.486348395474124e-07
quantitation O 0 3.4907329791167285e-06
of O 0 4.70558036980151e-09
hex O 0 7.624400950589916e-06
A O 0 1.4592480113151396e-07
by O 0 1.5653593976594493e-09
the O 0 3.961067918112349e-09
methods O 0 2.481111494034849e-07
described O 0 1.9460744624666404e-06
may O 0 1.1650382703010109e-07
prevent O 0 1.8630501585903403e-08
false O 0 2.0583698301379627e-07
- O 0 1.1668105798889883e-05
positive O 0 4.882861048827181e-07
prenatal O 0 2.7432530259829946e-05
diagnosis O 0 1.550833258079365e-05
of O 0 6.0210667562898834e-09
TSD B-Disease 0 7.055391324684024e-05
in O 0 3.350150450387446e-07
fetuses O 0 2.449742396493093e-06
having O 0 2.423728595601915e-08
the O 0 1.1072788019816926e-08
incomplete O 0 9.298498184762138e-07
hex B-Disease 0 0.00016839067393448204
A I-Disease 0 9.071083331946284e-05
deficiency I-Disease 0 5.037617665948346e-05
of O 0 3.2018029894054223e-10
the O 0 1.5594567415178062e-08
type O 0 6.437598472075479e-07
described O 0 1.3469301620716578e-06
in O 0 2.7680520098272154e-09
the O 0 4.4429939727308465e-09
four O 0 1.688215860440323e-07
healthy O 0 1.2624875580513617e-06
individuals O 0 1.50460778058914e-07

The O 0 3.090558266194421e-06
tumor B-Disease 0 0.00013754048268310726
suppressor O 0 3.786757224588655e-05
gene O 0 1.0328079952159896e-05
Smad4 O 0 0.00032884973916225135
/ O 0 0.0006808764301240444
Dpc4 O 0 2.503981340851169e-05
is O 0 1.9989020216826248e-08
required O 0 2.493491635391365e-09
for O 0 4.943299991566619e-09
gastrulation O 0 8.388606147491373e-07
and O 0 2.049484777444377e-07
later O 0 4.6335753722814843e-07
for O 0 7.84367060191471e-09
anterior O 0 2.482617219357053e-06
development O 0 1.4021820149423547e-08
of O 0 1.0288930818447284e-09
the O 0 9.838204029222197e-09
mouse O 0 1.0563235264271498e-05
embryo O 0 9.984398275264539e-06
. O 0 5.722814080399985e-07

Mutations O 0 0.00037536665331572294
in O 0 2.756358128408465e-07
the O 0 6.729914048264618e-08
SMAD4 O 0 0.004221463110297918
/ O 0 0.009675542823970318
DPC4 O 0 0.000585419125854969
tumor B-Disease 0 4.9437447160016745e-05
suppressor O 0 1.5652699403290171e-06
gene O 0 4.34749779287813e-07
, O 0 2.632813522751576e-09
a O 0 4.718972768102958e-09
key O 0 2.4396584308306046e-07
signal O 0 1.4700034398629214e-06
transducer O 0 2.429746359666751e-07
in O 0 3.1031355263166915e-09
most O 0 4.164439015852395e-09
TGFbeta O 0 7.509289389417972e-06
- O 0 1.0535127330513205e-05
related O 0 1.2480026612138317e-07
pathways O 0 1.0942184047735282e-07
, O 0 4.382111118417242e-09
are O 0 7.687174230497362e-10
involved O 0 1.4962056038569926e-09
in O 0 6.448775957679231e-10
50 O 0 1.457179443775658e-08
% O 0 1.1193486137983655e-08
of O 0 4.723774793546909e-08
pancreatic B-Disease 1 0.9460939168930054
cancers I-Disease 0 0.30283233523368835
. O 0 1.1253584943915484e-06

Homozygous O 0 0.0007489238632842898
Smad4 O 0 0.0003492275718599558
mutant O 0 0.0001762732135830447
mice O 0 0.016898950561881065
die O 0 0.01580914482474327
before O 0 1.7224292037099076e-07
day O 0 9.405193424072422e-08
7 O 0 2.99102225653769e-07
. O 0 1.9688398822381714e-07

5 O 0 4.417647232912714e-06
of O 0 1.5243615791860066e-07
embryogenesis O 0 3.0813658668193966e-05
. O 0 3.5741841202252544e-06

Mutant O 0 2.5501860363874584e-05
embryos O 0 1.1902786354767159e-05
have O 0 1.0926500237928849e-07
reduced O 0 8.693108100032987e-08
size O 0 1.5851850321269012e-07
, O 0 1.522002577303283e-07
fail O 0 9.754534175954177e-07
to O 0 4.946273435280091e-08
gastrulate O 0 1.1121586794615723e-05
or O 0 6.888642900548803e-08
express O 0 7.581859051697393e-08
a O 0 6.960966025815196e-09
mesodermal O 0 9.782677352632163e-07
marker O 0 4.042512045998592e-06
, O 0 2.6060307689590445e-08
and O 0 2.7655044476659896e-08
show O 0 2.6811687803274253e-06
abnormal O 0 5.9733174566645175e-06
visceral O 0 3.4955967294081347e-06
endoderm O 0 3.367544923094101e-05
development O 0 3.0039231546652445e-07
. O 0 4.410632641338452e-07

Growth B-Disease 1 0.9999992847442627
retardation I-Disease 1 0.9999997615814209
of O 0 4.984107349059741e-08
the O 0 7.853838468463437e-08
Smad4 O 0 0.0005976083921268582
- O 0 0.006980321370065212
deficient O 0 0.0006442262674681842
embryos O 0 9.715293344925158e-06
results O 0 1.2200131322970265e-06
from O 0 6.933457807889454e-09
reduced O 0 2.5711642592796125e-07
cell O 0 1.6805512132123113e-05
proliferation O 0 4.167667952970078e-07
rather O 0 1.0724749088808494e-08
than O 0 6.766027293991783e-09
increased O 0 5.9107975403094315e-08
apoptosis O 0 1.2454432862796239e-06
. O 0 1.9898283198926947e-07

Aggregation O 0 1.16789387902827e-05
of O 0 8.579876720204993e-08
mutant O 0 3.030307652807096e-06
Smad4 O 0 2.204887096013408e-05
ES O 0 6.633860721194651e-06
cells O 0 1.4844106033251592e-07
with O 0 1.481617273313418e-09
wild O 0 1.278479402344601e-07
- O 0 2.400715857220348e-05
type O 0 1.8463672404323006e-06
tetraploid O 0 9.632171895646024e-06
morulae O 0 4.5291923015611246e-05
rescues O 0 1.2756450814777054e-05
the O 0 1.092695924853615e-07
gastrulation B-Disease 0 4.9986316298600286e-05
defect I-Disease 0 6.66230043862015e-05
. O 0 1.0883461527555482e-06

These O 0 8.811815064291295e-07
results O 0 1.9498475012369454e-06
indicate O 0 8.62397726564268e-08
that O 0 4.531375719096786e-09
Smad4 O 0 2.8904457849421306e-06
is O 0 1.2092153056642019e-08
initially O 0 1.5923358631653173e-08
required O 0 5.280512138661209e-10
for O 0 2.3199812904106665e-10
the O 0 3.594902153736257e-10
differentiation O 0 4.75557548895722e-09
of O 0 3.516552882221191e-10
the O 0 6.929147922107859e-09
visceral O 0 3.4374363622191595e-07
endoderm O 0 4.6775171540502924e-06
and O 0 1.9605913337272796e-08
that O 0 7.325338113872704e-10
the O 0 2.4899557971025388e-09
gastrulation B-Disease 0 8.653898362354084e-07
defect I-Disease 0 5.071202053841262e-07
in O 0 1.0702633224113356e-09
the O 0 4.9387010037094115e-09
epiblast O 0 3.3501326015539235e-06
is O 0 1.0821653795289876e-08
secondary O 0 9.10517083951845e-09
and O 0 1.8162445769576152e-08
non O 0 3.563520749594318e-07
- O 0 2.104941631841939e-05
cell O 0 0.0004748463397845626
autonomous O 0 7.781884960422758e-06
. O 0 7.790368954374571e-07

Rescued O 0 0.000686165236402303
embryos O 0 0.00017608005146030337
show O 0 0.00011489063763292506
severe O 0 0.0002593656536191702
anterior O 0 0.0001864053774625063
truncations O 0 6.958637095522135e-05
, O 0 2.0474139716952777e-07
indicating O 0 5.397519231564729e-08
a O 0 1.3253480091179881e-08
second O 0 1.337573820592297e-07
important O 0 9.092778974206794e-09
role O 0 2.5765636735286535e-08
for O 0 1.496814405754776e-08
Smad4 O 0 1.239798712049378e-05
in O 0 5.91589568443851e-08
anterior O 0 4.570663804770447e-05
patterning O 0 0.0002225098869530484
during O 0 5.331890520210436e-07
embryogenesis O 0 6.95595144861727e-06
. O 0 2.9186446681706e-07

Prevalence O 0 0.00039394645136781037
of O 0 1.317218476515336e-07
p16 O 0 2.6897635052591795e-06
and O 0 1.494447303684865e-07
CDK4 O 0 5.890594911761582e-05
germline O 0 2.6525753128225915e-05
mutations O 0 8.998202247312292e-06
in O 0 2.115651120959683e-08
48 O 0 9.552258234180044e-06
melanoma B-Disease 1 0.9996017813682556
- O 0 0.1262166053056717
prone O 0 0.001089059398509562
families O 0 6.479370284750985e-08
in O 0 6.671380248235437e-08
France O 0 3.452770033618435e-05
. O 0 5.601548309641657e-07

The O 0 7.509609076805646e-07
French O 0 3.258776632719673e-05
Familial B-Disease 0 0.02590460516512394
Melanoma I-Disease 1 0.9997119307518005
Study O 0 2.0232303086231695e-06
Group O 0 5.61944807486725e-06
. O 0 5.13827103532094e-07

Germline O 0 0.0012955297715961933
mutations O 0 6.394275987986475e-05
in O 0 2.3316770736414583e-08
the O 0 5.941981573442945e-09
p16 O 0 2.9368351306402474e-07
and O 0 6.400012608764882e-08
CDK4 O 0 4.4315158447716385e-05
genes O 0 1.0883815093620797e-06
have O 0 6.162231613870972e-08
been O 0 9.159730041119474e-08
reported O 0 5.824333584314445e-07
in O 0 2.950032995663321e-10
a O 0 3.5302440970497173e-09
subset O 0 5.2540347184049097e-08
of O 0 1.9826277508627754e-08
melanoma B-Disease 0 0.11309510469436646
pedigrees O 0 1.695752757768787e-06
, O 0 3.3084997852483866e-08
but O 0 7.440018379156754e-09
their O 0 2.100797225068618e-08
prevalence O 0 1.954076878973865e-06
is O 0 1.607115862611863e-08
not O 0 1.0961899832295785e-08
well O 0 1.0042085385464361e-08
known O 0 2.719090730352036e-07
. O 0 3.5398412023823767e-07

We O 0 9.303421393269673e-07
searched O 0 2.986610070365714e-07
for O 0 3.977496110252332e-09
such O 0 1.2004272020860185e-09
germline O 0 1.223704657604685e-06
mutations O 0 7.604371035085933e-07
in O 0 8.679236884745478e-09
48 O 0 7.406733288917167e-07
French O 0 5.7826688134809956e-05
melanoma B-Disease 1 0.9985942244529724
- O 0 0.023412954062223434
prone O 0 9.894531831378117e-05
families O 0 1.7893418302605824e-08
selected O 0 7.80522579901799e-09
according O 0 3.0209947876613796e-09
to O 0 2.111377073177323e-09
two O 0 1.951609762684825e-09
major O 0 4.714348467160789e-09
criteria O 0 1.5490543958662784e-08
families O 0 3.704689610639633e-10
with O 0 6.292593113244038e-10
at O 0 1.3309774260505947e-07
least O 0 5.046242534945122e-09
three O 0 9.963822655834065e-09
affected O 0 8.391564776388805e-09
members O 0 1.0986571652438215e-09
( O 0 1.0471888911567362e-09
n O 0 4.661889363433147e-07
= O 0 6.400177312571032e-07
20 O 0 6.962960696910159e-08
) O 0 1.1841695402026176e-09
or O 0 6.683349429437158e-09
families O 0 5.077830933508665e-10
with O 0 1.1870031624283683e-09
two O 0 6.26978788886845e-08
affected O 0 3.997127606680806e-08
members O 0 1.1463603399874955e-09
, O 0 3.748788501845013e-10
one O 0 5.711359163385055e-10
of O 0 1.7652852790650542e-10
them O 0 6.843563049585555e-09
affected O 0 5.70004399236268e-09
before O 0 3.4035869678206154e-09
the O 0 9.847322957057258e-10
age O 0 1.083978573568345e-09
of O 0 9.492026609159154e-11
50 O 0 2.9744877672044368e-09
( O 0 1.6271048952631872e-09
n O 0 9.60494276114332e-07
= O 0 9.144949331130192e-07
28 O 0 3.2187432452701614e-07
) O 0 2.0569042025186945e-09
, O 0 4.5214556543271556e-09
and O 0 7.967067894298907e-09
one O 0 1.599294030540932e-08
additional O 0 1.81634849383272e-08
minor O 0 4.0757772268307235e-08
criterion O 0 1.775022838046425e-06
. O 0 2.5563525696270517e-07

Sixteen O 0 4.171407908870606e-06
different O 0 1.966128451158511e-07
p16 O 0 4.565238668874372e-06
germline O 0 3.512376133585349e-05
mutations O 0 5.8645768149290234e-05
were O 0 2.357422346221938e-07
found O 0 3.373110146753788e-08
in O 0 5.028544691754178e-09
21 O 0 4.2931286969860594e-08
families O 0 1.803436844305395e-09
, O 0 3.237767387531676e-09
while O 0 4.964692656983516e-09
one O 0 7.206273355819803e-09
germline O 0 9.446396234125132e-07
mutation O 0 2.565511181273905e-07
, O 0 5.279003900682255e-09
Arg24His O 0 3.242699904149049e-06
, O 0 2.362386375409642e-08
was O 0 1.168073211488263e-07
detected O 0 9.629498265439906e-08
in O 0 1.2257248549474298e-09
the O 0 9.430319636294371e-09
CDK4 O 0 5.4179563448997214e-05
gene O 0 2.2528222416440258e-06
. O 0 2.3451430308796262e-07

The O 0 1.2461758558401925e-07
frequency O 0 3.8936914847909065e-07
of O 0 5.368768096758458e-09
p16 O 0 2.0055973948274186e-07
gene O 0 1.713941486514159e-07
mutation O 0 1.3225782424797217e-07
in O 0 4.954362697873194e-09
our O 0 1.628530732489253e-08
sample O 0 3.462671216425406e-08
( O 0 3.313145535699391e-09
44 O 0 4.668622821668578e-09
% O 0 1.4784894419861416e-09
) O 0 6.803188568049734e-10
is O 0 7.201597651551594e-10
among O 0 2.505490259707699e-10
the O 0 1.2941198113125552e-09
highest O 0 3.1147243362283916e-07
rates O 0 1.7968989141081693e-06
yet O 0 9.737582473690054e-08
reported O 0 1.3952156905361335e-06
and O 0 2.5298374506377286e-09
the O 0 2.1959118967629365e-09
CDK4 O 0 1.2412680007400922e-05
mutation O 0 1.0569925734671415e-07
is O 0 5.56010404384466e-10
the O 0 4.904341932565615e-10
second O 0 2.2217729167550715e-07
mutation O 0 1.7850713618372538e-07
detected O 0 1.6405280689468782e-07
in O 0 4.731217639886154e-10
this O 0 1.0360494684391597e-09
gene O 0 1.981524633265508e-07
worldwide O 0 1.8202750595719408e-07
. O 0 1.1717752101958467e-07

In O 0 3.4914455682155676e-06
summary O 0 2.1708056010538712e-05
, O 0 2.1866016197691351e-07
our O 0 1.2943011995503184e-07
results O 0 4.645300180072809e-07
show O 0 1.931665281063033e-07
frequent O 0 7.11287171384356e-08
involvement O 0 4.036768785908862e-08
of O 0 7.787659961344673e-10
the O 0 2.483543148912304e-09
p16 O 0 7.146583413941698e-08
gene O 0 1.999764549509564e-07
in O 0 1.0422436247381484e-08
familial B-Disease 0 0.00031269629835151136
melanoma I-Disease 1 0.9999830722808838
and O 0 2.822449232553481e-06
confirm O 0 4.039937721245224e-06
the O 0 3.0140885343143964e-09
role O 0 9.07818797912796e-09
of O 0 3.5250477536941105e-10
the O 0 2.7895545873235505e-09
CDK4 O 0 3.760153504117625e-06
gene O 0 4.219747040679067e-08
as O 0 2.6203041958439144e-09
a O 0 1.736758150627793e-07
melanoma B-Disease 0 0.3604942560195923
- O 0 1.9995190086774528e-05
predisposing O 0 2.68293592853297e-06
gene O 0 6.314516554084548e-07
. O 0 1.5470112302296002e-08
. O 0 1.0599158173363321e-07

Progression O 0 0.00016916185268200934
of O 0 2.0716174731205683e-07
somatic O 0 3.780349652515724e-05
CTG O 0 0.0005352726439014077
repeat O 0 3.681027010316029e-05
length O 0 6.640758556386572e-07
heterogeneity O 0 1.9127630821458297e-06
in O 0 2.0842181314151276e-08
the O 0 1.6702280447589146e-08
blood O 0 9.061304808710702e-06
cells O 0 4.4367170630721375e-05
of O 0 3.7691650049964665e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.002498392015695572
. O 0 6.425067908821802e-07

The O 0 2.420111968604033e-07
genetic O 0 2.1613609533233102e-06
basis O 0 7.043183245514228e-07
of O 0 7.2571219789097086e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.7657760381698608
DM B-Disease 1 1.0
) O 0 2.5090824351536867e-07
is O 0 2.4087585259735533e-09
the O 0 3.639699930335638e-10
expansion O 0 8.924224914608203e-09
of O 0 1.2614487232553984e-09
an O 0 1.2574166419199173e-07
unstable O 0 0.0001913741580210626
CTG O 0 3.794363510678522e-05
repeat O 0 5.40823430128512e-06
in O 0 4.646777629346843e-09
the O 0 3.789711211510394e-09
34 O 0 1.9244128068862665e-08
UTR O 0 2.559372376254032e-07
of O 0 2.3914725755247446e-09
the O 0 2.0886359664018528e-07
DM B-Disease 1 0.9999998807907104
protein O 0 1.829099119277089e-06
kinase O 0 1.6145193058036966e-06
gene O 0 3.5721495805773884e-07
on O 0 4.527222756678384e-07
chromosome O 0 8.393999451072887e-05
19 O 0 9.065583412848355e-07
. O 0 2.2044493164230516e-07

One O 0 4.798268946615281e-07
of O 0 3.512660162741099e-09
the O 0 2.1067187994106007e-09
principal O 0 3.081802546489598e-08
features O 0 1.8283017766407283e-08
of O 0 1.6051698858987606e-09
the O 0 1.2018273309877259e-06
DM B-Disease 1 1.0
mutation O 0 4.505189281189814e-06
is O 0 6.7470056208662754e-09
an O 0 2.3196549125970023e-09
extraordinarily O 0 1.9666330786094477e-07
high O 0 3.501203593714308e-08
level O 0 1.140035443825127e-08
of O 0 1.464531940165159e-09
somatic O 0 6.615512120333733e-07
mosaicism O 0 5.98442511545727e-06
, O 0 2.1183970133620278e-08
due O 0 1.1059912985444953e-08
to O 0 1.1194254412316695e-08
an O 0 1.3130915910153362e-08
extremely O 0 4.55166500046289e-08
high O 0 4.462819092054815e-08
degree O 0 1.529699744651225e-08
of O 0 1.6684410519829385e-09
somatic O 0 4.4386356421455275e-06
instability O 0 5.25679183738248e-07
both O 0 7.635463816768606e-09
within O 0 2.9962734515720513e-09
and O 0 6.727704171538562e-09
between O 0 4.895708727303827e-09
different O 0 7.27431626046382e-08
tissues O 0 1.0107120033353567e-05
. O 0 3.414073432850273e-07

This O 0 5.488942065312585e-07
instability O 0 2.4676378416188527e-06
appears O 0 3.761520304124133e-07
to O 0 1.9742167012282152e-08
be O 0 1.2872373389427594e-08
biased O 0 1.5450302726094378e-07
towards O 0 6.242293792979581e-09
further O 0 2.621223682552909e-09
expansion O 0 8.476501278664728e-09
and O 0 7.339047147780775e-09
continuous O 0 1.799383397838028e-08
throughout O 0 4.256996088969345e-09
the O 0 2.745578431273543e-09
life O 0 1.027340523762632e-08
of O 0 9.138531598118504e-11
an O 0 3.0606892575946176e-09
individual O 0 2.2365334029217365e-09
, O 0 2.932810660993823e-09
features O 0 1.0265358696415205e-07
that O 0 5.3811241684798006e-08
could O 0 2.7447168804428657e-07
be O 0 1.7896695680974517e-08
associated O 0 4.342655568478904e-09
with O 0 1.3754329897253115e-09
the O 0 4.5447769991824316e-08
progressive O 0 1.7858013734439737e-06
nature O 0 1.561394391558224e-08
of O 0 1.1755977302740916e-09
the O 0 2.2899179441537854e-07
disease O 0 3.170870695612393e-05
. O 0 1.1176422987091428e-07

Although O 0 3.252913529649959e-07
increasing O 0 9.990926486125318e-08
measured O 0 4.320161508530873e-07
allele O 0 3.344350432143983e-07
size O 0 1.2292565543248202e-07
between O 0 1.6789068979505828e-07
patients O 0 1.460165663047519e-06
clearly O 0 3.247609114964689e-08
correlates O 0 2.3347034527887445e-08
with O 0 1.7720600542503462e-09
an O 0 1.8853850036748554e-08
increased O 0 1.99132799139079e-07
severity O 0 5.8309524320065975e-06
of O 0 6.053911505432552e-08
symptoms O 0 7.073222514009103e-05
and O 0 8.760616232450502e-09
an O 0 5.392104540646869e-09
earlier O 0 1.1560020993783837e-06
age O 0 1.3081470129350237e-08
of O 0 6.838953847676521e-10
onset O 0 3.197083628947439e-07
, O 0 2.914447794211128e-09
this O 0 5.206414743774701e-10
correlation O 0 4.790546270783125e-08
is O 0 1.1026696000726588e-08
not O 0 9.629201436212043e-09
precise O 0 1.4357782447405043e-06
and O 0 1.616856906139219e-07
measured O 0 1.074861529559712e-06
allele O 0 5.104809019940149e-07
length O 0 1.9744707060453948e-06
cannot O 0 7.589648589600984e-07
be O 0 3.141193971600842e-09
used O 0 6.934938845404304e-09
as O 0 5.069356490139398e-09
an O 0 5.101150613029404e-09
accurate O 0 3.808753717748914e-06
predictor O 0 2.8820650186389685e-05
of O 0 5.783405310211265e-09
age O 0 1.5372664918800183e-08
of O 0 8.019591213326294e-09
onset O 0 4.9299883357889485e-06
. O 0 4.957300347996352e-07

In O 0 5.911597895646992e-07
order O 0 7.693372339190319e-08
to O 0 2.2468903182470967e-08
further O 0 1.6975304717448125e-08
characterize O 0 1.1978636393905617e-06
the O 0 7.715738092883839e-08
dynamics O 0 1.4927344636816997e-05
of O 0 4.779183768732764e-07
DM B-Disease 1 1.0
CTG O 0 0.000878923456184566
repeat O 0 8.78029277373571e-06
somatic O 0 4.831499154533958e-06
instability O 0 1.7319744074484333e-06
, O 0 8.002797535766604e-09
we O 0 2.5133902070706426e-08
have O 0 2.8032300924962783e-09
studied O 0 1.3355212047372333e-08
repeat O 0 4.194218377051584e-07
length O 0 8.83019026787224e-08
changes O 0 4.398498898439129e-09
over O 0 3.94030053030292e-09
time O 0 1.2709066687932591e-08
in O 0 3.4004091986616913e-08
111 O 0 3.421568908379413e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 9.47189619182609e-06
with O 0 1.073931721329302e-09
varying O 0 8.599454304203391e-08
clinical O 0 4.301359695091378e-06
severity O 0 1.1650326086964924e-05
and O 0 3.0455331057055446e-07
CTG O 0 5.3340809245128185e-05
repeat O 0 2.8357480914564803e-06
size O 0 2.40574760113077e-08
over O 0 1.216977985052381e-08
time O 0 1.595138598986523e-08
intervals O 0 3.34100569432394e-08
of O 0 4.0604641871055946e-10
1 O 0 4.111859297495357e-08
- O 0 3.4395684451737907e-06
7 O 0 9.425573352928041e-07
years O 0 8.809363549744376e-08
. O 0 8.495621273141296e-08

We O 0 1.1506726877996698e-05
have O 0 2.6017000109845867e-08
found O 0 2.7916835509955717e-09
a O 0 2.177668045888481e-09
direct O 0 3.683267735254958e-08
progression O 0 1.5010549532235018e-06
of O 0 9.28866372706949e-10
the O 0 1.89813658124649e-08
size O 0 1.783951546485696e-07
heterogeneity O 0 2.8197300139254367e-07
over O 0 2.1767391444882378e-08
time O 0 2.9608703044914364e-08
related O 0 1.2696612650131556e-08
to O 0 9.70899982633e-09
initial O 0 7.980470684287866e-08
CTG O 0 4.691786671173759e-06
repeat O 0 1.4313048950498342e-06
size O 0 5.903338973212158e-08
and O 0 1.346155009684935e-08
the O 0 1.908452951226991e-09
time O 0 3.9666343099042933e-08
interval O 0 9.567873604510169e-08
and O 0 4.410733112081289e-08
always O 0 2.0180447535267376e-08
biased O 0 8.545578822349853e-08
towards O 0 3.7044938228092406e-09
further O 0 8.518902028242792e-09
expansion O 0 1.3242039642591408e-07
. O 0 1.468875012733406e-07

Attempts O 0 4.414749582792865e-06
to O 0 9.469003003914622e-08
mathematically O 0 4.4802010279454407e-07
model O 0 1.410242305155407e-07
the O 0 1.1482955031283382e-08
dynamics O 0 2.863906956918072e-06
have O 0 4.717463042425152e-08
proved O 0 5.780871603633386e-08
only O 0 4.415183774142406e-09
partially O 0 1.3937501535110641e-06
successful O 0 4.08612947921938e-08
suggesting O 0 2.121927344944652e-08
that O 0 2.2731219684324344e-10
individual O 0 7.635937021577277e-11
specific O 0 8.550902208526168e-10
genetic O 0 5.234469995230029e-07
and O 0 7.457082915607316e-07
/ O 0 0.0006272110622376204
or O 0 1.4080237633606885e-06
environmental O 0 1.737689245828733e-07
factors O 0 1.1582159231693367e-08
also O 0 2.6351107962341302e-08
play O 0 1.3397155385064252e-08
a O 0 3.147780702761338e-08
role O 0 5.241203382411186e-08
in O 0 2.9389607192342737e-08
somatic O 0 3.348193786223419e-06
mosaicism O 0 2.4351345928153023e-05
. O 0 6.123567430904586e-08
. O 0 2.902891083067516e-07

Aspartylglucosaminuria B-Disease 1 0.9999496936798096
among O 0 2.081137381537701e-06
Palestinian O 0 2.2521182472701184e-05
Arabs O 0 8.935442565416452e-06
. O 0 9.55517748479906e-07

Aspartylglucosaminuria B-Disease 1 0.9999997615814209
( O 0 0.13785165548324585
AGU B-Disease 1 0.9999998807907104
) O 0 6.742363893863512e-07
is O 0 3.758312328017155e-09
a O 0 1.290310081003554e-08
rare O 0 5.108208256388025e-07
disorder B-Disease 0 8.200186130125076e-05
of I-Disease 0 2.9135307499927876e-09
glycoprotein I-Disease 0 1.9819601220660843e-05
metabolism I-Disease 0 0.00290897348895669
caused O 0 1.2002077482975437e-06
by O 0 9.199084161082283e-09
the O 0 2.7321419793224777e-07
deficiency B-Disease 0 4.74449698231183e-05
of I-Disease 0 1.0567476893541539e-09
the I-Disease 0 4.821014698563886e-08
lysosomal I-Disease 0 0.00030045618768781424
enzyme I-Disease 0 1.1075355359935202e-05
aspartylglucosaminidase I-Disease 0 4.8578654968878254e-05
( O 0 4.153034538489919e-08
AGA O 0 3.608065298976726e-06
) O 0 7.351182773618348e-08
. O 0 2.423858518341149e-07

AGU B-Disease 1 0.9999992847442627
is O 0 1.955898551386781e-05
inherited O 0 3.7557067116722465e-05
as O 0 2.1695807816968227e-08
an O 0 1.7954954856236327e-08
autosomal O 1 0.5358067154884338
recessive O 0 0.14146527647972107
trait O 0 6.208280683495104e-05
and O 0 1.749613574020259e-07
occurs O 0 9.888169394400848e-09
with O 0 6.258933926694965e-10
a O 0 2.433576540283866e-08
high O 0 9.153198021749631e-08
frequency O 0 1.606636942597106e-06
in O 0 3.196863573862174e-08
Finland O 0 2.2791735318605788e-05
because O 0 1.3442306823208128e-08
of O 0 2.8476229707585787e-10
a O 0 3.869282139135066e-08
founder O 0 3.917483354598517e-06
effect O 0 4.7129216795838147e-07
. O 0 2.1483864998117497e-07

While O 0 1.4314018699224107e-06
very O 0 2.6288958565601206e-08
few O 0 1.9732528500071567e-08
patients O 0 2.416470294974715e-07
with O 0 1.7245135097709863e-07
AGU B-Disease 1 1.0
have O 0 7.645149935342488e-07
been O 0 1.0571820752147687e-07
reported O 0 5.300507268657384e-07
from O 0 9.981127035985082e-10
non O 0 6.918427430946394e-08
- O 0 3.5269526961201336e-06
Finnish O 0 4.82084033137653e-06
origin O 0 2.184125236226464e-08
, O 0 2.5296991168488603e-08
we O 0 1.733883578936002e-07
diagnosed O 0 7.097568868630333e-06
the O 0 1.113008618602862e-08
disorder O 0 3.424443548283307e-06
in O 0 2.5804378633864644e-09
8 O 0 1.0830288488250517e-07
patients O 0 9.182220317427436e-09
originating O 0 2.5979447482171736e-09
from O 0 2.5290944893896494e-09
3 O 0 4.183651824973822e-08
unrelated O 0 6.649770512012765e-08
families O 0 4.328712943646451e-09
, O 0 3.623113142836587e-09
all O 0 6.475225355906389e-10
Palestinian O 0 4.6869695324858185e-07
Arabs O 0 1.1073468897393468e-07
from O 0 3.1035796155265416e-09
the O 0 4.1805785500059756e-09
region O 0 5.038974109083938e-07
of O 0 6.329961443896082e-09
Jerusalem O 0 0.0005610059015452862
. O 0 1.4442458677876857e-06

The O 0 8.193283633772808e-07
clinical O 0 2.2817070203018375e-05
diagnosis O 0 0.0012909391662105918
of O 0 1.228189489665965e-06
AGU B-Disease 1 1.0
is O 0 1.8626576547831064e-06
often O 0 6.994934409476627e-08
difficult O 0 8.964626374563522e-08
, O 0 4.273910114704904e-09
in O 0 7.309789995524341e-10
particular O 0 1.2508111213449524e-09
early O 0 1.5872265279881503e-08
in O 0 1.3321775904628907e-09
the O 0 2.9806099810514297e-09
course O 0 9.470158346402968e-08
of O 0 8.206086921092037e-10
the O 0 1.1170221370093714e-07
disease O 0 2.5303965230705217e-05
, O 0 3.8526151158180255e-09
and O 0 2.1276322925700697e-09
most O 0 5.335140107476377e-10
of O 0 1.2882528377389235e-10
the O 0 4.894805627486676e-08
patients O 0 4.0484897567694134e-07
are O 0 5.9726494860967705e-09
diagnosed O 0 6.959561233088607e-06
after O 0 1.491237711093163e-08
the O 0 3.0792863814355087e-09
age O 0 2.29193930501026e-09
of O 0 4.4810338772904856e-10
5 O 0 6.608261315932396e-08
years O 0 5.663385493903661e-08
. O 0 9.01562273725176e-08

However O 0 1.6967460396699607e-06
, O 0 4.655366936390237e-08
since O 0 1.4624475852542673e-08
these O 0 1.0027476626817133e-09
patients O 0 8.852327759711898e-09
excrete O 0 1.8786078470611756e-08
early O 0 2.0287069801838697e-09
large O 0 1.2205014776611733e-09
amounts O 0 2.9722646566199273e-09
of O 0 1.2776749658272024e-09
aspartylglucosamine O 0 3.860134711430874e-06
in O 0 1.3020880373915134e-08
urine O 0 2.1820353879320464e-07
, O 0 7.565398307818327e-10
biochemical O 0 1.4400435510708576e-08
screening O 0 1.443211239404718e-08
is O 0 3.025054207128619e-09
easy O 0 6.97982116548701e-08
by O 0 1.0172402475916442e-08
urine O 0 2.5931151412805775e-06
chromatography O 0 6.905124791956041e-07
. O 0 2.9184599625864394e-08
. O 0 1.6276619874133758e-07

Detection O 0 8.431455171376001e-06
of O 0 7.724587192114996e-08
heterozygous O 0 1.5076026329552406e-06
carriers O 0 5.117731234349776e-07
of O 0 4.9714323324678844e-08
the O 0 6.168541585793719e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 2.071632707156823e-06
ATM O 0 6.675057375105098e-05
) O 0 6.6011529575860095e-09
gene O 0 4.482859239374193e-08
by O 0 4.47636328004819e-09
G2 O 0 2.6057377908728085e-05
phase O 0 1.4369288692250848e-06
chromosomal O 0 0.0006393967196345329
radiosensitivity O 0 9.097955626202747e-05
of O 0 4.9326406070804296e-08
peripheral O 0 0.0006160340853966773
blood O 0 0.00017011309682857245
lymphocytes O 0 6.788124301237985e-05
. O 0 5.038964445702732e-07

In O 0 0.006772033870220184
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.0007206099689938128
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.1273490372332162e-06
patients O 0 4.148364496359136e-07
, O 0 1.3421650457701162e-09
mutations O 0 7.006871527437397e-08
in O 0 5.885895104640326e-10
a O 0 1.033815433260088e-08
single O 0 2.9837602255611273e-07
gene O 0 2.2255815679272928e-07
, O 0 3.804253800865354e-09
ATM O 0 1.4528505744237918e-05
, O 0 6.398130469875696e-09
result O 0 3.760219691173461e-09
in O 0 9.577803439242416e-09
an O 0 0.00013656452938448638
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 7.695777526350867e-07
embraces O 0 2.424709464321495e-07
a O 0 1.4153859417831427e-08
variety O 0 1.2928475179307952e-08
of O 0 1.5912177131482963e-09
clinical O 0 5.6826028327350286e-08
features O 0 2.449433793572098e-07
and O 0 4.955499548486841e-07
manifests O 0 2.4808609850879293e-06
extreme O 0 6.580043532267155e-07
radiosensitivity O 0 4.355134933575755e-06
and O 0 4.01837629837587e-09
a O 0 6.688718467984245e-09
strong O 0 4.768894257267675e-08
pre O 0 9.060846423381008e-06
- O 0 5.2890860388288274e-05
disposition O 0 4.5958127884659916e-05
to O 0 8.169439524863265e-07
malignancy B-Disease 0 0.00014160755381453782
. O 0 5.196697543397022e-07

Heterozygotes O 0 9.391285857418552e-05
for O 0 7.731529905186107e-08
the O 0 2.1118854220958383e-08
ATM O 0 1.7828229829319753e-05
gene O 0 6.30353042652132e-07
have O 0 9.680984902615819e-09
no O 0 7.59792495585998e-09
clinical O 0 1.590684384211727e-08
expression O 0 9.126121192082337e-09
of O 0 1.1764686114190681e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
but O 0 8.074065408436581e-05
may O 0 7.849883331800811e-06
be O 0 6.134837349236477e-07
cancer B-Disease 0 1.4199053111951798e-05
prone O 0 2.514109951334831e-07
with O 0 1.6652045298215512e-09
a O 0 5.680478309955106e-08
moderate O 0 1.8966221659866278e-06
increase O 0 6.693340992569574e-08
in O 0 7.1218013708573835e-09
in O 0 4.4519623543237685e-08
vitro O 0 2.6008421627921052e-05
radiosensitivity O 0 3.683468094095588e-05
. O 0 3.640568309037917e-07

We O 0 3.977358119300334e-06
performed O 0 3.7766531590932573e-07
a O 0 3.292836225909923e-08
blind O 0 2.2133547190605896e-06
chromosomal O 0 8.960590639617294e-05
analysis O 0 1.5129893427001662e-07
on O 0 6.368778144860698e-07
G2 O 0 0.00011317856115056202
- O 0 3.0813072953606024e-05
phase O 0 9.134847687164438e-07
lymphocytes O 0 7.219509825517889e-07
from O 0 4.458426960951556e-09
7 O 0 7.724263184627489e-08
unrelated O 0 3.4933964343508705e-07
A B-Disease 1 0.9999995231628418
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.8701448172796518e-05
, O 0 1.5272384468190126e-09
13 O 0 5.710490746935193e-09
obligate O 0 5.577955164426385e-08
A B-Disease 1 0.9999829530715942
- I-Disease 1 0.9999991655349731
T I-Disease 1 1.0
heterozygotes O 0 6.718930671922863e-05
( O 0 6.065374424935044e-09
parents O 0 1.1314155168307138e-09
of O 0 1.4521892022223426e-10
the O 0 8.685947960884732e-08
patients O 0 4.585798478728975e-07
) O 0 2.8262185924887717e-09
, O 0 3.092352596212322e-09
and O 0 1.2461111253969648e-08
14 O 0 1.1923224185750314e-08
normal O 0 2.1056832721910723e-08
controls O 0 8.871480190464354e-07
following O 0 2.9465267559203312e-08
X O 0 2.583592322480399e-05
- O 0 1.261015995623893e-06
irradiation O 0 1.2326633225256955e-07
with O 0 2.7558251236570186e-09
1 O 0 4.078483328839866e-08
Gy O 0 3.141260776828858e-06
in O 0 1.4274770254729674e-09
order O 0 2.321708825192559e-09
to O 0 1.142144423482705e-08
evaluate O 0 2.944229393619935e-08
this O 0 1.3051855152212966e-09
cytogenetic O 0 2.6562349830783205e-07
method O 0 2.2928587029014125e-08
as O 0 1.6763388455132144e-09
a O 0 2.0336812234234003e-09
tool O 0 4.497212557907915e-08
for O 0 1.360690338181314e-09
detection O 0 1.7343127822755378e-08
of O 0 2.3340789301329323e-09
ATM O 0 0.00030918055563233793
carriers O 0 1.0472812164152856e-06
. O 0 3.600141837978299e-07

Both O 0 6.887124982313253e-06
A B-Disease 1 0.9985328912734985
- I-Disease 1 0.9999784231185913
T I-Disease 1 1.0
homozygotes O 0 0.0005929693579673767
and O 0 1.1259849230782493e-07
heterozygotes O 0 1.0973907365041669e-06
showed O 0 2.3398305870614422e-07
significantly O 0 4.4690374068068195e-08
increased O 0 1.0030733577082174e-08
levels O 0 1.0341388190227008e-08
of O 0 5.453251183951124e-09
radiation O 0 0.00023175223032012582
- O 0 0.09956926107406616
induced O 0 0.0029423199594020844
chromatid O 0 0.14200010895729065
damage O 0 8.785851241555065e-05
relative O 0 1.4344681176226004e-07
to O 0 2.797399112353105e-08
that O 0 3.3491387441131337e-09
of O 0 1.631047963357446e-09
normal O 0 5.28272380506678e-07
controls O 0 4.410322435433045e-05
. O 0 1.1588433608267223e-06

These O 0 6.490124633273808e-07
results O 0 2.029822553595295e-06
show O 0 9.657972555032757e-08
that O 0 2.2774371277733962e-09
the O 0 2.4478483684475805e-09
G2 O 0 1.5142774827836547e-05
- O 0 6.052495791664114e-06
phase O 0 3.8246312783485337e-07
chromosomal O 0 4.077561243320815e-05
radiosensitivity O 0 1.8351707922192873e-06
assay O 0 1.4627288464907906e-06
can O 0 1.828605178388898e-08
be O 0 1.2980008179397373e-09
used O 0 2.502697382666952e-09
for O 0 6.584086609251472e-10
the O 0 1.836440666203032e-09
detection O 0 1.288163815615917e-07
of O 0 2.0388519317293685e-08
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999973773956299
T I-Disease 1 1.0
heterozygotes O 0 0.0002714228758122772
. O 0 5.216131739871344e-07

In O 0 2.9081311936351995e-07
combination O 0 1.0598915878290427e-07
with O 0 7.297757065316546e-09
molecular O 0 4.793548669113079e-07
genetic O 0 4.3032960093114525e-06
analyses O 0 1.2871142871517804e-06
, O 0 2.4568116430145892e-08
this O 0 6.0228582121624186e-09
test O 0 7.105155930275942e-08
may O 0 1.0132342254109972e-07
be O 0 6.565051280382761e-10
of O 0 6.75352621049008e-11
value O 0 1.717769748665887e-08
in O 0 3.7158731647224386e-09
studies O 0 1.4513096280310833e-09
of O 0 7.450054462232458e-10
familial B-Disease 0 4.439262283995049e-06
and I-Disease 0 5.169787300474127e-07
sporadic I-Disease 0 9.134340871241875e-06
cancers I-Disease 0 0.00020125288574490696
aimed O 0 8.1460555634294e-08
at O 0 2.8646041982938186e-07
determination O 0 6.102114014083782e-08
of O 0 5.8621657528235e-10
the O 0 9.088652497268868e-09
potential O 0 1.5052487256639324e-08
involvement O 0 8.737971235461828e-09
of O 0 1.6192472918064027e-09
ATM O 0 0.00031373483943752944
mutations O 0 1.1981676834693644e-05
in O 0 9.558206670590152e-08
tumor B-Disease 0 0.0005052785272710025
risk O 0 9.125008659793821e-07
or O 0 4.3440987695930744e-08
development O 0 2.140965449370924e-08
. O 0 2.5548066773239952e-08
. O 0 2.8667056994891027e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
telangiectasia I-Disease 1 1.0
: O 0 7.989697792254447e-07
identification O 0 4.2784879639157225e-08
and O 0 3.3847673552855895e-09
detection O 0 3.4604926923975654e-08
of O 0 2.467969606456677e-09
founder O 0 6.957185632927576e-06
- O 0 3.7380941648734733e-05
effect O 0 1.0676152442101738e-06
mutations O 0 2.8175688271403487e-07
in O 0 6.492861803764072e-10
the O 0 1.7518727579712845e-09
ATM O 0 2.3389044145005755e-05
gene O 0 2.036205870581398e-07
in O 0 3.6232514766254553e-09
ethnic O 0 2.2498413443372556e-07
populations O 0 3.4486922118048824e-07
. O 0 1.501175148632683e-07

To O 0 1.4843624285276746e-07
facilitate O 0 7.941053326021574e-08
the O 0 6.26249496704645e-09
evaluation O 0 1.4931588410149743e-08
of O 0 8.421191521890137e-10
ATM O 0 1.3749973732046783e-05
heterozygotes O 0 2.3161551609973685e-07
for O 0 2.9813662649758044e-09
susceptibility O 0 1.739212933671297e-07
to O 0 1.3883355798327557e-08
other O 0 3.6616093268548866e-08
diseases O 0 1.1636491763056256e-05
, O 0 3.557789618469087e-09
such O 0 1.1082332829204233e-09
as O 0 4.812870429304894e-06
breast B-Disease 1 0.5852835178375244
cancer I-Disease 0 0.0008606401970610023
, O 0 5.5501921281120303e-08
we O 0 5.058580043737493e-08
have O 0 5.315133666528027e-09
attempted O 0 1.5515388440690003e-07
to O 0 3.752281596547391e-09
define O 0 1.921434567009328e-08
the O 0 1.337386534849827e-09
most O 0 1.1763469087711087e-09
common O 0 1.0546822970525227e-08
mutations O 0 2.768803994968039e-07
and O 0 2.298777834752741e-09
their O 0 1.1846243097579645e-08
frequencies O 0 8.863836228556465e-06
in O 0 3.645495598902926e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 6.704185216221958e-05
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999992847442627
T I-Disease 1 1.0
) O 0 2.867681985208037e-07
homozygotes O 0 2.4738253614486894e-06
from O 0 6.060032031740548e-09
10 O 0 7.926567846539001e-09
ethnic O 0 1.3752244854003948e-07
populations O 0 3.6743008990924864e-07
. O 0 2.425125558147556e-07

Both O 0 1.113632833948941e-06
genomic O 0 1.1897997865162324e-05
mutations O 0 4.474051092984155e-05
and O 0 7.23632993526735e-08
their O 0 4.857130520008468e-08
effects O 0 5.052086180512561e-07
on O 0 4.151645498495782e-07
cDNA O 0 1.5136894262468559e-06
were O 0 1.2190787401777925e-07
characterized O 0 7.295269028873008e-07
. O 0 3.3154486800412997e-07

Protein O 0 5.8511643146630377e-05
- O 0 3.1360254070023075e-05
truncation O 0 5.756632617703872e-06
testing O 0 8.437324794385859e-08
of O 0 9.28496224350539e-10
the O 0 1.022800066863283e-09
entire O 0 2.0530132260887513e-08
ATM O 0 2.7706739729183028e-06
cDNA O 0 2.0178836734885408e-07
detected O 0 5.021598781240755e-07
92 O 0 1.62358073652058e-08
( O 0 1.1949490286156106e-09
66 O 0 1.351279355077395e-08
% O 0 2.774664720206488e-09
) O 0 1.4261870573406554e-09
truncating O 0 4.3481031752889976e-07
mutations O 0 6.443119673349429e-07
in O 0 2.2656219123007304e-09
140 O 0 1.758773748861131e-08
mutant O 0 4.695330915183149e-07
alleles O 0 1.9965300452895463e-06
screened O 0 2.3206368496175855e-05
. O 0 9.8942075510422e-07

The O 0 5.997572429805587e-07
haplotyping O 0 1.7843554815044627e-05
of O 0 1.5862550384326823e-08
patients O 0 1.3150119571037067e-07
with O 0 1.8625624376156225e-09
identical O 0 3.284761987742968e-06
mutations O 0 2.827195930876769e-05
indicates O 0 6.333248734335939e-07
that O 0 1.3009957555709661e-08
almost O 0 7.240026356214457e-09
all O 0 5.051941087685918e-10
of O 0 1.423954842927344e-10
these O 0 6.285899578628573e-10
represent O 0 3.49047346581699e-09
common O 0 8.70224923232854e-08
ancestry O 0 1.097120730264578e-06
and O 0 1.1368373975528812e-07
that O 0 8.376389359909808e-09
very O 0 9.638958076152448e-09
few O 0 1.5338777359374944e-08
spontaneously O 0 6.897108164594101e-07
recurring O 0 9.007713401842921e-07
ATM O 0 0.00020341938943602145
mutations O 0 2.5273529900005087e-05
exist O 0 8.806404707684123e-07
. O 0 3.7697873267461546e-07

Assays O 0 2.222001967311371e-05
requiring O 0 6.755924459866947e-07
minimal O 0 1.5462478586414363e-07
amounts O 0 7.973848248354898e-09
of O 0 1.198336319063742e-09
genomic O 0 6.196861335183712e-08
DNA O 0 2.249614681204548e-06
were O 0 3.2575474762097656e-08
designed O 0 2.655302111520541e-08
to O 0 6.21584650417617e-09
allow O 0 3.6600851238688392e-09
rapid O 0 3.3571925683872905e-08
screening O 0 1.6836875005310503e-08
for O 0 1.172529850990145e-09
common O 0 3.836323614336834e-08
ethnic O 0 1.0212828556177556e-06
mutations O 0 2.8089372790418565e-05
. O 0 4.193934444174374e-07

These O 0 1.9320079047702166e-07
rapid O 0 8.061120979618863e-07
assays O 0 7.65053982831887e-07
detected O 0 1.0675063322196365e-06
mutations O 0 2.255745101820139e-07
in O 0 3.1712577008846665e-09
76 O 0 2.943471066885195e-08
% O 0 9.542714396459928e-10
of O 0 3.946240278995816e-10
Costa O 0 4.310248016281548e-07
Rican O 0 1.2171433638741291e-07
patients O 0 6.029711130395299e-08
( O 0 4.4780604224747833e-10
3 O 0 5.8547713344125896e-09
) O 0 1.0296410390964184e-09
, O 0 9.085597274527402e-10
50 O 0 1.196698518057815e-09
% O 0 2.8285848663323065e-10
of O 0 3.789521474395485e-10
Norwegian O 0 0.0008421606034971774
patients O 0 7.558365382465126e-07
( O 0 6.589714884874809e-10
1 O 0 2.1735944599754475e-08
) O 0 4.482813675821262e-09
, O 0 2.7616866571378296e-09
25 O 0 1.2067999932696694e-09
% O 0 3.0777344561805364e-10
of O 0 4.549655374663786e-10
Polish O 0 3.320906398585066e-05
patients O 0 2.416514064407238e-07
( O 0 8.541708451659247e-10
4 O 0 3.9774683102677955e-08
) O 0 6.8362839833469025e-09
, O 0 3.842377971352562e-09
and O 0 1.1939610189415362e-08
14 O 0 1.1465512095298891e-08
% O 0 4.4879280847176517e-10
of O 0 4.145694065815775e-10
Italian O 0 7.28962595530902e-06
patients O 0 3.208335783710936e-07
( O 0 9.230329833798123e-10
1 O 0 3.77502509252281e-08
) O 0 6.13726891529609e-09
, O 0 2.4822646160771455e-09
as O 0 3.136464199471334e-09
well O 0 1.3454098946041881e-09
as O 0 4.200208181259768e-09
in O 0 3.1773361719444893e-09
patients O 0 6.252111717230946e-09
of O 0 2.949628041815089e-10
Amish O 0 5.478255388879916e-06
/ O 0 9.85588485491462e-05
Mennonite O 0 4.955327767675044e-06
and O 0 1.639308067069578e-07
Irish O 0 3.53934154873059e-07
English O 0 7.935375379020115e-08
backgrounds O 0 2.8704317855954287e-07
. O 0 2.9712751370425394e-07

Additional O 0 9.540754035697319e-07
mutations O 0 1.003226589091355e-05
were O 0 4.824390487101482e-08
observed O 0 2.3135584115152596e-08
in O 0 1.0276967055133923e-09
Japanese O 0 1.7211544189876804e-08
, O 0 1.2664680415497287e-09
Utah O 0 6.641617922298337e-09
Mormon O 0 1.0804575900635882e-08
, O 0 1.5860939228673487e-09
and O 0 2.2197252924627264e-09
African O 0 3.041125351543883e-09
American O 0 3.410411864024354e-08
patients O 0 6.44619930767476e-08
. O 0 5.167805738892639e-08

These O 0 2.0469161654546042e-07
assays O 0 7.055431865410355e-07
should O 0 9.308905646321364e-09
facilitate O 0 7.603158103108854e-09
screening O 0 3.4919466429528256e-08
for O 0 2.273211130443542e-08
A B-Disease 1 0.9999964237213135
- I-Disease 1 0.9999974966049194
T I-Disease 1 1.0
heterozygotes O 0 3.4734118798951386e-06
in O 0 3.4851646013578375e-09
the O 0 4.8158379506446636e-09
populations O 0 3.7521115103800184e-08
studied O 0 2.649736963178384e-08
. O 0 1.417268880032907e-08
. O 0 1.4804351167185814e-07

The O 0 1.0723922969191335e-05
von B-Disease 1 0.9702600240707397
Hippel I-Disease 1 0.9985021352767944
- I-Disease 1 0.9988237023353577
Lindau I-Disease 1 0.9986535310745239
tumor I-Disease 0 0.011424493044614792
suppressor O 0 1.1363197700120509e-05
gene O 0 1.8365452660873416e-06
is O 0 1.2624868261923439e-08
required O 0 7.222565212572363e-09
for O 0 4.048471780038199e-09
cell O 0 1.6156644051079638e-05
cycle O 0 1.074354713637149e-05
exit O 0 8.082921340246685e-06
upon O 0 5.904904654130405e-08
serum O 0 9.57411430135835e-07
withdrawal O 0 2.1311889213393442e-06
. O 0 2.6037758971142466e-07

The O 0 3.3080141292884946e-07
inactivation O 0 1.675888961472083e-05
of O 0 9.877387796564108e-09
the O 0 4.8092129389942784e-08
von B-Disease 1 0.9768756628036499
Hippel I-Disease 1 0.9972707629203796
- I-Disease 1 0.9958129525184631
Lindau I-Disease 1 0.9927504062652588
( I-Disease 0 7.680160933887237e-07
VHL I-Disease 0 7.454236765624955e-05
) I-Disease 0 1.235926276876853e-07
tumor I-Disease 0 2.6908848667517304e-05
suppressor O 0 2.0428615243872628e-05
gene O 0 1.2871908438683022e-05
predisposes O 0 3.5548080631997436e-05
affected O 0 4.676267622016894e-07
individuals O 0 4.238741801998458e-09
to O 0 1.2995623244194121e-08
the O 0 1.8431515513839258e-07
human O 0 0.00015947931387927383
VHL B-Disease 1 0.9999936819076538
cancer I-Disease 1 0.9999991655349731
syndrome I-Disease 1 0.9999853372573853
and O 0 2.0590923099916836e-07
is O 0 5.310414152859266e-08
associated O 0 1.424125173343782e-07
with O 0 4.274283469385409e-07
sporadic B-Disease 1 0.6739606857299805
renal I-Disease 1 0.9999996423721313
cell I-Disease 1 0.9999994039535522
carcinomas I-Disease 1 1.0
( O 0 0.0003296721260994673
RCC B-Disease 1 0.9018017649650574
) O 0 1.013543055705668e-06
and O 0 1.893746684800135e-06
brain B-Disease 0 0.0032153395004570484
hemangioblastomas I-Disease 0 0.0006241430528461933
. O 0 7.473742584807042e-07

VHL O 0 0.02108769677579403
- O 0 0.0012037685373798013
negative O 0 1.3223983842181042e-05
786 O 0 6.683531864837278e-06
- O 0 2.88543105853023e-05
0 O 0 8.341331181327405e-07
RCC B-Disease 0 7.29733073967509e-05
cells O 0 1.511055756964197e-06
are O 0 4.646688811504873e-09
tumorigenic O 0 4.276218078302918e-06
in O 0 1.3933460252246732e-07
nude O 0 0.0012091847602277994
mice O 0 8.593916572863236e-05
which O 0 1.2509124758253165e-07
is O 0 1.802866833600092e-08
suppressed O 0 1.2209514288485934e-08
by O 0 3.6409703030315654e-10
the O 0 3.651111635250004e-09
reintroduction O 0 7.491361202482949e-07
of O 0 2.217961636574728e-08
VHL B-Disease 0 4.4977034121984616e-05
. O 0 6.303921509243082e-07

Remarkably O 0 0.00010217116505373269
, O 0 6.161139509686109e-08
this O 0 2.9631512798999893e-09
occurs O 0 3.464710962575168e-09
without O 0 8.550510854909987e-10
affecting O 0 9.528459798957556e-09
the O 0 1.981201869227789e-09
growth O 0 7.861322046665009e-07
rate O 0 3.1105034281608823e-07
and O 0 2.7749942788091175e-08
cell O 0 7.80946447775932e-06
cycle O 0 1.5632411987098749e-06
profile O 0 2.1059229027287074e-07
of O 0 6.942823538302889e-10
these O 0 1.8887675867773623e-09
cells O 0 8.191378952915329e-08
in O 0 6.724625301046672e-09
culture O 0 2.5238875878130784e-07
. O 0 3.98722164618448e-07

The O 0 8.543611897948722e-07
786 O 0 5.376515218813438e-06
- O 0 2.543771370255854e-05
0 O 0 5.372785949475656e-07
cell O 0 1.1671945685520768e-05
line O 0 4.765975518239429e-06
, O 0 7.089625775336117e-09
like O 0 3.644349266807012e-09
many O 0 4.124700136998172e-09
cancer B-Disease 0 1.2321596614128794e-06
cells O 0 1.3156567035821354e-07
, O 0 2.1083598866766806e-08
fails O 0 5.515867087524384e-07
to O 0 9.67976632182399e-09
exit O 0 8.843258001434151e-07
the O 0 9.883681428846103e-09
cell O 0 2.6610432541929185e-05
cycle O 0 2.6387983780296054e-06
upon O 0 6.989012746316803e-08
serum O 0 1.463161197534646e-06
withdrawal O 0 3.3131111649709055e-06
. O 0 2.8580251409948687e-07

Here O 0 3.234055611756048e-06
, O 0 8.155414121802096e-08
it O 0 7.82352937989117e-09
is O 0 1.1626952733934104e-09
shown O 0 2.772813090246018e-09
that O 0 2.541477583939411e-10
reintroduction O 0 3.3820779066218165e-08
of O 0 4.742203851826332e-10
the O 0 1.9176589205471828e-09
wild O 0 1.8041572502625058e-07
- O 0 8.249065103882458e-06
type O 0 4.796744974555622e-07
VHL B-Disease 0 3.1900221983960364e-06
gene O 0 3.4575177210172114e-07
restores O 0 1.034528509080701e-06
the O 0 4.967477096329276e-09
ability O 0 2.989162695143932e-08
of O 0 4.708696099697818e-09
VHL O 0 0.00027948583010584116
- O 0 0.01979552023112774
negative O 0 8.677641017129645e-05
RCC B-Disease 0 0.04095369577407837
cancer I-Disease 0 6.401695281965658e-05
cells O 0 3.009919566920871e-07
to O 0 1.5451709245439815e-08
exit O 0 1.065379706233216e-06
the O 0 8.38059133201341e-09
cell O 0 6.413885330402991e-06
cycle O 0 1.792996158656024e-06
and O 0 4.6990443536287785e-08
enter O 0 1.8049972538847214e-07
G0 O 0 1.5572442862321623e-05
/ O 0 1.4844481484033167e-05
quiescence O 0 1.4582077483282774e-06
in O 0 2.5335136655257884e-08
low O 0 6.188304269016953e-07
serum O 0 2.0126533399889013e-06
. O 0 3.087560287440283e-07

Both O 0 1.5591318742735893e-06
VHL O 0 0.0002817645145114511
- O 0 5.3018215112388134e-05
positive O 0 2.8348267733235843e-07
and O 0 5.077032483313815e-08
VHL O 0 0.00013516600301954895
- O 0 0.000203490984858945
negative O 0 4.8201504796452355e-06
RCC B-Disease 0 8.53475576150231e-05
cells O 0 1.245771159119613e-06
exit O 0 1.0588373697828501e-06
the O 0 7.958806058638856e-09
cell O 0 8.966531822807156e-06
cycle O 0 1.1840187426059856e-06
by O 0 8.501630510693303e-09
contact O 0 8.879047186383104e-07
inhibition O 0 1.4243711348171928e-06
. O 0 4.840197220801201e-07

The O 0 1.093569039767317e-06
cyclin O 0 5.9969133872073144e-05
- O 0 2.441028664179612e-05
dependent O 0 1.9713304482138483e-06
kinase O 0 6.8985823418188374e-06
inhibitor O 0 6.302940960267733e-07
, O 0 8.148786534434294e-09
p27 O 0 1.2074421817942493e-07
, O 0 2.3904418444686826e-09
accumulates O 0 3.736300158152517e-08
upon O 0 2.4616511051789303e-09
serum O 0 5.413366110929019e-08
withdrawal O 0 1.6686207970906253e-07
, O 0 1.7901226057048802e-09
only O 0 3.998290032392049e-10
in O 0 2.9075669649714087e-10
the O 0 7.776779775703346e-10
presence O 0 1.4645514800903925e-09
of O 0 7.873074414632697e-10
VHL B-Disease 0 2.4106409455271205e-06
, O 0 7.659663125991756e-09
as O 0 2.069307614149807e-09
a O 0 5.522417634296062e-09
result O 0 7.981852512273235e-09
of O 0 2.4906290918558227e-10
the O 0 7.107457733468436e-09
stabilization O 0 3.184545960266405e-08
of O 0 4.0630515618644836e-10
the O 0 6.675756392127141e-09
protein O 0 7.58706505621376e-07
. O 0 1.8389202693924744e-07

We O 0 2.1448929601319833e-06
propose O 0 2.3703194074187195e-07
that O 0 3.491765321328444e-09
the O 0 3.4164651108170574e-09
loss O 0 8.833980302824784e-08
of O 0 3.6682393234066524e-10
wild O 0 3.9767934367773705e-07
- O 0 3.06416186504066e-05
type O 0 1.691517809376819e-06
VHL B-Disease 0 9.565695108904038e-06
gene O 0 1.7306995232502231e-06
results O 0 8.744944324234893e-08
in O 0 2.3296389817240026e-10
a O 0 4.076762483151697e-09
specific O 0 9.177003157390118e-09
cellular O 0 2.0312989363446832e-05
defect O 0 2.183518517995253e-06
in O 0 7.304580940115102e-09
serum O 0 4.190492290945258e-07
- O 0 3.2938780805125134e-06
dependent O 0 5.090907507110387e-06
growth O 0 5.9956669247185346e-06
control O 0 1.344634142697032e-06
, O 0 3.201671816555063e-08
which O 0 9.134065948046555e-08
may O 0 5.681133075086109e-07
initiate O 0 4.952362360199913e-07
tumor B-Disease 0 1.9804336261586286e-05
formation O 0 3.17844467190298e-07
. O 0 2.4016679844862665e-07

This O 0 3.731415176844166e-07
is O 0 9.418172197683816e-08
corrected O 0 4.0563413676864e-06
by O 0 1.2208064559260379e-09
the O 0 1.4319464503032009e-09
reintroduction O 0 9.117199795127817e-08
of O 0 1.0017249252314286e-09
wild O 0 1.2321837061790575e-07
- O 0 5.5393862567143515e-05
type O 0 6.115051746746758e-06
VHL B-Disease 0 0.000106177365523763
, O 0 8.211605972974212e-08
implicating O 0 4.105968855583342e-06
VHL B-Disease 0 4.3304680730216205e-06
as O 0 8.827542252731746e-09
the O 0 1.7487745695987655e-09
first O 0 1.2640414581710502e-07
tumor B-Disease 0 1.452542051083583e-06
suppressor O 0 8.818843753033434e-07
involved O 0 2.4402698528547262e-08
in O 0 2.15727880004124e-09
the O 0 2.0670904987696304e-09
regulation O 0 1.1295143487188852e-08
of O 0 1.4169870832247966e-09
cell O 0 9.337516530649737e-06
cycle O 0 1.1193527825525962e-05
exit O 0 0.0001023923687171191
, O 0 4.266093966975859e-08
which O 0 1.259429982525262e-08
is O 0 6.821356812736212e-09
consistent O 0 2.3653530689671243e-08
with O 0 7.22836346334077e-10
its O 0 1.8768177767469751e-07
gatekeeper O 0 2.935453721875092e-06
function O 0 5.610092301822078e-08
in O 0 7.04050862054828e-09
the O 0 9.97342866071449e-08
kidney O 0 0.00011966257443418726
. O 0 4.573063350221673e-08
. O 0 1.5445839096628333e-07

Piebaldism B-Disease 1 0.9999992847442627
with O 0 0.008317193947732449
deafness B-Disease 1 1.0
: O 0 1.4564981256626197e-06
molecular O 0 1.6341974742317689e-06
evidence O 0 4.637987416344913e-08
for O 0 1.5518045515250378e-08
an O 0 1.7373113792018557e-07
expanded O 0 0.00015887885820120573
syndrome O 1 0.995672345161438
. O 0 8.734731409276719e-07

In O 0 2.399200411673519e-07
a O 0 7.344301167222511e-08
South O 0 1.1009677791662398e-07
African O 0 4.003208431413441e-08
girl O 0 7.705280609116016e-07
of O 0 3.576479556954837e-09
Xhosa O 0 5.137485277373344e-05
stock O 0 9.429957572137937e-06
with O 0 7.643743771268419e-08
severe O 0 1.614158281881828e-05
piebaldism B-Disease 0 0.0002347225818084553
and O 0 6.170010237838142e-06
profound O 0 0.00019682418496813625
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 9.237381163984537e-05
identified O 0 6.993273018451873e-07
a O 0 1.715975272986725e-08
novel O 0 7.221218112363204e-08
missense O 0 7.600912681482441e-07
substitution O 0 2.0333255079663104e-08
at O 0 2.4251249897133675e-08
a O 0 7.181191641336682e-09
highly O 0 1.127275961465557e-08
conserved O 0 3.8346630759633626e-08
residue O 0 1.2675904770276247e-07
in O 0 9.641987208652836e-10
the O 0 9.655826138654788e-10
intracellular O 0 4.198416192480181e-08
kinase O 0 7.938567705423338e-07
domain O 0 2.6009754350297953e-08
of O 0 7.415646430253275e-10
the O 0 4.549909338180669e-09
KIT O 0 6.499894425360253e-06
proto O 0 2.5011437173816375e-05
- O 0 1.1066538718296215e-05
oncogene O 0 8.846253876981791e-06
, O 0 1.3916390706469883e-08
R796G O 0 1.0679940487534623e-06
. O 0 2.600138202524249e-07

Though O 0 2.2517338948091492e-05
auditory B-Disease 0 0.0010445988737046719
anomalies I-Disease 0 0.1487468183040619
have O 0 3.89095589525823e-07
been O 0 7.955652847613237e-08
observed O 0 8.160206732554798e-08
in O 0 5.279245485212414e-09
mice O 0 9.83780182650662e-07
with O 0 7.807697599560015e-09
dominant O 0 6.3406009758182336e-06
white O 0 4.107210315851262e-06
spotting O 0 0.00011341559002175927
( O 0 5.420659476840228e-07
W O 0 0.033602215349674225
) O 0 1.9961511554811295e-08
due O 0 2.0733816441520503e-08
to O 0 3.0348804358482084e-08
KIT O 0 0.00021876997197978199
mutations O 0 0.00020528858294710517
, O 0 2.9607995202241e-06
deafness B-Disease 1 1.0
is O 0 2.3763014667110838e-07
not O 0 1.3669523291071073e-08
typical O 0 4.232143524518506e-08
in O 0 3.2291410434481804e-08
human O 0 1.9696437902894104e-07
piebaldism B-Disease 0 4.3079769966425374e-05
. O 0 5.226638108979387e-07

Thus O 0 2.0794350348296575e-06
, O 0 2.2067455418550708e-08
the O 0 3.991876162956487e-09
occurrence O 0 1.1775358643717482e-06
of O 0 4.600358636253077e-07
sensorineural B-Disease 1 0.9999967813491821
deafness I-Disease 1 1.0
in O 0 1.2186769708932843e-06
this O 0 6.801612073559227e-08
patient O 0 8.975522973742045e-07
extends O 0 4.38474714314907e-08
considerably O 0 2.8408348384800775e-07
the O 0 3.503052070641388e-09
phenotypic O 0 8.304155585392436e-08
range O 0 2.1704705588376783e-08
of O 0 2.324309411605441e-09
piebaldism B-Disease 0 8.05077979748603e-06
due O 0 2.939297161219656e-08
to O 0 4.847336310120909e-09
KIT O 0 5.637744493469654e-07
gene O 0 1.1874774941134092e-07
mutation O 0 5.1548994406402926e-08
in O 0 1.956884210230214e-09
humans O 0 2.0168286596344842e-08
and O 0 3.3367768992320634e-08
tightens O 0 8.156193507602438e-05
the O 0 2.0846952608621905e-08
clinical O 0 4.322922819710584e-08
similarity O 0 1.639720181856319e-08
between O 0 1.2287825867929314e-08
piebaldism B-Disease 0 1.853530375228729e-05
and O 0 1.097710988773315e-08
the O 0 4.4563841505862456e-10
various O 0 3.806203963119259e-10
forms O 0 1.989340603358869e-07
of O 0 7.186270067904843e-07
Waardenburg B-Disease 1 0.9999840259552002
syndrome I-Disease 1 0.9999018907546997
. O 0 5.9011888708937477e-08
. O 0 2.7955809400737053e-07

Cycloheximide O 0 0.00013010052498430014
facilitates O 0 1.7054741192623624e-06
the O 0 8.273828733251776e-09
identification O 0 2.1367309699371617e-08
of O 0 1.601182408883517e-09
aberrant O 0 2.6490299660508754e-06
transcripts O 0 3.828258286375785e-06
resulting O 0 7.311247429697687e-08
from O 0 2.1329429333860617e-09
a O 0 1.9762660841138313e-08
novel O 0 2.0051270155363454e-07
splice O 0 0.0004783025069627911
- O 0 7.175097562139854e-05
site O 0 6.298996595432982e-06
mutation O 0 4.2407739897498686e-07
in O 0 5.041028483532273e-09
COL17A1 O 0 1.319797956966795e-05
in O 0 4.722997548611829e-09
a O 0 7.57616334112754e-08
patient O 0 7.049177384033101e-07
with O 0 6.403822538914028e-08
generalized O 0 0.0002745588426478207
atrophic B-Disease 1 0.9985166192054749
benign I-Disease 1 0.9721899628639221
epidermolysis I-Disease 1 0.9937335848808289
bullosa I-Disease 1 0.7060064673423767
. O 0 1.339909249509219e-05

Patients O 0 0.0013146745041012764
with O 0 1.5070592098709312e-06
generalized O 0 0.0008253522682935
atrophic B-Disease 1 0.9998537302017212
benign I-Disease 1 0.9990658164024353
epidermolysis I-Disease 1 0.996368408203125
bullosa I-Disease 1 0.7702279686927795
often O 0 1.5308127331081778e-05
show O 0 1.211255607813655e-06
decreased O 0 8.399757120969298e-07
expression O 0 5.5888495609224265e-08
of O 0 3.502718115555581e-09
type O 0 3.716789933605469e-06
XVII O 0 0.00010369578376412392
collagen O 0 4.093754250789061e-05
, O 0 1.066567190122214e-08
a O 0 1.4336362319511409e-08
transmembrane O 0 1.769346340552147e-07
hemidesmosomal O 0 4.7595710839232197e-07
protein O 0 4.342566484183408e-08
encoded O 0 4.294602717891394e-08
by O 0 1.1120366849581842e-08
COL17A1 O 0 8.87697096914053e-05
. O 0 3.924724296666682e-07

This O 0 7.851297141314717e-07
report O 0 3.3292602097390045e-07
documents O 0 2.48317508777518e-08
a O 0 7.013220226781414e-09
novel O 0 6.23103062480368e-08
splice O 0 0.0004888966795988381
- O 0 4.36284790339414e-05
site O 0 2.7095541099697584e-06
mutation O 0 3.984534089340741e-07
in O 0 3.300228756941692e-09
COL17A1 O 0 2.2573454771190882e-05
in O 0 8.042245980277585e-09
a O 0 7.998772844075575e-08
patient O 0 5.492732952916413e-07
with O 0 4.307769785327764e-08
generalized O 0 0.0001527170679764822
atrophic B-Disease 1 0.9967156648635864
benign I-Disease 1 0.8986990451812744
epidermolysis I-Disease 1 0.8237258195877075
bullosa I-Disease 0 0.059748124331235886
, O 0 6.12408769029571e-07
and O 0 1.3670097054330199e-08
applies O 0 3.2104514602337986e-09
a O 0 2.897260653611511e-09
new O 0 1.735686083748078e-08
methodology O 0 7.045427707907947e-08
to O 0 6.467255619924117e-09
define O 0 1.154105859768606e-07
and O 0 4.371744921627396e-08
characterize O 0 7.487311677323305e-07
the O 0 9.679545165397485e-09
resulting O 0 6.386769513255786e-08
mRNA O 0 6.590525458705088e-07
splice O 0 0.0001444345252821222
variants O 0 5.984511062706588e-06
. O 0 5.952306310064159e-07

Mutational O 0 0.0006276039639487863
analysis O 0 2.22157041207538e-06
of O 0 2.9669983803159994e-08
COL17A1 O 0 4.4053831516066566e-05
identified O 0 9.046263471645943e-07
a O 0 1.1085027296076078e-07
maternally O 0 1.427516599505907e-05
inherited O 0 4.417979289428331e-05
G O 0 0.0004145486163906753
- O 0 1.809848254197277e-05
to O 0 1.235270474353456e-06
- O 0 5.5894997785799205e-05
T O 0 0.00012654140300583094
transversion O 0 6.879923262204102e-07
at O 0 1.83835489053763e-08
the O 0 7.859001227572548e-10
- O 0 3.253344686982018e-07
1 O 0 2.246560271146336e-08
position O 0 4.120188989986673e-08
of O 0 2.8726256928734983e-09
exon O 0 6.673976145066263e-07
32 O 0 1.609365227750459e-07
. O 0 1.2236608881721622e-07

This O 0 2.1949462336579018e-07
acceptor O 0 7.982622491908842e-07
splice O 0 7.29696184862405e-05
- O 0 2.91708256554557e-05
site O 0 1.21848756862164e-06
mutation O 0 5.16348052315152e-07
led O 0 9.864772998469107e-09
to O 0 3.33176419786696e-09
the O 0 8.237889814743937e-10
formation O 0 6.8414225395940775e-09
of O 0 8.860735478677384e-10
aberrant O 0 2.8280354058551893e-07
transcripts O 0 2.681549631233793e-07
present O 0 1.930850679343621e-08
at O 0 4.598402014721614e-08
extremely O 0 3.500181833260285e-08
low O 0 1.516337704288162e-07
levels O 0 5.526561608348857e-08
. O 0 1.2672956017922843e-07

Based O 0 2.130617758666631e-06
on O 0 4.860513627136243e-07
our O 0 6.301979738054797e-08
recent O 0 2.3767134038621407e-08
finding O 0 4.4412672650651075e-08
that O 0 1.9037129206367354e-08
cycloheximide O 0 1.0561713679635432e-05
stabilized O 0 2.669270361366216e-05
mutant O 0 5.898285735383979e-07
COL17A1 O 0 9.871278962236829e-06
transcripts O 0 4.2207250317005673e-07
in O 0 7.745785346457978e-09
keratinocytes O 0 1.3480121197062545e-06
homozygous O 0 2.6933597041534085e-07
for O 0 1.2341231370172068e-09
a O 0 4.206712489462916e-08
frameshift O 0 7.853713032091036e-05
mutation O 0 1.2250754934939323e-06
, O 0 4.102409523198958e-09
the O 0 2.862343473353235e-09
effects O 0 8.956149599725904e-08
of O 0 6.814279140954227e-10
the O 0 5.389801049915377e-09
splice O 0 0.003634994849562645
- O 0 1.4700085557706188e-05
site O 0 1.302062855756958e-06
mutation O 0 5.0203439627694024e-08
on O 0 6.593641188601396e-09
splicing O 0 1.40552430138996e-07
of O 0 1.8006871549403058e-09
COL17A1 O 0 8.768794941715896e-06
transcripts O 0 1.7695016651941842e-07
were O 0 3.5100882200822525e-09
determined O 0 3.368312517793015e-09
using O 0 5.047628537369064e-09
reverse O 0 1.2564138387460844e-06
transcriptase O 0 5.072888143331511e-06
polymerase O 0 6.054465870874992e-07
chain O 0 2.233108716609422e-06
reaction O 0 8.950511443117648e-09
of O 0 1.7693371767713018e-10
total O 0 2.090172701585402e-09
RNA O 0 1.8031182946742774e-07
from O 0 9.584125493233842e-09
keratinocytes O 0 7.875556775616133e-07
incubated O 0 1.6164715077593428e-07
for O 0 9.614079310438228e-09
2 O 0 5.626154830906671e-08
. O 0 2.707707551508065e-07

5 O 0 1.8157928707296378e-06
h O 0 1.674998929956928e-05
in O 0 7.1594050687906474e-09
the O 0 3.7299185962069714e-09
presence O 0 8.47003711612615e-09
or O 0 3.7472624114798236e-08
absence O 0 8.546308549739479e-09
of O 0 7.734001217230002e-10
10 O 0 3.103024681649913e-08
microg O 0 3.183931312378263e-06
cycloheximide O 0 3.1027518616610905e-06
per O 0 3.7815294717802317e-07
ml O 0 2.8317341275396757e-05
. O 0 3.6076067999601946e-07

Using O 0 3.9006826568765973e-07
this O 0 2.994789483068416e-08
approach O 0 1.7624046222408651e-07
, O 0 2.0395130917449933e-08
an O 0 9.718319482487914e-09
abnormally O 0 6.806102192058461e-06
spliced O 0 0.0010340347653254867
transcript O 0 0.0014191577211022377
was O 0 2.694731620067614e-06
identified O 0 6.40906421267573e-08
that O 0 2.33067898314232e-10
contains O 0 1.9958827646160415e-10
an O 0 4.791610441756688e-10
extra O 0 3.4790013092589334e-09
264 O 0 4.810733589266647e-09
bases O 0 3.1535962730089295e-09
upstream O 0 2.5824087757087e-08
from O 0 2.8509505867191365e-09
exon O 0 1.779754370545561e-07
32 O 0 5.037302130972421e-08
, O 0 2.015197342331021e-09
resulting O 0 5.583636220052313e-09
in O 0 3.8665799451109706e-09
a O 0 9.59577846515458e-07
premature O 0 1.4707039554195944e-05
termination O 0 3.7856827361792966e-07
codon O 0 1.152265326709312e-06
27 O 0 4.546545824268833e-07
bp O 0 9.164680704998318e-06
downstream O 0 1.031254100780643e-06
from O 0 6.985611644694245e-09
the O 0 1.383841308211231e-08
cryptic O 0 1.2107811016903725e-05
splice O 0 0.0002826073905453086
site O 0 7.72525709180627e-06
. O 0 4.4241051000426523e-07

Three O 0 3.176029679252679e-07
other O 0 1.1704188729311227e-08
splice O 0 1.0168580956815276e-05
variants O 0 5.502474209606589e-07
, O 0 4.823412780297076e-09
including O 0 3.440895346429329e-10
one O 0 1.071078115089108e-09
derived O 0 1.340573763108921e-09
from O 0 4.2841916125802015e-10
the O 0 4.00058625116273e-10
skipping O 0 5.689142312803597e-08
of O 0 9.29453014553161e-10
exon O 0 5.05561899899476e-07
32 O 0 9.823357061122806e-08
, O 0 6.373904071210745e-09
were O 0 1.3056394188026843e-08
also O 0 1.3501463058673835e-07
identified O 0 6.25403458798246e-07
. O 0 1.7464762436247838e-07

These O 0 9.85287101684662e-07
results O 0 1.588135660313128e-06
indicate O 0 2.7501554811237838e-08
the O 0 1.6870199681662257e-09
usefulness O 0 1.66129066059284e-08
of O 0 5.463325902788085e-10
cycloheximide O 0 3.5879784263670444e-06
treatment O 0 6.619488601700141e-08
in O 0 4.37315850199127e-10
evaluating O 0 1.0460615484930713e-08
the O 0 6.717702394354319e-09
abnormal O 0 3.691049528242729e-07
processing O 0 2.2127643717340106e-08
of O 0 2.562133560868318e-10
mRNA O 0 4.280210319507205e-08
due O 0 3.916706958762006e-08
to O 0 1.2448236219597675e-08
splice O 0 0.0002536480315029621
- O 0 5.5203599913511425e-05
site O 0 1.5210146557365078e-05
mutations O 0 1.1732970051525626e-05
, O 0 8.70046967804683e-09
because O 0 1.4852511220908582e-08
( O 0 1.7955503750499702e-08
i O 0 3.999633122475643e-07
) O 0 8.250599314862939e-09
aberrant O 0 1.1076975425794444e-07
splicing O 0 4.5577201035484904e-07
often O 0 2.110331287497047e-08
generates O 0 3.076634413901047e-08
a O 0 7.043304606213496e-08
premature O 0 1.9754631921387045e-06
termination O 0 9.976853476700853e-08
codon O 0 3.510197927880654e-07
, O 0 1.880185074298879e-08
( O 0 8.401910278621472e-09
ii O 0 7.909707164799329e-07
) O 0 1.1890929130231598e-08
transcripts O 0 1.15073405027033e-07
with O 0 1.813828198748979e-08
premature O 0 4.3148503436896135e-07
termination O 0 2.13477555632835e-08
codons O 0 1.1050407522361638e-07
can O 0 1.710472297133947e-08
occur O 0 5.75960523718777e-09
at O 0 8.273797647007086e-09
low O 0 2.3774667567977303e-07
or O 0 3.9623702718927234e-07
undetectable O 0 7.176878625614336e-06
levels O 0 1.7586060607754916e-08
due O 0 6.547821840285906e-09
to O 0 4.930155395044267e-09
nonsense O 0 2.832254040185944e-07
- O 0 7.607816314703086e-07
mediated O 0 3.815610796209512e-07
mRNA O 0 2.971291124254094e-08
decay O 0 2.2851861558592645e-07
, O 0 6.945978903161176e-09
and O 0 1.483637301902263e-08
( O 0 7.929199519196573e-09
iii O 0 8.105160986815463e-07
) O 0 5.271055592004359e-09
the O 0 7.4204042910253065e-09
levels O 0 1.2474381527738387e-08
of O 0 3.215180621740643e-10
these O 0 1.3890130157179215e-09
transcripts O 0 2.6042872036668996e-07
can O 0 1.62398965386501e-08
be O 0 7.043423178032526e-09
increased O 0 7.112597177894031e-09
by O 0 6.007667696650287e-09
cycloheximide O 0 7.103142252162797e-06
. O 0 2.854037575161783e-07

A O 0 1.3158039564586943e-06
deletion O 0 1.2254540706635453e-05
mutation O 0 2.0689356006187154e-06
in O 0 2.8970632115488115e-08
COL17A1 O 0 9.478745778324082e-05
in O 0 2.1545906392361758e-08
five O 0 4.3974946350999744e-08
Austrian O 0 6.2421868278761394e-06
families O 0 1.012540273848117e-08
with O 0 2.5477119081074306e-08
generalized O 0 7.15795176802203e-05
atrophic B-Disease 1 0.9894928932189941
benign I-Disease 1 0.8247454762458801
epidermolysis I-Disease 1 0.9124855399131775
bullosa I-Disease 0 0.07796846330165863
represents O 0 1.7809711607696954e-06
propagation O 0 6.422305318665167e-07
of O 0 4.014522936302001e-09
an O 0 1.3892124783865256e-08
ancestral O 0 1.3001125807932112e-05
allele O 0 0.00015671420260332525
. O 0 1.6987537492241245e-06

Patients O 0 0.0018767587607726455
with O 0 8.208205599657958e-07
generalized O 0 0.0011658763978630304
atrophic B-Disease 1 0.9997877478599548
benign I-Disease 1 0.9995318651199341
epidermolysis I-Disease 1 0.9987938404083252
bullosa I-Disease 1 0.8733147978782654
, O 0 4.2649469378375215e-07
a O 0 5.775912015337781e-08
usually O 0 3.3891360828874895e-08
nonlethal O 0 4.995304720978311e-07
form O 0 1.1932203847209166e-07
of O 0 5.776540135116193e-08
junctional B-Disease 0 0.07677539438009262
epidermolysis I-Disease 1 0.7884290814399719
bullosa I-Disease 0 0.04222000017762184
, O 0 8.740042289900884e-08
have O 0 8.411884522274704e-09
generalized O 0 2.4656989694449294e-07
blistering B-Disease 0 0.00018175033619627357
, O 0 2.1002358607802307e-06
nail B-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9997952580451965
, O 0 1.679721776781662e-06
patchy B-Disease 0 0.07644851505756378
alopecia I-Disease 1 0.9999860525131226
, O 0 6.609811293856183e-07
and O 0 1.7935843743543955e-06
dental B-Disease 0 0.026093516498804092
abnormalities I-Disease 1 0.5585235953330994
. O 0 1.064745902112918e-06

Skin B-Disease 1 0.9999723434448242
fragility I-Disease 0 0.08057603240013123
in O 0 2.041810063246885e-07
most O 0 1.7494860671263268e-08
cases O 0 1.0748995471487888e-08
is O 0 5.830855354105324e-09
due O 0 3.5663450859146906e-08
to O 0 4.9440380678333895e-08
mutations O 0 2.0363650321542082e-07
in O 0 8.662264794345731e-10
the O 0 2.4757489391902254e-09
gene O 0 1.832500515774882e-07
encoding O 0 2.6194365432274935e-07
type O 0 5.389122179622063e-06
XVII O 0 0.00022033978893887252
collagen O 0 0.0005479943938553333
( O 0 1.9542299867225665e-07
COL17A1 O 0 7.24635538063012e-05
) O 0 9.167349901417765e-08
. O 0 2.3840145502163068e-07

Recently O 0 9.193881851388142e-05
, O 0 2.7494954224493995e-07
we O 0 8.125928729896259e-08
reported O 0 2.8019414344271354e-07
five O 0 5.709140715737249e-09
Austrian O 0 1.9168755898135714e-06
families O 0 8.191844536042936e-09
with O 0 2.9288433012197856e-08
generalized O 0 7.084340904839337e-05
atrophic B-Disease 1 0.9844539761543274
benign I-Disease 1 0.8030984401702881
epidermolysis I-Disease 1 0.8589175343513489
bullosa I-Disease 1 0.54091876745224
who O 0 2.5415210984647274e-05
share O 0 1.0218917623205925e-06
the O 0 7.98234012222565e-09
same O 0 1.2689548611888313e-07
COL17A1 O 0 0.0002063051942968741
mutation O 0 9.313282134826295e-06
. O 0 3.1335034123003425e-07

Affected O 0 3.431551522226073e-05
individuals O 0 4.346593485138328e-08
in O 0 1.4444559326420858e-08
three O 0 8.669458928523e-09
families O 0 5.5444546731564515e-09
are O 0 2.035186907889397e-09
homozygous O 0 7.149827752073179e-08
for O 0 3.726448483121203e-09
4003delTC O 0 7.7331145575954e-07
, O 0 1.2042736585726743e-08
whereas O 0 1.4977082685163623e-08
those O 0 1.1305526514959752e-09
in O 0 2.1952251127999034e-09
two O 0 1.8699923387544004e-08
others O 0 1.4774506951198418e-07
are O 0 4.699274747110849e-09
compound O 0 4.911489668302238e-07
heterozygotes O 0 6.992745056777494e-06
. O 0 2.2134867094791844e-07

To O 0 1.9100307326880284e-06
determine O 0 2.865546662178531e-07
if O 0 1.7715709788035383e-08
the O 0 2.03938355092248e-09
occurrence O 0 5.014841164552308e-08
of O 0 1.0273830675089357e-09
4003delTC O 0 7.132916834962089e-07
in O 0 2.928730147289116e-09
these O 0 4.5073150767294123e-10
unrelated O 0 1.2469196342124178e-08
families O 0 2.4146140642500313e-09
signifies O 0 2.4419275490572545e-08
propagation O 0 3.3625241258050664e-08
of O 0 1.0040931419652566e-09
an O 0 1.814872363503639e-09
ancestral O 0 4.2542632172626327e-07
allele O 0 7.485736205126159e-06
or O 0 1.7662274842678016e-07
a O 0 2.6426100419030263e-08
mutational O 0 4.752214408654254e-06
hot O 0 4.354308657639194e-06
spot O 0 2.3937223886605352e-05
, O 0 3.483199151332883e-08
haplotypes O 0 2.485526465534349e-06
were O 0 7.038416072191467e-08
determined O 0 2.6417483312002332e-08
for O 0 2.7175384165190053e-09
polymorphisms O 0 3.092601673415629e-06
both O 0 1.4005621551405056e-08
within O 0 1.0855846888091492e-08
and O 0 2.1297331898040284e-07
flanking O 0 7.32380140107125e-05
COL17A1 O 0 0.0018329254817217588
. O 0 9.643840712669771e-07

Five O 0 3.861935510940384e-06
intragenic O 0 0.00013255114026833326
polymorphisms O 0 0.00012035731197101995
were O 0 5.583590336755151e-07
chosen O 0 9.582502968896733e-08
based O 0 6.486641268566018e-08
on O 0 1.5764470617796178e-07
their O 0 2.5214720267285884e-07
informativeness O 0 0.00012422144936863333
. O 0 7.052754540382011e-07

One O 0 7.68608117596159e-07
of O 0 1.0322804833151622e-08
these O 0 2.4901789519304884e-09
, O 0 9.413176016437319e-09
not O 0 4.1074539325336445e-08
previously O 0 8.242280955528258e-07
reported O 0 5.401635917223757e-06
, O 0 7.807340551835296e-09
was O 0 5.933445379469049e-08
2988 O 0 3.4213574195973706e-08
A O 0 1.1539496114210124e-07
or O 0 7.119331968397091e-08
C O 0 1.106121089833323e-06
that O 0 1.1975501701400049e-09
introduces O 0 1.1098923557995022e-08
a O 0 2.50516163369241e-09
new O 0 3.1967641866970098e-09
restriction O 0 2.5613628995557747e-09
site O 0 5.9102678306999223e-08
for O 0 5.561910043638818e-09
Eco0109 O 0 8.703077014615701e-07
I O 0 3.8013617995602544e-06
. O 0 1.6854521334153105e-07

All O 0 1.6876460051662434e-07
the O 0 3.053763109051033e-08
4003delTC O 0 1.078369905371801e-06
alleles O 0 4.29432049031675e-07
showed O 0 2.412571973309241e-07
the O 0 1.5624959104343361e-09
same O 0 8.711245946813051e-09
haplotype O 0 3.838003976852633e-06
for O 0 5.026032479094056e-09
these O 0 9.950409385339753e-10
five O 0 1.4604126796768924e-08
polymorphic O 0 6.559494977409486e-06
markers O 0 9.333777597930748e-06
. O 0 7.16562340130622e-07

Fourteen O 0 3.62349055649247e-05
microsatellite O 0 0.00013048989058006555
polymorphisms O 0 0.0002757474430836737
were O 0 1.2206625115140923e-06
selected O 0 2.885350447456858e-08
based O 0 2.9835575787728885e-08
on O 0 1.8051125039164617e-07
their O 0 6.471972113786251e-08
high O 0 1.678727556964077e-07
heterozygosity O 0 4.0711782389735163e-07
and O 0 1.2217015843418721e-08
their O 0 4.24720703051662e-09
location O 0 9.216422114377565e-08
within O 0 6.4200609273257214e-09
10q23 O 0 8.137054123835696e-07
- O 0 1.8701351791605703e-06
q25 O 0 1.774835027390509e-06
near O 0 1.6118624444061425e-06
COL17A1 O 0 0.00021276314510032535
. O 0 5.463336378852546e-07

Three O 0 7.791127245582175e-07
families O 0 1.0714243359188913e-07
shared O 0 9.467287043207762e-08
microsatellite O 0 9.709050573292188e-06
polymorphisms O 0 0.00011331559653626755
covering O 0 1.015054112940561e-05
at O 0 3.3097353480116e-06
most O 0 3.83089791000657e-08
19 O 0 1.0016073304086603e-07
cM O 0 1.5628266680778324e-07
, O 0 3.999672593124615e-09
whereas O 0 4.2568903957374005e-09
the O 0 2.128955900460028e-09
others O 0 1.9763715997100917e-08
shared O 0 2.1297232866146487e-09
smaller O 0 1.9056965783192936e-08
regions O 0 9.593163952104078e-08
consistent O 0 1.402126343919008e-07
with O 0 6.2835052716536666e-09
cross O 0 5.556702490139287e-06
- O 0 1.8445758541929536e-05
over O 0 1.7618803838104213e-07
events O 0 1.0095454250347302e-08
during O 0 7.778148791715012e-09
passage O 0 4.556222954477107e-09
of O 0 2.8527605278050316e-10
this O 0 1.5733306879539555e-09
mutation O 0 2.260697762324071e-08
through O 0 3.4508611523875743e-09
several O 0 1.3726531022939525e-08
generations O 0 1.9968905462519615e-07
. O 0 1.8959879355406883e-07

These O 0 1.2881777138318284e-06
results O 0 3.937052952096565e-06
indicate O 0 2.4482054072905157e-07
that O 0 5.112176904020771e-09
4003delTC O 0 5.753118443863059e-07
occurs O 0 5.587450058186505e-09
on O 0 4.4216390548967865e-09
a O 0 4.034480749481872e-09
single O 0 1.190420988450569e-07
ancestral O 0 1.0243203405480017e-06
allele O 0 7.864457984396722e-06
. O 0 8.129882189678028e-08
. O 0 2.3433902640590532e-07

The O 0 8.859229296831472e-07
haptoglobin O 0 8.063270070124418e-05
- O 0 0.0001480329956393689
gene O 0 1.3858263628208078e-05
deletion O 0 3.960110552725382e-05
responsible O 0 3.573604772100225e-06
for O 0 7.181508721032515e-08
anhaptoglobinemia B-Disease 0 0.00023098105157259852
. O 0 9.35736181872926e-07

We O 0 9.104223863687366e-06
have O 0 3.526947978116368e-08
found O 0 1.3006385302105627e-08
an O 0 2.179700198112755e-09
allelic O 0 2.946387382962712e-07
deletion O 0 1.5054962432259344e-06
of O 0 3.073770349359961e-09
the O 0 6.981591837984524e-08
haptoglobin O 0 2.9126964363968e-05
( O 0 5.84630441835543e-08
Hp O 0 1.9046192392124794e-06
) O 0 2.0202928219248406e-09
gene O 0 1.7399951701690952e-08
from O 0 1.3413563593189792e-09
an O 0 1.2925706061039932e-09
individual O 0 3.021698002925177e-09
with O 0 3.988445484992553e-08
anhaptoglobinemia B-Disease 0 0.00011796935723396018
. O 0 4.905773494101595e-07

The O 0 6.393144076355384e-07
Hp O 0 3.288639163656626e-06
gene O 0 3.379467159447813e-07
cluster O 0 1.2059588527790766e-07
consists O 0 6.139973418584077e-09
of O 0 8.986086319495712e-10
coding O 0 1.7877781601782772e-06
regions O 0 1.311500170686486e-07
of O 0 8.34173896624435e-10
the O 0 1.4572072437601946e-08
alpha O 0 1.7727717249726993e-07
chain O 0 2.777902182060643e-06
and O 0 8.15090039907318e-09
beta O 0 4.911187456713151e-09
chain O 0 5.668713498607758e-08
of O 0 3.0058311395464443e-10
the O 0 2.4358788319744917e-09
haptoglobin O 0 7.618068025294633e-07
gene O 0 1.7173266542158672e-07
( O 0 3.768447776053563e-09
Hp O 0 1.0305757314199582e-06
) O 0 1.1232125229909684e-09
and O 0 1.4057320862903566e-09
of O 0 2.5788915447577665e-10
the O 0 7.103080346126944e-09
alpha O 0 6.271725538908868e-08
chain O 0 1.023842855829571e-06
and O 0 5.132831493170897e-09
beta O 0 4.272907361269063e-09
chain O 0 6.758973825071735e-08
of O 0 2.867396597938665e-10
the O 0 5.220010201867353e-09
haptoglobin O 0 3.913738055416616e-06
- O 0 6.432513600884704e-06
related O 0 7.143843276935513e-07
gene O 0 2.6912337034445954e-06
( O 0 7.488140596478843e-08
Hpr O 0 1.767843059496954e-05
) O 0 1.800763449466558e-08
, O 0 2.858508096892365e-09
in O 0 2.8562734399883993e-09
tandem O 0 5.786243377770006e-07
from O 0 8.164126263920934e-09
the O 0 5.550750969973706e-09
5 O 0 1.0617915080501916e-07
side O 0 4.7502433631052554e-07
. O 0 4.943792646372458e-07

Southern O 0 3.680862209876068e-05
blot O 0 0.005522770807147026
and O 0 1.0600467703625327e-06
PCR O 0 1.6297248293994926e-05
analyses O 0 6.018526050866058e-07
have O 0 5.143791170780787e-08
indicated O 0 1.4536490766658972e-07
that O 0 6.514694339543325e-10
the O 0 5.105411648997915e-10
individual O 0 9.940072098757469e-10
with O 0 3.7863587820652356e-09
anhaptoglobinemia B-Disease 0 8.041855835472234e-06
was O 0 2.1976315167648863e-07
homozygous O 0 3.018461924853e-08
for O 0 3.7585254353267317e-10
the O 0 8.010475616160306e-10
gene O 0 1.8262547030190035e-07
deletion O 0 1.3352049563764012e-06
and O 0 2.4838902490387227e-08
that O 0 1.4812218118720466e-09
the O 0 1.583932207616101e-09
gene O 0 9.514878485106237e-08
deletion O 0 6.948989721422549e-07
was O 0 1.765951225252138e-07
included O 0 1.5500525307743374e-09
at O 0 4.30386073446698e-08
least O 0 3.4072502597126686e-09
from O 0 7.893222186972082e-10
the O 0 2.451058023211772e-09
promoter O 0 3.5059497349720914e-06
region O 0 3.1293313895730535e-07
of O 0 3.190721242773975e-09
Hp O 0 9.909147138387198e-07
to O 0 9.965077651941101e-09
Hpr O 0 5.927568622610124e-07
alpha O 0 2.6263599295361928e-08
but O 0 3.1127564970034882e-09
not O 0 1.4511600809896663e-09
to O 0 5.000005742772373e-09
Hpr O 0 2.9881534828746226e-06
beta O 0 7.470622165328678e-08
( O 0 8.378115090579286e-09
Hpdel O 0 3.861971890728455e-06
) O 0 4.372803985575047e-08
. O 0 1.2398918158851302e-07

In O 0 4.833089519706846e-07
addition O 0 5.024846316814546e-08
, O 0 4.7607692010842584e-08
we O 0 2.253740483126876e-08
found O 0 6.851112122063796e-09
seven O 0 3.256645397797797e-09
individuals O 0 9.559269348313748e-11
with O 0 3.944419235679675e-10
hypohaptoglobinemia B-Disease 0 2.0153615878371056e-06
in O 0 5.3919912978983575e-09
three O 0 1.6214022124927396e-08
families O 0 2.3266026882851065e-09
, O 0 6.079180270290863e-09
and O 0 1.0869936062363195e-08
the O 0 5.132361646786876e-09
genotypes O 0 7.066179819048557e-08
of O 0 2.2180354775080957e-10
six O 0 6.693172238669831e-09
of O 0 3.3096952956057635e-10
the O 0 1.4960038541289578e-08
seven O 0 8.431903353312009e-08
individuals O 0 5.082860243810217e-10
were O 0 1.8353061292941675e-09
found O 0 6.3379350656589395e-09
to O 0 9.199926154224158e-09
be O 0 5.074254261216993e-08
Hp2 O 0 2.97223923553247e-05
/ O 0 4.252425060258247e-05
Hpdel O 0 2.4079703507595696e-05
. O 0 4.430657725151832e-07

The O 0 2.0283370361084962e-07
phenotypes O 0 2.0552208752633305e-06
and O 0 5.5355183548044806e-08
genotypes O 0 6.252364528336329e-07
in O 0 1.6876773756280272e-08
one O 0 1.5969590094755404e-08
of O 0 8.455360300807513e-10
these O 0 2.799052101210009e-09
three O 0 2.484890160303621e-08
families O 0 3.175494533991241e-09
showed O 0 1.8757727104912192e-07
the O 0 2.161855139348745e-09
father O 0 4.102615136503118e-08
to O 0 1.588628784077173e-08
be O 0 3.359460265528469e-08
hypohaptoglobinemic B-Disease 0 7.110875230864622e-06
( O 0 6.769034666120888e-09
Hp2 O 0 9.353863674732565e-07
) O 0 4.393459818174961e-09
and O 0 1.5672064535010577e-08
Hp2 O 0 1.0104344255523756e-05
/ O 0 1.041844006977044e-05
Hpdel O 0 2.605459940241417e-06
, O 0 4.3454639886419955e-09
the O 0 2.948470578800766e-09
mother O 0 1.1355415097114019e-07
to O 0 3.452618857480161e-09
be O 0 3.1726430371747938e-09
Hp2 O 0 1.8988775707384775e-07
- O 0 4.528060344455298e-07
1 O 0 1.1522231346816625e-07
and O 0 3.7122475760043017e-08
Hp1 O 0 5.177847924642265e-06
/ O 0 4.527366399997845e-06
Hp2 O 0 1.117906094805221e-06
, O 0 1.8527088752051668e-09
one O 0 1.5362425775933275e-09
of O 0 1.1836587265889875e-10
the O 0 3.8458827233966986e-09
two O 0 5.444856299163803e-08
children O 0 1.7580493505420236e-08
to O 0 4.041589729553152e-09
be O 0 1.8115843047894487e-08
hypohaptoglobinemic B-Disease 0 4.750673724629451e-06
( O 0 2.3544051153123746e-09
Hp2 O 0 3.0398746275750455e-07
) O 0 3.184993602189934e-09
and O 0 1.741210198247245e-08
Hp2 O 0 1.6715986930648796e-05
/ O 0 1.7089067114284262e-05
Hpdel O 0 3.5116183880745666e-06
, O 0 6.063338719997091e-09
and O 0 2.579689795112472e-09
the O 0 1.1717092851526445e-09
other O 0 3.0850475507548936e-09
child O 0 2.8218353875786306e-08
to O 0 4.744251214106043e-09
be O 0 6.152576226270412e-09
Hp1 O 0 4.3868803345503693e-07
and O 0 3.4406362203753815e-08
Hp1 O 0 1.1699808055709582e-05
/ O 0 8.721075573703274e-06
Hpdel O 0 3.130969162157271e-06
, O 0 7.866698403802275e-09
showing O 0 5.9202754698617355e-08
an O 0 3.1179381299040188e-09
anomalous O 0 8.399012472182221e-07
inheritance O 0 1.2193152088002535e-06
of O 0 2.3437605634057945e-08
Hp O 0 5.2110048272879794e-05
phenotypes O 0 4.1755285451472446e-07
in O 0 5.646943801451698e-09
the O 0 1.2976352437021887e-08
child O 0 1.8552988478859334e-07
with O 0 2.2888475115223628e-08
Hp1 O 0 0.00012899913417641073
. O 0 8.822822792353691e-07

The O 0 1.0451569778524572e-06
Hp2 O 0 0.00023931075702421367
/ O 0 0.0025014302227646112
Hpdel O 0 6.143721839180216e-05
individuals O 0 4.422147270588539e-08
had O 0 1.344949254189487e-07
an O 0 3.1242601838954442e-09
extremely O 0 1.6557294202357298e-08
low O 0 7.015832181878068e-08
level O 0 1.3837357037971287e-08
of O 0 1.7957002551582946e-09
Hp O 0 3.025052592420252e-06
( O 0 1.805412375155413e-09
mean O 0 1.0877173828305331e-08
+ O 0 2.807055352604948e-07
/ O 0 2.277348357893061e-06
- O 0 1.541422989248531e-06
SD O 0 1.351336595689645e-05
= O 0 8.571436183046899e-08
0 O 0 3.6299334649214643e-09
. O 0 8.344063218146403e-10
049 O 0 6.93176787081029e-08
+ O 0 6.00961911345621e-08
/ O 0 3.8896016008038714e-07
- O 0 1.4188057662067877e-07
0 O 0 1.0563411478869966e-08
. O 0 1.014202055671376e-09
043 O 0 2.425042282538925e-07
mg O 0 1.7760794435162097e-06
/ O 0 9.644254532759078e-07
ml O 0 4.837368692278687e-07
; O 0 5.071194131289758e-09
n O 0 4.3926200987698394e-07
= O 0 1.3274483023906214e-07
6 O 0 4.33052349535501e-08
) O 0 1.6325076845902231e-09
, O 0 2.8035402888093586e-09
compared O 0 6.505286087588047e-09
with O 0 5.548345116679343e-10
the O 0 5.041913109238294e-09
level O 0 1.9167273990206013e-08
( O 0 8.095645820382913e-10
1 O 0 2.937132315139479e-09
. O 0 7.174424387912381e-10
64 O 0 5.2786215398725744e-09
+ O 0 3.2841303010400225e-08
/ O 0 4.4679464394903334e-07
- O 0 1.5504059547311044e-07
1 O 0 4.315047519298787e-08
. O 0 4.757517046982684e-09
07 O 0 5.753635434757598e-08
mg O 0 4.353814347268781e-06
/ O 0 2.0038758066220907e-06
ml O 0 4.278002734281472e-07
) O 0 6.834494081786602e-10
obtained O 0 3.949088611676643e-09
from O 0 3.243101343031185e-09
52 O 0 8.722255984139338e-08
healthy O 0 2.1469359623438322e-08
volunteers O 0 3.7703382638198946e-09
having O 0 7.630586829066033e-09
phenotype O 0 1.9888018698566157e-07
Hp2 O 0 7.713801437603252e-07
, O 0 3.686899452404191e-09
whereas O 0 3.3085862938264654e-09
the O 0 1.8093697651266893e-09
serum O 0 1.3867165193914843e-07
Hp O 0 2.9868263595744793e-07
level O 0 1.5425700716775737e-09
of O 0 8.510415289153528e-11
an O 0 7.973373072900358e-10
individual O 0 1.082561151832806e-09
with O 0 7.3083996632306025e-09
Hp1 O 0 0.00014785060193389654
/ O 0 3.505389395286329e-05
Hpdel O 0 9.468472853768617e-06
was O 0 3.283429350631195e-07
0 O 0 6.634289206886024e-08
. O 0 1.50285686117968e-07

50 O 0 5.5341101869998965e-06
mg O 0 0.00025512900901958346
/ O 0 0.00030225791851989925
ml O 0 3.8168280298123136e-05
, O 0 2.283092115362706e-08
which O 0 1.1029135826845504e-08
was O 0 3.9254199890592645e-08
approximately O 0 1.724242082445926e-09
half O 0 5.389472423900088e-09
the O 0 1.5092813665518179e-09
level O 0 2.370572849130781e-09
of O 0 3.982223717446942e-10
Hp O 0 5.132305886945687e-07
in O 0 3.390796088353909e-09
control O 0 3.645589004008798e-07
sera O 0 8.898222404241096e-06
from O 0 1.331415533378788e-09
the O 0 3.6103307010648678e-09
Hp1 O 0 2.9402613108686637e-06
phenotype O 0 5.202082888899895e-07
( O 0 8.86095530283626e-10
1 O 0 1.6835869365294798e-09
. O 0 9.777029186253117e-10
26 O 0 3.055282249420088e-09
+ O 0 4.655864316305269e-08
/ O 0 4.33123403809077e-07
- O 0 1.2564073870180437e-07
0 O 0 1.5494739713517447e-08
. O 0 2.3155704020894063e-09
33 O 0 2.969025203469755e-08
mg O 0 1.360804844807717e-06
/ O 0 1.027721623358957e-06
ml O 0 3.936247026103956e-07
; O 0 1.9408707974122308e-09
n O 0 2.349548680058433e-07
= O 0 1.5087762506027502e-07
9 O 0 7.028582871271283e-08
) O 0 1.2577009433911712e-09
, O 0 1.026724927299938e-09
showing O 0 1.685599215761613e-08
a O 0 1.2783021752227341e-08
gene O 0 3.4400696335978864e-07
- O 0 1.4342960639623925e-05
dosage O 0 5.542293001781218e-05
effect O 0 1.7894684560815222e-06
. O 0 3.0762180358578917e-07

The O 0 2.049981304708126e-07
other O 0 1.7047726785790474e-08
allele O 0 6.20012428953487e-07
( O 0 3.011613003423008e-08
Hp2 O 0 3.138781494271825e-06
) O 0 3.237761170282738e-09
of O 0 2.213733085731917e-10
individuals O 0 3.3636241014711743e-10
with O 0 2.8203488433575785e-09
Hp2 O 0 8.023813279578462e-05
/ O 0 9.301172394771129e-05
Hpdel O 0 1.31317783598206e-05
was O 0 2.130148459400516e-06
found O 0 5.062778996034467e-08
to O 0 1.3364231499224388e-08
have O 0 1.3850506519474948e-08
, O 0 2.4498896245006563e-09
in O 0 1.0045680953751912e-09
all O 0 9.714978821406817e-10
exons O 0 5.435692855826346e-07
, O 0 2.4881376958774126e-09
no O 0 1.5559115107421917e-09
mutation O 0 1.0557791974008524e-08
, O 0 3.6920419499431034e-10
by O 0 4.4821449329823793e-10
DNA O 0 3.894441533702775e-07
sequencing O 0 1.3564848586611333e-06
. O 0 2.532369478558394e-07

On O 0 1.5590486555083771e-06
the O 0 9.91052573340312e-09
basis O 0 1.0322115606697935e-08
of O 0 3.050500130274969e-10
the O 0 7.587193096014744e-09
present O 0 1.8901019416261988e-08
study O 0 4.5402606119182565e-09
, O 0 9.896164998579593e-10
the O 0 2.945877708437905e-10
mechanism O 0 2.654206854302288e-09
of O 0 8.520246175258706e-10
anhaptoglobinemia B-Disease 0 4.318318133300636e-06
and O 0 4.71547245695092e-09
the O 0 5.538406400162899e-10
mechanism O 0 9.1372509558596e-09
of O 0 1.7541029739831515e-09
anomalous O 0 1.2691245956375496e-06
inheritance O 0 1.0581943570286967e-06
of O 0 6.9509781042143e-08
Hp O 0 9.235301695298404e-05
phenotypes O 0 1.5743603398732375e-06
were O 0 4.88163109935158e-08
well O 0 3.574190188260218e-08
explained O 0 1.8788589386531385e-06
. O 0 1.8451565608756937e-07

However O 0 1.2514749414549442e-06
, O 0 1.4900066069856166e-08
the O 0 1.1545363554077426e-09
mechanism O 0 2.1851169762499012e-08
of O 0 6.724060863660952e-09
hypohaptoglobinemia B-Disease 0 8.386182162212208e-05
remains O 0 4.675496711570304e-06
unknown O 0 8.246272955148015e-06

ATM O 0 0.0029201225843280554
mutations O 0 0.00040942186024039984
and O 0 9.738286053107004e-07
phenotypes O 0 0.00013452580606099218
in O 0 9.574987780069932e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.0139568985323422e-05
in O 0 3.945973148233861e-08
the O 0 3.2829902352204954e-08
British O 0 2.4902835775719723e-06
Isles O 0 8.3579943748191e-06
: O 0 2.841157531463523e-09
expression O 0 1.2741583343967022e-09
of O 0 2.42515035830948e-10
mutant O 0 4.4057220094373406e-08
ATM O 0 7.236919827846577e-06
and O 0 1.3183817593187541e-08
the O 0 8.657050187821369e-09
risk O 0 2.1692378027182713e-07
of O 0 1.4464740516473285e-08
leukemia B-Disease 0 0.24185819923877716
, O 0 5.1816885388689116e-05
lymphoma B-Disease 1 1.0
, O 0 3.475075118331006e-06
and O 0 2.211619539593812e-05
breast B-Disease 1 0.7198886871337891
cancer I-Disease 0 0.00026315776631236076
. O 0 4.03288680672631e-07

We O 0 1.4538375580741558e-05
report O 0 2.081425947153548e-07
the O 0 1.8087038533565192e-09
spectrum O 0 1.083511946831095e-08
of O 0 9.448246629517598e-10
59 O 0 7.868202800409563e-08
ATM O 0 6.101647159084678e-05
mutations O 0 1.2883453564427327e-05
observed O 0 1.6365275996577111e-06
in O 0 1.3186605428927578e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.00041830711415968835
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.82712210516911e-06
patients O 0 2.1115437220942113e-07
in O 0 7.863648621153629e-10
the O 0 1.0596910016147376e-08
British O 0 6.23511277808575e-06
Isles O 0 2.715472692216281e-05
. O 0 4.810639779861958e-07

Of O 0 2.2634834806467552e-07
51 O 0 1.3579137885244563e-06
ATM O 0 6.82460013194941e-05
mutations O 0 4.494336735660909e-06
identified O 0 3.519060101098148e-07
in O 0 5.586064943940983e-09
families O 0 2.70800226687129e-09
native O 0 8.402584406042024e-09
to O 0 1.567738650010142e-08
the O 0 1.2737507937288228e-08
British O 0 1.3498054158844752e-06
Isles O 0 3.585214699342032e-06
, O 0 3.194504571979451e-08
11 O 0 1.1291911405919564e-08
were O 0 4.891601346201924e-09
founder O 0 2.474405391694745e-07
mutations O 0 6.034566268908748e-08
, O 0 1.1029404056728254e-09
and O 0 3.987386421044903e-09
2 O 0 3.166641704410722e-08
of O 0 4.3175130137740325e-10
these O 0 1.1716400072359079e-09
11 O 0 1.6120587531531783e-08
conferred O 0 7.77146080821467e-09
a O 0 3.1317672011255127e-08
milder O 0 1.850668922998011e-05
clinical O 0 4.0448236404699855e-07
phenotype O 0 1.1367565093678422e-06
with O 0 2.653776753902548e-09
respect O 0 7.441834704025041e-09
to O 0 1.311167494577603e-07
both O 0 9.888991598927532e-07
cerebellar B-Disease 0 0.31382623314857483
degeneration I-Disease 1 0.8612176775932312
and O 0 3.766201075450226e-07
cellular O 0 5.796704499516636e-06
features O 0 1.3001495062781032e-06
. O 0 5.66697792692139e-07

We O 0 2.169534855056554e-05
report O 0 1.7873347815111629e-06
, O 0 5.245980982948595e-09
in O 0 1.5209477011168815e-09
two O 0 5.947007153395134e-08
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999959468841553
T I-Disease 1 1.0
families O 0 5.837067362790549e-08
, O 0 1.4026039218961728e-09
an O 0 1.1739933469812058e-09
ATM O 0 2.5742221623659134e-05
mutation O 0 2.4119094632624183e-07
( O 0 2.762361006602987e-09
7271T O 0 7.966114878854569e-08
- O 0 2.143843857993488e-06
- O 0 1.8706808987190016e-05
> O 0 2.601115056677372e-07
G O 0 6.745984865119681e-05
) O 0 6.831565091403036e-09
that O 0 1.928255954908309e-08
may O 0 3.906173162704363e-07
be O 0 7.428504034123762e-09
associated O 0 6.273888963903573e-09
with O 0 4.796017472052938e-10
an O 0 1.1491412266195766e-08
increased O 0 2.417067435089848e-07
risk O 0 3.2957524354060297e-07
of O 0 3.8224900578143206e-08
breast B-Disease 0 0.17673856019973755
cancer I-Disease 0 3.43173487635795e-05
in O 0 8.048291810780484e-09
both O 0 5.702188943246256e-08
homozygotes O 0 1.6938043700065464e-05
and O 0 1.1515453479660209e-07
heterozygotes O 0 4.731728324713913e-07
( O 0 3.5732339309646477e-09
relative O 0 2.4665872899731767e-08
risk O 0 9.813057033625228e-08
12 O 0 5.5864060044541475e-09
. O 0 1.1698223500999916e-09
7 O 0 3.0408482842858575e-08
; O 0 1.2255876313815861e-08
P O 0 9.016080730361864e-05
= O 0 5.486791110342892e-07
. O 0 1.3082418703902476e-08
0025 O 0 2.1913153602781676e-07
) O 0 1.5843613088151187e-09
, O 0 8.933025430479802e-10
although O 0 1.3418579580815049e-09
there O 0 2.813330679529713e-10
is O 0 1.8344941121739566e-09
a O 0 8.483799973646455e-08
less O 0 9.922944173013093e-07
severe O 0 1.8289287254447117e-05
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
phenotype O 0 0.00017749548715073615
in O 0 8.561579889487803e-09
terms O 0 1.1976650782230536e-08
of O 0 5.613147169292176e-10
the O 0 8.832578224371446e-09
degree O 0 1.0669786121297875e-07
of O 0 2.0457198957046785e-07
cerebellar B-Disease 1 0.9337720274925232
degeneration I-Disease 1 0.994457483291626
. O 0 1.846430791374587e-06

This O 0 4.943627800457762e-07
mutation O 0 3.415220589886303e-06
( O 0 8.709139365237206e-08
7271T O 0 7.34532363821927e-07
- O 0 2.1843476133653894e-05
- O 0 8.759382762946188e-05
> O 0 4.6243312112892454e-07
G O 0 1.853537469287403e-05
) O 0 2.9418758540344925e-09
also O 0 1.162952512068216e-09
allows O 0 1.9969907671946174e-10
expression O 0 7.917256295009167e-10
of O 0 1.9247926863474873e-10
full O 0 6.061777746424468e-09
- O 0 1.175641344275391e-07
length O 0 7.994761119789473e-08
ATM O 0 2.5941960757336346e-06
protein O 0 6.842483202262883e-08
at O 0 6.97440194485921e-09
a O 0 4.049321322696642e-09
level O 0 6.761614823602713e-09
comparable O 0 2.7831253746057882e-08
with O 0 3.14903414455614e-09
that O 0 1.2282599826107798e-08
in O 0 2.254196118656182e-08
unaffected O 0 6.286957614065614e-06
individuals O 0 2.3098811752220172e-08
. O 0 1.1713327552342889e-07

In O 0 3.2450833487018826e-07
addition O 0 2.592120473821069e-08
, O 0 1.4022595529183945e-08
we O 0 1.143565775407751e-08
have O 0 2.4006310272994824e-09
studied O 0 1.6026040938754704e-08
18 O 0 1.7633864501931384e-07
A B-Disease 1 0.9999986886978149
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 2.517382199584972e-05
, O 0 1.4079994947735486e-09
in O 0 6.602409174938373e-10
15 O 0 4.592921154511487e-09
families O 0 5.420789372934109e-10
, O 0 3.434811990388198e-09
who O 0 1.327249634641703e-07
developed O 0 4.141357749176677e-06
leukemia B-Disease 0 0.07261266559362411
, O 0 1.4017285138834268e-05
lymphoma B-Disease 1 1.0
, O 0 3.2436847163808125e-07
preleukemic O 0 9.297225915361196e-05
T O 0 0.006481473799794912
- O 0 4.0513321437174454e-05
cell O 0 0.000518228393048048
proliferation O 0 8.186150807887316e-06
, O 0 2.0084185337054805e-07
or O 0 0.00245113717392087
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 2.1908431335759815e-07
mostly O 0 4.534721487203797e-09
in O 0 1.6192203133869043e-08
childhood O 0 1.2468539125620737e-06
. O 0 3.005699795721739e-07

A O 0 2.3543043425888754e-06
wide O 0 1.3807202492444048e-07
variety O 0 7.139046243054281e-09
of O 0 2.2639157215564865e-09
ATM O 0 3.6674042348749936e-05
mutation O 0 3.878160157455568e-07
types O 0 1.9003898898972693e-08
, O 0 1.7695269693973614e-09
including O 0 9.367498998713586e-10
missense O 0 2.0968916487618117e-06
mutations O 0 2.3408310880768113e-06
and O 0 2.6603411029668678e-08
in O 0 1.5269536746131962e-08
- O 0 3.1382784072775394e-05
frame O 0 0.01854725368320942
deletions O 0 4.667675239033997e-05
, O 0 5.08873405635768e-08
were O 0 6.824506293412469e-09
seen O 0 9.493922448200465e-08
in O 0 3.956069694055486e-09
these O 0 1.3549208865981655e-08
patients O 0 1.0374721881589721e-07
. O 0 4.3873740196431754e-08

We O 0 3.861684945150046e-06
also O 0 5.576944417384766e-08
show O 0 4.262954078626535e-08
that O 0 9.167341330496015e-10
25 O 0 9.132124501043393e-10
% O 0 2.0987045434850415e-10
of O 0 8.92854054579395e-11
all O 0 1.5209019821327274e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 8.408393114223145e-06
carried O 0 3.4949383831417435e-08
in O 0 3.790752600707492e-09
- O 0 2.1421619749162346e-06
frame O 0 6.190593558130786e-05
deletions O 0 4.448751496965997e-06
or O 0 1.4635936906870484e-07
missense O 0 4.301048193156021e-06
mutations O 0 3.8309167393890675e-06
, O 0 2.5895592337121798e-09
many O 0 1.519189912757568e-10
of O 0 7.007159852356892e-10
which O 0 3.175169638325315e-07
were O 0 1.1495757945567675e-07
also O 0 1.1343075811964809e-07
associated O 0 3.6158782634743147e-09
with O 0 6.51627252157283e-10
expression O 0 8.706861009954991e-09
of O 0 8.644439608573862e-10
mutant O 0 1.5315791301873105e-07
ATM O 0 1.8611608538776636e-05
protein O 0 2.6980924303643405e-06
. O 0 2.8663504281212226e-07

The O 0 1.0069801419376745e-06
DMPK O 0 7.41723706596531e-05
gene O 0 9.471174053032883e-06
of O 0 3.0030153652660374e-07
severely O 1 0.9613105058670044
affected O 0 0.11020166426897049
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.41784775257110596
is O 0 1.2077059352577635e-07
hypermethylated O 0 3.89594461012166e-05
proximal O 0 0.00010806944192154333
to O 0 1.484839486920464e-07
the O 0 1.2525402937058061e-08
largely O 0 1.4089329170019482e-07
expanded O 0 1.1353155286997207e-06
CTG O 0 7.628084858879447e-05
repeat O 0 1.7522415873827413e-05
. O 0 3.35757107450263e-07

Using O 0 1.4958689007471548e-06
methylation O 0 1.2107440852560103e-05
- O 0 3.593405199353583e-05
sensitive O 0 3.4718584629445104e-06
restriction O 0 3.810232129808355e-08
enzymes O 0 2.0885443063889397e-07
, O 0 7.288868175692187e-09
we O 0 3.9569751919543705e-09
characterized O 0 4.755122073873963e-09
the O 0 6.938600249917215e-10
methylation O 0 1.80371344526975e-07
pattern O 0 2.294154910487123e-06
on O 0 5.390527917370491e-07
the O 0 1.4403841674948126e-08
5 O 0 3.905070045107095e-08
side O 0 1.607281596704979e-08
of O 0 4.4096434836937703e-10
the O 0 1.8888981045961373e-08
CTG O 0 9.945664714905433e-06
repeat O 0 7.605545988553786e-07
in O 0 8.911089643959258e-10
the O 0 1.6065022645506133e-09
DMPK O 0 1.1432666724431328e-06
gene O 0 1.999150001097405e-08
of O 0 1.5884091264517508e-10
normal O 0 4.9030376203518244e-08
individuals O 0 7.865388895744729e-10
and O 0 2.8917950256612812e-09
of O 0 2.3353969869077673e-09
patients O 0 3.007423288181599e-07
affected O 0 7.27341458173214e-08
with O 0 3.1668216706748353e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 2.0255419030945632e-07
showing O 0 2.5956188665077207e-07
expansions O 0 9.041988136004875e-08
of O 0 9.647211918206722e-10
the O 0 1.8347400043694506e-08
repetitive O 0 1.3563822903961409e-05
sequence O 0 1.3129609897077898e-06
. O 0 5.718122224607214e-07

The O 0 4.631626779882936e-07
gene O 0 1.5204400369839277e-06
segment O 0 1.1153142622788437e-06
analyzed O 0 3.09489195160495e-07
corresponds O 0 8.205077506318048e-08
to O 0 1.19504548479199e-08
the O 0 4.490053218120238e-09
genomic O 0 5.095567416901758e-07
SacI O 0 1.95322536455933e-05
- O 0 5.6447292990924325e-06
HindIII O 0 5.22112623002613e-06
fragment O 0 4.3378895497880876e-07
carrying O 0 6.214141734517398e-08
exons O 0 8.690469712746562e-07
11 O 0 3.884752075578035e-08
- O 0 5.030519218962581e-07
15 O 0 8.723171163182997e-08
. O 0 1.6685412163042201e-07

There O 0 4.760723868457717e-07
is O 0 2.127747222857579e-08
constitutive O 0 1.6458653817608138e-07
methylation O 0 4.6140362996993645e-07
in O 0 3.777625323664324e-08
intron O 0 5.026202052249573e-05
12 O 0 2.2453829728874553e-07
at O 0 1.1243427522344973e-08
restriction O 0 1.5903074412904061e-09
sites O 0 2.941106913567637e-09
of O 0 5.477213682603121e-10
SacII O 0 1.8709824871621095e-06
and O 0 4.683082011069928e-08
HhaI O 0 8.924286589717667e-07
, O 0 2.37054575968898e-09
localized O 0 2.4580304014421017e-08
1 O 0 1.8134683088533166e-08
, O 0 3.417977234576597e-09
159 O 0 1.3906678475450462e-08
- O 0 5.328753900357697e-07
1 O 0 1.1668830524058649e-07
, O 0 8.285388375384173e-09
232 O 0 1.7211871039535254e-08
bp O 0 2.590317080830573e-06
upstream O 0 2.9103997434276607e-08
of O 0 4.016037224996438e-10
the O 0 1.3013531585670535e-08
CTG O 0 1.5696567061240785e-05
repeat O 0 2.3263166895048926e-06
, O 0 1.6590763207702253e-09
whereas O 0 2.0352801666234654e-09
most O 0 1.2263750015506503e-09
, O 0 3.5411555909803383e-09
if O 0 8.2930089462252e-09
not O 0 2.674575450001271e-09
all O 0 2.455788072897036e-10
, O 0 5.367669642097894e-10
of O 0 1.6884186757049058e-11
the O 0 3.203592668921118e-10
other O 0 4.0296646575121997e-10
sites O 0 7.479886932060253e-09
of O 0 9.038790271809205e-10
SacII O 0 7.694735018048959e-07
, O 0 3.384967639519232e-09
HhaI O 0 2.5997758257290116e-07
, O 0 2.8163924525870243e-09
and O 0 2.4798652020763257e-09
HpaII O 0 3.1518126775154087e-07
in O 0 1.019288764503301e-09
this O 0 1.4256458236161507e-09
region O 0 2.5470566811236495e-07
are O 0 5.948195269667167e-09
unmethylated O 0 4.5628999600921816e-07
, O 0 5.383903989297778e-09
in O 0 7.965590409497736e-10
normal O 0 7.984627359292062e-08
individuals O 0 7.061012885500872e-10
and O 0 2.8450619637965247e-09
most O 0 6.922301620804205e-10
of O 0 7.51980810953512e-10
the O 0 8.008710494777915e-08
patients O 0 8.817295906737854e-07
. O 0 1.0107982717499908e-07

In O 0 2.551792874783132e-07
a O 0 1.8576141513904076e-08
number O 0 4.645785089962828e-09
of O 0 1.5475534187459061e-09
young O 0 9.523685662315984e-08
and O 0 2.305723000972648e-06
severely O 0 0.012888391502201557
affected O 0 5.281998483042116e-07
patients O 0 1.1182458337088974e-07
, O 0 8.025478059892066e-10
however O 0 2.5591067043251314e-09
, O 0 5.481226583725629e-10
complete O 0 3.008023607975474e-09
methylation O 0 5.588359286434752e-08
of O 0 3.1861524529830376e-10
these O 0 8.255349737140705e-10
restriction O 0 4.204937731344671e-09
sites O 0 7.452789674289306e-08
was O 0 5.552944912778912e-07
found O 0 1.7442616240259667e-08
in O 0 1.0029868047212176e-09
the O 0 5.9648508354825935e-09
mutated O 0 4.622823780664476e-06
allele O 0 8.753530892136041e-06
. O 0 4.673641456065525e-07

In O 0 3.784909949899884e-07
most O 0 1.889416978428926e-08
of O 0 1.407908123418622e-09
these O 0 4.260301889047469e-09
patients O 0 7.536198154411977e-08
, O 0 1.4869482312107607e-09
the O 0 4.8315063061465935e-09
onset O 0 3.939517796425207e-07
of O 0 2.307308344384751e-09
the O 0 1.4242543784348527e-06
disease O 0 0.16785624623298645
was O 0 0.0001588405284564942
congenital O 1 0.9997352957725525
. O 0 2.1134144390089205e-06

Preliminary O 0 1.0563991054368671e-05
in O 0 5.008694756725163e-07
vivo O 0 0.00015951370005495846
footprinting O 0 0.00015617642202414572
data O 0 1.2293849067646079e-06
gave O 0 2.6601584934837774e-08
evidence O 0 3.1403071254487713e-09
for O 0 6.796250229257339e-10
protein O 0 4.651763774177198e-08
- O 0 1.4116310467215953e-06
DNA O 0 3.2250866297545144e-06
contact O 0 1.2243613412010745e-07
in O 0 2.121319342407446e-09
normal O 0 4.6496879235746746e-08
genes O 0 1.8544845659107523e-08
at O 0 1.971507401776762e-08
an O 0 2.9619986463558234e-09
Sp1 O 0 6.291236900324293e-07
consensus O 0 1.1733492399912393e-08
binding O 0 9.714779203306989e-09
site O 0 9.6857910136805e-08
upstream O 0 6.708064148597259e-08
of O 0 1.229410240277673e-09
the O 0 1.3519136032869028e-08
CTG O 0 1.4574941815226339e-05
repeat O 0 2.2209433154785074e-06
and O 0 5.103564681974149e-09
for O 0 5.119043522405775e-10
a O 0 3.691431160746106e-09
significant O 0 2.939418930480997e-09
reduction O 0 4.42032543901405e-08
of O 0 3.1768379593621887e-10
this O 0 7.169745908086611e-10
interaction O 0 1.3574060764298679e-09
in O 0 2.209499028182904e-09
cells O 0 3.472148790706342e-08
with O 0 1.4174006413014695e-09
a O 0 8.515088012472916e-08
hypermethylated O 0 2.1196505258558318e-05
DMPK O 0 6.391585884557571e-06
gene O 0 1.5518141083248338e-07
. O 0 7.711291161172085e-09
. O 0 1.0599340072303676e-07

The O 0 5.104106094222516e-06
hemochromatosis B-Disease 1 0.999994158744812
gene O 0 3.8077655517554376e-06
product O 0 1.7656969930612831e-07
complexes O 0 2.1148201412302114e-08
with O 0 1.2763378132163439e-09
the O 0 4.878073500691471e-09
transferrin O 0 2.1231909386187908e-07
receptor O 0 2.2414285538729928e-08
and O 0 8.531470641059968e-09
lowers O 0 1.4488646229438018e-06
its O 0 8.638346038480904e-09
affinity O 0 6.6649805674501295e-09
for O 0 2.073954341597073e-09
ligand O 0 1.1350413586797004e-07
binding O 0 7.313519745366648e-07
. O 0 1.8082533870256157e-07

We O 0 1.4525542610499542e-05
recently O 0 2.822836904670112e-06
reported O 0 1.0444406370879733e-06
the O 0 2.6859445778626423e-09
positional O 0 1.3796422138057096e-07
cloning O 0 5.563079952253247e-08
of O 0 5.159723759362578e-10
a O 0 2.896344852842958e-08
candidate O 0 7.942081197143125e-07
gene O 0 1.1013917173841037e-05
for O 0 6.407453474821523e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.01692787930369377
HFE O 0 0.02455904521048069
. O 0 1.4095003280090168e-06

The O 0 7.867346596412972e-08
gene O 0 4.818045908905333e-07
product O 0 2.1551831252963893e-07
, O 0 2.5946218507044705e-09
a O 0 3.398890280337241e-09
member O 0 7.273660784790081e-09
of O 0 1.4498256761807937e-10
the O 0 1.4070599130278083e-09
major O 0 7.484625363929354e-09
histocompatibility O 0 5.562952765103546e-08
complex O 0 2.0333215999812637e-08
class O 0 1.4118565871967803e-08
I O 0 2.3063473690854153e-06
- O 0 1.3455924090521876e-06
like O 0 7.792065304101925e-08
family O 0 2.3598290965765045e-07
, O 0 7.226288545325588e-08
was O 0 3.317238963518321e-07
found O 0 8.199363854544117e-09
to O 0 7.815202929251086e-10
have O 0 4.75614492234655e-10
a O 0 3.1218774232399937e-09
mutation O 0 4.176125756316651e-08
, O 0 3.6498863931200276e-09
Cys O 0 8.597577107138932e-06
- O 0 1.530809527139354e-06
282 O 0 7.49307616842998e-07
- O 0 5.526009317691205e-06
- O 0 3.008154635608662e-05
> O 0 4.340947725722799e-07
Tyr O 0 2.160343001378351e-06
( O 0 3.370774104283214e-09
C282Y O 0 3.8292402138040416e-08
) O 0 9.284572000112234e-10
, O 0 6.153969556166317e-10
in O 0 6.310453826152695e-10
85 O 0 3.6125831215372273e-09
% O 0 2.2638466656843548e-09
of O 0 2.3166393248175154e-09
patient O 0 5.957861048955237e-07
chromosomes O 0 2.4195844616770046e-06
. O 0 6.174256554913882e-07

This O 0 1.916680503200041e-07
mutation O 0 8.520723326910229e-07
eliminates O 0 5.17156252044515e-07
the O 0 5.846557460387203e-09
ability O 0 3.0007246465402204e-08
of O 0 3.1270501743563273e-09
HFE O 0 1.2848679943999741e-05
to O 0 1.3807097332119156e-07
associate O 0 1.331276990867991e-07
with O 0 5.44624523257653e-09
beta2 O 0 9.64860591921024e-05
- O 0 0.0007377887377515435
microglobulin O 0 0.00037601383519358933
( O 0 2.3926418180053588e-08
beta2m O 0 4.656038527173223e-06
) O 0 4.7842796391250886e-09
and O 0 5.49316059306193e-09
prevents O 0 3.547796367797673e-08
cell O 0 2.70894197456073e-05
- O 0 4.6981902414700016e-05
surface O 0 4.432965943124145e-05
expression O 0 1.8796706626744708e-06
. O 0 2.725217314036854e-07

A O 0 3.0051062367419945e-06
second O 0 2.418239546386758e-06
mutation O 0 1.1185908306288184e-06
that O 0 1.1487554907319009e-08
has O 0 1.894277446012893e-08
no O 0 1.1106505048985582e-08
effect O 0 6.33445722542092e-08
on O 0 2.093586545015569e-06
beta2m O 0 0.00013028625107835978
association O 0 1.4579717877438725e-08
, O 0 4.6731578606795665e-09
H63D O 0 6.4043015299830586e-06
, O 0 3.036385720633916e-08
was O 0 7.29123570408774e-08
found O 0 6.370537430910872e-09
in O 0 2.2602870686228016e-09
eight O 0 5.466330943448838e-09
out O 0 9.264957689936182e-09
of O 0 8.246505145415028e-10
nine O 0 2.735294231115404e-07
patients O 0 2.975544788341722e-08
heterozygous O 0 1.3062221526638496e-08
for O 0 5.794996149610654e-10
the O 0 3.049815067157624e-09
C282Y O 0 8.042523518270173e-07
mutant O 0 1.6868395960045746e-06
. O 0 3.2730935117797344e-07

In O 0 7.86429893651075e-07
this O 0 4.9322643747018446e-08
report O 0 8.362079597645788e-07
, O 0 5.690669269142745e-09
we O 0 3.4302227724936074e-09
demonstrate O 0 3.281774407781768e-09
in O 0 8.110112026393779e-10
cultured O 0 6.39199811303115e-07
293 O 0 5.684716697373915e-08
cells O 0 2.7282158043817617e-07
overexpressing O 0 1.2306869621170335e-06
wild O 0 8.144222363171139e-08
- O 0 1.9211488506698515e-06
type O 0 2.656558990565827e-07
or O 0 6.734754975923352e-08
mutant O 0 3.3284507594544266e-07
HFE O 0 2.06429035642941e-06
proteins O 0 3.840885298700414e-08
that O 0 1.262478899199948e-09
both O 0 6.22858931098591e-10
the O 0 1.3977833335232503e-09
wild O 0 9.248594778910046e-08
- O 0 1.957856147782877e-05
type O 0 2.5367494345118757e-06
and O 0 3.0332719802572683e-07
H63D O 0 4.737309063784778e-05
HFE O 0 1.4906140677339863e-06
proteins O 0 1.932327897691266e-08
form O 0 1.7218242831518182e-08
stable O 0 7.132855444069719e-07
complexes O 0 1.8561513215331615e-08
with O 0 1.927754844643914e-09
the O 0 1.6266124447383845e-08
transferrin O 0 1.0543975577093079e-06
receptor O 0 1.371141422623623e-07
( O 0 2.6060011037998265e-08
TfR O 0 2.110976993208169e-06
) O 0 3.114890390065739e-08
. O 0 1.7852926248451695e-07

The O 0 6.589594931938336e-07
C282Y O 0 5.8561422520142514e-06
mutation O 0 3.6073495266464306e-06
nearly O 0 2.862192900465743e-07
completely O 0 1.6718827282602433e-06
prevents O 0 3.8407826252750965e-08
the O 0 3.0731255318272588e-09
association O 0 1.5029586464265776e-09
of O 0 2.0097994102297179e-10
the O 0 3.999283570976786e-09
mutant O 0 3.4754685884763603e-07
HFE O 0 3.513939873300842e-06
protein O 0 1.8414068847505405e-07
with O 0 5.276869607939716e-09
the O 0 7.353791886544059e-08
TfR O 0 2.646867505973205e-05
. O 0 3.2220356160905794e-07

Studies O 0 2.4861783458618447e-06
on O 0 6.988732366153272e-07
cell O 0 3.232418748666532e-05
- O 0 3.965885116485879e-05
associated O 0 6.603995643672533e-07
transferrin O 0 2.9819739211234264e-07
at O 0 1.1967406976509665e-07
37 O 0 3.889675070922749e-08
degrees O 0 1.7034780341873557e-07
C O 0 2.359942300245166e-06
suggest O 0 2.0054667260183123e-08
that O 0 1.6837026217686457e-09
the O 0 4.1581369458754125e-09
overexpressed O 0 2.5782999273360474e-06
wild O 0 6.738571300957119e-08
- O 0 1.6920098460104782e-06
type O 0 4.1511069071020756e-07
HFE O 0 5.591382887359941e-06
protein O 0 2.3709183949449653e-07
decreases O 0 4.446319223916362e-08
the O 0 4.3973474861402906e-10
affinity O 0 2.7208939545886324e-09
of O 0 5.56806378781971e-10
the O 0 1.3901215289990887e-08
TfR O 0 2.551656962168636e-06
for O 0 2.2413173539348463e-08
transferrin O 0 1.7819905906435451e-06
. O 0 3.0362645020431955e-07

The O 0 8.003120228750049e-07
overexpressed O 0 6.390063936123624e-05
H63D O 0 6.595911690965295e-05
protein O 0 3.8023949855414685e-06
does O 0 8.737242040979254e-08
not O 0 4.035812573022213e-09
have O 0 8.075905499893565e-10
this O 0 5.646865752773067e-10
effect O 0 2.1209682898870597e-08
, O 0 4.320991564554788e-09
providing O 0 5.670859892781266e-10
the O 0 1.476136657352356e-09
first O 0 3.441017071281749e-08
direct O 0 2.1308702358169285e-08
evidence O 0 7.500172927166204e-09
for O 0 1.4471577269858926e-09
a O 0 1.5917406059884343e-08
functional O 0 1.891660446062815e-07
consequence O 0 2.6017694665370072e-08
of O 0 5.845462447418015e-10
the O 0 1.7768398308248834e-08
H63D O 0 0.0006791965570300817
mutation O 0 4.963320861861575e-06
. O 0 3.9387703054671874e-07

Addition O 0 5.243888381301076e-07
of O 0 2.559303524662937e-08
soluble O 0 5.601793873211136e-07
wild O 0 5.387695978242846e-07
- O 0 4.200264811515808e-05
type O 0 7.13852978151408e-06
HFE O 0 0.0007787394570186734
/ O 0 0.00011227680806769058
beta2m O 0 5.443233021651395e-06
heterodimers O 0 6.624356387874286e-07
to O 0 2.720459590932478e-08
cultured O 0 2.8499732707132353e-06
cells O 0 1.6396440969401738e-06
also O 0 7.874162832877118e-08
decreased O 0 1.1281884582103885e-07
the O 0 9.970319014840356e-10
apparent O 0 2.589600178737328e-08
affinity O 0 1.0132918504268673e-08
of O 0 5.725953600155265e-10
the O 0 4.583312840367171e-09
TfR O 0 2.11836933772247e-07
for O 0 7.422693570902084e-10
its O 0 6.8551120335769156e-09
ligand O 0 2.2594434767597704e-08
under O 0 3.882987265058091e-09
steady O 0 5.258351052361832e-07
- O 0 1.272138320018712e-06
state O 0 5.708642447643797e-08
conditions O 0 5.248721208772622e-07
, O 0 2.6281223863833247e-09
both O 0 5.383612999843024e-10
in O 0 1.3806715770670053e-09
293 O 0 1.3751400018691129e-08
cells O 0 7.716120364875678e-08
and O 0 1.723545928200565e-08
in O 0 3.0823905206034397e-08
HeLa O 0 7.321614975808188e-05
cells O 0 9.293034963775426e-06
. O 0 2.728754395775468e-07

Furthermore O 0 4.645974513550755e-06
, O 0 4.914731732696964e-08
at O 0 4.397662323185614e-08
4 O 0 3.239758328277276e-08
degrees O 0 2.741823266205756e-07
C O 0 3.493856866043643e-06
, O 0 6.738067881428833e-09
the O 0 3.4509730628684565e-09
added O 0 2.3883677613412146e-07
soluble O 0 8.442443544254274e-08
complex O 0 1.1017425194381758e-08
of O 0 7.124015599657696e-09
HFE O 0 0.0002052177005680278
/ O 0 4.766068741446361e-05
beta2m O 0 4.193401309748879e-06
inhibited O 0 1.539407605832821e-07
binding O 0 4.0522127875419756e-08
of O 0 1.4422858463092325e-09
transferrin O 0 1.8283301983501588e-07
to O 0 2.6319460388890548e-08
HeLa O 0 5.6259523262269795e-06
cell O 0 7.989203368197195e-06
TfR O 0 5.708070034415869e-07
in O 0 1.626605294902106e-09
a O 0 2.1437278618918754e-08
concentration O 0 9.015155910674366e-07
- O 0 1.6653801139909774e-05
dependent O 0 4.504476237343624e-06
manner O 0 2.0997013052692637e-06
. O 0 4.5514698854276503e-07

Scatchard O 0 0.000315319950459525
plots O 0 8.636011443741154e-06
of O 0 2.618456917957701e-08
these O 0 7.433776705312312e-09
data O 0 3.971767625898792e-07
indicate O 0 5.382458567737558e-08
that O 0 1.5621025584167114e-09
the O 0 3.457937269857325e-09
added O 0 2.4324171477019263e-07
heterodimer O 0 1.160197413696551e-07
substantially O 0 3.7818537634848326e-07
reduced O 0 3.0857080446367036e-08
the O 0 5.81601322657832e-10
affinity O 0 9.174133452916067e-09
of O 0 3.4209903798654295e-09
TfR O 0 1.8920713955594692e-06
for O 0 4.260377295395301e-08
transferrin O 0 4.9259747356700245e-06
. O 0 7.878817314121989e-07

These O 0 5.367008952816832e-07
results O 0 3.1288988111555227e-07
establish O 0 2.1394063409729824e-08
a O 0 2.178379610029424e-08
molecular O 0 3.4857953323808033e-07
link O 0 9.07032244867878e-06
between O 0 2.090106505647782e-07
HFE O 0 0.00019763885939028114
and O 0 2.6177033873864275e-07
a O 0 4.5715371044252606e-08
key O 0 3.6178397522235173e-07
protein O 0 1.3509706775494124e-07
involved O 0 4.806147924085735e-09
in O 0 6.682915998368344e-09
iron O 0 1.854244328569621e-05
transport O 0 1.3284048918649205e-06
, O 0 7.023086112667443e-09
the O 0 2.6087345617042956e-09
TfR O 0 4.49454574891206e-07
, O 0 5.188246721132828e-09
and O 0 5.265689662081741e-09
raise O 0 9.400920930602297e-09
the O 0 2.10617234763788e-09
possibility O 0 5.500048416706704e-09
that O 0 2.841954227505994e-09
alterations O 0 7.506444887894759e-08
in O 0 2.537744014929899e-09
this O 0 2.567232204597758e-09
regulatory O 0 3.1886909113154616e-08
mechanism O 0 3.535575743285335e-08
may O 0 2.861073937765468e-07
play O 0 3.4109828295214584e-09
a O 0 4.065146441689649e-09
role O 0 7.393110124098712e-09
in O 0 2.418255151681592e-09
the O 0 4.1594635291630766e-08
pathogenesis O 0 0.0001943878596648574
of O 0 5.557041731663048e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 3.922631549357902e-06
. O 0 6.486839652097842e-07

Genomic O 0 8.912969497032464e-05
organization O 0 1.0182476444242639e-06
of O 0 2.410956767562311e-08
the O 0 5.816440662442801e-08
UBE3A O 0 0.00017354148440063
/ O 0 7.068603008519858e-05
E6 O 0 5.6055025197565556e-05
- O 0 0.00010274545638822019
AP O 0 6.647982081631199e-05
gene O 0 4.619156754870346e-07
and O 0 1.4105699719380027e-08
related O 0 1.026412448368319e-07
pseudogenes O 0 8.376770892937202e-06
. O 0 4.433887283994409e-07

The O 0 1.2326720479904907e-06
UBE3A O 0 4.9949714593822137e-05
gene O 0 1.488646603320376e-06
encodes O 0 4.187276374523208e-07
the O 0 1.9273219464821523e-08
E6 O 0 2.146109181921929e-05
- O 0 3.840340650640428e-05
AP O 0 3.1451181712327525e-05
ubiquitin O 0 1.803422691182277e-07
- O 0 6.48716707019048e-07
protein O 0 1.1565463609031212e-07
ligase O 0 1.5639397332734006e-08
and O 0 2.814761579372771e-08
has O 0 3.681581972614367e-08
recently O 0 1.3590342007319123e-07
been O 0 7.280406943976914e-09
shown O 0 1.5040024781143302e-09
to O 0 1.8709547244810665e-09
be O 0 1.955131523345699e-08
mutated O 0 8.042981062317267e-05
in O 0 0.00031077279709279537
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0010724329622462392
who O 0 8.050967181816304e-08
lack O 0 1.5858255153489154e-08
15q11 O 0 9.622996230973513e-07
- O 0 9.37678760237759e-06
q13 O 0 3.6318303955340525e-06
deletions O 0 8.04919000074733e-06
or O 0 1.318837917096971e-06
chromosome O 0 0.00033991888631135225
15 O 0 6.016775273565145e-07
paternal O 0 2.2536694814334624e-05
uniparental B-Disease 0 0.0023723349440842867
disomy I-Disease 0 0.0026411754079163074
. O 0 1.9063237459704396e-06

Previous O 0 1.574086672917474e-05
UBE3A O 0 7.046892278594896e-05
cDNA O 0 4.42831060354365e-06
analysis O 0 3.878245422583859e-07
has O 0 2.774507379399438e-08
shown O 0 5.467936770031656e-09
a O 0 5.91065996147222e-09
coding O 0 6.308200227067573e-06
region O 0 1.019343699226738e-06
of O 0 4.5683532512441616e-09
approximately O 0 5.077265186059776e-08
2 O 0 2.1269970318371634e-07
. O 0 1.4361216926772613e-07

6 O 0 1.5552452168776654e-05
kb O 0 0.00016867720114532858
and O 0 6.11367099168092e-08
a O 0 2.3354962408461688e-08
3 O 0 6.906112162141653e-07
- O 0 0.003344219410791993
untranslated O 0 0.030647650361061096
region O 0 2.2048514438210987e-05
( O 0 1.3111595364989626e-08
UTR O 0 1.1608054819589597e-06
) O 0 1.5302067390976504e-09
of O 0 3.809901005791261e-10
< O 0 4.494759764384071e-08
50 O 0 2.4176847190915396e-08
bp O 0 6.897029834362911e-06
, O 0 3.2932991889111918e-09
whereas O 0 4.420154908757468e-09
Northern O 0 2.0205558115549138e-08
analysis O 0 4.5947199822649054e-08
has O 0 3.661134329036031e-08
indicated O 0 1.2685188011118953e-08
mRNA O 0 3.692290251322561e-09
sizes O 0 5.683846282522609e-09
of O 0 2.778836605266122e-10
5 O 0 6.063919499865733e-08
- O 0 2.646065695444122e-06
8 O 0 4.936994173476705e-07
kb O 0 3.166914393659681e-05
. O 0 3.3017329315043753e-07

We O 0 2.404345195827773e-06
have O 0 3.966966843904629e-08
analyzed O 0 1.121958916883159e-07
additional O 0 2.300463286530885e-08
cDNA O 0 4.562617164083349e-07
clones O 0 1.1053986781917047e-05
and O 0 5.115613177508749e-08
provide O 0 4.49934667301477e-09
evidence O 0 4.774498130188931e-09
for O 0 1.259580661994164e-09
an O 0 2.2922015396886763e-09
additional O 0 1.726717790972998e-08
0 O 0 1.7691000664399326e-07
. O 0 2.3672131987950706e-07

5 O 0 2.8523470518848626e-06
kb O 0 2.1056805053376593e-05
of O 0 2.3855605491007736e-08
5 O 0 1.494578327765339e-07
- O 0 4.2541228140180465e-06
UTR O 0 8.841556336847134e-06
and O 0 6.13362018953012e-08
> O 0 1.2256273329569467e-08
2 O 0 1.4752255417249671e-08
kb O 0 1.6497327806064277e-06
of O 0 1.8434103132847213e-09
3 O 0 1.5349202442394017e-07
- O 0 3.902057869709097e-05
UTR O 0 0.0005385438562370837
. O 0 1.5361986243078718e-06

We O 0 9.883033271762542e-06
have O 0 1.760136392192635e-08
established O 0 3.059802189397942e-09
the O 0 1.0312468656792362e-09
genomic O 0 7.668818113870657e-08
organization O 0 1.0784399151475554e-08
of O 0 2.5593607233531657e-09
UBE3A O 0 2.8112178824812872e-06
and O 0 4.13830125722825e-09
the O 0 6.1002231044327e-10
sequence O 0 8.28456681034595e-09
of O 0 4.153903887527122e-09
intron O 0 0.0002019578096223995
- O 0 2.1539473891607486e-05
exon O 0 1.6405827409471385e-05
borders O 0 5.456959570437903e-06
. O 0 4.5182511598795827e-07

We O 0 1.1024425475625321e-05
have O 0 6.335568514259649e-08
also O 0 2.894837081157675e-08
mapped O 0 7.289524432962935e-07
two O 0 5.016015158787468e-09
highly O 0 1.2825466022547971e-08
homologous O 0 8.494583880747086e-08
processed O 0 2.261652525703539e-06
pseudogenes O 0 9.165389087684161e-07
, O 0 1.2575744001708244e-08
UBE3AP1 O 0 3.736799726539175e-06
and O 0 3.580316842999309e-08
UBE3AP2 O 0 5.144712304172572e-06
, O 0 6.480888270488094e-09
to O 0 2.599456427887503e-09
chromosomes O 0 2.4859660996412458e-08
2 O 0 1.2510365365869802e-07
and O 0 6.806244812196383e-08
21 O 0 9.017617230711039e-08
, O 0 3.3651532671541418e-09
respectively O 0 8.96455816246089e-08
, O 0 3.4307525709209585e-09
and O 0 1.3743952642641943e-08
determined O 0 6.624300397106708e-08
their O 0 2.452766523219907e-08
genomic O 0 3.7541627762038843e-07
organization O 0 1.592840845887622e-07
. O 0 1.738632420256181e-07

These O 0 1.2931898254464613e-06
results O 0 1.812626578612253e-06
will O 0 2.1895976587416044e-08
form O 0 2.5783075674468137e-09
the O 0 6.488912185353968e-10
basis O 0 6.801791130328638e-09
for O 0 1.1458139992370775e-09
studies O 0 8.775027926510859e-10
of O 0 5.804952629695492e-10
mutation O 0 8.816305552272752e-08
and O 0 1.5743310655125242e-08
imprinting O 0 3.458745140960673e-06
of O 0 3.823955552206826e-08
UBE3A O 0 0.00021337853104341775
. O 0 8.27646601919696e-07

Mutation O 0 9.97151801129803e-05
spectrum O 0 6.557887445524102e-06
and O 0 4.848064918405726e-07
genotype O 0 0.00018629449186846614
- O 0 0.0020900219678878784
phenotype O 0 0.00033920217538252473
analyses O 0 1.365556386190292e-06
in O 0 5.433433969415091e-08
Cowden B-Disease 0 0.3738289177417755
disease I-Disease 0 0.017252760007977486
and O 0 2.699716787901707e-07
Bannayan B-Disease 1 0.6489975452423096
- I-Disease 1 0.9999932050704956
Zonana I-Disease 1 0.9999963045120239
syndrome I-Disease 1 0.9999961853027344
, O 0 3.64121035545395e-08
two O 0 1.9050611399507034e-07
hamartoma B-Disease 0 0.33372777700424194
syndromes I-Disease 0 0.004884469322860241
with O 0 2.487176402610203e-07
germline O 0 0.002156743546947837
PTEN O 0 0.004344361834228039
mutation O 0 0.0001624765427550301
. O 0 1.4080801520321984e-06

The O 0 3.550924884621054e-05
tumour B-Disease 1 0.9999988079071045
suppressor O 0 0.001298704999499023
gene O 0 0.00010606969590298831
PTEN O 0 0.000698185758665204
, O 0 1.2144788286150288e-07
which O 0 7.465605023071475e-09
maps O 0 1.0201936220255448e-06
to O 0 1.5873453662607062e-07
10q23 O 0 9.541441613691859e-06
. O 0 6.743945846210408e-07

3 O 0 1.9988713120255852e-06
and O 0 1.2343497779454538e-08
encodes O 0 6.823520237730918e-08
a O 0 9.303509074243266e-09
403 O 0 1.7270934904445312e-08
amino O 0 4.803391817631564e-08
acid O 0 1.1022073920230469e-07
dual O 0 4.48738887826039e-07
specificity O 0 3.475004746178456e-07
phosphatase O 0 0.0005489382310770452
( O 0 5.91096700475191e-08
protein O 0 3.1952180279404274e-07
tyrosine O 0 3.480700570435147e-06
phosphatase O 0 0.00018167257076129317
; O 0 7.047927397252352e-08
PTPase O 0 4.637917299987748e-06
) O 0 9.780241505552567e-09
, O 0 2.105384977468816e-09
was O 0 4.8072873681803685e-08
shown O 0 1.5539933784225468e-08
recently O 0 1.6273142477984948e-07
to O 0 8.025420328294786e-09
play O 0 1.4350697519205369e-08
a O 0 2.6018488696877284e-08
broad O 0 5.73590632768628e-08
role O 0 1.008110359634884e-07
in O 0 3.863470965370652e-08
human O 0 4.758835814300255e-07
malignancy B-Disease 0 9.56197691266425e-05
. O 0 3.9163714404821803e-07

Somatic O 0 0.000647285021841526
PTEN O 0 0.0019695444498211145
deletions O 0 0.00017402286175638437
and O 0 1.2867141094830004e-06
mutations O 0 1.5133750821405556e-05
were O 0 1.3244375907106587e-07
observed O 0 2.029412797810437e-07
in O 0 1.7554292242039082e-08
sporadic B-Disease 0 3.570776607375592e-05
breast I-Disease 1 0.5360566973686218
, I-Disease 0 2.177272335757152e-06
brain I-Disease 0 0.03447084501385689
, I-Disease 0 2.2897636426932877e-06
prostate I-Disease 1 0.8125247359275818
and I-Disease 0 2.3184449673863128e-05
kidney I-Disease 1 0.7441761493682861
cancer I-Disease 0 0.00028973515145480633
cell O 0 4.911443102173507e-05
lines O 0 8.101652201730758e-05
and O 0 1.488220675582852e-07
in O 0 5.637925681867273e-09
several O 0 2.4778003648862068e-08
primary O 0 2.1602672859444283e-05
tumours B-Disease 1 1.0
such O 0 1.876251687349395e-08
as O 0 2.990839220728958e-06
endometrial B-Disease 1 0.9878268837928772
carcinomas I-Disease 1 1.0
, O 1 0.6731484532356262
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.5797485709190369
thyroid B-Disease 1 0.9999979734420776
tumours I-Disease 1 1.0
. O 0 1.053145115292864e-05

In O 0 3.557866534720233e-07
addition O 0 9.501820841251174e-08
, O 0 7.36437471005047e-08
PTEN O 0 9.225770190823823e-05
was O 0 1.7555265685587074e-06
identified O 0 8.303918264118693e-08
as O 0 1.7617879377596068e-09
the O 0 2.5052284691184923e-09
susceptibility O 0 3.1920444598654285e-07
gene O 0 2.1732238053573383e-07
for O 0 1.2340719557357716e-08
two O 0 2.3264522042154567e-06
hamartoma B-Disease 1 0.9998965263366699
syndromes I-Disease 1 0.9974671602249146
Cowden B-Disease 1 0.9870185852050781
disease I-Disease 1 0.7769566178321838
( O 0 5.8004097525099496e-08
CD B-Disease 0 6.576327723450959e-05
; O 0 5.529149120775401e-07
MIM O 0 0.0008812142768874764
158350 O 0 1.381966740154894e-06
) O 0 3.348998189878216e-09
and O 0 1.309280239780719e-08
Bannayan B-Disease 0 7.961346273077652e-05
- I-Disease 0 0.003094038227573037
Zonana I-Disease 0 0.0021340306848287582
( I-Disease 0 3.507640400357559e-08
BZS I-Disease 0 1.942943981703138e-06
) I-Disease 0 7.700033499702386e-09
or I-Disease 0 3.732724351834804e-08
Ruvalcaba I-Disease 0 2.7652582502923906e-05
- I-Disease 0 0.0001178416350740008
Riley I-Disease 0 0.00021199991169851273
- I-Disease 1 0.8413012623786926
Smith I-Disease 1 0.824533998966217
syndrome I-Disease 1 0.9990038275718689
( O 0 7.012916114490508e-08
MIM O 0 0.0002115686220349744
153480 O 0 2.5197632567142136e-06
) O 0 4.086199467678853e-08
. O 0 1.302980336959081e-07

Constitutive O 0 2.763038719422184e-05
DNA O 0 7.604982329212362e-06
from O 0 4.897168182083078e-08
37 O 0 5.1842036441485106e-08
CD B-Disease 0 1.7060791606127168e-06
families O 0 7.582925398708085e-09
and O 0 1.1669103905376232e-08
seven O 0 5.224993770980291e-08
BZS B-Disease 0 3.976394509663805e-06
families O 0 8.84782114241034e-09
was O 0 3.172076290525183e-08
screened O 0 2.6727695967565523e-07
for O 0 4.144013843188077e-08
germline O 0 4.297259874874726e-05
PTEN O 0 0.00046731290058232844
mutations O 0 7.600558456033468e-05
. O 0 4.3319860765222984e-07

PTEN O 0 0.01601659320294857
mutations O 0 0.0009323844569735229
were O 0 3.247863560318365e-07
identified O 0 1.321625120453973e-07
in O 0 3.1910012410207855e-09
30 O 0 9.201646555823118e-09
of O 0 6.112079731224185e-10
37 O 0 8.887114688604925e-08
( O 0 4.783020202125954e-09
81 O 0 1.9678331852901465e-08
% O 0 1.4731917907795378e-09
) O 0 1.306296293357434e-09
CD B-Disease 0 3.023290446435567e-06
families O 0 7.420914105438214e-09
, O 0 2.328786941063754e-09
including O 0 1.5168338807214354e-09
missense O 0 2.114666358465911e-06
and O 0 6.463719159910397e-08
nonsense O 0 2.6248333142575575e-06
point O 0 8.165575877683295e-07
mutations O 0 3.888392541284702e-07
, O 0 1.7841131905171892e-09
deletions O 0 2.1646211223469436e-07
, O 0 5.490656818096795e-09
insertions O 0 3.959642924655782e-07
, O 0 5.120119883628149e-09
a O 0 2.904632090405812e-08
deletion O 0 1.7601987565285526e-05
/ O 0 2.827117896231357e-05
insertion O 0 1.1883807928825263e-06
and O 0 1.3124662245900254e-07
splice O 0 0.0010748493950814009
site O 0 3.969722456531599e-05
mutations O 0 5.757770122727379e-05
. O 0 6.175693556542683e-07

These O 0 3.933346022222395e-07
mutations O 0 1.0624905371514615e-05
were O 0 5.116540080507548e-08
scattered O 0 2.3367169532662047e-08
over O 0 1.895444867727747e-08
the O 0 8.363888248652529e-09
entire O 0 4.542168596799456e-08
length O 0 1.422794753125345e-07
of O 0 4.225833905024956e-09
PTEN O 0 5.990694717183942e-06
, O 0 1.8562955617085208e-09
with O 0 4.849221024727512e-10
the O 0 1.3359434669624193e-09
exception O 0 1.2968205398422583e-09
of O 0 1.0473041878178435e-10
the O 0 4.499715267058946e-09
first O 0 3.4346149391240033e-07
, O 0 3.384233338010745e-08
fourth O 0 2.3139218683354557e-06
and O 0 9.787467547539563e-08
last O 0 7.724137276454712e-07
exons O 0 1.3223000678408425e-05
. O 0 1.423185551630013e-07

A O 0 2.6274203719367506e-06
hot O 0 5.571878773480421e-06
spot O 0 3.772484433284262e-06
for O 0 3.754517052811934e-08
PTEN O 0 2.382453931204509e-05
mutation O 0 3.792931693169521e-07
in O 0 7.665084567065605e-09
CD B-Disease 0 3.1481129553867504e-05
was O 0 1.327042355114827e-06
identified O 0 3.859552677454303e-08
in O 0 8.988058075587446e-10
exon O 0 1.6316748485678545e-07
5 O 0 1.4815785043253982e-08
that O 0 6.57235543766177e-10
contains O 0 2.9423904979175575e-10
the O 0 2.0767965125401133e-09
PTPase O 0 6.893596946611069e-07
core O 0 2.010986861478159e-07
motif O 0 2.659108311320324e-08
, O 0 6.11082073831426e-10
with O 0 2.1443184727854003e-10
13 O 0 1.3846114255144926e-09
of O 0 2.1423970930634084e-10
30 O 0 7.818249159186053e-09
( O 0 7.077760044715831e-10
43 O 0 1.2868568433077598e-08
% O 0 1.3045085012208801e-09
) O 0 1.2838431429074149e-09
CD B-Disease 0 6.394554930011509e-06
mutations O 0 9.591550451659714e-07
identified O 0 8.008115059965348e-08
in O 0 1.691931039715655e-09
this O 0 8.290383490816566e-09
exon O 0 9.197171493724454e-06
. O 0 5.053797167420271e-07

Seven O 0 9.421088975614111e-07
of O 0 1.3989630787136775e-08
30 O 0 8.447598531802214e-08
( O 0 1.0846243903017694e-08
23 O 0 4.323120705862493e-08
% O 0 3.4769183088201316e-09
) O 0 1.1546598122080809e-09
were O 0 2.444340063689765e-09
within O 0 4.78634909484299e-10
the O 0 1.6992465212695151e-09
core O 0 6.967025001358707e-07
motif O 0 5.597094627773913e-07
, O 0 4.199511405289513e-09
the O 0 1.4425114436278363e-09
majority O 0 5.91723559040247e-09
( O 0 1.1156159329672732e-09
five O 0 2.9878730600785275e-09
of O 0 4.2046308101895136e-10
seven O 0 4.8851987344278314e-08
) O 0 2.027766843326617e-09
of O 0 2.4863666681085306e-10
which O 0 1.8454587191740757e-08
were O 0 2.6652472229216073e-08
missense O 0 1.1230481504753698e-06
mutations O 0 3.846651850381022e-07
, O 0 4.213101867378555e-09
possibly O 0 2.8135698215692173e-08
pointing O 0 4.2032155533888726e-07
to O 0 1.111527758723696e-08
the O 0 2.1483561596369327e-09
functional O 0 1.722553299998708e-08
significance O 0 2.8975701837907764e-09
of O 0 9.67603330792599e-10
this O 0 8.832814479831086e-09
region O 0 3.966607891925378e-06
. O 0 6.389121267602604e-07

Germline O 0 0.01817091554403305
PTEN O 0 0.008796611800789833
mutations O 0 0.0015118467854335904
were O 0 8.674207947478862e-07
identified O 0 1.1941949651372852e-07
in O 0 2.756182393426343e-09
four O 0 3.537881099191509e-09
of O 0 6.87175982783117e-10
seven O 0 4.5578328666806556e-08
( O 0 2.885359728921344e-09
57 O 0 3.42284565135742e-08
% O 0 2.6760957894111925e-09
) O 0 2.08616590668953e-09
BZS B-Disease 0 5.989513169879501e-07
families O 0 7.929018330798954e-09
studied O 0 8.2468744722064e-08
. O 0 1.4156078975702258e-07

Interestingly O 0 4.350487870397046e-05
, O 0 1.756448000378441e-07
none O 0 1.6062211116718572e-08
of O 0 6.841315292049899e-10
these O 0 5.622719179143587e-09
mutations O 0 1.5312241430365248e-06
was O 0 3.1766688834977685e-07
observed O 0 6.263405083473117e-08
in O 0 2.576985291824485e-09
the O 0 1.0354690438418857e-08
PTPase O 0 9.699204383650795e-06
core O 0 1.8520368030294776e-06
motif O 0 3.698082764458377e-06
. O 0 4.734937704142794e-07

It O 0 2.626706418595859e-06
is O 0 2.597277237725848e-08
also O 0 1.3179241697969246e-08
worthy O 0 9.80407399708838e-09
of O 0 1.0128952121490897e-09
note O 0 1.099714879160274e-07
that O 0 1.0506260306186732e-09
a O 0 8.532984985265557e-09
single O 0 4.421936807830207e-07
nonsense O 0 1.0350879620091291e-06
point O 0 2.917926735790388e-07
mutation O 0 1.0208267298139617e-07
, O 0 1.9282844210266603e-09
R233X O 0 5.019749949042307e-08
, O 0 8.104688475896182e-09
was O 0 1.3472728710439696e-07
observed O 0 1.8893954845111693e-08
in O 0 1.0340042155831952e-09
the O 0 2.494918938111823e-09
germline O 0 3.1087179763744643e-07
DNA O 0 5.567717948906648e-07
from O 0 1.7411628805419355e-09
two O 0 4.018920307657936e-09
unrelated O 0 6.686029507818603e-08
CD B-Disease 0 1.0131352610187605e-05
families O 0 1.4157693684069272e-08
and O 0 1.58488209223151e-08
one O 0 4.8117271944647655e-08
BZS B-Disease 0 2.7893600417883135e-05
family O 0 7.518150368923671e-07
. O 0 2.8067125867892173e-07

Genotype O 0 0.06518441438674927
- O 0 0.010050863958895206
phenotype O 0 0.0004743645549751818
studies O 0 7.937477448649588e-07
were O 0 9.316261895264688e-08
not O 0 7.890742281801977e-09
performed O 0 5.273532366345535e-08
on O 0 4.0089851438551705e-08
this O 0 1.0837469810454081e-09
small O 0 4.023644972761531e-09
group O 0 1.8712879068516486e-07
of O 0 2.35013852822874e-09
BZS B-Disease 0 5.169381438463461e-06
families O 0 3.763880940255149e-08
. O 0 9.587311211589622e-08

However O 0 2.6019017695944058e-06
, O 0 1.0023411789461534e-07
genotype O 0 1.046417310135439e-05
- O 0 3.990613549831323e-05
phenotype O 0 1.5075040209922008e-05
analysis O 0 1.45475866020206e-07
inthe O 0 7.338333034567768e-06
group O 0 1.507477463746909e-06
of O 0 2.6967812427614035e-09
CD B-Disease 0 2.698185562621802e-05
families O 0 3.1217005869166314e-08
revealed O 0 9.487909551353368e-07
two O 0 7.943640412122477e-09
possible O 0 5.357658761084849e-09
associations O 0 4.481786053389669e-10
worthy O 0 1.2590306575077648e-09
of O 0 3.5866698500086613e-10
follow O 0 2.250364161682228e-08
- O 0 2.5676529276097426e-06
up O 0 1.2881973816547543e-06
in O 0 5.5538137644361996e-08
independent O 0 5.270304654914071e-07
analyses O 0 8.031317975110142e-07
. O 0 1.8985861061082687e-07

The O 0 1.184416305477498e-06
first O 0 2.217087512690341e-06
was O 0 2.1620228380925255e-06
an O 0 2.4364423367728705e-08
association O 0 8.374375859432348e-09
noted O 0 8.270404805443832e-09
in O 0 9.680021229030444e-10
the O 0 3.001650261680311e-09
group O 0 2.653677597663773e-07
of O 0 4.815063903151895e-10
CD B-Disease 0 1.7215314073837362e-05
families O 0 1.0622469126531087e-08
with O 0 3.6791254842682974e-07
breast B-Disease 0 0.406464546918869
disease I-Disease 0 0.00022272767091635615
. O 0 2.5870829745144874e-07

A O 0 4.70466829938232e-06
correlation O 0 4.360313141660299e-06
was O 0 2.5086137611651793e-06
observed O 0 1.1889380857610377e-07
between O 0 3.6418961180118004e-09
the O 0 6.992610490641482e-09
presence O 0 4.965935573864044e-08
/ O 0 8.364126188098453e-06
absence O 0 4.940114095575154e-09
of O 0 2.0760904106964517e-10
a O 0 1.9224025038511172e-08
PTEN O 0 2.9206736144260503e-05
mutation O 0 3.2723943377277465e-07
and O 0 2.1544497297298904e-09
the O 0 1.4974131934408774e-09
type O 0 2.6203861125395633e-07
of O 0 9.545216528294986e-08
breast O 0 0.02164319157600403
involvement O 0 4.613200871972367e-06
( O 0 3.5198922887502704e-07
unaffected O 0 2.7972928364761174e-05
versus O 0 2.2945814635022543e-05
benign O 0 0.001684224116615951
versus O 0 0.0001129870506701991
malignant O 0 0.07269524782896042
) O 0 3.0567329645236896e-07
. O 0 5.479203650793352e-07

Specifically O 0 1.8346354409004562e-06
and O 0 1.4869694098251784e-07
more O 0 3.3836893287286784e-09
directly O 0 3.712042584425035e-08
, O 0 3.3984445479973147e-08
an O 0 2.43049651516003e-08
association O 0 8.271480567145773e-08
was O 0 1.3173131492294488e-06
also O 0 1.6696172622232552e-07
observed O 0 2.1896395807630142e-08
between O 0 8.201455070633301e-10
the O 0 1.183219078271236e-09
presence O 0 2.0621679919230473e-09
of O 0 4.3966597029765353e-10
a O 0 6.795983864549271e-08
PTEN O 0 0.0008027713629417121
mutation O 0 3.166751048411243e-05
and O 0 7.042242486932082e-06
malignant B-Disease 1 0.9999884366989136
breast I-Disease 1 0.99979168176651
disease I-Disease 0 0.12044663727283478
. O 0 1.8261013110532076e-06

Secondly O 0 0.0016909416299313307
, O 0 9.417414617018949e-07
there O 0 1.1475248307135644e-08
appeared O 0 1.4617147314766044e-07
to O 0 4.505615436301014e-09
be O 0 7.24508275595781e-09
an O 0 9.697988190282558e-09
interdependent O 0 5.2384082664502785e-05
association O 0 1.4630669120663242e-08
between O 0 3.6847060957967415e-09
mutations O 0 2.574260804522055e-07
upstream O 0 1.2409884675435023e-07
and O 0 1.0706149744521554e-08
within O 0 1.2396482729215563e-09
the O 0 1.92191751402504e-09
PTPase O 0 1.3282603958941763e-06
core O 0 6.070990252737829e-07
motif O 0 1.955788775376277e-07
, O 0 1.8525816436465448e-09
the O 0 5.478811848647069e-10
core O 0 6.83757690467246e-08
motif O 0 2.114691000087987e-08
containing O 0 2.3861508324785063e-09
the O 0 6.215534753550855e-10
majority O 0 1.2755929645891229e-09
of O 0 5.353447685152446e-10
missense O 0 1.9048918602493359e-06
mutations O 0 4.031212938571116e-06
, O 0 1.6654276180361194e-08
and O 0 1.3642719842721363e-08
the O 0 6.592559831375411e-09
involvement O 0 2.8746059754780617e-08
of O 0 3.589687991301105e-10
all O 0 2.6576314482440466e-09
major O 0 2.9120656108716503e-08
organ O 0 3.663953975774348e-05
systems O 0 1.897614674817305e-05
( O 0 3.5614643678627544e-08
central O 0 1.2464805649869959e-06
nervous O 0 7.993471626832616e-06
system O 0 2.1605623601317347e-07
, O 0 3.852301517781598e-07
thyroid O 0 0.012004087679088116
, O 0 6.081821197767567e-07
breast O 0 0.02181278169155121
, O 0 4.7164649004116654e-06
skin O 1 0.999993085861206
and O 0 0.0631251409649849
gastrointestinal O 1 0.9778640866279602
tract O 0 0.03306346759200096
) O 0 7.458291975126485e-07
. O 0 1.3295467624629964e-06

However O 0 1.2793749419870437e-06
, O 0 1.9398759931732457e-08
these O 0 4.5812911797504796e-10
observations O 0 2.716176972228368e-08
would O 0 2.351247019305447e-08
need O 0 1.9807031570451272e-09
to O 0 1.058448706459103e-08
be O 0 1.3443384183631224e-08
confirmed O 0 5.281232162701599e-08
by O 0 1.2318318587389854e-10
studying O 0 4.16264217539819e-10
a O 0 1.3218053318553302e-09
larger O 0 3.818676930222864e-09
number O 0 5.3546247436031535e-09
of O 0 1.0269520789307762e-09
CD B-Disease 0 4.9681497330311686e-05
families O 0 7.557977710348496e-08
. O 0 1.1194024551741677e-07

Molecular O 0 0.0037607569247484207
defects O 1 0.9996629953384399
leading O 0 3.4062722988892347e-06
to O 0 3.6525761970551684e-08
human O 0 2.467151993812422e-08
complement B-Disease 0 1.5761856957396958e-06
component I-Disease 0 0.010685780085623264
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.8823705261183932e-08
an O 0 3.6866607544538965e-09
African O 0 8.839690757156404e-09
- O 0 1.0551327704888536e-06
American O 0 2.105743988067843e-07
family O 0 3.1823665835872816e-07
. O 0 2.994955821122858e-07

Complement B-Disease 0 0.00011936193914152682
component I-Disease 0 0.12338025867938995
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.6787192862466327e-06
C6D B-Disease 0 0.00048266956582665443
) O 0 2.3912281221782905e-07
was O 0 4.116821401112247e-06
diagnosed O 0 2.9679564249818213e-05
in O 0 8.150586316979513e-10
a O 0 2.300827617318646e-08
16 O 0 9.46692537695526e-08
- O 0 1.975977511392557e-06
year O 0 2.9412663593575417e-07
- O 0 8.68733820880152e-07
old O 0 5.497607276083727e-07
African O 0 3.859065067501888e-09
- O 0 9.582484494785604e-08
American O 0 2.4608356241628826e-08
male O 0 2.699268186745485e-08
with O 0 1.059378220702456e-07
meningococcal B-Disease 1 0.9999966621398926
meningitis I-Disease 1 0.9999639987945557
. O 0 6.132591465757287e-07

The O 0 2.7114670047012623e-06
patients O 0 2.282886634930037e-05
father O 0 1.6377579186155344e-06
and O 0 1.0605427291920932e-07
two O 0 2.10866616612293e-07
brothers O 0 4.4834134314442053e-05
also O 0 7.083573336785776e-07
had O 0 5.758701604463567e-07
C6D B-Disease 0 1.6254100046353415e-05
, O 0 1.5513725415416957e-08
but O 0 1.3816673360977916e-09
gave O 0 9.909165044064139e-09
no O 0 1.7131063234643307e-09
history O 0 1.094002444190778e-09
of O 0 2.7172808003683713e-08
meningitis B-Disease 1 0.9996961355209351
or O 0 1.0911900716337186e-07
other O 0 5.1766843256473294e-08
neisserial B-Disease 0 0.0022223058622330427
infection I-Disease 0 0.00011574615200515836
. O 0 2.934329472736863e-07

By O 0 1.5673327879994758e-07
using O 0 2.781263503948139e-07
exon O 0 6.859364930278389e-06
- O 0 3.433757456150488e-06
specific O 0 4.910168627247913e-08
polymerase O 0 1.1335544058965752e-06
chain O 0 8.529295882908627e-06
reaction O 0 2.7240421474061804e-08
( O 0 2.5760809041486255e-09
PCR O 0 1.8844275473384187e-07
) O 0 2.877632576669953e-09
/ O 0 4.3507495206540625e-07
single O 0 1.861643994516271e-07
- O 0 3.818107416009298e-06
strand O 0 0.00021292125165928155
conformation O 0 2.552868636485073e-07
polymorphism O 0 2.346193994640089e-08
as O 0 7.375894894856572e-10
a O 0 7.691984826863063e-10
screening O 0 1.1217722750700432e-08
step O 0 1.7348785519288867e-08
and O 0 8.152140629213989e-10
nucleotide O 0 8.028482767485912e-09
sequencing O 0 1.6645955724925443e-08
of O 0 4.5396866821256765e-10
target O 0 5.306566777107946e-07
exons O 0 1.1875933978444664e-06
, O 0 2.8567653131972293e-08
we O 0 1.0871096911557743e-08
determined O 0 6.397008256442405e-09
that O 0 9.296728387120368e-10
the O 0 2.965689915868097e-09
proband O 0 6.702208338538185e-06
was O 0 3.3575126678897504e-08
a O 0 2.449707325880013e-09
compound O 0 3.771023671106377e-08
heterozygote O 0 1.1566952906605366e-07
for O 0 2.973512103210396e-09
two O 0 3.0626530644894956e-08
C6 O 0 0.00018767443543765694
gene O 0 5.0486414693295956e-06
mutations O 0 1.2826041711377911e-05
. O 0 2.138447996458126e-07

The O 0 2.111539743054891e-07
first O 0 1.3635363416142354e-07
, O 0 8.026676212580242e-09
1195delC O 0 1.2525765669124667e-07
located O 0 1.3624023686986675e-08
in O 0 5.354410248514796e-09
exon O 0 6.475132749983459e-07
7 O 0 3.826444299193099e-07
, O 0 2.2742074889947617e-09
is O 0 3.78377246201822e-10
a O 0 2.948864263885298e-09
novel O 0 4.3460300247488703e-08
mutation O 0 8.925709948925942e-08
, O 0 2.3419630679200054e-09
while O 0 1.2674539195955958e-09
the O 0 5.601276109601372e-10
second O 0 1.6152542059444386e-07
, O 0 3.2611580103036886e-09
1936delG O 0 2.3607467980468755e-08
in O 0 9.290542224427156e-10
exon O 0 1.7686242870240676e-07
12 O 0 5.481137677065817e-08
, O 0 7.3459234251060934e-09
has O 0 2.5588835939061028e-08
been O 0 2.2237946595282665e-08
described O 0 2.0500888808783202e-07
before O 0 4.2768562025230494e-08
to O 0 2.0228617003681393e-08
cause O 0 5.068653408102364e-08
C6D B-Disease 0 5.6071676226565614e-06
in O 0 3.938136483583321e-09
an O 0 3.5591334324180934e-09
unrelated O 0 5.021761140255876e-08
African O 0 9.737394002229394e-09
- O 0 8.837424729790655e-07
American O 0 1.6655332046866533e-07
individual O 0 4.218483695694886e-08
. O 0 2.8309659683145583e-07

Both O 0 6.751449745934224e-06
mutations O 0 0.00010808747174451128
result O 0 9.852776656771312e-07
in O 0 2.4989594749058597e-07
premature O 0 1.5487432392546907e-05
termination O 0 2.326086132597993e-06
codons O 0 8.464487109449692e-06
and O 0 6.764157660654746e-07
C6 O 0 0.0014081078115850687
null O 0 0.00041103875264525414
alleles O 0 1.2019043424515985e-05
. O 0 8.761496133047331e-07

Allele O 0 6.269250297918916e-05
- O 0 1.0180885510635562e-05
specific O 0 1.3660952902228019e-07
PCR O 0 3.7439911011460936e-06
indicated O 0 1.995184959469043e-07
that O 0 1.1686003276167867e-09
the O 0 1.6441726868876572e-09
probands O 0 4.405757408676436e-06
two O 0 1.1703546221042416e-07
brothers O 0 4.074342541571241e-06
also O 0 5.854852247466624e-08
inherited O 0 1.926003250218855e-07
the O 0 3.1726976601476053e-09
1195delC O 0 3.404105655135936e-07
mutation O 0 6.612106062675593e-08
from O 0 2.7257092138910366e-09
their O 0 2.2024229551220742e-08
heterozygous O 0 3.708416329573083e-07
mother O 0 5.597634071818902e-07
and O 0 1.15176126413985e-08
the O 0 4.706864231707186e-09
1936delG O 0 1.6173951280507026e-06
mutation O 0 1.662308761751774e-07
from O 0 2.450660785413561e-09
their O 0 3.2477885270054685e-08
homozygous O 0 1.8452284393788432e-06
father O 0 2.407740851140261e-07
. O 0 1.1040859781985546e-08
. O 0 1.2872968113697425e-07

PAX6 O 0 0.06365715712308884
mutations O 0 0.014793925918638706
reviewed O 0 0.00011151625221827999
. O 0 4.564263690554071e-06

Mutations O 0 0.0008472423069179058
in O 0 4.1300168618363386e-07
PAX6 O 0 0.0001361225004075095
are O 0 1.7123974771493522e-07
responsible O 0 8.932937589634093e-07
for O 0 1.1147937328814805e-07
human O 0 2.7449314075056463e-06
aniridia B-Disease 1 1.0
and O 0 7.338283921853872e-06
have O 0 2.3794740400262526e-07
also O 0 2.5469594788773975e-07
been O 0 3.069846599146331e-08
found O 0 2.013938171785412e-08
in O 0 9.029180070285747e-09
patients O 0 7.117593980865422e-08
with O 0 7.854662698036918e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999997615814209
, O 0 3.8997563933662605e-07
with O 0 4.650575647247024e-06
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999911785125732
, O 0 1.458194844872196e-07
with O 0 3.793120129103045e-07
autosomal B-Disease 1 0.9892399311065674
dominant I-Disease 0 0.16776050627231598
keratitis I-Disease 1 0.9861310720443726
, O 0 6.013115694258886e-08
and O 0 2.593287362628871e-08
with O 0 3.290184338311519e-07
isolated B-Disease 0 0.13376115262508392
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 0.9999998807907104
. O 0 9.225264875567518e-06

No O 0 2.0831130314036272e-06
locus O 0 2.8762513011315605e-06
other O 0 1.969425333925301e-08
than O 0 2.9657991618137203e-08
chromosome O 0 8.719812467461452e-05
11p13 O 0 8.15411203802796e-06
has O 0 6.565801413671579e-07
been O 0 7.98624171238771e-08
implicated O 0 1.7637307792028878e-06
in O 0 1.6494134058575582e-07
aniridia B-Disease 1 0.9999998807907104
, O 0 2.4774962525953015e-07
and O 0 2.6216252280164554e-08
PAX6 O 0 7.0224105002125725e-06
is O 0 1.9686629215698304e-08
clearly O 0 1.2159199869188342e-08
the O 0 1.2664583826094145e-09
major O 0 2.2135623112262692e-08
, O 0 2.141978505676434e-08
if O 0 5.172259953667435e-09
not O 0 5.328207208776803e-09
only O 0 2.2053305848146465e-09
, O 0 8.47042436191714e-09
gene O 0 3.0954879548517056e-07
responsible O 0 1.208069420499669e-06
. O 0 2.946412678284105e-07

Twenty O 0 1.067701214196859e-05
- O 0 1.6080801287898794e-05
eight O 0 2.493023032457131e-07
percent O 0 9.550705044603092e-07
of O 0 9.05019337249513e-10
identified O 0 1.317130511324649e-07
PAX6 O 0 5.147480351297418e-06
mutations O 0 1.729382915982569e-06
are O 0 7.706203675184042e-09
C O 0 2.5535266559018055e-06
- O 0 3.0579642043448985e-05
T O 0 0.0011281413026154041
changes O 0 4.15828154132214e-08
at O 0 1.8851981309353505e-08
CpG O 0 4.1988405996562506e-07
dinucleotides O 0 6.679846933366207e-07
, O 0 1.5769148209443529e-09
20 O 0 9.4312857523704e-10
% O 0 2.6289079246843983e-10
are O 0 2.436333079725017e-10
splicing O 0 5.384511609918263e-07
errors O 0 2.130587517967797e-06
, O 0 4.57143922716341e-09
and O 0 4.044296453287188e-09
more O 0 1.0513275805479338e-09
than O 0 2.5218065413668e-09
30 O 0 6.11176842468808e-09
% O 0 1.0590580634683988e-09
are O 0 8.898350944974709e-10
deletion O 0 2.695924479212408e-07
or O 0 4.834744515846978e-08
insertion O 0 1.1150185628139297e-06
events O 0 2.1408844474990474e-07
. O 0 5.502401450030447e-07

There O 0 3.7661220630980097e-07
is O 0 1.3469819926115179e-08
a O 0 2.666966025799411e-08
noticeably O 0 5.419102308223955e-06
elevated O 0 2.3161385342973517e-06
level O 0 1.592023046725899e-08
of O 0 7.238020738320472e-10
mutation O 0 4.777989559556772e-08
in O 0 1.2660550385845681e-09
the O 0 2.0307393544527486e-09
paired O 0 2.535068404085905e-07
domain O 0 8.722073374656247e-08
compared O 0 8.958132013958675e-08
with O 0 1.053686471408355e-09
the O 0 4.039054424254118e-09
rest O 0 1.711053165820431e-08
of O 0 8.586366617713281e-10
the O 0 9.21105858253668e-09
gene O 0 1.0390172064944636e-06
. O 0 1.5403753650389262e-07

Increased O 0 3.921872121281922e-06
mutation O 0 3.217108996977913e-06
in O 0 3.094077172249854e-08
the O 0 8.74187211508115e-09
homeodomain O 0 1.791095542102994e-06
is O 0 2.3594189713094238e-08
accounted O 0 1.2834452434162813e-07
for O 0 9.550125135149301e-10
by O 0 1.5286197863062512e-09
the O 0 1.703547169995545e-08
hypermutable O 0 0.00011016885400749743
CpG O 0 2.0585557649610564e-05
dinucleotide O 0 1.7013235265039839e-06
in O 0 2.7157730286830883e-08
codon O 0 1.475470980949467e-06
240 O 0 3.1729661031931755e-07
. O 0 1.9766248726682534e-07

Very O 0 1.3493190635927022e-06
nearly O 0 2.421691078779986e-07
all O 0 1.3267264620253627e-08
mutations O 0 8.510393740834843e-07
appear O 0 8.922796723709325e-07
to O 0 1.767848658573712e-07
cause O 0 1.4318687817649334e-06
loss O 0 7.832227879589482e-07
of O 0 4.59854654355496e-10
function O 0 1.2287427963997288e-08
of O 0 7.071822571980135e-10
the O 0 6.6693166544951055e-09
mutant O 0 1.195681988974684e-07
allele O 0 4.762903813571029e-07
, O 0 4.155203292555143e-09
and O 0 1.2871974597317148e-09
more O 0 4.0965589254149393e-10
than O 0 1.06038000602382e-09
80 O 0 2.407577914809167e-09
% O 0 6.30633822940041e-10
of O 0 2.2802261467891327e-10
exonic O 0 2.7989713089482393e-06
substitutions O 0 1.795595494513691e-07
result O 0 2.1519088733157332e-08
in O 0 1.5033492672955617e-08
nonsense O 0 7.727954653091729e-06
codons O 0 1.1007732609868981e-05
. O 0 3.166487658745609e-07

In O 0 1.6033598626563617e-07
a O 0 2.4389947839154047e-08
gene O 0 5.2502080905014736e-08
with O 0 1.8662571488192725e-09
such O 0 2.1488191226382014e-09
extraordinarily O 0 2.133487839728332e-07
high O 0 3.2003043770600925e-08
sequence O 0 8.629024605966151e-09
conservation O 0 3.5433174172538884e-09
throughout O 0 3.3497711271479602e-09
evolution O 0 7.479958874512249e-09
, O 0 2.0305648273932775e-09
there O 0 8.25705059881443e-10
are O 0 3.4570011298029613e-09
presumed O 0 3.307255155959865e-06
undiscovered O 0 1.6268893887172453e-05
missense O 0 1.0491743523743935e-05
mutations O 0 3.992521214968292e-06
, O 0 1.1132378574529866e-08
these O 0 1.0305507558427962e-09
are O 0 2.1547539308386376e-09
hypothesized O 0 1.3998844394791377e-07
to O 0 4.308501289074229e-08
exist O 0 3.102320533798775e-08
in O 0 6.038202826630368e-09
as O 0 6.032989574578096e-08
- O 0 2.1624911823892035e-05
yet O 0 4.6159686917235376e-07
unidentified O 0 5.05734396938351e-06
phenotypes O 0 2.5836067152340547e-07
. O 0 9.986425908437013e-09
. O 0 1.0729110044849222e-07

Genetic O 0 0.0009548736270517111
heterogeneity O 0 0.00020915870845783502
and O 0 8.735864867048804e-07
penetrance O 0 2.5260493202949874e-05
analysis O 0 1.6747888764712116e-07
of O 0 3.134144055394472e-09
the O 0 2.7063100205282353e-08
BRCA1 O 0 6.773084169253707e-05
and O 0 8.208816666410712e-07
BRCA2 O 0 0.00010985455446643755
genes O 0 3.7167014852457214e-06
in O 0 1.5976696658981382e-06
breast B-Disease 1 0.9271848201751709
cancer I-Disease 0 0.0032325168140232563
families O 0 2.1225390867130045e-07
. O 0 5.555921802624653e-07

The O 0 0.0013912261929363012
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999996423721313
Linkage O 0 0.000580132647883147
Consortium O 0 1.4555924281012267e-05
. O 0 1.2409522014422691e-06

The O 0 5.063373009761563e-07
contribution O 0 1.9581963783821266e-07
of O 0 1.368783753008529e-08
BRCA1 O 0 4.475207606446929e-05
and O 0 2.1749624465883244e-06
BRCA2 O 0 0.03909437358379364
to O 0 0.001671771053224802
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 4.144187914789654e-05
assessed O 0 8.362215453416866e-07
by O 0 3.7145408970928884e-09
linkage O 0 1.8539207076173625e-06
and O 0 6.551334763571504e-08
mutation O 0 3.9649247440820545e-08
analysis O 0 9.810864121106988e-09
in O 0 1.0944406492185976e-09
237 O 0 9.917654253399633e-09
families O 0 1.361617152362271e-09
, O 0 1.0165726038735556e-09
each O 0 1.7879934199882541e-09
with O 0 4.000947129156884e-09
at O 0 2.162545342798694e-07
least O 0 5.164511485133971e-09
four O 0 1.4490642463727e-08
cases O 0 1.2280702677003319e-08
of O 0 3.1000670475123115e-08
breast B-Disease 0 0.4015062153339386
cancer I-Disease 0 4.78144247608725e-05
, O 0 5.140983194706905e-09
collected O 0 8.534497553114306e-09
by O 0 1.5914249473780728e-08
the O 0 8.492870983900502e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999992847442627
Linkage O 0 6.514633423648775e-05
Consortium O 0 4.395407813717611e-06
. O 0 5.650243224408769e-07

Families O 0 5.574579063249985e-06
were O 0 2.3260454895535077e-07
included O 0 6.080339343128571e-09
without O 0 3.122383684939223e-09
regard O 0 3.2314129150279314e-09
to O 0 2.2114763353897615e-09
the O 0 6.174182942686457e-09
occurrence O 0 6.55936105431465e-07
of O 0 2.863476140646526e-07
ovarian B-Disease 0 0.02831622026860714
or I-Disease 0 6.144838380350848e-07
other I-Disease 0 2.3158945339218917e-07
cancers I-Disease 0 0.000798475812189281
. O 0 6.748417149538e-07

Overall O 0 0.0004442776262294501
, O 0 9.18341083888663e-06
disease O 0 0.0001443283836124465
was O 0 3.337506484513142e-07
linked O 0 1.959155952135916e-06
to O 0 9.882045759468383e-08
BRCA1 O 0 5.711348876502598e-06
in O 0 8.641015014632103e-09
an O 0 3.267658366112869e-09
estimated O 0 7.521708056401621e-08
52 O 0 4.696992661479271e-08
% O 0 2.3739654686494305e-10
of O 0 6.985004935566863e-11
families O 0 8.200986001405397e-10
, O 0 1.536541560653859e-09
to O 0 8.657181638227485e-09
BRCA2 O 0 2.8419963200576603e-06
in O 0 6.523451556716964e-09
32 O 0 9.765291686392175e-09
% O 0 2.8658875272924433e-10
of O 0 8.731198403166829e-11
families O 0 1.8427354087080516e-09
, O 0 5.199242369968715e-09
and O 0 5.973617600574244e-09
to O 0 3.53510887229902e-09
neither O 0 2.934534393261856e-09
gene O 0 1.0079812540197963e-08
in O 0 7.162229143098386e-10
16 O 0 4.3569086116690414e-09
% O 0 6.325999168943497e-10
( O 0 4.4334766413633986e-10
95 O 0 3.682464999599233e-09
% O 0 1.6459172913485531e-09
confidence O 0 2.083145034248446e-08
interval O 0 4.714494750146514e-08
[ O 0 5.95622502430615e-08
CI O 0 2.9917498977738433e-05
] O 0 1.782930247884451e-08
6 O 0 2.316498104448783e-09
% O 0 4.380972529194338e-10
- O 0 1.803950766543494e-07
28 O 0 1.9786730831583554e-07
% O 0 2.1416097784054955e-09
) O 0 1.067238186713837e-09
, O 0 2.006613541993829e-09
suggesting O 0 3.942535187206886e-08
other O 0 1.9194272837808057e-08
predisposition O 0 2.6856750992010348e-06
genes O 0 1.5220678051264258e-06
. O 0 4.279757206404611e-07

The O 0 2.89815005771743e-07
majority O 0 9.025291802799984e-08
( O 0 1.05346984469179e-08
81 O 0 1.548750105939689e-08
% O 0 1.0855468746129304e-09
) O 0 4.33994534754234e-10
of O 0 7.846808758316115e-10
the O 0 1.6316516848746687e-05
breast B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.2509095032319237e-08
were O 0 6.896843540715736e-09
due O 0 1.029191931678497e-08
to O 0 1.1275383293707364e-08
BRCA1 O 0 2.3294915081351064e-06
, O 0 2.973364665592726e-09
with O 0 1.4828669403499362e-09
most O 0 2.1068283118097497e-08
others O 0 1.4109055257449654e-07
( O 0 2.8718587508080873e-09
14 O 0 1.0063752498012946e-08
% O 0 2.561284739854841e-09
) O 0 1.718568509723184e-09
due O 0 2.9726347605674164e-08
to O 0 4.061367064878141e-07
BRCA2 O 0 0.0005595464608632028
. O 0 4.7558913252032653e-07

Conversely O 0 3.890969674102962e-05
, O 0 3.414499261111814e-08
the O 0 3.0955746854743893e-09
majority O 0 4.322195046313482e-09
of O 0 4.111643248094765e-10
families O 0 9.160315284084675e-10
with O 0 2.548167454818895e-09
male B-Disease 0 1.549443595649791e-07
and I-Disease 0 4.5867082576478424e-07
female I-Disease 0 9.664136086939834e-06
breast I-Disease 0 0.031025554984807968
cancer I-Disease 0 5.321378921507858e-05
were O 0 4.6324174718392896e-08
due O 0 3.6267934433453775e-08
to O 0 7.893319775575947e-08
BRCA2 O 0 9.1767571575474e-05
( O 0 1.967825546955737e-08
76 O 0 4.7985110995796276e-08
% O 0 4.983515378143011e-09
) O 0 1.2702935592301401e-08
. O 0 1.0859454135925262e-07

The O 0 2.3092738388186262e-07
largest O 0 5.342722033674363e-07
proportion O 0 1.0594631305593794e-07
( O 0 8.566463094439314e-09
67 O 0 6.328648538556081e-08
% O 0 2.529620291014112e-09
) O 0 6.067847335700094e-10
of O 0 3.132516745996128e-10
families O 0 2.8470106272493467e-09
due O 0 2.824183020777582e-08
to O 0 1.4598501074658543e-08
other O 0 5.959096771590566e-09
genes O 0 5.891067544894213e-08
was O 0 4.82007692426123e-07
found O 0 4.789970375895791e-08
in O 0 1.3797711861940343e-09
families O 0 5.812264558535674e-10
with O 0 1.2368943647089736e-09
four O 0 3.136208803766749e-08
or O 0 5.208238107456964e-08
five O 0 7.362040310709972e-09
cases O 0 1.2796431692052579e-09
of O 0 1.0383957027571e-09
female O 0 1.2680233339779079e-05
breast B-Disease 0 0.02123437076807022
cancer I-Disease 0 1.8315833585802466e-05
only O 0 2.674586951911806e-08
. O 0 2.9354322350627626e-07

These O 0 8.482778639518074e-07
estimates O 0 8.185082151612733e-06
were O 0 7.860057849029545e-08
not O 0 7.137439528293044e-09
substantially O 0 2.3073323518474353e-07
affected O 0 1.2964428641737413e-08
either O 0 2.895018003101768e-09
by O 0 6.92539192659325e-10
changing O 0 3.078183752336372e-08
the O 0 6.987637579669581e-09
assumed O 0 2.0684153412275919e-07
penetrance O 0 2.1829555407748558e-07
model O 0 3.400889170279697e-08
for O 0 4.527772823337273e-09
BRCA1 O 0 3.0769213026360376e-06
or O 0 4.6376072759812814e-08
by O 0 1.0092389146620917e-09
including O 0 3.7711944678164855e-09
or O 0 3.2177703701563587e-07
excluding O 0 2.0094150386285037e-05
BRCA1 O 0 0.00023136190429795533
mutation O 0 5.2763120947929565e-06
data O 0 2.321388137715985e-06
. O 0 3.5526861097423534e-07

Among O 0 2.9274369239828957e-07
those O 0 1.6430826477176197e-08
families O 0 3.6138028125520805e-09
with O 0 2.7467113028478707e-08
disease O 0 2.5322118744952604e-05
due O 0 9.547856905101071e-08
to O 0 1.2472268906549289e-07
BRCA1 O 0 5.2357914682943374e-05
that O 0 7.626807274618841e-08
were O 0 3.945461557464114e-08
tested O 0 1.7212364866736607e-08
by O 0 1.1752339379444976e-10
one O 0 6.459497936539549e-10
of O 0 4.407203074707766e-11
the O 0 4.26086055327346e-10
standard O 0 1.53607633279762e-08
screening O 0 4.027776334680766e-09
methods O 0 6.811319952504391e-09
, O 0 2.3372239699170905e-09
mutations O 0 1.1782296382989443e-07
were O 0 4.6882808746318005e-09
detected O 0 6.243391226234962e-08
in O 0 3.319589603201223e-10
the O 0 7.602109497462095e-10
coding O 0 4.321954349961743e-07
sequence O 0 3.8031817695127756e-08
or O 0 1.7292556719894492e-08
splice O 0 4.5782571760355495e-06
sites O 0 8.900057224536795e-08
in O 0 1.1806311484008347e-09
an O 0 1.7648686956306392e-09
estimated O 0 3.413678584252011e-08
63 O 0 3.095918899020944e-08
% O 0 8.884207813864009e-10
( O 0 6.16963535815529e-10
95 O 0 7.640198695924028e-09
% O 0 3.240504309331982e-09
CI O 0 2.1535162886721082e-05
51 O 0 5.303409622570143e-08
% O 0 2.951340283274817e-09
- O 0 3.502854042380932e-07
77 O 0 1.3740420001795428e-07
% O 0 8.703539222665313e-09
) O 0 1.208998590129795e-08
. O 0 1.4974918371990498e-07

The O 0 6.504885163849394e-07
estimated O 0 6.62423644826049e-07
sensitivity O 0 1.491060572789138e-07
was O 0 3.097112255545653e-07
identical O 0 6.594699897277678e-08
for O 0 1.4539222048526312e-09
direct O 0 1.6593524776453705e-08
sequencing O 0 5.191709533391986e-07
and O 0 1.7926383932831413e-08
other O 0 3.6698228900178265e-09
techniques O 0 5.089384558232268e-07
. O 0 4.2352854734417633e-07

The O 0 1.0354957566960366e-06
penetrance O 0 4.254217492416501e-05
of O 0 1.1484340234346746e-07
BRCA2 O 0 0.00041647718171589077
was O 0 7.997611533028248e-07
estimated O 0 1.621516609873197e-08
by O 0 1.7202608226796201e-09
maximizing O 0 1.9054718336519727e-07
the O 0 3.4471526078050374e-08
LOD O 0 0.0001550679444335401
score O 0 2.033190327210832e-07
in O 0 1.9581509747013115e-08
BRCA2 O 0 0.00021825100702699274
- O 0 4.0806731703924015e-05
mutation O 0 2.5658266622485826e-06
families O 0 1.2131680549032353e-08
, O 0 2.1408990136251305e-09
over O 0 5.381090684153378e-09
all O 0 4.902267924933312e-09
possible O 0 4.568434164298196e-08
penetrance O 0 7.022832960501546e-06
functions O 0 3.640509476099396e-07
. O 0 4.1929905592041905e-07

The O 0 2.897912452226592e-07
estimated O 0 6.828857408436306e-07
cumulative O 0 1.4898695326337474e-06
risk O 0 6.791894975322066e-07
of O 0 2.301599977272417e-08
breast B-Disease 0 0.19229476153850555
cancer I-Disease 0 0.00022694467043038458
reached O 0 4.317328148317756e-07
28 O 0 7.785646971569804e-08
% O 0 1.1484044826204354e-09
( O 0 2.738344273556237e-10
95 O 0 3.425129735390442e-09
% O 0 1.975044350288613e-09
CI O 0 4.245380750944605e-06
9 O 0 3.1184868021227885e-08
% O 0 1.0120803084490149e-09
- O 0 1.0948509299169018e-07
44 O 0 1.6787140566520975e-08
% O 0 4.4328085646583304e-10
) O 0 2.2221728623872394e-10
by O 0 4.444669632341913e-10
age O 0 1.4871212039579973e-09
50 O 0 1.996443454999053e-09
years O 0 1.7830721343869982e-09
and O 0 1.915220870785106e-09
84 O 0 1.7355362702531352e-09
% O 0 2.953607913802614e-10
( O 0 1.1880671446640179e-10
95 O 0 1.7231702731379528e-09
% O 0 1.673202132401741e-09
CI O 0 4.663099389290437e-06
43 O 0 1.1917109077330679e-08
% O 0 7.850445848944787e-10
- O 0 4.3744307731685694e-08
95 O 0 4.0918152421909326e-08
% O 0 1.769878021917748e-09
) O 0 3.788972469109808e-10
by O 0 1.459913301360416e-09
age O 0 6.469945468268179e-09
70 O 0 1.0554026097508995e-08
years O 0 1.9952262064748538e-08
. O 0 7.315068728530605e-08

The O 0 1.4498940799967386e-05
corresponding O 1 0.9093158841133118
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.000550714205019176
were O 0 2.598149819732498e-07
0 O 0 6.863055546091346e-07
. O 0 5.657986434925988e-07

4 O 0 1.8938080756925046e-06
% O 0 6.944657826579714e-08
( O 0 6.333741531250325e-09
95 O 0 1.2174911745432837e-08
% O 0 4.653127660958489e-09
CI O 0 4.077599896845641e-06
0 O 0 1.2092106871364194e-08
% O 0 5.676389358555411e-10
- O 0 2.8371029969775918e-08
1 O 0 2.8858181622126722e-08
% O 0 9.31932864212115e-10
) O 0 2.0052121074698448e-10
by O 0 2.3041847596605436e-10
age O 0 1.6329249064028772e-09
50 O 0 1.7315716638321987e-09
years O 0 1.7592293177770557e-09
and O 0 2.7550051129310305e-09
27 O 0 6.5657679293451565e-09
% O 0 1.5435493161408687e-10
( O 0 6.844495803459694e-11
95 O 0 1.0201504085927127e-09
% O 0 1.1068476135633887e-09
CI O 0 1.5569951301586116e-06
0 O 0 6.529775387065229e-09
% O 0 2.1540471628611613e-09
- O 0 2.6915827788798197e-07
47 O 0 2.432602741464507e-07
% O 0 2.1451009857287318e-09
) O 0 5.167188898980157e-10
by O 0 8.468643009074128e-10
age O 0 9.005651335769471e-09
70 O 0 1.2920610359401508e-08
years O 0 1.9153313601805166e-08
. O 0 7.889421027584831e-08

The O 0 6.816429731770768e-07
lifetime O 0 1.2314359310039436e-06
risk O 0 3.1303036394092487e-06
of O 0 7.760517917176912e-08
breast B-Disease 1 0.788200855255127
cancer I-Disease 0 0.0006304672569967806
appears O 0 2.1618195944483887e-07
similar O 0 3.7064726843283324e-09
to O 0 1.2408931659990685e-08
the O 0 3.251694025152574e-08
risk O 0 1.1925105525278923e-07
in O 0 3.2307225783512195e-09
BRCA1 O 0 3.239534862586879e-06
carriers O 0 9.810138124066725e-08
, O 0 1.1784966780226114e-08
but O 0 5.0600825751700995e-09
there O 0 1.2205549904109603e-09
was O 0 3.895562983302625e-08
some O 0 2.0462675998089708e-10
suggestion O 0 2.945879096216686e-09
of O 0 8.512136134841697e-11
a O 0 2.441508328843156e-08
lower O 0 2.189271526731318e-06
risk O 0 1.28614829009166e-07
in O 0 7.457806816546508e-09
BRCA2 O 0 9.443834642297588e-06
carriers O 0 4.690036803367548e-08
< O 0 4.495008099070219e-08
50 O 0 6.12503692209998e-09
years O 0 2.405397880878013e-09
of O 0 1.3212962945985396e-09
age O 0 4.5488793176673425e-08
. O 0 1.3034377843723632e-07

Eye B-Disease 1 0.9980623126029968
movement I-Disease 0 0.0007295780233107507
abnormalities I-Disease 1 0.9656544923782349
correlate O 0 5.57022121938644e-06
with O 0 6.114463957374028e-08
genotype O 0 0.00031146747642196715
in O 0 1.4160442560751108e-06
autosomal O 1 0.999650239944458
dominant O 1 0.9426360726356506
cerebellar B-Disease 1 0.9999315738677979
ataxia I-Disease 1 0.9999967813491821
type I-Disease 0 0.0002926749875769019
I I-Disease 0 0.00017408208805136383
. O 0 1.0087699138239259e-06

We O 0 3.7921176954114344e-06
compared O 0 1.952966385943e-06
horizontal O 0 5.7508448662701994e-05
eye O 1 0.8804892897605896
movements O 0 4.262249785824679e-05
( O 0 2.4110860863402195e-07
visually O 0 1.7936664562512306e-06
guided O 0 4.356555564299924e-06
saccades O 0 6.21343424427323e-05
, O 0 7.135646029610143e-08
antisaccades O 0 2.905762812588364e-06
, O 0 8.483035607298461e-09
and O 0 9.235863629442065e-09
smooth O 0 8.129259185807314e-07
pursuit O 0 1.241032691723376e-06
) O 0 1.5781010276327834e-08
in O 0 3.706882800713629e-09
control O 0 7.593413329232135e-07
subjects O 0 1.2300375828999677e-07
( O 0 1.7927238360471165e-08
n O 0 9.047575076692738e-06
= O 0 7.424529940180946e-06
14 O 0 6.09453707056673e-07
) O 0 1.2325382492406334e-08
and O 0 1.1759576068470778e-07
patients O 0 1.8387652289675316e-08
with O 0 1.6839586669537e-10
three O 0 6.844816269335752e-09
forms O 0 1.507760742924802e-07
of O 0 6.435278265826128e-08
autosomal O 1 0.9361063241958618
dominant O 0 0.0028676073998212814
cerebellar B-Disease 0 0.003604837926104665
ataxias I-Disease 0 0.0004619842511601746
type I-Disease 0 1.5309120499296114e-05
I I-Disease 0 3.031888627447188e-05
spinocerebellar B-Disease 0 0.017060430720448494
ataxias I-Disease 0 6.72370006213896e-05
1 I-Disease 0 1.6482940168316418e-07
and I-Disease 0 3.325810027376974e-08
2 I-Disease 0 1.301733476566369e-07
( O 0 7.511196109533103e-09
SCA1 B-Disease 0 3.5826581097353483e-06
, O 0 6.743943625764359e-09
n O 0 3.3393814646842657e-07
= O 0 1.1020456014421143e-07
11 O 0 3.521221003666142e-08
; O 0 3.9225587222802005e-09
SCA2 B-Disease 0 1.385380414831161e-06
, O 0 3.0288820340729217e-09
n O 0 3.200903222477791e-07
= O 0 1.887019038804283e-07
10 O 0 1.7943179386747943e-08
) O 0 3.079333232847148e-09
and O 0 2.603304096737702e-07
SCA3 B-Disease 1 1.0
/ O 0 0.000623335421551019
Machado B-Disease 0 3.4108556974388193e-06
- I-Disease 0 4.810676909983158e-05
Joseph I-Disease 0 0.0003840073477476835
disease I-Disease 0 0.005178204271942377
( O 0 2.07268669782934e-07
MJD B-Disease 1 0.9999997615814209
) O 0 1.360486550083806e-07
( O 0 1.1559030177465957e-08
n O 0 3.2218435990216676e-06
= O 0 8.890816616258235e-07
16 O 0 1.287083222223373e-07
) O 0 2.998115888885877e-08
. O 0 2.2712484337716887e-07

In O 0 9.016901572067582e-07
SCA1 B-Disease 0 6.85251216054894e-05
, O 0 8.255153005620741e-08
saccade O 0 3.3632607028266648e-06
amplitude O 0 1.7172300204038038e-07
was O 0 3.102303196556022e-07
significantly O 0 1.7553563225192192e-07
increased O 0 2.700669021749036e-08
, O 0 8.637258019916771e-09
resulting O 0 3.5063294490100816e-08
in O 0 3.6807811909511656e-08
hypermetria B-Disease 0 0.00017256660794373602
. O 0 7.704736617597518e-07

The O 0 7.160103336900647e-07
smooth O 0 5.874477665201994e-06
pursuit O 0 5.323213827068685e-06
gain O 0 2.165524711017497e-05
was O 0 2.6717959826783044e-06
decreased O 0 3.5256443879916333e-06
. O 0 2.9792425948471646e-07

In O 0 2.283071808051318e-06
SCA2 B-Disease 0 0.00016528797277715057
, O 0 1.39845923285975e-07
saccade O 0 1.7575788660906255e-05
velocity O 0 5.003627848054748e-06
was O 0 1.3621823882203898e-06
markedly O 0 1.195070581161417e-05
decreased O 0 5.58987903787056e-06
. O 0 5.100317252981768e-07

The O 0 3.5884121984963713e-07
percentage O 0 9.30169107959955e-07
of O 0 4.766472994077731e-09
errors O 0 1.0632014664224698e-06
in O 0 1.6067419394971694e-08
antisaccades O 0 4.8558002163190395e-05
was O 0 7.35511662242061e-07
greatly O 0 1.7975892774302338e-08
increased O 0 2.5579955931220866e-08
and O 0 4.5299177742208485e-08
was O 0 3.3468262472524657e-07
significantly O 0 8.711365495628343e-08
correlated O 0 5.1953794155679134e-08
with O 0 4.762583660777864e-09
age O 0 6.580288669510992e-08
at O 0 1.961139332706807e-06
disease O 0 0.00012235762551426888
onset O 0 7.449346412613522e-06
. O 0 5.129272153681086e-07

In O 0 3.105603809672175e-07
addition O 0 2.8315563227465645e-08
, O 0 5.216944654051758e-09
a O 0 4.973848444222995e-09
correlation O 0 6.941399988136254e-08
between O 0 2.2251311904142312e-08
smooth O 0 1.2422272448020522e-05
pursuit O 0 5.322553988662548e-06
gain O 0 1.1492098565213382e-05
and O 0 1.7430442866839257e-08
the O 0 1.100334934278635e-09
number O 0 7.530763568297516e-09
of O 0 4.912826589986707e-09
trinucleotide O 0 8.076043741311878e-05
repeats O 0 3.1693980417912826e-05
was O 0 1.8197992801560758e-07
found O 0 1.5611999515385833e-07
. O 0 1.6599626917468413e-07

In O 0 1.341760616924148e-05
SCA3 B-Disease 1 0.9999979734420776
, O 0 3.6620640457840636e-06
gaze B-Disease 0 0.0006833405350334942
- I-Disease 0 0.0009529241360723972
evoked I-Disease 0 1.908207377709914e-05
nystagmus I-Disease 0 0.0001262338482774794
was O 0 5.672389988831128e-07
often O 0 4.243903006795335e-09
present O 0 1.136248983790722e-09
as O 0 5.388320900578947e-09
was O 0 6.819200137897496e-08
saccade O 0 2.387755785093759e-06
hypometria O 0 8.94647655513836e-06
and O 0 2.7301489069486706e-08
smooth O 0 5.61294939416257e-07
pursuit O 0 5.515188377103186e-07
gain O 0 4.541299404081656e-06
was O 0 1.6053949138949974e-06
markedly O 0 7.532614290539641e-06
decreased O 0 5.72595990888658e-06
. O 0 2.3574693841510452e-07

Three O 0 7.448326755365997e-07
major O 0 2.4755453864599986e-07
criteria O 0 1.15225169849964e-07
, O 0 1.0176284703788951e-08
saccade O 0 1.2388096592985676e-06
amplitude O 0 7.587095751659945e-08
, O 0 9.777704867985904e-09
saccade O 0 7.050172143863165e-07
velocity O 0 2.1841465525085368e-07
, O 0 4.314436363728191e-09
and O 0 2.136371302086104e-09
presence O 0 4.964550548436364e-09
of O 0 4.1878172041265316e-09
gaze B-Disease 0 7.267517503350973e-05
- I-Disease 0 9.672853047959507e-05
evoked I-Disease 0 1.4464817468251567e-06
nystagmus I-Disease 0 4.021843324153451e-06
, O 0 2.4181951996382622e-09
permitted O 0 1.2095283663526857e-09
the O 0 1.2650122060975377e-09
correct O 0 4.584880173297279e-07
assignment O 0 9.46746414598465e-09
of O 0 1.8156814940439858e-10
90 O 0 1.3950453014999198e-09
% O 0 4.6209491788573587e-10
of O 0 8.367135456710528e-11
the O 0 3.214176702570626e-09
SCA1 B-Disease 0 1.2531501852208748e-05
, O 0 1.8998418394033934e-09
90 O 0 4.2313971770902015e-10
% O 0 1.7939157104240877e-10
of O 0 6.583292244677352e-11
the O 0 5.917597079019288e-09
SCA2 B-Disease 0 2.8171491067041643e-05
, O 0 1.4595745057022214e-08
and O 0 5.766288779796014e-09
93 O 0 2.989491765248431e-09
% O 0 2.441035429345817e-10
of O 0 7.711077609773298e-11
the O 0 1.2699906903890223e-08
patients O 0 3.370724499518474e-08
with O 0 6.439339728103732e-09
SCA3 B-Disease 1 1.0
to O 0 1.0112977122389566e-07
their O 0 5.973129901803986e-08
genetically O 0 7.970208571350668e-06
confirmed O 0 6.269229743338656e-06
patient O 0 2.941608840956178e-07
group O 0 1.8908380639004463e-07
and O 0 4.975786538352622e-08
, O 0 2.188603964725644e-08
therefore O 0 1.3781885854768916e-08
, O 0 1.1576770653221047e-08
may O 0 6.688044607017218e-08
help O 0 1.000159954855917e-08
orient O 0 0.006356606725603342
diagnoses O 0 0.000135155045427382
of O 0 2.7076925146474196e-09
SCA1 B-Disease 0 6.729998858645558e-05
, O 0 3.9197335155449764e-08
SCA2 B-Disease 0 8.892690857464913e-06
, O 0 3.87278902280741e-08
and O 0 1.751714080455713e-07
SCA3 B-Disease 1 0.9999998807907104
at O 0 6.316010967566399e-07
early O 0 3.4731751696881474e-08
clinical O 0 3.036582540971722e-08
stages O 0 4.108809292802107e-08
of O 0 2.3716402175466555e-09
the O 0 2.0335509987035039e-07
diseases O 0 8.119657286442816e-05
. O 0 2.5796911273801015e-08
. O 0 1.9287641350729245e-07

Genetic O 0 2.4314264010172337e-05
basis O 0 5.560591489484068e-07
and O 0 8.123913630697643e-08
molecular O 0 1.732400505716214e-06
mechanism O 0 1.3084275451547e-05
for O 0 0.00017692623077891767
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999990463256836
fibrillation I-Disease 1 1.0
. O 0 9.532806143397465e-05

Ventricular B-Disease 1 0.9998273253440857
fibrillation I-Disease 1 0.9999550580978394
causes O 0 7.054449088172987e-05
more O 0 2.378862973273499e-08
than O 0 1.0657009497094805e-08
300 O 0 3.029032136225851e-09
, O 0 2.7634308175095157e-09
000 O 0 1.221613032953428e-08
sudden O 0 9.737675554788439e-08
deaths O 0 7.665980206184031e-08
each O 0 5.150582627067024e-09
year O 0 1.613190647731244e-08
in O 0 2.378326646734763e-09
the O 0 2.1206284728236824e-08
USA O 0 3.3802662073867396e-05
alone O 0 3.354463160576415e-07
. O 0 7.355614428661283e-08

In O 0 3.102658183706808e-07
approximately O 0 5.6471410658787136e-08
5 O 0 5.4322839559972635e-08
- O 0 2.224247737103724e-06
12 O 0 7.507905053216746e-08
% O 0 9.254692567850498e-10
of O 0 9.023730374035921e-11
these O 0 8.815137508833004e-10
cases O 0 3.3583245073742773e-09
, O 0 2.7834055060793617e-09
there O 0 9.449003801620393e-10
are O 0 1.4579988327767524e-09
no O 0 4.7955467152860365e-08
demonstrable O 0 9.460558067075908e-05
cardiac O 0 0.0005471018957905471
or O 0 8.575553920309176e-07
non O 0 4.0242124669020995e-05
- O 1 0.9602545499801636
cardiac O 1 0.9880111813545227
causes O 0 7.430816708620114e-07
to O 0 7.927659595452496e-08
account O 0 1.7504514460142673e-07
for O 0 1.0895758073559136e-08
the O 0 1.999577037281597e-08
episode O 0 3.045473704332835e-06
, O 0 1.7311830191601985e-08
which O 0 1.0210269074661937e-08
is O 0 6.697105092712263e-09
therefore O 0 1.5387946916689543e-08
classified O 0 7.66419088904513e-06
as O 0 0.00024394677893724293
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999995231628418
fibrillation I-Disease 1 1.0
( O 0 0.0010719017591327429
IVF B-Disease 1 1.0
) O 0 7.652101317034976e-07
. O 0 6.261422527131799e-07

A O 0 9.108827612180903e-07
distinct O 0 3.414760385567206e-07
group O 0 2.532417965994682e-06
of O 0 1.735815970960175e-07
IVF B-Disease 1 1.0
patients O 0 0.005878069903701544
has O 0 3.2544863870498375e-07
been O 0 8.305058685209588e-08
found O 0 2.394933851235237e-08
to O 0 2.8862296996834402e-09
present O 0 6.511216010807175e-10
with O 0 2.567505097417211e-10
a O 0 4.854083712757529e-08
characteristic O 0 2.386692813161062e-06
electrocardiographic O 0 0.00014527986058965325
pattern O 0 2.315998608537484e-05
. O 0 5.62446984986309e-07

Because O 0 6.454627055063611e-07
of O 0 6.513057648760423e-09
the O 0 2.9102760201737965e-09
small O 0 3.340602461321396e-09
size O 0 2.0826284696795483e-08
of O 0 1.0199830979829017e-09
most O 0 4.3127088567018745e-09
pedigrees O 0 8.463177181283754e-08
and O 0 2.3719490371831853e-08
the O 0 4.617339843804302e-09
high O 0 1.1577525782513476e-07
incidence O 0 9.106342986342497e-06
of O 0 1.7698114973541124e-08
sudden B-Disease 0 7.614387868670747e-06
death I-Disease 0 1.1556317076610867e-06
, O 0 3.064094533655748e-09
however O 0 1.3108487628699095e-09
, O 0 4.261795083504438e-10
molecular O 0 1.1130723009955545e-08
genetic O 0 1.5026533617401583e-07
studies O 0 1.1893197537915512e-08
of O 0 4.444640211431761e-08
IVF B-Disease 1 1.0
have O 0 2.771131221379619e-06
not O 0 6.917306194509365e-08
yet O 0 4.269121944844301e-08
been O 0 3.643753387905235e-08
done O 0 1.1733854421436263e-07
. O 0 8.412401797386337e-08

Because O 0 0.0005821956438012421
IVF B-Disease 1 0.9999998807907104
causes O 0 0.001995859667658806
cardiac O 1 0.9355937838554382
rhythm O 0 0.27504345774650574
disturbance O 0 0.00017995967937167734
, O 0 1.1091224649817377e-07
we O 0 4.1192691924152314e-08
investigated O 0 1.6519700807293702e-07
whether O 0 3.5711643420199835e-08
malfunction O 0 2.234611747553572e-05
of O 0 1.6325324425636722e-09
ion O 0 1.6968075442491681e-06
channels O 0 3.1996962661651196e-06
could O 0 9.951763786375523e-07
cause O 0 2.82804336393383e-07
the O 0 3.447737739747936e-08
disorder O 0 3.6941207781637786e-06
by O 0 5.224031762729453e-10
studying O 0 3.600146625259981e-09
mutations O 0 4.6610671233793255e-07
in O 0 7.831576276373653e-09
the O 0 1.0447698883808698e-07
cardiac O 0 0.00022212239855434746
sodium O 0 3.1039064651849912e-06
channel O 0 1.7862283129943535e-05
gene O 0 3.6049148093297845e-06
SCN5A O 0 7.491834549000487e-05
. O 0 7.203568088698376e-07

We O 0 1.7503241906524636e-05
have O 0 1.1988082349034812e-07
now O 0 2.0781445897455342e-08
identified O 0 2.720210545703594e-08
a O 0 1.4536928105712832e-08
missense O 0 5.440980658022454e-06
mutation O 0 6.786547146475641e-07
, O 0 3.744352827794728e-09
a O 0 7.639353150068473e-09
splice O 0 0.002015461912378669
- O 0 0.00020262805628590286
donor O 0 3.0019009500392713e-06
mutation O 0 2.086896756736678e-06
, O 0 6.086256831849823e-09
and O 0 6.164275312414702e-09
a O 0 4.305437073526264e-08
frameshift O 0 7.726987678324804e-05
mutation O 0 2.0588920790487464e-07
in O 0 1.6193986152046591e-09
the O 0 6.0459930395495576e-09
coding O 0 1.5951003661029972e-05
region O 0 1.5158113910729298e-06
of O 0 3.617257604560109e-09
SCN5A O 0 3.848931009997614e-05
in O 0 2.539832522074903e-08
three O 0 3.022354349013767e-07
IVF B-Disease 1 0.999998927116394
families O 0 1.1132383548329017e-07
. O 0 1.661294390942203e-07

We O 0 3.959471996495267e-06
show O 0 4.6700148459422053e-07
that O 0 5.2782391790628935e-09
sodium O 0 3.4320503772278244e-08
channels O 0 1.9988142696547584e-08
with O 0 8.203363544012632e-10
the O 0 7.356622422349801e-09
missense O 0 5.311981112754438e-06
mutation O 0 1.5869712797211832e-06
recover O 0 5.051627340435516e-06
from O 0 2.1594782850797856e-08
inactivation O 0 3.1586903332936345e-06
more O 0 3.0098257219890456e-09
rapidly O 0 4.171898382310246e-08
than O 0 5.165220695602102e-09
normal O 0 6.158965248914683e-08
and O 0 1.7281148956271863e-08
that O 0 6.1316525190591165e-09
the O 0 1.5159294264321943e-08
frameshift O 0 0.000236635678447783
mutation O 0 1.6703894516467699e-06
causes O 0 3.041370533196641e-08
the O 0 1.4379457624613678e-09
sodium O 0 1.4948207649467804e-07
channel O 0 1.7498617808087147e-06
to O 0 1.0216950840913341e-08
be O 0 7.189030259979745e-09
non O 0 8.697901421328424e-08
- O 0 1.943618599398178e-06
functional O 0 1.6469219872305985e-06
. O 0 3.4195480225207575e-07

Our O 0 1.317365877184784e-05
results O 0 4.632723630493274e-06
indicate O 0 1.6978874839423952e-07
that O 0 4.1987022747491665e-09
mutations O 0 2.1799057492444263e-07
in O 0 1.1266440225199403e-08
cardiac O 0 5.1672657718881965e-05
ion O 0 2.1882592591282446e-06
- O 0 1.3524866517400369e-05
channel O 0 1.93257747014286e-05
genes O 0 1.0018653284760148e-07
contribute O 0 7.903229182204541e-09
to O 0 3.692994354764778e-09
the O 0 6.5006964256042465e-09
risk O 0 9.005448475818412e-08
of O 0 1.6808084923880529e-09
developing O 0 1.6150861483765766e-06
IVF B-Disease 1 0.9999985694885254
. O 0 9.503126108256765e-08
. O 0 2.256029176805896e-07

Molecular O 0 5.8110170357394964e-05
heterogeneity O 0 3.9013953937683254e-05
in O 0 2.839883848082536e-07
mucopolysaccharidosis B-Disease 0 9.244721150025725e-05
IVA I-Disease 0 0.015489847399294376
in O 0 2.461376311657659e-07
Australia O 0 9.484493546096928e-08
and O 0 8.521404915029507e-09
Northern O 0 9.982296944599511e-08
Ireland O 0 7.836545705686149e-07
: O 0 2.2776107666544476e-09
nine O 0 6.669151009219831e-09
novel O 0 1.6088273824266253e-08
mutations O 0 1.1695210844209214e-07
including O 0 8.754482139217146e-10
T312S O 0 9.425809821550502e-08
, O 0 9.888730945206703e-10
a O 0 2.3570021490115778e-09
common O 0 1.039771646560439e-08
allele O 0 3.5027304079449095e-07
that O 0 7.1070100915449075e-09
confers O 0 1.7442756927721348e-07
a O 0 3.3329928328384995e-07
mild O 0 1.8814278519130312e-05
phenotype O 0 3.909894803655334e-05
. O 0 3.003215738317522e-07

Mucopolysaccharidosis B-Disease 1 0.7424802780151367
IVA I-Disease 1 0.9997944235801697
( O 0 0.004506326280534267
MPS B-Disease 1 0.9999982118606567
IVA I-Disease 1 0.9999998807907104
) O 0 3.03580122817948e-07
is O 0 1.2402353810614386e-08
an O 0 7.293642312333759e-08
autosomal B-Disease 1 0.9993385672569275
recessive I-Disease 1 0.999896764755249
lysosomal I-Disease 1 0.9999935626983643
storage I-Disease 1 0.9999866485595703
disorder I-Disease 1 0.9999194145202637
caused O 0 4.166056442045374e-06
by O 0 9.624463892521362e-09
a O 0 3.4807203519449104e-06
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.9999980926513672
in O 0 4.4116163167018385e-08
N O 0 0.00015745637938380241
- O 0 3.206695328117348e-05
acetylgalactosamine O 0 0.0003619639028329402
- O 0 3.627833575592376e-05
6 O 0 5.145732757227961e-06
- O 0 0.003682094858959317
sulfate O 0 2.799564208544325e-05
sulfatase O 0 2.7432530259829946e-05
( O 0 3.085602173769075e-08
GALNS O 0 5.820124897581991e-06
) O 0 4.318728130670024e-08
. O 0 1.4983403673340945e-07

Previous O 0 6.914416189829353e-06
studies O 0 1.195765264583315e-07
of O 0 2.517894559517231e-09
patients O 0 4.663151997874593e-08
from O 0 8.596116596315539e-10
a O 0 3.542792015309715e-08
British O 0 5.3649496294383425e-06
- O 0 5.8437202824279666e-05
Irish O 0 4.776609785039909e-06
population O 0 2.1587698739722327e-08
showed O 0 4.76880295252613e-08
that O 0 2.968773005207481e-10
the O 0 1.8040276217323736e-10
I113F O 0 2.2588013237623272e-08
mutation O 0 1.215011291577639e-08
is O 0 2.752834349362132e-10
the O 0 1.345209083014609e-10
most O 0 5.389325652416233e-10
common O 0 2.482056116193121e-09
single O 0 2.573951576323452e-07
mutation O 0 1.7431862033845391e-06
among O 0 3.1948647460922075e-07
MPS B-Disease 1 0.9999986886978149
IVA I-Disease 1 1.0
patients O 0 4.534317849902436e-05
and O 0 9.503557940604423e-09
produces O 0 3.90912475722871e-07
a O 0 1.7239129874724313e-06
severe O 0 6.742987898178399e-05
clinical O 0 3.2602101782686077e-06
phenotype O 0 3.6140107113169506e-05
. O 0 1.0622406989568844e-06

We O 0 1.7352246004520566e-06
studied O 0 4.0739902829045604e-07
mutations O 0 5.290472699925886e-07
in O 0 3.890578970100478e-09
the O 0 2.921722197513077e-09
GALNS O 0 1.2529638297564816e-05
gene O 0 3.0179273835528875e-07
from O 0 1.2689397976828332e-08
23 O 0 7.118218547930155e-08
additional O 0 1.670349831783824e-07
MPS B-Disease 1 0.9999957084655762
IVA I-Disease 1 1.0
patients O 0 3.6202953197062016e-05
( O 0 1.541040850483455e-09
15 O 0 1.866726995203294e-09
from O 0 1.7878808433735571e-09
Australia O 0 2.040582991469364e-08
, O 0 2.6069937320016834e-09
8 O 0 1.224921586384653e-08
from O 0 8.422315067591057e-10
Northern O 0 9.558115721119975e-08
Ireland O 0 7.177462180152361e-07
) O 0 1.6621393150728636e-09
, O 0 4.2968431590573175e-10
with O 0 4.4432882373435234e-10
various O 0 5.618891574243889e-09
clinical O 0 6.637174578827398e-07
phenotypes O 0 3.4967570172739215e-06
( O 0 3.0786893034928653e-07
severe O 0 1.1370404536137357e-05
, O 0 3.1153714274978483e-08
16 O 0 2.764022610790562e-08
cases O 0 2.178482505499346e-09
; O 0 1.398055227141981e-09
intermediate O 0 5.585940243690857e-08
, O 0 9.972263903534895e-09
4 O 0 8.262398409897287e-08
cases O 0 5.2604420375246264e-08
; O 0 9.610378270963338e-08
mild O 0 1.8297412225365406e-06
, O 0 1.158061380124309e-08
3 O 0 1.8342753094202635e-07
cases O 0 2.7857703699396552e-08
) O 0 1.661065596181288e-08
. O 0 1.1404991795416208e-07

We O 0 2.7121343464386882e-06
found O 0 5.311295581122977e-08
two O 0 2.553149025530388e-09
common O 0 1.4423223504422822e-08
mutations O 0 2.701864900700457e-07
that O 0 2.5924058455473187e-09
together O 0 9.068910955534193e-09
accounted O 0 3.473275285159616e-07
for O 0 3.1775908571063383e-09
32 O 0 6.814321551473768e-09
% O 0 4.845633339023436e-10
of O 0 8.94686685848356e-11
the O 0 6.203126012849225e-09
44 O 0 2.304094692817671e-08
unrelated O 0 2.039680246923581e-08
alleles O 0 2.9631529230300657e-08
in O 0 8.000417217601807e-09
these O 0 6.807036356804019e-08
patients O 0 1.2825634030377842e-06
. O 0 2.2219890638552897e-07

One O 0 4.768052974668535e-07
is O 0 1.1247846209982981e-08
the O 0 2.497356765829295e-09
T312S O 0 2.3222153799906664e-07
mutation O 0 2.61149494917845e-07
, O 0 1.9719650357075125e-09
a O 0 5.681310089045155e-09
novel O 0 8.489077174544946e-08
mutation O 0 2.420384248580376e-07
found O 0 2.269381482733479e-08
exclusively O 0 2.9781961785602107e-08
in O 0 2.8416144104426166e-08
milder O 0 6.027598647051491e-05
patients O 0 2.9662317047041142e-06
. O 0 2.7654579071167973e-07

The O 0 3.450139729466173e-07
other O 0 2.0729903127403304e-08
is O 0 3.18439830060413e-09
the O 0 1.8327069861712175e-09
previously O 0 3.070148579809029e-07
described O 0 2.6013881893049984e-07
I113F O 0 1.5301205280593422e-07
that O 0 4.404787201650606e-09
produces O 0 2.0163332692391123e-07
a O 0 6.000490202495712e-07
severe O 0 3.8810743717476726e-05
phenotype O 0 5.387455894378945e-05
. O 0 6.886644996484392e-07

The O 0 2.2374203467734333e-07
I113F O 0 1.4209955452315626e-06
and O 0 3.070443455044369e-08
T312S O 0 3.703768527429929e-07
mutations O 0 5.711696644539188e-07
accounted O 0 1.738645636351066e-07
for O 0 3.611343002418721e-09
8 O 0 2.3277491933981764e-08
( O 0 1.3075027727182942e-09
18 O 0 8.422030184362939e-09
% O 0 1.1485008499789728e-09
) O 0 1.1532687027582256e-09
and O 0 2.1472102318398356e-08
6 O 0 1.0063660482728665e-07
( O 0 3.19116555402843e-09
14 O 0 1.4367897094302862e-08
% O 0 9.246046706046229e-10
) O 0 3.050389663084019e-10
of O 0 4.455576740891587e-10
44 O 0 1.6076677766818648e-08
unrelated O 0 4.8753410197832636e-08
alleles O 0 1.1995516047136334e-07
, O 0 2.6706819866717524e-08
respectively O 0 1.363610863336362e-06
. O 0 6.055562948859006e-07

The O 0 1.6316344897404633e-07
relatively O 0 4.359413097176912e-08
high O 0 3.765841327663111e-08
residual O 0 5.425728204500047e-07
GALNS O 0 2.8143000236013904e-05
activity O 0 8.402010820418582e-08
seen O 0 3.297694561865683e-08
when O 0 7.010355074221764e-10
the O 0 4.2112602294253065e-10
T312S O 0 1.6061170171610684e-08
mutant O 0 2.1606155087283696e-08
cDNA O 0 6.89560977207293e-08
is O 0 6.867570956359259e-09
overexpressed O 0 5.459737053570279e-07
in O 0 4.600645642227619e-09
mutant O 0 1.7464746804307651e-07
cells O 0 3.481343355815625e-07
provides O 0 7.629568088418637e-09
an O 0 2.89899637628821e-09
explanation O 0 1.3235216478335587e-08
for O 0 4.35993463554496e-09
the O 0 3.74117803403351e-08
mild O 0 8.813901331450325e-06
phenotype O 0 6.054476216377225e-06
in O 0 3.9908197635440956e-08
patients O 0 8.486324531986611e-08
with O 0 7.339043262000189e-10
this O 0 1.3932644371550396e-08
mutation O 0 1.3544024568545865e-06
. O 0 3.337563612149097e-07

The O 0 1.8003348145612108e-07
distribution O 0 1.3527704822990927e-07
and O 0 1.1943254385471391e-08
relative O 0 4.827425570397281e-09
frequencies O 0 2.4025652578529844e-08
of O 0 8.228436265689254e-10
the O 0 3.794586422856128e-09
I113F O 0 1.704900114418706e-07
and O 0 7.124532519497961e-09
T312S O 0 5.904375299792264e-08
mutations O 0 5.930413138344193e-08
in O 0 8.8471746595431e-10
Australia O 0 5.737325725618803e-09
corresponded O 0 2.1291315377425235e-08
to O 0 2.8195583645640454e-09
those O 0 6.940890640017017e-10
observed O 0 1.8593864226090773e-08
in O 0 1.6119595658281582e-09
Northern O 0 2.4338791604350263e-07
Ireland O 0 5.952147716925538e-07
and O 0 2.5285702420774214e-08
are O 0 3.142426874269688e-10
unique O 0 9.218295571322699e-10
to O 0 6.2824985214149365e-09
these O 0 3.824943695107663e-10
two O 0 5.697240013091687e-09
populations O 0 8.29582447181565e-09
, O 0 2.0467134653756602e-09
suggesting O 0 9.032383729845606e-09
that O 0 1.223869894317886e-09
both O 0 3.7434744193376446e-09
mutations O 0 1.1367355767788467e-07
were O 0 1.5948769416240793e-08
probably O 0 1.1007784017635913e-08
introduced O 0 1.3971923173983214e-08
to O 0 6.635438420943274e-09
Australia O 0 6.0175535665507596e-09
by O 0 5.064657582209975e-10
Irish O 0 1.2589977060883939e-08
migrants O 0 6.491527759777682e-09
during O 0 8.913775828567339e-10
the O 0 4.817213294927569e-10
19th O 0 1.0648357573472822e-07
century O 0 2.270793544312255e-07
. O 0 4.718570210116013e-07

Haplotype O 0 0.0009209521813318133
analysis O 0 1.9033972193938098e-06
using O 0 2.99692118232997e-07
6 O 0 2.1892891766128741e-07
RFLPs O 0 9.651173513702815e-07
provides O 0 6.3766401048326316e-09
additional O 0 2.556706402145892e-09
data O 0 2.663453457785181e-08
that O 0 5.991415696904312e-10
the O 0 1.6898025201328437e-09
I113F O 0 1.9643275095404533e-07
mutation O 0 3.8127549117916715e-08
originated O 0 3.894825351125064e-09
from O 0 9.291800107114057e-10
a O 0 5.098272026771156e-09
common O 0 6.152050247010266e-08
ancestor O 0 2.4794112505333032e-06
. O 0 5.219416152613121e-07

The O 0 1.8509867061311525e-07
other O 0 1.6513551415187067e-08
9 O 0 5.6883610710656285e-08
novel O 0 6.227870130715019e-08
mutations O 0 8.722902862245974e-07
identified O 0 3.9766419490661065e-07
in O 0 9.904138842387056e-09
these O 0 1.0374994197093201e-08
23 O 0 3.457082584645832e-07
patients O 0 1.743656241615099e-08
were O 0 7.727247730571207e-10
each O 0 1.93487537103465e-09
limited O 0 1.1919313536168374e-08
to O 0 1.3259422004807675e-08
a O 0 5.2366665670433576e-08
single O 0 1.8450277821102645e-06
family O 0 1.3494052382156951e-06
. O 0 4.661053480958799e-07

These O 0 1.9036517073800496e-07
data O 0 4.905226660412154e-07
provide O 0 6.619157666420961e-09
further O 0 7.811749469510687e-09
evidence O 0 3.718368724037191e-09
for O 0 1.5786782991966675e-09
extensive O 0 5.015481718828596e-08
allelic O 0 1.8923960851680022e-06
heterogeneity O 0 9.642502845963463e-06
in O 0 3.689463028422324e-06
MPS B-Disease 1 0.999992847442627
IVA I-Disease 1 0.9999998807907104
in O 0 1.634325457189334e-07
British O 0 1.5306503655665438e-06
- O 0 0.00017743778880685568
Irish O 0 2.2430711396737024e-05
patients O 0 1.3631388355861418e-06
and O 0 2.2065804738957695e-09
provide O 0 2.5982618279130065e-09
evidence O 0 2.781118224604029e-09
for O 0 1.4499592637662317e-09
their O 0 1.6316709761099446e-08
transmission O 0 6.377910267474363e-06
to O 0 5.977529582423813e-08
Australia O 0 1.2279695482675379e-08
by O 0 1.8296648640614421e-09
British O 0 1.5982638501554902e-07
- O 0 4.284378064767225e-06
Irish O 0 4.0526927591599815e-07
migrants O 0 3.9762241499374795e-08
. O 0 5.297664529280155e-09
. O 0 5.061929542193866e-08

Identification O 0 2.3614011297468096e-06
of O 0 7.613871133571593e-08
constitutional O 0 3.04484473190314e-07
WT1 O 0 0.0002754571323748678
mutations O 0 9.946495265467092e-05
, O 0 1.3814414501212013e-08
in O 0 4.930568842098637e-09
patients O 0 1.1165727187290031e-07
with O 0 1.6069748198788147e-08
isolated O 0 0.005319325719028711
diffuse B-Disease 1 0.9998347759246826
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 3.216239576886437e-07
and O 0 1.260602733310634e-08
analysis O 0 1.1651022369107977e-08
of O 0 7.973407711858727e-09
genotype O 0 0.0003897957503795624
/ O 0 0.017029257491230965
phenotype O 0 3.6191697290632874e-05
correlations O 0 6.187070766827674e-07
by O 0 2.039185265090282e-09
use O 0 1.748108502397372e-08
of O 0 1.7834124177440458e-09
a O 0 1.1008859246430802e-07
computerized O 0 0.00032574316719546914
mutation O 0 1.5989689927664585e-05
database O 0 4.2796327761607245e-06
. O 0 6.175775979500031e-07

Constitutional O 0 5.923917342443019e-06
mutations O 0 6.159651093184948e-06
of O 0 9.376495135882124e-09
the O 0 6.247057982022852e-09
WT1 O 0 4.3473382902448066e-06
gene O 0 1.6039196282235935e-07
, O 0 9.353537944178925e-10
encoding O 0 8.733739065291957e-09
a O 0 6.566195764889926e-08
zinc O 0 0.00037377935950644314
- O 0 0.00010231722262687981
finger O 0 0.0001197302553919144
transcription O 0 3.6877491993436706e-07
factor O 0 2.0434690384263376e-08
involved O 0 1.6871108954319425e-08
in O 0 9.30585457581401e-08
renal O 0 0.26854634284973145
and O 0 1.2637367490242468e-06
gonadal O 0 8.67005655891262e-05
development O 0 9.343043672060958e-08
, O 0 8.83306672250228e-09
are O 0 7.442711447147587e-10
found O 0 6.555194609347836e-09
in O 0 9.785368071391076e-10
most O 0 3.817307803188896e-09
patients O 0 1.681008043874499e-08
with O 0 2.0372967313164736e-08
Denys B-Disease 1 0.9998863935470581
- I-Disease 1 0.9999970197677612
Drash I-Disease 1 0.9999991655349731
syndrome I-Disease 1 0.9999998807907104
( O 0 2.0970135210518492e-06
DDS B-Disease 1 1.0
) O 0 2.8137370122749417e-07
, O 0 4.086885496690229e-08
or O 0 2.8937862225575373e-05
diffuse B-Disease 1 0.9999454021453857
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 1.5407236787723377e-05
DMS B-Disease 0 0.2085181474685669
) O 0 4.1782687532077034e-08
associated O 0 4.852592994097904e-08
with O 0 6.872802060797767e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 1.3636182302434463e-05
/ O 0 0.006384314503520727
or O 0 1.1267545232840348e-05
Wilms B-Disease 1 0.7723748087882996
tumor I-Disease 0 0.055185362696647644
( O 0 1.7468905753048602e-06
WT B-Disease 1 0.9999879598617554
) O 0 1.7157731235784013e-07
. O 0 3.455184014455881e-07

Most O 0 1.2934797268826514e-06
mutations O 0 9.730283636599779e-05
in O 0 1.936213038788992e-06
DDS B-Disease 1 1.0
patients O 0 0.014550401829183102
lie O 0 1.7587389038453694e-06
in O 0 8.50803782981302e-09
exon O 0 1.256236373592401e-06
8 O 0 9.631445152535889e-08
or O 0 9.146108759239269e-09
exon O 0 2.1295909391483292e-07
9 O 0 6.471861269119472e-08
, O 0 1.5362777716632081e-09
encoding O 0 8.575638332786184e-08
zinc O 0 8.724920189706609e-05
finger O 0 0.0004134885093662888
2 O 0 1.255807546840515e-06
or O 0 8.965359938883921e-07
zinc O 0 8.535593951819465e-05
finger O 0 6.777231465093791e-05
3 O 0 3.234818848341092e-07
, O 0 1.3927143882597193e-08
respectively O 0 5.100930167145634e-08
, O 0 5.490894960935577e-10
with O 0 2.472105020689952e-10
a O 0 3.375027901597605e-08
hot O 0 1.06776333268499e-05
spot O 0 9.731769387144595e-05
( O 0 1.0106763426165344e-08
R394W O 0 4.687702670480576e-08
) O 0 1.0398227834329532e-09
in O 0 2.5606887721352223e-09
exon O 0 2.0030179257446434e-06
9 O 0 4.7299823791036033e-07
. O 0 1.9973515463789226e-07

We O 0 3.1872366434981814e-06
analyzed O 0 4.986104613635689e-07
a O 0 7.716970173987647e-09
series O 0 8.251591410157744e-09
of O 0 1.5272675346622577e-09
24 O 0 2.166587336205339e-07
patients O 0 2.058585124586898e-08
, O 0 3.1735430949808574e-10
10 O 0 2.329835657732815e-09
with O 0 1.581460828958825e-08
isolated B-Disease 0 0.0006100987084209919
DMS I-Disease 1 0.9032817482948303
( O 0 1.0853863585680301e-07
IDMS B-Disease 0 3.976117295678705e-05
) O 0 1.3910339546896466e-08
, O 0 4.267507236477286e-09
10 O 0 7.801713053368076e-09
with O 0 7.911739174915056e-08
DDS B-Disease 1 1.0
, O 0 3.646430286607938e-07
and O 0 1.5870570635456716e-08
4 O 0 4.785176344057618e-08
with O 0 9.952126589496402e-08
urogenital B-Disease 0 0.03526149317622185
abnormalities I-Disease 1 0.976949155330658
and O 0 9.316721616414725e-07
/ O 0 0.064960777759552
or O 0 0.0001433879224350676
WT B-Disease 1 0.999994158744812
. O 0 1.5191934608083102e-06

We O 0 1.0026287782238796e-05
report O 0 8.665319910505787e-07
WT1 O 0 1.2129873539379332e-05
heterozygous O 0 1.779876015461923e-06
mutations O 0 6.105331976868911e-06
in O 0 5.314335638217926e-08
16 O 0 6.43992564164364e-07
patients O 0 3.9562380038660194e-07
, O 0 2.9939029033698716e-09
4 O 0 2.8314106614857337e-08
of O 0 2.6146027565232544e-09
whom O 0 5.003481078347249e-07
presented O 0 1.8495573783638974e-07
with O 0 1.1742027083982975e-07
IDMS B-Disease 0 0.0029822008218616247
. O 0 1.337695380243531e-06

One O 0 2.669048171810573e-06
male O 0 7.350018336182984e-07
and O 0 4.627277760960169e-08
two O 0 3.8175649308413995e-08
female O 0 1.3614719591714675e-06
IDMS B-Disease 0 0.0022445237264037132
patients O 0 1.829765551519813e-06
with O 0 2.3599094234327822e-08
WT1 O 0 0.001709874253720045
mutations O 0 0.00045717842294834554
underwent O 0 0.00011501758126541972
normal O 0 1.206545130116865e-05
puberty O 0 2.0010927983094007e-05
. O 0 8.553125780963455e-07

Two O 0 1.8877763068303466e-06
mutations O 0 2.769882485154085e-05
associated O 0 2.9674350798813975e-07
with O 0 4.754580373855788e-08
IDMS B-Disease 0 0.0017850258154794574
are O 0 7.86425324861284e-09
different O 0 1.168090069114669e-09
from O 0 8.44548431189196e-09
those O 0 1.0810677686379222e-08
described O 0 2.6108475594810443e-06
in O 0 2.490319275239017e-06
DDS B-Disease 1 1.0
patients O 0 0.00013220678374636918
. O 0 3.3790479392337147e-07

No O 0 4.887528575636679e-06
WT1 O 0 0.00019577695638872683
mutations O 0 9.177632455248386e-05
were O 0 2.883706144984899e-07
detected O 0 7.977044447216031e-07
in O 0 3.5556595445740413e-09
the O 0 2.617686734041058e-09
six O 0 3.026786998816533e-08
other O 0 1.0551715945439355e-07
IDMS B-Disease 0 0.009127047844231129
patients O 0 1.6268671743091545e-06
, O 0 2.4860551395278208e-09
suggesting O 0 5.910775158213255e-08
genetic O 0 4.0394959910372563e-07
heterogeneity O 0 7.820203791197855e-07
of O 0 1.0301739017393174e-08
this O 0 3.451923475950025e-07
disease O 0 0.0001901167124742642
. O 0 4.4655570263785194e-07

We O 0 9.201557986671105e-06
analyzed O 0 1.2666140719375107e-05
genotype O 0 0.0002656268479768187
/ O 0 0.03461158275604248
phenotype O 0 6.623936496907845e-05
correlations O 0 1.1552280739124399e-05
, O 0 3.179835772471051e-08
on O 0 9.602353401305663e-08
the O 0 3.799134340454202e-09
basis O 0 9.452469917903272e-09
of O 0 5.624078425192636e-10
the O 0 1.5318077473125413e-08
constitution O 0 6.247367512202118e-09
of O 0 2.6165072886108476e-10
a O 0 3.4746527433071606e-08
WT1 O 0 4.424781764100771e-06
mutation O 0 8.043645749467032e-08
database O 0 1.9976670984078737e-08
of O 0 1.7593903001156264e-09
84 O 0 1.1647006203929777e-07
germ O 0 3.695648774737492e-05
- O 0 7.313785317819566e-05
line O 0 0.0011947277234867215
mutations O 0 3.894154815498041e-06
, O 0 1.7585046752088829e-09
to O 0 1.3719981817317262e-09
compare O 0 2.2403513710855805e-08
the O 0 8.646187654726134e-10
distribution O 0 1.0575027431514172e-07
and O 0 2.4378042695616386e-08
type O 0 2.908745955210179e-08
of O 0 2.5333526387782968e-09
mutations O 0 1.3809667507302947e-06
, O 0 2.7086428655564987e-09
according O 0 7.278209146477366e-10
to O 0 8.698854969679815e-10
the O 0 2.6877280401294e-09
different O 0 7.737371987559527e-08
symptoms O 0 6.5010726757464e-06
. O 0 1.1276312505970054e-07

This O 0 2.67137806986284e-07
demonstrated O 0 3.366471617027855e-07
( O 0 2.1434580332879705e-08
1 O 0 4.9334971663483884e-08
) O 0 1.1900027629963006e-08
the O 0 7.036011329120129e-09
association O 0 4.576376610998523e-09
between O 0 1.7520532802350886e-09
mutations O 0 1.378078593461396e-07
in O 0 2.4304118717566325e-09
exons O 0 5.780540277555701e-07
8 O 0 7.294698889381834e-08
and O 0 3.120866765016217e-08
9 O 0 2.725378749346419e-07
and O 0 2.398832066319301e-07
DMS B-Disease 0 0.00046926585491746664
; O 0 1.8095295928333144e-08
( O 0 3.615623134223256e-09
2 O 0 8.237662996180006e-08
) O 0 8.699356790486945e-09
among O 0 5.651523693472882e-09
patients O 0 4.8234888083698024e-08
with O 0 3.0473730205926586e-09
DMS B-Disease 0 0.0011286921799182892
, O 0 1.2578352803771509e-09
a O 0 2.8778410765539775e-09
higher O 0 6.325592494249577e-09
frequency O 0 2.9457964956236538e-08
of O 0 8.916904437050732e-10
exon O 0 3.0428185482378467e-07
8 O 0 5.438016614789376e-08
mutations O 0 1.234785855785958e-07
among O 0 1.1970637814329166e-09
46 O 0 4.55276776278879e-08
, O 0 2.2066403815301783e-08
XY O 0 2.0413717720657587e-05
patients O 0 7.423124515071322e-08
with O 0 7.527485301750403e-10
female O 0 5.739758890399571e-08
phenotype O 0 5.518739385479421e-07
than O 0 8.648171068159627e-09
among O 0 4.136399667231672e-09
46 O 0 6.123509166400254e-08
, O 0 2.3511619318128396e-08
XY O 0 2.0127677998971194e-05
patients O 0 6.750354941686965e-08
with O 0 8.315592103791403e-10
sexual O 0 2.018706801720782e-08
ambiguity O 0 5.977928196898574e-08
or O 0 2.778408543235855e-07
male O 0 2.1989269782807241e-07
phenotype O 0 2.867306648113299e-06
; O 0 3.208873522453359e-08
and O 0 1.7582547684469318e-07
( O 0 1.6278972836403227e-08
3 O 0 8.220020930593819e-08
) O 0 8.51882031582818e-09
statistically O 0 5.327178769221064e-07
significant O 0 9.409693468853675e-09
evidence O 0 2.3687933392579907e-08
that O 0 1.323849740941796e-08
mutations O 0 1.2878838617780275e-07
in O 0 2.2158210821743296e-09
exons O 0 1.113194230129011e-06
8 O 0 8.099561199514937e-08
and O 0 1.0852678755668421e-08
9 O 0 3.646798418799335e-08
preferentially O 0 5.050375762039039e-08
affect O 0 2.3924409120468226e-08
amino O 0 1.7605559676781013e-08
acids O 0 1.5625502669536218e-08
with O 0 2.6918772766393317e-10
different O 0 1.2828101914053036e-09
functions O 0 1.105322766647987e-08
. O 0 1.928984438848147e-08
. O 0 1.3174597768284002e-07

The O 0 5.68058112548897e-07
185delAG O 0 1.2484681064961478e-05
BRCA1 O 0 4.807173536391929e-05
mutation O 0 1.1304819054203108e-06
originated O 0 8.103656057301123e-08
before O 0 3.696477790526842e-08
the O 0 1.792264892053197e-09
dispersion O 0 1.3223386474692234e-07
of O 0 1.0877728717773039e-09
Jews O 0 6.506293459551671e-08
in O 0 5.043067297094694e-09
the O 0 6.964392618158399e-09
diaspora O 0 4.6983455348481584e-08
and O 0 4.2435974734189585e-08
is O 0 1.1432734758898278e-08
not O 0 2.55179566366337e-09
limited O 0 2.744002802756995e-09
to O 0 3.541657278560706e-08
Ashkenazim O 0 9.698741450847592e-06
. O 0 1.5958086407863448e-07

The O 0 5.288227953315072e-07
185delAG O 0 7.83773521106923e-06
mutation O 0 2.387778749834979e-06
in O 0 2.7106702660262272e-08
BRCA1 O 0 2.278180545545183e-05
is O 0 3.6152179916371097e-08
detected O 0 1.186806571240595e-06
in O 0 5.6645923507403495e-09
Ashkenazi O 0 3.0406538371607894e-06
Jews O 0 3.3597931548001725e-08
both O 0 3.4204161725170934e-09
in O 0 2.8647207273024833e-08
familial B-Disease 0 0.08211740851402283
breast I-Disease 1 0.9999991655349731
and I-Disease 1 0.9999978542327881
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.0286369445111632e-07
in O 0 5.918860956910521e-09
the O 0 9.411883716836655e-09
general O 0 2.1853587384157436e-08
population O 0 7.019630654525599e-09
. O 0 4.2811983291812794e-08

All O 0 3.8644370192741917e-07
tested O 0 1.0666017260518856e-06
Ashkenazi O 0 1.5482972230529413e-05
mutation O 0 9.64351897891902e-07
carriers O 0 6.162913734897302e-08
share O 0 1.0215104140343101e-07
the O 0 3.6474225861837795e-09
same O 0 9.541809120605649e-09
allelic O 0 2.1763619884040963e-07
pattern O 0 1.327194240730023e-06
at O 0 1.4751584842542798e-07
the O 0 6.816638631335081e-08
BRCA1 O 0 5.318238618201576e-05
locus O 0 1.6592897736700252e-05
. O 0 1.4512597772409208e-06

Our O 0 3.907689006155124e-06
previous O 0 7.758798687973467e-07
study O 0 5.4223150414145493e-08
showed O 0 7.579111382938208e-08
that O 0 8.628592840231875e-10
this O 0 3.3361071682946886e-09
Ashkenazi O 0 2.7993879484711215e-05
mutation O 0 3.7536796071435674e-07
also O 0 2.1740794053926038e-08
occurs O 0 1.2616989675251489e-09
in O 0 5.290734517160445e-10
Iraqi O 0 1.130842175456337e-08
Jews O 0 5.737085029267064e-09
with O 0 9.299956360564465e-10
a O 0 2.5288787952604252e-08
similar O 0 6.913256100915532e-08
allelic O 0 3.9872402339824475e-06
pattern O 0 1.846022132667713e-05
. O 0 7.066636840136198e-07

We O 0 1.5165850300036254e-06
extended O 0 8.47183372343352e-08
our O 0 8.190828459930799e-09
analysis O 0 4.016942778406474e-09
to O 0 1.4596767128338684e-09
other O 0 5.771985667202273e-10
non O 0 6.635706739643865e-08
- O 0 2.1195908175286604e-06
Ashkenazi O 0 3.777016672756872e-06
subsets O 0 1.1690539025721591e-07
354 O 0 2.673250598661525e-08
of O 0 8.725542510745754e-10
Moroccan O 0 2.247658130727359e-07
origin O 0 2.1960428142620003e-08
, O 0 2.169161739118408e-09
200 O 0 2.169612711711011e-09
Yemenites O 0 1.8063265372347814e-07
and O 0 4.240439999136925e-09
150 O 0 3.970402229214187e-09
Iranian O 0 1.1456707937895771e-07
Jews O 0 3.529007983615884e-07
. O 0 2.0591905069977656e-07

Heteroduplex O 0 0.00010575318447081372
analysis O 0 7.216096378215298e-07
complemented O 0 2.4152330979632097e-07
by O 0 2.5453401608643844e-09
direct O 0 1.3061574044570534e-08
DNA O 0 2.399538914232835e-07
sequencing O 0 1.5643222184280603e-07
of O 0 3.684678118176521e-09
abnormally O 0 9.171903911919799e-07
migrating O 0 7.66448877698167e-08
bands O 0 1.4628805899974395e-07
were O 0 3.0887228774645337e-08
employed O 0 3.068213629831007e-07
. O 0 2.209390999041716e-07

Four O 0 5.790168415842345e-07
of O 0 7.934918500041022e-09
Moroccan O 0 5.458945793179737e-07
origin O 0 1.97309475424845e-08
( O 0 2.6947195586046746e-09
1 O 0 3.0629316860597555e-09
. O 0 8.43134839723092e-10
1 O 0 1.0540688322180358e-08
% O 0 3.7760310434009625e-09
) O 0 1.398778204375617e-09
and O 0 1.5898139693604207e-08
none O 0 3.178154406313638e-09
of O 0 1.242402986045832e-10
the O 0 3.779388801916639e-09
Yemenites O 0 1.3844030490872683e-06
or O 0 3.6567378458585154e-08
Iranians O 0 3.030518769264745e-08
was O 0 9.433161807237411e-09
a O 0 1.7524542927915832e-09
carrier O 0 2.2915994435379616e-08
of O 0 3.669611281509333e-10
the O 0 7.282087377546986e-09
185delAG O 0 3.824273335339967e-06
mutation O 0 1.3880253391107544e-06
. O 0 1.2783610259248235e-07

BRCA1 O 0 0.002131908666342497
allelic O 0 8.830316801322624e-05
patterns O 0 7.823560008546337e-05
were O 0 5.717991484743834e-07
determined O 0 8.094819037296475e-08
for O 0 2.299251455895046e-09
four O 0 6.982082023654357e-09
of O 0 6.066123159342851e-10
these O 0 1.6813215264477321e-09
individuals O 0 2.685113520417559e-10
and O 0 3.5102489803762182e-09
for O 0 1.3021816958058707e-09
12 O 0 4.173551282349308e-09
additional O 0 2.7160926840963384e-09
non O 0 7.281145997239946e-08
- O 0 5.46138016943587e-06
Ashkenazi O 0 1.9748000340769067e-05
185delAG O 0 6.375967700478213e-07
mutation O 0 1.7313389832906978e-07
carriers O 0 4.723693791675032e-08
who O 0 3.4094074408130837e-07
had O 0 9.134832362178713e-05
breast B-Disease 1 0.9999740123748779
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
. O 0 1.7945031913768617e-06

Six O 0 7.890331289672758e-06
non O 0 1.0194816240982618e-05
- O 0 0.0011228588409721851
Ashkenazi O 0 0.000422069919295609
individuals O 0 6.123518137002293e-09
shared O 0 3.4360045919612503e-09
the O 0 2.716932012702955e-09
common O 0 2.0467932415613177e-07
Ashkenazi O 0 0.00013574789045378566
haplotype O 0 2.11067235795781e-05
, O 0 2.893208872478681e-08
four O 0 1.7794512530144857e-08
had O 0 7.0857900880128e-08
a O 0 9.463149375221747e-09
closely O 0 3.2192684784604353e-07
related O 0 9.143147394752305e-08
pattern O 0 9.659437637310475e-06
, O 0 1.0047108389699133e-07
and O 0 3.430472972354437e-08
the O 0 1.1623654039283338e-08
rest O 0 1.5378476803107333e-07
( O 0 5.6595275133020095e-09
n O 0 1.440323217138939e-06
= O 0 9.516319323665812e-07
6 O 0 1.315358133524569e-07
) O 0 1.9750516777605753e-09
displayed O 0 1.3474856785933298e-08
a O 0 2.678629940078281e-08
distinct O 0 4.4926858322469343e-07
BRCA1 O 0 8.818535570753738e-05
allelic O 0 1.6197867807932198e-05
pattern O 0 3.45204898621887e-05
. O 0 9.431112175661838e-07

We O 0 5.358552698453423e-06
conclude O 0 1.1557981451915111e-06
that O 0 5.468155706012112e-09
the O 0 3.447387486588127e-09
185delAG O 0 1.831996996770613e-06
BRCA1 O 0 1.3862268133379985e-05
mutation O 0 4.2604017380654113e-07
occurs O 0 6.794841134194485e-09
in O 0 6.119592055320311e-10
some O 0 8.659786776554768e-10
non O 0 2.1366174962622608e-07
- O 0 1.1060060387535486e-05
Ashkenazi O 0 4.1333900298923254e-05
populations O 0 3.3797498133480985e-08
at O 0 2.211776894966988e-08
rates O 0 3.1837743108553695e-08
comparable O 0 6.261587248701517e-09
with O 0 1.397842064321253e-09
that O 0 9.18999987220559e-09
of O 0 8.830421727168414e-09
Ashkenazim O 0 3.131784615106881e-05
. O 0 5.420639013209438e-07

The O 0 2.7174419869879785e-07
majority O 0 4.2436866465322964e-08
of O 0 2.109975971720246e-09
Jewish O 0 1.5497613503612229e-07
185delAG O 0 3.7203114970907336e-06
mutation O 0 6.299840720203065e-07
carriers O 0 4.128747832510271e-08
have O 0 2.6952848841688137e-09
a O 0 3.7179996859038056e-09
common O 0 4.905619377382209e-08
allelic O 0 8.684414183335321e-07
pattern O 0 9.9540602604975e-06
, O 0 2.3535443816058432e-08
supporting O 0 4.860974289755404e-09
the O 0 3.4825997641263484e-09
founder O 0 8.686691330694885e-07
effect O 0 1.6436468186498132e-08
notion O 0 4.370842354717297e-09
, O 0 2.751959105040669e-09
but O 0 1.0590701648993672e-09
dating O 0 4.433056144392822e-09
the O 0 2.094538542607438e-09
mutations O 0 4.5973234108487304e-08
origin O 0 4.1001411155150436e-09
to O 0 7.94448951069171e-09
an O 0 7.82175391123019e-09
earlier O 0 2.3585826625094342e-07
date O 0 2.4595601644250564e-07
than O 0 7.253074585378272e-09
currently O 0 2.631409046216504e-08
estimated O 0 8.026251663295625e-08
. O 0 1.6454292506296042e-07

However O 0 5.856772986589931e-07
, O 0 5.010832193619308e-09
the O 0 1.766558427318543e-10
different O 0 5.123155788488987e-10
allelic O 0 3.687154759290934e-08
pattern O 0 4.667396922286571e-07
at O 0 5.8773078848162186e-08
the O 0 1.110686476124556e-08
BRCA1 O 0 3.4961599340022076e-06
locus O 0 2.747723613083508e-07
even O 0 1.6178249850895554e-08
in O 0 7.461273821007808e-10
some O 0 3.11368125727185e-10
Jewish O 0 2.131793053194997e-08
mutation O 0 1.6377470046791132e-07
carriers O 0 2.156123990459946e-08
, O 0 6.580901157349217e-09
might O 0 3.3871845772637243e-08
suggest O 0 2.5293614314136903e-08
that O 0 2.0056492022746397e-09
the O 0 5.148912851637988e-09
mutation O 0 3.527634930833301e-07
arose O 0 3.147090410493547e-08
independently O 0 3.8515815958817257e-07
. O 0 3.081320798514753e-08
. O 0 1.958017179504168e-07

Crystal O 0 0.0010942092631012201
structure O 0 3.2350703804695513e-06
of O 0 5.505635058966618e-08
the O 0 4.270286240171117e-07
hemochromatosis B-Disease 1 0.9999997615814209
protein O 0 2.6653529857867397e-05
HFE O 0 8.573445666115731e-05
and O 0 3.424590033773711e-07
characterization O 0 1.0248235184917576e-06
of O 0 2.128570208981273e-09
its O 0 5.6755833810484546e-08
interaction O 0 1.6159622973077603e-08
with O 0 7.40075689620312e-09
transferrin O 0 1.5110672393348068e-06
receptor O 0 7.258502137119649e-07
. O 0 1.7605803748210747e-07

HFE O 0 0.00229308707639575
is O 0 6.587264351765043e-07
an O 0 3.521234503978121e-08
MHC O 0 1.7333260302621056e-06
- O 0 1.7514681530883536e-05
related O 0 1.4168614370646537e-07
protein O 0 8.117516614447595e-08
that O 0 9.935580136399835e-10
is O 0 4.741245174244568e-10
mutated O 0 3.643899404437434e-08
in O 0 1.9932093753283198e-09
the O 0 3.892064981414478e-08
iron B-Disease 1 0.9959418177604675
- I-Disease 1 0.9999980926513672
overload I-Disease 1 0.9999591112136841
disease I-Disease 1 0.9999929666519165
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 7.702717266511172e-05

HFE O 0 0.0008050611359067261
binds O 0 1.291839453188004e-05
to O 0 4.223032590289222e-07
transferrin O 0 3.3220997011085274e-06
receptor O 0 4.0400047396360605e-07
( O 0 4.124450470044394e-08
TfR O 0 1.4752727111044805e-06
) O 0 6.532640650647181e-09
and O 0 5.903032285203835e-09
reduces O 0 2.5849416829260008e-08
its O 0 3.9769498805242165e-09
affinity O 0 2.4357020844689714e-09
for O 0 3.523281888462293e-09
iron O 0 6.291822046478046e-06
- O 0 3.83990027330583e-06
loaded O 0 4.434504603523237e-07
transferrin O 0 2.664498310878116e-07
, O 0 1.2463678977781001e-08
implicating O 0 1.8212314216725645e-06
HFE O 0 1.2918468200950883e-05
in O 0 4.3287151640925003e-08
iron O 0 0.0002542662259656936
metabolism O 0 0.00034631634480319917
. O 0 1.2356250636003097e-06

The O 0 6.977338102842623e-07
2 O 0 9.461181775805017e-07
. O 0 1.1632257610472152e-06

6 O 0 8.928227543947287e-06
A O 0 6.085296604396717e-07
crystal O 0 9.030009823618457e-05
structure O 0 9.578735671311733e-07
of O 0 1.665307003406724e-08
HFE O 0 3.8122187106637284e-05
reveals O 0 1.174307271867292e-06
the O 0 1.5136027986528688e-09
locations O 0 2.558899154792016e-07
of O 0 8.207065604892705e-08
hemochromatosis B-Disease 1 1.0
mutations O 0 0.0006386521854437888
and O 0 9.883685692102517e-08
a O 0 2.1276116513035959e-07
patch O 0 0.11928246915340424
of O 0 2.3788174985384103e-08
histidines O 0 4.234692096360959e-05
that O 0 9.373834330972386e-08
could O 0 7.902719545427317e-08
be O 0 3.092234690527107e-09
involved O 0 1.791451431643054e-09
in O 0 5.142111181299924e-09
pH O 0 7.769782314426266e-06
- O 0 5.1119797717547044e-05
dependent O 0 8.174028153007384e-06
interactions O 0 2.0586172411185544e-07
. O 0 1.519000960570338e-07

We O 0 2.567927140262327e-06
also O 0 4.9911758281950824e-08
demonstrate O 0 2.7329779328510995e-08
that O 0 6.034679422839417e-09
soluble O 0 2.2692520929012971e-07
TfR O 0 2.8108454444009112e-06
and O 0 5.605813768738699e-08
HFE O 0 6.535598458867753e-06
bind O 0 4.5889919420005754e-07
tightly O 0 4.4948200184080633e-07
at O 0 1.0573433684157862e-07
the O 0 8.548537433483716e-10
basic O 0 2.0721047988558894e-08
pH O 0 1.2785561409600632e-07
of O 0 3.1358884933219144e-10
the O 0 1.724322018503699e-08
cell O 0 3.5578403185354546e-05
surface O 0 6.1919799918541685e-06
, O 0 4.3073921318637076e-08
but O 0 9.032659953334132e-09
not O 0 1.125356918763032e-09
at O 0 8.522704320057528e-09
the O 0 8.047186916826377e-09
acidic O 0 8.073815479292534e-06
pH O 0 5.150339461579279e-07
of O 0 2.895509387812467e-09
intracellular O 0 9.78560706244025e-07
vesicles O 0 6.69527025820571e-06
. O 0 6.962276302147075e-07

TfR O 0 0.018326137214899063
HFE O 0 0.0027263746596872807
stoichiometry O 0 4.465836536837742e-05
( O 0 7.00737984971056e-07
2 O 0 7.139049529314434e-08
1 O 0 4.2382104936677933e-08
) O 0 7.542722890718778e-09
differs O 0 7.32910478973281e-08
from O 0 2.6208452297282747e-08
TfR O 0 2.747463895502733e-06
transferrin O 0 4.642864155357529e-07
stoichiometry O 0 1.4849939589112182e-07
( O 0 6.386279505221637e-09
2 O 0 2.474296145749122e-08
2 O 0 5.873441821790948e-08
) O 0 2.2850428216258933e-09
, O 0 9.842028303452821e-10
implying O 0 5.5202060700310085e-09
a O 0 6.552203224430286e-10
different O 0 3.1455091309418037e-10
mode O 0 2.2550477041249906e-08
of O 0 6.41508846044303e-10
binding O 0 6.261828389142465e-08
for O 0 1.653495118603132e-08
HFE O 0 1.0347649549657945e-05
and O 0 7.37421359531254e-08
transferrin O 0 1.823092787844871e-07
to O 0 3.904854395386792e-08
TfR O 0 1.0400116252640146e-06
, O 0 5.505726985433057e-09
consistent O 0 1.1951503786633566e-08
with O 0 9.436755821212728e-10
our O 0 3.427144434908769e-08
demonstration O 0 8.220522573765265e-08
that O 0 6.423956477874526e-09
HFE O 0 2.0860095446550986e-06
, O 0 1.1972174362995247e-08
transferrin O 0 1.3637236406793818e-07
, O 0 7.269362001238733e-09
and O 0 1.2988881969988597e-08
TfR O 0 9.082518204195367e-07
form O 0 2.1095464930454e-08
a O 0 4.7177596940173316e-08
ternary O 0 6.747123393324728e-07
complex O 0 1.0827949381564395e-06
. O 0 8.876126003087847e-07

Identification O 0 6.086677899475035e-07
of O 0 1.2408317040524253e-08
three O 0 1.2093813950286858e-08
novel O 0 1.31743334463863e-07
mutations O 0 3.1500865134148626e-06
and O 0 1.0593535826330935e-08
a O 0 1.7555329634433292e-08
high O 0 3.817557114871306e-08
frequency O 0 1.0780227910345275e-07
of O 0 6.095268734185311e-10
the O 0 9.574989690008806e-09
Arg778Leu O 0 1.0753777132777032e-05
mutation O 0 2.704695702959725e-07
in O 0 2.5990252172647388e-09
Korean O 0 7.648644384516956e-08
patients O 0 4.1757751034765533e-08
with O 0 6.832868493233946e-09
Wilson B-Disease 0 2.369215144426562e-05
disease I-Disease 0 6.354612560244277e-05
. O 0 1.738367103598648e-07

Four O 0 1.6572955701121828e-06
mutations O 0 1.667827928031329e-05
- O 0 1.590831743669696e-05
- O 0 2.1158963136258535e-05
R778L O 0 6.347579528664937e-07
, O 0 2.6087048077272357e-09
A874V O 0 1.4164257322590856e-08
, O 0 1.029211049718981e-09
L1083F O 0 1.104789504324799e-08
, O 0 7.015210079508449e-10
and O 0 8.081560975981006e-10
2304delC O 0 1.0641738157346481e-07
- O 0 3.887321042839176e-07
- O 0 4.695335746873752e-07
in O 0 1.5607511727466772e-08
the O 0 7.525881251524424e-09
copper O 0 1.2120783594582463e-06
- O 0 6.5768752222084e-08
transporting O 0 2.742528515398135e-08
enzyme O 0 1.886428258046635e-08
, O 0 2.3477593202869684e-09
P O 0 1.9651233742479235e-05
- O 0 8.739289683035167e-07
type O 0 4.0927835698312265e-07
ATPase O 0 1.760275881679263e-05
( O 0 2.016959577133548e-08
ATP7B O 0 7.876700692577288e-06
) O 0 3.55018392461659e-09
, O 0 2.1357846602398922e-09
were O 0 5.470576436295005e-09
identified O 0 3.75718904876976e-08
in O 0 1.197806076547181e-09
Korean O 0 7.128000589773364e-08
Patients O 0 1.2854855846455848e-08
with O 0 5.353705478938764e-09
Wilson B-Disease 0 2.7338719519320875e-05
disease I-Disease 0 3.608796396292746e-05
. O 0 1.6871278774033271e-07

Arg778Leu O 0 0.0006990773254074156
, O 0 1.87538645946006e-07
the O 0 5.8628395471771455e-09
most O 0 4.381409013376469e-09
frequently O 0 8.225823933116772e-08
reported O 0 6.118232249718858e-07
mutation O 0 1.8402705137532394e-08
of O 0 2.139171478843238e-10
this O 0 7.060285689419743e-10
enzyme O 0 5.94529510067332e-08
, O 0 1.853996600686969e-08
was O 0 2.0912749221224658e-07
found O 0 1.057625365064041e-08
in O 0 1.2820470240981763e-09
six O 0 4.5485299970948745e-09
of O 0 2.7640673083695333e-10
eight O 0 1.4072217169314172e-08
unrelated O 0 8.961959707676215e-08
patients O 0 3.5794840869129985e-08
studied O 0 2.6870874414441914e-09
, O 0 1.0032661368342133e-09
an O 0 8.866602452251016e-10
allele O 0 1.644415732471316e-07
frequency O 0 3.262622385591385e-07
of O 0 1.7554425468802037e-08
37 O 0 9.344680051981413e-07
. O 0 4.395532471335173e-07

5 O 0 3.47060404237709e-06
% O 0 9.296736180886e-08
, O 0 9.271393430765329e-09
which O 0 3.173447948867647e-09
is O 0 2.5554096616531297e-09
considerably O 0 8.572450127530828e-08
higher O 0 2.011788069467002e-08
than O 0 2.382798847122558e-09
those O 0 4.04430960943003e-10
in O 0 3.8946751379498323e-10
other O 0 1.9272585749519067e-09
Asian O 0 4.09614102636624e-08
populations O 0 1.1753589035379264e-07
. O 0 1.265179889742285e-07

The O 0 1.4169694395604893e-07
novel O 0 1.92067290072373e-07
single O 0 1.0922332904783616e-07
nucleotide O 0 5.297243319546396e-07
deletion O 0 3.351640998516814e-06
, O 0 3.2447918130174e-08
2304delC O 0 1.4247407307266258e-06
, O 0 2.971744628155193e-08
was O 0 1.5783847118200356e-07
found O 0 1.3592306835619183e-08
in O 0 2.6558983901026068e-09
one O 0 9.077741225382852e-08
patient O 0 1.1015744121323223e-06
. O 0 1.7321251277735428e-07

Since O 0 8.220771405831329e-07
a O 0 1.0290902707765781e-07
mutation O 0 3.8321263673424255e-07
at O 0 8.900701686798129e-08
cDNA O 0 1.595136154719512e-06
nucleotide O 0 1.030555085890228e-05
2302 O 0 8.919720858102664e-05
( O 0 5.791974189151006e-08
2302insC O 0 1.0657496432031621e-06
) O 0 5.178106476932953e-08
had O 0 5.367929816202377e-07
been O 0 1.0436605180075276e-07
previously O 0 3.34861738338077e-07
described O 0 7.326923991968215e-07
, O 0 3.3190024062434986e-09
this O 0 4.235321260370739e-10
region O 0 3.460736763827299e-08
of O 0 4.5547782212551624e-10
the O 0 6.123611839825571e-09
ATP7B O 0 5.866780338692479e-05
gene O 0 2.1056148398201913e-06
may O 0 5.364349249248335e-07
be O 0 1.666533400168646e-08
susceptible O 0 1.2512482499005273e-06
to O 0 3.811358695315903e-08
gene O 0 2.7187195883016102e-05
rearrangements O 0 0.0007611349574290216
causing O 0 0.00025517106405459344
Wilson B-Disease 0 0.00012376258382573724
disease I-Disease 0 0.0003094400162808597
. O 0 4.750401956243877e-07

Disruption O 0 4.0612692828290164e-05
of O 0 3.154356065238062e-08
splicing O 0 1.6241465345956385e-06
regulated O 0 2.2784641373618797e-07
by O 0 5.532180047396196e-09
a O 0 1.7295064935751725e-08
CUG O 0 5.2240658988012e-05
- O 0 7.48442334952415e-06
binding O 0 2.788298388622934e-06
protein O 0 7.182158242358128e-06
in O 0 3.197996875314857e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 0.9999998807907104
. O 0 8.670115676068235e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9996415376663208
DM B-Disease 1 1.0
) O 0 1.4088180250837468e-05
is O 0 1.259428046296307e-07
caused O 0 7.485228081804962e-08
by O 0 1.4351455579486583e-09
a O 0 4.237903183934577e-08
CTG O 0 7.973569154273719e-06
expansion O 0 4.0215908825302904e-08
in O 0 3.3119831321926085e-09
the O 0 3.617630417451778e-09
3 O 0 1.489066789872595e-07
untranslated O 0 1.0296355867467355e-05
region O 0 6.092752755648689e-07
of O 0 1.5802275044052294e-08
the O 0 8.342175306097488e-07
DM B-Disease 1 0.9999998807907104
gene O 0 2.1444784579216503e-05
. O 0 4.1807521711234585e-07

One O 0 1.1027747177649871e-06
model O 0 1.774139491317328e-06
of O 0 1.0298266062136463e-07
DM B-Disease 1 1.0
pathogenesis O 0 0.00045067115570418537
suggests O 0 1.9489257852001174e-07
that O 0 3.6568406081016747e-09
RNAs O 0 9.045093207760146e-08
from O 0 1.6393316704110816e-09
the O 0 6.988007394959084e-10
expanded O 0 1.5030483524469673e-08
allele O 0 3.827560135505337e-08
create O 0 3.635351797370845e-09
a O 0 1.2186109898948416e-08
gain O 0 8.483709734719014e-07
- O 0 8.06229024874483e-07
of O 0 6.895159554431984e-09
- O 0 4.582511792250443e-06
function O 0 7.711059879511595e-08
mutation O 0 3.98102031340386e-08
by O 0 3.5702485412514307e-10
the O 0 1.4598939834797875e-09
inappropriate O 0 5.486409193622421e-08
binding O 0 1.522440307155648e-08
of O 0 2.2906007646206206e-10
proteins O 0 1.5779528794723774e-09
to O 0 4.481770954356534e-09
the O 0 1.98523881778101e-08
CUG O 0 0.00020260234305169433
repeats O 0 3.796049713855609e-05
. O 0 2.3383718428249267e-07

Data O 0 3.255887713748962e-05
presented O 0 6.803589940318489e-07
here O 0 3.838966122771126e-08
indicate O 0 1.416004291598938e-08
that O 0 5.371868505577027e-10
the O 0 6.29829688403305e-10
conserved O 0 9.316191551533848e-08
heterogeneous O 0 1.2549576240417082e-06
nuclear O 0 1.0136155879081343e-06
ribonucleoprotein O 0 2.3218832723159721e-07
, O 0 4.091126104555087e-09
CUG O 0 1.243756628355186e-06
- O 0 8.83972575138614e-07
binding O 0 1.5409571574309666e-07
protein O 0 1.9421590025103797e-07
( O 0 8.006981744301811e-09
CUG O 0 2.1679154087905772e-05
- O 0 7.334655674640089e-05
BP O 0 0.012097939848899841
) O 0 6.718829936858128e-09
, O 0 4.4962238376911046e-09
may O 0 7.631813048192271e-08
mediate O 0 7.536599468949134e-07
the O 0 1.5505767336776444e-08
trans O 0 9.488756404607557e-06
- O 0 7.5756729529530276e-06
dominant O 0 2.79347250398132e-06
effect O 0 5.40854614428099e-08
of O 0 5.209523923355164e-10
the O 0 3.5757496963384483e-09
RNA O 0 2.028974904533243e-06
. O 0 2.44251481262836e-07

CUG O 0 0.03917369619011879
- O 0 0.1451529860496521
BP O 0 0.3313484191894531
was O 0 2.03427771339193e-06
found O 0 1.2065243915060364e-08
to O 0 1.4521457369909285e-09
bind O 0 1.4973341677659846e-08
to O 0 5.887930587533674e-09
the O 0 1.000530058803406e-08
human O 0 1.180758886221156e-06
cardiac O 0 0.00025348798953928053
troponin O 0 1.5279845683835447e-05
T O 0 0.00018102031026501209
( O 0 1.0678332884594965e-08
cTNT O 0 2.0625239471883106e-07
) O 0 5.515701673175499e-09
pre O 0 4.814499448002607e-07
- O 0 1.6825723605506937e-06
messenger O 0 9.097229280996544e-07
RNA O 0 1.4805961257025047e-07
and O 0 2.4633890483016785e-09
regulate O 0 1.7919511208219774e-08
its O 0 1.7744014257914387e-08
alternative O 0 2.1401984895419446e-07
splicing O 0 4.316358626965666e-06
. O 0 2.525717377466208e-07

Splicing O 0 3.7956517189741135e-05
of O 0 3.527066496644693e-07
cTNT O 0 2.545363167882897e-05
was O 0 1.5947817928463337e-06
disrupted O 0 0.00012673861056100577
in O 0 2.957726110253134e-06
DM B-Disease 1 1.0
striated O 0 0.008026540279388428
muscle O 0 0.0003321384429000318
and O 0 4.3393125537249944e-08
in O 0 6.838800636899123e-09
normal O 0 5.656108896801015e-07
cells O 0 1.919868736877106e-06
expressing O 0 7.375577837365199e-08
transcripts O 0 2.512307730739849e-07
that O 0 1.0648596671103405e-08
contain O 0 7.640347376991485e-08
CUG O 0 0.00020616753317881376
repeats O 0 5.19012137374375e-05
. O 0 2.370072991197958e-07

Altered O 0 3.783151987590827e-05
expression O 0 5.320593459146039e-07
of O 0 4.8395949470148025e-09
genes O 0 1.0091569890846586e-07
regulated O 0 2.2065104587909445e-07
posttranscriptionally O 0 3.447926701483084e-06
by O 0 1.3884230654070961e-08
CUG O 0 0.00024991994723677635
- O 0 0.0009200325584970415
BP O 0 0.024166004732251167
therefore O 0 4.3702362972908304e-07
may O 0 8.282974306439428e-08
contribute O 0 2.320452630044656e-08
to O 0 1.2635813391170814e-06
DM B-Disease 1 1.0
pathogenesis O 0 0.0002976384712383151
. O 0 4.82161226500466e-08
. O 0 1.9899250958133052e-07

Identification O 0 1.0202207931797602e-06
of O 0 1.1948448452869798e-08
a O 0 2.8318643430225166e-08
novel O 0 2.7426341375758057e-07
nonsense O 0 3.101382390013896e-06
mutation O 0 3.3863258863675583e-07
and O 0 5.3585376136311424e-09
a O 0 4.731147917880207e-09
missense O 0 4.4699584123009117e-07
substitution O 0 8.349161362275481e-09
in O 0 3.0174822640560706e-09
the O 0 1.200933841261076e-08
vasopressin O 0 2.0589404812199064e-06
- O 0 1.9321185391163453e-05
neurophysin O 0 1.8168762835557573e-05
II O 0 1.0240869414701592e-06
gene O 0 4.918539175946535e-08
in O 0 1.1607054206663747e-09
two O 0 3.7045360112841763e-09
Spanish O 0 1.8486105091142235e-07
kindreds O 0 5.10415429744171e-06
with O 0 5.825444659990353e-08
familial B-Disease 0 0.004199433606117964
neurohypophyseal I-Disease 1 0.9954698085784912
diabetes I-Disease 1 0.999687910079956
insipidus I-Disease 0 0.12116020172834396
. O 0 2.58127920460538e-06

Familial B-Disease 1 0.999897837638855
neurohypophyseal I-Disease 1 0.9999897480010986
diabetes I-Disease 1 0.9999997615814209
insipidus I-Disease 1 0.9999898672103882
( O 0 0.0006538426387123764
FNDI B-Disease 1 1.0
) O 0 1.1577717486943584e-06
is O 0 9.492000074828866e-09
an O 0 3.796036196490604e-08
autosomal B-Disease 1 0.9993720650672913
dominant I-Disease 1 0.9973698854446411
disease I-Disease 1 0.9994949102401733
caused O 0 1.3714928172703367e-05
by O 0 3.592651296457916e-07
deficiency O 0 0.0003736621583811939
in O 0 1.1502859109668861e-08
the O 0 1.6718622930511629e-07
antidiuretic O 0 0.0005138550768606365
hormone O 0 5.4172469390323386e-06
arginine O 0 8.570582963329798e-07
vasopressin O 0 5.190585739001108e-07
( O 0 5.280645698491071e-09
AVP O 0 5.979599677630176e-07
) O 0 8.903580650532206e-10
encoded O 0 4.433462041930625e-09
by O 0 1.0625990087831383e-09
the O 0 1.0024441721157018e-08
AVP O 0 0.00010755275434348732
- O 0 7.743354217382148e-05
neurophysin O 0 7.802258915035054e-05
II O 0 4.9402297008782625e-06
( O 0 1.619893730264721e-08
AVP O 0 1.7883214241010137e-05
- O 0 5.017375315219397e-06
NPII O 0 1.255394090549089e-05
) O 0 4.697769284689457e-09
gene O 0 6.752672732091014e-08
on O 0 2.0189732197195553e-07
chromosome O 0 5.691605474567041e-05
20p13 O 0 8.888502634363249e-06
. O 0 4.4361456730257487e-07

In O 0 3.9457972889067605e-07
this O 0 1.8899577014508395e-08
study O 0 5.250115453492299e-09
, O 0 4.156622157580614e-09
we O 0 1.0197385158505767e-08
analyzed O 0 3.8476603236858864e-08
two O 0 2.018082367882812e-09
families O 0 1.1583168868511962e-09
with O 0 3.9770564619345805e-09
FNDI B-Disease 1 0.9999895095825195
using O 0 4.4351303074563475e-08
direct O 0 2.4138188337019528e-08
automated O 0 2.0970096556993667e-06
fluorescent O 0 1.603913517556066e-07
, O 0 4.058529956552093e-09
solid O 0 4.775502659981612e-08
phase O 0 1.7945575692124294e-08
, O 0 1.3519798613970124e-09
single O 0 4.234945549796976e-08
- O 0 6.28369946298335e-07
stranded O 0 9.779200382808995e-08
DNA O 0 4.866004843506744e-08
sequencing O 0 1.29232970991211e-08
of O 0 8.716127819496933e-10
PCR O 0 1.3980554740555817e-06
- O 0 2.3275397325051017e-06
amplified O 0 6.840127753093839e-06
AVP O 0 1.4036214452062268e-05
- O 0 3.66734843737504e-06
NPII O 0 1.5238749256241135e-05
DNA O 0 3.4309227885387372e-06
. O 0 1.650345069492687e-07

In O 0 2.712636444357486e-07
one O 0 1.455440656883411e-08
of O 0 5.62475399590312e-10
the O 0 5.181759021866128e-09
families O 0 4.799332486982166e-09
, O 0 1.1734432980858855e-08
affected O 0 7.09660685771496e-09
individuals O 0 1.3241262253327335e-10
presented O 0 4.251275331768056e-09
a O 0 8.396047412873031e-09
novel O 0 6.326584411908698e-08
nonsense O 0 1.0436132242830354e-06
mutation O 0 3.733799758265377e-08
in O 0 1.4415955096325206e-09
exon O 0 1.500299191548038e-07
3 O 0 1.4891202049227559e-08
of O 0 2.0363469244166765e-10
the O 0 1.9153523211912216e-09
gene O 0 7.956062120229035e-08
, O 0 1.0611164169560539e-09
consisting O 0 1.985869246823313e-10
in O 0 4.5075301824404335e-10
a O 0 2.8040229693715446e-08
G O 0 6.969994137762114e-05
to O 0 8.726732403374626e-08
T O 0 4.0501923649571836e-05
transition O 0 3.8424385451207854e-08
at O 0 1.822678541429923e-08
nucleotide O 0 2.3076952970768616e-07
2101 O 0 5.447717512652162e-07
, O 0 5.5768243356624225e-09
which O 0 1.7980787969662515e-09
produces O 0 1.003477212435655e-08
a O 0 5.572762695749134e-09
stop O 0 2.3593271691879636e-07
signal O 0 4.156609634264896e-07
in O 0 1.1795310506101941e-08
codon O 0 2.0251297883078223e-06
82 O 0 2.8527097128971945e-07
( O 0 2.1998536325895657e-08
Glu O 0 3.4750970371533185e-05
) O 0 1.367447843847458e-08
of O 0 8.801298356786447e-09
NPII O 0 0.000262128101894632
. O 0 8.897950465325266e-07

The O 0 4.75793740406516e-06
premature O 0 2.4670689526828937e-05
termination O 0 7.261604082486883e-07
eliminates O 0 2.256648912180026e-07
part O 0 9.925223309892317e-09
of O 0 6.453894085822753e-10
the O 0 1.1821775558473746e-08
C O 0 1.3355104783840943e-05
- O 0 4.512047325988533e-06
terminal O 0 6.8095241658738814e-06
domain O 0 3.7738516311947023e-08
of O 0 1.0253197180176699e-09
NPII O 0 4.91913942823885e-06
, O 0 7.856227890457035e-10
including O 0 4.3232792346081794e-11
a O 0 4.804514008860394e-10
cysteine O 0 5.01900077054529e-09
residue O 0 9.333496109320549e-08
in O 0 4.3872967481206615e-09
position O 0 2.459238430674304e-07
85 O 0 1.9678031648595606e-08
, O 0 4.46262138353859e-09
which O 0 2.7228006516111236e-08
could O 0 1.0175997289252336e-07
be O 0 1.2985958974809364e-08
involved O 0 2.066389059862672e-09
in O 0 1.1807257394025328e-09
the O 0 7.80495756913524e-09
correct O 0 2.839029548340477e-05
folding O 0 8.678617859914084e-07
of O 0 3.2428104645987332e-09
the O 0 8.862485145755272e-08
prohormone O 0 0.00020623144519049674
. O 0 7.787872959852393e-07

In O 0 5.864558829671296e-07
the O 0 1.9433423759096513e-08
second O 0 3.926551244148868e-07
family O 0 3.680732518773766e-08
, O 0 9.696319303031942e-10
a O 0 6.522651307960814e-10
G279A O 0 5.638215672121305e-09
substitution O 0 7.420004610736441e-10
at O 0 1.1883674488899487e-08
position O 0 9.853098958956252e-08
- O 0 3.792591485307639e-07
1 O 0 3.7144008757650226e-08
of O 0 3.832107409174057e-10
the O 0 3.727528952168768e-09
signal O 0 4.860448257204553e-07
peptide O 0 4.2789288556832616e-08
was O 0 8.995079525675465e-08
observed O 0 8.795005612682871e-09
in O 0 8.651416805172119e-10
all O 0 1.2680972938383661e-09
affected O 0 2.767372464518303e-08
individuals O 0 6.2022742497447325e-09
. O 0 1.0306008135785305e-07

This O 0 1.1755398645618698e-06
missense O 0 8.88687209226191e-05
mutation O 0 1.3228248462837655e-05
, O 0 6.11140862361026e-08
which O 0 2.5337019593507648e-08
replaces O 0 1.0037863830802962e-05
Ala O 0 5.527860139409313e-06
with O 0 1.915904945803959e-08
Thr O 0 0.0005221220199018717
, O 0 7.447173988595068e-09
is O 0 1.317576714399138e-09
frequent O 0 6.56130154652601e-08
among O 0 8.465938350354918e-08
FNDI B-Disease 1 1.0
patients O 0 2.12490267585963e-05
and O 0 6.97244662006824e-09
is O 0 2.9246327581944342e-09
thought O 0 1.0731398880636789e-08
to O 0 4.159326660868601e-09
reduce O 0 3.265753178993691e-08
the O 0 1.5287393573260033e-09
efficiency O 0 1.830426654692019e-08
of O 0 1.4887218124925994e-09
cleavage O 0 2.200237304350594e-06
by O 0 1.7996990564483895e-08
signal O 0 3.2107463994179852e-06
peptidases O 0 4.328849172452465e-06
. O 0 3.146832128209098e-08
. O 0 1.3213831095981732e-07

Genetic O 0 0.00013872631825506687
heterogeneity O 0 2.389263863733504e-05
of O 0 2.5884551746457873e-07
Saethre B-Disease 0 0.2362610250711441
- I-Disease 1 0.9999147653579712
Chotzen I-Disease 1 0.999956488609314
syndrome I-Disease 1 0.9999977350234985
, O 0 2.903601981074644e-08
due O 0 2.0797109812065173e-08
to O 0 1.1898734442183923e-08
TWIST O 0 2.1558647858910263e-05
and O 0 1.0162782473344123e-06
FGFR O 0 0.0005938861286267638
mutations O 0 1.8658505723578855e-05
. O 0 1.924515942164362e-07

Thirty O 0 3.598809053073637e-05
- O 0 8.532037463737652e-05
two O 0 1.0427213226193999e-07
unrelated O 0 4.962640787198325e-07
patients O 0 8.421311292750033e-08
with O 0 3.175589791126754e-10
features O 0 3.215944488488276e-08
of O 0 1.537169680432271e-08
Saethre B-Disease 1 0.5705584287643433
- I-Disease 1 0.9994804263114929
Chotzen I-Disease 1 0.9986403584480286
syndrome I-Disease 1 0.9989998936653137
, O 0 1.496628154740165e-09
a O 0 6.709238498103787e-09
common O 0 5.172204282644088e-07
autosomal B-Disease 0 0.20260420441627502
dominant I-Disease 0 0.0005666277720592916
condition I-Disease 0 5.5942295148270205e-05
of O 0 5.98638365545412e-08
craniosynostosis B-Disease 0 0.24355241656303406
and O 0 4.866991366725415e-05
limb B-Disease 1 0.9814342260360718
anomalies I-Disease 1 0.5611730813980103
, O 0 1.6097119726055098e-07
were O 0 1.2200715104881965e-08
screened O 0 7.674509561184095e-08
for O 0 6.115790984750902e-09
mutations O 0 3.1821326729186694e-07
in O 0 4.262139086108618e-09
TWIST O 0 1.9586570488172583e-05
, O 0 8.320676414541595e-08
FGFR2 O 0 2.3001901354291476e-05
, O 0 1.948523653538814e-08
and O 0 2.1718289389127676e-08
FGFR3 O 0 6.966890941839665e-05
. O 0 2.3826326867038006e-07

Nine O 0 8.120496204355732e-06
novel O 0 9.605859077055356e-07
and O 0 4.961892585697569e-08
three O 0 5.971774186264156e-08
recurrent O 0 0.00011183198512298986
TWIST O 0 0.0004571993194986135
mutations O 0 0.00026165787130594254
were O 0 1.1322865844931584e-07
found O 0 3.376856838599451e-08
in O 0 5.689898774363655e-09
12 O 0 5.1621707797266936e-08
families O 0 2.1135377892278484e-08
. O 0 7.393297352109585e-08

Seven O 0 1.4385220765689155e-06
families O 0 7.67956152003535e-08
were O 0 4.2745483597173006e-08
found O 0 1.7366000193419495e-08
to O 0 5.558050020226801e-09
have O 0 1.5997629887465337e-09
the O 0 2.3211863542371702e-09
FGFR3 O 0 3.923536951333517e-06
P250R O 0 8.202198387152748e-08
mutation O 0 5.56908901216957e-08
, O 0 2.891188177756021e-09
and O 0 9.462336691967721e-09
one O 0 1.7388869011369934e-08
individual O 0 8.349049451794599e-09
was O 0 1.687224084889749e-06
found O 0 3.3750406913668485e-08
to O 0 7.1823147429483924e-09
have O 0 2.681496580336784e-09
an O 0 2.0003656509004486e-09
FGFR2 O 0 1.2639689884963445e-05
VV269 O 0 4.3502268454176374e-07
- O 0 1.0346004728489788e-06
270 O 0 4.919524485558213e-07
deletion O 0 1.549059379613027e-05
. O 0 3.7575011901935795e-07

To O 0 6.624780439778988e-07
date O 0 3.756118189812696e-07
, O 0 8.236040294207214e-09
our O 0 4.619550963980146e-09
detection O 0 4.299397460272303e-08
rate O 0 4.25999537867483e-08
for O 0 1.0375008629992521e-09
TWIST O 0 2.882020226024906e-06
or O 0 3.7031398392173287e-07
FGFR O 0 5.201676322030835e-05
mutations O 0 1.0381248785051866e-06
is O 0 2.750762728709333e-09
68 O 0 1.625467938026759e-08
% O 0 6.888268289095834e-10
in O 0 6.12687955925395e-10
our O 0 1.3264941856050427e-07
Saethre B-Disease 0 0.00906001403927803
- I-Disease 1 0.9868336319923401
Chotzen I-Disease 1 0.9993584752082825
syndrome I-Disease 1 0.9999904632568359
patients O 0 4.343744876678102e-06
, O 0 7.432610638069548e-10
including O 0 5.783821199756289e-10
our O 0 5.961555160638454e-08
five O 0 1.067968113943607e-07
patients O 0 5.810242598158766e-08
elsewhere O 0 1.7720678258115186e-08
reported O 0 4.007609391010192e-07
with O 0 8.08932210105695e-09
TWIST O 0 0.00012936645362060517
mutations O 0 7.44361022952944e-05
. O 0 3.3815109645729535e-07

More O 0 2.081715848589738e-07
than O 0 1.6181736839371297e-08
35 O 0 6.1003428974970575e-09
different O 0 1.0668026462212765e-09
TWIST O 0 3.1458414468943374e-06
mutations O 0 1.0917539839283563e-05
are O 0 8.786872562893677e-09
now O 0 1.9735162837264397e-08
known O 0 1.253764025932469e-08
in O 0 4.50846959765272e-09
the O 0 1.312295427879917e-08
literature O 0 7.096528520378342e-08
. O 0 3.030319817298732e-07

The O 0 1.21292544008611e-07
most O 0 1.200368160425569e-08
common O 0 1.9989212063364903e-08
phenotypic O 0 1.8631394027579518e-07
features O 0 2.2313707859211718e-07
, O 0 3.011136229247313e-08
present O 0 3.2439613217860597e-09
in O 0 1.25082544322197e-09
more O 0 1.032380292365076e-09
than O 0 1.3363895545737137e-09
a O 0 1.5877807513220432e-08
third O 0 3.183580474797054e-07
of O 0 1.937028093479398e-09
our O 0 2.9083750519021123e-07
patients O 0 1.2768254009642988e-08
with O 0 4.619997995281011e-10
TWIST O 0 9.56002259044908e-06
mutations O 0 3.8067237255745567e-06
, O 0 2.845843338761256e-09
are O 0 1.518576486780887e-09
coronal B-Disease 0 2.147437771782279e-05
synostosis I-Disease 0 6.105838838266209e-05
, O 0 3.051504293694052e-08
brachycephaly B-Disease 0 5.749774118157802e-06
, O 0 2.093573137074145e-08
low B-Disease 0 4.394218194647692e-06
frontal I-Disease 1 0.7862578630447388
hairline I-Disease 1 0.9999864101409912
, O 0 1.7971759007195942e-05
facial B-Disease 1 0.9098242521286011
asymmetry I-Disease 0 9.134902211371809e-05
, O 0 6.949711632842082e-07
ptosis B-Disease 0 0.0068227979354560375
, O 0 1.712902104600289e-07
hypertelorism B-Disease 0 0.00014565604215022177
, O 0 4.114542306865587e-08
broad B-Disease 0 2.1933726657152874e-07
great I-Disease 0 2.5531900860187307e-07
toes I-Disease 0 0.021774761378765106
, O 0 8.393377726179096e-08
and O 0 9.750890228588105e-08
clinodactyly B-Disease 0 7.840207399567589e-05
. O 0 3.7958085385980667e-07

Significant O 0 1.8917718307420728e-06
intra O 0 1.55168236233294e-05
- O 0 0.00016818527365103364
and O 0 6.470034463745833e-07
interfamilial O 0 1.495754077041056e-05
phenotypic O 0 2.2419815195462434e-06
variability O 0 2.3413513190462254e-06
is O 0 5.607564190768244e-09
present O 0 1.6453899354118562e-09
for O 0 1.7451325939887852e-09
either O 0 3.758844613344081e-08
TWIST O 0 3.0263307053246535e-05
mutations O 0 1.6934829545789398e-05
or O 0 3.997402586719545e-07
FGFR O 0 0.0007149775046855211
mutations O 0 5.740335473092273e-05
. O 0 5.747941713707405e-07

The O 0 1.3411171551069856e-07
overlap O 0 6.340222284961783e-07
in O 0 5.881580378286344e-08
clinical O 0 1.2501658375185798e-07
features O 0 1.181053335130855e-07
and O 0 4.591671043385759e-08
the O 0 4.700440481286705e-09
presence O 0 1.1755759032894275e-08
, O 0 1.9401673601038283e-09
in O 0 2.194805448496595e-10
the O 0 3.554667671323841e-10
same O 0 3.769928813568413e-09
genes O 0 9.015171720250237e-09
, O 0 8.40812697244786e-10
of O 0 2.816165356467337e-10
mutations O 0 2.7896463805632266e-08
for O 0 4.441084999751155e-10
more O 0 2.0162200797813057e-09
than O 0 4.533044162258193e-09
one O 0 3.951644700350698e-08
craniosynostotic B-Disease 0 1.5704099496360868e-05
condition I-Disease 0 8.183834552255576e-07
- O 0 3.1370220199278265e-08
such O 0 3.492575950669874e-10
as O 0 1.052827158787295e-08
Saethre B-Disease 0 2.1536902750085574e-06
- I-Disease 0 2.8322506295808125e-06
Chotzen I-Disease 0 2.9545094548666384e-06
, I-Disease 0 4.629782779375091e-09
Crouzon I-Disease 0 2.1390597737536154e-07
, I-Disease 0 4.256095031962559e-09
and I-Disease 0 1.0647890036352692e-07
Pfeiffer I-Disease 0 0.26713281869888306
syndromes I-Disease 0 0.00011598745186347514
- O 0 1.2624141163541935e-06
support O 0 1.2527074488843937e-08
the O 0 7.179493000109005e-09
hypothesis O 0 2.7003288494142907e-08
that O 0 1.6785401957264412e-09
TWIST O 0 1.0066200957226101e-06
and O 0 5.035246530837867e-08
FGFRs O 0 4.4815766386818723e-07
are O 0 5.723376217403597e-10
components O 0 8.432929021751079e-09
of O 0 1.5105794393122096e-10
the O 0 8.964037845338169e-10
same O 0 3.3096403395660445e-09
molecular O 0 1.2282248995632017e-08
pathway O 0 9.632544539783794e-09
involved O 0 4.015817012259504e-09
in O 0 6.164530552688063e-10
the O 0 1.9444463816853386e-09
modulation O 0 2.8412301844582544e-07
of O 0 3.393023462194833e-08
craniofacial O 0 0.2819151282310486
and O 0 8.241155228461139e-06
limb O 0 0.000359400175511837
development O 0 4.2614338724433765e-08
in O 0 1.0888984824930503e-08
humans O 0 5.2948490036897056e-08
. O 0 9.664823608090956e-09
. O 0 1.0039732956101943e-07

Mutation O 0 0.00016489728295709938
analysis O 0 2.1188229766266886e-06
of O 0 4.097056205409899e-07
UBE3A O 1 0.6788857579231262
in O 0 0.040255140513181686
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.09608970582485199
. O 0 2.568625177445938e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.08945157378911972
AS B-Disease 1 0.9999959468841553
) O 0 8.172712000487081e-07
is O 0 4.7866734576018644e-08
caused O 0 6.450848388794839e-08
by O 0 6.342868896780374e-09
chromosome O 0 6.230540020624176e-05
15q11 O 0 4.654711119655985e-06
- O 0 8.752428584557492e-06
q13 O 0 1.1004781299561728e-06
deletions O 0 6.096379365772009e-07
of O 0 3.9304226540082254e-09
maternal O 0 4.1891215118994296e-07
origin O 0 3.913369184260773e-08
, O 0 1.2299127938319998e-08
by O 0 1.2091875944975072e-08
paternal O 0 8.449806955468375e-06
uniparental B-Disease 0 0.0034511659760028124
disomy I-Disease 0 0.2865103781223297
( O 0 4.6556078814319335e-06
UPD B-Disease 1 0.9999996423721313
) O 0 1.0479771361815438e-07
15 O 0 1.5511773199250456e-08
, O 0 1.6555011805863273e-09
by O 0 5.248643741850856e-09
imprinting O 0 0.0009009165805764496
defects O 1 0.9792097806930542
, O 0 1.2453721609517743e-08
and O 0 6.152622855637446e-09
by O 0 3.069991150184137e-09
mutations O 0 3.818001914623892e-07
in O 0 3.4475191590388476e-09
the O 0 4.124411390193927e-08
UBE3A O 0 0.00011178432032465935
gene O 0 5.152185167389689e-06
. O 0 4.532886634933675e-07

UBE3A O 0 0.0008994592935778201
encodes O 0 1.821339719754178e-05
a O 0 2.967152283872565e-07
ubiquitin O 0 9.435016750103387e-07
- O 0 1.9068473875449854e-06
protein O 0 2.875917459732591e-07
ligase O 0 1.0545458906108252e-07
and O 0 2.8685592567967433e-08
shows O 0 2.4300521772602224e-07
brain O 0 1.6943067748798057e-05
- O 0 3.3914950563485036e-06
specific O 0 2.820929694280494e-07
imprinting O 0 2.991533256135881e-05
. O 0 5.382175345403084e-07

Here O 0 2.1116252355568577e-06
we O 0 6.900648941154941e-08
describe O 0 1.7042661681898608e-07
UBE3A O 0 1.7910795577336103e-05
coding O 0 6.741483230143785e-05
- O 0 0.0002385210245847702
region O 0 8.708791028766427e-06
mutations O 0 1.151060132542625e-05
detected O 0 5.855656013409316e-07
by O 0 9.7617491867652e-10
SSCP O 0 3.60582566827361e-06
analysis O 0 2.936338638903635e-08
in O 0 1.2112605141112454e-08
13 O 0 5.013693566979782e-07
AS B-Disease 1 0.9994725584983826
individuals O 0 5.561273663801103e-09
or O 0 6.565081633880254e-08
families O 0 3.601171627565236e-08
. O 0 1.3748127969392954e-07

Two O 0 7.696100396969996e-07
identical O 0 2.311649950570427e-06
de O 0 3.3162818908749614e-06
novo O 0 1.4237983123166487e-05
5 O 0 1.7633830395880068e-07
- O 0 7.898996955191251e-06
bp O 0 5.9781734307762235e-05
duplications O 0 2.1707933228753973e-06
in O 0 2.2805156874028398e-08
exon O 0 1.9860472093569115e-06
16 O 0 1.2851623409915192e-07
were O 0 2.456015124607802e-08
found O 0 9.406969070369087e-08
. O 0 1.4482220933587087e-07

Among O 0 8.572335019607635e-08
the O 0 5.995831386940154e-09
other O 0 1.2237392210678877e-09
11 O 0 2.067544135897492e-09
unique O 0 2.035784651965855e-09
mutations O 0 2.987116829444858e-07
, O 0 3.741604359674966e-09
8 O 0 9.007867340926623e-09
were O 0 1.7172676614052307e-09
small O 0 1.7703675192493051e-09
deletions O 0 8.470862553622283e-07
or O 0 1.1264554444778696e-07
insertions O 0 1.2884731404483318e-05
predicted O 0 5.218414298724383e-05
to O 0 2.2168838142988534e-07
cause O 0 5.836677701154258e-07
frameshifts O 0 3.737110455404036e-05
, O 0 3.065153819648003e-08
1 O 0 3.568876394410836e-08
was O 0 1.0145821249807341e-07
a O 0 1.2298987606129685e-08
mutation O 0 2.2723007475633494e-08
to O 0 1.7316972300562838e-09
a O 0 5.865703034402259e-09
stop O 0 6.807458703406155e-07
codon O 0 3.0889796676092374e-07
, O 0 2.5794635316600534e-09
1 O 0 4.6251140695119375e-09
was O 0 2.0263449584945192e-08
a O 0 6.847767686224415e-09
missense O 0 1.1734050531231333e-06
mutation O 0 1.9710303433839726e-07
, O 0 6.9231367305633285e-09
and O 0 1.6676910519208832e-08
1 O 0 4.1783130200201413e-07
was O 0 5.459661224449519e-06
predicted O 0 5.706993306375807e-06
to O 0 2.4375346185934177e-08
cause O 0 1.4465954656373015e-08
insertion O 0 4.5760039313336165e-08
of O 0 1.6566257254879702e-09
an O 0 7.15794712391471e-08
isoleucine O 0 0.021516669541597366
in O 0 4.046705726068467e-08
the O 0 5.769104749475673e-09
hect O 0 1.0610834806357161e-06
domain O 0 9.003555234698979e-09
of O 0 2.218788763830304e-10
the O 0 2.4033433021486417e-09
UBE3A O 0 1.2003519032077747e-06
protein O 0 1.778251146333787e-07
, O 0 1.6680463676976842e-09
which O 0 6.908386085413554e-10
functions O 0 1.0325537092015225e-09
in O 0 2.2365076457475652e-09
E2 O 0 1.270175630452286e-06
binding O 0 1.205135760073972e-07
and O 0 1.3563507650360407e-08
ubiquitin O 0 1.7338372515496303e-07
transfer O 0 2.4339533410966396e-07
. O 0 4.372725186385651e-07

Eight O 0 8.462497476102726e-07
of O 0 4.9352353315157416e-09
the O 0 2.479718652637075e-09
cases O 0 1.8566222337312865e-08
were O 0 1.99945500156673e-08
familial O 0 2.7626053906715242e-06
, O 0 2.0745414985867683e-07
and O 0 6.865150936619102e-08
five O 0 8.977306009683161e-08
were O 0 1.0567384833848337e-07
sporadic O 0 2.4081914489215706e-06
. O 0 5.601275461231126e-07

In O 0 3.6526361668620666e-07
two O 0 6.73258497840834e-08
familial O 0 1.8188020476372913e-05
cases O 0 8.547051493223989e-07
and O 0 7.37832266395344e-08
one O 0 7.137700919201961e-08
sporadic O 0 1.5081101309988298e-06
case O 0 1.7340637725737906e-07
, O 0 1.0176207432266438e-08
mosaicism O 0 1.6614638980172458e-06
for O 0 8.360109049476705e-09
UBE3A O 0 1.869057996373158e-05
mutations O 0 5.366367076931056e-06
was O 0 3.81351867417834e-07
detected O 0 2.4460908321088937e-07
in O 0 1.530924831349978e-09
the O 0 5.553133064495341e-09
mother O 0 5.576347916758095e-07
of O 0 6.569509936049656e-10
three O 0 2.6680248765842407e-07
AS B-Disease 1 0.9999991655349731
sons O 0 7.6259279921941925e-06
, O 0 2.202396709449772e-09
in O 0 6.362204096888036e-10
the O 0 1.9592110156452236e-09
maternal O 0 5.577859241157057e-08
grandfather O 0 3.943129556205349e-08
of O 0 9.62544932647802e-10
two O 0 2.053632499610103e-07
AS B-Disease 1 0.9999922513961792
first O 0 1.0322961543351994e-06
cousins O 0 2.1990540517435875e-06
, O 0 1.1490271845104871e-08
and O 0 4.9236992261114665e-09
in O 0 1.33914768163379e-09
the O 0 6.344853531459194e-09
mother O 0 5.337568040886254e-07
of O 0 1.2000287430424805e-09
an O 0 1.9139842777349259e-07
AS B-Disease 1 0.9999982118606567
daughter O 0 0.00022415525745600462
. O 0 4.0001711454351607e-07

The O 0 2.2569759039470227e-07
frequencies O 0 2.2515970954373188e-07
with O 0 6.8474412806551754e-09
which O 0 1.6737232044761186e-08
we O 0 1.3410705435035197e-08
detected O 0 1.0294770191876523e-07
mutations O 0 5.341570030736875e-08
were O 0 3.2661253701604664e-09
5 O 0 3.247576652043449e-09
( O 0 1.3999765791083973e-09
14 O 0 6.865422896851214e-09
% O 0 9.633605024816916e-10
) O 0 3.73979708312433e-10
of O 0 1.1623176726649476e-10
35 O 0 1.275340721917928e-08
in O 0 2.5874460352071083e-09
sporadic O 0 2.564420356065966e-07
cases O 0 2.13957349615157e-08
and O 0 2.1040293063379067e-08
8 O 0 6.696303245234958e-08
( O 0 1.4970849004924958e-09
80 O 0 2.252312558681524e-09
% O 0 9.118948374187141e-10
) O 0 1.7889716097396757e-10
of O 0 2.2948207223372208e-10
10 O 0 3.070373466584897e-08
in O 0 1.304479368968714e-08
familial O 0 5.978201897960389e-06
cases O 0 1.2900645174340752e-07
. O 0 1.743440058987744e-08
. O 0 2.0332872452399897e-07

The O 0 7.524544798798161e-06
hemochromatosis B-Disease 1 0.9999973773956299
845 O 0 4.769920269609429e-05
G O 0 0.00029980289400555193
- O 0 1.6602409232291393e-05
- O 0 5.7878714869730175e-06
> O 0 2.7497987886704323e-08
A O 0 1.6697979887680958e-08
and O 0 6.485908699005449e-09
187 O 0 3.485669974878647e-09
C O 0 1.5053642243856302e-07
- O 0 1.1415769449740765e-06
- O 0 1.1764453120122198e-05
> O 0 1.3614936733574723e-07
G O 0 1.0881835805776063e-05
mutations O 0 7.61707269703038e-07
: O 0 3.564303518999168e-09
prevalence O 0 1.8275075319706957e-07
in O 0 3.0364941672189616e-09
non O 0 9.971904546546284e-07
- O 0 7.961065421113744e-05
Caucasian O 0 8.331143908435479e-05
populations O 0 2.1275659491948318e-06
. O 0 3.196912530256668e-07

Hemochromatosis B-Disease 1 0.988734781742096
, O 0 8.223020813602488e-06
the O 0 1.2773872185789514e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 7.6083395583737e-08
iron I-Disease 0 0.04421079531311989
metabolism I-Disease 0 0.003842775709927082
, O 0 5.130240410267106e-08
leads O 0 2.378083365783823e-07
, O 0 2.0634439934497095e-08
if O 0 4.441106682406826e-08
untreated O 0 4.527168130152859e-06
, O 0 2.0642578757446017e-09
to O 0 2.2939653732123588e-08
progressive O 0 1.433347279089503e-05
iron B-Disease 0 0.22169524431228638
overload I-Disease 0 0.010932195000350475
and O 0 6.911508990015136e-06
premature B-Disease 0 3.2587173336651176e-05
death I-Disease 0 1.7946931620826945e-06
. O 0 3.675253879009688e-07

The O 0 1.3744598618359305e-05
hemochromatosis B-Disease 1 0.9999986886978149
gene O 0 0.0001526918786112219
, O 0 2.609294256217254e-07
HFE O 0 7.187733717728406e-05
, O 0 1.7211156944085815e-07
recently O 0 8.869923249221756e-07
has O 0 7.245223798690859e-08
been O 0 5.420526250077273e-08
identified O 0 1.6394956503518188e-07
, O 0 3.2480349521080143e-09
and O 0 3.663305214729462e-09
characterization O 0 8.003596008165914e-08
of O 0 4.200174097412912e-10
this O 0 3.2713001196782443e-09
gene O 0 1.9498627068514907e-07
has O 0 6.14467410287034e-08
shown O 0 2.5735580777563882e-08
that O 0 1.1292164980858388e-09
it O 0 5.7987694646044474e-09
contains O 0 5.952051629343202e-10
two O 0 3.7181773215877456e-09
mutations O 0 1.118367407570986e-07
that O 0 5.360926702557833e-10
result O 0 8.091168846036112e-10
in O 0 3.151123528777333e-10
amino O 0 7.628448095431395e-09
acid O 0 1.294693330322616e-08
substitutions O 0 7.27671434219701e-09
- O 0 1.96355163240014e-08
cDNA O 0 4.123278429801758e-08
nucleotides O 0 4.9036266602797696e-08
845 O 0 4.143618781426994e-08
G O 0 1.2621710538951447e-06
- O 0 7.519118980781059e-07
- O 0 1.3521555501938565e-06
> O 0 2.1613820067045708e-08
A O 0 4.241428896989419e-08
( O 0 2.650847541474377e-09
C282Y O 0 2.710525492943816e-08
) O 0 4.4181802660858693e-10
and O 0 5.807211933550604e-10
187 O 0 2.315490910120843e-09
C O 0 2.9466966111613146e-07
- O 0 3.364546955708647e-06
- O 0 5.325485471985303e-05
> O 0 7.468498779417132e-07
G O 0 2.6001083824667148e-05
( O 0 9.474743656312512e-09
H63D O 0 1.0665482477634214e-05
) O 0 2.3633598189576333e-08
. O 0 1.433929384120347e-07

Although O 0 8.390181028516963e-05
hemochromatosis B-Disease 1 0.9999994039535522
is O 0 1.419429622728785e-07
common O 0 3.2325118581866263e-08
in O 0 2.56876653281779e-08
Caucasians O 0 7.597812782478286e-06
, O 0 2.7046382911066758e-08
affecting O 0 3.7004987518685084e-08
> O 0 4.0984385663023204e-08
= O 0 5.086861847303226e-07
1 O 0 3.198327647169208e-07
/ O 0 2.7422258881415473e-06
300 O 0 4.220050531245079e-09
individuals O 0 3.0403465856032597e-10
of O 0 2.546125532632004e-10
northern O 0 1.2680307293067017e-07
European O 0 3.874965841532685e-07
origin O 0 4.594377855937637e-08
, O 0 3.4600571297005445e-08
it O 0 4.592117619495184e-08
has O 0 1.1213598583026396e-07
not O 0 9.210145535121228e-09
been O 0 5.405831338123335e-09
recognized O 0 8.171662790878997e-10
in O 0 4.5924808400599204e-10
other O 0 6.120692397360017e-09
populations O 0 8.948585161761002e-08
. O 0 2.2624519147029787e-07

The O 0 2.534297323109058e-07
present O 0 5.60847652764096e-08
study O 0 3.3538820609635422e-09
used O 0 5.651739076739659e-09
PCR O 0 5.628945132230001e-07
and O 0 2.2142072619857345e-09
restriction O 0 1.985143383009813e-09
- O 0 4.954071997076426e-08
enzyme O 0 5.326624830104265e-08
digestion O 0 9.497364317212487e-08
to O 0 7.772572807596134e-09
analyze O 0 2.9201025597558328e-08
the O 0 6.573169786250332e-10
frequency O 0 3.082866584236399e-08
of O 0 2.5785718005266745e-10
the O 0 2.416240540981107e-09
845 O 0 5.8487916732019585e-08
G O 0 4.1820949263637885e-06
- O 0 4.6987040036583494e-07
- O 0 6.253927153920813e-07
> O 0 5.798272084689415e-09
A O 0 1.2738042620696888e-08
and O 0 6.1416249863555095e-09
187 O 0 3.6469429698371414e-09
C O 0 1.2820188999285165e-07
- O 0 8.315732316077629e-07
- O 0 6.337929335131776e-06
> O 0 6.865595736371688e-08
G O 0 3.325285661048838e-06
mutations O 0 1.2779905489423982e-07
in O 0 3.5971541301194065e-09
HLA O 0 3.4460827009752393e-06
- O 0 7.330774565161846e-07
typed O 0 6.149036266833718e-07
samples O 0 2.814986821420007e-08
from O 0 8.484067337555246e-10
non O 0 3.7872059266419456e-08
- O 0 3.6846313378191553e-06
Caucasian O 0 2.531577592890244e-06
populations O 0 7.086519815402426e-08
, O 0 9.243966148098082e-10
comprising O 0 4.492981264814233e-10
Australian O 0 1.628505219564147e-09
Aboriginal O 0 9.172973491899938e-10
, O 0 3.479530552574772e-10
Chinese O 0 5.459763752213576e-10
, O 0 2.495718520734158e-09
and O 0 1.491675760689759e-08
Pacific O 0 1.775363642764205e-07
Islanders O 0 4.722274695723172e-07
. O 0 9.233630748894939e-08

Results O 0 0.00017976366507355124
showed O 0 1.4618083241657587e-06
that O 0 2.1412545070376154e-09
the O 0 1.5845578182904774e-09
845 O 0 1.0411752526806595e-07
G O 0 3.653743988252245e-05
- O 0 4.9085674618254416e-06
- O 0 8.214429726649541e-06
> O 0 1.9439170273471973e-08
A O 0 8.97905252372766e-08
mutation O 0 1.0295752161937344e-07
was O 0 4.576204659656469e-08
present O 0 1.2377440183897193e-09
in O 0 1.0723679721991175e-09
these O 0 4.4057932302443703e-10
populations O 0 4.370592332492151e-09
( O 0 7.053071460205729e-10
allele O 0 1.690144912913638e-08
frequency O 0 3.7472624114798236e-08
0 O 0 3.656833724718922e-09
. O 0 9.836059744472436e-10
32 O 0 3.111706003977588e-09
% O 0 5.309922501695041e-10
) O 0 4.085697058453519e-10
, O 0 4.516913509888809e-09
and O 0 2.9020183589523185e-08
, O 0 1.161135632088417e-08
furthermore O 0 2.795233555730192e-08
, O 0 4.535742448297242e-09
it O 0 4.782448215223667e-08
was O 0 4.5440057760970376e-07
always O 0 8.238711046715252e-09
seen O 0 1.5508813788756015e-08
in O 0 3.1742575234972037e-10
conjunction O 0 4.121271324208919e-09
with O 0 5.427020166592911e-09
HLA O 0 1.6580037481617182e-05
haplotypes O 0 5.578996820077009e-07
common O 0 2.4456749514456533e-08
in O 0 6.131302132672545e-09
Caucasians O 0 7.859605375415413e-07
, O 0 7.046500272167577e-09
suggesting O 0 1.5521569807219748e-08
that O 0 1.9148846952532494e-09
845 O 0 4.115547014293952e-08
G O 0 2.8770673452527262e-05
- O 0 1.234560022567166e-05
- O 0 4.682119833887555e-05
> O 0 2.631992117585469e-07
A O 0 4.280416760593653e-06
may O 0 3.3368553431500914e-06
have O 0 6.006865671537298e-09
been O 0 4.12517975334481e-09
introduced O 0 1.907670466039235e-09
into O 0 1.8598395046254268e-09
these O 0 3.2434890884225354e-10
populations O 0 3.3173761515570277e-09
by O 0 1.9787471661203426e-09
Caucasian O 0 1.6175523569472716e-06
admixture O 0 1.6923438579397043e-06
. O 0 4.0195672568188456e-07

187 O 0 6.537556146213319e-06
C O 0 1.760705708875321e-05
- O 0 3.3909338526427746e-05
- O 0 3.569278851500712e-05
> O 0 5.964865295027266e-07
G O 0 2.3696920834481716e-05
was O 0 1.1713304814975345e-07
present O 0 1.8017108915913127e-09
at O 0 4.224504301930665e-09
an O 0 9.32923516216988e-10
allele O 0 5.700123395513401e-08
frequency O 0 9.327249728130482e-08
of O 0 2.5062225628147417e-09
2 O 0 4.1744218037820247e-07
. O 0 3.9859290268395853e-07

68 O 0 4.852023266721517e-05
% O 0 7.772323584731566e-08
in O 0 6.268590091451642e-09
the O 0 3.3353819706150034e-09
two O 0 2.623095696208111e-08
populations O 0 3.260208103483819e-08
analyzed O 0 1.2434589962140308e-06
( O 0 5.0887414282385635e-09
Australian O 0 6.5190484122013e-09
Aboriginal O 0 2.3261323978118753e-09
and O 0 1.7840383614853295e-09
Chinese O 0 3.065637965704582e-09
) O 0 8.036097121078e-09
. O 0 4.8678149511260926e-08

In O 0 3.719700885085331e-07
the O 0 9.472774564756037e-09
Australian O 0 1.2350469091870764e-08
Aboriginal O 0 3.797888226131363e-09
samples O 0 6.3379350656589395e-09
, O 0 6.693334775320636e-10
187 O 0 2.148524025358256e-09
C O 0 1.1789984455390368e-07
- O 0 2.1468188151629874e-06
- O 0 2.4620978365419433e-05
> O 0 2.64855771092698e-07
G O 0 0.00011726256343536079
was O 0 7.080844284246268e-07
found O 0 1.5582674706138278e-08
to O 0 4.436888190184618e-09
be O 0 8.2205033891114e-09
associated O 0 5.6076925325498905e-09
with O 0 4.589558511014502e-09
HLA O 0 3.102300252066925e-05
haplotypes O 0 4.4880522409584955e-07
common O 0 2.9787928568225652e-08
in O 0 8.171760157438257e-09
Caucasians O 0 2.0370111997181084e-06
, O 0 1.8026776515966958e-08
suggesting O 0 9.37387056865191e-08
that O 0 3.5900939998612102e-09
it O 0 2.77620131328149e-08
was O 0 3.604312226457296e-08
introduced O 0 4.874613601657529e-09
by O 0 1.1754385242923604e-09
recent O 0 2.4793084918428576e-08
admixture O 0 1.751867216626124e-06
. O 0 2.8533517593132274e-07

In O 0 2.1250910720027605e-07
the O 0 2.4369104512089734e-09
Chinese O 0 1.0219693979962585e-09
samples O 0 1.1572178770791197e-08
analyzed O 0 2.742622662310623e-08
, O 0 1.1880041395073704e-09
187 O 0 5.882015319258471e-09
C O 0 1.4181510721300583e-07
- O 0 1.023645609166124e-06
- O 0 6.846673841209849e-06
> O 0 2.7846925831909175e-07
G O 0 6.46324479021132e-05
was O 0 7.710785894232686e-07
present O 0 3.062826658961626e-09
in O 0 3.707172568923056e-09
association O 0 1.015652117963839e-09
with O 0 2.186452963126584e-10
a O 0 9.694030467244374e-09
wide O 0 1.0660098581638522e-08
variety O 0 9.583102311694347e-09
of O 0 2.6751720838547044e-09
HLA O 0 1.9245586372562684e-05
haplotypes O 0 1.419440650352044e-06
, O 0 4.357789684661384e-09
showing O 0 3.3124333498335545e-08
this O 0 5.611220377232939e-10
mutation O 0 3.313223118084352e-08
to O 0 1.400356541836345e-08
be O 0 2.243305985416555e-08
widespread O 0 3.1935891708911868e-09
and O 0 2.7269118518802316e-08
likely O 0 2.5638277278972055e-08
to O 0 5.516354040224769e-09
predate O 0 2.0304079839661426e-07
the O 0 9.085666108354928e-10
more O 0 1.0443087505862536e-09
genetically O 0 4.831702327123821e-08
restricted O 0 5.374710454475462e-09
845 O 0 6.806439500905981e-08
G O 0 5.067618076282088e-06
- O 0 4.012606495962245e-06
- O 0 8.602867637819145e-06
> O 0 1.4669039671844075e-07
A O 0 5.49625440271484e-07
mutation O 0 2.953120656457031e-06
. O 0 1.641913200955969e-07

Genotype O 0 0.043393708765506744
- O 0 0.011851109564304352
phenotype O 0 0.0046708895824849606
correlations O 0 0.0002731723361648619
in O 0 1.2504186997830402e-05
attenuated B-Disease 1 0.9973546266555786
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999959468841553
coli I-Disease 1 0.9999988079071045
. O 0 3.030535845027771e-05

Germ O 0 0.012114501558244228
- O 0 0.00042998610297217965
line O 0 2.9582752176793292e-05
mutations O 0 3.098038860116503e-06
of O 0 3.92546306571262e-09
the O 0 3.7750684356296915e-08
tumor B-Disease 0 5.3941177611704916e-05
suppressor O 0 9.453065285924822e-05
APC O 0 3.71611095033586e-05
are O 0 5.206063136142802e-08
implicated O 0 1.3169992598704994e-05
in O 0 8.167414193849254e-07
attenuated B-Disease 1 0.9988597631454468
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999996423721313
coli I-Disease 1 1.0
( O 0 0.001875482965260744
AAPC B-Disease 1 0.9999998807907104
) O 0 4.7302665961979073e-07
, O 0 6.276701380869554e-09
a O 0 3.554040617359533e-08
variant O 0 0.0004815721185877919
of O 0 2.4196366211981513e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 1.0
( O 0 2.3013508325675502e-05
FAP B-Disease 0 2.5472134439041838e-05
) O 0 4.6886549398550414e-07
. O 0 6.254952609197062e-07

AAPC B-Disease 1 0.9999967813491821
is O 0 4.297017767385114e-06
recognized O 0 2.3450038355576908e-08
by O 0 1.1758982676468577e-09
the O 0 1.935595239643817e-09
occurrence O 0 8.437179843667764e-08
of O 0 4.961568489392221e-09
< O 0 3.268339696660405e-07
100 O 0 3.58020777468937e-08
colonic B-Disease 0 5.68056566407904e-06
adenomas I-Disease 0 9.656540350988507e-05
and O 0 2.4567228251726192e-08
a O 0 3.631077660770643e-08
later O 0 2.510300873836968e-06
onset O 0 3.547635060385801e-05
of O 0 0.001189619884826243
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.604465976219217e-07
age O 0 4.006003706535921e-08
> O 0 5.0704134224588415e-08
40 O 0 6.125015517000065e-08
years O 0 2.8019700337722497e-08
) O 0 2.960181433309117e-08
. O 0 1.373507529933704e-07

The O 0 1.8503125431834633e-07
aim O 0 3.034235476206959e-07
of O 0 1.8415056146636744e-09
this O 0 3.3228790830008847e-09
study O 0 3.9119791850339425e-09
was O 0 8.166045262214539e-08
to O 0 2.1679632311588648e-08
assess O 0 5.991524290038797e-07
genotype O 0 6.058076905901544e-05
- O 0 0.00023312895791605115
phenotype O 0 0.00031066202791407704
correlations O 0 1.669372977630701e-05
in O 0 3.6178887512505753e-06
AAPC B-Disease 1 0.9999992847442627
families O 0 4.093622010259423e-06
. O 0 7.42275688025984e-07

By O 0 2.6990500145984697e-07
protein O 0 2.7689277430908987e-06
- O 0 2.3584647351526655e-05
truncation O 0 3.977304368163459e-05
test O 0 8.682583825248003e-07
( O 0 1.1915813225016336e-08
PTT O 0 4.766920937981922e-06
) O 0 3.348557653382045e-09
assay O 0 3.4650561531179846e-08
, O 0 5.172987593837775e-10
the O 0 6.368905958176185e-10
entire O 0 1.125555115777388e-08
coding O 0 2.4801229301374406e-06
region O 0 1.2100301205464348e-07
of O 0 4.054891700189245e-10
the O 0 5.902919486544533e-09
APC B-Disease 0 2.0529355992948695e-07
gene O 0 3.7709661171447806e-08
was O 0 2.7533886282071762e-08
screened O 0 8.45059560106165e-08
in O 0 1.8790082823016974e-09
affected O 0 1.3272478227577267e-08
individuals O 0 8.142631013896562e-10
from O 0 1.3538695498027664e-08
11 O 0 1.6927118622334092e-06
AAPC B-Disease 1 0.9999978542327881
kindreds O 0 0.00010175773059017956
, O 0 7.40948848942935e-08
and O 0 9.34407395902781e-09
their O 0 2.653732344981563e-08
phenotypic O 0 1.3888303556086612e-06
differences O 0 6.775875931452902e-07
were O 0 2.8623213665923686e-07
examined O 0 1.760180225574004e-06
. O 0 4.328285854171554e-07

Five O 0 2.1804992229590425e-06
novel O 0 3.7261665966070723e-06
germ O 0 0.00047768032527528703
- O 0 0.000454868859378621
line O 0 0.00042553822277113795
APC B-Disease 0 2.5374039978487417e-05
mutations O 0 4.320761036069598e-06
were O 0 2.268576437813863e-08
identified O 0 7.335776075478861e-08
in O 0 6.845469080474231e-09
seven O 0 2.7567315896703803e-07
kindreds O 0 5.2116312872385606e-05
. O 0 1.0488095085747773e-06

Mutations O 0 0.0008723621722310781
were O 0 4.168685450167686e-07
located O 0 8.761807634982688e-08
in O 0 4.404761888565645e-09
three O 0 3.258944225592586e-09
different O 0 1.9875641132927058e-09
regions O 0 1.6835171479101518e-08
of O 0 7.067992302545179e-10
the O 0 1.1846650771474287e-08
APC B-Disease 0 4.763230947446573e-07
gene O 0 4.602034664458188e-08
( O 0 1.5432145561433686e-09
1 O 0 7.23747239916861e-09
) O 0 3.1084135265757595e-09
at O 0 2.1812775585772215e-08
the O 0 5.939647440555973e-09
5 O 0 4.428055433436384e-08
end O 0 1.4067875042655942e-07
spanning O 0 4.194750502506395e-08
exons O 0 2.983723277338868e-07
4 O 0 2.777149354926678e-08
and O 0 7.762142928413596e-09
5 O 0 9.164723202559344e-09
, O 0 5.779149159224062e-09
( O 0 6.84045375898279e-10
2 O 0 7.853865113816028e-09
) O 0 1.166240104488736e-09
within O 0 9.116322141622391e-10
exon O 0 1.114832031134938e-07
9 O 0 1.9383749361168157e-07
, O 0 5.000711400526825e-09
and O 0 1.6557924809035285e-08
( O 0 3.3703049240330074e-09
3 O 0 7.551896885615861e-08
) O 0 4.7452193285835165e-09
at O 0 6.191474000161179e-08
the O 0 1.540421479262477e-08
3 O 0 4.6294849198602606e-07
distal O 0 1.3773083992418833e-05
end O 0 6.45978104785172e-07
of O 0 2.069315385710979e-09
the O 0 2.672353360821944e-08
gene O 0 1.3288153013490955e-06
. O 0 1.7626786075197742e-07

Variability O 0 0.0003034480905625969
in O 0 9.347160556671952e-08
the O 0 9.123285238388235e-09
number O 0 2.3317534214584157e-07
of O 0 4.0496095607522875e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.0003506491775624454
most O 0 1.25748087498323e-08
apparent O 0 1.11190566087771e-07
in O 0 1.8489739739280253e-09
individuals O 0 1.8763142428657176e-10
with O 0 1.2926518744293958e-09
mutations O 0 3.8049526551731105e-07
in O 0 3.755388888748712e-09
region O 0 4.6022717015148373e-07
1 O 0 2.69637695282654e-07
, O 0 2.4145371924078063e-08
and O 0 1.2656408898692462e-07
upper O 0 6.826475146226585e-05
- O 1 0.9994914531707764
gastrointestinal O 1 0.6839963793754578
manifestations O 0 9.384186341776513e-06
were O 0 3.395055969690475e-08
more O 0 1.8853132388585436e-08
severe O 0 5.53128529645619e-07
in O 0 4.8160129217933445e-09
them O 0 4.8032269717168674e-08
. O 0 2.8741570190504717e-07

In O 0 4.40705008486475e-07
individuals O 0 7.59985230303073e-09
with O 0 2.6642394956866156e-09
mutations O 0 5.879302875655412e-07
in O 0 1.6379821943246498e-08
either O 0 1.3145067612185812e-07
region O 0 8.918866569729289e-07
2 O 0 7.31963211819675e-07
or O 0 1.8662194634089246e-07
region O 0 2.5358542643516557e-07
3 O 0 6.452373924048516e-08
, O 0 2.0222359342625396e-09
the O 0 4.764243444199678e-10
average O 0 1.4665844538797046e-08
number O 0 3.2388236537173043e-09
of O 0 2.7063395968696113e-09
adenomas B-Disease 0 4.188257298665121e-05
tended O 0 4.5983148311279365e-07
to O 0 3.3359622619855145e-08
be O 0 4.182877688663211e-08
lower O 0 3.684620537569572e-07
than O 0 6.22491080903842e-09
those O 0 9.712458615140918e-10
in O 0 5.811643943864908e-10
individuals O 0 9.06471772643691e-11
with O 0 1.4376634327462057e-09
mutations O 0 2.6913414785667555e-07
in O 0 6.03490946105012e-09
region O 0 5.438710672933667e-07
1 O 0 4.709133918368025e-07
, O 0 1.4879844911774853e-08
although O 0 5.6504023682180105e-09
age O 0 5.747643694320459e-09
at O 0 6.421189624461476e-08
diagnosis O 0 6.780383046134375e-06
was O 0 6.198208524210713e-08
similar O 0 2.7060984564286628e-08
. O 0 1.9552926744381693e-07

In O 0 3.9092728911782615e-06
all O 0 1.0296110986018903e-06
AAPC B-Disease 1 0.9999953508377075
kindreds O 0 0.00012854469241574407
, O 0 9.129864864121373e-09
a O 0 5.920973045192568e-09
predominance O 0 1.7942910801593825e-07
of O 0 3.499407341678307e-08
right O 0 0.002392013091593981
- O 1 0.9999990463256836
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.028918473049998283
rectal B-Disease 1 0.9999829530715942
polyp I-Disease 0 0.4826255142688751
sparing O 0 2.0099249013583176e-05
was O 0 2.2233678009797586e-06
observed O 0 8.142403089550498e-07
. O 0 3.542874082995695e-07

No O 0 9.936180140357465e-05
desmoid B-Disease 1 0.9707903265953064
tumors I-Disease 1 1.0
were O 0 1.8222948483526125e-06
found O 0 7.268754842471026e-08
in O 0 1.029710272604234e-08
these O 0 3.096733891538861e-08
kindreds O 0 3.735967038664967e-05
. O 0 5.545535373130406e-07

Our O 0 1.4458859141086577e-06
data O 0 5.726815857087786e-07
suggest O 0 4.3004881433716946e-08
that O 0 5.596985985789615e-09
, O 0 1.437853480723561e-08
in O 0 1.4445942042584647e-07
AAPC B-Disease 1 0.9999998807907104
families O 0 5.7178286994030714e-08
, O 0 9.805826151065844e-10
the O 0 2.4931290365515224e-10
location O 0 5.046014450726943e-08
of O 0 5.488068333114882e-10
the O 0 3.573515172661246e-08
APC B-Disease 0 6.159066106192768e-05
mutation O 0 4.524776613834547e-06
may O 0 6.145788233880012e-07
partially O 0 1.6330088783433894e-06
predict O 0 3.3120579701062525e-07
specific O 0 2.6850752732343608e-08
phenotypic O 0 2.7062951630796306e-06
expression O 0 1.128155645346851e-06
. O 0 4.996576308258227e-07

This O 0 6.929824394319439e-07
should O 0 3.8825891834903814e-08
help O 0 3.257092817676721e-09
in O 0 8.679034158021182e-10
the O 0 8.898046188754449e-10
design O 0 2.84889523527454e-07
of O 0 5.4548738859239165e-09
tailored O 0 1.2368099078230443e-06
clinical O 0 2.0160459826001897e-06
- O 0 2.9285358323249966e-05
management O 0 1.4235916978577734e-06
protocols O 0 2.3875541543816325e-08
in O 0 3.892298428009866e-10
this O 0 2.454963732301252e-10
subset O 0 1.7703854382489226e-08
of O 0 5.0912558613447345e-09
FAP B-Disease 0 1.4814083897363162e-06
patients O 0 2.633915414662624e-07
. O 0 4.724403090961005e-09
. O 0 7.865020990038829e-08

Wilms B-Disease 0 0.05677124485373497
' I-Disease 0 0.0001730961084831506
tumor I-Disease 0 9.20067832339555e-05
1 O 0 1.0982181919416689e-07
and O 0 3.583842556054151e-08
Dax O 0 0.23280033469200134
- O 0 7.764930160192307e-06
1 O 0 7.389561318404958e-08
modulate O 0 2.8355000836199906e-07
the O 0 4.580550605481903e-09
orphan O 0 1.1634527652404358e-07
nuclear O 0 8.014561103664164e-07
receptor O 0 4.0817752733346424e-08
SF O 0 9.221011714544147e-05
- O 0 7.457346100636641e-07
1 O 0 1.8293587089601715e-08
in O 0 9.085770469319243e-10
sex O 0 1.4717124408036852e-08
- O 0 6.506305538778179e-08
specific O 0 6.4827920809307216e-09
gene O 0 2.677680583929032e-07
expression O 0 1.448578501594966e-07
. O 0 8.4640007003145e-08

Products O 0 3.932302661269205e-06
of O 0 2.968889312171541e-08
steroidogenic O 0 2.6376887944934424e-06
factor O 0 7.17267951699796e-08
1 O 0 1.302663577007479e-07
( O 0 1.1057702664629687e-07
SF O 0 0.01596822217106819
- O 0 6.257319910218939e-06
1 O 0 3.28689452544495e-07
) O 0 6.95150603746697e-09
and O 0 1.1956295509207848e-07
Wilms B-Disease 0 0.00014897534856572747
tumor I-Disease 0 1.414321013726294e-05
1 O 0 7.728007034302209e-08
( O 0 7.185205763704516e-09
WT1 O 0 3.1467839107790496e-06
) O 0 3.159219552628656e-09
genes O 0 1.5456132373969922e-08
are O 0 6.608859570711445e-10
essential O 0 5.010067471999946e-09
for O 0 5.077562370559008e-09
mammalian O 0 1.170072778222675e-06
gonadogenesis O 0 1.1702663869073149e-05
prior O 0 3.817193316990597e-08
to O 0 2.5738327025237595e-08
sexual O 0 5.8757386511842924e-08
differentiation O 0 1.9151637786762876e-07
. O 0 1.7544107322464697e-07

In O 0 1.1730022606570856e-06
males O 0 3.034573978766275e-07
, O 0 1.0736540900779801e-07
SF O 0 0.1895235925912857
- O 0 4.579311280394904e-05
1 O 0 1.5907549766325246e-07
participates O 0 2.551889544122332e-08
in O 0 2.910164775826729e-09
sexual O 0 3.630944434007688e-09
development O 0 6.231429261482901e-10
by O 0 5.717288309448065e-10
regulating O 0 2.5879016263274934e-08
expression O 0 1.2457785025787871e-08
of O 0 9.783222010284476e-10
the O 0 1.43580072275995e-08
polypeptide O 0 1.0172053407586645e-05
hormone O 0 4.074977084655984e-07
Mullerian O 0 1.3881074210075894e-06
inhibiting O 0 1.1938947181988624e-06
substance O 0 1.3045959121882333e-06
( O 0 1.2495436862991482e-07
MIS O 0 0.006581997033208609
) O 0 2.0955272361788957e-07
. O 0 3.337630687383353e-07

Here O 0 4.749622348754201e-06
, O 0 1.060724770240995e-07
we O 0 2.862645231971328e-08
show O 0 1.035366850032915e-07
that O 0 9.103000131460703e-09
WT1 O 0 1.5894425814622082e-05
- O 0 1.926020013343077e-05
KTS O 0 2.884022796934005e-05
isoforms O 0 2.0856545290826034e-07
associate O 0 1.236084301581286e-07
and O 0 6.428577226103016e-09
synergize O 0 1.3598914847534616e-06
with O 0 7.717386552030803e-08
SF O 1 0.6787843704223633
- O 0 4.1458089981460944e-05
1 O 0 1.26199864780574e-07
to O 0 1.7095917570486563e-08
promote O 0 1.4426626648855745e-07
MIS O 0 0.004366373177617788
expression O 0 2.205756118200952e-06
. O 0 2.9422429292935703e-07

In O 0 9.465839525546471e-07
contrast O 0 1.655845267123368e-06
, O 0 8.863702305461629e-08
WT1 O 0 7.153202750487253e-05
missense O 0 0.00011452748731244355
mutations O 0 2.8528385882964358e-05
, O 0 6.8644538941953215e-09
associated O 0 8.873678680743069e-09
with O 0 5.809807301915271e-09
male B-Disease 0 2.3561506168334745e-06
pseudohermaphroditism I-Disease 1 0.9999995231628418
in O 0 1.8859103647628217e-06
Denys B-Disease 1 0.9995476603507996
- I-Disease 1 0.9999064207077026
Drash I-Disease 1 0.9999605417251587
syndrome I-Disease 1 0.9999948740005493
, O 0 8.693722008956684e-08
fail O 0 4.765148275964748e-07
to O 0 8.693750608301798e-09
synergize O 0 1.1776957762776874e-05
with O 0 2.5918046731021605e-07
SF O 1 0.9773831367492676
- O 0 0.00010807779472088441
1 O 0 2.1008088424423477e-06
. O 0 6.285791300797428e-07

Additionally O 0 2.8175816169095924e-06
, O 0 3.914488644340963e-08
the O 0 1.1779909492304341e-08
X O 0 0.000503978633787483
- O 0 0.00013352870882954448
linked O 0 0.00011367446859367192
, O 0 2.486113181987548e-08
candidate O 0 4.913466611355943e-08
dosage O 0 4.876247885476914e-07
- O 0 9.556654276821064e-07
sensitive O 0 1.5747236830065958e-06
sex O 0 1.2478764688239607e-07
- O 0 3.201892297965969e-07
reversal O 0 4.74681513651376e-07
gene O 0 8.268026618907243e-08
, O 0 2.474974447608247e-09
Dax O 0 0.011001807637512684
- O 0 2.0282882360334042e-06
1 O 0 3.9846359101147755e-08
, O 0 2.4251420871479468e-09
antagonizes O 0 1.617319611568746e-07
synergy O 0 6.046525413694326e-08
between O 0 1.3538023146963951e-08
SF O 0 0.042582347989082336
- O 0 6.979580120969331e-06
1 O 0 1.5884991455550335e-07
and O 0 4.767875694255963e-08
WT1 O 0 1.094050958272419e-06
, O 0 2.981132896096028e-09
most O 0 7.632970366877601e-10
likely O 0 3.8468366270194565e-09
through O 0 3.275069382357998e-10
a O 0 5.469626529475136e-09
direct O 0 2.0951230084165218e-08
interaction O 0 1.1617315998080358e-08
with O 0 7.849076411048372e-08
SF O 1 0.9718154668807983
- O 0 4.835550862480886e-05
1 O 0 1.349956164631294e-06
. O 0 5.795034780931019e-07

We O 0 3.796546707235393e-06
propose O 0 1.7463942185713677e-06
that O 0 3.3536469601358476e-08
WT1 O 0 8.373472155653872e-06
and O 0 3.1462627703149337e-07
Dax O 1 0.7869962453842163
- O 0 6.179493357194588e-05
1 O 0 2.943115475773084e-07
functionally O 0 4.928291446049116e-07
oppose O 0 1.1240875785745175e-08
each O 0 2.092151119015284e-09
other O 0 1.403944849265315e-09
in O 0 4.237537432061345e-09
testis O 0 1.92878383131756e-06
development O 0 2.8590751988133434e-09
by O 0 3.73555009147708e-09
modulating O 0 5.217522357270354e-06
SF O 0 0.42250171303749084
- O 0 3.725691567524336e-05
1 O 0 2.1725431906816084e-06
- O 0 3.977369124186225e-05
mediated O 0 6.582502828678116e-05
transactivation O 0 2.7528207283467054e-05
. O 0 3.4737848153554296e-08
. O 0 1.4774562373531808e-07

A O 0 1.8421022787151742e-06
mouse O 0 1.0032801583292894e-05
model O 0 2.02010119210172e-06
for O 0 3.2511936751689063e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
imprinting O 0 0.0029985751025378704
- O 0 0.00026148633332923055
centre O 0 6.685229891445488e-05
mutations O 0 5.484892972162925e-05
. O 0 4.5337293386182864e-07

Imprinting O 0 0.0003540056059136987
in O 0 4.317978437029524e-07
the O 0 7.167113835748751e-08
15q11 O 0 2.963624638141482e-06
- O 0 1.2699219041678589e-05
q13 O 0 1.1662760925901239e-06
region O 0 8.521342920175812e-08
involves O 0 8.026584730203012e-09
an O 0 3.5135176990053196e-09
imprinting O 0 2.2014230580680305e-06
centre O 0 7.085491233738139e-06
( O 0 2.9639441123663346e-08
IC O 0 6.202818894962547e-06
) O 0 5.774543065939497e-09
, O 0 1.978826436044301e-09
mapping O 0 1.341035300583826e-07
in O 0 1.4079573062986128e-08
part O 0 3.358697853172998e-08
to O 0 3.105096979538757e-08
the O 0 9.363395392369966e-09
promoter O 0 2.5837643988779746e-06
and O 0 1.1545590261619054e-08
first O 0 1.7631535342843563e-08
exon O 0 4.3741138711084204e-07
of O 0 1.0306140829641208e-08
SNRPN O 0 8.099443948594853e-05
. O 0 4.5258198611008993e-07

Deletion O 0 0.00015216352767311037
of O 0 1.1157765555935839e-07
this O 0 2.3977127838747947e-08
IC O 0 2.7913985832128674e-05
abolishes O 0 4.309390533308033e-06
local O 0 3.5595629555018604e-08
paternally O 0 5.725778464693576e-07
derived O 0 1.3641081153537016e-08
gene O 0 1.5520627982823498e-07
expression O 0 7.853194716744838e-08
and O 0 5.242903000635124e-08
results O 0 6.120197667769389e-06
in O 0 2.6678653739509173e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.3932111869507935e-05
PWS B-Disease 1 0.999998927116394
) O 0 6.851336138424813e-07
. O 0 3.7455302503985877e-07

We O 0 3.0897417673259042e-06
have O 0 1.52126187202839e-08
created O 0 2.6516162598966275e-09
two O 0 5.71458746989606e-09
deletion O 0 1.9816843632725067e-06
mutations O 0 2.0774527911271434e-06
in O 0 2.9044494809227217e-08
mice O 0 3.8539925299119204e-05
to O 0 3.3701380743877962e-06
understand O 0 1.2994456483284011e-05
PWS B-Disease 1 0.9999998807907104
and O 0 9.859021332658813e-08
the O 0 1.2600637200321785e-09
mechanism O 0 1.2040645813726769e-08
of O 0 1.7775169114386813e-09
this O 0 3.503955881001275e-08
IC O 0 0.0001645747834118083
. O 0 5.30329828052345e-07

Mice O 0 0.009861316531896591
harbouring O 0 0.000313590164296329
an O 0 9.227925801269521e-08
intragenic O 0 1.9573781173676252e-05
deletion O 0 6.738186129950918e-06
in O 0 2.226192563625773e-08
Snrpn O 0 1.8221457139588892e-05
are O 0 2.238847862656712e-08
phenotypically O 0 3.3480725960544078e-06
normal O 0 5.707030368284904e-07
, O 0 7.721946637673227e-09
suggesting O 0 4.709614387365946e-08
that O 0 4.881144377577584e-09
mutations O 0 1.6073083486389805e-07
of O 0 1.7972215937689384e-09
SNRPN O 0 0.00013730002683587372
are O 0 1.2867489296297663e-08
not O 0 4.743436754495178e-09
sufficient O 0 8.155566000311865e-09
to O 0 8.160938591572631e-08
induce O 0 8.531458661309443e-06
PWS B-Disease 1 0.9999864101409912
. O 0 2.739079036473413e-06

Mice O 0 0.0009641745127737522
with O 0 3.027474093642013e-08
a O 0 2.7730576945828034e-08
larger O 0 4.474581416502588e-08
deletion O 0 1.3980367157273577e-06
involving O 0 4.040841883323765e-09
both O 0 8.238020043904726e-09
Snrpn O 0 4.929254828311969e-06
and O 0 2.187969627698294e-08
the O 0 3.7472624114798236e-08
putative O 0 0.0001805857173167169
PWS O 1 0.9999998807907104
- O 0 0.010517776012420654
IC O 0 8.984855958260596e-05
lack O 0 2.039477919879573e-08
expression O 0 6.351391856895816e-09
of O 0 2.5239804690713186e-10
the O 0 4.262496577922548e-09
imprinted O 0 1.4590323189622723e-05
genes O 0 8.479123039251135e-07
Zfp127 O 0 8.324314876517747e-06
( O 0 9.00245655799381e-09
mouse O 0 3.1469289751839824e-07
homologue O 0 1.5416244423249736e-06
of O 0 1.6477274655812835e-08
ZNF127 O 0 8.225913916248828e-05
) O 0 3.335217968469806e-08
, O 0 1.3650347518989747e-08
Ndn O 0 1.0231595297227614e-05
and O 0 2.706888402315144e-08
Ipw O 0 1.2219087466291967e-06
, O 0 1.8568560022913516e-08
and O 0 1.5911366446630382e-08
manifest O 0 2.6345034598307393e-07
several O 0 2.7626667620239687e-09
phenotypes O 0 2.0736770522944425e-07
common O 0 1.6686398396359436e-07
to O 0 1.0888416909438092e-05
PWS B-Disease 1 1.0
infants O 0 0.006734024733304977
. O 0 2.8775278337889176e-07

These O 0 3.1943497447173286e-07
data O 0 2.3148987793319975e-07
demonstrate O 0 1.6253409285127418e-08
that O 0 1.1773164665385139e-09
both O 0 1.0454606069743022e-09
the O 0 6.130366436707391e-09
position O 0 1.9298515496757318e-07
of O 0 5.976212857916607e-10
the O 0 1.1070508065813556e-08
IC O 0 1.788193367247004e-05
and O 0 3.583132013318391e-08
its O 0 2.0034251591027896e-08
role O 0 1.985976494367492e-09
in O 0 7.191550133178737e-10
the O 0 7.901778120711356e-10
coordinate O 0 5.110200973490464e-08
expression O 0 7.148720726490865e-09
of O 0 2.195659487558288e-10
genes O 0 9.375905385411443e-09
is O 0 1.603379762293855e-09
conserved O 0 9.232165254502434e-09
between O 0 9.369612641307867e-09
mouse O 0 1.4925251889508218e-05
and O 0 1.1007258535755682e-06
human O 0 1.9386301630675007e-07
, O 0 4.3198237875685663e-08
and O 0 3.484448640733717e-08
indicate O 0 3.255032510196543e-08
that O 0 1.1353542550551765e-09
the O 0 1.968001095420391e-09
mouse O 0 4.736821210826747e-07
is O 0 4.106872175668741e-09
a O 0 6.166439359134301e-09
suitable O 0 4.4261472709195004e-08
model O 0 1.2847726793552283e-07
system O 0 2.5626642141673983e-08
in O 0 7.474096896942228e-09
which O 0 3.8320749240483565e-08
to O 0 2.230753182175249e-08
investigate O 0 7.65014362968941e-09
the O 0 4.677471188152538e-10
molecular O 0 6.969255839095467e-09
mechanisms O 0 1.9120671712613557e-09
of O 0 5.756175536220098e-10
imprinting O 0 2.591747715996462e-06
in O 0 4.625257332691035e-08
this O 0 9.576925918963752e-09
region O 0 1.228159760557901e-07
of O 0 5.983786244279088e-10
the O 0 5.680421466536245e-09
genome O 0 2.1487511503437418e-07
. O 0 1.0641734604632802e-08
. O 0 6.806880747944888e-08

Mutations O 0 0.0001420688786311075
of O 0 3.480409915823657e-08
the O 0 1.1437358615751236e-08
ATM O 0 3.96539326175116e-05
gene O 0 1.3012385124966386e-06
detected O 0 1.2173121604064363e-06
in O 0 1.7008622066327916e-08
Japanese O 0 8.90603696461767e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.8432245850563049
: O 0 1.0421700835649972e-08
possible O 0 1.246729297577076e-08
preponderance O 0 6.281039333089211e-08
of O 0 7.70373154157511e-10
the O 0 5.720978357715012e-09
two O 0 8.923701244611948e-08
founder O 0 8.536236236977857e-06
mutations O 0 9.83449012892379e-07
4612del165 O 0 2.2471566296644596e-07
and O 0 2.2300852720036346e-08
7883del5 O 0 1.5717859014330315e-06
. O 0 2.6538953079580097e-07

The O 0 2.4853131890267832e-06
ATM O 0 0.000716166861820966
( O 0 5.89475939705153e-06
A O 1 0.9999620914459229
- O 1 0.9999878406524658
T O 1 1.0
, O 0 1.7319928247161442e-07
mutated O 0 4.3479292344272835e-07
) O 0 3.393151093433744e-09
gene O 0 3.765151745938056e-08
on O 0 1.349240079662195e-07
human O 0 3.2376027547798003e-07
chromosome O 0 0.00015468928904738277
11q22 O 0 1.2648034498852212e-05
. O 0 8.585340651734441e-07

3 O 0 1.0916081919276621e-05
has O 0 7.101889991645294e-07
recently O 0 4.395272696910979e-07
been O 0 1.2002629112828345e-08
identified O 0 2.2535253663136245e-08
as O 0 8.681533825161125e-10
the O 0 7.948819935599261e-10
gene O 0 5.968517768906167e-08
responsible O 0 2.8784574723772494e-08
for O 0 1.0971118458158458e-09
the O 0 4.554313903781804e-08
human O 0 3.9512837247457355e-05
recessive B-Disease 1 0.9999983310699463
disease I-Disease 1 0.9999997615814209
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.00022964549134485424
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
) O 0 7.643698722858971e-07
. O 0 1.8116642763743585e-07

In O 0 5.940476626165037e-07
order O 0 3.2768348035006056e-08
to O 0 7.536453239254115e-09
define O 0 7.264735302214831e-08
the O 0 3.6738008191150584e-09
types O 0 4.3569112762043005e-08
of O 0 1.2794973969221246e-08
disease O 0 9.972450061468408e-05
- O 0 5.521207640413195e-05
causing O 0 8.507126949552912e-06
ATM O 0 5.180933294468559e-05
mutations O 0 1.6612373201496666e-06
in O 0 4.0295282666136245e-09
Japanese O 0 5.707291848011664e-07
A B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 3.6208133678883314e-05
as O 0 6.528479978840096e-09
well O 0 3.092853972930243e-09
as O 0 4.548226240075337e-09
to O 0 4.097701733485337e-09
look O 0 2.7023073556620147e-08
for O 0 1.9492920610986175e-09
possible O 0 1.903429769356535e-08
mutational O 0 7.843207754376635e-07
hotspots O 0 1.2941509339725599e-06
, O 0 2.0510523057737373e-08
reverse O 0 3.4542094908829313e-06
- O 0 6.615659913222771e-06
transcribed O 0 5.234577201918e-06
RNA O 0 8.95259759658984e-08
derived O 0 7.669282098277108e-09
from O 0 1.3994480019263733e-09
ten O 0 2.3074239408060748e-08
patients O 0 1.2950316374826798e-08
belonging O 0 3.4080953614790133e-09
to O 0 2.249543440413504e-09
eight O 0 5.4177946573474856e-09
unrelated O 0 3.293941830406766e-08
Japanese O 0 3.4699280604399974e-07
A B-Disease 1 0.999904990196228
- I-Disease 1 0.9998465776443481
T I-Disease 1 1.0
families O 0 2.3668474113947013e-07
was O 0 8.775452329246036e-07
analyzed O 0 1.3503135676273814e-07
for O 0 2.387079423016303e-09
mutations O 0 3.05794820576466e-08
by O 0 4.5569767403996764e-10
the O 0 1.8192738426847654e-09
restriction O 0 4.334547654138987e-08
endonuclease O 0 1.2030359357595444e-06
fingerprinting O 0 1.4907307104294887e-06
method O 0 5.484593543769734e-07
. O 0 4.3522683768060233e-07

As O 0 4.550182438833872e-06
has O 0 3.060650328734482e-07
been O 0 9.069070472378371e-08
reported O 0 5.781278673566703e-07
by O 0 1.2765715151630275e-09
others O 0 2.7564151849901464e-08
, O 0 3.5610823179155204e-09
mutations O 0 2.5267189229793985e-08
that O 0 4.909265216568315e-10
lead O 0 1.2662368931160017e-08
to O 0 5.302456251854437e-09
exon O 0 5.494545689543884e-07
skipping O 0 1.4288964393927017e-06
or O 0 1.0092818456541863e-06
premature O 0 8.413426257902756e-07
protein O 0 1.426005979965339e-07
truncation O 0 4.117614480492193e-06
were O 0 5.137976799574062e-08
also O 0 1.509630465079681e-08
predominant O 0 1.996959184680236e-07
in O 0 6.377394168310957e-09
our O 0 1.210517268646072e-07
mutants O 0 3.858327545458451e-06
. O 0 1.398533981955552e-07

Six O 0 3.3574622193555115e-07
different O 0 2.6035168687599253e-08
mutations O 0 1.4523895970341982e-06
were O 0 5.7158768385079384e-08
identified O 0 9.462177530394911e-08
on O 0 1.8699891768392263e-07
12 O 0 1.7871384372369903e-08
of O 0 5.364752531100692e-10
the O 0 4.477823445370177e-09
16 O 0 1.6860083462688635e-07
alleles O 0 2.508108707388601e-07
examined O 0 1.6189829921131604e-06
. O 0 2.680368424989865e-07

Four O 0 2.811110562106478e-06
were O 0 1.7918355865731428e-07
deletions O 0 3.749296979549399e-07
involving O 0 1.0008011308570985e-08
a O 0 9.138579315504103e-08
loss O 0 1.1949449572057347e-06
of O 0 1.0071927736277075e-09
a O 0 2.718664759981948e-08
single O 0 2.585327081305877e-07
exon O 0 9.407270908923238e-07
exon O 0 7.92922321579681e-07
7 O 0 7.955819825156141e-08
, O 0 3.0051792165863844e-09
exon O 0 2.19489592723221e-07
16 O 0 1.6977830696873752e-08
, O 0 2.354176187324697e-09
exon O 0 6.954777518330957e-07
33 O 0 9.809108547642609e-08
or O 0 8.409273277720786e-08
exon O 0 8.067157978075556e-06
35 O 0 8.402088838010968e-07
. O 0 5.310155870574818e-07

The O 0 5.641660436594975e-07
others O 0 3.0883524004821084e-07
were O 0 1.6077045472684404e-08
minute O 0 4.1342321566162354e-08
deletions O 0 3.267916213189892e-07
, O 0 7.050533490371436e-09
4649delA O 0 1.1506308794650977e-07
in O 0 2.301730583909034e-09
exon O 0 4.780578706231609e-07
33 O 0 6.901557014771242e-08
and O 0 4.248179141796982e-09
7883del5 O 0 8.26842097012559e-08
in O 0 9.723473581857434e-09
exon O 0 2.845378276106203e-06
55 O 0 6.193546937538486e-07
. O 0 2.691824363409978e-07

The O 0 6.213655865394685e-07
mutations O 0 6.454223239416024e-06
4612del165 O 0 1.0059608257506625e-06
and O 0 4.714044976594778e-08
7883del5 O 0 2.662108045115019e-07
were O 0 5.6783445501196184e-08
found O 0 6.094992954785994e-09
in O 0 9.147639867812529e-10
more O 0 7.01674884862058e-10
than O 0 1.1594574189643936e-09
two O 0 1.5688147447789902e-09
unrelated O 0 9.809666856597232e-09
families O 0 9.063650385776612e-10
; O 0 1.192585696863091e-09
44 O 0 3.5903955364346984e-09
% O 0 6.389529461081622e-10
( O 0 4.623126881320161e-10
7 O 0 1.3962199396644337e-08
of O 0 6.807030494826449e-10
16 O 0 4.059693381464058e-08
) O 0 4.485172511170532e-10
of O 0 7.685602154694493e-11
the O 0 2.381240538085194e-09
mutant O 0 1.9347625368482113e-07
alleles O 0 1.2180328212707536e-07
had O 0 2.526787170609168e-07
one O 0 3.4167257911832394e-09
of O 0 2.5408086745670744e-10
the O 0 3.29668048415499e-09
two O 0 7.607803098608201e-08
mutations O 0 3.30710372509202e-06
. O 0 1.4718547447500896e-07

The O 0 2.8681196795332653e-07
4612del165 O 0 1.140139602284762e-06
mutations O 0 1.8754628854367184e-06
in O 0 2.7340556485455636e-09
three O 0 2.594463532901159e-09
different O 0 1.6168616445710882e-09
families O 0 2.6486846049778023e-09
were O 0 4.3128896010102835e-09
all O 0 5.882707654336627e-10
ascribed O 0 2.0429663294407874e-08
to O 0 4.136714970570665e-09
the O 0 1.9049180011165845e-09
same O 0 3.4981994190275145e-08
T O 0 4.004027505288832e-05
- O 0 7.583882393191743e-07
- O 0 8.710815677659411e-07
> O 0 3.956280636430165e-09
A O 0 2.2530901588879715e-09
substitution O 0 2.047279679118219e-09
at O 0 2.518999231426733e-09
the O 0 2.3960200490336092e-09
splice O 0 2.1969868612359278e-05
donor O 0 1.0041150488859785e-07
site O 0 1.8050849348583142e-07
in O 0 1.6189979135106114e-08
intron O 0 5.47673407709226e-05
33 O 0 8.777913080848521e-07
. O 0 2.680465627236117e-07

Microsatellite O 0 0.00018209207337349653
genotyping O 0 8.990701462607831e-05
around O 0 4.6580674961660407e-07
the O 0 3.6030538552722646e-08
ATM O 0 5.7774490414885804e-05
locus O 0 3.337386715429602e-06
also O 0 4.5735302478533413e-07
indicated O 0 1.4378922230662283e-07
that O 0 8.251524463709359e-10
a O 0 8.511007898448497e-09
common O 0 5.6895107292120883e-08
haplotype O 0 2.6066923965117894e-05
was O 0 4.6565307343371387e-07
shared O 0 3.4158131878569975e-09
by O 0 5.77106085142276e-10
the O 0 1.7709045341263163e-09
mutant O 0 1.2492934331476135e-07
alleles O 0 6.166217758618586e-08
in O 0 5.044837436685157e-09
both O 0 7.962742643030651e-08
mutations O 0 1.2459668141673319e-05
. O 0 4.4843642399428063e-07

This O 0 3.424158876441652e-07
suggests O 0 2.027853582831085e-07
that O 0 6.863812185287088e-09
these O 0 1.0456301380301625e-09
two O 0 1.4770301426381138e-08
founder O 0 6.6825632529798895e-06
mutations O 0 7.1987324190558866e-06
may O 0 2.6239422368234955e-07
be O 0 2.1692940777029435e-09
predominant O 0 7.382559630286778e-08
among O 0 1.326746046359517e-09
Japanese O 0 3.5657468089311806e-08
ATM O 0 3.5747877973335562e-06
mutant O 0 9.495278163740295e-07
alleles O 0 1.3703821650778991e-06
. O 0 3.9400586615556676e-07

W474C O 0 1.5613710274919868e-05
amino O 0 1.455956521567714e-06
acid O 0 7.514444746448135e-07
substitution O 0 2.910943841527569e-08
affects O 0 4.1301891684497605e-08
early O 0 4.586880208989896e-09
processing O 0 9.09326480780237e-09
of O 0 1.0554357388059543e-10
the O 0 5.804586811208878e-10
alpha O 0 4.629641559006359e-09
- O 0 3.5916283280812422e-09
subunit O 0 2.5184132557143357e-09
of O 0 2.874569748900768e-10
beta O 0 5.935049784966395e-09
- O 0 3.099227683378558e-07
hexosaminidase O 0 9.105961567001941e-07
A O 0 1.4646255408479192e-07
and O 0 2.1646000547548283e-08
is O 0 3.784756064106887e-09
associated O 0 9.269712997195256e-09
with O 0 2.5233283906800352e-08
subacute O 0 0.0003299670643173158
G B-Disease 0 0.001819755183532834
( I-Disease 0 5.22825338578059e-08
M2 I-Disease 0 0.00011340987111907452
) I-Disease 0 1.14062970624218e-07
gangliosidosis I-Disease 0 2.6125184376724064e-05
. O 0 4.454986708424258e-07

Mutations O 0 0.0002949790796265006
in O 0 3.5235800055488653e-07
the O 0 3.252171509871005e-08
HEXA O 0 3.8743110053474084e-05
gene O 0 6.813303343733423e-07
, O 0 1.8382348976331286e-09
encoding O 0 8.371485726854644e-09
the O 0 1.939475469114882e-09
alpha O 0 4.83638658010932e-08
- O 0 2.71162168274941e-08
subunit O 0 1.3548408617225505e-08
of O 0 1.2591964138053413e-09
beta O 0 2.687012035096359e-08
- O 0 7.156533570196189e-07
hexosaminidase O 0 1.9419660475250566e-06
A O 0 2.981322779760376e-07
( O 0 3.6744665088406236e-09
Hex O 0 3.2185684517571644e-07
A O 0 2.485542722752143e-07
) O 0 2.213396577133153e-09
, O 0 7.865509354942901e-10
that O 0 7.202353158319852e-10
abolish O 0 3.2428864926714596e-08
Hex O 0 1.7967055043754954e-07
A O 0 1.3641575868916789e-08
enzyme O 0 1.690142426014063e-07
activity O 0 3.788268543303275e-07
cause O 0 0.0003067664511036128
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9996564388275146
( O 0 1.1118421383571331e-07
TSD B-Disease 0 1.4100035514275078e-05
) O 0 9.17675802014628e-09
, O 0 3.0884741430980966e-09
the O 0 2.3307345387024725e-08
fatal O 0 0.0014617013512179255
infantile B-Disease 0 5.087755198474042e-05
form I-Disease 0 6.925900208898383e-08
of I-Disease 0 1.2515420699799051e-08
G I-Disease 0 0.001621935167349875
( I-Disease 0 2.3650823521847997e-08
M2 I-Disease 0 7.609224849147722e-05
) I-Disease 0 2.2833622992379787e-08
gangliosidosis I-Disease 0 1.3925478015153203e-06
, I-Disease 0 5.722877283176331e-09
Type I-Disease 0 3.494018585570302e-08
1 I-Disease 0 1.5390361340905656e-07
. O 0 3.273374318268907e-07

Less O 0 8.157803677022457e-05
severe O 0 0.0011308693792670965
, O 0 7.299361186596798e-07
subacute O 0 0.0032439061906188726
( O 0 3.1565764402330387e-06
juvenile O 0 0.0016082106158137321
- O 1 0.8854528665542603
onset O 0 0.07552841305732727
) O 0 7.914106276984967e-07
and O 0 6.730627774231834e-06
chronic O 0 0.02677915245294571
( O 0 6.737877100704281e-08
adult O 0 3.835252300632419e-06
- O 0 0.31706392765045166
onset O 0 0.00017837686755228788
) O 0 1.4253474844849734e-08
variants O 0 2.047617186917705e-07
are O 0 2.3232147317031604e-09
characterized O 0 1.4449243579406357e-08
by O 0 5.236521216644974e-10
a O 0 1.4576965412516074e-08
broad O 0 5.815774883899394e-08
spectrum O 0 1.3999537884501478e-07
of O 0 3.4270377646805628e-09
clinical O 0 2.870409616662073e-07
manifestations O 0 4.781718985213956e-07
and O 0 4.885860249714824e-08
are O 0 2.9170672544154286e-09
associated O 0 4.509553175324754e-09
with O 0 7.190209316831897e-09
residual O 0 2.4839246179908514e-06
levels O 0 4.0743550755451e-08
of O 0 6.818751674408929e-10
Hex O 0 1.5683659739806899e-06
A O 0 2.1587869980521646e-07
enzyme O 0 6.743392759744893e-07
activity O 0 5.106824687572953e-07
. O 0 3.002946584729216e-07

We O 0 1.7139494730145088e-06
identified O 0 2.394706086761289e-07
a O 0 3.412962712445733e-08
1422 O 0 3.875585662171943e-06
G O 0 0.00011895845091203228
- O 0 1.1207776879018638e-05
- O 0 4.338485450716689e-05
> O 0 2.045396030325719e-07
C O 0 1.472068333896459e-06
( O 0 1.5817707144094584e-09
amino O 0 8.290352404571877e-09
acid O 0 9.643758680510928e-09
W474C O 0 3.4635612156108664e-09
) O 0 5.962502019896121e-11
substitution O 0 2.4156354694326865e-10
in O 0 2.2151015743876457e-10
the O 0 8.389640093753314e-10
first O 0 3.382284319286555e-08
position O 0 4.860077851276401e-08
of O 0 5.737957331497512e-10
exon O 0 1.984887347816766e-07
13 O 0 8.318355781966602e-09
of O 0 3.90090487689676e-10
HEXA O 0 4.980248377250973e-06
of O 0 9.585200411166284e-10
a O 0 2.997864356757418e-08
non O 0 5.325202891981462e-07
- O 0 3.7783352127007674e-06
Jewish O 0 2.3918105398479383e-06
proband O 0 0.00010272370127495378
who O 0 4.919074285680836e-07
manifested O 0 9.679106227622469e-08
a O 0 2.2774162999894543e-08
subacute O 0 6.885975381010212e-06
variant O 0 2.6855216219701106e-06
of O 0 1.7164596854968295e-08
G B-Disease 0 0.0009954903507605195
( I-Disease 0 4.947877485506069e-08
M2 I-Disease 0 0.0001655422238400206
) I-Disease 0 9.63923767471897e-08
gangliosidosis I-Disease 0 2.9933968107798137e-05
. O 0 4.1183980670211895e-07

On O 0 1.1341534218445304e-06
the O 0 2.7266308322282384e-08
second O 0 6.808757007092936e-07
maternally O 0 1.4712960364704486e-05
inherited O 0 2.1124162230989896e-05
allele O 0 5.815054009872256e-06
, O 0 5.4092378576342526e-08
we O 0 8.64602700545447e-09
identified O 0 2.389750264342183e-08
the O 0 4.392554764365286e-09
common O 0 2.6848967991099926e-06
infantile O 1 0.8590596914291382
disease O 0 0.2591361999511719
- O 0 9.518217848381028e-05
causing O 0 4.022670691483654e-05
4 O 0 5.831458906868647e-07
- O 0 3.1867704819887877e-05
bp O 0 0.0002252715203212574
insertion O 0 5.37878349859966e-07
, O 0 1.2713091024352252e-08
+ O 0 3.007896509643615e-07
TATC O 0 7.826142791600432e-06
1278 O 0 6.295660455180041e-07
, O 0 1.7999590706807567e-09
in O 0 2.287401823508617e-09
exon O 0 3.402755964998505e-06
11 O 0 1.938123688205451e-07
. O 0 1.9113814175852895e-07

Pulse O 0 0.0021753187756985426
- O 0 9.507450886303559e-05
chase O 0 2.2765319954487495e-05
analysis O 0 1.4275572368660505e-07
using O 0 6.027871535252416e-08
proband O 0 8.50889591674786e-06
fibroblasts O 0 2.150004775103298e-06
revealed O 0 6.580476110684685e-07
that O 0 1.2244116831539031e-09
the O 0 5.318244178376119e-10
W474C O 0 4.5294768824533094e-08
- O 0 4.665633923650603e-08
containing O 0 3.3749170125219052e-09
alpha O 0 9.379625076633147e-09
- O 0 6.7036234341344425e-09
subunit O 0 5.281642678767184e-09
precursor O 0 2.635668749917386e-08
was O 0 2.5138406911651145e-08
normally O 0 3.6649263623900197e-09
synthesized O 0 2.8948536012762816e-08
, O 0 8.335568346673483e-10
but O 0 4.29836805038164e-10
not O 0 3.1709837533533403e-10
phosphorylated O 0 5.749968057244814e-09
or O 0 6.650846096079022e-09
secreted O 0 1.351776912628111e-08
, O 0 1.4458279018469966e-09
and O 0 1.3043865987327763e-09
the O 0 2.479189076254329e-09
mature O 0 4.841333023364314e-08
lysosomal O 0 3.915953072919365e-07
alpha O 0 2.8006876817698867e-08
- O 0 9.748193718905895e-08
subunit O 0 2.6957437171404308e-08
was O 0 2.2659477849629184e-07
not O 0 2.7895346477180283e-08
detected O 0 5.509285188054491e-07
. O 0 1.0862685684287499e-07

When O 0 5.348054514797695e-07
the O 0 1.1744643479971728e-08
W474C O 0 1.732356196271212e-07
- O 0 1.0270861849903667e-07
containing O 0 1.1244671860310973e-08
alpha O 0 2.5643362988603258e-08
- O 0 5.53052608154303e-08
subunit O 0 3.5544747589710823e-08
was O 0 1.387200541103084e-07
transiently O 0 2.971241030991223e-07
co O 0 5.401782345870743e-07
- O 0 1.7145627850823075e-07
expressed O 0 2.2395298948652e-09
with O 0 1.870518323565662e-10
the O 0 6.383499284723371e-10
beta O 0 2.388381936668793e-09
- O 0 6.78709533019628e-09
subunit O 0 2.575294866247191e-09
to O 0 2.466962412128737e-09
produce O 0 1.0087312318773911e-08
Hex O 0 3.928705041289504e-07
A O 0 1.1729849802577519e-07
( O 0 3.5269462905773707e-09
alphabeta O 0 2.6215209913971194e-07
) O 0 1.3051580927125883e-09
in O 0 7.837090088003151e-09
COS O 0 0.0021195728331804276
- O 0 4.610118139680708e-06
7 O 0 1.735031531779896e-07
cells O 0 7.325484574494112e-08
, O 0 1.259744086823389e-09
the O 0 1.252312697985758e-09
mature O 0 1.661163828714507e-08
alpha O 0 4.717379820107226e-09
- O 0 8.041525667579208e-09
subunit O 0 4.809614484457825e-09
was O 0 9.632014297267233e-08
present O 0 1.7348378289483435e-09
, O 0 1.2507396229821666e-09
but O 0 9.527473254777874e-10
its O 0 7.176809813103091e-09
level O 0 4.972747547071776e-09
was O 0 4.2353899942781936e-08
much O 0 2.8657303197121564e-09
lower O 0 9.116782706541926e-08
than O 0 1.4091332545262958e-09
that O 0 7.039873684000497e-10
from O 0 2.691338263360876e-10
normal O 0 6.20696072317628e-09
alpha O 0 8.203289603159192e-09
- O 0 1.1682153022718467e-08
subunit O 0 4.87706852680958e-09
transfections O 0 1.564751954674648e-07
, O 0 5.861069407586683e-10
although O 0 4.1329747957341567e-10
higher O 0 1.407655880747427e-09
than O 0 5.6959331695694e-10
in O 0 1.9642698578792306e-09
those O 0 3.871827303214559e-09
cells O 0 2.1771461078401444e-08
transfected O 0 9.461871286475798e-08
with O 0 1.2117080672169322e-09
an O 0 2.787692965355859e-09
alpha O 0 3.214301003140463e-08
- O 0 2.0104806708332035e-07
subunit O 0 3.302799456150751e-08
associated O 0 6.153798892682971e-08
with O 0 5.7363223504580674e-08
infantile O 0 0.0008848170400597155
TSD B-Disease 0 0.0005012382753193378
. O 0 8.160321272043802e-07

Furthermore O 0 4.997976702725282e-06
, O 0 1.4518916735539733e-08
the O 0 2.0567236802548905e-09
precursor O 0 2.4575427914896864e-08
level O 0 2.635581974885781e-09
of O 0 2.117009484381427e-10
the O 0 1.3450712765816775e-09
W474C O 0 1.7653745132406584e-08
alpha O 0 5.306989070419377e-09
- O 0 6.609291780534932e-09
subunit O 0 3.0394087247032076e-09
was O 0 3.375491530732688e-08
found O 0 3.9112477701053194e-09
to O 0 3.801453818397249e-09
accumulate O 0 5.1121698874112553e-08
in O 0 4.974320400030763e-10
comparison O 0 4.856924196161572e-09
to O 0 1.5260154251350855e-09
the O 0 1.4888524857425978e-09
normal O 0 1.8480299956991075e-08
alpha O 0 1.9656123839695283e-08
- O 0 2.750270944318345e-08
subunit O 0 6.202702707014396e-08
precursor O 0 2.6162609856328345e-07
levels O 0 1.5858957169712085e-07
. O 0 8.409000429310254e-08

We O 0 4.900475232716417e-06
conclude O 0 3.9214916114360676e-07
that O 0 3.3998368564880366e-09
the O 0 6.492790749490496e-09
1422 O 0 1.2600133914020262e-06
G O 0 7.334998372243717e-05
- O 0 1.4546571037499234e-05
- O 0 4.957775672664866e-05
> O 0 3.880424515045888e-07
C O 0 2.2350752715283306e-06
mutation O 0 1.223880445877512e-07
is O 0 3.381392721379939e-09
the O 0 3.966783790332329e-09
cause O 0 4.188410329675207e-08
of O 0 1.5127630259570424e-09
Hex B-Disease 0 0.00013311921793501824
A I-Disease 0 0.002414329908788204
enzyme I-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
in O 0 1.6258864476981216e-08
the O 0 6.356727055845113e-08
proband O 0 0.00017275841673836112
. O 0 5.981755748507567e-07

The O 0 2.434584871480183e-07
resulting O 0 1.7311721478563413e-07
W474C O 0 2.499307356629288e-07
substitution O 0 4.433675471204879e-08
clearly O 0 4.785614748925582e-08
interferes O 0 8.71314398409595e-08
with O 0 1.1026102253453018e-09
alpha O 0 1.1066328298170447e-08
- O 0 1.1729084370415421e-08
subunit O 0 4.8222354998017636e-09
processing O 0 4.0660946609705206e-08
, O 0 1.7752129766179792e-09
but O 0 3.6154970683988097e-10
because O 0 2.6796442842424995e-10
the O 0 3.943539106376903e-10
base O 0 4.069677039808539e-09
substitution O 0 5.5778879293200134e-09
falls O 0 1.213011614709103e-06
at O 0 1.769558188868814e-08
the O 0 7.340359431395882e-10
first O 0 2.7005194525031584e-08
position O 0 4.404285292025634e-08
of O 0 2.33268931948416e-10
exon O 0 1.4463174125012301e-07
13 O 0 1.4138318071843514e-08
, O 0 1.5672325659465969e-09
aberrant O 0 7.113346356391048e-08
splicing O 0 3.062486030103173e-06
may O 0 1.8606656340125483e-06
also O 0 2.121097786300652e-08
contribute O 0 6.118288098377889e-09
to O 0 2.2090450357836744e-08
Hex B-Disease 0 3.43889623763971e-05
A I-Disease 0 4.060277933604084e-05
deficiency I-Disease 0 3.346377343405038e-05
in O 0 2.266274501394605e-09
this O 0 6.865082280427259e-09
proband O 0 1.2494162547227461e-05
. O 0 1.723815579168786e-08
. O 0 7.060292261940049e-08

Two O 0 1.393233219459944e-06
frequent O 0 2.5345116227981634e-05
missense O 0 0.004019699525088072
mutations O 0 0.04302024096250534
in O 0 0.0001264403254026547
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.2617168977158144e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.00011685225763358176
an O 0 0.00129895459394902
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.06159563735127449
by O 0 4.083286455625057e-07
early O 0 4.9757742090150714e-05
childhood O 1 0.6039098501205444
deafness B-Disease 1 1.0
and O 0 0.14071810245513916
goiter B-Disease 1 1.0
. O 0 1.4842116797808558e-05

A O 0 2.127476818714058e-06
century O 0 1.6631111066089943e-07
after O 0 1.1640121044820262e-07
its O 0 9.821779833885103e-09
recognition O 0 3.56238660792485e-09
as O 0 2.2003822763849712e-08
a O 0 1.9981414425274124e-06
syndrome O 0 0.1642061173915863
by O 0 3.101744860956046e-09
Vaughan O 0 5.759926011705829e-07
Pendred O 0 1.6559858977416297e-06
, O 0 6.238365379829247e-09
the O 0 1.841415198100549e-08
disease O 0 1.4526344784826506e-05
gene O 0 7.064157330205489e-07
( O 0 1.002949403527964e-07
PDS O 0 0.00017588889750186354
) O 0 3.073543197729123e-08
was O 0 2.2367953533830587e-07
mapped O 0 6.372821189870592e-06
to O 0 1.9380681237635144e-07
chromosome O 0 5.70624579268042e-05
7q22 O 0 3.3148019156215014e-06
- O 0 1.7704747733660042e-05
q31 O 0 1.09080683614593e-05
. O 0 4.0330601791538356e-07

1 O 0 6.947704150661593e-06
and O 0 5.380897505347093e-07
, O 0 4.460853020304967e-08
recently O 0 4.230376475788944e-07
, O 0 4.698863076413318e-09
found O 0 3.82955978039945e-09
to O 0 1.8997436956880165e-09
encode O 0 1.1649116515854985e-07
a O 0 2.95971972263942e-07
putative O 0 4.619108949555084e-05
sulfate O 0 3.3876629458973184e-05
transporter O 0 0.0004971364978700876
. O 0 7.298372679542808e-07

We O 0 2.9182040179875912e-06
performed O 0 3.961999937018845e-07
mutation O 0 1.1211738382144176e-07
analysis O 0 1.1115977471831684e-08
of O 0 5.698084226679612e-10
the O 0 1.2690221318223394e-08
PDS B-Disease 0 5.561155921895988e-05
gene O 0 9.378213121635781e-07
in O 0 1.3831182421597532e-08
patients O 0 8.2043413840438e-08
from O 0 1.3682819322013984e-09
14 O 0 1.7184447642648593e-08
Pendred B-Disease 0 4.4391927644937823e-07
families O 0 7.733735318815604e-10
originating O 0 5.011539627730599e-09
from O 0 7.277643820913227e-09
seven O 0 1.4110301371772493e-08
countries O 0 2.5364423894558286e-09
and O 0 8.847466759220879e-09
identified O 0 2.0031161795941443e-07
all O 0 7.2938335371475205e-09
mutations O 0 1.5297543995984597e-06
. O 0 8.367466364234133e-08

The O 0 3.0910456416677334e-07
mutations O 0 2.3970990241650725e-06
include O 0 9.462571171070522e-09
three O 0 6.201919422466062e-09
single O 0 1.6433466498710914e-07
base O 0 1.5268174990978878e-07
deletions O 0 9.863391596809379e-07
, O 0 1.2004734983861454e-08
one O 0 7.705542870439785e-09
splice O 0 9.82302735792473e-05
site O 0 3.4615006825333694e-06
mutation O 0 6.422886826840113e-07
and O 0 2.460999937170527e-08
10 O 0 8.865190181950311e-08
missense O 0 2.7151387257617898e-05
mutations O 0 1.4262322110880632e-05
. O 0 4.253074337157159e-07

One O 0 2.511905449864571e-06
missense O 0 0.00023132265778258443
mutation O 0 3.2114759960677475e-05
( O 0 1.901430977113705e-07
L236P O 0 1.2924808743264293e-06
) O 0 5.7835514155613055e-08
was O 0 2.07100114835157e-07
found O 0 2.1653102422192205e-08
in O 0 1.5521885998737162e-09
a O 0 1.9268441064923536e-08
homozygous O 0 7.870844598301119e-08
state O 0 1.867097365604309e-09
in O 0 1.654797299188715e-09
two O 0 9.954989721450147e-09
consanguineous O 0 1.1804356745415134e-06
families O 0 1.7367922211519726e-08
and O 0 1.314946196373512e-08
in O 0 1.4173872076028715e-09
a O 0 1.115929304518204e-08
heterozygous O 0 2.2931734733333542e-08
state O 0 9.326103223017412e-10
in O 0 1.0403226058386394e-09
five O 0 1.270535121555838e-09
additional O 0 3.270738568872389e-09
non O 0 3.0810684847892844e-07
- O 0 8.451806024822872e-06
consanguineous O 0 1.3466666132444516e-05
families O 0 1.0607571709897456e-07
. O 0 1.3251892028165457e-07

Another O 0 2.835269242495997e-06
missense O 0 0.00035746421781368554
mutation O 0 5.1768540288321674e-05
( O 0 2.361348663271201e-07
T416P O 0 1.6805996665425482e-06
) O 0 7.109385791181921e-08
was O 0 2.9663908662769245e-07
found O 0 1.2362370682694745e-08
in O 0 1.2189730336231719e-09
a O 0 2.322662240317186e-08
homozygous O 0 1.2982891917090456e-07
state O 0 2.9607276630372326e-09
in O 0 1.5471174563685963e-08
one O 0 1.5088598104284756e-07
family O 0 2.986439255892037e-07
and O 0 3.55598004375679e-08
in O 0 1.3160446066251552e-09
a O 0 9.937385136993271e-09
heterozygous O 0 3.525172331819704e-08
state O 0 5.27924259863255e-10
in O 0 1.6131221913795457e-09
four O 0 1.890166778650837e-08
families O 0 3.724680652794632e-08
. O 0 1.3865789583178412e-07

Pendred B-Disease 0 0.002360354410484433
patients O 0 9.705690172268078e-05
in O 0 3.981863017088472e-08
three O 0 2.7120458767626587e-08
non O 0 7.898875082901213e-07
- O 0 3.918636866728775e-05
consanguineous O 0 1.4800915778323542e-05
families O 0 9.130825873171489e-08
were O 0 1.3153024447376538e-08
shown O 0 8.732373046882458e-09
to O 0 3.272123905162516e-09
be O 0 4.11881151407556e-09
compound O 0 5.7055725477539454e-08
heterozygotes O 0 2.2067105476253346e-07
for O 0 2.7282838210851423e-09
L236P O 0 2.213558474295496e-07
and O 0 3.255355096598578e-08
T416P O 0 2.0942834453308024e-06
. O 0 1.7714873479235393e-07

In O 0 4.684958412326523e-07
total O 0 9.090944530498746e-08
, O 0 1.1265537835924988e-08
one O 0 5.697620153455318e-09
or O 0 1.6395764745880115e-08
both O 0 1.2775921431895654e-09
of O 0 5.043603312770983e-10
these O 0 7.65423013859845e-09
mutations O 0 7.621577537975099e-07
were O 0 4.842709344643481e-08
found O 0 3.0690035401903515e-08
in O 0 2.145473354531191e-09
nine O 0 1.6303831174013794e-08
of O 0 7.53610451820208e-10
the O 0 9.09791353365108e-09
14 O 0 4.737200853810464e-08
families O 0 5.684453352472474e-09
analyzed O 0 5.068465611657302e-07
. O 0 2.365362661294057e-07

The O 0 1.2263690507552383e-07
identification O 0 6.37931805158587e-08
of O 0 3.563168204934186e-09
two O 0 1.6329662955172353e-08
frequent O 0 1.4301001556304982e-06
PDS B-Disease 0 0.001466947142034769
mutations O 0 3.7961340240144636e-06
will O 0 3.7218739201705375e-09
facilitate O 0 3.8405754132497805e-09
the O 0 3.4590852404647876e-09
molecular O 0 3.96804534830153e-06
diagnosis O 0 0.00859200581908226
of O 0 6.183960067573935e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.923890067700995e-06

Insertional O 0 0.0002267569216201082
mutation O 0 1.4540371012117248e-05
by O 0 8.218469105258919e-08
transposable O 0 1.1333272595948074e-05
element O 0 6.79894583299756e-07
, O 0 8.764950365502955e-08
L1 O 0 1.6774176401668228e-05
, O 0 2.593752412849426e-08
in O 0 3.977337126315206e-09
the O 0 1.1155934487305785e-07
DMD B-Disease 1 0.9999998807907104
gene O 0 1.8860630007111467e-05
results O 0 1.077766341950337e-06
in O 0 3.2176256326010844e-08
X B-Disease 1 0.9954417943954468
- I-Disease 1 0.9989016056060791
linked I-Disease 1 0.9999935626983643
dilated I-Disease 1 0.9998985528945923
cardiomyopathy I-Disease 1 0.9999997615814209
. O 0 2.8343933990981895e-06

X B-Disease 1 0.9996505975723267
- I-Disease 1 0.9999465942382812
linked I-Disease 1 0.999947190284729
dilated I-Disease 1 0.9999885559082031
cardiomyopathy I-Disease 1 1.0
( O 0 2.0342647985671647e-05
XLDCM B-Disease 0 0.0025939408224076033
) O 0 1.1525110465981925e-07
is O 0 2.9546294300075715e-09
a O 0 6.768030402781733e-08
clinical O 0 6.391034617081459e-07
phenotype O 0 2.6113852982234675e-06
of O 0 1.4285263638669221e-08
dystrophinopathy B-Disease 0 0.00031682325061410666
which O 0 2.7347778086550534e-07
is O 0 1.10742881531678e-08
characterized O 0 6.633340632333784e-08
by O 0 6.431839505438575e-09
preferential O 0 1.133867772296071e-05
myocardial B-Disease 0 0.08306294679641724
involvement I-Disease 0 4.51916491783777e-07
without O 0 1.6417480708241783e-08
any O 0 9.890037233617477e-09
overt O 0 5.274317231851455e-07
clinical O 0 6.317426368696033e-07
signs O 0 1.5626419553882442e-06
of O 0 1.1802713970610057e-06
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 3.147437746520154e-05

To O 0 5.710585355700459e-07
date O 0 3.72834875861372e-07
, O 0 5.18927611992126e-09
several O 0 1.653592041073182e-09
mutations O 0 1.781466067996007e-07
in O 0 6.777599814711266e-09
the O 0 5.471773079079867e-07
Duchenne B-Disease 1 0.9999915361404419
muscular I-Disease 1 0.8101806640625
dystrophy I-Disease 1 0.6988186836242676
gene O 0 3.889352228725329e-05
, O 0 7.771714081172831e-07
DMD O 1 1.0
, O 0 4.901027637060906e-07
have O 0 3.2132771110582325e-08
been O 0 6.243260486371582e-08
identified O 0 2.429537744319532e-07
in O 0 7.822305470028823e-09
patients O 0 3.340833387710518e-08
with O 0 1.432104879128815e-09
XLDCM B-Disease 0 6.358747486956418e-05
, O 0 1.4201318343509683e-08
but O 0 9.281420632056836e-10
a O 0 9.47792067051978e-10
pathogenic O 0 1.011791184168942e-08
correlation O 0 1.4072217169314172e-08
of O 0 6.900392479636253e-10
these O 0 4.73833638992005e-09
cardiospecific O 0 5.5491731473011896e-05
mutations O 0 1.1916303265024908e-05
in O 0 1.2317161690589273e-07
DMD O 1 1.0
with O 0 6.900872762116705e-08
the O 0 1.0570812492005643e-07
XLDCM B-Disease 0 0.0309271402657032
phenotype O 0 6.466395279858261e-05
has O 0 2.2714846181770554e-07
remained O 0 3.19541300086712e-07
to O 0 1.467978183455898e-08
be O 0 6.80353196003125e-08
elucidated O 0 8.542400792066474e-06
. O 0 2.2330780780066561e-07

We O 0 2.7582998882280663e-05
report O 0 5.196023948883521e-07
here O 0 3.6941778525090285e-09
the O 0 5.31450217167162e-10
identification O 0 5.044981765678358e-09
of O 0 2.6704397027010884e-10
a O 0 4.762392702417628e-09
unique O 0 3.920033009308099e-08
de O 0 8.669725275467499e-07
novo O 0 5.068898644822184e-06
L1 O 0 1.643087898628437e-06
insertion O 0 1.4695139327614015e-07
in O 0 3.1919813459069246e-09
the O 0 4.061224689877463e-09
muscle O 0 1.8724018957527733e-07
exon O 0 4.744117916288815e-07
1 O 0 2.5788409629967646e-07
in O 0 2.1249249471111398e-07
DMD O 1 1.0
in O 0 1.1919796349957323e-07
three O 0 1.1829651924699647e-07
XLDCM B-Disease 0 0.0017994865775108337
patients O 0 2.809671855175111e-07
from O 0 5.628349453168369e-10
two O 0 2.69933875252093e-09
unrelated O 0 1.7013302056057e-07
Japanese O 0 1.2254922410193103e-07
families O 0 2.7652829359681164e-08
. O 0 1.1765207119651677e-07

The O 0 2.771874108020711e-07
insertion O 0 9.657858299760846e-07
was O 0 1.1735264848766747e-07
a O 0 1.0328772503953587e-08
5 O 0 3.9665209783379396e-08
- O 0 1.2734200254271855e-06
truncated O 0 9.863701961876359e-07
form O 0 2.5213221732656166e-08
of O 0 1.298297913621127e-09
human O 0 1.1093907126280556e-08
L1 O 0 1.6827583522172063e-06
inversely O 0 1.0480410850277622e-07
integrated O 0 2.773619200979738e-07
in O 0 1.7931880424981728e-09
the O 0 2.2824029333179396e-09
5 O 0 1.3261070819226006e-07
- O 0 1.1368822015356272e-05
untranslated O 0 8.096485544228926e-05
region O 0 8.905828394745186e-07
in O 0 8.975641563324643e-09
the O 0 3.3318783287938913e-09
muscle O 0 1.3197509929341322e-07
exon O 0 1.1299974289613601e-07
1 O 0 3.7964415611213553e-08
, O 0 4.775773110310411e-09
which O 0 8.166852083490994e-09
affected O 0 1.7755041881173383e-09
the O 0 4.147109600172172e-10
transcription O 0 6.271127972468094e-08
or O 0 4.7871207442540253e-08
the O 0 6.734251378759382e-09
stability O 0 1.235817848055376e-07
of O 0 1.0020460017301502e-09
the O 0 5.8116027545906945e-09
muscle O 0 2.6317459855818015e-07
form O 0 6.773166916218543e-09
of O 0 1.4745468179810928e-09
dystrophin O 0 8.647479035062133e-07
transcripts O 0 7.228327945085766e-07
but O 0 8.863478839771233e-09
not O 0 1.3131935538979178e-09
that O 0 2.1270592232003338e-10
of O 0 2.3791690839658486e-10
the O 0 6.467800517384603e-08
brain O 0 5.0628103053895757e-05
or O 0 3.518546520808741e-07
Purkinje O 0 0.0001739095605444163
cell O 0 0.00013719964772462845
form O 0 5.185015083952749e-07
, O 0 1.630035626476456e-07
probably O 0 2.1729690047322947e-07
due O 0 2.082398253833162e-08
to O 0 4.6289172495050934e-09
its O 0 2.0236335274148587e-08
unique O 0 3.8701069016156e-09
site O 0 1.577927122298206e-07
of O 0 2.6951458842461307e-09
integration O 0 3.6928560120941256e-07
. O 0 2.1633911728713429e-07

We O 0 5.805738510389347e-06
speculate O 0 7.955559340189211e-07
that O 0 2.422008149594035e-09
this O 0 3.4039357443838014e-10
insertion O 0 9.313948723388421e-09
of O 0 4.5113060509471836e-10
an O 0 4.660624774999178e-09
L1 O 0 1.0845707947737537e-05
sequence O 0 3.8091206988610793e-07
in O 0 9.94760739558842e-07
DMD O 1 1.0
is O 0 2.022412218138925e-06
responsible O 0 3.9661506434640614e-07
for O 0 2.0033630310223316e-09
some O 0 1.8161042114606119e-10
of O 0 1.1817299916394575e-10
the O 0 1.860606002601628e-09
population O 0 7.059154927269162e-10
of O 0 2.160254752858748e-10
Japanese O 0 1.2300844787205278e-07
patients O 0 7.951432401398506e-09
with O 0 6.775580096984868e-10
XLDCM B-Disease 0 1.4741511222382542e-05
. O 0 2.6066173219874145e-08
. O 0 9.168399373038483e-08

Severe O 0 0.004040626809000969
early O 0 2.1619613107759506e-05
- O 1 0.9939454197883606
onset O 1 0.9981535077095032
obesity B-Disease 1 1.0
, O 0 0.001454792683944106
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 2.8319129796727793e-06
red O 0 4.4798358430853114e-05
hair O 1 0.9987794756889343
pigmentation O 0 0.07942651212215424
caused O 0 3.352209887452773e-06
by O 0 1.4488265698275882e-08
POMC O 0 7.897489558672532e-05
mutations O 0 3.193096290488029e-06
in O 0 8.752465419092914e-09
humans O 0 1.9006839124813268e-07
. O 0 1.761063970207033e-07

Sequential O 0 5.0306472985539585e-05
cleavage O 0 2.1968067812849768e-05
of O 0 1.736139587649177e-08
the O 0 3.3775702235061544e-09
precursor O 0 1.492894625698682e-07
protein O 0 2.1951262851871434e-07
pre O 0 6.862512123007036e-07
- O 0 1.2677573067776393e-05
pro O 0 8.391843039134983e-06
- O 0 4.501908551901579e-05
opiomelanocortin O 0 4.537354107014835e-05
( O 0 3.2361516133505575e-08
POMC O 0 2.3114866962714586e-06
) O 0 5.371410427557066e-09
generates O 0 1.238134217373954e-08
the O 0 4.169135703335769e-09
melanocortin O 0 3.2467783057654742e-06
peptides O 0 3.637119050381443e-07
adrenocorticotrophin O 0 1.3356405361264478e-05
( O 0 4.958534205456999e-08
ACTH O 0 2.9070322398183635e-06
) O 0 1.977818797627151e-09
, O 0 2.428650835994972e-09
melanocyte O 0 3.4243587379023666e-06
- O 0 4.816304863197729e-05
stimulating O 0 1.0061718967335764e-05
hormones O 0 1.3171711543691345e-06
( O 0 5.1086090913088356e-09
MSH O 0 2.031340954999905e-06
) O 0 1.3079866079124258e-09
alpha O 0 4.549484344806842e-09
, O 0 3.831610584370537e-10
beta O 0 1.46284850899292e-09
and O 0 9.88026660486696e-10
gamma O 0 6.849909528483522e-09
as O 0 1.3544370069951128e-09
well O 0 4.2351355755698705e-10
as O 0 5.736338071216096e-10
the O 0 6.514048189742994e-10
opioid O 0 1.043932851274576e-08
- O 0 3.862284714273301e-08
receptor O 0 1.7302850707778816e-08
ligand O 0 7.228949527871009e-08
beta O 0 3.1940419376041973e-07
- O 0 2.799662752295262e-06
endorphin O 0 7.108018326107413e-05
. O 0 7.550700047431746e-07

While O 0 4.549091556782514e-07
a O 0 3.132747039558126e-08
few O 0 4.864378233548905e-09
cases O 0 3.201902298854975e-09
of O 0 1.03847144217184e-08
isolated O 0 0.03263009712100029
ACTH B-Disease 1 0.999875545501709
deficiency I-Disease 0 0.04129684343934059
have O 0 7.273969515608769e-08
been O 0 2.5181029172927083e-07
reported O 0 3.419885251787491e-05
( O 0 3.850398755389506e-08
OMIM O 0 5.436319042928517e-05
201400 O 0 6.245856525310955e-07
) O 0 5.101880695690397e-09
, O 0 3.94042087847879e-09
an O 0 8.913341531524566e-08
inherited O 0 0.029521659016609192
POMC O 1 0.9759559631347656
defect O 0 0.1954636424779892
has O 0 1.4917575299477903e-06
not O 0 5.6460422115378606e-08
been O 0 3.115918190133016e-08
described O 0 8.96897063284996e-08
so O 0 1.828702878015065e-08
far O 0 6.583150735650634e-08
. O 0 2.5371289780196093e-07

Recent O 0 3.437577788645285e-06
studies O 0 1.722304432405508e-07
in O 0 9.752188390166339e-09
animal O 0 2.566832790762419e-07
models O 0 6.574629765054851e-07
elucidated O 0 4.112836506919848e-07
a O 0 7.82358888784529e-09
central O 0 1.4217362398483147e-08
role O 0 7.039232752248381e-09
of O 0 5.044498152528831e-10
alpha O 0 9.523903088393126e-08
- O 0 9.68940366874449e-06
MSH O 0 1.8187294699600898e-05
in O 0 1.7946251151812476e-09
the O 0 6.876113012310725e-10
regulation O 0 4.194587788219906e-09
of O 0 4.121339935991841e-10
food O 0 1.778067115765225e-08
intake O 0 1.3932165643382177e-08
by O 0 3.3561392553949077e-10
activation O 0 6.881889280663245e-09
of O 0 7.860424533490118e-10
the O 0 2.7743908503907733e-08
brain O 0 1.5216994142974727e-05
melanocortin O 0 1.8883471284425468e-06
- O 0 2.391087491560029e-06
4 O 0 1.5585207790991262e-07
- O 0 8.002951972230221e-07
receptor O 0 3.464302977818079e-08
( O 0 3.2528584270608008e-09
MC4 O 0 1.5981968317646533e-06
- O 0 1.424098286406661e-06
R O 0 2.622008423713851e-06
; O 0 6.2373777254265406e-09
refs O 0 1.0553708307270426e-07
3 O 0 2.1034193053992567e-08
- O 0 6.092357693887607e-07
5 O 0 7.899479470552251e-08
) O 0 8.554849606490222e-10
and O 0 9.716460969144691e-10
the O 0 1.053742648693401e-09
linkage O 0 6.935549095032911e-07
of O 0 1.0820084384022266e-08
human O 0 4.513889507506974e-06
obesity B-Disease 1 0.999998927116394
to O 0 3.070397553983639e-07
chromosome O 0 4.0327799069928005e-05
2 O 0 6.342943947856838e-07
in O 0 1.168137320206597e-08
close O 0 1.8822345282387687e-07
proximity O 0 6.291170961958414e-08
to O 0 1.5236466310852848e-07
the O 0 6.206773406347565e-08
POMC O 0 1.7969974578591064e-05
locus O 0 2.7412534109316766e-07
, O 0 6.8424799160027305e-09
led O 0 2.980916846695436e-09
to O 0 3.9722047873169686e-09
the O 0 1.3966746648108597e-09
proposal O 0 3.876136744906944e-08
of O 0 8.674417295573278e-10
an O 0 1.888019340867686e-08
association O 0 6.798198448620951e-09
of O 0 2.698196110983986e-09
POMC O 0 3.35579170496203e-05
with O 0 1.5146467546856002e-07
human O 0 2.191554449382238e-05
obesity B-Disease 1 0.999974250793457
. O 0 2.2375299977284158e-06

The O 0 2.2716449166182429e-07
dual O 0 4.3866796772817906e-07
role O 0 1.0556969698427565e-07
of O 0 1.2501367940842556e-08
alpha O 0 6.43289752133569e-07
- O 0 2.0472767573664896e-05
MSH O 0 5.652444815495983e-05
in O 0 8.381247695865568e-09
regulating O 0 7.044648242526819e-08
food O 0 8.867861822636769e-08
intake O 0 1.7354220460674696e-07
and O 0 2.3716822283859074e-08
influencing O 0 2.0952766135451384e-06
hair O 1 0.5359794497489929
pigmentation O 0 0.002886583097279072
predicts O 0 9.580823098076507e-05
that O 0 3.5002070131184837e-09
the O 0 3.561184458433786e-09
phenotype O 0 3.1552460768580204e-06
associated O 0 3.704679230054353e-08
with O 0 2.708916868598976e-09
a O 0 7.084964863679488e-07
defect O 0 1.2112984222767409e-05
in O 0 1.1927363985364536e-08
POMC O 0 1.826924017223064e-05
function O 0 1.4678863635708694e-07
would O 0 6.841908373189654e-08
include O 0 1.5778218198647664e-07
obesity B-Disease 1 0.9999986886978149
, O 0 5.8294570948191904e-08
alteration O 0 1.5164187061600387e-06
in O 0 2.662890210558544e-07
pigmentation O 1 0.6002863645553589
and O 0 0.0007468462572433054
ACTH B-Disease 1 0.9869497418403625
deficiency I-Disease 0 0.0021386914886534214
. O 0 4.256146155512397e-07

The O 0 3.8971538174337184e-07
observation O 0 1.4835983392913477e-06
of O 0 1.1130616428545181e-08
these O 0 4.968521949422211e-08
symptoms O 0 4.072275714861462e-06
in O 0 1.7749082203977196e-09
two O 0 1.587387110646432e-08
probands O 0 1.4838156857877038e-05
prompted O 0 4.323698021835298e-08
us O 0 2.221577410921327e-08
to O 0 1.3032949164326624e-09
search O 0 1.0407974926351926e-08
for O 0 4.122269636752662e-09
mutations O 0 9.858325000777768e-08
within O 0 3.58165408442801e-09
their O 0 4.816612175773116e-08
POMC O 0 0.00017914561612997204
genes O 0 4.577567324304255e-06
. O 0 4.613789883478603e-07

Patient O 0 0.006862087640911341
1 O 0 4.808525318367174e-06
was O 0 1.1256730658715242e-06
found O 0 1.9366448000823766e-08
to O 0 4.353668980883185e-09
be O 0 2.056582459886158e-09
a O 0 3.5959466515578242e-09
compound O 0 4.888843463390913e-08
heterozygote O 0 8.460804679089051e-08
for O 0 1.8672754453774587e-09
two O 0 3.249795099691255e-09
mutations O 0 1.1176892655839765e-07
in O 0 1.4823099414584817e-09
exon O 0 3.2620562251395313e-07
3 O 0 1.1229158758396807e-07
( O 0 3.546549498523177e-09
G7013T O 0 1.11762098242707e-07
, O 0 1.1654223364132577e-08
C7133delta O 0 1.3438149153444101e-06
) O 0 3.049524410769777e-09
which O 0 3.3892897377540976e-09
interfere O 0 1.37345459449989e-08
with O 0 4.956042798376359e-10
appropriate O 0 4.450771307062951e-09
synthesis O 0 1.3486946670582256e-07
of O 0 8.82619577424748e-09
ACTH O 0 1.6031159248086624e-05
and O 0 4.84242299592097e-08
alpha O 0 4.0698193970456487e-07
- O 0 7.643037861271296e-06
MSH O 0 0.00022491460549645126
. O 0 2.292531320335911e-07

Patient O 0 0.0044018118642270565
2 O 0 2.5128110792138614e-06
was O 0 4.1016613749889075e-07
homozygous O 0 9.70963327517893e-08
for O 0 1.3650391927910732e-09
a O 0 1.2967099394245452e-08
mutation O 0 9.617365037684067e-08
in O 0 5.832835547892046e-09
exon O 0 1.4496317817247473e-06
2 O 0 3.654047304735286e-07
( O 0 5.900645749790101e-09
C3804A O 0 2.451006366754882e-07
) O 0 1.587381071033178e-08
which O 0 6.228808757668958e-08
abolishes O 0 3.9839211240177974e-05
POMC O 0 0.00020498539379332215
translation O 0 5.84040299145272e-06
. O 0 6.231244924492785e-07

These O 0 5.437419190457149e-07
findings O 0 2.2581686209832696e-07
represent O 0 8.235600645889463e-09
the O 0 2.1617354573066905e-09
first O 0 1.2109463654041974e-08
examples O 0 2.1906785274694585e-09
of O 0 9.164754510848638e-10
a O 0 4.132177764404332e-06
genetic B-Disease 1 0.9999998807907104
defect I-Disease 1 0.9999693632125854
within O 0 1.6809407199502857e-08
the O 0 8.929605499474746e-09
POMC O 0 9.705894626677036e-06
gene O 0 1.409607648383826e-07
and O 0 4.325254820969349e-09
define O 0 5.164248406686056e-08
a O 0 9.933068412237844e-08
new O 0 1.0674395525711589e-05
monogenic B-Disease 1 0.9857087135314941
endocrine I-Disease 1 0.999595582485199
disorder I-Disease 0 0.010077535174787045
resulting O 0 2.3117763703339733e-08
in O 0 3.4419933570006833e-09
early O 0 2.346013616261189e-06
- O 1 0.999809205532074
onset O 1 0.9993147850036621
obesity B-Disease 1 1.0
, O 0 0.00072394625749439
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 0.9999998807907104
and O 0 7.154636136874615e-07
red O 0 1.1622782949416433e-05
hair O 1 0.9635270237922668
pigmentation O 0 0.00045485544251278043
. O 0 8.115318905765889e-08
. O 0 1.9437469234162563e-07

A O 0 9.924052392307203e-06
European O 0 5.830785994476173e-06
multicenter O 0 0.00013567155110649765
study O 0 1.7623605117478292e-06
of O 0 1.9613132735685213e-06
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
: O 0 7.978430716093499e-08
classification O 0 9.454781491058384e-08
of O 0 1.0810321526832922e-09
105 O 0 2.5185679319861265e-08
mutations O 0 4.998425424673769e-07
and O 0 4.1370071812707465e-09
a O 0 1.6864674989847117e-08
general O 0 5.552031723254913e-09
system O 0 4.6540509224257676e-09
for O 0 5.05845187959153e-09
genotype O 0 4.574843842419796e-06
- O 0 1.7961494449991733e-05
based O 0 6.239311915123835e-06
prediction O 0 9.57661268330412e-06
of O 0 2.9629493525362705e-08
metabolic O 0 0.0008041932596825063
phenotype O 0 0.00021165517682675272
. O 0 8.123066663756617e-07

Phenylketonuria B-Disease 1 0.9926818013191223
( O 0 1.5080085177032743e-05
PKU B-Disease 0 0.0004884220543317497
) O 0 7.646688118256861e-07
and O 0 2.921088480434264e-06
mild B-Disease 0 0.03568051755428314
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.0021850697230547667
MHP B-Disease 1 1.0
) O 0 1.1623991014175772e-07
are O 0 3.5403875386919026e-08
allelic B-Disease 0 8.907184383133426e-05
disorders I-Disease 1 0.8614770770072937
caused O 0 9.832632485995418e-07
by O 0 1.1349304607222166e-08
mutations O 0 1.3495814528141636e-06
in O 0 3.396699588265051e-09
the O 0 1.479624245348532e-08
gene O 0 4.376493961899541e-06
encoding O 0 1.115437589760404e-05
phenylalanine O 0 0.0031890326645225286
hydroxylase O 0 0.037360288202762604
( O 0 1.0469836979609681e-06
PAH O 0 0.0003620995266828686
) O 0 1.413444152831289e-07
. O 0 3.8863868212501984e-07

Previous O 0 2.8628406653297134e-05
studies O 0 4.8999152113538e-07
have O 0 3.403017245773299e-08
suggested O 0 4.366886230400269e-08
that O 0 1.4310455043187176e-09
the O 0 1.596495380340457e-09
highly O 0 4.755814231316435e-08
variable O 0 2.1192595340835396e-06
metabolic O 0 0.00014100110274739563
phenotypes O 0 9.574384421284776e-06
of O 0 5.947721319898847e-07
PAH B-Disease 1 0.9999815225601196
deficiency I-Disease 1 0.8930119872093201
correlate O 0 1.355687800241867e-05
with O 0 4.7315660367530654e-07
PAH O 1 0.5817431211471558
genotypes O 0 0.00025117528275586665
. O 0 5.678788284058101e-07

We O 0 9.896548363030888e-07
identified O 0 1.0889093005062023e-07
both O 0 5.056040475182044e-09
causative O 0 8.093026622191246e-07
mutations O 0 5.540151505556423e-06
in O 0 4.760651250990122e-08
686 O 0 5.9262229115120135e-06
patients O 0 3.658419927887735e-06
from O 0 4.9424326853397815e-09
seven O 0 2.1143522488387134e-08
European O 0 2.9127389211680565e-07
centers O 0 2.565677448274073e-07
. O 0 2.977515691782173e-07

On O 0 1.5194036677712575e-06
the O 0 7.724421990928931e-09
basis O 0 5.141905123906554e-09
of O 0 2.58040699918638e-10
the O 0 9.874482342908664e-10
phenotypic O 0 7.855111761045919e-08
characteristics O 0 1.6910995270791318e-08
of O 0 1.4291007266464817e-09
297 O 0 1.8127600753814477e-07
functionally O 0 4.45794603365357e-06
hemizygous O 0 2.616547681100201e-05
patients O 0 8.537422218068969e-07
, O 0 5.573461692165438e-10
105 O 0 8.848491384050305e-10
of O 0 2.5673679848736697e-10
the O 0 1.1947902223141682e-08
mutations O 0 2.0830932498938637e-06
were O 0 8.38938785108212e-09
assigned O 0 3.7291219001645e-09
to O 0 1.6829513338478819e-09
one O 0 1.6385344192570983e-09
of O 0 2.6062019209405207e-10
four O 0 1.9892301139634583e-08
arbitrary O 0 6.579597879863286e-07
phenotype O 0 5.700237579731038e-06
categories O 0 8.825995223560312e-07
. O 0 1.855274263107276e-07

We O 0 1.7393468851878424e-06
proposed O 0 1.1010496336893993e-07
and O 0 5.591984120201232e-08
tested O 0 5.614577602841564e-08
a O 0 3.5211655813327525e-09
simple O 0 7.446975480718265e-09
model O 0 3.589082453459014e-08
for O 0 1.7578540845164525e-09
correlation O 0 5.520409374071278e-08
between O 0 3.4431508311172365e-08
genotype O 0 1.671040809014812e-05
and O 0 1.9579498200528178e-07
phenotypic O 0 3.672356797324028e-06
outcome O 0 1.1127611969641293e-06
. O 0 3.550586029632541e-07

The O 0 6.389242912518966e-07
observed O 0 7.886545176916115e-07
phenotype O 0 2.615929133753525e-06
matched O 0 6.32425553703797e-07
the O 0 2.7435959282229305e-08
predicted O 0 6.559538633155171e-06
phenotype O 0 1.1268986099821632e-06
in O 0 6.196787971646245e-09
79 O 0 4.2977575276381685e-08
% O 0 7.019386183415577e-10
of O 0 9.814354190451624e-11
the O 0 8.054096944931644e-09
cases O 0 2.660523712449958e-08
, O 0 9.016960511587513e-09
and O 0 1.1029409385798772e-08
in O 0 2.1478112621764467e-09
only O 0 1.8228654141694278e-09
5 O 0 4.69776040290526e-09
of O 0 3.186906016861002e-10
184 O 0 2.7254039025592647e-08
patients O 0 5.837546268594451e-08
was O 0 2.3356921730055547e-08
the O 0 3.272435877832436e-09
observed O 0 1.8654613143098686e-07
phenotype O 0 2.146932303048743e-07
more O 0 3.0298814568396892e-09
than O 0 1.3521862518572902e-09
one O 0 9.360967112570506e-09
category O 0 3.970752260329391e-08
away O 0 6.095054061461269e-08
from O 0 3.998185338360827e-09
that O 0 1.2745771549305118e-08
expected O 0 6.327127266558819e-07
. O 0 1.697006837275694e-07

Among O 0 2.8799573215110286e-07
the O 0 2.2563209967074727e-08
seven O 0 9.430680236732769e-09
contributing O 0 1.5784623386139174e-08
centers O 0 6.128846763431284e-09
, O 0 8.529367767629026e-10
the O 0 9.649862020566502e-10
proportion O 0 6.968192689527086e-09
of O 0 2.3072646015975806e-09
patients O 0 5.5015199507124635e-08
for O 0 1.2847323205278371e-09
whom O 0 2.7124702484115915e-08
the O 0 4.528792008073879e-09
observed O 0 5.37535299827141e-07
phenotype O 0 6.011682671669405e-07
did O 0 1.586158902000534e-07
not O 0 1.871193644475966e-09
match O 0 1.2823313966237038e-08
the O 0 5.089411114767017e-09
predicted O 0 2.8408123853296274e-06
phenotype O 0 1.4020996275121433e-07
was O 0 2.0801035560680248e-08
4 O 0 7.508718979920559e-09
% O 0 1.4226143596474117e-09
- O 0 1.9698390474331973e-07
23 O 0 8.883707636186955e-08
% O 0 3.006394466709139e-09
( O 0 4.247757701136834e-09
P O 0 6.236009357962757e-05
< O 0 4.848985213357082e-08
. O 0 2.8678355246114506e-09
0001 O 0 4.923223286823486e-07
) O 0 2.9701734405307434e-09
, O 0 2.1811681349959144e-09
suggesting O 0 1.408078187381534e-08
that O 0 1.3217650307595363e-09
differences O 0 7.799749290882119e-09
in O 0 7.345569708050448e-10
methods O 0 4.765163819087093e-09
used O 0 1.2598551535347724e-08
for O 0 1.92936600029725e-09
mutation O 0 6.005688391041986e-08
detection O 0 1.6000025482298952e-07
or O 0 4.842663088311383e-07
phenotype O 0 2.9581116905319504e-05
classification O 0 1.1059681128244847e-05
may O 0 4.773694854520727e-06
account O 0 8.668305895298545e-08
for O 0 8.238251192338453e-10
a O 0 4.907807049647772e-09
considerable O 0 4.243676521298312e-09
proportion O 0 6.346441949744985e-08
of O 0 1.491741308257133e-08
genotype O 0 0.0002672832051757723
- O 0 0.019205888733267784
phenotype O 0 0.004879585932940245
inconsistencies O 0 0.00037602687370963395
. O 0 9.90359239949612e-07

Our O 0 2.159088808184606e-06
data O 0 1.220398416990065e-06
indicate O 0 1.1541785482904743e-07
that O 0 5.431483263151904e-09
the O 0 1.0905113256853838e-08
PAH O 0 0.0005002882098779082
- O 0 9.099812450585887e-05
mutation O 0 1.7067773114831652e-06
genotype O 0 7.57632051318069e-07
is O 0 2.14655804242625e-09
the O 0 3.3281166711418564e-10
main O 0 5.303440175907781e-08
determinant O 0 8.472591730424028e-07
of O 0 7.808472091141994e-09
metabolic O 0 9.088469232665375e-05
phenotype O 0 1.9805658666882664e-05
in O 0 2.7686077430644218e-08
most O 0 1.6185664719614579e-07
patients O 0 2.2885478756506927e-06
with O 0 5.162751790521725e-07
PAH B-Disease 1 0.9998552799224854
deficiency I-Disease 0 0.09872102737426758
. O 0 4.2100074892914563e-07

In O 0 2.5673588766039757e-07
the O 0 1.1876604588678674e-08
present O 0 6.852785006117301e-09
study O 0 2.4910580265213866e-09
, O 0 9.6879992916854e-10
the O 0 1.0388989668541626e-09
classification O 0 4.4870677839981e-08
of O 0 1.511073044468958e-09
105 O 0 6.659124807129047e-08
PAH O 0 7.17865041224286e-05
mutations O 0 1.6709627743694e-05
may O 0 2.1598206956241484e-07
allow O 0 1.3719981817317262e-09
the O 0 2.21898877050819e-09
prediction O 0 9.058383625415445e-07
of O 0 4.964424982212279e-10
the O 0 3.385471014638597e-09
biochemical O 0 2.604950566365005e-07
phenotype O 0 5.243338137006504e-07
in O 0 3.0159861275080857e-09
> O 0 2.0038493531160384e-08
10 O 0 1.0893617563567659e-08
, O 0 1.7100539873027287e-09
000 O 0 4.948526033388134e-09
genotypes O 0 9.79445147208935e-08
, O 0 1.2538692750752034e-08
which O 0 2.558572020916472e-07
may O 0 7.259353651534184e-07
be O 0 6.046708023177416e-09
useful O 0 2.9281268520975345e-09
for O 0 1.815322447917822e-09
the O 0 9.883606821858848e-09
management O 0 1.6877310144991498e-06
of O 0 1.3661390241281879e-08
hyperphenylalaninemia B-Disease 1 0.9999994039535522
in O 0 3.669272246042965e-07
newborns O 0 6.888983534736326e-06
. O 0 1.54366645688242e-07

Somatic O 0 0.00046955799916759133
instability O 0 2.6807729227584787e-05
of O 0 3.244061730356407e-08
the O 0 4.56174689134059e-08
CTG O 0 0.00010399116581538692
repeat O 0 8.135144526022486e-06
in O 0 1.4034744033608604e-08
mice O 0 6.953437150514219e-07
transgenic O 0 4.794367214344675e-07
for O 0 3.152058525301982e-08
the O 0 4.270117642590776e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 4.747561615658924e-05
is O 0 2.1893309565257368e-07
age O 0 1.643866198719479e-08
dependent O 0 5.135909120213e-08
but O 0 1.5081511151038285e-08
not O 0 3.861244213254622e-09
correlated O 0 1.568618124281329e-08
to O 0 2.0727204397275045e-09
the O 0 2.9908377996434865e-09
relative O 0 1.1626914542262057e-08
intertissue O 0 9.60614329414966e-07
transcription O 0 2.844423931946949e-07
levels O 0 5.3899270824331325e-08
and O 0 5.9006712405107464e-08
proliferative O 0 8.433007315034047e-05
capacities O 0 1.5961070403136546e-06
. O 0 2.0862511007635476e-07

A O 0 2.7599098757491447e-05
( O 0 1.1588853112698416e-06
CTG O 0 3.70173693227116e-05
) O 0 3.496245426504174e-08
nexpansion O 0 8.931174306781031e-07
in O 0 3.767060885451201e-09
the O 0 3.896274414216805e-09
3 O 0 6.168977506604278e-07
- O 0 0.001313164015300572
untranslated O 0 0.0032130111940205097
region O 0 1.1981367606495041e-05
( O 0 1.6779328149141293e-08
UTR O 0 1.2627441492440994e-06
) O 0 2.0953938584256093e-09
of O 0 5.359280796923827e-10
the O 0 2.5916119739122223e-07
DM O 1 1.0
protein O 0 3.652594386949204e-06
kinase O 0 4.809777692571515e-06
gene O 0 9.507873528491473e-07
( O 0 8.802775397498408e-09
DMPK O 0 1.3454150575853419e-05
) O 0 6.960355847240862e-09
is O 0 7.994910511399667e-09
responsible O 0 1.4643841268480173e-06
for O 0 2.784373464237433e-06
causing O 1 0.987272322177887
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00016796891577541828
DM B-Disease 1 1.0
) O 0 1.331841190221894e-06
. O 0 3.92879854871353e-07

Major O 0 9.836564458964858e-06
instability O 0 3.4334300380578497e-06
, O 0 1.6143172132387917e-08
with O 0 2.0013311008426626e-09
very O 0 1.4143949345069018e-09
large O 0 2.6436424160891647e-09
expansions O 0 7.01441393857749e-08
between O 0 6.2540679302003355e-09
generations O 0 2.8561279563632525e-08
and O 0 2.3167642027033253e-08
high O 0 1.2515969594062426e-08
levels O 0 5.566877181450991e-09
of O 0 1.1925423981651306e-09
somatic O 0 4.266627229299047e-07
mosaicism O 0 1.4465382264461368e-05
, O 0 1.552225015188924e-08
is O 0 4.183346113961761e-09
observed O 0 7.028167203770863e-08
in O 0 3.708553464321085e-08
patients O 0 4.52326105460088e-07
. O 0 1.090959074190323e-07

There O 0 4.825656105822418e-07
is O 0 1.0550584406132657e-08
a O 0 9.617105334314147e-09
good O 0 4.4058733550400575e-08
correlation O 0 7.187689732290892e-08
between O 0 3.0092074609910924e-08
repeat O 0 1.4914139683241956e-05
size O 0 4.6436434786301106e-07
( O 0 2.018025391237188e-08
at O 0 7.03420255376841e-08
least O 0 9.168744874443746e-09
in O 0 2.120709474695559e-08
leucocytes O 0 1.2155709555372596e-05
) O 0 7.05167657599759e-09
, O 0 5.133419023195529e-09
clinical O 0 5.534283076258362e-08
severity O 0 1.1953279681620188e-06
and O 0 8.356142444654324e-08
age O 0 2.4799184927815077e-08
of O 0 9.239458087506591e-09
onset O 0 5.3796334213984665e-06
. O 0 7.609601198055316e-07

The O 0 3.935855602321681e-06
trinucleotide O 0 0.0008287020027637482
repeat O 0 0.00010986880079144612
instability O 0 1.7108791325881612e-06
mechanisms O 0 2.002165047088056e-07
involved O 0 1.3027207046434341e-07
in O 0 2.1372115952544846e-06
DM B-Disease 1 1.0
and O 0 1.8516890349928872e-06
other O 0 7.323445316842481e-08
human O 0 2.959924358947319e-06
genetic B-Disease 1 0.9999997615814209
diseases I-Disease 1 0.9999998807907104
are O 0 5.6293643524440995e-08
unknown O 0 8.338206498592626e-07
. O 0 4.23569730401141e-07

We O 0 2.4224170829256764e-06
studied O 0 3.153042200665368e-07
somatic O 0 2.9078057650622213e-06
instability O 0 5.089787578071991e-07
by O 0 9.827138214291153e-09
measuring O 0 3.285131469965563e-06
the O 0 2.3637797141873307e-07
CTG O 0 8.610724762547761e-05
repeat O 0 5.601555585599272e-06
length O 0 2.232562792414683e-07
at O 0 1.5956931065375102e-07
several O 0 1.9546944063364435e-09
ages O 0 1.9358360248133977e-08
in O 0 6.674632513359313e-10
various O 0 7.530759349450022e-10
tissues O 0 1.031464123002479e-07
of O 0 3.9834924248083325e-10
transgenic O 0 1.4006911897013197e-06
mice O 0 2.150921545762685e-06
carrying O 0 4.1534068628834575e-08
a O 0 7.860072770426996e-08
( O 0 3.478976395854261e-08
CTG O 0 6.527674941025907e-06
) O 0 3.4286200545352585e-09
55expansion O 0 1.2404275651078933e-07
surrounded O 0 1.7413130493082463e-08
by O 0 2.0451524918030373e-09
45 O 0 4.155020771889895e-09
kb O 0 5.889752969778783e-07
of O 0 1.5132045616539358e-09
the O 0 1.2637279667160328e-07
human O 0 1.4062032278161496e-05
DM B-Disease 1 1.0
region O 0 4.9017235141946e-06
, O 0 1.8458661266151921e-09
using O 0 4.185461310868277e-09
small O 0 1.2196155196875225e-08
- O 0 3.5689081414602697e-06
pool O 0 5.952675223852566e-07
PCR O 0 4.928765974909766e-06
. O 0 9.554579349924097e-08

These O 0 1.1089643976447405e-06
mice O 0 5.5345502914860845e-05
have O 0 2.464151549474991e-08
been O 0 9.614923079936943e-09
shown O 0 1.439153951565686e-08
to O 0 9.975993364719216e-09
reproduce O 0 1.4589198826797656e-06
the O 0 6.9856787021649325e-09
intergenerational O 0 9.545032071400783e-07
and O 0 3.320656816185874e-08
somatic O 0 3.0339893442032917e-07
instability O 0 2.3882556376975117e-08
of O 0 6.884984249388992e-10
the O 0 8.803614726105025e-09
55 O 0 1.5052492585709842e-07
CTG O 0 8.159059689205606e-06
repeat O 0 2.6678824269765755e-06
suggesting O 0 6.521662498926162e-08
that O 0 8.820351116156644e-10
surrounding O 0 3.962730588114027e-09
sequences O 0 1.1979301106634921e-08
and O 0 7.197756168864089e-09
the O 0 2.2594379700535683e-09
chromatin O 0 2.52477320827893e-07
environment O 0 2.942228718438855e-07
are O 0 2.210544414182891e-09
involved O 0 5.981849682257234e-09
in O 0 7.103581722844865e-09
instability O 0 6.852591241113259e-07
mechanisms O 0 6.573513928742614e-07
. O 0 5.661872819473501e-07

As O 0 1.0418818874313729e-06
observed O 0 4.764648338095867e-07
in O 0 3.57753693336349e-09
some O 0 4.609541082167823e-10
of O 0 5.53653678458943e-10
the O 0 1.2045654251835458e-08
tissues O 0 6.063681212253869e-06
of O 0 6.299744086391001e-07
DM B-Disease 1 1.0
patients O 0 0.0001762053434504196
, O 0 4.026408984003638e-09
there O 0 5.358350985140703e-10
is O 0 1.0798555383217945e-09
a O 0 2.2222893747425587e-08
tendency O 0 1.3529329123684875e-07
for O 0 6.954039122319955e-09
repeat O 0 1.3287874480738537e-06
length O 0 2.2387224873909872e-07
and O 0 4.823442978363346e-08
somatic O 0 1.2428337470282713e-07
mosaicism O 0 4.6056968017182953e-07
to O 0 9.235775699778515e-09
increase O 0 8.745741020277364e-09
with O 0 5.117991364045338e-09
the O 0 2.6527304797241413e-08
age O 0 1.0915726988969254e-08
of O 0 4.86394924337219e-10
the O 0 1.4649182311643472e-08
mouse O 0 1.791802242223639e-05
. O 0 5.757723897659162e-07

Furthermore O 0 2.3177351977210492e-05
, O 0 2.4396516096203413e-07
we O 0 2.9588154148996182e-08
observed O 0 9.997403793704507e-09
no O 0 1.363909762908122e-09
correlation O 0 8.820692620759019e-09
between O 0 9.118304999944371e-10
the O 0 3.932042247356549e-09
somatic O 0 6.241867254175304e-07
mutation O 0 7.781978297316527e-07
rate O 0 4.294111306535342e-07
and O 0 6.698193999454816e-08
tissue O 0 2.9832799555151723e-05
proliferation O 0 2.015844074776396e-06
capacity O 0 2.145094413208426e-07
. O 0 2.051381642331762e-07

The O 0 1.471732673508086e-07
somatic O 0 2.347716872463934e-06
mutation O 0 1.995342245209031e-06
rates O 0 1.9609153412147862e-07
in O 0 3.784784929905527e-09
different O 0 6.855007228523391e-09
tissues O 0 2.1959335754218046e-06
were O 0 1.1892000628677124e-07
also O 0 3.586878705164054e-08
not O 0 4.234305794881266e-09
correlated O 0 1.8545518898349656e-08
to O 0 3.3246161379452133e-09
the O 0 1.5842465117543725e-09
relative O 0 1.540368721464347e-08
inter O 0 2.8937720344401896e-06
- O 0 0.00010746385669335723
tissue O 0 2.9404038286884315e-05
difference O 0 2.5476923681821972e-08
in O 0 6.112942374514319e-10
transcriptional O 0 1.7203534596887948e-08
levels O 0 4.072123083176393e-09
of O 0 1.0209908613001417e-10
the O 0 1.1854758286133915e-09
three O 0 1.8163207826660255e-08
genes O 0 8.174662724513837e-08
( O 0 1.1026465074337466e-08
DMAHP O 0 6.9845605139562394e-06
, O 0 2.088312633929945e-08
DMPK O 0 9.73972782958299e-06
and O 0 6.725743872948442e-08
59 O 0 5.013396631170508e-08
) O 0 6.131720131641316e-10
surrounding O 0 2.8475917179804355e-09
the O 0 8.889093905395384e-09
repeat O 0 6.144378858152777e-06
. O 0 2.2696845292102807e-08
. O 0 1.1265176880215222e-07

A O 0 2.2907267975824652e-06
novel O 0 1.252277115781908e-06
missense O 0 5.4364332754630595e-05
mutation O 0 1.4880014532536734e-05
in O 0 1.4944829729302e-07
patients O 0 6.586101335415151e-07
from O 0 4.314206325517489e-09
a O 0 2.245794092914366e-07
retinoblastoma B-Disease 0 0.0004372364783193916
pedigree O 0 7.901603385107592e-05
showing O 0 2.304651752638165e-05
only O 0 1.0038335318540703e-07
mild O 0 3.118814504432521e-07
expression O 0 1.3414644506326567e-08
of O 0 1.2996210774218753e-09
the O 0 1.4489846478227264e-07
tumor B-Disease 0 0.00028204938280396163
phenotype O 0 3.975499566877261e-05
. O 0 4.993318043489126e-07

We O 0 2.4276625936181517e-06
have O 0 1.2422856521254744e-08
used O 0 7.059871798276163e-09
single O 0 8.45798098225714e-08
strand O 0 2.4503600798198022e-05
conformation O 0 1.1313987897665356e-06
polymorphism O 0 2.0337294870387268e-07
analysis O 0 2.5484020227395376e-08
to O 0 9.91706716746421e-09
study O 0 2.397537723908272e-09
the O 0 2.427451573083772e-09
27 O 0 7.290248049685033e-08
exons O 0 9.058663152927693e-08
of O 0 5.015266535401963e-10
the O 0 3.178663554592731e-09
RB1 O 0 3.4899208003480453e-06
gene O 0 2.1032394670328358e-07
in O 0 3.0543092499613067e-09
individuals O 0 5.140666781144887e-10
from O 0 1.5468156755460427e-09
a O 0 1.1394315890811413e-07
family O 0 1.3843898614140926e-06
showing O 0 1.7577262042323127e-05
mild O 0 1.4687562952531152e-06
expression O 0 1.3452155833704182e-08
of O 0 1.4341413612228848e-09
the O 0 5.304562833430282e-08
retinoblastoma B-Disease 0 0.000702391320373863
phenotype O 0 0.00017799869237933308
. O 0 6.549622639795416e-07

In O 0 2.6759039428725373e-07
this O 0 5.106914446884048e-09
family O 0 4.218354732188345e-08
affected O 0 3.83067160214523e-08
individuals O 0 1.8241315125067104e-09
developed O 0 4.112761757824046e-07
unilateral B-Disease 0 0.13223189115524292
tumors I-Disease 1 1.0
and O 0 1.210226855619112e-06
, O 0 7.281407032877496e-09
as O 0 3.068732601363422e-09
a O 0 1.0945039541354618e-08
result O 0 1.0535180727799798e-08
of O 0 6.03069538751555e-10
linkage O 0 1.4245546253732755e-06
analysis O 0 1.0532774297189462e-07
, O 0 1.9557695907224115e-08
unaffected O 0 1.245716475750669e-06
mutation O 0 2.416622635337262e-07
carriers O 0 5.2627402880034424e-08
were O 0 3.148369387417915e-08
also O 0 5.734593599981963e-08
identified O 0 9.691501645647804e-08
within O 0 2.586922898117905e-09
the O 0 2.1397653426902252e-08
pedigree O 0 7.78094181441702e-06
. O 0 6.999418360464915e-07

A O 0 6.695281058455294e-07
single O 0 3.6906732248098706e-07
band O 0 3.4196489195892354e-07
shift O 0 1.6981239525648562e-07
using O 0 4.80474824371413e-08
SSCP O 0 2.1507374185603112e-05
was O 0 3.32019197912814e-07
identified O 0 2.913487762157274e-08
in O 0 2.0297479252917583e-09
exon O 0 7.146268785618304e-07
21 O 0 1.473519120054334e-07
which O 0 5.594552376919637e-09
resulted O 0 3.43282113846044e-09
in O 0 4.059983738091688e-10
a O 0 1.108255087700627e-08
missense O 0 9.963159754988737e-07
mutation O 0 4.869309577770764e-08
converting O 0 4.455487712107242e-08
a O 0 1.2230425738835038e-07
cys O 0 0.0009018699056468904
- O 0 5.137249900144525e-05
- O 0 2.8923956051585265e-05
> O 0 1.3193910319841962e-07
arg O 0 1.5911615491859266e-07
at O 0 6.203078939392981e-09
nucleotide O 0 4.6246043439168716e-08
position O 0 9.07360373503252e-08
28 O 0 8.155410569088417e-09
in O 0 1.0279476159169576e-09
the O 0 1.4278562332492584e-08
exon O 0 8.528792022843845e-06
. O 0 5.235368689682218e-07

The O 0 6.707603006361751e-07
mutation O 0 3.819156063400442e-06
destroyed O 0 2.027496975642862e-06
an O 0 1.4487822497244451e-08
NdeI O 0 3.651542783700279e-06
restriction O 0 4.9337696594875524e-08
enzyme O 0 4.476561912269972e-07
site O 0 1.1778695352404611e-06
. O 0 5.458414875647577e-07

Analysis O 0 1.640687401049945e-06
of O 0 1.4781687873721694e-08
all O 0 8.199300793876318e-09
family O 0 2.7040087502427923e-08
members O 0 2.328272019624933e-09
demonstrated O 0 4.123937191735649e-09
that O 0 3.930210601410522e-10
the O 0 1.2773215818384642e-09
missense O 0 1.719676561151573e-06
mutation O 0 4.403999867008679e-07
co O 0 1.6903856021599495e-06
- O 0 2.1006544557167217e-06
segregated O 0 1.7552926578900951e-07
with O 0 3.5006426202244256e-08
patients O 0 1.558638246024202e-06
with O 0 7.94702884832077e-07
tumors B-Disease 1 1.0
or O 0 3.583870056900196e-05
who O 0 2.9657651339221047e-06
, O 0 1.078962430511865e-08
as O 0 2.666598275524734e-09
a O 0 7.661270728931413e-09
result O 0 1.6506747968492164e-08
of O 0 1.584524622622041e-09
linkage O 0 8.190289918275084e-06
analysis O 0 2.3317277282330906e-06
had O 0 2.766897978290217e-06
been O 0 4.1882267964865605e-07
predicted O 0 1.7591599998922902e-06
to O 0 3.9622918279746955e-09
carry O 0 3.8887701947487585e-08
the O 0 1.2859245224206006e-08
predisposing O 0 3.638527687144233e-06
mutation O 0 1.6833715790198767e-06
. O 0 1.4695811501042044e-07

These O 0 2.4756846528362075e-07
observations O 0 8.668617965668091e-07
point O 0 2.779211456527264e-07
to O 0 1.7574256716557102e-08
another O 0 2.1185424969871747e-08
region O 0 2.58902787209081e-07
of O 0 1.8809769297689627e-09
the O 0 2.0486828233856613e-08
RB1 O 0 3.913260570698185e-06
gene O 0 7.999779683132147e-08
where O 0 4.158041466695295e-09
mutations O 0 6.547474384888119e-08
only O 0 1.010325156869385e-09
modify O 0 6.637061034098224e-08
the O 0 1.6014848336354248e-09
function O 0 3.4633234058389917e-09
of O 0 1.3483712757444977e-10
the O 0 3.524726954751145e-09
gene O 0 1.1432128133037622e-07
and O 0 1.7901440330092555e-08
raise O 0 9.691146551915608e-09
important O 0 3.206424681323483e-09
questions O 0 3.584032182146757e-09
for O 0 1.6413277403870552e-09
genetic O 0 8.811598917191077e-08
counseling O 0 1.1056075166493429e-08
in O 0 1.6635919308782832e-09
families O 0 1.0371645764450932e-09
with O 0 9.88627957276833e-10
these O 0 4.315473312033191e-09
distinctive O 0 5.659471753460821e-06
phenotypes O 0 2.3733532543701585e-06
. O 0 2.195670134597094e-08
. O 0 1.2929207571232837e-07

Maternal B-Disease 0 0.0020698693115264177
disomy I-Disease 0 0.07620466500520706
and O 0 0.0014739170437678695
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 3.865450253215386e-06
with O 0 2.304837565247908e-08
gamete O 0 1.8625901248014998e-06
complementation O 0 2.031760050158482e-05
in O 0 1.1230697261055411e-08
a O 0 1.9188380662171767e-08
case O 0 5.0210431368213904e-08
of O 0 3.1377567211166024e-09
familial O 0 3.9756287151249126e-06
translocation O 0 3.8241072616074234e-05
( O 0 4.701447053889751e-08
3 O 0 7.374467259069206e-08
; O 0 3.178210761234368e-08
15 O 0 4.481534077172e-08
) O 0 4.968386591031049e-09
( O 0 1.4341934306827397e-09
p25 O 0 2.6095971605855084e-08
; O 0 3.3656346598576192e-09
q11 O 0 5.689673798769945e-08
. O 0 3.5254397179329544e-09
2 O 0 4.4782698438439184e-08
) O 0 1.723092424299466e-08
. O 0 9.759393293506946e-08

Maternal B-Disease 0 0.012504758313298225
uniparental I-Disease 1 0.5452708601951599
disomy I-Disease 1 0.9168075919151306
( I-Disease 0 0.00012405063898768276
UPD I-Disease 1 0.9999992847442627
) I-Disease 0 7.775894914630044e-07
for I-Disease 0 3.4190090758556835e-08
chromosome I-Disease 0 0.0001319183938903734
15 I-Disease 0 8.981173778010998e-07
is O 0 3.245825652697931e-08
responsible O 0 1.66193473205567e-07
for O 0 6.842753919045208e-09
an O 0 7.398442747330591e-09
estimated O 0 1.229500412591733e-07
30 O 0 1.0196684385732624e-08
% O 0 4.1218273238996517e-10
of O 0 1.6099736821484356e-10
cases O 0 1.3942745624717645e-08
of O 0 9.256718840333633e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.0512286937446333e-05
PWS B-Disease 1 0.9999988079071045
) O 0 3.9589630773662066e-07
. O 0 2.780123509182886e-07

We O 0 2.082359787891619e-05
report O 0 4.0092533026836463e-07
on O 0 1.2792436443476163e-08
an O 0 1.3763542527911454e-09
unusual O 0 2.6094215677119337e-09
case O 0 1.3510241814174151e-08
of O 0 1.3163834466922708e-09
maternal B-Disease 0 4.146884862166189e-07
disomy I-Disease 0 2.5952180294552818e-05
15 I-Disease 0 6.820708335908421e-07
in O 0 2.779248688966618e-07
PWS B-Disease 1 0.9999998807907104
that O 0 1.0016685081382093e-07
is O 0 4.046657675615961e-09
most O 0 9.78072178803302e-10
consistent O 0 7.050721340107202e-09
with O 0 4.804917574929846e-10
adjacent O 0 1.2050530528995296e-07
- O 0 4.845009243581444e-06
1 O 0 1.4241170731565944e-07
segregation O 0 8.495049996781745e-09
of O 0 6.802380880799319e-11
a O 0 1.5732084079900233e-08
paternal O 0 5.219774266151944e-07
t O 0 4.049906783620827e-05
( O 0 5.095686095302199e-09
3 O 0 1.733793375535697e-08
; O 0 1.5603523806362318e-08
15 O 0 1.6272856839805172e-08
) O 0 1.3005484467143447e-09
( O 0 6.679268249598636e-10
p25 O 0 1.2215710221141762e-08
; O 0 1.7641619276531628e-09
q11 O 0 2.0963941693707966e-08
. O 0 8.153509534203351e-10
2 O 0 1.6211176401270677e-08
) O 0 1.200820998192853e-09
with O 0 9.403822165410247e-10
simultaneous O 0 1.5689524843764957e-06
maternal O 0 4.912285476166289e-06
meiotic O 0 2.2818941943114623e-05
nondisjunction O 0 3.411650686757639e-05
for O 0 6.580803102451682e-08
chromosome O 0 4.365536369732581e-05
15 O 0 5.616525982077292e-07
. O 0 2.0304796066739073e-07

The O 0 2.20450078813883e-06
patient O 0 2.213744301116094e-05
( O 0 1.0453121035425283e-07
J O 0 0.00013542674423661083
. O 0 1.8879472207800063e-08
B O 0 2.6551506948635506e-07
. O 0 1.1189467130634512e-09
) O 0 5.181924334074495e-10
, O 0 4.876229420247569e-10
a O 0 5.738420405521083e-09
17 O 0 2.3447892516514912e-08
- O 0 4.510501696586289e-07
year O 0 2.3195660503461113e-07
- O 0 1.7694118241706747e-06
old O 0 1.2349477174211643e-06
white O 0 8.276688845398894e-08
male O 0 2.4628405981275137e-08
with O 0 1.8680815117022576e-08
PWS B-Disease 1 0.9999983310699463
, O 0 1.224387062848109e-07
was O 0 8.578616217391755e-08
found O 0 1.0801402439142294e-08
to O 0 5.530428559552547e-09
have O 0 1.2322797005026587e-08
47 O 0 1.634184521037696e-08
chromosomes O 0 1.1924680798358622e-08
with O 0 6.553803610920284e-10
a O 0 4.163980094062936e-08
supernumerary O 0 6.455984021158656e-06
, O 0 7.176182492685257e-08
paternal O 0 1.8135533537133597e-06
der O 1 0.996325671672821
( O 0 8.306879806241341e-08
15 O 0 1.750247058396326e-08
) O 0 1.0787726267835751e-09
consisting O 0 4.11474215811225e-10
of O 0 7.503918597606685e-10
the O 0 4.3440330443900166e-08
short O 0 4.7270104914787225e-06
arm O 0 0.0006898363353684545
and O 0 2.4608036142126366e-07
the O 0 3.199950171506316e-08
proximal O 0 4.310746953706257e-05
long O 0 4.63200331068947e-06
arm O 0 3.766219015233219e-05
of O 0 1.0314716192283413e-08
chromosome O 0 3.452266173553653e-05
15 O 0 7.984809968775153e-08
, O 0 9.967529912557893e-09
and O 0 1.708363726038442e-07
distal O 0 0.03385934978723526
chromosome O 1 0.8689097166061401
arm O 0 0.056594040244817734
3p O 0 0.002843385562300682
. O 0 2.5830447611951968e-06

The O 0 8.567559461880592e-07
t O 0 3.614858724176884e-05
( O 0 9.291273528333477e-09
3 O 0 1.5684745946487055e-08
; O 0 1.2535249283018857e-08
15 O 0 4.1088643598641283e-08
) O 0 3.4921447955582607e-09
was O 0 1.0008300677100124e-07
present O 0 2.879696925361941e-09
in O 0 7.978545046860575e-10
the O 0 2.680581090430678e-09
balanced O 0 1.663647282157399e-07
state O 0 4.167776346264418e-09
in O 0 3.946987625624843e-09
the O 0 1.0049331677919326e-07
patients O 0 3.991360983945924e-07
father O 0 4.473736581189769e-08
and O 0 1.1432690349977292e-08
a O 0 1.4457188513006258e-07
sister O 0 3.390846904949285e-05
. O 0 2.2072723027122265e-07

Fluorescent O 0 9.25279800867429e-06
in O 0 1.6840702699028043e-07
situ O 0 9.135736149801232e-07
hybridization O 0 1.0207430278796892e-07
analysis O 0 5.4407660599054e-08
demonstrated O 0 4.283101162627645e-08
that O 0 4.695780653207748e-09
the O 0 8.763428382962957e-08
PWS B-Disease 1 0.9999994039535522
critical O 0 1.0132716852240264e-06
region O 0 3.587399532989366e-07
resided O 0 1.315398350243413e-07
on O 0 1.0943102068949884e-07
the O 0 5.147694714935369e-09
derivative O 0 4.185367856734956e-07
chromosome O 0 1.796097967599053e-05
3 O 0 1.5206271086753986e-07
and O 0 3.849113738851884e-08
that O 0 8.548949104181247e-09
there O 0 2.829627421263581e-09
was O 0 1.0846020614962981e-07
no O 0 1.0579441322988714e-08
deletion O 0 1.5176021861407207e-07
of O 0 2.225978956715835e-09
the O 0 1.261032821275876e-06
PWS B-Disease 1 1.0
region O 0 7.79659330873983e-06
on O 0 9.873771205093362e-07
the O 0 8.811410268094733e-09
normal O 0 7.551464165089783e-08
pair O 0 5.997915764055506e-08
of O 0 1.6579945194550305e-09
15s O 0 3.0852962851213306e-08
present O 0 1.4129233782966821e-08
in O 0 2.3688025763135556e-08
J O 0 0.0006932287360541523
. O 0 9.397623443874181e-07

B O 0 0.0006664437823928893
. O 0 1.4541938071488403e-05

Methylation O 0 2.0745086658280343e-05
analysis O 0 1.4753740060768905e-06
at O 0 1.1598532978496223e-07
exon O 0 3.1575737580169516e-07
alpha O 0 5.395677149522271e-08
of O 0 2.796937403903854e-10
the O 0 5.532240776595643e-10
small O 0 5.647795120466981e-09
nuclear O 0 1.393226625623356e-06
ribonucleoprotein O 0 8.079808822003542e-07
- O 0 1.5258713119692402e-06
associated O 0 1.0161624430793381e-07
polypeptide O 0 9.020367315315525e-07
N O 0 1.2838610928156413e-05
( O 0 4.66165550605524e-09
SNRPN O 0 2.5518490929243853e-06
) O 0 2.7277946568204925e-09
gene O 0 4.2342918504800764e-08
showed O 0 3.427242134534936e-08
a O 0 6.08321659711919e-09
pattern O 0 9.330698844678409e-07
characteristic O 0 2.5459198127464333e-07
of O 0 1.094829116254914e-09
only O 0 2.8285591646692865e-09
the O 0 6.044424960549577e-09
maternal O 0 2.721124587878876e-07
chromosome O 0 1.0588812074274756e-05
15 O 0 9.147891688598975e-08
in O 0 2.9090678310694784e-08
J O 0 0.008235880173742771
. O 0 4.831655928683176e-07

B O 0 0.000402331817895174
. O 0 1.216570490214508e-05

Maternal B-Disease 0 0.006784506142139435
disomy I-Disease 0 0.011725267395377159
was O 0 2.591733391454909e-05
confirmed O 0 5.967169158793695e-07
by O 0 5.499376953821411e-09
polymerase O 0 8.744524961912248e-07
chain O 0 6.298966582107823e-06
reaction O 0 3.2826022788867704e-08
analysis O 0 1.141880812127738e-08
of O 0 1.4349375021538435e-09
microsatellite O 0 1.672755161052919e-06
repeats O 0 3.708328222273849e-06
at O 0 1.4515649127133656e-08
the O 0 2.3005630733763383e-09
gamma O 0 2.495173134775541e-07
- O 0 2.6062205051857745e-06
aminobutyric O 0 5.716040504921693e-06
acid O 0 1.879769797596964e-07
receptor O 0 4.545522358512244e-08
beta3 O 0 2.0252869603609724e-07
subunit O 0 7.490555731237691e-08
( O 0 1.253304926507326e-08
GABRB3 O 0 6.40513826510869e-06
) O 0 3.9727975575942764e-08
locus O 0 1.907720616145525e-06
. O 0 4.831352384826459e-07

A O 0 2.0202138330205344e-05
niece O 0 0.00022229021124076098
( O 0 2.606247733183409e-07
B O 0 7.729118465249485e-07
. O 0 5.902807131974441e-09
B O 0 9.868841743809753e-08
. O 0 6.45933750931249e-10
) O 0 4.203892789433894e-10
with O 0 4.483769466823162e-10
45 O 0 4.147159060607919e-09
chromosomes O 0 9.711760284858428e-09
and O 0 3.668926940036954e-09
the O 0 1.6444110517710442e-09
derivative O 0 7.692769798950394e-08
3 O 0 1.6641829247987516e-08
but O 0 2.870933046850155e-09
without O 0 2.388764519523079e-09
the O 0 2.2040282487978402e-08
der O 1 0.743585467338562
( O 0 1.4323159547302566e-08
15 O 0 7.67226726594572e-09
) O 0 8.609752910615498e-10
demonstrated O 0 4.9264330392873035e-09
a O 0 2.711301227975582e-08
phenotype O 0 4.314000307203969e-06
consistent O 0 1.6648377254568913e-07
with O 0 4.390075414306693e-09
that O 0 2.8324043555016942e-08
reported O 0 1.6943043874562136e-06
for O 0 3.323779251829251e-09
haploinsufficiency O 0 4.311782959121047e-06
of O 0 5.343809839075675e-09
distal O 0 0.00010157431825064123
3 O 0 4.003371486760443e-06
p O 0 0.0003918404399883002
. O 0 5.059188765699218e-07

Uniparental B-Disease 1 0.9999744892120361
disomy I-Disease 1 0.9999918937683105
associated O 0 6.949704402359203e-05
with O 0 1.1698590896003225e-07
unbalanced O 0 5.182756285648793e-05
segregation O 0 4.363506320714805e-07
of O 0 5.5712532365248535e-09
non O 0 1.2698716318482184e-06
- O 0 6.77856951369904e-05
Robertsonian O 0 0.0001693997619440779
translocations O 0 0.00014048225420992821
has O 0 1.2474486084101954e-06
been O 0 2.427481149425148e-07
reported O 0 4.946452463627793e-06
previously O 0 5.296545850796974e-07
but O 0 3.4988335784191804e-08
has O 0 1.0323262245037768e-07
not O 0 2.1333631750053428e-08
, O 0 1.8376880017711983e-09
to O 0 2.038178070762342e-09
our O 0 6.400156848940242e-09
knowledge O 0 4.982764423289154e-09
, O 0 8.479865698518552e-09
been O 0 1.1349563955320718e-08
observed O 0 1.8148247349358826e-08
in O 0 6.539169206121187e-10
a O 0 2.6811603603960066e-08
case O 0 1.4021985350609611e-07
of O 0 1.1063757909823835e-07
PWS B-Disease 1 0.9999970197677612
. O 0 1.939509957082919e-06

Furthermore O 0 8.222494216170162e-06
, O 0 1.6242692879586684e-07
our O 0 1.1130430266348412e-07
findings O 0 8.236924031734816e-08
are O 0 1.1078867823144378e-09
best O 0 1.5767772865160623e-08
interpreted O 0 4.131717901145748e-08
as O 0 5.8718820916681125e-09
true O 0 3.4035952722888396e-08
gamete O 0 1.472939061386569e-06
complementation O 0 1.4257588190957904e-05
resulting O 0 3.4967129636243044e-07
in O 0 1.4289493321939517e-07
maternal B-Disease 0 7.810693932697177e-05
UPD I-Disease 1 0.9999997615814209
15 I-Disease 0 2.691472582228016e-05
and O 0 1.2116312063881196e-05
PWS B-Disease 1 0.999993085861206

Schwartz B-Disease 1 0.9855829477310181
- I-Disease 1 0.9920706152915955
Jampel I-Disease 1 0.9731307625770569
syndrome I-Disease 1 0.9998188614845276
type I-Disease 0 2.7042210604122374e-07
2 I-Disease 0 1.7960680054329714e-07
and O 0 2.1081814338685945e-07
Stuve B-Disease 0 0.3555154502391815
- I-Disease 1 0.9999932050704956
Wiedemann I-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.9999785423278809
: O 0 4.569294276279834e-09
a O 0 1.3645478524892951e-08
case O 0 1.194804326587473e-07
for O 0 1.8463600426343874e-08
" O 0 5.065638220003166e-07
lumping O 0 7.471148819604423e-07
" O 0 7.193929150162148e-07
. O 0 1.1428487312059588e-07

Recent O 0 4.819516107090749e-06
studies O 0 3.4484818911550974e-07
demonstrated O 0 8.64537099687368e-08
the O 0 3.4555571737371338e-09
existence O 0 1.8674189306011613e-08
of O 0 7.014286929063474e-10
a O 0 1.7900585902452804e-08
genetically O 0 4.1470710243629583e-07
distinct O 0 3.283767213702049e-08
, O 0 3.655160174531602e-09
usually O 0 1.4622960620158665e-09
lethal O 0 3.894617517374854e-09
form O 0 9.034722414646978e-10
of O 0 4.718178070461931e-10
the O 0 8.548789764972753e-08
Schwartz B-Disease 1 0.9369575381278992
- I-Disease 1 0.9995906949043274
Jampel I-Disease 1 0.999987006187439
syndrome I-Disease 1 0.9999966621398926
( O 0 5.906684350520663e-07
SJS B-Disease 0 0.3657868802547455
) O 0 4.0291226355293475e-08
of O 0 2.9237975596174692e-08
myotonia B-Disease 1 0.8625172972679138
and O 0 9.051648703461979e-06
skeletal B-Disease 0 0.3887985050678253
dysplasia I-Disease 1 0.996269941329956
, O 0 2.0029901293128205e-07
which O 0 3.948600735270702e-08
we O 0 5.5711076640818646e-08
called O 0 1.2934549431520281e-06
SJS B-Disease 0 0.23386313021183014
type I-Disease 0 5.24370307175559e-07
2 I-Disease 0 1.7519312223157613e-07
. O 0 1.792300423630877e-07

This O 0 4.662739229388535e-06
disorder O 0 0.0005293142166920006
is O 0 1.2009132355217389e-08
reminiscent O 0 6.328950519218779e-08
of O 0 1.891810486043255e-09
another O 0 8.177985222346251e-08
rare O 0 1.726333351825815e-07
condition O 0 2.730868118305807e-06
, O 0 3.830070482990777e-09
the O 0 1.8419385128254362e-08
Stuve B-Disease 0 0.23672930896282196
- I-Disease 1 0.9999959468841553
Wiedemann I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999998807907104
( O 0 1.9719620922842296e-06
SWS B-Disease 1 0.6432820558547974
) O 0 3.1985038617676764e-08
, O 0 3.6966307792596353e-09
which O 0 2.245903685249573e-09
comprises O 0 5.397228441950119e-09
campomelia B-Disease 0 1.7381363477397827e-06
at O 0 1.0747604761718321e-07
birth O 0 2.847279176876327e-07
with O 0 6.726166645876219e-08
skeletal B-Disease 1 0.7711260318756104
dysplasia I-Disease 1 0.9922288060188293
, O 0 1.6408974090609263e-07
contractures B-Disease 0 0.00022841017926111817
, O 0 2.028862766678685e-08
and O 0 1.942934702015009e-08
early B-Disease 0 4.0276711388287367e-07
death I-Disease 0 1.453469053558365e-06
. O 0 2.2843603630917642e-07

To O 0 1.6409032923547784e-06
test O 0 9.730527494866692e-08
for O 0 6.998935209168167e-09
possible O 0 2.143237232132833e-08
nosologic O 0 3.0654662168672075e-06
identity O 0 4.2205923023175274e-07
between O 0 2.066721016547035e-08
these O 0 1.1582925907305253e-07
disorders O 0 0.0007844902575016022
, O 0 3.4113877944719206e-08
we O 0 7.302077165149967e-08
reviewed O 0 3.247881963375221e-08
the O 0 1.2188194897788662e-09
literature O 0 1.351175615837974e-09
and O 0 6.750996206505988e-09
obtained O 0 5.076506770507194e-09
a O 0 4.065829006805188e-09
follow O 0 1.980688679736886e-08
- O 0 1.618371811673569e-06
up O 0 3.850274197247927e-07
of O 0 3.553257688082567e-10
the O 0 1.575483743465611e-09
only O 0 3.9834331388988176e-09
two O 0 1.1392421228606509e-08
surviving O 0 3.634192751178489e-07
patients O 0 2.698053336303019e-08
, O 0 1.429506096828348e-10
one O 0 8.281623720129971e-10
with O 0 8.074877655417367e-09
SJS B-Disease 0 0.01965203694999218
type I-Disease 0 1.0697866059672378e-07
2 I-Disease 0 9.314911864066744e-08
at O 0 2.0681412138401356e-07
age O 0 5.040720729709847e-09
10 O 0 2.9688878022682275e-09
years O 0 2.576159507938769e-09
and O 0 2.8219631076353835e-09
another O 0 5.6742273102372565e-09
with O 0 6.499334403997636e-08
SWS B-Disease 0 0.02316691167652607
at O 0 2.911413901074411e-07
age O 0 7.078182040487491e-09
7 O 0 2.39860931117164e-08
years O 0 2.0339655293355463e-08
. O 0 7.119033540448072e-08

Patients O 0 0.03942429646849632
reported O 0 4.3705680582206696e-05
as O 0 4.559398192327535e-08
having O 0 2.0882296780655452e-07
either O 0 4.3202749111515e-06
neonatal O 1 0.9999456405639648
SJS B-Disease 1 0.9999967813491821
or O 0 7.687871402595192e-05
SWS B-Disease 0 0.24771910905838013
presented O 0 4.9213920050306115e-08
a O 0 3.849023766377968e-09
combination O 0 2.7881835507059805e-08
of O 0 1.0402770866946298e-09
a O 0 5.587580176324991e-07
severe O 0 2.4202503482229076e-05
, O 0 1.1994097803835757e-07
prenatal O 0 0.0016741147264838219
- O 1 0.996898889541626
onset O 1 0.9560768604278564
neuromuscular B-Disease 1 0.9999744892120361
disorder I-Disease 1 0.9983407258987427
( O 0 1.1109220565685973e-07
with O 0 1.5637064052498317e-06
congenital B-Disease 1 0.9999997615814209
joint I-Disease 0 0.035470474511384964
contractures I-Disease 1 0.9999871253967285
, O 0 1.9891820556949824e-05
respiratory O 1 0.5361050367355347
and O 0 8.040268539843964e-07
feeding O 0 1.452235574106453e-05
difficulties O 0 4.6431964051407704e-07
, O 0 2.062790649404178e-08
tendency O 0 1.9713499455065175e-07
to O 0 1.234140682981888e-07
hyperthermia B-Disease 0 0.00021876225946471095
, O 0 3.0650490145944786e-08
and O 0 2.56403307474784e-08
frequent O 0 7.737164651189232e-07
death O 0 5.4497982091561425e-06
in O 0 2.018769009737298e-07
infancy O 0 2.90008210868109e-06
) O 0 7.988123496005528e-10
with O 0 4.5353248934176804e-10
a O 0 3.9192030953927315e-08
distinct O 0 8.214659033001226e-07
campomelic B-Disease 0 0.0011255398858338594
- I-Disease 0 0.09947032481431961
metaphyseal I-Disease 0 0.3961082994937897
skeletal I-Disease 1 0.7458941340446472
dysplasia I-Disease 1 0.9737637042999268
. O 0 2.4014327664190205e-06

The O 0 2.1207786460308853e-07
similarity O 0 2.61989129057838e-07
of O 0 2.113423658300917e-09
the O 0 1.8841340931885497e-08
clinical O 0 2.111866024279152e-07
and O 0 5.7014823084955424e-08
radiographic O 0 3.718241350725293e-05
findings O 0 1.113666712626582e-06
is O 0 1.1775844299677374e-08
so O 0 1.1227783147660375e-08
extensive O 0 5.681550874214736e-08
that O 0 8.978795307257315e-08
these O 0 7.953391900628048e-08
disorders O 0 0.00016100204084068537
appear O 0 1.31947416548428e-07
to O 0 1.410376349042508e-08
be O 0 1.214096201351822e-08
a O 0 2.584547331707654e-08
single O 0 1.3882715848012595e-06
entity O 0 1.2714755939668976e-05
. O 0 5.601361294793605e-07

The O 0 1.213999496485485e-07
follow O 0 1.2596923681940098e-07
- O 0 3.1874435535428347e-06
up O 0 4.802475928045169e-07
observation O 0 7.115246347666471e-08
of O 0 3.621992150648623e-10
an O 0 1.80510251190924e-09
identical O 0 1.2631208790025994e-07
and O 0 2.082048666807168e-08
unique O 0 2.981316526984301e-08
pattern O 0 1.181826155516319e-05
of O 0 8.138569995708167e-08
progressive O 0 0.0002631688257679343
bone B-Disease 1 0.9680925607681274
dysplasia I-Disease 1 0.9140303134918213
in O 0 2.3785771574580394e-08
the O 0 1.1590644888315182e-08
two O 0 9.082327778742183e-07
patients O 0 1.208936737384647e-07
( O 0 3.3938873933436753e-10
one O 0 7.894942477548739e-09
with O 0 7.88611131952166e-08
SJS B-Disease 1 0.7598767876625061
type I-Disease 0 4.245334537245071e-07
2 I-Disease 0 2.519169299830537e-07
, O 0 9.744267615019453e-09
one O 0 1.2772077617739797e-08
with O 0 8.727897693461273e-08
SWS B-Disease 0 0.0896226093173027
) O 0 5.1522133226455935e-09
surviving O 0 4.050304269753724e-08
beyond O 0 1.693249771506089e-07
infancy O 0 8.929420118874987e-07
adds O 0 9.339373008288021e-08
to O 0 7.492737985614895e-09
the O 0 2.1864374755153904e-09
evidence O 0 1.3126133069363277e-08
in O 0 1.3335630377753205e-09
favor O 0 4.590407609583735e-09
of O 0 7.664949785990416e-10
identity O 0 1.998751258724951e-06
. O 0 3.757336344278883e-07

The O 0 1.1322698583171587e-06
hypothesis O 0 5.020850949222222e-06
that O 0 2.418358349132177e-07
SWS B-Disease 0 0.020654894411563873
and O 0 1.129734073401778e-06
SJS B-Disease 0 0.13529087603092194
type I-Disease 0 5.90685317547468e-07
2 I-Disease 0 9.424120150924864e-08
are O 0 1.3985460567411678e-09
the O 0 2.622704275978549e-09
same O 0 4.260076877926622e-07
disorder O 0 3.7687161238864064e-05
should O 0 6.276701380869554e-09
be O 0 1.2689391759579394e-09
testable O 0 1.9515997706776034e-08
by O 0 8.951462904249752e-10
molecular O 0 3.6788442514534836e-08
methods O 0 1.5044371082240104e-07
. O 0 3.397063963461733e-08
. O 0 1.1645939679283401e-07

A O 0 2.609050397950341e-06
mouse O 0 1.0691287570807617e-05
model O 0 2.9088071187288733e-06
of O 0 1.3757573924522148e-06
severe O 1 0.9023019075393677
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.0017202097224071622
defects O 1 0.9998319149017334
in O 0 3.548375843820395e-06
hemostasis O 1 0.5796733498573303
and O 0 0.0001107997159124352
thrombosis B-Disease 0 0.20508860051631927
. O 0 2.083035496980301e-06

von B-Disease 1 0.9926067590713501
Willebrand I-Disease 1 0.9613284468650818
factor I-Disease 0 6.0455880884546787e-05
( I-Disease 0 7.735032340860926e-06
vWf I-Disease 0 0.0021883067674934864
) I-Disease 0 0.00039264358929358423
deficiency I-Disease 1 0.9893680214881897
causes O 0 0.005035544745624065
severe O 1 0.9994159936904907
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 2.8074537112843245e-06
humans O 0 9.445942851016298e-06
. O 0 1.5888339248704142e-06

We O 0 5.818492923026497e-07
generated O 0 1.3820106836703872e-08
a O 0 6.0555720438060234e-09
mouse O 0 2.859808319044532e-07
model O 0 1.194839711615714e-07
for O 0 6.226964721633976e-09
this O 0 1.6290092830217873e-08
disease O 0 6.450454748119228e-07
by O 0 7.315801298091174e-10
using O 0 4.215829108034086e-08
gene O 0 1.3341879139261437e-06
targeting O 0 4.64790628029732e-06
. O 0 8.123942620841262e-07

vWf B-Disease 0 0.01866469718515873
- I-Disease 1 0.9363374710083008
deficient I-Disease 0 0.4639541506767273
mice O 0 0.0006311155739240348
appeared O 0 1.9283240817458136e-06
normal O 0 2.51839821885369e-07
at O 0 6.78598382819473e-07
birth O 0 6.268030006140179e-07
; O 0 1.8138143431656317e-08
they O 0 1.8886064268031078e-08
were O 0 2.0109133913592814e-08
viable O 0 2.767642399703618e-07
and O 0 2.446155633606395e-08
fertile O 0 1.535568799226894e-06
. O 0 6.893642989780346e-07

Neither O 0 0.00010391265095677227
vWf O 0 0.000509308185428381
nor O 0 3.784371801884845e-05
vWf O 0 0.0001693535887170583
propolypeptide O 0 0.0011388187995180488
( O 0 1.5089474345586495e-06
von B-Disease 0 0.21457602083683014
Willebrand I-Disease 0 0.3637861907482147
antigen O 0 0.0001994619087781757
II O 0 6.718801887473091e-05
) O 0 2.8714877586821785e-08
were O 0 1.598159649063291e-08
detectable O 0 1.271039309358457e-07
in O 0 3.09296610545573e-09
plasma O 0 1.8869664017984178e-06
, O 0 2.8036327037739284e-08
platelets O 0 1.4082226016398636e-06
, O 0 1.158923090827102e-08
or O 0 7.382164568525695e-08
endothelial O 0 2.93962330033537e-07
cells O 0 1.498711981184897e-07
of O 0 8.093546388643347e-10
the O 0 1.913490876859214e-08
homozygous O 0 3.647755875135772e-06
mutant O 0 5.0103990361094475e-06
mice O 0 6.313899211818352e-05
. O 0 5.206927085055213e-07

The O 0 1.013421297102468e-06
mutant O 0 2.2464875655714422e-05
mice O 0 0.004077504388988018
exhibited O 0 0.0006786329904571176
defects O 1 0.8444444537162781
in O 0 5.739255470871285e-08
hemostasis O 0 2.080049853248056e-05
with O 0 2.1965833596482298e-08
a O 0 4.773744990416162e-07
highly O 0 5.5856908147688955e-06
prolonged O 0 9.38665762078017e-05
bleeding O 0 0.26524704694747925
time O 0 2.599979325168533e-07
and O 0 1.7349255188037205e-07
spontaneous O 0 8.095620387393865e-07
bleeding O 0 0.0008059788960963488
events O 0 5.78466297085356e-09
in O 0 2.6606441494436694e-09
approximately O 0 1.4706966311450742e-08
10 O 0 7.459655115837904e-09
% O 0 2.0460109162456774e-09
of O 0 4.8275730080149515e-09
neonates O 0 5.496985522768227e-06
. O 0 2.616994549953233e-07

As O 0 3.0070444267948915e-07
in O 0 2.815738753270125e-08
the O 0 1.8553125258335967e-08
human O 0 1.5197456093574147e-07
disease O 0 4.261232788849156e-06
, O 0 4.085480842519473e-09
the O 0 2.701290968687431e-09
factor O 0 2.6553070853196914e-08
VIII O 0 8.858310138748493e-06
level O 0 6.505734972961363e-08
in O 0 5.426564531063605e-09
these O 0 4.170400469405422e-09
mice O 0 3.75188665202586e-06
was O 0 4.961032118444564e-07
reduced O 0 6.051440948340314e-08
strongly O 0 1.9610887136423116e-08
as O 0 1.772911928377141e-09
a O 0 4.55396431675581e-09
result O 0 4.729235225653383e-09
of O 0 2.9444507942955056e-10
the O 0 4.519015828208239e-09
lack O 0 1.266488069973093e-08
of O 0 1.1162885060755912e-09
protection O 0 1.3513669294695774e-08
provided O 0 6.7758030297682126e-09
by O 0 1.5050478197053963e-08
vWf O 0 6.152617515908787e-06
. O 0 6.353338903863914e-07

Defective O 1 0.702231228351593
thrombosis B-Disease 0 0.4301919937133789
in O 0 5.366497362047085e-07
mutant O 0 1.8162767446483485e-05
mice O 0 0.006483887322247028
was O 0 4.081070073880255e-06
also O 0 8.24160721890621e-08
evident O 0 1.6916994027837973e-08
in O 0 9.033033765426524e-10
an O 0 2.3714412655806427e-09
in O 0 9.202278050679524e-09
vivo O 0 2.4237036996055394e-05
model O 0 1.9132271233957e-07
of O 0 4.732973835075427e-08
vascular B-Disease 1 0.5487989783287048
injury I-Disease 0 0.00014826310507487506
. O 0 5.577645083576499e-07

In O 0 2.566445971297071e-07
this O 0 6.269905483691218e-09
model O 0 5.24428287462797e-08
, O 0 4.551272247965699e-09
the O 0 3.695967976113934e-09
exteriorized O 0 5.369121481635375e-06
mesentery O 0 9.468924872635398e-06
was O 0 4.152643100496789e-07
superfused O 0 5.058493570686551e-07
with O 0 4.668507358474017e-09
ferric O 0 7.682285172450065e-07
chloride O 0 2.512750825189869e-07
and O 0 1.0588526500043827e-08
the O 0 3.528453307310997e-09
accumulation O 0 7.214499930796592e-08
of O 0 4.432870071013895e-09
fluorescently O 0 3.481343446765095e-05
labeled O 0 2.857330946426373e-05
platelets O 0 2.496618435543496e-05
was O 0 3.9450557665077213e-07
observed O 0 3.206188026183554e-08
by O 0 4.893505156644551e-09
intravital O 0 5.493045136972796e-06
microscopy O 0 1.888483893708326e-06
. O 0 4.3689820472536667e-07

We O 0 1.729528776195366e-05
conclude O 0 2.054290007436066e-06
that O 0 9.622701746536677e-09
these O 0 9.966061309540919e-10
mice O 0 5.006659762329946e-07
very O 0 1.2149811823292112e-08
closely O 0 1.137281401497603e-06
mimic O 0 0.0014814260648563504
severe O 0 0.0005514908698387444
human O 0 0.000116271163278725
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.2517622053564992e-05
will O 0 1.8707861499933642e-06
be O 0 3.918537672120692e-08
very O 0 3.2409432915159186e-09
useful O 0 3.859867092614877e-09
for O 0 2.1276689299298823e-09
investigating O 0 1.6478342246273314e-08
the O 0 1.3375752727640133e-09
role O 0 1.0773872460845269e-08
of O 0 7.002376456455295e-10
vWf O 0 2.5956708782359783e-07
in O 0 2.657470687950081e-08
normal O 0 6.472366749221692e-07
physiology O 0 1.1573589517865912e-06
and O 0 6.405276309351393e-08
in O 0 5.048247686545437e-08
disease O 0 6.715547442581737e-06
models O 0 2.638778084929072e-07
. O 0 1.2244263380978282e-08
. O 0 8.131060269533918e-08

Oral O 0 0.0012732621980831027
contraceptives O 0 0.015555852092802525
and O 0 3.0208011025933956e-07
the O 0 1.079160441008753e-07
risk O 0 8.4784960563411e-06
of O 0 2.0087932171009015e-06
hereditary B-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 3.609606892496231e-06

Hereditary B-Disease 1 0.9999995231628418
Ovarian I-Disease 1 0.9999995231628418
Cancer I-Disease 1 0.9933590292930603
Clinical O 0 0.00010069517884403467
Study O 0 4.6078667992333067e-07
Group O 0 7.52504729462089e-06
. O 0 1.0744157634690055e-06

BACKGROUND O 0 3.533872586558573e-05
Women O 0 6.752447347935231e-07
with O 0 9.580507054351983e-09
mutations O 0 2.2296562462997827e-07
in O 0 1.8681731717151706e-09
either O 0 1.2108286817635872e-08
the O 0 1.3855262714912442e-08
BRCA1 O 0 2.4755367121542804e-05
or O 0 1.340381885484021e-07
the O 0 1.877404187666798e-08
BRCA2 O 0 2.5298320906586014e-05
gene O 0 2.298244794474158e-07
have O 0 2.3865240894593853e-09
a O 0 5.7862079572146285e-09
high O 0 3.12165923332941e-07
lifetime O 0 1.4645936516899383e-06
risk O 0 1.3620066965813749e-05
of O 0 1.8424063455313444e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
. O 0 1.6177158386199153e-06

Oral O 0 0.0005082163843326271
contraceptives O 0 0.043511804193258286
protect O 0 0.00016962492372840643
against O 0 0.13798339664936066
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.6744456843298394e-07
general O 0 1.6780289158191408e-08
, O 0 1.1612176109565553e-08
but O 0 1.0419674012496216e-08
it O 0 3.090703160069097e-08
is O 0 1.519487113910145e-08
not O 0 7.180807504170161e-09
known O 0 7.861538087183817e-09
whether O 0 1.2959904260867461e-08
they O 0 5.704579475462879e-09
also O 0 3.414147542457613e-08
protect O 0 1.0874373401748016e-08
against O 0 1.1267622390676024e-08
hereditary B-Disease 0 7.402525807265192e-05
forms I-Disease 0 6.077738362364471e-06
of I-Disease 0 0.001711730845272541
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
. O 0 1.0618761052683112e-06

METHODS O 0 5.106467142468318e-06
We O 0 1.0948802042776151e-07
enrolled O 0 6.108705008500692e-08
207 O 0 2.115591257734195e-07
women O 0 1.8134724655283208e-07
with O 0 5.9618500927172136e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.04749733004428e-07
161 O 0 2.7068987051848126e-08
of O 0 9.301943104667032e-10
their O 0 2.407625743217068e-07
sisters O 0 5.853495167684741e-06
as O 0 3.072605636589287e-08
controls O 0 1.5108726074686274e-06
in O 0 9.70509361764016e-09
a O 0 1.0086374402362708e-07
case O 0 5.843940584782104e-07
- O 0 4.239047484588809e-05
control O 0 3.07891023112461e-05
study O 0 2.5519727842038264e-07
. O 0 1.8202646856479987e-07

All O 0 2.4005368004509364e-07
the O 0 4.37748575166097e-08
patients O 0 1.0026701602328103e-07
carried O 0 6.9234800115225426e-09
a O 0 4.437218148467537e-09
pathogenic O 0 9.741130213569704e-08
mutation O 0 1.4049453511688625e-07
in O 0 3.809133009013976e-09
either O 0 7.829547854498742e-08
BRCA1 O 0 2.1482081137946807e-05
( O 0 2.2332903526489645e-08
179 O 0 3.5328795888744935e-08
women O 0 3.25751656760076e-08
) O 0 1.3046436819763585e-08
or O 0 1.1756003459595377e-06
BRCA2 O 0 0.005118160974234343
( O 0 2.3968539153429447e-07
28 O 0 5.489591217155976e-07
women O 0 8.767575110368853e-08
) O 0 2.9422363212461278e-08
. O 0 1.4218289834388997e-07

The O 0 9.058271643880289e-07
control O 0 3.088978928644792e-06
women O 0 2.8212659231030557e-07
were O 0 1.8081701469441214e-08
enrolled O 0 8.37369018569234e-09
regardless O 0 2.314810787495958e-09
of O 0 4.3103379199216363e-10
whether O 0 3.4518766511837384e-08
or O 0 3.887628565735213e-07
not O 0 4.240838435976002e-08
they O 0 8.740404844331806e-09
had O 0 6.027986643175609e-08
either O 0 4.2481087092482994e-08
mutation O 0 6.721767817907676e-07
. O 0 1.1520968001832443e-07

Lifetime O 0 1.0031003512267489e-05
histories O 0 1.0729044106483343e-06
of O 0 3.29077707306169e-08
oral O 0 1.1124461707368027e-06
- O 0 1.8202787032350898e-05
contraceptive O 0 1.625875120225828e-05
use O 0 3.593548569824634e-08
were O 0 5.5640323459726915e-09
obtained O 0 3.860228137142485e-09
by O 0 3.290674843725583e-09
interview O 0 3.0459038953267736e-06
or O 0 1.0884126488974744e-08
by O 0 1.2022534079392244e-09
written O 0 7.164309145935022e-09
questionnaire O 0 9.682683987932705e-09
and O 0 4.735300596081515e-09
were O 0 5.73780756241149e-09
compared O 0 1.5284747689747746e-08
between O 0 5.202029917938944e-09
patients O 0 1.9820045338292402e-07
and O 0 4.798639352543432e-08
control O 0 2.270170625706669e-06
women O 0 7.759985010125092e-08
, O 0 7.522523048919538e-09
after O 0 1.4080271171224013e-08
adjustment O 0 1.0463847566200002e-08
for O 0 1.7211534419914187e-09
year O 0 1.0853900000995509e-08
of O 0 1.1230455454480648e-09
birth O 0 2.5996965291597007e-07
and O 0 5.366825206465364e-08
parity O 0 1.0679849538064445e-06
. O 0 3.202533491730719e-07

RESULTS O 0 3.065386772505008e-05
The O 0 4.527291608269479e-08
adjusted O 0 5.372618034016341e-05
odds O 0 9.164295988739468e-06
ratio O 0 8.793071174295619e-06
for O 0 0.043975379317998886
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 2.7770363431045553e-07
with O 0 2.219009864745658e-09
any O 0 7.4511383729714e-09
past O 0 3.532057490929219e-08
use O 0 4.591338509385423e-08
of O 0 7.254721268168396e-09
oral O 0 1.4429738257604185e-06
contraceptives O 0 0.00010092723096022382
was O 0 2.0109600029627472e-07
0 O 0 1.4193064146184042e-07
. O 0 2.713081528327166e-07

5 O 0 2.9605059808091028e-06
( O 0 7.420690195658608e-08
95 O 0 1.6709169869955076e-07
percent O 0 4.713249836640898e-06
confidence O 0 8.610762591843013e-08
interval O 0 2.0250004340027772e-08
, O 0 1.4292451666619854e-09
0 O 0 1.9791850380812548e-09
. O 0 8.401762063847684e-10
3 O 0 5.934845948019074e-09
to O 0 5.268381730871852e-09
0 O 0 7.70943842098859e-09
. O 0 3.844151663656703e-09
8 O 0 1.9874324408419852e-08
) O 0 7.77329844936503e-09
. O 0 8.035395637762122e-08

The O 0 2.790591452139779e-06
risk O 0 4.217593414068688e-06
decreased O 0 3.921981601706648e-07
with O 0 5.196189256650996e-09
increasing O 0 1.3566561207767336e-08
duration O 0 4.6676994713834574e-08
of O 0 9.181586047013468e-10
use O 0 1.1509425945632756e-07
( O 0 1.9188709288187056e-08
P O 0 2.1488349375431426e-05
for O 0 4.769182826436236e-09
trend O 0 3.686494096655224e-07
, O 0 1.7898358350976196e-09
< O 0 6.675247021803443e-09
0 O 0 1.4100474121647721e-09
. O 0 9.365926922910717e-10
001 O 0 5.8827667182015375e-09
) O 0 4.33358432472275e-10
; O 0 4.3263498339385364e-10
use O 0 5.3615227812997546e-09
for O 0 1.187791820456141e-08
six O 0 3.837180173604793e-08
or O 0 5.0279908236916526e-08
more O 0 1.9047046606601725e-08
years O 0 3.003931325906706e-08
was O 0 1.7614671321553033e-07
associated O 0 1.2907327429090287e-09
with O 0 1.4202278242336774e-10
a O 0 1.0048791132533097e-08
60 O 0 2.230608409092838e-08
percent O 0 1.6977576251520077e-06
reduction O 0 8.904625303784997e-08
in O 0 1.9246328974986682e-08
risk O 0 1.1298342315058107e-06
. O 0 3.130991217403789e-07

Oral O 0 9.346374281449243e-05
- O 0 5.7303488574689254e-05
contraceptive O 0 3.9007110899547115e-05
use O 0 2.5027995320670016e-07
protected O 0 2.5168710635625757e-05
against O 0 0.002665806794539094
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
both O 0 7.632944942770337e-09
for O 0 1.4941438086779613e-09
carriers O 0 5.242819955952882e-09
of O 0 2.6106150574634057e-10
the O 0 1.8074977958804084e-08
BRCA1 O 0 3.2725725759519264e-05
mutation O 0 1.209381139233301e-06
( O 0 9.513368759428431e-09
odds O 0 3.624829787440831e-07
ratio O 0 2.5834236083710493e-08
, O 0 2.732819970319156e-09
0 O 0 1.577077135550553e-09
. O 0 5.684580584031096e-10
5 O 0 2.029260093294738e-09
; O 0 6.199857849331636e-10
95 O 0 7.58602070050074e-09
percent O 0 2.3106977096176706e-06
confidence O 0 1.2736196985940751e-08
interval O 0 7.7013551091909e-09
, O 0 9.620787499997618e-10
0 O 0 1.5819517917847747e-09
. O 0 6.962582732583655e-10
3 O 0 2.618115946262378e-09
to O 0 6.1189648903337e-09
0 O 0 7.507615862323291e-09
. O 0 5.678211678628031e-09
9 O 0 6.70897222221356e-08
) O 0 7.052641248783686e-10
and O 0 1.7713300826116551e-09
for O 0 1.7666131890692327e-09
carriers O 0 3.2436766606025458e-09
of O 0 3.1401081734827585e-10
the O 0 4.530816255510217e-08
BRCA2 O 0 0.000163703050930053
mutation O 0 8.410041232309595e-07
( O 0 6.2138667544786585e-09
odds O 0 2.773968219571543e-07
ratio O 0 1.7130485474581292e-08
, O 0 3.858446451232567e-09
0 O 0 2.1813719719432356e-09
. O 0 7.1671485413205e-10
4 O 0 3.1729818772419094e-09
; O 0 1.130988303010838e-09
95 O 0 1.7938456053911978e-08
percent O 0 3.3349815566907637e-06
confidence O 0 1.981444519572051e-08
interval O 0 6.0438254401162794e-09
, O 0 5.200331276711267e-10
0 O 0 1.141673422466738e-09
. O 0 4.5597850495404657e-10
2 O 0 7.526139711444557e-09
to O 0 4.586408142159826e-09
1 O 0 1.4061806830056867e-08
. O 0 1.8582794192312235e-09
1 O 0 3.183598451528269e-08
) O 0 1.6353537191093892e-08
. O 0 1.409779741834427e-07

CONCLUSIONS O 0 0.00010096564801642671
Oral O 0 1.3165874406695366e-05
- O 0 3.05736975860782e-05
contraceptive O 0 7.826156070223078e-05
use O 0 2.5928554236998025e-07
may O 0 2.1019441476255452e-07
reduce O 0 3.342949739248979e-08
the O 0 3.542089643815416e-08
risk O 0 5.340894858818501e-06
of O 0 2.3649196009500884e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 4.872700998248547e-08
women O 0 1.043817299262173e-08
with O 0 1.384585113228809e-09
pathogenic O 0 1.7715278488594777e-07
mutations O 0 6.712018603138858e-07
in O 0 2.4572039958314917e-09
the O 0 3.813605431446376e-08
BRCA1 O 0 0.00025732198264449835
or O 0 3.173275035806e-05
BRCA2 O 0 0.011836260557174683
gene O 0 0.0003783330030273646

A O 0 9.715652140585007e-07
Japanese O 0 3.044998777568253e-07
family O 0 1.4423008565245254e-07
with O 0 1.3473602678004681e-07
adrenoleukodystrophy B-Disease 1 0.9999996423721313
with O 0 1.4786988522530464e-08
a O 0 3.818496807639349e-08
codon O 0 6.353042181217461e-07
291 O 0 1.3969557244308817e-07
deletion O 0 1.6399161495428416e-06
: O 0 3.53300566580117e-09
a O 0 2.6859256152533817e-08
clinical O 0 2.447668236982281e-07
, O 0 8.035943466211393e-09
biochemical O 0 4.248497873504675e-07
, O 0 2.9499346965167206e-08
pathological O 0 2.0651959857787006e-06
, O 0 8.188079547721827e-09
and O 0 7.585720851466249e-08
genetic O 0 7.588956577819772e-06
report O 0 4.687989530793857e-06
. O 0 3.8840116189930995e-07

We O 0 6.610349373659119e-06
report O 0 4.0632963305142766e-07
a O 0 9.506639919720783e-09
Japanese O 0 5.337802377880507e-08
family O 0 1.6123685497859697e-07
with O 0 1.7907693745655706e-06
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.0013055569725111127
ALD B-Disease 1 1.0
) O 0 1.735861410168127e-08
with O 0 1.688822970358217e-09
a O 0 2.425310086096033e-08
three O 0 1.5265140262954446e-08
base O 0 4.066831493787504e-08
pair O 0 2.789109885270591e-07
deletion O 0 1.3027037084611948e-06
( O 0 4.8796180429633296e-09
delGAG O 0 2.040439568418151e-07
291 O 0 4.246374984973045e-08
) O 0 3.907713264084123e-09
in O 0 1.1582380388119873e-08
the O 0 1.4009597180120181e-06
ALD B-Disease 1 0.9999998807907104
gene O 0 2.2738218831364065e-05
. O 0 4.874755177297629e-07

A O 0 1.546800945106952e-06
variety O 0 4.974533851509477e-08
of O 0 4.9708130944736695e-09
phenotypes O 0 2.4490859686920885e-06
were O 0 7.888984754345074e-08
observed O 0 5.0884334967804534e-08
within O 0 1.708309937953345e-09
this O 0 5.665327318382651e-09
family O 0 2.7837447191814135e-07
. O 0 4.772616080117587e-07

While O 0 9.75496163846401e-07
the O 0 5.156541860174002e-08
proband O 0 4.511268707574345e-05
( O 0 3.049415795430832e-07
patient O 0 9.049162486007845e-07
1 O 0 1.330982399849745e-07
) O 0 1.4795396019451346e-08
was O 0 5.84499957767548e-07
classified O 0 3.5879946835848386e-07
as O 0 1.2541084615236286e-08
having O 0 6.4289817913731895e-09
a O 0 5.700435234956558e-09
rare O 0 3.6174923057075148e-09
intermediate O 0 2.069991467124055e-08
type O 0 4.5132896531185906e-08
of O 0 1.755816714243963e-09
adult O 0 9.877567208604887e-07
cerebral O 0 1.0320459296053741e-05
and O 0 3.843890397092764e-07
cerebello O 0 0.03676612675189972
- O 0 0.44467130303382874
brain O 0 0.14405937492847443
stem O 0 1.0964680541292182e-06
forms O 0 1.7531077389776328e-07
, O 0 5.4081542799622184e-08
his O 0 5.330487056198763e-07
younger O 0 8.008617555788078e-07
brother O 0 1.1723748229997e-06
( O 0 3.451474839266666e-08
patient O 0 2.091025521622214e-07
2 O 0 7.057868600668371e-08
) O 0 2.416928523985007e-08
and O 0 5.345239628695708e-07
nephew O 0 2.5535493477946147e-05
( O 0 1.93676001458698e-07
patient O 0 1.1597144293773454e-06
3 O 0 2.2213703232409898e-07
) O 0 2.264417631181459e-08
had O 0 8.173444712156197e-07
a O 0 4.844487193622626e-06
childhood O 0 0.0002307917457073927
ALD B-Disease 1 1.0
type O 0 2.5714592993608676e-05
. O 0 8.4200405581214e-07

Another O 0 9.282636710850056e-06
nephew O 0 0.00025435059797018766
( O 0 1.3692051652469672e-06
patient O 0 1.4480192476185039e-06
4 O 0 1.1071948335938941e-07
) O 0 9.49649070491887e-09
of O 0 1.6752169651468307e-09
patient O 0 1.0108539072462008e-06
1 O 0 2.430633969652263e-07
was O 0 2.455285766700399e-06
classified O 0 1.503458975093963e-06
as O 0 7.3201910311127e-08
having O 0 2.9635485176982e-08
an O 0 9.150715740702253e-09
adolescent O 0 4.028163118618977e-07
form O 0 1.2991264952688653e-07
. O 0 7.598694651278493e-07

The O 0 2.283375835077095e-07
tau O 0 7.619390203217336e-07
level O 0 5.573562589233916e-08
in O 0 8.836605225326366e-09
the O 0 1.4277600257628364e-07
cerebrospinal O 0 0.0007785169291310012
fluid O 0 6.378302350640297e-05
( O 0 3.5223474696977064e-06
CSF O 1 0.9928227663040161
) O 0 5.437581407363723e-08
in O 0 3.1338824868498705e-08
patient O 0 1.2911417570649064e-06
1 O 0 1.4604397335915564e-07
was O 0 1.8500703617974068e-06
as O 0 2.811402666225149e-08
high O 0 2.476378213600583e-08
as O 0 1.1224400076059737e-08
that O 0 2.5029742722892934e-09
of O 0 3.309469809309462e-09
patients O 0 2.8946558927600563e-07
with O 0 1.650244314532756e-07
Alzheimers B-Disease 1 0.9999197721481323
disease I-Disease 0 0.3860791325569153
( O 0 4.530038566485928e-08
AD B-Disease 0 2.4315120754181407e-05
) O 0 2.793187832139665e-07
. O 0 4.708365963779215e-07

His O 0 1.1466295291029382e-05
brain O 0 0.0003575302253011614
magnetic O 0 8.669347153045237e-06
resonance O 0 8.406108463532291e-06
image O 0 0.00018393095524515957
( O 0 1.0699023960114573e-06
MRI O 0 0.009608314372599125
) O 0 5.482287406266551e-07
showed O 0 1.8333992557018064e-05
abnormalities B-Disease 0 0.00028412140090949833
in I-Disease 0 3.8628797938145e-09
the I-Disease 0 2.286347289270907e-08
bilateral I-Disease 0 3.657425850178697e-06
cerebellar I-Disease 0 0.021451879292726517
hemispheres I-Disease 0 0.02877877652645111
and O 0 1.3115620276948903e-05
brain O 0 0.005789098795503378
stem O 0 3.3254789286729647e-06
, O 0 2.4583773239328366e-08
but O 0 2.2568462654248833e-08
not O 0 5.199440877845518e-09
in O 0 4.23458823561873e-09
the O 0 4.1758070778996625e-08
cerebral O 0 1.3965594916953705e-05
white O 0 2.650071166954149e-07
matter O 0 2.3625171152730218e-08
, O 0 2.655118347405505e-09
where O 0 2.031335988306182e-09
marked O 0 1.8228872633585524e-08
reductions O 0 1.9116055227641482e-07
of O 0 7.97174604105777e-10
the O 0 1.8060870843328303e-07
cerebral O 0 3.553052738425322e-05
blood O 0 1.5197905440800241e-06
flow O 0 1.5549369436484994e-06
and O 0 1.1563015789306519e-07
oxygen O 0 1.1889528650499415e-07
metabolism O 0 6.943756147848035e-07
were O 0 7.656916878318043e-09
clearly O 0 6.991437206949058e-09
demonstrated O 0 1.1065605098892206e-09
by O 0 3.379707902428919e-10
positron O 0 1.2427915407897672e-06
emission O 0 5.95507663092576e-06
tomography O 0 0.0005796402110718191
( O 0 1.238831544014829e-07
PET O 0 5.2317183872219175e-05
) O 0 1.754927865249556e-07
. O 0 4.706597280801361e-07

In O 0 3.5488496905600186e-06
patients O 0 7.67403525969712e-06
2 O 0 9.946357693024765e-08
and O 0 5.443039086117096e-08
3 O 0 1.2345704192284757e-07
, O 0 1.5081340620781702e-08
the O 0 2.2091123597078877e-08
autopsy O 0 9.832678915699944e-05
findings O 0 4.5748998900307924e-07
showed O 0 9.319182936451398e-07
massive O 0 5.061639853920497e-07
demyelination B-Disease 1 0.9999986886978149
of I-Disease 0 4.924763175040425e-08
the I-Disease 0 1.9238039783431304e-07
cerebral I-Disease 0 2.202890391345136e-05
white I-Disease 0 1.9696361164278642e-07
matter I-Disease 0 3.9119791850339425e-09
with O 0 7.696153159209018e-10
sparing O 0 8.54529780269786e-09
of O 0 5.114183521115478e-10
the O 0 1.3493862915936461e-08
U O 0 0.0030093758832663298
- O 0 0.0006927139475010335
fibers O 0 0.0012539720628410578
, O 0 1.3660452324870676e-08
compatible O 0 4.661435681896364e-08
with O 0 1.223452228416022e-09
the O 0 2.481063354764501e-08
findings O 0 2.7430789373283915e-07
of O 0 2.0973621062125858e-08
childhood O 0 4.869061740464531e-05
ALD B-Disease 1 0.9999998807907104
. O 0 2.9473501399479574e-06

Oleic O 0 0.0033355592750012875
and O 0 3.9255583033082075e-06
erucic O 0 0.0006910199881531298
acids O 0 1.1727376659109723e-05
( O 0 4.5145814198122025e-08
Lorenzos O 0 2.678516011656029e-06
Oil O 0 2.1722139535995666e-06
) O 0 4.200721104297145e-09
were O 0 3.2163782748284575e-09
administered O 0 1.8422188219346936e-09
to O 0 3.42335511049896e-08
patients O 0 8.3909243997482e-09
1 O 0 4.730363212246402e-09
and O 0 5.614288056676742e-08
4 O 0 1.0648194859186333e-07
, O 0 1.4444063722862666e-08
but O 0 7.254223000074944e-09
sufficient O 0 5.847004214132312e-09
effectiveness O 0 2.5343545928535605e-08
was O 0 1.3045520574905822e-07
not O 0 6.215620906857566e-09
obtained O 0 9.210763352029971e-08
. O 0 9.570830883376402e-08

The O 0 8.587109618929389e-07
findings O 0 5.35953233793407e-07
in O 0 8.945015395056544e-09
this O 0 3.204419396496405e-09
family O 0 5.225790644658446e-08
suggest O 0 4.895860428177912e-08
that O 0 3.2101943325812954e-09
delGAG291 O 0 4.869124268225278e-07
is O 0 3.6368079658899433e-09
part O 0 3.047093910524268e-09
of O 0 6.475200930999847e-10
the O 0 1.6749879705457715e-08
cause O 0 7.859743078597603e-08
of O 0 2.726629588778451e-09
Japanese O 0 4.4367775444698054e-06
ALD B-Disease 1 0.9999995231628418
with O 0 2.9431342696284446e-08
phenotypic O 0 2.6489417450648034e-06
variations O 0 6.32895944363554e-06
. O 0 1.2178346651126049e-06

Moreover O 0 1.7183474483317696e-05
, O 0 7.87664120593945e-08
although O 0 4.339451020740626e-09
the O 0 5.447385320600517e-10
scale O 0 3.485525112978394e-08
of O 0 2.1006358874586795e-09
the O 0 1.9269103646024632e-08
study O 0 1.1713769509924532e-08
is O 0 8.83185347078097e-09
limited O 0 7.9050082035792e-09
, O 0 1.343987054980289e-08
there O 0 5.55556711745453e-10
is O 0 1.0662207783340705e-09
a O 0 7.981487470942739e-09
possibility O 0 7.266769408431628e-09
that O 0 2.4886834815163184e-09
PET O 0 2.948022029158892e-06
can O 0 6.672512142813503e-08
detect O 0 2.876117150663049e-06
an O 0 5.8921347800833246e-08
insidious B-Disease 0 6.478591967606917e-05
lesion I-Disease 0 0.2154419869184494
which O 0 1.1264779686825932e-07
is O 0 7.0402532692526165e-09
undetectable O 0 1.5397849040255096e-07
by O 0 9.006745904649449e-10
computed O 0 1.8185431827077991e-06
tomogram O 0 7.959373033372685e-05
( O 0 1.7020410325585544e-07
CT O 1 0.9711766242980957
) O 0 3.482129784515564e-08
or O 0 2.7470554186947993e-07
MRI O 0 0.0003348035679664463
analysis O 0 1.5324484081702394e-07
, O 0 1.9093130632086286e-08
and O 0 1.0565668340234424e-08
that O 0 7.554987191404905e-10
the O 0 1.2207879152015266e-09
higher O 0 3.194876185830253e-08
level O 0 3.5938074738339765e-09
of O 0 3.548686067222917e-10
tau O 0 1.0212060530534472e-08
reflects O 0 5.42942180103978e-09
the O 0 6.606893920846346e-10
process O 0 4.166313960496382e-09
of O 0 3.543067395028743e-09
neuronal B-Disease 0 0.0003457347338553518
degeneration I-Disease 1 0.9686254262924194
in O 0 1.1084305697295349e-05
ALD B-Disease 1 1.0
. O 0 4.451607310329564e-06

Lorenzos O 0 0.0009655129979364574
Oil O 0 5.374037573346868e-05
should O 0 5.892809085139561e-08
be O 0 1.142261507602882e-09
given O 0 2.3075977240161194e-10
in O 0 4.4277298494321826e-10
the O 0 1.0381442372420224e-09
early O 0 3.28730145326972e-08
stage O 0 1.3554772237966972e-07
. O 0 6.875906954917355e-09
. O 0 7.684690217502066e-08

Nonsense O 0 9.363912249682471e-05
mutation O 0 9.032728485180996e-06
in O 0 5.0888214531141784e-08
exon O 0 1.3409295434030355e-06
4 O 0 7.526803358359757e-08
of O 0 1.5497451100188187e-09
human O 0 9.80295133956588e-09
complement O 0 6.478789060793133e-08
C9 O 0 2.5876554445858346e-06
gene O 0 7.575179665764153e-07
is O 0 6.0104188293053085e-09
the O 0 2.714539037995678e-09
major O 0 4.4348425376483647e-08
cause O 0 3.011389182461244e-08
of O 0 1.1126471965994256e-09
Japanese O 0 2.1145584128134942e-07
complement B-Disease 0 2.053720209005405e-06
C9 I-Disease 0 0.0051561142317950726
deficiency I-Disease 0 0.0019229190656915307
. O 0 3.8530183132934326e-07

Deficiency B-Disease 1 0.9834532141685486
of I-Disease 0 2.41996378491649e-08
the I-Disease 0 1.3977787816088494e-08
ninth I-Disease 0 3.8993471207504626e-07
component I-Disease 0 9.555308366770987e-08
of I-Disease 0 1.7189193401989655e-09
human I-Disease 0 1.3078776284203286e-08
complement I-Disease 0 8.202198387152748e-08
( O 0 2.139724486482919e-08
C9 O 0 1.1747911230486352e-06
) O 0 8.811039897693718e-09
is O 0 6.116254724908288e-10
the O 0 2.026969286861302e-10
most O 0 6.511455374891284e-09
common O 0 2.4516216399206314e-06
complement B-Disease 1 0.9999997615814209
deficiency I-Disease 1 0.9999998807907104
in O 0 1.3714127611308413e-08
Japan O 0 4.097817907222634e-07
but O 0 1.6276519687608015e-08
is O 0 1.4118612945424047e-09
rare O 0 1.8948655977624185e-09
in O 0 1.292149054421543e-09
other O 0 3.6203569031556526e-09
countries O 0 1.6336578312348138e-08
. O 0 1.3999751047322206e-07

We O 0 5.82578934427147e-07
studied O 0 5.2687763485437245e-08
the O 0 1.704498542309807e-09
molecular O 0 2.088396477972765e-08
basis O 0 2.3528620829438296e-08
of O 0 1.498582591352715e-08
C9 B-Disease 0 0.022865377366542816
deficiency I-Disease 0 0.0019481789786368608
in O 0 2.815286226365288e-09
four O 0 5.480382814226914e-09
Japanese O 0 9.822869628806075e-08
C9 B-Disease 0 7.618983363499865e-05
- I-Disease 0 0.14694096148014069
deficient I-Disease 0 0.29330968856811523
patients O 0 2.692586713237688e-05
who O 0 1.100254621633212e-06
had O 0 2.499372021702584e-05
suffered O 0 0.031612105667591095
from O 0 3.5134103200107347e-06
meningococcal B-Disease 1 0.9999996423721313
meningitis I-Disease 1 0.9999926090240479
. O 0 1.979396984097548e-06

Direct O 0 1.4988862631071243e-06
sequencing O 0 2.526522166590439e-06
of O 0 5.2888932344785644e-08
amplified O 0 1.7689663991404814e-06
C9 O 0 5.389507805375615e-06
cDNA O 0 1.0992656598318717e-06
and O 0 8.005809348787807e-08
DNA O 0 5.231495379121043e-07
revealed O 0 3.756469482141256e-07
a O 0 5.846000128428841e-09
nonsense O 0 6.47525695285367e-08
substitution O 0 6.787198802982175e-09
( O 0 2.9776436871742362e-09
CGA O 0 5.927376491854375e-07
- O 0 4.371867817098973e-06
- O 0 1.1164720490342006e-05
> O 0 1.0579203291172234e-07
TGA O 0 9.12528662411205e-07
) O 0 1.451849418465656e-09
at O 0 3.707264495389495e-09
codon O 0 2.8490601877706467e-08
95 O 0 3.41445849372235e-09
in O 0 1.0166734121241916e-09
exon O 0 5.7438217737626474e-08
4 O 0 7.264857160294014e-09
in O 0 6.891001103070948e-10
the O 0 2.9783482347056633e-09
four O 0 1.3740380211402226e-07
C9 B-Disease 0 0.00020848136045970023
- I-Disease 0 0.012229462154209614
deficient I-Disease 0 0.0005471055628731847
individuals O 0 5.534652558480957e-08
. O 0 1.2985134389964514e-07

An O 0 2.7089859599982447e-07
allele O 0 4.937818175676512e-06
- O 0 5.9608209994621575e-06
specific O 0 4.718578949791663e-08
polymerase O 0 1.0203590363744297e-06
chain O 0 7.794050361553673e-06
reaction O 0 4.426687283398678e-08
system O 0 8.997461442561416e-09
designed O 0 3.996342101686423e-08
to O 0 3.4836446616282046e-08
detect O 0 4.7452536477976537e-07
exclusively O 0 5.359948040961626e-09
only O 0 1.095184165578189e-09
one O 0 1.8044071792289174e-09
of O 0 1.3984173541370382e-10
the O 0 2.0360060304369654e-09
normal O 0 7.043600191991573e-08
and O 0 8.073291368759783e-09
mutant O 0 4.8726636947549196e-08
alleles O 0 4.309734080720773e-08
indicated O 0 3.35850614874289e-07
that O 0 1.4205807641332058e-09
all O 0 4.531027775200869e-10
the O 0 2.7961974957690927e-09
four O 0 6.46933102643743e-08
patients O 0 3.3164351265213554e-08
were O 0 5.127818725192412e-10
homozygous O 0 4.052883362248849e-09
for O 0 3.1714977866137417e-10
the O 0 8.971717813111013e-10
mutation O 0 5.595601137997619e-08
in O 0 2.9530631273644303e-09
exon O 0 3.288923267064092e-07
4 O 0 1.3195696624279663e-07
and O 0 2.466921422694668e-08
that O 0 2.935396370418175e-09
the O 0 3.494910139067997e-09
parents O 0 4.028898104024847e-09
of O 0 1.4934314895853618e-09
patient O 0 1.751744065359162e-07
2 O 0 3.800701975364973e-08
were O 0 6.312023970167502e-08
heterozygous O 0 1.1112840638816124e-06
. O 0 2.2322902282212453e-07

The O 0 1.2572847651881602e-07
common O 0 7.961375558807049e-08
mutation O 0 3.0532163464158657e-07
at O 0 4.02564310775233e-08
codon O 0 1.842840333665663e-07
95 O 0 2.3693717210448995e-08
in O 0 4.217451721189036e-09
exon O 0 7.835447490833758e-07
4 O 0 4.4465568294072e-07
might O 0 9.31819883476237e-08
be O 0 9.692625368984409e-09
responsible O 0 6.84897258906858e-08
for O 0 2.6392439345102048e-09
most O 0 7.807845925356105e-09
Japanese O 0 6.513433277177683e-07
C9 B-Disease 0 0.0008069520117715001
deficiency I-Disease 0 7.65070435591042e-05
. O 0 1.0113398118960504e-08
. O 0 9.52586489688656e-08

BRCA1 O 0 0.000355052383383736
required O 0 2.9698131243094394e-07
for O 0 1.4328761288595615e-08
transcription O 0 1.5842283573874738e-06
- O 0 6.971110997255892e-05
coupled O 0 9.57299653236987e-06
repair O 0 8.066776354098693e-05
of O 0 1.8739699569891854e-08
oxidative O 0 1.8584718191050342e-06
DNA O 0 0.0001162822445621714
damage O 0 0.00018606158846523613
. O 0 9.882871836452978e-07

The O 0 2.52947738772491e-05
breast B-Disease 1 0.9999479055404663
and I-Disease 1 0.996085524559021
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
susceptibility O 0 0.00011778254702221602
gene O 0 5.742666417063447e-06
BRCA1 O 0 4.1750499804038554e-05
encodes O 0 2.8341230517980875e-06
a O 0 7.42066163184063e-07
zinc O 0 0.00048437860095873475
finger O 0 0.00011212786921532825
protein O 0 7.305503118004708e-07
of O 0 1.6675500980056768e-09
unknown O 0 4.1971912168037306e-08
function O 0 1.4687462623896863e-07
. O 0 2.560002485552104e-07

Association O 0 1.7074546576623106e-06
of O 0 6.87580170577462e-09
the O 0 6.38179908918346e-09
BRCA1 O 0 1.4051385051061516e-06
protein O 0 1.7107259964177501e-07
with O 0 1.1651728470951639e-09
the O 0 2.27856666867865e-09
DNA O 0 7.70760266277648e-07
repair O 0 5.308902018441586e-06
protein O 0 3.308623206521588e-07
Rad51 O 0 2.9127406833140412e-06
and O 0 1.3593083991736421e-08
changes O 0 1.3096043138816071e-09
in O 0 2.092992168467589e-10
the O 0 2.913017882466562e-10
phosphorylation O 0 6.82992329359422e-09
and O 0 4.055854674334114e-08
cellular O 0 6.340040954455617e-07
localization O 0 4.678538090274742e-08
of O 0 4.473339754174077e-10
the O 0 1.992373155346172e-09
protein O 0 7.120215173017641e-08
after O 0 4.872831027569191e-08
exposure O 0 6.595190171765353e-08
to O 0 4.125974673030441e-09
DNA O 0 3.173902769049164e-06
- O 0 0.0007285976898856461
damaging O 0 4.348978109192103e-05
agents O 0 1.0802128258546873e-07
are O 0 5.07237141178507e-10
consistent O 0 3.116832125726887e-09
with O 0 4.2905864972020424e-10
a O 0 2.4778808338510316e-08
role O 0 4.2282792378500744e-08
for O 0 1.4265497227938795e-08
BRCA1 O 0 6.702182417939184e-06
in O 0 4.890317129024879e-08
DNA O 0 2.0841380319325253e-05
repair O 0 0.00031997167388908565
. O 0 5.262896252133942e-07

Here O 0 2.952416707557859e-06
, O 0 5.833272354038854e-08
it O 0 5.6361941780380675e-09
is O 0 2.2413588762759673e-09
shown O 0 2.9920703692454254e-09
that O 0 1.1380882902756184e-09
mouse O 0 8.178325856533775e-07
embryonic O 0 3.0184332899807487e-06
stem O 0 4.275614628568292e-06
cells O 0 3.41302074957639e-05
deficient B-Disease 0 4.725081817014143e-05
in I-Disease 0 5.7575984868663e-08
BRCA1 I-Disease 0 5.1620845624711365e-05
are O 0 4.2027508584396855e-08
defective O 0 7.031021596048959e-06
in O 0 7.716911554211947e-09
the O 0 5.849257078693881e-09
ability O 0 3.059091469026498e-08
to O 0 4.852581447778448e-09
carry O 0 2.1667437621886165e-08
out O 0 1.1016374479311253e-08
transcription O 0 1.4495734035335772e-07
- O 0 4.641652139980579e-06
coupled O 0 2.0044778921146644e-06
repair O 0 9.195434358844068e-06
of O 0 2.322913417174277e-09
oxidative O 0 1.2606513166701916e-07
DNA O 0 1.6220048564719036e-05
damage O 0 4.2785643017850816e-05
, O 0 2.6056133251017854e-08
and O 0 2.3058797538055842e-08
are O 0 8.2292723746491e-09
hypersensitive O 0 5.675816737493733e-06
to O 0 1.0088413660014339e-07
ionizing O 0 2.659633764778846e-06
radiation O 0 4.773412911163177e-06
and O 0 1.555811479647673e-08
hydrogen O 0 9.043057502822194e-08
peroxide O 0 9.351132575829979e-06
. O 0 2.7288118076285173e-07

These O 0 8.85999781985447e-07
results O 0 1.3410856354312273e-06
suggest O 0 1.147211250440705e-07
that O 0 1.5035386269346418e-08
BRCA1 O 0 5.077825335320085e-06
participates O 0 3.796402268108068e-07
, O 0 1.435871865851368e-08
directly O 0 2.2288180190344065e-08
or O 0 9.337449569102318e-08
indirectly O 0 3.841105353785679e-07
, O 0 2.6571245204110028e-09
in O 0 9.638345677132065e-10
transcription O 0 4.236392214806983e-07
- O 0 2.6561980121186934e-05
coupled O 0 8.146161235345062e-06
repair O 0 4.596373764798045e-05
of O 0 9.030832970324809e-09
oxidative O 0 9.577117907610955e-07
DNA O 0 3.874033791362308e-05
damage O 0 1.7268255760427564e-05
. O 0 6.155818255138001e-08
. O 0 1.8560103853815235e-07

Truncation O 0 0.0003623566299211234
mutations O 0 0.00017386347462888807
in O 0 3.8602301799528504e-08
the O 0 1.5506183004276863e-08
transactivation O 0 3.047097379749175e-05
region O 0 3.221367251171614e-06
of O 0 7.730303508424186e-09
PAX6 O 0 1.3577528079622425e-05
result O 0 4.746869564087319e-08
in O 0 3.655752811582147e-09
dominant O 0 3.3608300782361766e-06
- O 0 5.039736788603477e-05
negative O 0 2.3163086098065833e-06
mutants O 0 4.815620741283055e-06
. O 0 2.414498396774434e-07

PAX6 O 0 0.0014862763928249478
is O 0 1.7308106237123866e-07
a O 0 9.558148050814452e-09
transcription O 0 8.224819936231142e-08
factor O 0 9.895640751267365e-09
with O 0 8.584827293489639e-10
two O 0 1.0396210115004578e-08
DNA O 0 2.5274523522966774e-06
- O 0 1.386660551361274e-05
binding O 0 1.0035729474111577e-06
domains O 0 2.014513000858642e-07
( O 0 5.063809371819161e-09
paired O 0 2.7252045242676104e-07
box O 0 3.2498887776455376e-06
and O 0 1.6006373471100233e-07
homeobox O 0 2.9280565172484785e-07
) O 0 1.0419312079790188e-09
and O 0 1.225266665905167e-09
a O 0 2.2531903454137137e-08
proline O 0 1.0960990948660765e-05
- O 0 8.3351660578046e-06
serine O 0 1.3130137631378602e-05
- O 0 2.5439630917389877e-05
threonine O 0 0.0002044381108134985
( O 0 4.5738655529703465e-08
PST O 0 3.573686262825504e-05
) O 0 1.0858124177559603e-08
- O 0 1.029939994623419e-06
rich O 0 1.99801831968216e-07
transactivation O 0 3.386422758921981e-05
domain O 0 2.2409062694350723e-06
. O 0 4.4364250584294496e-07

PAX6 O 0 0.014421327970921993
regulates O 0 0.0010385975474491715
eye O 0 0.014195227064192295
development O 0 9.688987745448685e-08
in O 0 1.5080621196261745e-08
animals O 0 2.3082428413090383e-08
ranging O 0 2.141978505676434e-08
from O 0 4.933955466412954e-09
jellyfish O 0 4.904721251364208e-08
to O 0 1.2624459699850377e-08
Drosophila O 0 5.716782069953297e-08
to O 0 2.003524457450112e-08
humans O 0 1.6362000110348163e-07
. O 0 1.6088434051653167e-07

Heterozygous O 0 0.00018846579769160599
mutations O 0 0.00013102030789013952
in O 0 5.6265303527425203e-08
the O 0 1.812859729000138e-08
human O 0 7.398953982828971e-08
PAX6 O 0 1.0579799891274888e-05
gene O 0 1.026591235131491e-06
result O 0 2.9430781367523196e-08
in O 0 1.8973538296052084e-09
various O 0 1.374643621154803e-09
phenotypes O 0 7.772544563522388e-07
, O 0 2.019415390464019e-08
including O 0 6.026284893323464e-08
aniridia B-Disease 1 1.0
, O 0 4.7374534915434197e-05
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999984502792358
, O 0 2.9758550113001547e-07
autosomal B-Disease 0 0.035812798887491226
dominant I-Disease 0 0.0010359480511397123
keratitis I-Disease 1 0.9976956248283386
, O 0 3.9860583456174936e-07
and O 0 6.069624305382604e-07
familial B-Disease 0 0.011353886686265469
foveal I-Disease 1 0.9849032163619995
dysplasia I-Disease 1 0.999875545501709
. O 0 6.701805432385299e-06

It O 0 1.937016349984333e-06
is O 0 2.9105219567782115e-08
believed O 0 4.978473455707899e-08
that O 0 6.20579754251338e-10
the O 0 6.786418649262771e-10
mutated O 0 2.437963075863081e-07
allele O 0 1.8225644282665598e-07
of O 0 1.2550027683744247e-09
PAX6 O 0 4.480470579437679e-06
produces O 0 1.2183325281966972e-07
an O 0 3.4501765888705904e-09
inactive O 0 9.464127259661836e-08
protein O 0 4.0116856325767003e-07
and O 0 1.443488599761622e-06
aniridia B-Disease 1 1.0
is O 0 1.4121442291070707e-06
caused O 0 5.246023988547677e-07
due O 0 6.48883116127763e-08
to O 0 3.3508719354813365e-08
genetic O 0 3.964032202929957e-06
haploinsufficiency O 0 0.00014787963300477713
. O 0 8.241668183472939e-07

However O 0 8.232634058913391e-07
, O 0 1.033344254608437e-08
several O 0 3.20009507781549e-09
truncation O 0 3.463964276306797e-06
mutations O 0 1.6878157111932524e-05
have O 0 7.257782641545418e-08
been O 0 3.59158178753205e-08
found O 0 1.4599613962218427e-08
to O 0 8.527045736173022e-09
occur O 0 5.078840903394166e-09
in O 0 5.149449755492697e-10
the O 0 6.6317693558914925e-09
C O 0 1.5666673789382912e-05
- O 0 6.213191682036268e-06
terminal O 0 1.5333489500335418e-05
half O 0 1.1547520983867798e-07
of O 0 1.1847547387588975e-09
PAX6 O 0 1.3604271771328058e-06
in O 0 9.419408364408355e-09
patients O 0 2.769220408538331e-08
with O 0 3.0282811813719945e-09
Aniridia B-Disease 1 0.9999990463256836
resulting O 0 1.1855311754516151e-07
in O 0 2.202043880572546e-09
mutant O 0 2.2221664508492722e-08
proteins O 0 6.116188000504508e-09
that O 0 1.2442035179915933e-09
retain O 0 2.4098532946936757e-08
the O 0 1.1120319109991783e-09
DNA O 0 2.7911588063034287e-07
- O 0 1.0142624660147703e-06
binding O 0 1.7390735251865408e-07
domains O 0 1.592354834656362e-07
but O 0 4.412862253388994e-08
have O 0 8.453348243619985e-09
lost O 0 2.2427461487950495e-07
most O 0 6.629110038680608e-10
of O 0 4.850330692640625e-10
the O 0 1.1303332492218487e-08
transactivation O 0 1.670765232120175e-05
domain O 0 1.2590776350407396e-06
. O 0 4.961873969477892e-07

It O 0 1.62539390657912e-06
is O 0 1.9514061477821087e-08
not O 0 8.560387065870145e-09
clear O 0 9.910638532062421e-09
whether O 0 1.3489507288966252e-09
such O 0 4.4682912925253504e-10
mutants O 0 3.813726152657182e-07
really O 0 2.386216237937333e-07
behave O 0 8.843825582971476e-08
as O 0 5.785148360359926e-09
loss O 0 5.502244349031571e-08
- O 0 6.975122346375429e-07
of O 0 6.491688964160858e-09
- O 0 1.222742230311269e-05
function O 0 8.566399287701643e-07
mutants O 0 1.1905815426871413e-06
as O 0 3.383826552294522e-08
predicted O 0 3.560107018074632e-07
by O 0 8.231988424256542e-09
haploinsufficiency O 0 1.6499861885677092e-05
. O 0 3.4317565678065876e-07

Contrary O 0 7.005227416811977e-06
to O 0 1.0503664782390842e-07
this O 0 1.85737936142516e-09
theory O 0 9.105413312227029e-09
, O 0 1.336994337464148e-08
our O 0 3.960057526342098e-08
data O 0 5.996406002850563e-07
showed O 0 1.0952833662258854e-07
that O 0 4.978430445667925e-10
these O 0 1.4778965551354162e-10
mutants O 0 3.621719102397947e-08
are O 0 4.394563601906043e-10
dominant O 0 2.634297402437369e-07
- O 0 2.2658059606328607e-06
negative O 0 1.1232757657353432e-07
in O 0 2.4351680671941267e-09
transient O 0 1.1157807477957249e-07
transfection O 0 2.6804862045537448e-06
assays O 0 4.184681472452212e-07
when O 0 9.13979647521046e-09
they O 0 2.0869139749635224e-09
are O 0 5.43144973441656e-10
coexpressed O 0 2.25844004830833e-07
with O 0 2.1742525557755243e-09
wild O 0 2.1950383199964563e-07
- O 0 4.149614323978312e-05
type O 0 6.951746854610974e-06
PAX6 O 0 0.0001896895410027355
. O 0 5.326305085873173e-07

We O 0 2.869870058930246e-06
found O 0 3.9001498919333244e-08
that O 0 1.5364594041500368e-09
the O 0 1.2743381905266915e-09
dominant O 0 2.7677133402903564e-06
- O 0 0.00010972902964567766
negative O 0 3.842413207166828e-06
effects O 0 6.051319587641046e-07
result O 0 1.5935754049678508e-08
from O 0 6.900853222191472e-10
the O 0 6.279668451902864e-10
enhanced O 0 2.7602347074662248e-08
DNA O 0 4.129047965761856e-07
binding O 0 4.9894907760972274e-08
ability O 0 9.891489405333687e-09
of O 0 5.100467270757747e-10
these O 0 4.8899222448994806e-09
mutants O 0 2.120618091794313e-06
. O 0 2.0849385862220515e-07

Kinetic O 0 5.704522664018441e-06
studies O 0 1.745363960026225e-07
of O 0 8.016761476881129e-09
binding O 0 3.5611051885098277e-07
and O 0 4.499219983244984e-07
dissociation O 0 1.0164993682337808e-06
revealed O 0 7.577491487609223e-07
that O 0 5.197038910331742e-10
various O 0 2.8962646170249684e-10
truncation O 0 2.215974888031269e-07
mutants O 0 5.849315698469582e-07
have O 0 6.464419222140805e-09
3 O 0 9.51538403626273e-09
- O 0 3.4068497711814416e-07
5 O 0 8.956662611581123e-08
- O 0 3.939078396797413e-07
fold O 0 7.365525789282401e-07
higher O 0 5.13249842626351e-09
affinity O 0 8.572441090315408e-10
to O 0 4.071740444810956e-10
various O 0 1.7990108014398487e-10
DNA O 0 8.554319919085174e-08
- O 0 1.5599661651322094e-07
binding O 0 2.0729071792402465e-08
sites O 0 7.941276969347655e-09
when O 0 4.5894359423925835e-09
compared O 0 2.7457933704511106e-09
with O 0 1.1636730468111978e-10
the O 0 2.9193658601656125e-09
wild O 0 2.906592158069543e-07
- O 0 1.284469817619538e-05
type O 0 3.3681233162496937e-06
PAX6 O 0 9.047758067026734e-05
. O 0 4.1836517539195484e-07

These O 0 8.011068644009356e-07
results O 0 5.308895083544485e-07
provide O 0 4.2607735117883294e-09
a O 0 6.174748268250596e-09
new O 0 3.7247236406301454e-08
insight O 0 5.67448985577812e-08
into O 0 2.048631042583793e-09
the O 0 1.1404416300209164e-09
role O 0 4.080262794303735e-09
of O 0 9.918349475057653e-10
mutant O 0 4.244609783654596e-07
PAX6 O 0 1.7310650946456008e-05
in O 0 1.2792563097718812e-07
causing O 0 3.2012598239816725e-05
aniridia B-Disease 1 0.9999949932098389
. O 0 1.777311808837112e-07
. O 0 1.920310239711398e-07

Reversal O 0 0.0008335583261214197
of O 0 1.8816831470758189e-06
severe O 0 0.051195178180933
hypertrophic B-Disease 1 0.9996403455734253
cardiomyopathy I-Disease 1 1.0
and O 0 9.564399988448713e-06
excellent O 0 1.7816593071984244e-06
neuropsychologic O 0 7.751696102786809e-05
outcome O 0 5.628901931231667e-07
in O 0 1.0342454004330648e-08
very B-Disease 0 2.097350026986078e-08
- I-Disease 0 1.2375093319860753e-05
long I-Disease 0 3.896249836543575e-06
- I-Disease 0 3.352765997988172e-05
chain I-Disease 0 4.2832878534682095e-05
acyl I-Disease 0 2.5673614345578244e-07
- I-Disease 0 1.2949349184054881e-06
coenzyme I-Disease 0 2.4072011228781776e-07
A I-Disease 0 1.051103481586324e-06
dehydrogenase I-Disease 0 0.0004390520043671131
deficiency I-Disease 0 0.0007903113146312535
. O 0 3.825010423952335e-07

Very B-Disease 0 2.3120160221878905e-06
- I-Disease 0 2.6795205485541373e-05
long I-Disease 0 1.0782732715597376e-06
- I-Disease 0 6.744885467924178e-06
chain I-Disease 0 9.417213732376695e-06
acyl I-Disease 0 2.3314912311889202e-07
- I-Disease 0 7.391244594145974e-07
coenzyme I-Disease 0 5.506054989723452e-08
A I-Disease 0 4.140956022524733e-08
dehydrogenase I-Disease 0 1.7241728755834629e-06
( I-Disease 0 6.056151846678404e-08
VLCAD I-Disease 0 0.0003961144248023629
) I-Disease 0 2.141126515198266e-06
deficiency I-Disease 0 3.212511364836246e-05
is O 0 7.279698177597993e-09
a O 0 4.941813358527725e-07
disorder O 0 0.00022062381322029978
of O 0 2.377201768766213e-09
fatty O 0 1.860873226178228e-06
acid O 0 1.4146958164928947e-06
beta O 0 6.016328057967257e-08
oxidation O 0 5.870921526707207e-08
that O 0 8.034702680959072e-09
reportedly O 0 3.840519582354318e-07
has O 0 1.1177143655061172e-08
high O 0 1.1094584806414787e-08
rates O 0 1.3817134458804503e-07
of O 0 1.0576616915614068e-08
morbidity O 0 0.005358942784368992
and O 0 1.5747222050777054e-06
mortality O 0 3.960526373703033e-05
. O 0 4.937950279781944e-07

We O 0 2.1247376480459934e-06
describe O 0 1.5102331474281527e-07
the O 0 5.768400868078061e-09
outcome O 0 2.1765147906194215e-08
of O 0 2.558178391343091e-10
a O 0 8.38660429991478e-09
5 O 0 1.213654456933e-07
- O 0 2.116791165462928e-06
year O 0 3.336510303597606e-07
- O 0 5.331231022864813e-06
old O 0 1.5088039617694449e-05
girl O 0 7.1463015046902e-05
with O 0 1.8032558273262111e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 1.1080458079959499e-06
was O 0 1.1948179690079996e-07
first O 0 3.993279307223929e-08
seen O 0 3.680241320580535e-07
at O 0 6.486913406433814e-08
5 O 0 1.5364896910341486e-08
months O 0 1.181595976618155e-08
of O 0 2.8723720624235227e-10
age O 0 1.4008239901386332e-08
with O 0 2.394797604665655e-07
severe O 0 0.005749774631112814
hypertrophic B-Disease 1 0.9894540309906006
cardiomyopathy I-Disease 1 1.0
, O 0 0.0011380861978977919
hepatomegaly B-Disease 1 1.0
, O 0 7.545651169493794e-05
encephalopathy B-Disease 1 0.9965487122535706
, O 0 7.856415606966038e-08
and O 0 4.4773861418434535e-07
hypotonia B-Disease 0 0.0006220244686119258
. O 0 1.1315972869851976e-06

Biochemical O 0 0.0006612532888539135
studies O 0 8.678568701725453e-05
indicated O 0 0.13801375031471252
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 1.887149664980825e-05
by O 0 4.502969552788727e-09
a O 0 6.076446368297184e-08
stable O 0 2.1679898054571822e-05
yet O 0 1.186739311265228e-07
inactive O 0 4.3177399788874027e-07
enzyme O 0 7.127810022211634e-07
. O 0 2.0185612470413616e-07

Molecular O 0 8.567742042941973e-06
genetic O 0 5.0719404498522636e-06
analysis O 0 1.29747363075694e-07
of O 0 6.457838264140037e-09
her O 0 2.8254710287001217e-06
VLCAD O 0 0.001657581189647317
gene O 0 5.159457487025065e-06
revealed O 0 1.46984632465319e-06
a O 0 3.21314850282306e-08
T1372C O 0 7.530866241722833e-07
( O 0 9.903797781873891e-09
F458L O 0 1.7129349316746811e-07
) O 0 1.0865914390478792e-08
missense O 0 3.837440090137534e-06
mutation O 0 3.279872316852561e-06
and O 0 1.2890805578535947e-07
a O 0 1.5047412489366252e-06
1668 O 0 0.0006012116209603846
ACAG O 0 0.007123242598026991
1669 O 0 2.0240859157638624e-05
splice O 0 0.0011311705457046628
site O 0 2.4342549295397475e-05
mutation O 0 2.7676958779920824e-05
. O 0 4.4463234871727764e-07

After O 0 3.205297389285988e-06
initial O 0 3.396708336822485e-07
treatment O 0 6.960397769262272e-08
with O 0 4.725575042385799e-09
intravenous O 0 1.8676986428545206e-06
glucose O 0 7.382532930932939e-05
and O 0 1.5500791050726548e-07
carnitine O 0 5.739309472119203e-07
, O 0 6.247844019924287e-09
the O 0 4.289966604176243e-09
patient O 0 3.239208581362618e-07
has O 0 1.1784360154365459e-08
thrived O 0 1.564261964404068e-08
on O 0 1.7936677920715738e-08
a O 0 3.793293146259202e-08
low O 0 8.021978601391311e-07
- O 0 9.354468602396082e-06
fat O 0 1.9603745386120863e-05
diet O 0 2.1300250452327418e-08
supplemented O 0 3.547862004182889e-09
with O 0 5.192719032542925e-10
medium O 0 7.336013396752605e-08
- O 0 2.7992141440336127e-06
chain O 0 3.493175972835161e-05
triglyceride O 0 2.8292351998970844e-06
oil O 0 1.8251836308991187e-06
and O 0 3.770959011717423e-08
carnitine O 0 2.1369025660078478e-07
and O 0 4.422769261935855e-09
avoidance O 0 1.2944617822086002e-07
of O 0 9.465225048188586e-09
fasting O 0 3.4965235045092413e-06
. O 0 3.0003988626958744e-07

Her O 0 0.0006632660515606403
ventricular O 0 0.10850273072719574
hypertrophy O 0 0.014381051994860172
resolved O 0 1.544159385957755e-05
significantly O 0 1.3027198519921512e-06
over O 0 2.6682686282697432e-08
1 O 0 1.0903890768076963e-07
year O 0 1.0236284708753374e-07
, O 0 1.2993838893748944e-08
and O 0 1.6631000221423164e-07
cognitively O 0 2.3473835426557343e-06
, O 0 1.2737192633949235e-08
she O 0 6.413320363662933e-08
is O 0 1.453761333536363e-09
in O 0 3.0796327710191918e-09
the O 0 1.1541318123420297e-08
superior O 0 1.8637010157362965e-07
range O 0 5.3192639626331584e-08
for O 0 2.347339744801502e-08
age O 0 5.409382097809612e-08
. O 0 1.1635614782790071e-07

Clinical O 0 9.385233715875074e-05
recognition O 0 7.544337563558656e-07
of O 0 3.5015257253689924e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.684133733055205e-07
important O 0 1.839175745033117e-08
because O 0 2.716384095435842e-08
it O 0 4.261198327526472e-08
is O 0 2.6393245367017926e-09
one O 0 1.4385904689717677e-09
of O 0 1.2102085999998735e-10
the O 0 2.1286756801686124e-09
few O 0 1.2128140269851428e-08
directly O 0 7.765624445710273e-07
treatable O 0 0.00030426817829720676
causes O 0 1.475515887250367e-07
of O 0 3.9891759229249146e-08
cardiomyopathy B-Disease 1 0.9999998807907104
in O 0 8.392110544264142e-07
children O 0 2.6226410909657716e-07
. O 0 4.061157099499724e-08
. O 0 5.179232971386227e-07

Cloning O 0 8.558693480154034e-06
of O 0 3.655880220776453e-08
a O 0 7.02721578704768e-08
novel O 0 1.7655605688560172e-07
member O 0 2.5025745031825863e-08
of O 0 5.459221963377558e-10
the O 0 8.794082795304803e-09
low O 0 1.5675033182560583e-06
- O 0 3.647255289251916e-05
density O 0 1.127133941736247e-06
lipoprotein O 0 1.1069293577747885e-05
receptor O 0 1.1795691534643993e-06
family O 0 1.4836167565590586e-06
. O 0 4.5745812826680776e-07

A O 0 1.1365809768904e-06
gene O 0 1.257154394807003e-06
encoding O 0 3.601415983212064e-07
a O 0 3.983982566069244e-08
novel O 0 3.38076915795682e-07
transmembrane O 0 1.1856368473672774e-06
protein O 0 1.7455316765335738e-06
was O 0 2.887011021357466e-07
identified O 0 1.4233914491512678e-08
by O 0 3.0091296121526057e-10
DNA O 0 9.862289651607625e-09
sequence O 0 4.445808166053666e-09
analysis O 0 2.0247832299702395e-09
within O 0 6.742628122502481e-10
the O 0 1.864137644247421e-08
insulin B-Disease 1 0.5648312568664551
- I-Disease 1 0.9996334314346313
dependent I-Disease 1 0.9999932050704956
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 1.944358245964395e-06
IDDM B-Disease 0 0.00031011932878755033
) O 0 4.2083254214730914e-08
locus O 0 1.2155732065366465e-06
IDDM4 O 0 0.00010877900058403611
on O 0 4.203414846415399e-06
chromosome O 0 0.0003602158685680479
11q13 O 0 1.844355938374065e-05
. O 0 8.574801881877647e-07

Based O 0 3.1005040455056587e-06
on O 0 3.757336344278883e-07
its O 0 2.3096394841104484e-07
chromosomal O 0 0.0003039324365090579
position O 0 4.962937509844778e-06
, O 0 5.834949412530932e-09
this O 0 3.9832492859659396e-10
gene O 0 1.670798432940046e-08
is O 0 1.707547547802335e-09
a O 0 7.9834965305281e-09
candidate O 0 4.5416836513823e-08
for O 0 3.3765394924500924e-09
conferring O 0 6.016201723468839e-07
susceptibility O 0 4.1400646296096966e-05
to O 0 7.257592642417876e-06
diabetes B-Disease 0 0.32997286319732666
. O 0 1.0471284213053877e-06

The O 0 1.9225568337333243e-07
gene O 0 4.974610305907845e-07
, O 0 2.1005288175501846e-08
termed O 0 4.793352559318009e-07
low O 0 4.1292409491688886e-07
- O 0 8.536585482943337e-06
density O 0 4.2773703512466454e-07
lipoprotein O 0 2.2897395410836907e-06
receptor O 0 1.393376578562311e-07
related O 0 7.625599351968049e-08
protein O 0 2.578890132554079e-07
5 O 0 8.577814014643081e-08
( O 0 6.045116851538523e-09
LRP5 O 0 6.069570645195199e-06
) O 0 2.581333813367337e-09
, O 0 3.9667966134082633e-10
encodes O 0 7.015093395068561e-09
a O 0 5.6683213678354605e-09
protein O 0 4.478389215023526e-08
of O 0 1.5943955045116809e-09
1615 O 0 1.0924536582024302e-06
amino O 0 1.2815299044177664e-07
acids O 0 3.278960392094632e-08
that O 0 2.2697253798664718e-10
contains O 0 1.376038588629669e-10
conserved O 0 3.884542909560196e-09
modules O 0 8.06411915021954e-09
which O 0 5.493935972822328e-09
are O 0 1.0480415840730117e-10
characteristic O 0 2.364323403725166e-09
of O 0 1.4692007332950396e-10
the O 0 2.7842175231995725e-09
low O 0 5.620105412162957e-07
- O 0 1.0754392860690132e-05
density O 0 9.626502333048848e-07
lipoprotein O 0 2.0401086658239365e-05
( O 0 2.632303619520826e-07
LDL O 0 5.8833076764130965e-05
) O 0 3.7768543847960245e-08
receptor O 0 6.043746481054768e-08
family O 0 1.563332006071505e-07
. O 0 3.539037720656779e-07

These O 0 1.5308357603771583e-07
modules O 0 1.1583775716417222e-07
include O 0 4.1269192507797925e-09
a O 0 1.7029915255761807e-08
putative O 0 6.511557444355276e-07
signal O 0 3.1799211797078897e-07
peptide O 0 2.522313025110634e-08
for O 0 1.014958672662658e-09
protein O 0 8.065226708708906e-09
export O 0 1.2629251422424659e-08
, O 0 1.3721708214120554e-09
four O 0 5.177787532062439e-09
epidermal O 0 1.1046926147173508e-06
growth O 0 9.75550051407481e-07
factor O 0 2.7937092639263028e-08
( O 0 1.0419892504387462e-08
EGF O 0 7.781904400872008e-07
) O 0 1.2384318459623955e-08
repeats O 0 4.3386427250879933e-07
with O 0 1.4638589229676313e-09
associated O 0 1.705709351540463e-08
spacer O 0 2.4763651254033903e-06
domains O 0 1.925547792325233e-07
, O 0 4.561388156076873e-09
three O 0 1.5116244256319078e-08
LDL O 0 7.001324411248788e-05
- O 0 3.1093135476112366e-05
receptor O 0 2.79186679108534e-07
( O 0 2.477441363168964e-08
LDLR O 0 1.9264571164967492e-05
) O 0 2.0419419044515053e-08
repeats O 0 1.136360879172571e-06
, O 0 1.7130474816440255e-09
a O 0 4.5737409415380625e-09
single O 0 7.021507713034225e-07
transmembrane O 0 5.292122864375415e-07
spanning O 0 1.6407720693223382e-07
domain O 0 2.8315196232142625e-07
, O 0 9.713427395752205e-09
and O 0 3.4834435336250635e-09
a O 0 2.32627552776421e-08
cytoplasmic O 0 7.073359029163839e-06
domain O 0 2.7395203687774483e-06
. O 0 4.2312035475333687e-07

The O 0 1.2758059142470302e-07
encoded O 0 4.1073684542425326e-07
protein O 0 5.52873302694934e-07
has O 0 1.3050120095670081e-08
a O 0 2.380672992075006e-09
unique O 0 9.035312942273777e-09
organization O 0 1.0259032734438733e-08
of O 0 2.3653607961193757e-09
EGF O 0 1.0395139042884693e-06
and O 0 2.6242423700750805e-07
LDLR O 0 8.247466030297801e-05
repeats O 0 7.175865903263912e-06
; O 0 3.036668028144618e-09
therefore O 0 3.6373353218266402e-09
, O 0 1.6722385698386688e-09
LRP5 O 0 8.480258657073136e-06
likely O 0 2.916200969593774e-08
represents O 0 1.1703110702754316e-09
a O 0 2.0672561440449044e-09
new O 0 2.7713868533396635e-08
category O 0 4.817016474589764e-08
of O 0 9.91891790924626e-10
the O 0 4.958524968401434e-08
LDLR O 0 0.00021146393555682153
family O 0 5.21520632901229e-07
. O 0 2.0366543651562097e-07

Both O 0 1.4976875490901875e-06
human O 0 2.975080235501082e-07
and O 0 1.4140617565772118e-07
mouse O 0 1.554511436552275e-05
LRP5 O 0 0.00034611878800205886
cDNAs O 0 1.5170917322393507e-05
have O 0 4.9811230695695485e-08
been O 0 1.843017471969688e-08
isolated O 0 4.6150439914072194e-08
and O 0 2.235995832933213e-09
the O 0 4.170422340799007e-10
encoded O 0 1.1672776523141692e-08
mature O 0 1.5817112952731804e-08
proteins O 0 1.3471586068902752e-09
are O 0 1.9588138056025883e-10
95 O 0 2.889991801424685e-09
% O 0 1.029572316291194e-09
identical O 0 3.4546363991694307e-08
, O 0 5.109993317375938e-09
indicating O 0 2.6350805981678604e-08
a O 0 1.5141694120757165e-08
high O 0 4.188538227367644e-08
degree O 0 9.811293999462123e-09
of O 0 1.5473172743085684e-09
evolutionary O 0 3.531148351498814e-08
conservation O 0 2.3786860481322947e-08
. O 0 1.8778555599396896e-08
. O 0 9.846805681945625e-08

The O 0 1.1118268048448954e-06
APC B-Disease 0 9.648150808061473e-06
variants O 0 6.406791044355487e-07
I1307K O 0 6.616811560888891e-07
and O 0 9.699615333147449e-09
E1317Q O 0 2.997055617015576e-07
are O 0 1.1853023451635636e-08
associated O 0 1.4791905869060429e-06
with O 1 0.9815502166748047
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 7.941142030176707e-06
but O 0 7.120200962162926e-08
not O 0 1.6391947355032244e-08
always O 0 5.5570956725148335e-09
with O 0 9.531654354688612e-10
a O 0 6.387171680444226e-08
family O 0 2.8706617172247206e-07
history O 0 1.4424301753024338e-07
. O 0 3.868921396588121e-07

Classical O 0 0.255622535943985
familial B-Disease 1 0.9999998807907104
adenomatous I-Disease 1 0.9999990463256836
polyposis I-Disease 1 1.0
( O 0 0.0010934809688478708
FAP B-Disease 0 6.295658386079594e-05
) O 0 1.935570850264412e-07
is O 0 6.136753771812664e-09
a O 0 2.766749673810409e-08
high O 0 9.785460861166939e-06
- O 1 0.9972726702690125
penetrance O 1 0.9551530480384827
autosomal B-Disease 1 0.9997668862342834
dominant I-Disease 0 0.0615246444940567
disease I-Disease 0 0.05011874809861183
that O 0 1.0047105369892506e-08
predisposes O 0 4.117506762213452e-07
to O 0 5.514281475882399e-09
hundreds O 0 5.893638466147877e-09
or O 0 1.4566792216896829e-08
thousands O 0 5.992209395344616e-08
of O 0 1.4690735952171963e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9747070074081421
carcinoma I-Disease 1 1.0
and O 0 3.554465592969791e-06
that O 0 3.466669440399528e-08
results O 0 2.0127519917423342e-07
from O 0 3.690417305080018e-09
truncating O 0 1.4231586646928918e-06
mutations O 0 6.973160679990542e-07
in O 0 3.2111620029695587e-09
the O 0 2.145588950952515e-08
APC B-Disease 0 6.821946044510696e-06
gene O 0 1.8996054222952807e-06
. O 0 1.8934238710244244e-07

A O 0 2.332982148800511e-06
variant O 0 2.6917909053736366e-05
of O 0 1.549255870259003e-07
FAP B-Disease 0 6.674254836980253e-05
is O 0 3.249997234888724e-06
attenuated B-Disease 1 0.6418231725692749
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999977350234985
coli I-Disease 1 1.0
, O 0 1.317358396590862e-06
which O 0 9.32636012862531e-08
results O 0 3.714054628289887e-07
from O 0 1.391145332263477e-08
germ O 0 7.216221274575219e-05
- O 0 3.743192064575851e-05
line O 0 0.0006574370781891048
mutations O 0 8.521844847564353e-07
in O 0 1.2322156628385983e-09
the O 0 2.5701718531223605e-09
5 O 0 7.570211835172813e-08
and O 0 2.4310251589554355e-08
3 O 0 3.0984470100747785e-08
regions O 0 1.6058228524684637e-08
of O 0 5.857247464824411e-10
the O 0 1.4219830646311493e-08
APC B-Disease 0 2.9254097171360627e-06
gene O 0 8.663873813929968e-07
. O 0 1.2904483526199328e-07

Attenuated B-Disease 1 0.9998561143875122
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999995231628418
coli I-Disease 1 1.0
patients O 1 0.9399279356002808
have O 0 1.45811031870835e-06
" O 0 3.31196429215197e-06
multiple O 0 0.00019117939518764615
" O 1 0.9999544620513916
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 1.5753530533402227e-06
typically O 0 5.4828422690889056e-08
fewer O 0 1.8400388768213816e-08
than O 0 3.1420925861169735e-09
100 O 0 3.4625837752599864e-09
) O 0 1.2326739629031636e-09
without O 0 1.320419551475993e-09
the O 0 4.331735414808691e-09
florid O 0 7.133985491236672e-05
phenotype O 0 7.055411515466403e-06
of O 0 4.352298965670798e-09
classical O 0 2.2329459170578048e-07
FAP B-Disease 0 7.451178589690244e-06
. O 0 3.3202010740751575e-07

Another O 0 2.025307594522019e-06
group O 0 1.1129766335216118e-06
of O 0 6.132050422991142e-09
patients O 0 7.329762041763388e-08
with O 0 2.8194184764629426e-09
multiple O 0 6.419753844966181e-06
adenomas B-Disease 0 0.04958542436361313
has O 0 1.4485578958556289e-06
no O 0 4.101597994576878e-08
mutations O 0 1.232743187529195e-07
in O 0 1.7132761875870983e-09
the O 0 5.242760447998762e-09
APC B-Disease 0 5.481016955855011e-07
gene O 0 1.5476389592095074e-07
, O 0 3.969796047442742e-09
and O 0 8.299402054490201e-09
their O 0 3.433006057207422e-08
phenotype O 0 6.4578130150039215e-06
probably O 0 4.378805158467003e-07
results O 0 1.230856696565752e-07
from O 0 5.326964425123037e-10
variation O 0 3.0647683502138534e-08
at O 0 4.976602596684643e-08
a O 0 1.720346887168489e-08
locus O 0 6.013488587086613e-07
, O 0 3.6016384541426305e-08
or O 0 2.2350077344412966e-08
loci O 0 4.369410788740424e-08
, O 0 7.588583095241574e-09
elsewhere O 0 1.3447384539233553e-08
in O 0 1.9588521915636647e-09
the O 0 1.2095936696709941e-08
genome O 0 1.4041593203728553e-06
. O 0 3.5910963447349786e-07

Recently O 0 8.209410589188337e-05
, O 0 6.210065350842342e-08
however O 0 6.215229664263688e-09
, O 0 1.277828509671508e-09
a O 0 6.631187154937379e-09
missense O 0 2.2577908111998113e-06
variant O 0 3.9046790334396064e-06
of O 0 1.8189487249742342e-08
APC B-Disease 0 1.7925560314324684e-05
( O 0 5.893056709282973e-08
I1307K O 0 4.24573528334804e-07
) O 0 1.8712269067577836e-08
was O 0 4.44870295268629e-07
described O 0 1.2725529074941733e-07
that O 0 1.516052949845914e-09
confers O 0 6.859742107678812e-09
an O 0 1.983387232229461e-09
increased O 0 2.905819087573036e-07
risk O 0 4.1219904233003035e-05
of O 0 0.041874028742313385
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 8.187668072423548e-07
including O 0 1.3871656712183267e-08
multiple O 0 4.111854195798514e-06
adenomas B-Disease 0 0.018362123519182205
, O 0 8.006893637002577e-08
in O 0 4.3282852857373655e-08
Ashkenazim O 0 0.0002235326828667894
. O 0 1.0833052783709718e-06

We O 0 3.246146661695093e-06
have O 0 9.822716862117886e-09
studied O 0 6.038755273607421e-09
a O 0 3.4196334652847327e-09
set O 0 3.088805300421882e-08
of O 0 9.728663430408346e-10
164 O 0 2.0458251981381181e-07
patients O 0 1.1611050609872109e-07
with O 0 4.18766745724497e-08
multiple O 1 0.9998996257781982
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.004278271459043026
/ I-Disease 1 0.9924919009208679
or I-Disease 0 0.2146340161561966
carcinoma I-Disease 1 1.0
and O 0 1.1008687579305843e-05
analyzed O 0 6.579932687600376e-06
codons O 0 8.791385880613234e-06
1263 O 0 7.480698059225688e-06
- O 0 3.204794120392762e-05
1377 O 0 1.122720459534321e-05
( O 0 2.6453637502754646e-08
exon O 0 1.2560699360619765e-06
15G O 0 1.1884056902999873e-06
) O 0 2.406701060664318e-09
of O 0 2.246502289748875e-10
the O 0 4.8483999037785e-09
APC B-Disease 0 4.130674540192558e-07
gene O 0 7.672768020938747e-08
for O 0 8.067534196243287e-09
germ O 0 7.161228859331459e-05
- O 0 4.1580475226510316e-05
line O 0 8.139837154885754e-05
variants O 0 7.654388355149422e-06
. O 0 1.8583764926916047e-07

Three O 0 2.4036094146140385e-06
patients O 0 1.3543080967792775e-06
with O 0 3.0024061015154757e-09
the O 0 7.79085862490092e-09
I1307K O 0 6.302701081040141e-07
allele O 0 1.3982074733576155e-06
were O 0 6.511358208172169e-08
detected O 0 2.877557960800914e-07
, O 0 1.388559933701572e-09
each O 0 3.6522120883120124e-09
of O 0 1.3440383916929477e-08
Ashkenazi O 0 0.00025765979080460966
descent O 0 2.817318272718694e-05
. O 0 9.245196679330547e-07

Four O 0 3.889956587954657e-06
patients O 0 7.530452421633527e-06
had O 0 6.6247174856926e-08
a O 0 5.26791232857704e-08
germ O 0 0.0001709687930997461
- O 0 4.352932228357531e-05
line O 0 6.946755456738174e-05
E1317Q O 0 1.3687755426872172e-06
missense O 0 1.5195413425317383e-06
variant O 0 6.765189937141258e-07
of O 0 6.114741601948026e-09
APC O 0 2.36963728639239e-06
that O 0 1.8454867856121382e-08
was O 0 1.451913078653888e-07
not O 0 3.934923054060846e-09
present O 0 1.659184012403614e-09
in O 0 3.234459144962898e-09
controls O 0 2.980588533318951e-06
; O 0 5.778236911169188e-08
one O 0 1.024112439296232e-08
of O 0 7.086891629093373e-10
these O 0 3.889213395780189e-09
individuals O 0 1.5245606999059191e-09
had O 0 1.7258955153920397e-07
an O 0 5.146987724913288e-09
unusually O 0 2.058176917785204e-08
large O 0 4.26349666682313e-09
number O 0 1.6860559171050227e-08
of O 0 6.176798184043264e-09
metaplastic B-Disease 0 0.00010326417395845056
polyps I-Disease 0 1.185586370411329e-05
of I-Disease 0 1.6052035256564068e-09
the I-Disease 0 4.651674956335228e-08
colorectum I-Disease 0 0.00011514179641380906
. O 0 4.555269583761401e-07

There O 0 3.7490681847884844e-07
is O 0 1.0205128297968713e-08
increasing O 0 2.9333255824326443e-09
evidence O 0 5.0835611276056625e-09
that O 0 1.1079289707893736e-09
there O 0 7.818676817095138e-10
exist O 0 1.4215464361200247e-08
germ O 0 8.83140182850184e-06
- O 0 4.620756953954697e-06
line O 0 7.723039743723348e-06
variants O 0 2.677649213467248e-08
of O 0 2.345140193149575e-10
the O 0 2.9841595861057613e-09
APC B-Disease 0 1.6951111092566862e-07
gene O 0 1.6469670072183362e-08
that O 0 4.4995329684383023e-10
predispose O 0 1.8293134118607668e-08
to O 0 1.972235930125521e-09
the O 0 8.320573674502896e-10
development O 0 1.5728783608892627e-08
of O 0 2.6384131501799857e-07
multiple O 1 0.9999616146087646
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9353864192962646
carcinoma I-Disease 1 1.0
, O 0 1.1627466847130563e-06
but O 0 1.7254338402494795e-08
without O 0 2.210417848758084e-09
the O 0 3.7901739524670575e-09
florid O 0 1.2089420124539174e-05
phenotype O 0 1.03766365100455e-06
of O 0 8.180925936684957e-10
classical O 0 1.8773398835492117e-08
FAP B-Disease 0 9.906560194394842e-08
, O 0 3.3032392376952657e-09
and O 0 1.6414622994176398e-09
possibly O 0 3.272823123623425e-09
with O 0 5.577321382510547e-10
importance O 0 2.343354594813718e-07
for O 1 0.9552103877067566
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 8.802527190709952e-06
in O 0 4.9859778528116294e-09
the O 0 4.850185142402097e-09
general O 0 7.921686417944329e-09
population O 0 2.8047009159593017e-09
. O 0 4.912807938239894e-09
. O 0 9.347036211693194e-08

Genomic O 0 4.2886418668786064e-05
structure O 0 1.5093432921275962e-06
of O 0 2.3139909544056536e-08
the O 0 4.049007316098141e-07
human O 0 0.002492261817678809
congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999940395355225
diarrhea I-Disease 1 1.0
( O 0 3.5690172808244824e-06
CLD B-Disease 0 0.004254627041518688
) O 0 1.8534881007781223e-07
gene O 0 2.783959416774451e-06
. O 0 4.1933185457310174e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999988079071045
diarrhea I-Disease 1 1.0
( O 0 0.0002383157261647284
CLD B-Disease 1 0.716353714466095
) O 0 1.9503625026118243e-06
is O 0 9.336505257806493e-08
caused O 0 1.789710921684673e-07
by O 0 4.133623221491689e-09
mutations O 0 4.5040542318020016e-07
in O 0 2.2395896248639247e-09
a O 0 4.798895858471042e-08
gene O 0 7.120778491298552e-07
which O 0 4.739658621133458e-08
encodes O 0 2.992588406414143e-06
an O 0 5.257984980744368e-07
intestinal O 0 0.0008316423045471311
anion O 0 1.3434520042210352e-05
transporter O 0 0.001049298676662147
. O 0 1.1663316854537698e-06

We O 0 2.092147224175278e-05
report O 0 5.224091523814423e-07
here O 0 4.335521275322662e-09
the O 0 7.958650405370804e-10
complete O 0 1.664557558456181e-08
genomic O 0 1.4887289978560148e-07
organization O 0 9.992636940125976e-09
of O 0 9.967049408032835e-10
the O 0 1.856105313891021e-08
human O 0 1.0532914984651143e-07
CLD B-Disease 0 1.4319276488095056e-05
gene O 0 4.2443019765414647e-07
which O 0 2.098066254063724e-08
spans O 0 2.741441562648106e-07
approximately O 0 6.443974598369095e-08
39kb O 0 6.0256229517108295e-06
, O 0 1.1335544947144172e-08
and O 0 5.2669548722406034e-09
comprises O 0 7.543802027498714e-09
21 O 0 3.94012964477497e-08
exons O 0 4.125947725697188e-06
. O 0 4.549955292532104e-07

All O 0 1.7791750224205316e-06
exon O 0 4.058095146319829e-05
/ O 0 0.0003043203614652157
intron O 0 0.0001155626232502982
boundaries O 0 5.911451808060519e-07
conform O 0 2.3271645659406204e-06
to O 0 2.3987647423950875e-08
the O 0 2.0051377447316554e-08
GT O 0 0.00016725595924071968
/ O 0 0.009476917795836926
AG O 1 0.9999929666519165
rule O 0 1.1568247373361373e-06
. O 0 2.720161944580468e-07

An O 0 2.925968658473721e-07
analysis O 0 7.096691234664831e-08
of O 0 2.844519286782088e-09
the O 0 1.5738386593966425e-08
putative O 0 1.5061583553688251e-06
promoter O 0 4.4663124754151795e-06
region O 0 2.2242788588755502e-07
sequence O 0 3.263611247916742e-08
shows O 0 4.007570453268272e-08
a O 0 3.944400717159624e-08
putative O 0 2.260690507682739e-06
TATA O 0 0.000244255643337965
box O 0 2.560185976108187e-06
and O 0 8.978248189350779e-08
predicts O 0 1.7661545825831126e-06
multiple O 0 4.184306234833457e-08
transcription O 0 2.5948912707463023e-07
factor O 0 3.70393067328223e-08
binding O 0 2.6118684104403656e-07
sites O 0 9.915187320075347e-07
. O 0 4.7300500227720477e-07

The O 0 3.785195303862565e-07
genomic O 0 4.1907223931048065e-06
structure O 0 1.9536948911991203e-06
was O 0 1.5991130339898518e-06
determined O 0 2.7216014331088445e-08
using O 0 9.061372985286198e-09
DNA O 0 1.8530673173700052e-07
from O 0 8.368958859250597e-10
several O 0 7.483793584839304e-10
sources O 0 5.2123296789829965e-09
including O 0 4.2991551985060994e-10
multiple O 0 1.4794578007126802e-08
large O 0 5.8787204437749097e-08
- O 0 0.00030168925877660513
insert O 0 0.00011232607357669622
libaries O 0 9.696762390376534e-06
and O 0 5.665748759042799e-09
genomic O 0 4.570054912278465e-08
DNA O 0 9.610761253497913e-07
from O 0 4.5280604155095716e-08
Finnish O 0 0.0003437285195104778
CLD B-Disease 0 0.19644156098365784
patients O 0 7.911172360763885e-06
and O 0 2.6395374774779157e-08
controls O 0 2.18899567698827e-05
. O 0 9.739642337081023e-07

Exon O 0 0.00014520467084366828
- O 0 2.202386167482473e-05
specific O 0 8.238558280027064e-08
primers O 0 2.476648660376668e-06
developed O 0 1.2083407341378916e-07
in O 0 2.9431104220378757e-09
this O 0 9.233216968773661e-10
study O 0 2.2115058673222165e-09
will O 0 4.623570415418499e-09
facilitate O 0 8.259920747377691e-09
mutation O 0 9.225672670254426e-08
screening O 0 4.9413603875336776e-08
studies O 0 5.73831071548625e-09
of O 0 1.069632604711046e-09
patients O 0 1.4722971286573738e-07
with O 0 2.0136528000591625e-09
the O 0 6.94825416758249e-07
disease O 0 0.00011524734873091802
. O 0 3.892065478794393e-07

Genomic O 0 1.963242539204657e-05
sequencing O 0 3.2874913813429885e-06
of O 0 1.7122090412158286e-08
a O 0 1.828860405339583e-07
BAC O 0 0.0003506220818962902
clone O 0 0.0010542977834120393
H O 1 0.9999998807907104
_ O 0 4.4387527964317997e-07
RG364P16 O 0 2.8881095204269513e-07
revealed O 0 2.5888601840051706e-07
the O 0 9.30306109925283e-10
presence O 0 1.3674106291716726e-09
of O 0 1.735081939235883e-10
another O 0 9.750180218759397e-09
, O 0 1.7417707276479177e-09
highly O 0 2.0525385835412635e-09
homologous O 0 8.196924028425201e-09
gene O 0 3.648120383559217e-08
3 O 0 4.678669451863016e-09
of O 0 4.386474239392868e-10
the O 0 3.0225180580600863e-08
CLD B-Disease 0 3.652135274023749e-05
gene O 0 2.746830034539016e-07
, O 0 8.249336769239335e-10
with O 0 8.304808923886853e-11
a O 0 5.901613864267574e-09
similar O 0 2.1534063421313476e-09
genomic O 0 6.696469512235126e-08
structure O 0 5.897267669752182e-07
, O 0 1.0206495204556632e-07
recently O 0 3.8712684613528836e-07
identified O 0 1.0465787880775679e-07
as O 0 1.0548693474277115e-08
the O 0 2.780897375487257e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 8.998905286716763e-06
( O 0 4.2603204519764404e-08
PDS B-Disease 0 4.566128336591646e-05
) O 0 1.0450325049760067e-08
. O 0 8.733239020841665e-09
. O 0 1.454594951155741e-07

The O 0 6.455808829741727e-07
APCI1307K O 0 0.00010762496822280809
allele O 0 9.758792293723673e-05
and O 0 8.702331797394436e-06
cancer B-Disease 0 0.00040303735295310616
risk O 0 9.977926538340398e-07
in O 0 4.526607533250626e-09
a O 0 6.860032897293422e-08
community O 0 3.1331950367530226e-08
- O 0 6.483563993242569e-06
based O 0 1.3912110716773896e-06
study O 0 8.362007086759604e-09
of O 0 4.636719896922159e-09
Ashkenazi O 0 1.984138725674711e-05
Jews O 0 6.940803132238216e-07
. O 0 1.9511611526468187e-07

Mutations O 0 0.0009289945010095835
in O 0 3.9452513078686025e-07
APC O 0 3.935571658075787e-05
are O 0 8.310747290352083e-08
classically O 0 5.5837943364167586e-05
associated O 0 1.2145546861574985e-05
with O 0 9.49731984292157e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 4.930734939989634e-05
FAP B-Disease 0 7.144414212234551e-06
) O 0 3.011906102301509e-08
, O 0 2.7238589161981963e-09
a O 0 7.692021597449639e-08
highly O 0 1.5907922715996392e-05
penetrant O 1 0.9997921586036682
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.9999985694885254
disorder I-Disease 1 1.0
characterized O 0 5.459942985908128e-05
by O 0 1.8227035525342217e-07
multiple O 0 0.00019562004308681935
intestinal O 1 0.9859867691993713
polyps B-Disease 0 0.3010604977607727
and O 0 8.288337767226039e-07
, O 0 3.0225180580600863e-08
without O 0 2.570967438941807e-08
surgical O 0 3.656644594229874e-06
intervention O 0 1.249848313733537e-08
, O 0 8.904021964184494e-10
the O 0 1.5675286624272644e-09
development O 0 2.4836398893057776e-07
of O 0 0.013055600225925446
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.163625256594969e-06
CRC B-Disease 0 0.00015856785466894507
) O 0 1.3412373789378762e-07
. O 0 3.2242979841612396e-07

APC B-Disease 0 0.0003148360410705209
is O 0 4.860137892137573e-07
a O 0 7.413722755700292e-07
tumour O 1 1.0
- O 0 0.0010994409676641226
suppressor O 0 4.621945845428854e-05
gene O 0 2.7967753339908086e-06
, O 0 1.1112395448265033e-08
and O 0 1.0238839109888431e-08
somatic O 0 2.1054881926829694e-06
loss O 0 4.016622824565275e-06
occurs O 0 9.351030172410901e-08
in O 0 3.67951855650972e-07
tumours B-Disease 1 1.0
. O 0 2.2912774966243887e-06

The O 0 1.482564584875945e-06
germline O 0 7.651528721908107e-05
T O 0 0.00030497825355269015
- O 0 2.9978355087223463e-06
to O 0 7.536083046488784e-08
- O 0 2.51808387474739e-06
A O 0 7.013028380242758e-07
transversion O 0 4.920227638649521e-06
responsible O 0 9.310488735536637e-08
for O 0 9.722542770873588e-10
the O 0 2.70425526416318e-09
APC O 0 1.4533108583236753e-07
I1307K O 0 1.3539728449529775e-08
allele O 0 2.2107562003270687e-08
converts O 0 1.5325674951327528e-08
the O 0 7.987330796765946e-10
wild O 0 1.3854680958047538e-08
- O 0 2.5237622480744903e-07
type O 0 2.9784008148681096e-08
sequence O 0 9.235811226915303e-09
to O 0 9.545522594578415e-09
a O 0 1.947301768723264e-07
homopolymer O 0 0.014441341161727905
tract O 0 0.0024653442669659853
( O 0 6.572900446144558e-08
A8 O 0 0.016455622389912605
) O 0 2.4362238448816242e-08
that O 0 7.978534277697236e-09
is O 0 3.680339233369523e-08
genetically O 0 3.334202483529225e-05
unstable O 0 0.0025713304057717323
and O 0 7.474940275642439e-07
prone O 0 9.581792255630717e-06
to O 0 1.0250840887238155e-07
somatic O 0 6.1686691879003774e-06
mutation O 0 1.1644505320873577e-05
. O 0 9.012697432808636e-07

The O 0 5.452109235193348e-07
I1307K O 0 4.1527960092935245e-06
allele O 0 5.272785529086832e-06
was O 0 5.122677748659044e-07
found O 0 1.9312224708301073e-08
in O 0 1.6028975480253393e-08
6 O 0 4.49946469416318e-07
. O 0 4.4079413896724873e-07

1 O 0 1.4919139630364953e-06
% O 0 5.3258123244859235e-08
of O 0 6.983733591425789e-09
unselected O 0 1.6831110769999214e-05
Ashkenazi O 0 0.00010548688442213461
Jews O 0 3.9864536915956705e-07
and O 0 2.8024189191455662e-08
higher O 0 1.077300915142132e-08
proportions O 0 3.5739716963689716e-08
of O 0 2.6726783008967914e-09
Ashkenazim O 0 7.350078703893814e-06
with O 0 3.5354212002403074e-08
family O 0 4.0249526023217186e-07
or O 0 2.038243849256105e-07
personal O 0 4.2541330458334414e-07
histories O 0 3.0340473244905297e-07
of O 0 5.586206341945399e-08
CRC B-Disease 0 0.001698733656667173
( O 0 7.301658655478604e-08
ref O 0 5.576998319156701e-06
. O 0 8.748677338132893e-09
2 O 0 8.697006137481367e-08
) O 0 3.3012440781021724e-08
. O 0 1.3852005054104666e-07

To O 0 1.3076402183287428e-06
evaluate O 0 4.871186547461548e-07
the O 0 4.628908811810106e-09
role O 0 1.1335501426401606e-08
of O 0 8.947178553597723e-10
I1307K O 0 1.9045415911023156e-07
in O 0 3.489902411502044e-08
cancer B-Disease 0 2.039318360402831e-06
, O 0 7.379064470569574e-09
we O 0 1.8467474660610605e-08
genotyped O 0 9.000680734061461e-07
5 O 0 3.664480985321461e-08
, O 0 8.650052230052552e-09
081 O 0 7.624820455021109e-07
Ashkenazi O 0 3.1831298201723257e-06
volunteers O 0 5.482076126384072e-09
in O 0 6.02614180778005e-10
a O 0 2.647281682754965e-08
community O 0 5.568589500626331e-08
survey O 0 1.130779537561466e-06
. O 0 1.6789644519121794e-07

Risk O 0 6.793706415919587e-05
of O 0 1.3761757600150304e-07
developing O 0 7.467527757398784e-05
colorectal B-Disease 1 1.0
, I-Disease 0 1.656042513786815e-05
breast I-Disease 0 0.0455734021961689
and I-Disease 0 7.660987648705486e-07
other I-Disease 0 2.419013469534548e-07
cancers I-Disease 0 0.0032462039962410927
were O 0 2.517813868507801e-08
compared O 0 1.1423492374262878e-08
between O 0 1.679949401811598e-09
genotyped O 0 2.8663223474723054e-06
I1307K O 0 4.195422320663056e-08
carriers O 0 4.977074752332555e-09
and O 0 2.7565503213367037e-09
non O 0 5.783452294849667e-08
- O 0 2.4097262212308124e-06
carriers O 0 3.2357192480958474e-08
and O 0 4.429125954885649e-09
their O 0 4.749130866343876e-09
first O 0 1.3913104623952677e-07
- O 0 1.1122445357614197e-05
degree O 0 3.452818759797083e-07
relatives O 0 4.1242742554459255e-07
. O 0 2.1774746983282967e-07

Sperm O 0 5.602178498520516e-05
DNA O 0 7.000472578511108e-06
analysis O 0 1.9824619812425226e-07
in O 0 2.0611940598769252e-08
a O 0 3.1417580430570524e-06
Friedreich B-Disease 1 0.9999485015869141
ataxia I-Disease 1 0.99998939037323
premutation O 0 0.005708751734346151
carrier O 0 8.595519830123521e-06
suggests O 0 1.828469748943462e-07
both O 0 4.746115500608994e-09
meiotic O 0 1.5257418226610753e-06
and O 0 1.4816180282650748e-08
mitotic O 0 4.495643111113168e-07
expansion O 0 4.8607635250164094e-08
in O 0 1.0191551602645177e-08
the O 0 3.84705138856134e-08
FRDA B-Disease 0 0.00015881632862146944
gene O 0 4.1184785004588775e-06
. O 0 2.453969614180096e-07

Friedreich B-Disease 1 0.999975323677063
ataxia I-Disease 1 0.9999978542327881
is O 0 3.763551285373978e-05
usually O 0 7.098667538230075e-07
caused O 0 2.8038792265761003e-07
by O 0 1.2261364146226583e-09
an O 0 1.9948751539544674e-09
expansion O 0 1.7139864638693325e-08
of O 0 1.4722226771013425e-09
a O 0 5.753184950663126e-07
GAA O 0 2.5311832359875552e-05
trinucleotide O 0 2.4171824406948872e-05
repeat O 0 1.151988385572622e-06
in O 0 6.424777154734329e-09
intron O 0 4.273971626389539e-06
1 O 0 1.2965169382539443e-08
of O 0 7.967611570514066e-10
the O 0 1.4627878464068544e-08
FRDA B-Disease 0 6.240219954634085e-05
gene O 0 2.785810465866234e-06
. O 0 1.466048047404911e-07

Occasionally O 0 8.707727829460055e-06
, O 0 5.2522814542044216e-08
a O 0 3.0862320699043266e-08
fully O 0 1.1118886789063254e-07
expanded O 0 4.681751519797217e-08
allele O 0 7.631527410012495e-07
has O 0 1.6928268564697646e-07
been O 0 2.8915373206928052e-08
found O 0 1.8318727867949747e-08
to O 0 1.9932521411192283e-08
arise O 0 2.1681948680907226e-08
from O 0 1.9125743211390045e-09
a O 0 1.4359677891206957e-08
premutation O 0 1.8031026911558001e-06
of O 0 5.44640887945036e-10
100 O 0 5.224911170387259e-09
or O 0 4.438015821506269e-08
less O 0 1.9214901669784012e-07
triplet O 0 0.0007448738324455917
repeats O 0 0.00015455749235115945
. O 0 5.335787136573344e-07

We O 0 1.5865924069657922e-05
have O 0 5.655063262111071e-08
examined O 0 6.507509908715292e-08
the O 0 1.7891430559302535e-09
sperm O 0 4.703438349906719e-08
DNA O 0 6.391924500803725e-08
of O 0 4.5577155938225644e-10
a O 0 7.064441120974152e-08
premutation O 0 2.889688403229229e-05
carrier O 0 2.5405311134818476e-06
. O 0 3.762883977742604e-07

This O 0 2.626215405143739e-07
mans O 0 1.1565431123017333e-05
leucocyte O 0 1.797847835405264e-05
DNA O 0 5.3805265451956075e-06
showed O 0 3.180928160873009e-07
one O 0 4.147356680306302e-09
normal O 0 2.5108937151685495e-08
allele O 0 1.6295631155571755e-07
and O 0 9.554520730148397e-09
one O 0 4.307562306848922e-09
allele O 0 1.3414394572919264e-07
of O 0 1.244367164865423e-09
approximately O 0 4.380684615057362e-08
100 O 0 3.252996449987222e-08
repeats O 0 1.0918976840912364e-05
. O 0 1.3856960379143857e-07

His O 0 2.3459533622371964e-06
sperm O 0 2.179037983296439e-05
showed O 0 6.452712568716379e-07
an O 0 9.850140703093757e-10
expanded O 0 6.335928670608837e-09
allele O 0 9.321541227791386e-08
in O 0 2.3424633344149015e-09
a O 0 2.7614353470539754e-08
tight O 0 5.58831573016505e-07
range O 0 6.778584804578713e-08
centering O 0 1.0119171633959922e-07
on O 0 2.240356309357594e-07
a O 0 1.3110844854224979e-08
size O 0 5.1504869702512224e-08
of O 0 5.462026386737762e-09
approximately O 0 2.92613037800038e-07
320 O 0 1.1056296216338524e-06
trinucleotide O 0 8.047775918385014e-05
repeats O 0 2.6624775273376144e-05
. O 0 3.8968082094470446e-07

His O 0 2.224087802460417e-05
affected O 0 1.6636276995996013e-05
son O 0 1.4466196262219455e-05
has O 0 2.570296544490702e-07
repeat O 0 1.0967734169753385e-06
sizes O 0 9.72831912804395e-08
of O 0 5.657174728668224e-09
1040 O 0 6.310149728960823e-06
and O 0 1.5946221765261726e-07
540 O 0 1.0920807653747033e-06
. O 0 1.9842097742639453e-07

These O 0 1.610584234867929e-07
data O 0 3.2892870649448014e-07
suggest O 0 2.5528922975581736e-08
that O 0 1.0126518512620919e-09
expansion O 0 1.2109325098208501e-08
occurs O 0 3.3971920831987745e-09
in O 0 1.7126325912997231e-09
two O 0 4.524992824883611e-09
stages O 0 1.4257668112804822e-07
, O 0 3.164888795481602e-09
the O 0 6.027612853287678e-10
first O 0 1.772987445747276e-08
during O 0 2.0279562473746182e-09
meiosis O 0 4.824949773052367e-09
followed O 0 9.748017948396637e-10
by O 0 1.1922257625585075e-10
a O 0 3.524848191105434e-09
second O 0 9.84981127771789e-08
mitotic O 0 1.3620186791740707e-06
expansion O 0 5.358295425139659e-07
. O 0 3.0404805784201017e-07

We O 0 3.2323905543307774e-06
also O 0 7.198060814062046e-08
show O 0 5.854874629562801e-08
that O 0 6.124356022318977e-10
in O 0 7.47186978955483e-10
all O 0 8.382218252833695e-10
informative O 0 4.925063379346284e-08
carrier O 0 4.656308760786487e-07
father O 0 7.724057127234119e-08
to O 0 1.9625668201683766e-08
affected O 0 3.363512135479141e-08
child O 0 1.4262739966852678e-07
transmissions O 0 7.313238256756449e-06
, O 0 3.4442591001493383e-09
with O 0 3.811020388155839e-10
the O 0 1.5912905437787117e-09
notable O 0 3.460985942282946e-09
exception O 0 1.6012526860009757e-09
of O 0 2.1474497180484775e-10
the O 0 4.918855989188842e-09
premutation O 0 3.7324759887269465e-06
carrier O 0 1.2743710442464362e-07
, O 0 4.2125616883659234e-10
the O 0 2.5772098344312155e-10
expansion O 0 4.807688025465495e-09
size O 0 2.3203464039056598e-08
decreases O 0 1.97963188952599e-07
. O 0 1.2094967694054048e-08
. O 0 1.2519817005340883e-07

The O 0 2.0604319672656857e-07
R496H O 0 1.8402727164357202e-06
mutation O 0 9.737254913488869e-07
of O 0 8.94777940629865e-09
arylsulfatase O 0 1.9663715647766367e-05
A O 0 2.320104613318108e-06
does O 0 9.065488484338857e-07
not O 0 4.0563273273619416e-07
cause O 0 1.9145451005897485e-05
metachromatic B-Disease 1 0.9999979734420776
leukodystrophy I-Disease 1 0.9999990463256836
. O 0 7.096106855897233e-06

Deficiency B-Disease 1 0.9956477284431458
of I-Disease 0 7.033571023384866e-07
arylsulfatase I-Disease 0 0.00019813206745311618
A I-Disease 0 1.2878282177553046e-05
( O 0 1.2458067430998199e-06
ARSA O 0 0.0010674857767298818
) O 0 6.259296725374952e-08
enzyme O 0 2.2401691239792854e-06
activity O 0 5.37407458978123e-06
causes O 0 0.0003401739813853055
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 1.0
( O 0 0.00016164194676093757
MLD B-Disease 1 0.9999967813491821
) O 0 1.0000512702390552e-06
. O 0 4.6412483811764105e-07

A O 0 8.642780358059099e-07
number O 0 6.701337440517818e-08
of O 0 1.3404926058058209e-08
ARSA O 0 0.0018860874697566032
gene O 0 4.156774957664311e-05
mutations O 0 7.356923742918298e-05
responsible O 0 8.843571777106263e-06
for O 0 3.681326461446588e-06
MLD B-Disease 1 1.0
have O 0 3.056350124097662e-06
been O 0 2.0522934107702895e-07
identified O 0 1.4873794498271309e-06
. O 0 2.117767365916734e-07

Recently O 0 1.8639033442013897e-05
, O 0 1.781414127322023e-08
the O 0 2.7428934679107897e-09
R496H O 0 2.0987552318274538e-07
mutation O 0 2.453761283049971e-07
of O 0 8.666895645603745e-09
ARSA O 0 0.0006145755760371685
was O 0 8.577329140280199e-07
proposed O 0 1.9339022827580266e-08
to O 0 2.256450315485381e-08
be O 0 9.538752010485041e-09
a O 0 5.1761510633241414e-08
cause O 0 4.824639177058998e-07
of O 0 1.1280700817906109e-07
MLD B-Disease 1 0.9999997615814209
( O 0 1.588253866202649e-07
Draghia O 0 1.66230856848415e-05
et O 0 6.974774441914633e-05
al O 0 6.817724624852417e-06
. O 0 2.6151626641990333e-08
, O 0 1.3283064426161673e-08
1997 O 0 3.192853625932912e-08
) O 0 1.6653642020969528e-08
. O 0 1.3557382771978155e-07

We O 0 1.27426746985293e-05
have O 0 4.935096953317952e-08
investigated O 0 7.643947697033582e-08
the O 0 1.4284193827762692e-09
R496H O 0 1.4019204286341846e-07
mutation O 0 1.261416286979511e-07
and O 0 5.482954534841156e-09
found O 0 4.621454330333563e-09
this O 0 6.959077758494914e-10
mutation O 0 2.2473702898651027e-08
at O 0 1.07659028358853e-08
a O 0 5.857708540446538e-09
relatively O 0 4.106276652038332e-09
high O 0 1.0393830685018202e-08
frequency O 0 1.1642318753501968e-07
in O 0 3.38934125210244e-09
an O 0 2.9966165104866604e-09
African O 0 2.0044677029318336e-09
American O 0 5.241240330633445e-09
population O 0 6.686253217758065e-10
( O 0 6.349644698921963e-10
f O 0 8.336943579934086e-08
= O 0 4.756140725703517e-08
0 O 0 8.616952484885587e-09
. O 0 3.339360343801445e-09
09 O 0 1.7401013963080914e-08
, O 0 4.42915171205982e-09
n O 0 6.864829060759803e-07
= O 0 5.215733835939318e-07
61 O 0 1.9886159918769408e-07
subjects O 0 5.8276675929391786e-08
) O 0 2.436902413194275e-08
. O 0 2.7354454346095736e-07

The O 0 9.718653473100858e-07
ARSA O 0 0.00013956685143057257
enzyme O 0 1.3768992630502908e-06
activity O 0 1.688227087015548e-07
in O 0 6.073095359937497e-09
subjects O 0 1.4960608751835025e-08
with O 0 4.85177631404099e-09
and O 0 2.3072169952342847e-08
without O 0 3.677951720959527e-09
the O 0 2.3029731455181945e-09
R496H O 0 1.0551474360909197e-07
mutation O 0 8.563952036411138e-08
was O 0 1.4806893489094364e-07
determined O 0 9.770177200607577e-08
and O 0 1.978340513630883e-08
found O 0 3.7565655475191306e-08
to O 0 1.182407505240235e-08
be O 0 1.4967087125228318e-08
normal O 0 2.0517454402124713e-07
. O 0 2.816668711602688e-07

It O 0 2.2510139388032258e-06
is O 0 2.926905295908e-08
therefore O 0 1.515406111707307e-08
concluded O 0 2.6055934299051842e-08
that O 0 6.642678629376064e-10
the O 0 6.534506269417761e-10
R496H O 0 1.0929251459401712e-07
mutation O 0 3.9323889922115995e-08
of O 0 2.271606236448065e-09
ARSA O 0 0.000135349269839935
does O 0 2.703852430840925e-07
not O 0 1.3671868970277501e-08
negatively O 0 3.287840755206162e-08
influence O 0 5.316735496307956e-09
the O 0 2.1316253207004365e-09
activity O 0 2.62667043671172e-08
of O 0 4.356975225050519e-09
ARSA O 0 0.005267216358333826
and O 0 1.5768621608458488e-07
is O 0 1.266961557888635e-08
not O 0 1.0211397949433376e-08
a O 0 1.1472189243022513e-07
cause O 0 2.996775037900079e-06
of O 0 1.1707290923368419e-06
MLD B-Disease 1 0.9999958276748657

Down O 0 8.944456203607842e-05
- O 0 1.2990999493922573e-05
regulation O 0 5.782536618426093e-07
of O 0 3.595289754798614e-08
transmembrane O 0 4.699546934716636e-06
carbonic O 0 5.427223368315026e-05
anhydrases O 0 6.172731082187966e-05
in O 0 1.5607325849487097e-06
renal B-Disease 1 0.9999816417694092
cell I-Disease 1 0.9999949932098389
carcinoma I-Disease 1 1.0
cell O 1 0.9011099338531494
lines O 0 4.077619450981729e-05
by O 0 1.1050845571958234e-08
wild O 0 5.717441240449261e-07
- O 0 0.0005807660636492074
type O 0 5.8065073972102255e-05
von B-Disease 1 0.9971175193786621
Hippel I-Disease 1 0.9470762014389038
- I-Disease 1 0.5180850028991699
Lindau I-Disease 1 0.8260296583175659
transgenes O 0 0.0006505783530883491
. O 0 1.8981602352141635e-06

To O 0 1.1842785170301795e-06
discover O 0 2.279927684867289e-06
genes O 0 5.391036665969295e-07
involved O 0 1.3296123313466524e-07
in O 0 1.7630534898671613e-07
von B-Disease 1 0.9997621178627014
Hippel I-Disease 1 0.9999138116836548
- I-Disease 1 0.9997689127922058
Lindau I-Disease 1 0.9994224309921265
( O 0 1.2799924888895475e-06
VHL B-Disease 0 8.233894914155826e-05
) O 0 1.0749593570835714e-07
- O 0 1.2962400433025323e-05
mediated O 0 0.00013667682651430368
carcinogenesis O 0 0.000568529823794961
, O 0 4.564697420050834e-08
we O 0 2.592526016087504e-08
used O 0 4.961957984050969e-06
renal B-Disease 1 0.99989914894104
cell I-Disease 1 0.9999899864196777
carcinoma I-Disease 1 1.0
cell O 1 0.9943020343780518
lines O 0 0.004635797813534737
stably O 0 0.00046126122470013797
transfected O 0 3.4438944567227736e-05
with O 0 1.0157473973038122e-08
wild O 0 4.770949999510776e-07
- O 0 9.34387935558334e-05
type O 0 1.2380074622342363e-05
VHL O 0 0.0009045596234500408
- O 0 6.751533510396257e-05
expressing O 0 1.3435728760669008e-06
transgenes O 0 3.7093344872118905e-05
. O 0 4.4692421852232656e-07

Large O 0 4.351015263637237e-07
- O 0 4.790427738043945e-06
scale O 0 3.737822282801062e-07
RNA O 0 4.067918268901849e-07
differential O 0 4.388947729694337e-07
display O 0 6.416146192123051e-08
technology O 0 7.110362076900856e-08
applied O 0 1.7944206121001116e-08
to O 0 6.384112349877569e-09
these O 0 2.12052242432037e-09
cell O 0 1.969994445971679e-05
lines O 0 3.9161710446933284e-05
identified O 0 1.0030189514509402e-06
several O 0 5.613193021503093e-09
differentially O 0 2.29238267479559e-07
expressed O 0 3.2956872786371605e-09
genes O 0 9.298772418731005e-09
, O 0 5.304051642340823e-10
including O 0 3.1776134501448894e-10
an O 0 3.720596275513799e-09
alpha O 0 2.428903087547951e-07
carbonic O 0 3.526582531776512e-06
anhydrase O 0 2.3602033252245747e-06
gene O 0 4.540661393548362e-07
, O 0 1.8960234271503396e-08
termed O 0 1.549134822198539e-06
CA12 O 0 0.00020812860748264939
. O 0 8.096879469121632e-07

The O 0 2.924551552041521e-07
deduced O 0 1.053811502060853e-06
protein O 0 1.5532961583630822e-07
sequence O 0 6.190458634591778e-08
was O 0 1.1406535804781015e-07
classified O 0 4.874151215972233e-08
as O 0 2.921822561674503e-09
a O 0 8.465159240245157e-09
one O 0 4.3132864391282055e-08
- O 0 4.100262958672829e-05
pass O 0 5.427542419056408e-06
transmembrane O 0 6.204907549545169e-06
CA O 0 1.3850812138116453e-05
possessing O 0 6.919377426584106e-08
an O 0 4.158215993754766e-09
apparently O 0 4.5989375507815566e-07
intact O 0 1.4751333310414338e-07
catalytic O 0 2.215869159272188e-07
domain O 0 6.499409010984891e-08
in O 0 3.27115023956992e-09
the O 0 2.165983659097037e-08
extracellular O 0 3.1945160117174964e-06
CA O 0 0.0001264602324226871
module O 0 2.626415152917616e-05
. O 0 5.448304705168994e-07

Reintroduced O 0 4.704210732597858e-05
wild O 0 5.5629166126891505e-06
- O 0 0.00014258378359954804
type O 0 5.901508757233387e-06
VHL B-Disease 0 0.00011861252278322354
strongly O 0 1.9319674038342782e-07
inhibited O 0 5.255979118601317e-08
the O 0 1.5148100551698462e-09
overexpression O 0 6.120694706623908e-08
of O 0 2.548870836616146e-10
the O 0 2.679553912088295e-09
CA12 O 0 2.6146221898670774e-06
gene O 0 5.8360324572959144e-08
in O 0 1.8279242564034348e-09
the O 0 9.681580337428386e-08
parental O 0 6.761997065041214e-05
renal B-Disease 1 0.9999901056289673
cell I-Disease 1 0.9999963045120239
carcinoma I-Disease 1 1.0
cell O 1 0.9782434701919556
lines O 0 0.0015844813315197825
. O 0 2.8752228899975307e-06

Similar O 0 2.1306889266270446e-06
results O 0 4.912473286822205e-06
were O 0 5.094551625006716e-08
obtained O 0 3.080368671248834e-08
with O 0 1.126742876778053e-08
CA9 O 0 0.00016541867807973176
, O 0 1.757858214546104e-08
encoding O 0 6.062010982077481e-08
another O 0 1.341798991916221e-07
transmembrane O 0 3.3034034458978567e-06
CA O 0 5.649614195135655e-06
with O 0 1.9714161414441378e-09
an O 0 1.1652933729067172e-08
intact O 0 6.093234787840629e-07
catalytic O 0 2.3071461328072473e-06
domain O 0 2.1159778498258675e-06
. O 0 5.176309514354216e-07

Although O 0 6.114242978583206e-07
both O 0 1.763981138935833e-08
domains O 0 7.831923198864388e-08
of O 0 3.3338618532496866e-09
the O 0 1.9788121363717437e-08
VHL B-Disease 0 4.92566960019758e-06
protein O 0 4.6746666271246795e-07
contribute O 0 1.1730963755951507e-08
to O 0 4.500067429802357e-09
regulation O 0 1.1654711862263412e-08
of O 0 2.286202338552812e-09
CA12 O 0 1.701445762591902e-05
expression O 0 4.957503563218779e-08
, O 0 1.8084417297004052e-09
the O 0 1.1514575959381546e-09
elongin O 0 6.715316089866974e-07
binding O 0 1.0085508250767816e-07
domain O 0 7.607658147890106e-08
alone O 0 2.569732657775603e-07
could O 0 9.605724216044109e-08
effectively O 0 7.58624025820609e-07
regulate O 0 1.0017895874625538e-05
CA9 O 0 0.0012887439224869013
expression O 0 6.872638095956063e-06
. O 0 6.594611932086991e-07

We O 0 1.0840723916771822e-05
mapped O 0 7.869952241890132e-05
CA12 O 0 0.0005596226546913385
and O 0 7.739319585198245e-07
CA9 O 0 0.0002544917515479028
loci O 0 2.012450067923055e-06
to O 0 1.8593728157156875e-07
chromosome O 0 3.205622124369256e-05
bands O 0 5.808828973385971e-07
15q22 O 0 9.936476317307097e-07
and O 0 6.040128397444278e-08
17q21 O 0 2.7506073365657357e-06
. O 0 3.127326522189833e-07

2 O 0 3.817604920186568e-06
respectively O 0 1.315914346378122e-06
, O 0 2.2769951257828325e-08
regions O 0 3.8341079289239133e-07
prone O 0 7.891407221904956e-06
to O 0 4.4357140183137744e-08
amplification O 0 3.7524841900449246e-07
in O 0 2.881971772339398e-09
some O 0 1.0355520885241276e-08
human O 0 9.037278800860804e-07
cancers B-Disease 0 0.00104811682831496
. O 0 4.7402372160831874e-07

Additional O 0 7.700703577029344e-07
experiments O 0 9.294144547311589e-07
are O 0 3.800337378123686e-09
needed O 0 8.402616380465133e-09
to O 0 3.9311123245511226e-09
define O 0 4.2962085444742115e-08
the O 0 1.004300465012875e-08
role O 0 5.344189446532255e-08
of O 0 2.508031649028908e-08
CA O 0 4.687078399001621e-05
IX O 0 6.398574896593345e-06
and O 0 3.0674052595713874e-06
CA O 0 2.8751115678460337e-05
XII O 0 6.10606150530657e-07
enzymes O 0 2.8509084870620427e-08
in O 0 6.898339677263721e-10
the O 0 1.1026227708654801e-09
regulation O 0 1.225774592938933e-08
of O 0 1.9125268035935505e-09
pH O 0 4.333614072038472e-07
in O 0 1.1064591465270723e-09
the O 0 1.5792566143701947e-09
extracellular O 0 3.221666489139352e-08
microenvironment O 0 6.981085221013927e-07
and O 0 1.5240033235386363e-08
its O 0 7.197182583240647e-08
potential O 0 3.423570760219263e-08
impact O 0 5.326431917751506e-08
on O 0 3.7353672723838827e-06
cancer B-Disease 0 1.5987066944944672e-05
cell O 0 2.0119194232393056e-05
growth O 0 2.2697486201650463e-06
. O 0 2.0451503246476932e-07

A O 0 6.906086014168977e-07
gene O 0 5.325314305082429e-07
encoding O 0 2.907526663875615e-07
a O 0 5.974052896817739e-08
transmembrane O 0 7.84817586918507e-07
protein O 0 2.4711181367820245e-07
is O 0 4.1538719131040125e-09
mutated O 0 4.753179894123605e-07
in O 0 6.335182689554131e-08
patients O 0 1.1672947948682122e-05
with O 0 0.00015918548160698265
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9469873309135437
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999961853027344
( O 0 0.001793562201783061
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 1.0077160368382465e-06
. O 0 5.258285682430142e-07

Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
( O 0 0.0005167089402675629
WFS B-Disease 0 0.19720084965229034
; O 0 3.5992811717733275e-06
OMIM O 0 0.0015426860190927982
222300 O 0 8.262071787612513e-06
) O 0 3.183926011729454e-08
is O 0 7.405417168371287e-09
an O 0 2.627828621371009e-07
autosomal B-Disease 1 0.9999938011169434
recessive I-Disease 1 0.9999992847442627
neurodegenerative I-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9995461106300354
defined O 0 6.544777875205909e-07
by O 0 8.104455773150221e-09
young O 0 7.951071268053056e-08
- O 0 0.00016704428708180785
onset O 0 6.542805931530893e-05
non O 0 1.1941033335460816e-05
- O 0 0.1595301330089569
immune O 0 0.001112236874178052
insulin B-Disease 1 0.9052513837814331
- I-Disease 1 0.9963645339012146
dependent I-Disease 1 0.9999492168426514
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.00012868385238107294
progressive O 0 0.08862313628196716
optic B-Disease 1 0.9999945163726807
atrophy I-Disease 0 0.3593212068080902
. O 0 2.627848971314961e-06

Linkage O 0 0.00020186036999803036
to O 0 1.1390571899028146e-06
markers O 0 1.843369500420522e-05
on O 0 4.733389141620137e-05
chromosome O 0 0.20572315156459808
4p O 1 0.8353728652000427
was O 0 2.874900383176282e-05
confirmed O 0 1.171771259578236e-06
in O 0 4.495452010644385e-09
five O 0 1.4207928167309092e-08
families O 0 1.4425644678794924e-08
. O 0 8.71281216063835e-08

On O 0 8.369883062187e-07
the O 0 8.409252849617133e-09
basis O 0 1.1390943299716128e-08
of O 0 2.5880877441153416e-09
meiotic O 0 1.6690466509317048e-05
recombinants O 0 0.0016135652549564838
and O 0 1.0962434316752478e-05
disease O 0 0.0002721470664255321
- O 0 2.0269157175789587e-05
associated O 0 2.0095847048651194e-06
haplotypes O 0 1.1300678124825936e-05
, O 0 1.2316781372589958e-08
the O 0 1.1620040929471998e-08
WFS B-Disease 0 3.677553468151018e-05
gene O 0 3.7852421996831254e-07
was O 0 4.226085792424783e-08
localized O 0 7.396160128791962e-08
to O 0 8.637571546898926e-09
a O 0 1.8330126749788178e-07
BAC O 0 0.0002702281344681978
/ O 0 3.1869894883129746e-05
P1 O 0 8.1557736848481e-05
contig O 0 5.157051873538876e-06
of O 0 1.5652013019007427e-09
less O 0 1.1066455307684464e-08
than O 0 6.918450701220991e-09
250 O 0 2.2866439408630868e-08
kb O 0 2.0628063793992624e-05
. O 0 1.8750215247109736e-07

Mutations O 0 0.0003480407176539302
in O 0 1.0731259436624896e-07
a O 0 6.526664719785913e-08
novel O 0 3.5600459113993566e-07
gene O 0 2.878172153941705e-06
( O 0 4.412424203792398e-08
WFS1 O 0 7.4866070463031065e-06
) O 0 2.3205044552554455e-09
encoding O 0 8.661179329294555e-09
a O 0 1.844818164897788e-08
putative O 0 4.814839940081583e-07
transmembrane O 0 2.5286530558332743e-07
protein O 0 4.1796960204010247e-07
were O 0 1.0325305055403078e-08
found O 0 6.810034314241875e-09
in O 0 1.4889688371155785e-09
all O 0 2.2530515231267145e-09
affected O 0 1.1046083159271802e-08
individuals O 0 1.6541179537199469e-10
in O 0 2.3424278072781135e-09
six O 0 1.0345910084197385e-07
WFS B-Disease 0 1.8923668903880753e-05
families O 0 9.174133452916067e-09
, O 0 2.0466470740387877e-09
and O 0 3.144184912429182e-09
these O 0 1.2618145417420124e-09
mutations O 0 2.131915692871189e-07
were O 0 3.5121641150936966e-09
associated O 0 2.1995043564260186e-09
with O 0 3.2671971794684396e-09
the O 0 3.5419685673332424e-07
disease O 0 0.00016458546451758593
phenotype O 0 3.877420022035949e-05
. O 0 4.975919978278398e-07

WFS1 O 0 0.0025934285949915648
appears O 0 7.257820925588021e-06
to O 0 3.186696773127551e-08
function O 0 1.674230887260819e-08
in O 0 8.025252462573462e-09
survival O 0 7.286924414984242e-07
of O 0 5.30451993441261e-09
islet O 0 1.8427894246997312e-05
beta O 0 9.188257195091865e-07
- O 0 9.002595106721856e-06
cells O 0 4.7775979510333855e-06
and O 0 5.872064079426309e-08
neurons O 0 5.673553573615209e-07
. O 0 1.1007594835632517e-08
. O 0 6.290151333132599e-08

Stable O 0 4.599249950842932e-05
interaction O 0 1.6900749244541657e-07
between O 0 1.1430161706016406e-08
the O 0 5.074784148462186e-09
products O 0 5.060331886852509e-07
of O 0 1.7002385055420177e-09
the O 0 2.2577157920977697e-08
BRCA1 O 0 5.555325697059743e-05
and O 0 1.0075373211293481e-06
BRCA2 O 0 0.00019815056293737143
tumor B-Disease 0 1.3728668818657752e-05
suppressor O 0 2.4851590296748327e-06
genes O 0 4.131718753797031e-07
in O 0 8.599975842571439e-09
mitotic O 0 2.1936892153462395e-05
and O 0 8.264950679404137e-07
meiotic O 0 0.00011286096560070291
cells O 0 4.541484304354526e-05
. O 0 4.319510935602011e-07

BRCA1 O 0 0.07759437710046768
and O 0 6.914812274771975e-06
BRCA2 O 0 0.00029283296316862106
account O 0 6.910381671332289e-07
for O 0 3.271499959822677e-09
most O 0 2.0281303303448794e-09
cases O 0 1.0228782265642167e-09
of O 0 5.298571581491274e-10
familial O 0 2.261156396343722e-06
, O 0 8.162729159266746e-08
early O 0 4.3297060869917914e-07
onset O 0 7.542239018221153e-06
breast B-Disease 0 0.0027462581638246775
and I-Disease 0 1.2239835086802486e-05
/ I-Disease 1 0.9999922513961792
or I-Disease 1 0.9999926090240479
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.3527905906585147e-08
encode O 0 7.766085019511593e-08
products O 0 9.280169024350471e-07
that O 0 7.055063200311906e-10
each O 0 7.604836205210574e-10
interact O 0 9.8843981888308e-09
with O 0 6.456988277392384e-09
hRAD51 O 0 1.3670594853465445e-05
. O 0 4.908038704343198e-07

Results O 0 4.167356382822618e-05
presented O 0 2.508395766653848e-07
here O 0 1.879503841450969e-08
show O 0 1.1561626678258108e-07
that O 0 1.3524035225032094e-08
BRCA1 O 0 1.2291490747884382e-05
and O 0 2.503902294392901e-07
BRCA2 O 0 3.7805046304129064e-05
coexist O 0 9.568783525537583e-07
in O 0 2.5714959051015285e-09
a O 0 1.7478985370189548e-08
biochemical O 0 5.029324370298127e-07
complex O 0 1.5119090335247165e-07
and O 0 2.0932263566919573e-07
colocalize O 0 7.805416316841729e-06
in O 0 2.0394120170408314e-08
subnuclear O 0 3.2298944461217616e-06
foci O 0 1.0296492973793647e-06
in O 0 4.557109356539968e-09
somatic O 0 2.1067886279979575e-07
cells O 0 1.4743443443876458e-06
and O 0 8.099789283733116e-09
on O 0 5.8536908653650244e-08
the O 0 2.189329162405329e-09
axial O 0 5.836054839392091e-08
elements O 0 1.5035098499538435e-08
of O 0 1.3098041540260397e-09
developing O 0 6.686080666895577e-08
synaptonemal O 0 8.585491741541773e-06
complexes O 0 4.879727839579573e-07
. O 0 2.1721277221331547e-07

Like O 0 9.811214113142341e-06
BRCA1 O 0 0.0006230681319721043
and O 0 4.768098733620718e-06
RAD51 O 0 0.0012217415496706963
, O 0 4.905928108200897e-07
BRCA2 O 0 2.9554415959864855e-05
relocates O 0 2.9183738661231473e-06
to O 0 6.217603498726021e-08
PCNA O 0 1.4034888408787083e-05
+ O 0 1.979126125206676e-07
replication O 0 9.935171618735694e-08
sites O 0 6.974524779934654e-08
following O 0 1.1516030795633014e-08
exposure O 0 1.8660023215488764e-07
of O 0 1.4944515625003874e-09
S O 0 0.0001269872154807672
phase O 0 1.0306224140776976e-07
cells O 0 1.9147037733091565e-07
to O 0 1.972748542300451e-08
hydroxyurea O 0 5.783446795248892e-06
or O 0 2.0724375815461826e-07
UV O 0 2.6122594135813415e-05
irradiation O 0 2.7376008802093565e-06
. O 0 4.338029953032674e-07

Thus O 0 8.68624397298845e-07
, O 0 8.103779691737145e-08
BRCA1 O 0 8.242616786446888e-06
and O 0 2.8685761321867176e-07
BRCA2 O 0 2.1696818294003606e-05
participate O 0 1.593089216100907e-08
, O 0 3.4978178131694904e-09
together O 0 7.78108688592738e-09
, O 0 3.136464199471334e-09
in O 0 8.430319220487092e-10
a O 0 2.353634265261917e-08
pathway O 0 1.3195281667321979e-07
( O 0 1.9730146050278563e-07
s O 0 0.0010955348843708634
) O 0 1.2234925073073555e-08
associated O 0 9.97420457338194e-09
with O 0 5.319207851961494e-10
the O 0 2.69554711884723e-09
activation O 0 8.329088529990258e-09
of O 0 7.25844051530089e-10
double O 0 1.2486757441365626e-06
- O 0 6.216006295289844e-05
strand O 0 0.15942983329296112
break O 0 0.00016775635594967753
repair O 0 0.0008730218978598714
and O 0 4.0410452584183076e-07
/ O 0 1.3399999261309858e-05
or O 0 5.616119835849531e-08
homologous O 0 5.757147505391913e-07
recombination O 0 7.396780006274639e-07
. O 0 4.2793288912434946e-07

Dysfunction O 0 0.07774919271469116
of O 0 3.3148918276992845e-08
this O 0 8.01954502804847e-09
pathway O 0 1.1311295367022467e-07
may O 0 3.013807827301207e-06
be O 0 7.960536230200432e-09
a O 0 1.437113095192899e-08
general O 0 5.623105536756157e-09
phenomenon O 0 1.07376436631057e-08
in O 0 1.4752613575197415e-09
the O 0 1.934635562861331e-09
majority O 0 3.466178233324513e-09
of O 0 5.855225748696569e-10
cases O 0 4.875785108993114e-09
of O 0 8.272124318864371e-09
hereditary B-Disease 1 0.9951372742652893
breast I-Disease 1 0.984175980091095
and I-Disease 0 0.0007424781215377152
/ I-Disease 1 0.999996542930603
or I-Disease 1 0.9999960660934448
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 4.470981096460491e-08
. O 0 2.0016113921883516e-07

A O 0 1.391691512253601e-06
novel O 0 8.973913736554096e-07
Arg362Ser O 0 8.18232638266636e-06
mutation O 0 7.699719617448864e-07
in O 0 5.060546204305183e-09
the O 0 6.9150210002533186e-09
sterol O 0 2.1974185074213892e-05
27 O 0 3.2186680982704274e-06
- O 0 2.7228426915826276e-05
hydroxylase O 0 5.094931839266792e-05
gene O 0 1.686241148490808e-06
( O 0 1.1642580233228728e-08
CYP27 O 0 1.0604042472550645e-05
) O 0 6.036958932753578e-09
: O 0 6.877581837372304e-10
its O 0 1.982291308877393e-08
effects O 0 2.0758615448812634e-07
on O 0 2.190410697266998e-07
pre O 0 7.653655416106631e-07
- O 0 1.6889180187718011e-07
mRNA O 0 3.110289270580324e-08
splicing O 0 1.2883850786238327e-07
and O 0 4.396880193269226e-09
enzyme O 0 8.66923173248324e-08
activity O 0 5.4250982373105217e-08
. O 0 8.081860869424418e-08

A O 0 3.373787876626011e-06
novel O 0 7.859837864998553e-07
C O 0 3.2199511679209536e-06
to O 0 1.843636177056851e-08
A O 0 5.111604650664958e-08
mutation O 0 1.7805250251967664e-07
in O 0 4.628105010340278e-09
the O 0 1.0342927403428348e-08
sterol O 0 9.977392437576782e-06
27 O 0 1.6004877352315816e-06
- O 0 1.0815011592058e-05
hydroxylase O 0 3.637265763245523e-05
gene O 0 2.0954742012690986e-06
( O 0 1.3794982933745814e-08
CYP27 O 0 2.16888129216386e-05
) O 0 1.575424413147175e-08
was O 0 1.1444051040143677e-07
identified O 0 1.9828132025168088e-08
by O 0 8.621945934983444e-10
sequencing O 0 1.2328044363130175e-07
amplified O 0 7.497637284359371e-07
CYP27 O 0 3.472600610621157e-06
gene O 0 1.737637802534664e-07
products O 0 2.3829188933177647e-07
from O 0 7.950305414006209e-10
a O 0 4.589893620732255e-08
patient O 0 1.613044901205285e-06
with O 0 9.019162803269865e-07
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 0.9999998807907104
( O 0 6.616091923206113e-07
CTX B-Disease 0 0.00028078112518414855
) O 0 1.0274114714547977e-07
. O 0 1.673829359560841e-07

The O 0 7.351042086156667e-07
mutation O 0 2.9134712349332403e-06
changed O 0 1.5004252418293618e-07
the O 0 4.3087373668981854e-09
adrenodoxin O 0 1.1013643188562128e-06
cofactor O 0 2.2452029213582136e-07
binding O 0 1.28285051914645e-07
residue O 0 5.093730806038366e-07
362Arg O 0 8.167756959664985e-07
to O 0 2.3528890835677885e-08
362Ser O 0 3.3096657716669142e-06
( O 0 2.7220790954629592e-08
CGT O 0 2.2692427592119202e-05
362Arg O 0 7.583332717331359e-07
to O 0 4.859132118895104e-08
AGT O 0 2.4429080440313555e-05
362Ser O 0 1.7167155874631135e-06
) O 0 9.687894042542666e-09
, O 0 4.898978112066743e-09
and O 0 5.6853455276950626e-08
was O 0 2.86053045783774e-06
responsible O 0 4.256326519680442e-06
for O 0 8.324817599714152e-07
deficiency O 0 5.062082891527098e-06
in O 0 1.1515057796174233e-09
the O 0 1.0840825126479103e-08
sterol O 0 7.854489012970589e-06
27 O 0 9.684947599453153e-07
- O 0 2.2686124339088565e-06
hydroxylase O 0 1.340283688477939e-05
activity O 0 2.0321282079294178e-07
, O 0 1.972235930125521e-09
as O 0 5.5087201467074465e-09
confirmed O 0 3.117915881034605e-08
by O 0 1.0693954749507739e-10
expression O 0 7.625344800032963e-10
of O 0 2.2452986692123034e-10
mutant O 0 1.3143846011587357e-08
cDNA O 0 7.636690924073264e-08
into O 0 7.340310759218482e-08
COS O 0 0.0016888243844732642
- O 0 4.858928150497377e-06
1 O 0 2.7345481612428557e-07
cells O 0 1.4085435395827517e-06
. O 0 1.9569418441278685e-07

Quantitative O 0 3.055108027183451e-05
analysis O 0 1.0599213737805258e-06
showed O 0 6.518609438899148e-07
that O 0 1.206224786720611e-09
the O 0 1.0616589829481882e-09
expression O 0 5.508573153178986e-09
of O 0 7.009526292733881e-10
CYP27 O 0 1.2093972827642574e-06
gene O 0 2.4582600843814362e-08
mRNA O 0 1.6015588855111673e-08
in O 0 1.934233218037207e-09
the O 0 1.2002536742272696e-08
patient O 0 4.43446253939328e-07
represented O 0 1.5639336936601467e-08
52 O 0 4.002422429039143e-07
. O 0 9.742858964045809e-08

5 O 0 1.3762034996034345e-06
% O 0 3.49423849854702e-08
of O 0 1.7220794790162586e-09
the O 0 7.930742285111592e-09
normal O 0 5.586077236330311e-07
level O 0 2.245845536208435e-07
. O 0 2.454266905260738e-07

As O 0 2.14865693237698e-07
the O 0 1.596453458319047e-08
mutation O 0 1.9982546461960737e-07
occurred O 0 5.0272621621161306e-08
at O 0 7.750484698476612e-09
the O 0 7.289142622823874e-10
penultimate O 0 9.815715884542442e-08
nucleotide O 0 1.9543747953321144e-08
of O 0 4.847315326905743e-10
exon O 0 1.2096656121229898e-07
6 O 0 3.246791635547197e-08
( O 0 1.3790451003359294e-09
- O 0 9.806957734781463e-08
2 O 0 4.7544805426014136e-08
position O 0 1.1513245823380203e-07
of O 0 1.0113392345800776e-09
exon O 0 2.650040755725058e-07
6 O 0 7.391012957214116e-08
- O 0 1.6127480648719938e-06
intron O 0 1.587119186297059e-05
6 O 0 4.519043983464144e-08
splice O 0 3.84193708669045e-06
site O 0 3.4126378523069434e-07
) O 0 6.562209109439721e-10
of O 0 1.1683078116053736e-10
the O 0 1.0982298404016433e-09
gene O 0 1.0956698304198653e-07
, O 0 1.0336024480750439e-08
we O 0 7.943580015989937e-09
hypothesized O 0 1.8833112847005395e-08
that O 0 9.7558294775979e-10
the O 0 8.198361989286695e-09
mutation O 0 1.190792772831628e-06
may O 0 5.11476457631943e-07
partially O 0 9.065384460882342e-07
affect O 0 1.0027290109348996e-08
the O 0 6.576781341749438e-10
normal O 0 8.120951022760892e-09
splicing O 0 6.803752938822072e-08
efficiency O 0 2.1758632229307295e-08
in O 0 2.959062328500295e-09
exon O 0 5.101076112623559e-07
6 O 0 9.135738565646534e-08
and O 0 1.0066958822108063e-08
cause O 0 3.8612073538502045e-09
alternative O 0 6.481827963256137e-09
splicing O 0 2.3334440868438833e-07
elsewhere O 0 2.3876526711319457e-07
, O 0 3.448222818391855e-09
which O 0 5.605190533941595e-09
resulted O 0 1.6156693760649432e-08
in O 0 1.2026323936709105e-08
decreased O 0 1.4789746956012095e-06
transcript O 0 9.815013072511647e-06
in O 0 8.936249962232523e-09
the O 0 5.0858623978911055e-08
patient O 0 3.1456736451218603e-06
. O 0 2.23446704694652e-07

Transfection O 0 0.0006431042565964162
of O 0 1.8603731177790905e-07
constructed O 0 9.732362968861707e-07
minigenes O 0 3.0173225241014734e-05
, O 0 1.253639680953711e-08
with O 0 1.507385549714968e-09
or O 0 1.4601229558763862e-08
without O 0 2.0520920518407593e-09
the O 0 5.9121108009208e-10
mutation O 0 3.6021535976260566e-08
, O 0 1.0582341669618245e-09
into O 0 2.7725713280801756e-08
COS O 0 0.007650061044842005
- O 0 4.441807504917961e-06
1 O 0 2.1230290769835847e-07
cells O 0 3.6212912846167455e-07
confirmed O 0 1.8926890277271013e-07
that O 0 4.87591300668555e-10
the O 0 6.712396749541938e-10
mutant O 0 1.3488849504028622e-07
minigene O 0 6.734473572578281e-06
was O 0 2.729889274633024e-07
responsible O 0 2.414491007129982e-08
for O 0 3.1836924763162244e-10
a O 0 2.189053827095222e-09
mRNA O 0 2.7366240828996524e-08
species O 0 2.227966922063729e-09
alternatively O 0 3.8813894320810505e-08
spliced O 0 1.4537446077156346e-05
at O 0 5.776198364060292e-08
an O 0 6.7410370618858906e-09
activated O 0 6.121711066953139e-07
cryptic O 0 7.745514380985696e-07
5 O 0 1.7774704375028705e-08
splice O 0 7.109179932740517e-06
site O 0 7.49903847463429e-07
88 O 0 1.3365728079861583e-07
bp O 0 2.8889851364510832e-06
upstream O 0 6.684601316919725e-08
from O 0 2.307035673609903e-09
the O 0 1.3436276535827574e-09
3 O 0 3.1328426075560856e-08
end O 0 2.7968228621944036e-08
of O 0 2.6478661485640487e-09
exon O 0 1.6275546386168571e-06
6 O 0 2.1370779279550334e-07
. O 0 1.5564933164569084e-07

Our O 0 7.801680112606846e-06
data O 0 2.081176944557228e-06
suggest O 0 3.153369476649459e-08
that O 0 8.037948084904656e-10
the O 0 1.6343238984362074e-09
C O 0 1.1265816510785953e-06
to O 0 4.4317540748295414e-09
A O 0 3.7219535897747846e-08
mutation O 0 4.3905217239625927e-08
at O 0 5.798559854497398e-09
the O 0 3.938074588649698e-10
penultimate O 0 1.1916954179014283e-07
nucleotide O 0 2.3978408592029155e-08
of O 0 3.7732936220002955e-10
exon O 0 6.94921524768688e-08
6 O 0 8.565483433642385e-09
of O 0 1.785194769787779e-10
the O 0 2.5441899698108728e-09
CYP27 O 0 9.143876013695262e-06
gene O 0 1.3628630313178292e-07
not O 0 7.55533680063536e-09
only O 0 1.8428337744680334e-09
causes O 0 1.5202523684365588e-08
the O 0 6.117520001680532e-08
deficiency B-Disease 0 9.162189599010162e-06
in I-Disease 0 8.22068690897737e-10
the I-Disease 0 4.605474668295528e-09
sterol I-Disease 0 6.020270120643545e-06
27 I-Disease 0 5.462169383463333e-07
- I-Disease 0 1.756809410835558e-06
hydroxylase I-Disease 0 1.2676219739660155e-05
activity I-Disease 0 1.3735100878875528e-07
, O 0 5.451878060114268e-09
but O 0 3.305243190254714e-09
also O 0 5.109469469743999e-08
partially O 0 6.089406952014542e-07
leads O 0 2.0819374668690216e-08
to O 0 8.338717494282832e-10
alternative O 0 9.301202474887305e-09
pre O 0 6.728001977762688e-08
- O 0 2.4478030269392548e-08
mRNA O 0 1.771000057715355e-08
splicing O 0 4.7579550965792805e-08
of O 0 1.3444402258144805e-09
the O 0 6.1046612209736395e-09
gene O 0 7.154602030823298e-07
. O 0 1.6750365716688975e-07

To O 0 6.312445748335449e-07
our O 0 8.403597462347534e-08
knowledge O 0 1.0161040009393218e-08
, O 0 2.355357464622898e-09
this O 0 2.9482669083868984e-10
is O 0 9.790800392650567e-10
the O 0 2.0397843414343697e-09
first O 0 2.7174991146239336e-07
report O 0 3.8014817960174696e-07
regarding O 0 3.3653200226524405e-09
effects O 0 1.9047663002424997e-08
on O 0 9.432913827822631e-08
pre O 0 3.823525958068785e-07
- O 0 4.3732960364195606e-08
mRNA O 0 9.153263924588373e-09
splicing O 0 1.2992549258683539e-08
of O 0 9.809487944156814e-11
a O 0 1.8030378301503447e-09
mutation O 0 1.2930299497782016e-08
at O 0 1.0546721718185381e-08
the O 0 2.201884230501605e-09
- O 0 1.4224245887817233e-06
2 O 0 3.9452214650737005e-07
position O 0 1.4647204693574167e-07
of O 0 3.53835183375395e-10
a O 0 1.3430620171561714e-08
5 O 0 7.76479680553166e-08
splice O 0 8.10981509857811e-05
site O 0 3.5804994240606902e-06
. O 0 2.8074219926566e-07

ATM O 0 0.004303468391299248
germline O 0 0.0024936397094279528
mutations O 0 0.00039583095349371433
in O 0 3.143890410228778e-07
classical O 0 0.0008032886544242501
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9880704879760742
in O 0 1.6598589169802835e-08
the O 0 1.7523012374454083e-08
Dutch O 0 2.5828137950156815e-05
population O 0 4.973367140337359e-08
. O 0 1.2318923836573958e-07

Germline O 0 0.006681748200207949
mutations O 0 0.000430481944931671
in O 0 7.94344714449835e-08
the O 0 1.0134599826017165e-08
ATM O 0 2.748702172539197e-05
gene O 0 5.197946961743583e-07
are O 0 1.0652125848054084e-09
responsible O 0 5.212133302734401e-08
for O 0 9.308287474141252e-08
the O 0 0.012383527122437954
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0011052523041144013
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
) O 0 2.3610045900568366e-06
. O 0 4.6458495717160986e-07

In O 0 1.2087239156244323e-06
our O 0 1.8562121795184794e-07
study O 0 3.5592098157621876e-08
, O 0 1.0552194673607573e-08
we O 0 5.6240598844681244e-09
have O 0 1.1803699129231404e-09
determined O 0 6.5670207050061435e-09
the O 0 1.1433470836763604e-09
ATM O 0 7.08715379005298e-06
mutation O 0 1.0089914326272265e-07
spectrum O 0 2.5336102993378518e-08
in O 0 2.221974604310617e-09
19 O 0 4.3758578982533436e-08
classical O 0 1.522496120287542e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.7168300221092068e-05
, O 0 2.7154073434232373e-10
including O 0 9.552033469750754e-11
some O 0 1.6349280262950572e-10
immigrant O 0 2.0571878422970258e-08
populations O 0 9.861123473342559e-09
, O 0 4.002152831361627e-09
as O 0 2.216412831046455e-09
well O 0 3.1929678900866065e-09
as O 0 6.191932300225744e-09
12 O 0 4.781880225124269e-09
of O 0 4.90160190214084e-10
Dutch O 0 1.0434191608510446e-06
ethnic O 0 1.687094055569105e-07
origin O 0 2.1138325223546417e-07
. O 0 2.5630117761465954e-07

Both O 0 1.7242405192519072e-07
the O 0 2.4350624627800244e-08
protein O 0 1.7966129917112994e-07
truncation O 0 2.4626021968288114e-06
test O 0 3.394286238744826e-07
( O 0 1.693610762742992e-08
PTT O 0 1.0786789061967283e-05
) O 0 2.751345151708051e-09
and O 0 8.470840695551374e-10
the O 0 4.755845162129901e-10
restriction O 0 5.670170111216066e-09
endonuclease O 0 3.405024244784727e-07
fingerprinting O 0 1.9604660792538198e-06
( O 0 1.0006522721539568e-08
REF O 0 2.0275531369406963e-06
) O 0 9.280924917476341e-10
method O 0 1.6920479239956876e-08
were O 0 5.929573276830524e-09
used O 0 3.797470071731368e-08
and O 0 3.664536762926218e-08
compared O 0 1.2000110238830075e-08
for O 0 1.3159785761107656e-10
their O 0 8.225988223919956e-10
detection O 0 6.489088821837186e-09
efficiency O 0 7.378431643445538e-09
, O 0 5.316185269776952e-10
identifying O 0 4.283654764236644e-09
76 O 0 3.7809892994289385e-09
% O 0 3.0972505116189097e-10
and O 0 3.283112670615651e-10
60 O 0 1.2496831347519333e-09
% O 0 2.376493168920746e-10
of O 0 1.339213462347999e-10
the O 0 1.3458135939004023e-08
mutations O 0 2.7450910238258075e-06
, O 0 2.4889411420758734e-08
respectively O 0 4.5028605200059246e-07
. O 0 1.1261622034908214e-07

Most O 0 3.0927901661925716e-06
patients O 0 1.4455341442953795e-05
were O 0 6.269010555115528e-08
found O 0 2.2028180168831568e-08
to O 0 5.793938218090489e-09
be O 0 1.5174075329582593e-08
compound O 0 6.875869189570949e-07
heterozygote O 0 5.858588792762021e-06
. O 0 2.613148808450205e-07

Seventeen O 0 2.4919940187828615e-05
mutations O 0 3.387352990102954e-05
were O 0 1.4034159789844125e-07
distinct O 0 2.0026917013638013e-08
, O 0 4.754233451365053e-09
of O 0 4.0253472777251886e-10
which O 0 5.3412851030998354e-08
10 O 0 8.036591481186406e-08
were O 0 7.91377630093848e-08
not O 0 4.062551894890021e-08
reported O 0 3.821188784058904e-06
previously O 0 6.890822987770662e-07
. O 0 3.8259699408627057e-07

Mutations O 0 0.0012056658742949367
are O 0 1.1483113127042088e-07
small O 0 3.103699697248885e-08
deletions O 0 1.1246278518228792e-05
or O 0 1.8629116311785765e-06
point O 0 1.0081812433782034e-05
mutations O 0 2.7097843485535122e-05
frequently O 0 4.825669748242944e-07
affecting O 0 2.842772346411948e-07
splice O 0 0.00035852170549333096
sites O 0 1.3904264960729051e-05
. O 0 7.363910299318377e-07

Moreover O 0 2.2297646864899434e-05
, O 0 1.6115413359329978e-07
a O 0 7.088764419904692e-08
16 O 0 4.145983609760151e-07
. O 0 3.7031256283626135e-07

7 O 0 3.21042571158614e-05
- O 0 5.535378659260459e-05
kb O 0 7.704986637691036e-05
genomic O 0 2.417190444248263e-06
deletion O 0 3.975098024966428e-06
of O 0 5.352704945948972e-09
the O 0 6.734200308500249e-09
3 O 0 7.218051223389921e-08
end O 0 5.297515670577013e-08
of O 0 1.4839866835369975e-10
the O 0 1.1156265911083096e-09
gene O 0 7.411991020944697e-08
, O 0 5.1065831563334996e-09
most O 0 2.0023736002627857e-09
likely O 0 5.123246271665494e-09
a O 0 3.776319257298155e-09
result O 0 2.2130755006344316e-09
of O 0 1.1278555867022533e-10
recombination O 0 3.981276197606576e-09
between O 0 3.260940406590862e-09
two O 0 1.392364339380947e-07
LINE O 0 0.001995291793718934
elements O 0 5.814720793750894e-07
, O 0 7.41985530794409e-08
was O 0 2.553360616275313e-07
identified O 0 4.0230492004411644e-07
. O 0 1.392114796772148e-07

The O 0 1.5871847836024244e-07
most O 0 2.543487553907653e-08
frequently O 0 8.380420268849775e-08
found O 0 3.7441118649894634e-08
mutation O 0 1.3914390706304403e-07
, O 0 6.066994018283367e-09
identified O 0 2.6994330326601812e-08
in O 0 5.916871437250393e-10
three O 0 3.971523110379849e-09
unrelated O 0 6.305803168515922e-08
Turkish O 0 9.4628342139913e-07
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999997615814209
T I-Disease 1 1.0
individuals O 0 5.491895649356593e-08
, O 0 5.9416898068320734e-08
was O 0 5.602793180514709e-07
previously O 0 2.7415094905336446e-07
described O 0 1.225835859486324e-07
to O 0 3.118544755764674e-09
be O 0 2.299216150802863e-09
a O 0 8.563081799195515e-09
Turkish O 0 7.227349101412983e-07
A B-Disease 1 0.9999977350234985
- I-Disease 1 0.9999889135360718
T I-Disease 1 1.0
founder O 0 0.0001521100348327309
mutation O 0 4.0741715565673076e-06
. O 0 2.1918086190453323e-07

The O 0 1.3011798216666648e-07
presence O 0 4.459491975694618e-08
of O 0 1.443642649867627e-09
a O 0 2.0150292101561718e-08
founder O 0 6.352448167490365e-07
mutation O 0 1.1117763420998017e-07
among O 0 8.857930500205669e-10
relatively O 0 9.872523909493225e-10
small O 0 7.515434385929609e-10
ethnic O 0 1.5553604626461492e-08
population O 0 1.4546738258403025e-09
groups O 0 1.9960769148674729e-10
in O 0 8.65877924915992e-10
Western O 0 2.7107217803745698e-08
Europe O 0 3.878961706504924e-06
could O 0 1.577003558850265e-07
indicate O 0 5.694436921999113e-09
a O 0 3.6910436929105117e-09
high O 0 2.641390572932778e-08
carrier O 0 1.833051186395096e-07
frequency O 0 1.7733736967784353e-07
in O 0 3.986382779430642e-09
such O 0 4.048240409559867e-09
communities O 0 1.2094717760646745e-07
. O 0 2.6645210482456605e-07

In O 0 3.409206783544505e-06
patients O 0 2.3384436644846573e-06
of O 0 3.6308751560909514e-09
Dutch O 0 3.903770448232535e-06
ethnic O 0 6.730953572287035e-08
origin O 0 2.4498861606048195e-08
, O 0 1.5020251709074728e-08
however O 0 4.742224390952288e-09
, O 0 2.0665544830933413e-09
no O 0 2.924275710469715e-09
significant O 0 2.5202007147839822e-09
founder O 0 1.3341688145374064e-06
effect O 0 1.2889896083834174e-07
could O 0 1.6506943723015866e-07
be O 0 3.1019357749073606e-08
identified O 0 7.795140390953748e-07
. O 0 1.360524066740254e-07

The O 0 8.351631777259172e-07
observed O 0 7.682372711315111e-07
genetic O 0 5.246184286988864e-07
heterogeneity O 0 3.6028279737365665e-07
including O 0 4.390494634520792e-09
the O 0 6.2359859498428705e-09
relative O 0 3.182978858262686e-08
high O 0 3.696054662327697e-08
percentage O 0 3.4550257055343536e-07
of O 0 4.05000877279349e-09
splice O 0 0.007460533641278744
- O 0 0.0006698890938423574
site O 0 3.584426667657681e-05
mutations O 0 5.160750515642576e-05
had O 0 6.430444159377657e-07
no O 0 6.347008252305386e-09
reflection O 0 1.8202536367084576e-08
on O 0 7.362394427445906e-08
the O 0 3.236089796132546e-08
phenotype O 0 1.2699607395916246e-05
. O 0 4.271117290954862e-07

All O 0 1.023029767566186e-06
patients O 0 2.177535861846991e-06
manifested O 0 4.2636455077627033e-07
classical O 0 6.142049642221536e-07
A B-Disease 1 0.9999954700469971
- I-Disease 1 0.9999830722808838
T I-Disease 1 1.0
and O 0 3.8322215800690174e-07
increased O 0 7.740220553387189e-08
cellular O 0 1.2596217402460752e-06
radioresistant O 0 1.1823015029222006e-06
DNA O 0 8.911810027711908e-07
synthesis O 0 2.391680482105585e-06
. O 0 5.476753131006262e-07

Determination O 0 2.5654721866885666e-06
of O 0 5.647838197120336e-09
the O 0 2.65800670362637e-09
genomic O 0 9.224388719530907e-08
structure O 0 8.743093360408238e-08
of O 0 1.9487791380612407e-09
the O 0 1.9265428363723913e-08
COL4A4 O 0 3.8332862459355965e-05
gene O 0 1.8075742502787762e-07
and O 0 2.4975186363462853e-09
of O 0 1.4310073126466705e-09
novel O 0 3.992916845163563e-06
mutations O 0 0.00442866375669837
causing O 0 0.011148049496114254
autosomal B-Disease 1 0.9999982118606567
recessive I-Disease 1 0.9999995231628418
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 2.4856995878508314e-05

Autosomal B-Disease 1 0.9999994039535522
recessive I-Disease 1 0.9999998807907104
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 2.794719421217451e-06
a O 0 1.0907995147135807e-06
progressive O 0 0.0017540599219501019
hematuric B-Disease 1 0.9869641661643982
glomerulonephritis I-Disease 1 0.9999998807907104
characterized O 0 7.55958171794191e-05
by O 0 7.923124911712875e-08
glomerular B-Disease 0 0.002067113295197487
basement I-Disease 1 0.7461055517196655
membrane I-Disease 0 0.012149425223469734
abnormalities I-Disease 1 0.9990800619125366
and O 0 2.750607279722317e-07
associated O 0 7.699875226307995e-08
with O 0 1.7616276437593115e-08
mutations O 0 3.0418921141972532e-06
in O 0 7.58172546966307e-09
either O 0 5.1651451116185854e-08
the O 0 1.4511885026990967e-08
COL4A3 O 0 5.745067755924538e-05
or O 0 6.663622542646408e-08
the O 0 5.801347402467627e-09
COL4A4 O 0 6.587467396457214e-06
gene O 0 1.631652963851593e-07
, O 0 1.5917216433791737e-09
which O 0 1.1730532101239532e-09
encode O 0 1.4114553970046018e-08
the O 0 7.478432095808785e-09
alpha3 O 0 1.5466075637959875e-05
and O 0 7.875229357523494e-08
alpha4 O 0 1.4528284737025388e-05
type O 0 1.930692178575555e-06
IV O 0 0.0012719229562208056
collagen O 0 5.2171202696627006e-05
chains O 0 4.372043986222707e-05
, O 0 4.662947361566694e-08
respectively O 0 5.97550638303801e-07
. O 0 1.1688722167946253e-07

To O 0 8.071891670624609e-07
date O 0 2.1131069161128835e-07
, O 0 7.46970751919207e-09
mutation O 0 1.919068459699247e-08
screening O 0 1.931119442133422e-08
in O 0 1.1332685900811157e-09
the O 0 1.1740023397877053e-09
two O 0 4.642262041443246e-08
genes O 0 4.866598715125292e-07
has O 0 3.225608224965981e-07
been O 0 9.388686095235244e-08
hampered O 0 8.242658395829494e-07
by O 0 2.50456921868647e-09
the O 0 2.7018935977451974e-09
lack O 0 6.863158041880979e-09
of O 0 1.5930156083143743e-09
genomic O 0 1.4988491159328987e-07
structure O 0 6.250611477298662e-07
information O 0 9.671813359091175e-07
. O 0 3.354447244419134e-07

We O 0 2.160151780117303e-05
report O 0 4.976465675099462e-07
here O 0 3.2610958378143096e-09
the O 0 1.3319590985716445e-09
complete O 0 1.142754602057039e-08
characterization O 0 1.564453668834176e-07
of O 0 1.1730174609425603e-09
the O 0 9.001426271026958e-09
48 O 0 2.0918328402785846e-08
exons O 0 7.659564005280117e-08
of O 0 4.800868036447525e-10
the O 0 4.25073221066441e-09
COL4A4 O 0 5.601843895419734e-06
gene O 0 1.0542039774463774e-07
, O 0 7.159005610546387e-10
a O 0 1.1528376031577636e-09
comprehensive O 0 2.3345965161070126e-08
gene O 0 1.0837604236257903e-07
screen O 0 1.7121213886639453e-06
, O 0 2.594039472114673e-08
and O 0 6.639794047913483e-09
the O 0 9.908196485497456e-10
subsequent O 0 2.7982087758005036e-09
detection O 0 1.7863035495224722e-08
of O 0 5.144296100212387e-10
10 O 0 1.4202671927421306e-08
novel O 0 3.514793078807088e-08
mutations O 0 5.40894234291045e-07
in O 0 3.764482503498812e-09
eight O 0 1.1993449788860744e-06
patients O 0 6.661933639406925e-06
diagnosed O 0 0.00010388242662884295
with O 0 8.192048994715151e-07
autosomal B-Disease 1 0.9999958276748657
recessive I-Disease 1 0.9999994039535522
Alport I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
. O 0 1.3297533769218717e-05

Furthermore O 0 1.0815218047355302e-05
, O 0 9.181068350017085e-08
we O 0 2.0166671887977827e-08
identified O 0 1.3769115625450468e-08
a O 0 4.490944061075197e-09
glycine O 0 4.211762529848784e-07
to O 0 6.38289421317495e-09
alanine O 0 9.757940944155052e-08
substitution O 0 7.266866663968585e-09
in O 0 1.865381848986658e-09
the O 0 4.354906657511037e-09
collagenous O 0 1.6380112356273457e-05
domain O 0 2.0597288141743775e-07
that O 0 1.0470077249635779e-08
is O 0 1.0238624170710864e-08
apparently O 0 1.2608869326413696e-07
silent O 0 1.8023440517822564e-08
in O 0 4.65384453196549e-10
the O 0 9.933457389976752e-10
heterozygous O 0 3.608783316622066e-08
carriers O 0 8.821701591443798e-09
, O 0 1.5728355284849727e-09
in O 0 4.807339859524973e-09
11 O 0 7.853793704271084e-08
. O 0 2.137897467946459e-07

5 O 0 1.779952413016872e-06
% O 0 4.0890999031262254e-08
of O 0 9.382412624603376e-10
all O 0 1.7936327978418376e-09
control O 0 4.48187165602576e-07
individuals O 0 2.0959534108300204e-09
, O 0 3.925971991947108e-09
and O 0 1.4342897536323562e-08
in O 0 4.655453800239684e-09
one O 0 2.3807649185414448e-08
control O 0 1.781262142230844e-07
individual O 0 1.0195829958092872e-08
homozygous O 0 1.0433878117055428e-07
for O 0 1.4750110022276886e-09
this O 0 2.5348607657349476e-09
glycine O 0 5.802456257697486e-07
substitution O 0 1.4133202341781725e-07
. O 0 1.4622166588651453e-07

There O 0 7.976215783855878e-06
has O 0 2.0876402118119586e-07
been O 0 3.0284386554058074e-08
no O 0 4.286106580764226e-09
previous O 0 7.632202425611467e-09
finding O 0 2.3498738510596695e-09
of O 0 1.425128626220129e-10
a O 0 2.6070385850118782e-09
glycine O 0 1.468185928388266e-07
substitution O 0 6.9332455332471454e-09
that O 0 4.0051615357583614e-09
is O 0 2.514535024644715e-09
not O 0 3.74920494650155e-09
associated O 0 3.940345383313115e-09
with O 0 1.1589975645875938e-09
any O 0 2.1841920272436255e-08
obvious O 0 1.102266367070115e-07
phenotype O 0 2.329291646674392e-06
in O 0 1.4794041547361303e-08
homozygous O 0 2.819592282321537e-06
individuals O 0 2.6767200012045578e-08
. O 0 1.242819394065009e-07

Founder O 0 0.00027583789778873324
BRCA1 O 0 0.0009015223477035761
and O 0 1.5443262100234278e-06
BRCA2 O 0 0.00019208421872463077
mutations O 0 1.4898560039000586e-05
in O 0 3.1367289210493254e-08
French O 0 2.8774926249752752e-05
Canadian O 0 9.860651334747672e-05
breast B-Disease 1 0.9982068538665771
and I-Disease 1 0.9879214763641357
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
families O 0 6.557941674145695e-07
. O 0 4.2473391204111977e-07

We O 0 8.061136213655118e-06
have O 0 2.8480931391072772e-08
identified O 0 3.711766538572192e-08
four O 0 4.779390661013849e-09
mutations O 0 4.29248174782515e-08
in O 0 4.83342088575256e-10
each O 0 1.5958590005027418e-09
of O 0 2.025918988124431e-09
the O 0 9.217791330229375e-07
breast B-Disease 1 0.5165977478027344
cancer I-Disease 0 0.00019900998449884355
- O 0 2.3281158064492047e-05
susceptibility O 0 1.4910926438460592e-05
genes O 0 1.7805398329073796e-06
, O 0 3.0005587348114204e-08
BRCA1 O 0 9.84370581136318e-06
and O 0 1.6906712119180156e-07
BRCA2 O 0 2.9794586225762032e-05
, O 0 7.665581946980637e-09
in O 0 2.9489657382697487e-09
French O 0 4.649825768865412e-06
Canadian O 0 1.7914999261847697e-05
breast B-Disease 0 0.33116212487220764
cancer I-Disease 0 0.010026558302342892
and O 0 0.0006402419530786574
breast B-Disease 1 0.9999995231628418
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.683583772977727e-07
from O 0 9.168959280714262e-08
Quebec O 0 2.3296084691537544e-05
. O 0 6.949307476133981e-07

To O 0 1.6842773220560048e-06
identify O 0 1.976156454475131e-06
founder O 0 1.5812209312571213e-05
effects O 0 7.066447778925067e-06
, O 0 2.1566380681292685e-08
we O 0 2.0891373964104787e-08
examined O 0 8.00327484284935e-08
independently O 0 3.932764798264543e-07
ascertained O 0 2.665176680238801e-06
French O 0 3.0005928692844464e-06
Canadian O 0 1.4506897514365846e-06
cancer B-Disease 0 1.5584480479446938e-06
families O 0 8.441324861330202e-10
for O 0 7.733322315850444e-10
the O 0 1.6339124497832813e-09
distribution O 0 9.114765475715103e-08
of O 0 9.976197645755747e-10
these O 0 5.6752993415898345e-09
eight O 0 1.643556544195235e-07
mutations O 0 7.150235433073249e-06
. O 0 2.101859877257084e-07

Mutations O 0 0.002221400151029229
were O 0 1.1181950867467094e-06
found O 0 3.336936060804874e-08
in O 0 4.886612892107678e-09
41 O 0 4.259678476614681e-08
of O 0 8.744169277541403e-10
97 O 0 4.783561280419235e-08
families O 0 4.161550393178004e-08
. O 0 2.0493168051416433e-07

Six O 0 1.9063965055465815e-06
of O 0 1.184809583776314e-08
eight O 0 8.788938998804952e-08
mutations O 0 1.7922199049280607e-06
were O 0 2.0819532764448923e-08
observed O 0 4.8263235186141173e-08
at O 0 6.879648140056815e-08
least O 0 3.8049449813115643e-08
twice O 0 1.4840640005786554e-06
. O 0 3.610105636653316e-07

The O 0 6.792879503336735e-07
BRCA1 O 0 5.72404642298352e-05
C4446T O 0 3.018674988197745e-06
mutation O 0 3.299216132290894e-06
was O 0 7.184139150240298e-08
the O 0 7.302808358033985e-10
most O 0 2.8713600386254257e-09
common O 0 3.113090940587426e-08
mutation O 0 4.891734874945541e-07
found O 0 1.0676340167492526e-07
, O 0 2.4715780533313136e-09
followed O 0 2.5024873284706928e-09
by O 0 1.2771997903726628e-09
the O 0 4.190783542412646e-08
BRCA2 O 0 0.00024760558153502643
8765delAG O 0 1.3615755051432643e-05
mutation O 0 5.583101938100299e-06
. O 0 4.1477312606730266e-07

Together O 0 1.948568524312577e-06
, O 0 2.3519199032762117e-08
these O 0 1.691966566852443e-09
mutations O 0 1.341486779438128e-07
were O 0 1.0494629165691549e-08
found O 0 2.2531473575782002e-08
in O 0 6.145187025907717e-09
28 O 0 5.5260347409102906e-08
of O 0 5.972315975100173e-10
41 O 0 4.331770497856269e-08
families O 0 1.2129197646260081e-09
identified O 0 9.203826323300746e-08
to O 0 1.565037877071518e-08
have O 0 7.195615214783402e-09
a O 0 4.959082744449006e-08
mutation O 0 1.6763434587119264e-06
. O 0 1.0226507640709315e-07

The O 0 4.249681069268263e-07
odds O 0 4.725126473204e-06
of O 0 6.395104890088987e-09
detection O 0 1.0950430606726513e-07
of O 0 9.349471197239723e-10
any O 0 2.6571347344628293e-09
of O 0 7.267278445688419e-10
the O 0 1.1431382063165074e-08
four O 0 4.921753316011745e-07
BRCA1 O 0 0.00012062927999068052
mutations O 0 4.206077392154839e-06
was O 0 3.3144939948215324e-07
18 O 0 5.7026134925308725e-08
. O 0 8.567104714529705e-08

7x O 0 0.001959879184141755
greater O 0 1.489956275690929e-06
if O 0 9.47617593283212e-08
one O 0 6.384428541394982e-09
or O 0 9.743524209682164e-09
more O 0 2.6299828981279916e-09
cases O 0 6.102067828805957e-08
of O 0 2.2430240278481506e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 5.640014251184766e-07
also O 0 7.725574846517702e-08
present O 0 6.793648754666037e-09
in O 0 1.5474471704024495e-09
the O 0 6.2298162184504235e-09
family O 0 4.047848847221758e-07
. O 0 3.63328155117415e-07

The O 0 4.5164159701016615e-07
odds O 0 4.7654298214183655e-06
of O 0 4.466043979078904e-09
detection O 0 1.0510999715052094e-07
of O 0 1.2809568961102968e-09
any O 0 2.4689961186652454e-09
of O 0 7.803168111664149e-10
the O 0 1.4243201285069063e-08
four O 0 4.452786299680156e-07
BRCA2 O 0 0.00019649715977720916
mutations O 0 3.3276935482717818e-06
was O 0 1.444792729898836e-07
5 O 0 6.010352393559515e-08
. O 0 1.1998422166925593e-07

3x O 0 0.003004223108291626
greater O 0 1.1818866596513544e-06
if O 0 1.2546401251256611e-07
there O 0 3.7911571659776655e-09
were O 0 4.02539512833755e-09
at O 0 1.7374084393395606e-08
least O 0 1.9122714522978868e-09
five O 0 4.638719186544904e-09
cases O 0 4.647495721599171e-09
of O 0 1.4578188434200001e-08
breast B-Disease 0 0.1865435391664505
cancer I-Disease 0 6.527468940475956e-05
in O 0 1.3878882043627527e-08
the O 0 4.9841357707691714e-08
family O 0 1.215453721670201e-06
. O 0 4.4765278062186553e-07

Interestingly O 0 3.1521081837126985e-05
, O 0 5.226847221706521e-08
the O 0 1.8276140600903545e-09
presence O 0 2.572187352001265e-09
of O 0 5.949327142040772e-10
a O 0 7.837943485355936e-07
breast B-Disease 0 0.08921048045158386
cancer I-Disease 0 2.4400696929660626e-05
case O 0 4.689518107170443e-08
< O 0 4.459449343130473e-08
36 O 0 4.4994344250426366e-08
years O 0 4.815544407676953e-09
of O 0 8.289240960301925e-10
age O 0 1.3511504803886965e-08
was O 0 2.0468499428716314e-07
strongly O 0 8.99433860723775e-09
predictive O 0 2.7010552017259215e-08
of O 0 5.230642030618071e-10
the O 0 4.606994341571635e-09
presence O 0 3.993460229168022e-09
of O 0 2.772568286069088e-10
any O 0 8.209718460605586e-10
of O 0 2.720488001539678e-10
the O 0 4.95434360203717e-09
eight O 0 1.4912070867012517e-07
mutations O 0 1.7139853980552289e-06
screened O 0 1.4896152151777642e-06
. O 0 1.4695503125494724e-07

Carriers O 0 2.1448295228765346e-06
of O 0 1.3025203138283814e-08
the O 0 3.1560154489795877e-09
same O 0 1.3852408997649945e-08
mutation O 0 8.060047207436583e-08
, O 0 3.7066001379315594e-09
from O 0 3.206312992887206e-10
different O 0 4.738234804513297e-10
families O 0 1.523066894826286e-09
, O 0 1.1951427625334077e-09
shared O 0 2.3747999122747387e-09
similar O 0 2.8254962813889506e-09
haplotypes O 0 1.432072281204455e-06
, O 0 9.844999482311323e-09
indicating O 0 1.911098301832226e-08
that O 0 4.5803388859511074e-10
the O 0 4.904903150304563e-10
mutant O 0 3.633121181678689e-08
alleles O 0 3.404016979402513e-08
were O 0 3.227853895282351e-08
likely O 0 4.1673011708098784e-08
to O 0 6.243436878605735e-09
be O 0 6.7329928299386665e-09
identical O 0 1.9254559902037727e-07
by O 0 4.149026011646129e-09
descent O 0 4.5232093270897167e-07
for O 0 4.384117957556555e-09
a O 0 2.7634323274128292e-08
mutation O 0 1.6883414843960054e-07
in O 0 2.6218738291561294e-09
the O 0 1.2484854039485072e-08
founder O 0 3.882532837451436e-06
population O 0 3.171682649849572e-08
. O 0 7.167606241864632e-08

The O 0 4.771077755094666e-08
identification O 0 4.8078739212087385e-08
of O 0 4.773788031542381e-09
common O 0 1.6516187884008104e-07
BRCA1 O 0 0.00010185889550484717
and O 0 1.345017608400667e-06
BRCA2 O 0 0.0003310029860585928
mutations O 0 6.728939752065344e-06
will O 0 1.2041358132819369e-08
facilitate O 0 1.1367156105279719e-08
carrier O 0 4.118614356229955e-07
detection O 0 4.026438205073646e-07
in O 0 1.4332752762413747e-08
French O 0 5.903557848796481e-06
Canadian O 0 2.7435300580691546e-05
breast B-Disease 0 0.45327597856521606
cancer I-Disease 0 0.00834118016064167
and O 0 0.00022053190332371742
breast B-Disease 1 0.9999997615814209
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 6.440779429794929e-07
. O 0 2.848973963409662e-07

Are O 0 1.1638982186923386e-06
Dp71 O 0 6.135886360425502e-05
and O 0 5.363070272323966e-07
Dp140 O 0 1.2648854863073211e-05
brain O 0 6.98800286045298e-05
dystrophin O 0 8.060744221438654e-06
isoforms O 0 5.577900878961373e-07
related O 0 1.981702268949448e-07
to O 0 2.6188945412286557e-07
cognitive B-Disease 0 4.5778087951475754e-05
impairment I-Disease 0 0.0007004513754509389
in O 0 5.758252427767729e-06
Duchenne B-Disease 1 0.9999969005584717
muscular I-Disease 1 0.9998600482940674
dystrophy I-Disease 1 0.9998306035995483
? O 0 0.0001071217266144231

Molecular O 0 3.1495274015469477e-05
study O 0 9.384529562339594e-07
and O 0 4.477577988382109e-07
neuropsychological O 0 4.861482011619955e-06
analysis O 0 1.1048616244124787e-07
were O 0 1.752518663522551e-08
performed O 0 4.707190015551532e-08
concurrently O 0 2.054145120666817e-08
on O 0 3.245832544962468e-07
49 O 0 1.1899254559466499e-06
patients O 0 8.21260854877437e-08
with O 0 1.1870404392766432e-07
Duchenne B-Disease 1 0.9999986886978149
muscular I-Disease 1 0.9999350309371948
dystrophy I-Disease 1 0.9999616146087646
( O 0 6.223504442459671e-06
DMD B-Disease 1 1.0
) O 0 2.405431871466135e-07
in O 0 4.767964245644407e-09
order O 0 3.5306078061125845e-09
to O 0 1.5787694707114497e-08
find O 0 6.726908807763721e-09
a O 0 4.693694322099873e-09
molecular O 0 5.1244413157292e-08
explanation O 0 8.709053034294811e-09
for O 0 3.0313382914926024e-09
the O 0 4.33560636281527e-08
cognitive B-Disease 0 7.294737315532984e-06
impairment I-Disease 0 5.132500064064516e-06
observed O 0 1.0483749690592958e-07
in O 0 1.9137392115453622e-08
most O 0 3.099815330642741e-06
DMD B-Disease 1 1.0
patients O 0 0.00010287799523212016
. O 0 3.49560593804199e-07

Complete O 0 2.998387344632647e-06
analysis O 0 1.743657094266382e-07
of O 0 2.29420482611431e-09
the O 0 9.326321936953264e-09
dystrophin O 0 1.6796975614852272e-06
gene O 0 7.034778946035658e-07
was O 0 2.0560194968766154e-07
performed O 0 5.5503193152617314e-08
to O 0 2.7751834164035927e-09
define O 0 3.7595043522742344e-08
the O 0 6.157999887790311e-09
localization O 0 1.034987775483387e-07
of O 0 2.4889492689084136e-09
deletions O 0 1.8534257151259226e-06
and O 0 1.232075703683222e-07
duplications O 0 1.9836925275740214e-06
in O 0 1.3351494132507469e-08
relation O 0 9.869707895404645e-08
to O 0 4.148331811393291e-08
the O 0 1.9866440936766594e-08
different O 0 2.866664772227523e-07
DMD B-Disease 1 0.9999997615814209
promoters O 0 0.00013084450620226562
. O 0 7.255803211592138e-07

Qualitative O 0 1.3362329809751827e-05
analysis O 0 1.671627813948362e-07
of O 0 1.5049265167377257e-09
the O 0 5.427092553134116e-09
Dp71 O 0 5.389780653786147e-06
transcript O 0 1.394321043335367e-05
and O 0 1.0602065891873735e-08
testing O 0 1.2478514888059067e-09
for O 0 6.685357128999314e-11
the O 0 9.190587180185616e-11
specific O 0 5.885356646473383e-10
first O 0 1.0755967672082534e-08
exon O 0 1.1871988192524441e-07
of O 0 1.4284439187051134e-09
Dp140 O 0 3.7784903383908386e-07
were O 0 2.872238269446825e-08
also O 0 9.136659429032079e-09
carried O 0 6.869866098213606e-08
out O 0 9.353224328378928e-08
. O 0 2.350270165152324e-07

Neuropsychological O 0 0.001156784244813025
analysis O 0 3.1695017241872847e-06
assessed O 0 3.7546499243035214e-06
verbal O 0 3.4439699447830208e-06
and O 0 4.967821496393299e-07
visuospatial O 0 0.00013178563676774502
intelligence O 0 2.357454377488466e-06
, O 0 3.620855792973998e-08
verbal O 0 2.7111622102893307e-07
memory O 0 1.429096664651297e-05
, O 0 4.3706279484467814e-08
and O 0 4.331853276084985e-08
reading O 0 3.6075451248507306e-07
skills O 0 2.7216955800213327e-07
. O 0 1.758791370320978e-07

Comparison O 0 2.4533756004530005e-06
of O 0 2.8194952150784047e-08
molecular O 0 6.020098908265936e-07
and O 0 1.2994783560316137e-07
psychometric O 0 6.0832876442873385e-06
findings O 0 1.0085140047522145e-06
demonstrated O 0 7.556276671039086e-08
that O 0 4.8019148657374444e-09
deletions O 0 5.108329901304387e-07
and O 0 8.1379646132973e-08
duplications O 0 3.880075382767245e-06
that O 0 2.38229578286564e-08
were O 0 9.570169545725093e-09
localized O 0 1.4164182005060866e-07
in O 0 1.015360062694981e-08
the O 0 1.7003237928747694e-08
distal O 0 3.5468874557409436e-05
part O 0 1.3394887332651706e-07
of O 0 1.0322819266050942e-09
the O 0 3.719844210436918e-09
gene O 0 1.5324044966291694e-07
seemed O 0 3.254771385741151e-08
to O 0 1.6358396859317281e-09
be O 0 3.0559350605585678e-09
preferentially O 0 9.234545927938598e-08
associated O 0 5.2860997357129236e-08
with O 0 7.484200637009053e-08
cognitive B-Disease 0 3.7211328162811697e-05
impairment I-Disease 0 6.872392987133935e-05
. O 0 2.815608013406745e-07

Two O 0 7.543891342720599e-07
altered O 0 2.403971302555874e-05
Dp71 O 0 2.098954064422287e-05
transcripts O 0 2.556082563387463e-06
and O 0 1.2746840916122437e-08
two O 0 3.3818117195494324e-09
deleted O 0 1.353294294403895e-07
Dp140 O 0 3.4573258034242826e-08
DNA O 0 5.852741935541417e-08
sequences O 0 1.186550946385978e-08
were O 0 5.809895675668031e-09
found O 0 6.740844327168816e-09
in O 0 1.5247352269653902e-09
four O 0 1.1755225415299719e-07
patients O 0 2.5058085384443984e-07
with O 0 1.350877880668122e-07
severe O 0 0.001003009732812643
cerebral B-Disease 0 0.046553704887628555
dysfunction I-Disease 0 0.0016697174869477749
. O 0 1.105240585275169e-06

These O 0 1.039744802255882e-06
findings O 0 1.2111366913813981e-06
suggest O 0 4.456363100757699e-08
that O 0 5.812973991048409e-10
some O 0 1.8582643757092399e-10
sequences O 0 1.2035451524283758e-09
located O 0 1.1382342179899751e-08
in O 0 4.8219042092512154e-09
the O 0 1.3198964587957107e-08
distal O 0 1.3661875527759548e-05
part O 0 3.4741226784262835e-08
of O 0 6.827067799974884e-10
the O 0 2.0720090088133247e-09
gene O 0 2.0740232287153049e-07
and O 0 3.325492770045457e-08
, O 0 3.766636780255794e-09
in O 0 6.998370771782447e-10
particular O 0 2.4880379978498013e-09
, O 0 8.217462266202347e-09
some O 0 8.035759613278515e-09
DMD B-Disease 1 0.9999881982803345
isoforms O 0 1.190220046964896e-07
expressed O 0 2.41774333886724e-09
in O 0 2.375098784312968e-09
the O 0 1.016001576203962e-07
brain O 0 0.07931633293628693
may O 0 5.7122747421090025e-06
be O 0 1.0400037275815066e-08
related O 0 1.0953310258798865e-08
to O 0 3.142316273851975e-08
the O 0 6.98344280181118e-08
cognitive B-Disease 0 1.5208477634587325e-05
impairment I-Disease 0 8.231776519096456e-06
associated O 0 1.4485067367786542e-07
with O 0 3.814551803316135e-07
DMD B-Disease 1 1.0
. O 0 7.029024686744378e-07
. O 0 4.12722101827967e-07

I1307K O 0 0.00014094477228354663
APC O 0 7.606351573485881e-05
and O 0 1.738508075277423e-07
hMLH1 O 0 1.8477289813745301e-06
mutations O 0 1.6885617242223816e-06
in O 0 4.415436016813601e-09
a O 0 1.4894497191164646e-08
non O 0 4.841600684812875e-07
- O 0 3.4875884011853486e-06
Jewish O 0 4.042213106458803e-07
family O 0 9.006548395973368e-08
with O 0 6.291435283856117e-08
hereditary B-Disease 1 0.7899821400642395
non I-Disease 0 0.38309919834136963
- I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999997615814209
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.119036475458415e-06

We O 0 7.894341251812875e-07
describe O 0 1.3859759917522751e-07
a O 0 1.6004840119876462e-08
French O 0 1.0409721653559245e-06
Canadian O 0 1.3924309314461425e-06
hereditary B-Disease 1 0.5905762910842896
non I-Disease 1 0.5854954123497009
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 7.730870856903493e-05
HNPCC B-Disease 1 0.9012966156005859
) O 0 9.266796610063466e-07
kindred O 0 4.0366776374867186e-05
which O 0 9.221028562933498e-08
carries O 0 1.0751336532166533e-07
a O 0 2.149611511015337e-08
novel O 0 1.5857399660035298e-07
truncating O 0 1.5442168660229072e-05
mutation O 0 7.515780453104526e-06
in O 0 7.693591896895668e-08
hMLH1 O 0 2.126090657839086e-05
. O 0 4.6405222065004637e-07

Interestingly O 0 3.386784374015406e-05
, O 0 5.116461920806614e-08
the O 0 5.247982493017389e-09
I1307K O 0 3.8709879390808055e-07
APC O 0 6.5609003740974e-07
polymorphism O 0 3.0945287221584294e-07
, O 0 5.4903006585504954e-09
associated O 0 1.9988972699280794e-09
with O 0 4.863744962335659e-10
an O 0 6.091018356357836e-09
increased O 0 9.141314194494043e-07
risk O 0 3.2690448279026896e-05
of O 0 0.0025388493668287992
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 5.657694828187232e-07
is O 0 1.7001616114953322e-08
also O 0 4.116983731705659e-08
present O 0 2.5437678630169103e-09
in O 0 2.3942565707812946e-09
this O 0 8.986725141824081e-09
family O 0 3.154121941406629e-07
. O 0 4.6122809749249427e-07

The O 0 5.259404360913322e-07
I1307K O 0 2.4649425540701486e-06
polymorphism O 0 3.665232952698716e-06
has O 0 2.399447396328469e-07
previously O 0 1.7438797783597693e-07
only O 0 1.9124173356033225e-09
been O 0 1.1776540631558419e-08
identified O 0 6.243820394047361e-08
in O 0 1.3538171694804646e-09
individuals O 0 6.364194171659676e-10
of O 0 1.42886891207894e-09
self O 0 1.3486239367921371e-05
- O 0 0.16858649253845215
reported O 0 0.008003944531083107
Ashkenazi O 0 3.7366655305959284e-05
Jewish O 0 3.505330710140697e-07
origins O 0 1.5722836224085768e-06
. O 0 5.748391345150594e-07

In O 0 3.321715098536515e-07
addition O 0 2.5947322512820392e-08
, O 0 5.434312555507859e-09
in O 0 2.0972890091286445e-09
this O 0 3.992759012305669e-09
family O 0 7.997308415497173e-08
, O 0 2.3028777107469978e-08
there O 0 3.499752931901412e-09
appears O 0 1.0038124997890918e-07
to O 0 2.3542986227198526e-08
be O 0 1.632804114137798e-08
no O 0 4.355263261146547e-09
relationship O 0 3.451611663152221e-09
between O 0 9.938195821845852e-10
the O 0 3.478795473910168e-09
I1307K O 0 8.710103571729633e-08
polymorphism O 0 4.049068280664869e-08
and O 0 3.898192435514147e-09
the O 0 1.3872629711642048e-09
presence O 0 1.2143972938361003e-08
or O 0 5.998807495188885e-08
absence O 0 1.2233268620320814e-08
of O 0 2.2001629407242262e-09
cancer B-Disease 0 1.5225759852910414e-06
. O 0 1.1408403111090593e-08
. O 0 1.8007675350872887e-07

Identification O 0 3.020716803803225e-06
of O 0 2.7820426851121738e-08
a O 0 3.282026028728069e-08
novel O 0 7.929958911745416e-08
mutation O 0 2.2805271271408856e-07
of O 0 1.7450327849388714e-09
the O 0 3.937552861543736e-08
CPO O 0 0.0001462821091990918
gene O 0 5.5903630169495955e-08
in O 0 7.3223488383789e-10
a O 0 2.8450743982944005e-08
Japanese O 0 1.814084498619195e-06
hereditary B-Disease 0 0.0010429848916828632
coproporphyria I-Disease 0 0.00011074320354964584
family O 0 1.3976741684018634e-06
. O 0 6.235476917026972e-07

Hereditary B-Disease 1 0.9999252557754517
coproporphyria I-Disease 1 0.9679742455482483
( O 0 0.00011953016655752435
HCP B-Disease 0 0.03130218759179115
) O 0 3.902278820078209e-07
is O 0 1.292137508102087e-08
an O 0 6.327429247221517e-08
autosomal B-Disease 1 0.9997603297233582
dominant I-Disease 1 0.9928544163703918
disease I-Disease 1 0.9060404300689697
characterized O 0 7.917548714431177e-07
by O 0 9.165423087154068e-09
a O 0 4.83590656585875e-06
deficiency B-Disease 0 0.00041172010242007673
of I-Disease 0 3.9469347790088705e-09
coproporphyrinogen I-Disease 0 8.61132430145517e-05
oxidase I-Disease 0 2.53942175731936e-06
( O 0 8.632238746031362e-08
CPO O 0 0.0005865307757630944
) O 0 1.667525495463451e-08
caused O 0 2.5886913945782908e-08
by O 0 3.3637395646657353e-10
a O 0 1.3380862640133273e-08
mutation O 0 1.1716701919795014e-07
in O 0 4.135460862642049e-09
the O 0 2.917024310988836e-08
CPO O 0 0.0005201484891586006
gene O 0 7.02678619290964e-07
. O 0 1.1310346081927491e-07

Only O 0 6.322434842331859e-07
11 O 0 1.5741156289550418e-07
mutations O 0 2.2297328428066976e-07
of O 0 1.5457214397329722e-09
the O 0 5.528994151404731e-09
gene O 0 6.756395123375114e-07
have O 0 1.0782079584714666e-07
been O 0 4.51998374728646e-07
reported O 0 1.5272938981070183e-05
in O 0 6.64649846271459e-08
HCP B-Disease 0 0.06938378512859344
patients O 0 5.4558304327656515e-06
. O 0 2.1353727674977563e-07

We O 0 1.165803951153066e-05
report O 0 3.9041918853399693e-07
another O 0 1.2295843454523947e-08
mutation O 0 5.6272284609804046e-08
in O 0 1.2321075271159998e-09
a O 0 1.760559342756096e-08
Japanese O 0 6.052410981283174e-07
family O 0 3.2256758686344256e-07
. O 0 2.2712050906648074e-07

Polymerase O 0 0.00010396370635135099
chain O 0 6.603854126296937e-05
reaction O 0 3.787722846482211e-07
- O 0 4.789093850376958e-07
single O 0 2.114735906388887e-07
strand O 0 3.98341981053818e-05
conformational O 0 2.2964482582210621e-07
polymorphism O 0 1.7346377489957376e-07
and O 0 3.6687171078853e-09
direct O 0 1.427036711021401e-08
sequence O 0 7.769136800561682e-08
analyses O 0 1.6859553397807758e-07
demonstrated O 0 2.554202715998599e-08
a O 0 1.3475061955148249e-08
C O 0 2.754744627964101e-07
to O 0 5.987237816640345e-09
T O 0 8.368023145521875e-07
substitution O 0 3.459223796298261e-09
in O 0 6.698354093614967e-10
exon O 0 1.9482934376924277e-08
1 O 0 6.356664083995156e-09
of O 0 2.910651997201086e-10
the O 0 6.802180596565677e-09
CPO O 0 1.4198647477314807e-05
gene O 0 1.4178636931205801e-08
at O 0 3.1775968523106712e-09
nucleotide O 0 2.9141881796590496e-08
position O 0 1.604355759354803e-07
85 O 0 1.618794343016816e-08
, O 0 1.8874999341278453e-09
which O 0 3.6697109795369443e-09
lies O 0 6.876316405168836e-08
in O 0 3.2718119324925965e-09
the O 0 8.291221931244763e-09
putative O 0 3.644351238563104e-07
presequence O 0 8.0899252452582e-07
for O 0 1.4196760433904387e-09
targeting O 0 8.070554002870267e-08
to O 0 4.153715593702145e-08
mitochondria O 0 1.6961279243332683e-06
. O 0 2.8219977821208886e-07

This O 0 2.79259381841257e-07
mutation O 0 4.877922492596554e-07
changes O 0 2.1188737875377228e-08
the O 0 1.3585559344164722e-09
codon O 0 7.937615720265967e-08
for O 0 1.2344903987937528e-09
glutamine O 0 2.7875614705408225e-08
to O 0 2.5251372104406755e-09
a O 0 5.361318056174014e-09
termination O 0 2.2994893100758418e-08
codon O 0 8.603769430237662e-08
at O 0 1.1391986021180855e-08
amino O 0 6.396888352355745e-08
acid O 0 4.5647846036445117e-07
position O 0 3.2202353850152576e-07
29 O 0 3.9377110283567163e-07
. O 0 1.8117091826752585e-07

MaeI O 0 0.00014010649465490133
restriction O 0 1.2339329487076611e-06
analysis O 0 2.0110557841235277e-07
showed O 0 4.7722426899099446e-08
two O 0 6.335417745972904e-10
other O 0 6.276866248988711e-10
carriers O 0 5.821642723446985e-09
in O 0 1.7059686996390155e-09
the O 0 2.1685588436071157e-08
family O 0 3.495705982459185e-07
. O 0 3.708420024395309e-07

The O 0 2.0543861865007784e-06
C O 0 0.00041984874405898154
- O 0 0.010009714402258396
T O 0 0.021087391301989555
mutation O 0 1.6171097740880214e-06
is O 0 6.956878184638526e-09
located O 0 9.399720113378862e-09
within O 0 2.699493295565958e-09
a O 0 3.5825166833092226e-08
recently O 0 4.408706502090354e-07
proposed O 0 2.2037845326394745e-08
putative O 0 8.92834961518929e-08
alternative O 0 4.040219536705081e-08
translation O 0 8.399815243365083e-08
initiation O 0 3.931766556775074e-08
codon O 0 1.6495281442985288e-06
( O 0 2.8817918718004876e-08
TIC O 0 1.1567140973056667e-05
- O 0 2.1288406060193665e-06
1 O 0 8.028884934674352e-08
) O 0 1.6441978889503162e-09
, O 0 6.904420923881105e-10
supporting O 0 1.692579854051246e-09
that O 0 1.1157674784101346e-08
TIC O 0 5.765945388702676e-06
- O 0 5.19218986028136e-07
1 O 0 4.397729469474143e-08
is O 0 2.1366850511128632e-09
the O 0 2.066987914162155e-09
real O 0 1.7408589769729588e-07
TIC O 0 3.3363746752002044e-06
rather O 0 4.464349334654116e-09
than O 0 4.2792285270820685e-09
TIC O 0 1.589179532857088e-06
- O 0 1.5565156274988112e-07
2 O 0 4.79561990118782e-08
. O 0 4.170447986950876e-09
. O 0 6.998056534257557e-08

Human B-Disease 0 1.8200837530457648e-06
complement I-Disease 0 1.8982145775225945e-06
factor I-Disease 0 1.834849354054313e-05
H I-Disease 1 1.0
deficiency I-Disease 1 0.9566497206687927
associated O 0 5.638397396978689e-06
with O 0 4.841443296754733e-05
hemolytic B-Disease 1 0.9999997615814209
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 1.161972431873437e-05

This O 0 2.3521222658473562e-07
study O 0 9.863252614650264e-08
reports O 0 1.0891876200957995e-07
on O 0 7.669987667213718e-08
six O 0 2.6857103208044464e-08
cases O 0 9.08269104371584e-09
of O 0 1.0192679589238196e-08
deficiency B-Disease 0 1.3079920790914912e-05
in I-Disease 0 2.1504265035332537e-09
the I-Disease 0 2.812838628685199e-09
human I-Disease 0 4.3772829805277524e-09
complement I-Disease 0 1.200732313577646e-08
regulatory I-Disease 0 1.4555738836463661e-08
protein I-Disease 0 1.0095227054307543e-07
Factor I-Disease 0 1.0707623943062572e-07
H I-Disease 1 1.0
( O 0 4.227694603287091e-07
FH O 0 0.00010793689580168575
) O 0 2.0117871812885824e-09
in O 0 3.4070404830721657e-10
the O 0 6.917365569236722e-10
context O 0 7.2220829316904656e-09
of O 0 9.58483870050486e-09
an O 0 2.3220136426971294e-05
acute B-Disease 1 0.9954541921615601
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 6.879955890326528e-06

Five O 0 4.132897117870016e-07
of O 0 4.526641728119785e-09
the O 0 2.2132866650537153e-09
cases O 0 8.637488946305893e-09
were O 0 1.298635599056297e-08
observed O 0 2.145404920383953e-08
in O 0 3.420625116490328e-09
children O 0 2.8637810345344406e-08
presenting O 0 4.813310852114228e-07
with O 0 1.0921236025751568e-05
idiopathic O 1 0.999998927116394
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00010625171853462234
HUS B-Disease 1 0.9999967813491821
) O 0 3.1925055736792274e-06
. O 0 1.1813040146080311e-06

Two O 0 2.3483433153614897e-07
of O 0 4.001458275837422e-09
the O 0 8.825370656495579e-09
children O 0 8.25603478915582e-08
exhibited O 0 5.913458949180495e-07
a O 0 1.1530578376550693e-06
homozygous O 0 0.02610059455037117
deficiency O 0 0.003635370172560215
characterized O 0 4.4024420731147984e-07
by O 0 2.147573674449177e-09
the O 0 6.877270308791594e-09
absence O 0 1.0826483709536205e-08
of O 0 2.0576369774705228e-10
the O 0 1.4039609474991721e-09
150 O 0 1.5405853259764513e-09
- O 0 1.6766362875841878e-07
kD O 0 1.7118227901846694e-07
form O 0 4.692736421674226e-09
of O 0 5.502459043960073e-10
Factor O 0 2.5261117642116915e-08
H O 1 0.9999998807907104
and O 0 8.833997355850443e-08
the O 0 3.573929152622668e-09
presence O 0 2.0052590699037864e-09
, O 0 6.372575800384084e-10
upon O 0 4.713222034880005e-10
immunoblotting O 0 1.8410170810057025e-07
, O 0 5.596235697069574e-10
of O 0 4.649228918518489e-11
the O 0 6.033226140900183e-10
42 O 0 1.356314527356517e-08
- O 0 8.083171110229159e-08
kD O 0 4.0568068016000325e-07
Factor O 0 3.172953455532479e-08
H O 1 0.9999438524246216
- O 0 4.351176983163896e-07
like O 0 5.956494852910055e-09
protein O 0 2.5183567231579218e-08
1 O 0 1.6365707011800623e-08
( O 0 2.301559387518637e-09
FHL O 0 2.452409262332367e-07
- O 0 4.2633362795641006e-07
1 O 0 2.2155346002250553e-08
) O 0 6.506560290553409e-10
and O 0 1.2623344591844443e-09
other O 0 1.197879839764937e-08
FH O 0 0.00033130988595075905
- O 0 3.507625024212757e-06
related O 0 4.153938562012627e-07
protein O 0 8.165342251231777e-07
( O 0 1.2718475161932474e-08
FHR O 0 7.782515240251087e-06
) O 0 7.981547867075278e-09
bands O 0 2.1014909634686774e-07
. O 0 1.6366526267574955e-07

Southern O 0 2.2732776415068656e-05
blot O 0 0.003004847327247262
and O 0 1.6981820749606413e-07
PCR O 0 6.902490667926031e-07
analysis O 0 7.822201553153718e-09
of O 0 2.2266870292053653e-10
DNA O 0 4.509159623466985e-08
of O 0 7.568183857387112e-10
one O 0 4.4640877661095146e-08
patient O 0 4.866032554673438e-07
with O 0 4.512308748871874e-08
homozygous O 0 0.0035158139653503895
deficiency O 0 0.0018282311502844095
ruled O 0 1.929658282051605e-07
out O 0 2.2174795333285147e-08
the O 0 1.3778566065880682e-09
presence O 0 1.4435957984559877e-09
of O 0 6.961570209185197e-11
a O 0 1.6581273021287757e-09
large O 0 6.162417687249899e-09
deletion O 0 3.5119055041832326e-07
of O 0 8.781574911687073e-10
the O 0 2.6522599227973842e-08
FH O 0 0.00010703208681661636
gene O 0 1.3465586334859836e-07
as O 0 3.3574791835633278e-09
the O 0 5.644047451625056e-09
underlying O 0 6.039672371116467e-06
defect O 0 1.999359483306762e-06
for O 0 6.756238679628268e-09
the O 0 1.0086871498060646e-06
deficiency O 0 0.0003712017205543816
. O 0 3.7796905871800845e-07

The O 0 1.224283181500141e-07
other O 0 1.1061980664806015e-08
four O 0 1.8505062371332315e-08
children O 0 3.051690455890821e-08
presented O 0 2.4372695861529792e-08
with O 0 5.8435730920791684e-08
heterozygous O 0 9.55533905653283e-05
deficiency O 0 0.00021941945306025445
and O 0 3.627983247156408e-08
exhibited O 0 1.9665054651341052e-07
a O 0 1.928439807841187e-08
normal O 0 6.119843192209373e-07
immunoblotting O 0 6.531854069180554e-06
pattern O 0 2.980356157422648e-07
of O 0 4.263095987333543e-10
proteins O 0 4.232795447478566e-09
of O 0 7.101695342903724e-10
the O 0 1.3470017279360036e-07
FH O 0 0.007320646662265062
family O 0 5.408132892625872e-07
. O 0 2.073853124784364e-07

Factor B-Disease 0 0.003080505644902587
H I-Disease 1 1.0
deficiency I-Disease 1 0.9927064776420593
is O 0 3.380788271556412e-08
the O 0 1.173684971433886e-08
only O 0 7.291374117812666e-07
complement B-Disease 1 0.9999916553497314
deficiency I-Disease 1 0.9999996423721313
associated O 0 9.269572274206439e-07
with O 0 3.5812772125609627e-07
HUS B-Disease 1 0.9999701976776123
. O 0 2.9289606118254596e-06

These O 0 3.763928191347077e-07
observations O 0 8.533270374755375e-07
suggest O 0 6.812491903929185e-08
a O 0 1.4842939322079474e-08
role O 0 2.8989205702600884e-08
for O 0 4.36163389849753e-08
FH O 0 0.007917915470898151
and O 0 2.897859303629957e-06
/ O 0 0.00015554465062450618
or O 0 1.0518837143536075e-06
FH O 0 0.00013011888950131834
receptors O 0 1.6189522966669756e-07
in O 0 2.825981226806107e-09
the O 0 1.3897954787012168e-08
pathogenesis O 0 4.736369373858906e-05
of O 0 1.0869774058619441e-07
idiopathic O 0 0.16450531780719757
HUS B-Disease 1 0.9999682903289795
. O 0 1.2723749023280106e-06
. O 0 6.584895686501113e-07

Further O 0 1.4659602811661898e-06
evidence O 0 1.0295398311654935e-07
for O 0 2.108817342971747e-09
a O 0 6.772172600477688e-09
major O 0 1.0823263174586373e-08
ancient O 0 1.7190323831073329e-07
mutation O 0 0.0022225533612072468
underlying O 0 0.17315170168876648
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.918007455969928e-06
linkage O 0 5.89417977607809e-05
disequilibrium O 0 0.00016365808551199734
studies O 0 8.706067688990515e-08
in O 0 4.168841716278848e-09
the O 0 7.411903091281147e-09
Japanese O 0 2.828259368925501e-07
population O 0 4.464700609219108e-08
. O 0 1.0438616016017477e-07

The O 0 0.0010723170125856996
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.4809677004814148
DM B-Disease 1 1.0
) O 0 1.4762888440600364e-06
mutation O 0 1.7641850718064234e-06
is O 0 2.2959833145819175e-08
an O 0 8.126331607627435e-08
unstable O 0 0.06374483555555344
( O 0 4.547842422653048e-07
CTG O 0 4.208331665722653e-05
) O 0 2.4334420700711235e-08
n O 0 3.5956372812506743e-06
repeat O 0 3.474952563919942e-06
, O 0 5.453792084608722e-09
present O 0 1.5642730444298536e-09
at O 0 9.789311583574545e-09
a O 0 4.744042936266624e-09
copy O 0 4.1089236901825643e-07
number O 0 2.7874482722012317e-09
of O 0 2.9112573463052627e-10
5 O 0 4.7259018032264066e-08
- O 0 1.8015679188465583e-06
37 O 0 2.430098504646594e-07
repeats O 0 6.536781143040571e-07
on O 0 2.2926319331872946e-07
normal O 0 1.0962175167605892e-07
chromosomes O 0 1.5937297348500579e-07
but O 0 5.889075893605877e-09
amplified O 0 4.909185591372989e-08
to O 0 4.165694011959431e-09
50 O 0 3.987735919253055e-09
- O 0 2.1155305773845612e-07
3000 O 0 8.005442708736155e-08
copies O 0 3.9017309063638095e-06
on O 0 8.003623952390626e-05
DM B-Disease 1 0.9999997615814209
chromosomes O 0 3.80016426788643e-05
. O 0 3.6355552879285824e-07

Previous O 0 1.5547411749139428e-05
findings O 0 9.022569997796381e-07
in O 0 2.2721318160279225e-08
Caucasian O 0 6.6627530941332225e-06
populations O 0 1.2217253697599517e-07
of O 0 1.055569764929487e-08
a O 0 1.4947887393645942e-05
DM B-Disease 1 1.0
founder O 0 9.47772350627929e-05
chromosome O 0 7.081409421516582e-05
raise O 0 1.1280830136684017e-07
a O 0 3.943039317277908e-08
question O 0 1.8649132016435033e-08
about O 0 1.6569164928981195e-09
the O 0 1.7971462096255664e-09
molecular O 0 7.084506137289281e-08
events O 0 1.0201470779236388e-08
involved O 0 1.1357359497310426e-08
in O 0 2.0664085997879056e-09
the O 0 6.320479251087363e-09
expansion O 0 3.8532644452971e-07
mutation O 0 2.3594830054207705e-06
. O 0 1.5359306360096525e-07

To O 0 2.4932278392952867e-06
investigate O 0 7.15595319888962e-07
whether O 0 3.7315142975558047e-08
a O 0 2.7791681844746563e-08
founder O 0 3.488237098281388e-06
chromosome O 0 3.081048998865299e-05
for O 0 2.5607439724240066e-08
the O 0 7.397387093988073e-07
DM B-Disease 1 1.0
mutation O 0 1.7248898984689731e-06
exists O 0 4.66669103360573e-09
in O 0 4.83953710439522e-10
the O 0 7.320226647067329e-10
Japanese O 0 2.817151667500184e-08
population O 0 1.0142987560968209e-09
, O 0 8.002122298123027e-10
we O 0 1.946439009969936e-09
genotyped O 0 6.757078807595462e-08
families O 0 2.820622069243939e-10
using O 0 2.842762025778711e-09
polymorphic O 0 2.742914091413695e-07
markers O 0 1.1663884151857928e-06
near O 0 1.3493061032932019e-06
the O 0 1.267764559997886e-07
( O 0 1.5933862584915914e-07
CTG O 0 2.3952636183821596e-05
) O 0 2.2680918476680745e-08
n O 0 5.693370439985301e-06
repeat O 0 1.0112239579029847e-05
region O 0 1.6016039126043324e-06
and O 0 2.0799616606836935e-07
constructed O 0 6.341683729260694e-06
haplotypes O 0 9.309611050412059e-05
. O 0 7.387981213469175e-07

Six O 0 1.2536369240478962e-06
different O 0 4.258159691516994e-08
haplotypes O 0 6.726360879838467e-06
were O 0 1.4655505253813317e-07
found O 0 6.522222406601941e-07
and O 0 1.0434388059366029e-05
DM B-Disease 1 1.0
alleles O 0 5.682477876689518e-06
were O 0 2.1130144034486875e-07
always O 0 1.4200348630311055e-07
haplotype O 0 1.1607154192461167e-05
A O 0 1.127084487961838e-06
. O 0 7.221899522846797e-07

To O 0 6.223725677045877e-07
find O 0 1.0782017767496654e-07
an O 0 2.6377542372557627e-09
origin O 0 5.073051756454561e-09
of O 0 1.4460319608389227e-09
the O 0 3.174890750301529e-08
( O 0 1.331906815948969e-07
CTG O 0 7.418810582748847e-06
) O 0 8.602009771152552e-09
n O 0 1.4347269825520925e-06
repeat O 0 8.367329087377584e-07
mutation O 0 2.4182111246773275e-07
and O 0 3.0974426579177816e-08
to O 0 1.3697030176729186e-08
investigate O 0 1.8409515689654654e-08
the O 0 6.947167840998247e-10
mechanism O 0 1.5551104848299246e-09
of O 0 6.131226082395358e-11
the O 0 7.832692827669518e-10
expansion O 0 1.3478532956412437e-08
mutation O 0 1.9429679198879057e-08
in O 0 3.3598540616353034e-10
the O 0 7.638956134314867e-10
Japanese O 0 1.729783605242119e-08
population O 0 6.595461399250269e-10
we O 0 1.5827877897223175e-09
have O 0 2.614297112124575e-10
studied O 0 1.7900646520629948e-09
90 O 0 2.8360791493042825e-09
Japanese O 0 2.7132520585837483e-07
DM B-Disease 1 0.9999992847442627
families O 0 3.4398865977891546e-09
comprising O 0 1.042841701881514e-09
190 O 0 6.419644371646882e-09
affected O 0 1.2273350336045041e-08
and O 0 1.07659028358853e-08
130 O 0 3.5585852486974545e-08
unaffected O 0 1.5284477967725252e-06
members O 0 3.2811623640327525e-08
. O 0 1.011762691405238e-07

The O 0 3.64302763955493e-06
results O 0 8.596880434197374e-06
suggest O 0 6.875201563616429e-08
that O 0 1.339334199101927e-09
a O 0 1.4689240934728787e-09
few O 0 8.670033579960545e-10
common O 0 1.486661682648105e-09
ancestral O 0 8.935793971431849e-08
mutations O 0 1.0171868325414835e-06
in O 0 1.0170670972087237e-09
both O 0 3.816427174285764e-09
Caucasian O 0 1.492548676651495e-06
and O 0 5.642543499106978e-08
Japanese O 0 2.4498769235492546e-08
populations O 0 1.5070348302614889e-09
have O 0 2.529242926208042e-10
originated O 0 3.964746864149049e-10
by O 0 1.0098968883376358e-10
expansion O 0 1.84992998697453e-09
of O 0 2.0824438007327473e-10
an O 0 1.727342935353704e-09
ancestral O 0 1.5093692695700156e-07
n O 0 5.729466920456616e-06
= O 0 2.59693621273982e-07
5 O 0 3.068669585104544e-08
repeat O 0 3.136942154924327e-07
to O 0 1.7983506239716007e-08
n O 0 7.78468063344917e-07
= O 0 3.5078755900030956e-07
19 O 0 9.863384775599116e-08
- O 0 6.130024416961533e-07
37 O 0 6.367951499441915e-08
copies O 0 8.40575125948817e-07
. O 0 1.8901241105595545e-07

These O 0 1.6958743742634397e-07
data O 0 2.4548498345211556e-07
support O 0 8.99531649167784e-09
multistep O 0 3.1689015145275334e-07
models O 0 1.3905371076816664e-07
of O 0 3.819186744635772e-09
triplet O 0 0.0001195032600662671
repeat O 0 1.5223555237753317e-05
expansion O 0 3.981634932870293e-08
that O 0 6.005560049260339e-09
have O 0 1.5695000854520913e-09
been O 0 1.426657680880794e-09
proposed O 0 3.392309766425683e-09
for O 0 1.612237099379854e-08
both O 0 2.624072294565849e-06
DM B-Disease 1 1.0
and O 0 1.0248910257359967e-05
Friedreichs B-Disease 0 0.0005775423487648368
ataxia I-Disease 0 0.08806703984737396
. O 0 6.400317431598523e-08
. O 0 1.9506437354266382e-07

The O 0 1.2681589112162328e-07
molecular O 0 6.528457561216783e-07
basis O 0 3.2441241160086065e-07
of O 0 2.2123713279142976e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.3292121059957935e-08
the O 0 7.349076902585239e-09
western O 0 1.2242666969086713e-07
Cape O 0 1.6516676737410307e-07
, O 0 2.7286064518960984e-09
South O 0 8.189860345453326e-09
Africa O 0 3.7144573639125156e-08
. O 0 7.087384545911846e-08

Deficiency B-Disease 1 0.9311391115188599
of I-Disease 0 1.5309664647134014e-08
the I-Disease 0 1.1677586009284369e-08
sixth I-Disease 0 9.803671900954214e-07
component I-Disease 0 9.079784746290898e-08
of I-Disease 0 1.2712745300902384e-09
human I-Disease 0 1.2258985826463231e-08
complement I-Disease 0 1.384961478834157e-07
( O 0 6.433216270806952e-08
C6 O 0 5.9373076510382816e-05
) O 0 5.4062052612380285e-08
has O 0 1.3689697198060458e-07
been O 0 1.1678147870952671e-07
reported O 0 1.3562275853473693e-06
in O 0 9.337103312745398e-10
a O 0 7.928306899884774e-09
number O 0 5.708334693821371e-09
of O 0 4.769890038502922e-10
families O 0 1.1333204374963657e-09
from O 0 1.2265339854877766e-09
the O 0 2.8188968936859737e-09
western O 0 7.058703488382889e-08
Cape O 0 8.376472493409892e-08
, O 0 3.6039664585985065e-09
South O 0 8.466515488692039e-09
Africa O 0 2.3955093908512026e-08
. O 0 7.224759457358232e-08

Meningococcal B-Disease 1 0.986090898513794
disease I-Disease 1 0.9315545558929443
is O 0 2.1434503594264243e-07
endemic O 0 1.6320637996614096e-07
in O 0 8.847179877591316e-09
the O 0 2.456183878507545e-08
Cape O 0 6.884372965032526e-07
and O 0 3.437068230027762e-08
almost O 0 2.306164592624782e-09
all O 0 2.500892271051214e-10
pedigrees O 0 3.7076482328757265e-08
of O 0 1.034837282531953e-08
total O 0 0.00031571733416058123
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 2.409077524134773e-07
C6Q0 O 0 8.625401824247092e-05
) O 0 1.4050411500932114e-08
have O 0 8.13623834972077e-09
been O 0 5.40524638381612e-08
ascertained O 0 1.559121415084519e-06
because O 0 8.059998002352131e-09
of O 0 3.685368810124601e-08
recurrent O 0 0.055399972945451736
disease O 0 0.0018439621198922396
. O 0 6.696110972370661e-07

We O 0 5.537235665542539e-06
have O 0 2.627401940458185e-08
sequenced O 0 1.956626363153191e-07
the O 0 2.989720027102294e-09
expressed O 0 2.948256971890828e-09
exons O 0 9.568385195279916e-08
of O 0 4.20774332043905e-10
the O 0 7.597576789919458e-09
C6 O 0 8.446617357549258e-06
gene O 0 2.2079713346556673e-07
from O 0 1.7111828620741676e-09
selected O 0 3.5155824917865175e-09
cases O 0 3.1832323443836685e-09
and O 0 1.3168286905340665e-08
have O 0 1.1620019613189925e-08
found O 0 2.3797433357231057e-08
three O 0 2.2031793278642908e-08
molecular O 0 4.12540521210758e-06
defects O 0 0.014383858069777489
leading O 0 3.542941442447045e-07
to O 0 1.7018494702369935e-07
total O 0 2.322951786482008e-06
deficiency O 0 2.7532012609299272e-05
879delG O 0 6.161398573567567e-07
, O 0 1.011663908201399e-08
which O 0 2.573674384720448e-09
is O 0 2.3603672349992166e-09
the O 0 2.7009869896232885e-09
common O 0 2.2023732526577078e-07
defect O 0 2.975002644234337e-06
in O 0 2.119685094115198e-09
the O 0 4.014048204936671e-09
Cape O 0 1.9977591136921546e-07
and O 0 2.1211139511478905e-08
hitherto O 0 1.8146003810670663e-07
unreported O 0 7.493142106795858e-08
, O 0 4.608611270384699e-09
and O 0 4.20805035261651e-09
1195delC O 0 2.408420414212742e-07
and O 0 2.685438893479386e-08
1936delG O 0 7.891713948993129e-07
, O 0 9.819325796911471e-09
which O 0 2.1649633197284857e-08
have O 0 1.9192002653767304e-08
been O 0 5.328331909026929e-08
previously O 0 2.5586453489268024e-07
reported O 0 8.133191045089916e-07
in O 0 8.291154429684866e-10
African O 0 4.40068914642211e-09
- O 0 8.814588454697514e-07
Americans O 0 1.2634941981559678e-07
. O 0 1.2016286632388073e-07

We O 0 4.062330390297575e-06
also O 0 4.925448848780434e-08
show O 0 2.1296758134781157e-08
that O 0 4.3335349197981543e-10
the O 0 1.0196251620797625e-09
879delG O 0 8.661048696012585e-07
and O 0 2.027656336167638e-07
1195delC O 0 5.871503526577726e-05
defects O 0 0.0045750499702990055
are O 0 1.5209651316183681e-09
associated O 0 1.0817360340809046e-08
with O 0 1.2620992251299867e-08
characteristic O 0 0.00024378843954764307
C6 O 1 0.9958130717277527
/ O 0 0.03160185366868973
C7 O 0 0.00022883219935465604
region O 0 8.011650152184302e-07
DNA O 0 1.1762665508285863e-06
marker O 0 1.0027224561781622e-06
haplotypes O 0 4.112889200769132e-06
, O 0 1.20309584517031e-08
although O 0 2.18226259285359e-09
small O 0 4.984237911287437e-09
variations O 0 1.5722852140243049e-06
were O 0 1.7247700156985957e-07
observed O 0 6.639048137913051e-07
. O 0 2.467729132149543e-07

The O 0 7.481480110982375e-07
1936delG O 0 3.976784864789806e-05
defect O 0 7.453853322658688e-05
was O 0 4.6469395442727546e-07
observed O 0 4.737525927112074e-08
only O 0 2.0220429775008597e-09
once O 0 1.2089339307408409e-08
in O 0 1.7651246020378153e-09
the O 0 3.786987168297173e-09
Cape O 0 1.0373454983891861e-07
, O 0 5.579569251068506e-09
but O 0 1.8297486858998013e-09
its O 0 3.29433156309733e-08
associated O 0 2.387195081610116e-07
haplotype O 0 2.6427560442243703e-05
could O 0 9.154408076028631e-07
be O 0 5.400887204132232e-08
deduced O 0 1.1064026921303594e-06
. O 0 2.7602092700362846e-07

The O 0 5.523220352188218e-07
data O 0 9.456599627810647e-07
from O 0 1.085706813341858e-08
the O 0 5.256577839674037e-09
haplotypes O 0 4.2562533053569496e-06
indicate O 0 1.951473791450553e-07
that O 0 1.3435148549234555e-09
these O 0 3.521015978780184e-10
three O 0 1.557177142785804e-08
molecular O 0 1.2710183909803163e-05
defects O 0 0.1727076768875122
account O 0 3.166614703786763e-07
for O 0 4.805481168546066e-08
the O 0 1.3596800272352993e-06
defects O 0 0.10500669479370117
in O 0 4.183195123630412e-09
all O 0 1.59407942401657e-09
the O 0 3.269441384290417e-09
38 O 0 1.9198996170644023e-08
unrelated O 0 1.1117609943767093e-08
C6Q0 O 0 7.639714567631017e-06
individuals O 0 2.830944811904601e-09
we O 0 9.837134662404878e-09
have O 0 2.1023274232589984e-09
studied O 0 6.7384400281866874e-09
from O 0 2.7642637068225895e-09
the O 0 1.4275839177457783e-08
Cape O 0 1.9294516278023366e-06
. O 0 2.971419519326446e-07

We O 0 8.652662472741213e-06
have O 0 9.074278750631493e-08
also O 0 1.46823300184451e-08
observed O 0 4.22114752041125e-08
the O 0 5.490866428203844e-09
879delG O 0 3.3058836379495915e-06
defect O 0 1.144615112025349e-06
in O 0 3.482533150744871e-09
two O 0 1.0928230409490425e-07
Dutch O 1 0.692261815071106
C6 B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
deficient I-Disease 1 0.9999998807907104
kindreds O 0 5.224269989412278e-05
, O 0 6.5745529020944105e-09
but O 0 7.131203960675236e-10
the O 0 1.0302735331535473e-09
879delG O 0 6.46016928840254e-07
defect O 0 3.3480233696536743e-07
in O 0 2.3599262544138355e-09
the O 0 4.093179128972224e-09
Cape O 0 3.728796684754343e-07
probably O 0 3.810988289387751e-07
did O 0 3.1271827793943885e-08
not O 0 1.293414042535801e-09
come O 0 6.727136625528374e-10
from O 0 4.1214029411484887e-10
The O 0 1.9924337735233166e-09
Netherlands O 0 1.050297782967391e-06
. O 0 2.034058610433931e-08
. O 0 1.1241116482096913e-07

Complement B-Disease 0 0.27802926301956177
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 5.234809350440628e-07
seven O 0 3.157859751468095e-08
further O 0 5.790185042542362e-08
molecular O 0 1.7490494428784586e-05
defects O 1 0.8134865164756775
and O 0 1.529128610400221e-07
their O 0 2.733121959863638e-07
associated O 0 1.0285266398568638e-06
marker O 0 2.9478303986252286e-05
haplotypes O 0 0.00030586609500460327
. O 0 1.323677679465618e-06

Seven O 0 1.0348313708163914e-06
further O 0 9.97287727955154e-08
molecular O 0 3.1214895557241107e-07
bases O 0 8.577696917200228e-07
of O 0 1.2049995348206721e-05
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 1.4661907243862515e-07
described O 0 1.8327449424759834e-06
. O 0 3.7906536931586743e-07

All O 0 1.1075326966647481e-07
these O 0 5.957358162334003e-09
new O 0 2.8243123395554903e-08
molecular O 0 3.2405544061475666e-06
defects O 0 0.00028127708355896175
involve O 0 1.942534488819092e-08
single O 0 3.009230624684278e-07
- O 0 4.340390660217963e-06
nucleotide O 0 1.0410902859803173e-06
events O 0 2.0125865418663125e-08
, O 0 6.468057645037106e-09
deletions O 0 2.8513335337265744e-07
and O 0 2.360490114483582e-08
substitutions O 0 1.314623290227246e-07
, O 0 3.1854188176083653e-09
some O 0 2.0757182084274461e-10
of O 0 2.1138905903494987e-10
which O 0 3.6627621824436574e-08
alter O 0 7.302672202058602e-06
splice O 0 4.071708826813847e-05
sites O 0 4.740924737234309e-07
, O 0 1.505317648309301e-08
and O 0 1.9195994127585436e-08
others O 0 8.671017326378205e-08
codons O 0 3.224265583412489e-06
. O 0 2.5114596269304457e-07

They O 0 4.993485163140576e-07
are O 0 3.20644932827463e-09
distributed O 0 4.624531868557824e-09
along O 0 7.553635938961634e-09
the O 0 8.188314026824628e-09
C7 O 0 3.52673523593694e-05
gene O 0 7.146296070459357e-07
, O 0 2.088052841742183e-09
but O 0 4.037712109106195e-10
predominantly O 0 6.605507807400102e-10
towards O 0 2.021580236544196e-09
the O 0 3.20099857731293e-09
3 O 0 6.838738642045428e-08
end O 0 8.847704293657443e-07
. O 0 2.587023857358872e-07

All O 0 6.141095241218864e-07
were O 0 1.0176481879398125e-07
found O 0 1.3562318379456428e-08
in O 0 3.856313046668447e-09
compound O 0 6.804654617553751e-07
heterozygous O 0 1.7264154621443595e-06
individuals O 0 3.3385148867637326e-08
. O 0 2.3088092859779863e-07

The O 0 5.742097073380137e-06
C6 O 0 0.05134963244199753
/ O 0 0.04002339020371437
C7 O 0 0.0004983976250514388
marker O 0 1.0679496881493833e-05
haplotypes O 0 2.3152433641371317e-05
associated O 0 3.418752214656706e-07
with O 0 2.4156980416023544e-08
most O 0 1.793498881852429e-06
C7 B-Disease 1 0.9999140501022339
defects I-Disease 1 0.9979894161224365
are O 0 6.041868516604154e-08
tabulated O 0 1.4208682159733144e-06
. O 0 2.5296893468862436e-08
. O 0 1.432343879059772e-07

A O 0 5.224179403739981e-06
genome O 0 7.1500921876577195e-06
- O 0 6.331718395813368e-06
wide O 0 1.4683820381833357e-07
search O 0 1.5140864206841798e-07
for O 0 2.0747069839899268e-08
chromosomal O 0 0.00011321159399813041
loci O 0 2.536493184379651e-06
linked O 0 0.00032724716584198177
to O 0 4.660934337152867e-06
mental O 0 0.0002006139693548903
health O 0 9.882108997771866e-07
wellness O 0 1.7965014649234945e-06
in O 0 4.5824581462738934e-08
relatives O 0 9.643191134500739e-08
at O 0 2.0905370945456525e-07
high O 0 1.2040436558891088e-06
risk O 0 5.734905698773218e-06
for O 0 2.6496768441575114e-06
bipolar B-Disease 1 0.9999960660934448
affective I-Disease 1 0.9991389513015747
disorder I-Disease 0 0.19996628165245056
among O 0 3.846073237667724e-09
the O 0 2.71194089407345e-09
Old O 0 5.164091021470085e-07
Order O 0 1.4570106543487782e-07
Amish O 0 4.857200110564008e-06
. O 0 4.2857041648858285e-07

Bipolar B-Disease 1 0.9999978542327881
affective I-Disease 1 0.9999819993972778
disorder I-Disease 1 0.9999793767929077
( O 0 2.776676592475269e-05
BPAD B-Disease 1 1.0
; O 0 0.0010009024990722537
manic B-Disease 1 0.9999985694885254
- I-Disease 1 0.9999996423721313
depressive I-Disease 1 1.0
illness I-Disease 1 0.9928868412971497
) O 0 6.995013990263033e-08
is O 0 6.1884724011918024e-09
characterized O 0 6.284994213956452e-08
by O 0 2.731199488792413e-09
episodes O 0 2.8008915364807763e-07
of O 0 3.4354410427539506e-09
mania B-Disease 0 0.00019435466674622148
and O 0 1.6808530745038297e-06
/ O 0 0.0009251900482922792
or O 0 2.1686080344807124e-06
hypomania B-Disease 0 0.000829140713904053
interspersed O 0 1.2549324992505717e-06
with O 0 6.756780024375075e-09
periods O 0 8.437453402621031e-08
of O 0 2.5518845703231818e-08
depression B-Disease 0 5.105624950374477e-06
. O 0 3.669366890335368e-07

Compelling O 0 5.5263840295083355e-06
evidence O 0 1.8154727854380326e-07
supports O 0 2.499020901325366e-08
a O 0 5.408151704244801e-09
significant O 0 2.9126303591198166e-09
genetic O 0 8.98299248319745e-08
component O 0 8.003930673794457e-08
in O 0 5.5754947325681314e-09
the O 0 2.376667929127052e-08
susceptibility O 0 4.961191734764725e-06
to O 0 4.5767285428155446e-07
develop O 0 1.7192704035551287e-05
BPAD B-Disease 1 0.9999994039535522
. O 0 3.505164158923435e-06

To O 0 1.4528967540172744e-06
date O 0 2.0283403046050807e-06
, O 0 1.3220455841178591e-08
however O 0 4.1155368002421255e-09
, O 0 1.9544186269371266e-09
linkage O 0 4.776030664288555e-07
studies O 0 1.7628913440148608e-08
have O 0 9.620719332303906e-09
attempted O 0 4.808144922208157e-07
only O 0 4.834889377747231e-09
to O 0 2.1113457648880285e-08
identify O 0 5.502070052898489e-07
chromosomal O 0 8.795181202003732e-05
loci O 0 1.7451056919526309e-06
that O 0 3.4839541740439017e-07
cause O 0 5.154339532964514e-07
or O 0 7.460128159664237e-08
increase O 0 9.060875072464114e-08
the O 0 2.456741476919433e-08
risk O 0 1.9943594509186369e-07
of O 0 6.066763091894245e-09
developing O 0 6.882994512125151e-06
BPAD B-Disease 1 0.999998927116394
. O 0 4.103733317606384e-06

To O 0 8.2816933399954e-07
determine O 0 4.286125090402493e-07
whether O 0 2.2746162287035077e-08
there O 0 5.088576671141709e-09
could O 0 2.886820027470094e-08
be O 0 2.7316475748051516e-09
protective O 0 2.1398470551048376e-08
alleles O 0 3.7223156112986544e-08
that O 0 3.799641490331851e-09
prevent O 0 3.953982030679981e-08
or O 0 1.0569542041594104e-07
reduce O 0 1.8157047065869847e-07
the O 0 1.7344815361752808e-08
risk O 0 5.68130218425722e-08
of O 0 4.928864538733535e-10
developing O 0 1.0248011221847264e-06
BPAD B-Disease 1 0.9999998807907104
, O 0 1.323885179260742e-08
similar O 0 6.246458905678764e-10
to O 0 3.1256310872862514e-09
what O 0 1.7631796023209745e-09
is O 0 2.8323599021717882e-09
observed O 0 1.519191528132069e-08
in O 0 3.2365510271858966e-09
other O 0 7.797951298016415e-07
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 4.269423214964263e-08
we O 0 4.138603060255264e-08
used O 0 4.324524979892885e-06
mental O 0 2.046086228801869e-05
health O 0 2.3389337400203658e-07
wellness O 0 1.0530127383390209e-06
( O 0 1.3597544423760155e-08
absence O 0 1.7897413329137635e-08
of O 0 7.855183170590863e-09
any O 0 3.835139068542048e-06
psychiatric B-Disease 0 0.33712199330329895
disorder I-Disease 0 0.0003951570251956582
) O 0 2.5995061658790064e-09
as O 0 2.574980451086617e-09
the O 0 8.23468937483085e-09
phenotype O 0 2.2726185306964908e-06
in O 0 1.354122591834539e-08
our O 0 1.2232993640282075e-07
genome O 0 7.946338769215799e-07
- O 0 4.517210072663147e-06
wide O 0 4.125591885895119e-07
linkage O 0 8.35412174637895e-06
scan O 0 7.423250644933432e-05
of O 0 4.73036942949534e-10
several O 0 9.931979683130976e-10
large O 0 8.009517493690055e-09
multigeneration O 0 5.552930815611035e-06
Old O 0 7.200862484069148e-08
Order O 0 3.5287830435493106e-09
Amish O 0 1.6135143710016564e-07
pedigrees O 0 5.970192091808713e-07
exhibiting O 0 2.7062850449510734e-07
an O 0 5.688683302196296e-09
extremely O 0 6.796683749143995e-08
high O 0 3.4127680237361346e-07
incidence O 0 3.474809636827558e-05
of O 0 6.57043642604549e-07
BPAD B-Disease 1 0.9999998807907104
. O 0 8.525961675331928e-06

We O 0 2.5370847652084194e-05
have O 0 1.4484652410828858e-07
found O 0 7.672021951066199e-08
strong O 0 1.1745359351778006e-08
evidence O 0 2.9039937121666526e-09
for O 0 6.507416272505395e-10
a O 0 7.783388156212823e-09
locus O 0 4.771751491716714e-07
on O 0 1.267912102775881e-05
chromosome O 0 0.0011135865934193134
4p O 0 0.00031522466451860964
at O 0 3.314645766749891e-07
D4S2949 O 0 1.7484761372088542e-07
( O 0 2.595171189057055e-09
maximum O 0 1.0995152344150938e-08
GENEHUNTER O 0 1.031625743053155e-05
- O 0 1.565590991958743e-06
PLUS O 0 4.0891436015044746e-07
nonparametric O 0 3.9790660366634256e-07
linkage O 0 2.454620471326052e-07
score O 0 3.084084099214124e-08
= O 0 7.282451974788273e-08
4 O 0 8.537998752444764e-09
. O 0 3.6352960641750087e-09
05 O 0 8.096024117776324e-08
, O 0 6.527334228678683e-09
P O 0 6.330160886136582e-06
= O 0 3.408447923902713e-08
5 O 0 5.115161627600173e-09
. O 0 1.7669974372580555e-09
22 O 0 7.124382861434242e-09
x O 0 4.364455037375592e-07
10 O 0 1.912549585370016e-08
( O 0 2.0434094416543758e-09
- O 0 9.037700579028751e-07
4 O 0 1.7846849686975474e-07
) O 0 5.371707967327666e-09
; O 0 2.421832512311539e-09
SIBPAL O 0 9.549356718707713e-07
Pempirical O 0 1.0574260755902287e-07
value O 0 5.119670909436991e-09
< O 0 4.401142117416157e-09
3 O 0 3.803136472413371e-09
x O 0 1.0609306855258183e-06
10 O 0 4.384120089184762e-08
( O 0 6.020354881286494e-09
- O 0 1.266352342099708e-06
5 O 0 2.418856581698492e-07
) O 0 9.205930240341331e-09
) O 0 5.431514349396593e-09
and O 0 4.324613200878957e-08
suggestive O 0 1.4838757351753884e-06
evidence O 0 4.104115713943202e-09
for O 0 7.278153635326134e-10
a O 0 4.3481442446591245e-08
locus O 0 3.952568022214109e-06
on O 0 0.0001894193555926904
chromosome O 1 0.950231671333313
4q O 1 0.9997147917747498
at O 0 4.268340489943512e-07
D4S397 O 0 4.228488990065671e-07
( O 0 2.74668376931686e-09
maximum O 0 9.377211007688402e-09
GENEHUNTER O 0 3.411184252399835e-06
- O 0 9.007146672956878e-07
PLUS O 0 3.4464497389308235e-07
nonparametric O 0 6.48774289402354e-07
linkage O 0 2.6494015514799685e-07
score O 0 5.0909186199987744e-08
= O 0 8.15449681113023e-08
3 O 0 1.2113528846668942e-08
. O 0 2.7761679621818303e-09
29 O 0 2.138329335821254e-08
, O 0 1.5425435373472851e-09
P O 0 4.120843641430838e-06
= O 0 3.273623860877706e-08
2 O 0 7.1785350996833586e-09
. O 0 1.3251931774149739e-09
57 O 0 1.0693904428649148e-08
x O 0 2.574348911821289e-07
10 O 0 1.1678789491043062e-08
( O 0 1.5023280397485905e-09
- O 0 2.55940193483184e-07
3 O 0 1.2941900706664455e-07
) O 0 3.813647175832102e-09
; O 0 2.8131283968946263e-09
SIBPAL O 0 8.038643386498734e-07
Pempirical O 0 1.2859470643888926e-07
value O 0 2.234665563705107e-09
< O 0 3.364845069242506e-09
1 O 0 2.6102278116724165e-09
x O 0 9.469721931054664e-07
10 O 0 6.552684084226712e-08
( O 0 8.382095018077962e-09
- O 0 3.211943521819194e-06
3 O 0 1.5370485471066786e-06
) O 0 3.0780370252614375e-08
) O 0 4.193347891146004e-09
that O 0 5.178261375249349e-09
are O 0 1.0977277753454473e-08
linked O 0 5.395049447542988e-05
to O 0 7.255246146087302e-06
mental O 0 4.755794725497253e-05
health O 0 4.092124186172441e-07
wellness O 0 2.5139136141660856e-06
. O 0 2.711534534682869e-07

These O 0 4.409484404277464e-07
findings O 0 5.57431633296801e-07
are O 0 3.4431688611391564e-09
consistent O 0 1.779003433455273e-08
with O 0 8.837291454177887e-10
the O 0 2.4474002824348418e-09
hypothesis O 0 1.5598940805716666e-08
that O 0 4.1043640708338103e-10
certain O 0 5.249121137751445e-10
alleles O 0 1.696426821240493e-08
could O 0 3.967965866991108e-08
prevent O 0 2.4060872405584632e-08
or O 0 3.94564985128909e-08
modify O 0 1.5838083982089302e-06
the O 0 4.72587444733108e-08
clinical O 0 2.260515259422391e-07
manifestations O 0 2.6364537575318536e-07
of O 0 2.3731528742132468e-08
BPAD B-Disease 1 1.0
and O 0 5.774038527306402e-07
perhaps O 0 2.1192215982068774e-08
other O 0 1.549769557129821e-08
related O 0 8.40305528981844e-06
affective B-Disease 1 0.9937441945075989
disorders I-Disease 1 0.846523642539978
. O 0 9.24740106711397e-07

Segregation O 0 0.0010130404261872172
distortion O 0 0.0990917831659317
in O 0 0.00012793215864803642
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
. O 0 2.840806519088801e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999256432056427
DM B-Disease 1 1.0
) O 0 5.358670023269951e-06
is O 0 3.423870964525122e-08
an O 0 4.2301987690507303e-08
autosomal B-Disease 1 0.9892882108688354
dominant I-Disease 1 0.8937866687774658
disease I-Disease 1 0.8960453271865845
which O 0 1.1484799244954047e-07
, O 0 9.893716068631875e-09
in O 0 2.6508981676443e-09
the O 0 3.831174044677255e-09
typical O 0 1.9509825222030486e-07
pedigree O 0 2.0007557850476587e-06
, O 0 1.294974882881661e-08
shows O 0 6.607035807348893e-09
a O 0 1.921162562368295e-09
three O 0 8.159238618077325e-09
generation O 0 1.4401553016796242e-07
anticipation O 0 1.0509094749977521e-07
cascade O 0 2.524118826841004e-06
. O 0 2.9262841394483985e-07

This O 0 5.58040142095706e-07
results O 0 2.821641828631982e-06
in O 0 3.179763439220551e-07
infertility B-Disease 1 0.9856274127960205
and O 1 0.6134066581726074
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.4540288248099387e-05
CDM B-Disease 0 9.113150008488446e-05
) O 0 3.5288724831161744e-08
with O 0 2.6224040716726904e-09
the O 0 4.9932989298895336e-08
disappearance O 0 1.798463381419424e-05
of O 0 4.2073304484802065e-07
DM B-Disease 1 1.0
in O 0 4.1643386339274e-07
that O 0 6.205258529234925e-08
pedigree O 0 2.6826032808457967e-06
. O 0 3.0592494226766576e-07

The O 0 1.6187331652872672e-07
concept O 0 8.265283213404473e-08
of O 0 4.145632725993664e-09
segregation O 0 1.8442487714764866e-07
distortion O 0 2.950634188891854e-05
, O 0 1.6474539066280158e-08
where O 0 2.2440622693409296e-09
there O 0 2.000231091869864e-10
is O 0 4.879541215530026e-10
preferential O 0 1.8081840025274687e-08
transmission O 0 2.2545236788573675e-07
of O 0 4.397817388035463e-10
the O 0 8.779296734040543e-10
larger O 0 6.004242436574714e-09
allele O 0 4.711501162546483e-07
at O 0 3.33253524331667e-07
the O 0 3.204537790679751e-07
DM B-Disease 1 1.0
locus O 0 5.550961304834345e-06
, O 0 7.070251228924462e-08
has O 0 5.4836895913012995e-08
been O 0 2.2952695744038465e-08
put O 0 4.376792617222236e-08
forward O 0 2.256041398140951e-08
to O 0 1.056588949666093e-08
explain O 0 3.500055001381952e-08
partially O 0 8.719642323740118e-07
the O 0 1.280586303664677e-08
maintenance O 0 1.702922304502863e-06
of O 0 7.947114255557608e-08
DM B-Disease 1 1.0
in O 0 7.757705589028774e-08
the O 0 2.3730169829150327e-08
population O 0 7.067284713002664e-08
. O 0 1.7715836975185084e-07

In O 0 4.7508686407127243e-07
a O 0 4.1532334194016585e-07
survey O 0 4.600130978360539e-06
of O 0 6.346962777570297e-08
DM B-Disease 1 1.0
in O 0 7.687085030738672e-07
Northern O 0 8.003745506357518e-07
Ireland O 0 2.73062846645189e-06
, O 0 2.5435360484493685e-08
59 O 0 4.414697230004094e-08
pedigrees O 0 1.890762177936267e-07
were O 0 7.705678228830948e-08
ascertained O 0 2.937192675744882e-06
. O 0 3.409124644804251e-07

Sibships O 0 0.000331711838953197
where O 0 5.451126412481244e-07
the O 0 5.5010134225597085e-09
status O 0 3.137313964174382e-09
of O 0 3.552607097390137e-10
all O 0 1.6869428076660142e-09
the O 0 8.986725141824081e-09
members O 0 1.7499866444836698e-08
had O 0 2.767357329958031e-07
been O 0 1.1905044949855892e-08
identified O 0 8.839137422000931e-08
were O 0 5.877170750068217e-09
examined O 0 1.1425715484847387e-08
to O 0 4.9683488434482115e-09
determine O 0 4.460264158012706e-09
the O 0 1.4278991322669299e-09
transmission O 0 1.1895147054019617e-06
of O 0 1.2430696472165437e-09
the O 0 2.0437659031813382e-07
DM B-Disease 1 1.0
expansion O 0 6.041672691026179e-07
from O 0 2.529341891488457e-08
affected O 0 4.3788467962713185e-08
parents O 0 3.925193503562241e-09
to O 0 2.0097161712584466e-09
their O 0 4.384161655934804e-08
offspring O 0 1.0769588243420003e-06
. O 0 2.193175987486029e-07

Where O 0 1.0228717428617529e-06
the O 0 6.378807881901594e-08
transmitting O 0 0.00013399642193689942
parent O 0 3.484648550511338e-05
was O 0 9.153308724307863e-07
male O 0 6.219952553010444e-08
, O 0 9.354416796725218e-09
58 O 0 1.2067319232755835e-07
. O 0 9.912665177580493e-08

3 O 0 2.150829232050455e-06
% O 0 1.7931888862676715e-08
of O 0 4.5973361229023624e-10
the O 0 5.6336797449318965e-09
offspring O 0 9.104911100621393e-07
were O 0 2.331033073232902e-07
affected O 0 2.8532692653016056e-08
, O 0 8.249309679797534e-09
and O 0 1.175479447113048e-08
in O 0 2.5468116504612226e-09
the O 0 2.7314912554032844e-09
case O 0 1.571354957263793e-08
of O 0 3.986928009958035e-10
a O 0 4.2026705671105447e-08
female O 0 2.5324177954644256e-07
transmitting O 0 2.3763772333040833e-05
parent O 0 1.1256612424404011e-06
, O 0 1.2111681435555965e-08
68 O 0 2.1599525723559054e-07
. O 0 1.68604046280052e-07

7 O 0 2.2847858417662792e-05
% O 0 4.1048818388844666e-07
were O 0 1.7638977567457914e-07
affected O 0 3.3937942589545855e-07
. O 0 2.3765463197378267e-07

Studies O 0 2.899139190049027e-06
on O 0 3.87457788519896e-07
meiotic O 0 2.9234324756544083e-05
drive O 0 3.171581192873418e-05
in O 0 9.195540769724175e-06
DM B-Disease 1 1.0
have O 0 1.3228901707407204e-06
shown O 0 3.684384708435573e-08
increased O 0 1.1199849936360806e-08
transmission O 0 4.0000756484914746e-07
of O 0 3.070686760420216e-10
the O 0 9.190030958450279e-10
larger O 0 4.2693475421629046e-09
allele O 0 1.440373722516597e-07
at O 0 1.8829814507625997e-07
the O 0 2.0151220780917356e-07
DM B-Disease 1 0.9999998807907104
locus O 0 1.6586458286838024e-06
in O 0 3.514109181423919e-08
non O 0 1.8570881366031244e-05
- O 1 0.9071978330612183
DM O 1 1.0
heterozygotes O 0 1.9508463083184324e-05
for O 0 6.630241244920398e-08
CTGn O 0 1.891933789011091e-05
. O 0 4.880263304585242e-07

This O 0 4.401535136366874e-07
study O 0 4.844649481583474e-08
provides O 0 2.088324535520769e-08
further O 0 7.337591867440096e-09
evidence O 0 7.04818026164844e-09
that O 0 3.865370690192549e-09
the O 0 9.844964665717271e-08
DM B-Disease 1 1.0
expansion O 0 3.296657666851388e-07
tends O 0 1.635250015397105e-07
to O 0 9.540535472751799e-09
be O 0 2.2562437251849587e-08
transmitted O 0 4.2574429244268686e-06
preferentially O 0 2.140616061296896e-06
. O 0 3.581738212687924e-07

Diagnosis O 1 0.9898778796195984
of O 0 2.197607136622537e-05
hemochromatosis B-Disease 1 0.9999994039535522
. O 0 3.790226037381217e-05

If O 0 4.994061964680441e-05
untreated O 0 0.456463098526001
, O 0 1.1905693099834025e-05
hemochromatosis B-Disease 1 1.0
can O 0 0.0005220125312916934
cause O 0 8.479680400341749e-05
serious O 0 2.8644135454669595e-05
illness O 0 0.00013403870980255306
and O 0 1.4350429466958303e-07
early B-Disease 0 1.0604067028907593e-06
death I-Disease 0 1.9847996099997545e-06
, O 0 2.291337253268466e-08
but O 0 8.567166531747716e-09
the O 0 1.9440616227939245e-08
disease O 0 5.149959633854451e-06
is O 0 1.1052532222777245e-08
still O 0 7.16227575026096e-08
substantially O 0 1.2773389244102873e-06
under O 0 9.990735350129398e-08
- O 1 0.613571286201477
diagnosed O 0 0.37736889719963074
. O 0 3.2791737680781807e-07

The O 0 3.339712861816224e-07
cornerstone O 0 7.886756066000089e-07
of O 0 4.486423677008133e-09
screening O 0 5.859656226903098e-08
and O 0 2.1684678941369384e-08
case O 0 4.486269578052315e-09
detection O 0 3.9919541450217366e-08
is O 0 1.7640878757774203e-09
the O 0 1.1385897780158416e-09
measurement O 0 3.9584347177878954e-07
of O 0 4.421571553336889e-09
serum O 0 2.5416406401745917e-07
transferrin O 0 1.7740198643423355e-07
saturation O 0 4.1056210875467514e-08
and O 0 4.181575530282089e-09
the O 0 1.363093815598404e-08
serum O 0 3.7838054822714184e-07
ferritin O 0 3.0491530651488574e-06
level O 0 2.382719088700469e-07
. O 0 1.8461668105373974e-07

Once O 0 5.823139417771017e-06
the O 0 1.451878404168383e-07
diagnosis O 0 9.61951955105178e-05
is O 0 2.0739552297754926e-08
suspected O 0 4.21848199039232e-06
, O 0 1.0016857032724147e-07
physicians O 0 2.032964907527912e-08
must O 0 5.938446623332538e-09
use O 0 2.4781124707828894e-08
serum O 0 5.438114385469817e-07
ferritin O 0 5.756742666562786e-06
levels O 0 1.5333225178437715e-07
and O 0 9.25546004282296e-08
hepatic O 0 0.00034979774500243366
iron O 0 0.0004314021789468825
stores O 0 0.0013044605730101466
on O 0 1.2869220881839283e-05
liver O 0 0.0004975825431756675
biopsy O 0 0.004436045419424772
specimens O 0 1.1241674258144485e-07
to O 0 7.221618147923436e-08
assess O 0 3.0897656415618258e-06
patients O 0 2.137683310365901e-07
for O 0 4.487671068087451e-10
the O 0 1.9976471588023514e-09
presence O 0 2.4398696396588093e-08
of O 0 1.978574282190948e-08
iron B-Disease 0 0.002841343404725194
overload I-Disease 0 0.00020036219211760908
. O 0 9.722649565446773e-07

Liver O 1 0.9999366998672485
biopsy O 1 0.9997110962867737
is O 0 6.326795300992671e-07
also O 0 2.9009337154661807e-08
used O 0 2.1619921852789048e-08
to O 0 7.929320311461652e-09
establish O 0 1.89526421223718e-08
the O 0 5.68810820666954e-09
presence O 0 1.087267342825271e-08
or O 0 3.731827646902275e-08
absence O 0 8.747642610273942e-09
of O 0 3.037090801072395e-09
cirrhosis B-Disease 0 5.3340860176831484e-05
, O 0 2.808894272732232e-08
which O 0 9.788139010424857e-08
can O 0 5.916685381635034e-07
affect O 0 8.421313395956531e-06
prognosis O 0 0.00020914553897455335
and O 0 1.6605815744696883e-07
management O 0 1.8687926512939157e-06
. O 0 1.3045942637290864e-07

A O 0 2.3894847345218295e-06
DNA O 0 6.72521855449304e-06
- O 0 2.3840198991820216e-05
based O 0 4.972267220182403e-07
test O 0 1.729235954428532e-08
for O 0 5.188967033831204e-10
the O 0 1.8045998029236898e-09
HFE O 0 7.846454650461965e-07
gene O 0 6.163971733030849e-08
is O 0 1.32567856692134e-09
commercially O 0 1.750791334131918e-08
available O 0 6.759345083651169e-09
, O 0 1.868272869742782e-09
but O 0 6.798726581713765e-10
its O 0 4.8532107221888054e-09
place O 0 6.873548841213051e-08
in O 0 4.82372586319002e-09
the O 0 2.121704767432675e-08
diagnosis O 0 5.9368889196775854e-05
of O 0 6.371791272385963e-08
hemochromatosis B-Disease 1 1.0
is O 0 2.059195821857429e-06
still O 0 3.606220673191274e-07
being O 0 1.5425068511376594e-07
evaluated O 0 3.047218228857673e-07
. O 0 1.1994075066468213e-07

Currently O 0 2.832412519637728e-06
, O 0 3.0336128276076124e-08
the O 0 7.973905424840666e-10
most O 0 3.189758179811264e-10
useful O 0 1.1587278914149124e-09
role O 0 2.744808824672873e-09
for O 0 1.5797023689145817e-09
this O 0 1.2198149157427451e-09
test O 0 3.023196804008421e-09
is O 0 6.120653983643365e-10
in O 0 1.6140845604528664e-10
the O 0 9.093503172685757e-10
detection O 0 1.8348420383063058e-07
of O 0 4.199016956363266e-08
hemochromatosis B-Disease 1 1.0
in O 0 1.0355090296343405e-07
the O 0 1.1812445244174796e-08
family O 0 9.937824785311022e-08
members O 0 2.213160099628908e-09
of O 0 4.1805206518752414e-10
patients O 0 8.047186916826377e-09
with O 0 3.263072867465411e-10
a O 0 2.7468379926176567e-07
proven O 0 2.603691200420144e-06
case O 0 1.3107794849531729e-08
of O 0 7.833738657758715e-10
the O 0 1.5281241871889506e-07
disease O 0 4.4089007133152336e-05
. O 0 2.1489377388661524e-07

It O 0 6.165148533909814e-07
is O 0 3.8740672891890426e-08
crucial O 0 2.659920426140161e-07
to O 0 4.798278041562298e-06
diagnose O 1 0.9999535083770752
hemochromatosis B-Disease 1 1.0
before O 0 0.04154619202017784
hepatic B-Disease 1 0.9999964237213135
cirrhosis I-Disease 1 0.9996428489685059
develops O 0 0.00017568795010447502
because O 0 6.876984457448998e-07
phlebotomy O 0 0.00046236751950345933
therapy O 0 3.685850606416352e-05
can O 0 6.902819791321235e-07
avert O 0 0.0017620634753257036
serious O 0 0.0199599526822567
chronic O 1 0.9984650611877441
disease O 0 0.16167408227920532
and O 0 2.409059050023643e-07
can O 0 2.2406810273878364e-07
even O 0 1.5428246058490913e-07
lead O 0 9.96085987026163e-07
to O 0 7.533697754524837e-08
normal O 0 6.739104492226033e-07
life O 0 1.439094035049493e-07
expectancy O 0 4.174616776708717e-07
. O 0 1.1945760824971785e-08
. O 0 8.612438051613935e-08

Prevalence O 0 0.0002851610188372433
of O 0 3.476873544627779e-08
the O 0 1.8240209342934577e-08
I1307K O 0 1.7410362715963856e-06
APC B-Disease 0 1.901312771224184e-06
gene O 0 2.178899762839137e-07
variant O 0 7.52958101202239e-07
in O 0 1.16596030608207e-08
Israeli O 0 1.560478040119051e-07
Jews O 0 3.452034391671077e-08
of O 0 1.1728742421723837e-09
differing O 0 1.3409452215285e-08
ethnic O 0 2.7464336582738724e-08
origin O 0 4.089029559395385e-08
and O 0 5.614555220745387e-07
risk O 0 2.0248426153557375e-05
for O 0 0.003455223748460412
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.8044244118063943e-06

BACKGROUND O 0 7.982647366588935e-05
& O 0 9.79562901193276e-05
AIMS O 0 2.644176447574864e-06
Israeli O 0 3.5784333363153564e-07
Jews O 0 4.608719095244851e-08
of O 0 1.0647372983285663e-09
European O 0 2.126883487107989e-07
birth O 0 5.423410698313091e-07
, O 0 2.0302215020251424e-08
i O 0 8.941180595911646e-08
. O 0 1.8461618900289523e-09
e O 0 3.4554336281189535e-08
. O 0 2.1093604640753938e-09
, O 0 4.496909955520323e-09
Ashkenazim O 0 5.380194352255785e-07
, O 0 1.4710073159562853e-09
have O 0 1.379573788540256e-09
the O 0 1.083183818195721e-07
highest O 1 0.9976906776428223
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.00011132903455290943
of O 0 4.442942902471714e-09
any O 0 2.925705366862985e-08
Israeli O 0 3.803795152634848e-06
ethnic O 0 5.343007387637044e-07
group O 0 3.7750578485429287e-06
. O 0 2.66220979483478e-07

The O 0 6.136534125289472e-07
I1307K O 0 7.373295829893323e-06
APC B-Disease 0 5.5085884014260955e-06
gene O 0 5.27454801613203e-07
variant O 0 4.454410373000428e-06
was O 0 6.155431151455559e-07
found O 0 6.175492472948463e-08
in O 0 1.5916768347778998e-08
6 O 0 6.287763767431898e-07
. O 0 5.863619207957527e-07

1 O 0 6.449882334891299e-07
% O 0 1.1090500962041006e-08
of O 0 4.0437544979177176e-10
American O 0 4.343947868079567e-09
Jews O 0 1.9572173215465227e-08
, O 0 3.128040493294293e-09
28 O 0 4.5604484633088305e-09
% O 0 3.1401381495044234e-10
of O 0 3.6791564239635477e-10
their O 0 2.034573299170006e-05
familial O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 1.6086117966551683e-06
, O 0 1.1636520191871114e-08
but O 0 6.9166561367239865e-09
not O 0 2.8541822238992154e-09
in O 0 1.8074520768962543e-09
non O 0 1.5331997360590321e-07
- O 0 5.748091098212171e-06
Jews O 0 4.903140052192612e-06
. O 0 4.281116616766667e-07

We O 0 1.4040547284821514e-06
assessed O 0 4.195918847926805e-07
the O 0 9.087179009270585e-09
I1307K O 0 1.2234783071107813e-06
prevalence O 0 2.531102154534892e-06
in O 0 5.661222601816007e-09
Israeli O 0 1.6347649989256752e-07
Jews O 0 1.496488977181798e-08
of O 0 3.0499766601188583e-10
differing O 0 6.7693317618022775e-09
ethnic O 0 3.078465837802469e-08
origin O 0 6.92496229248718e-08
and O 0 1.0499272775632562e-06
risk O 0 3.118168388027698e-05
for O 0 0.008952472358942032
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.3309648895519786e-06

METHODS O 0 5.121811227581929e-06
DNA O 0 1.6572687400184805e-06
samples O 0 1.222552867830018e-07
from O 0 2.6146824705364224e-09
500 O 0 2.3799509030197896e-09
unrelated O 0 6.070489444454097e-09
Jews O 0 9.614995910567359e-09
of O 0 4.563909250521192e-10
European O 0 7.615308561526035e-08
or O 0 5.173762573917884e-08
non O 0 1.2468177601476782e-07
- O 0 1.0028170436271466e-06
European O 0 1.9222085256842547e-07
origin O 0 6.111371853023684e-09
, O 0 1.4006710236103004e-09
with O 0 5.922878298925127e-10
or O 0 2.1410800243870654e-08
without O 0 3.5553273658450735e-09
a O 0 9.863569516710413e-09
personal O 0 4.839431539949146e-07
and O 0 2.192487045249436e-06
/ O 0 0.001863474608398974
or O 0 6.304300086412695e-07
family O 0 7.868847973213633e-08
history O 0 4.719828083921129e-09
of O 0 5.749397846699367e-09
neoplasia B-Disease 0 3.825507883448154e-05
, O 0 7.715752303738554e-08
were O 0 1.4911124779359852e-08
examined O 0 2.515332298003159e-08
for O 0 9.117365751265538e-10
the O 0 2.3812225524721953e-09
I1307K O 0 6.579359990155353e-08
variant O 0 1.4618150601108937e-07
by O 0 6.404475838550638e-10
the O 0 3.148812099951215e-09
allele O 0 6.143279733805684e-07
- O 0 1.4192877415553085e-06
specific O 0 9.790398536324574e-08
oligonucleotide O 0 3.44274849339854e-05
( O 0 7.307106386633677e-08
ASO O 0 3.939409725717269e-05
) O 0 7.33473726199918e-09
method O 0 1.5188938107257854e-07
. O 0 2.2918669628779753e-07

RESULTS O 0 0.0001384670176776126
In O 0 1.6059361840348174e-08
persons O 0 1.0191940624793006e-08
at O 0 7.228673126746799e-08
average O 0 1.861354235188628e-06
risk O 0 4.189064202364534e-05
for O 0 0.3579012453556061
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.0547531676129438e-07
I1307K O 0 8.670147053635446e-07
was O 0 2.502207507859566e-07
found O 0 2.9707246440580093e-08
in O 0 5.847583750551166e-09
5 O 0 1.5825808930003404e-07
. O 0 4.0781185361993266e-07

0 O 0 3.3417436497984454e-06
% O 0 8.144455421188468e-08
of O 0 1.7735749535674472e-09
120 O 0 1.6751412701410118e-08
European O 0 9.95199442854755e-08
and O 0 3.897078926229369e-08
1 O 0 1.7135394614342658e-07
. O 0 3.024779005045275e-07

6 O 0 1.6998604905893444e-06
% O 0 4.3324646981091064e-08
of O 0 1.0075271728027246e-09
188 O 0 1.704980689964941e-08
non O 0 8.902909343078136e-08
- O 0 2.150593218175345e-06
European O 0 1.2588988056450034e-06
Jews O 0 2.3136340132623445e-07
( O 0 8.53617532214912e-09
P O 0 9.495744052401278e-06
= O 0 6.588690837361355e-08
0 O 0 1.295898943709517e-08
. O 0 8.496540360170002e-09
08 O 0 5.817006254460466e-08
) O 0 1.1445608016913411e-08
. O 0 8.463435818839571e-08

It O 0 9.787781891645864e-07
occurred O 0 7.820927407919953e-07
in O 0 4.132592579253469e-08
15 O 0 1.301676348930414e-07
. O 0 1.5974684686170804e-07

4 O 0 3.1885683711152524e-06
% O 0 8.903554515882206e-08
of O 0 6.4080474260208575e-09
52 O 0 3.2007136496758903e-07
Ashkenazi O 0 1.2443590094335377e-05
Israelis O 0 3.32968056682148e-06
with O 0 9.780748655430216e-08
familial O 0 0.003226346569135785
cancer B-Disease 0 0.027475927025079727
( O 0 8.645140070484558e-08
P O 0 0.0007145756389945745
= O 0 1.1657422192001832e-06
0 O 0 3.6067739017653366e-08
. O 0 1.257670412257994e-08
02 O 0 2.6742807079926934e-08
) O 0 2.0513328813365206e-09
and O 0 1.5750789117419117e-08
was O 0 4.4711305235978216e-07
not O 0 5.851444218052393e-09
detected O 0 7.487555109264576e-08
in O 0 1.2303555951831413e-09
51 O 0 4.081035598346716e-08
non O 0 1.7744929081686678e-08
- O 0 2.967140915188793e-07
European O 0 1.8915413591003016e-07
Jews O 0 4.611242587770903e-08
at O 0 6.128357910029081e-08
increased O 0 5.330761041477672e-07
cancer B-Disease 0 2.056542507489212e-05
risk O 0 4.4984264491176873e-07
. O 0 1.701206855386772e-07

Colorectal B-Disease 1 0.9997572302818298
neoplasia I-Disease 0 0.08304155617952347
occurred O 0 0.00028226515860296786
personally O 0 2.7849397156387568e-05
or O 0 2.14094569628287e-07
in O 0 7.797637202600072e-09
the O 0 2.94654789456672e-09
families O 0 1.917611180957124e-09
of O 0 4.1593642419179844e-10
13 O 0 3.59338248046015e-09
of O 0 4.817452547989376e-10
20 O 0 1.0790942361893485e-08
Ashkenazi O 0 7.367464718299743e-07
I1307K O 0 2.271031362965914e-08
carriers O 0 6.581792000304176e-09
, O 0 1.2293680518027372e-09
8 O 0 1.0294629149143475e-08
of O 0 2.429818568572273e-09
whom O 0 1.7544386992085492e-06
also O 0 9.063880384019285e-07
had O 0 8.444430363852007e-07
a O 0 8.786459204657149e-08
personal O 0 1.1397546586522367e-06
or O 0 7.544409186266421e-07
family O 0 1.0974686404097156e-07
history O 0 1.849003083975731e-08
of O 0 6.257828744082872e-08
noncolonic O 0 0.0032176263630390167
neoplasia B-Disease 0 0.0005726627423427999
. O 0 1.3092225117361522e-06

CONCLUSIONS O 0 4.1520608647260815e-05
The O 0 1.1756122120232249e-07
I1307K O 0 4.382169208838604e-06
APC O 0 6.960610335227102e-06
variant O 0 1.1043176527891774e-05
may O 0 2.6701326305555995e-07
represent O 0 3.0422042662792137e-09
a O 0 5.494889876445086e-09
susceptibility O 0 6.80178004586196e-07
gene O 0 2.546707264627912e-06
for O 0 4.586324394040275e-06
colorectal B-Disease 1 1.0
, I-Disease 0 5.165229026715679e-07
or I-Disease 0 1.2095547674562113e-07
other I-Disease 0 2.2131272814363e-08
, I-Disease 0 1.707314822851913e-07
cancers I-Disease 0 4.9610207497607917e-05
in O 0 1.9464101441712955e-08
Ashkenazi O 0 2.0343344658613205e-05
Jews O 0 2.894388160257222e-07
, O 0 1.865820387081385e-08
and O 0 2.1309595865659503e-08
partially O 0 2.6181955945503432e-06
explains O 0 1.4960986050027714e-07
the O 0 2.968791656954295e-09
higher O 0 2.144235367040892e-07
incidence O 0 0.0028966607060283422
of O 0 0.010466561652719975
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 7.257450818087818e-08
European O 0 8.354467695426138e-07
Israelis O 0 1.9055067241424695e-05
. O 0 5.154329869583307e-07

Systematic O 0 1.3015205695410259e-05
analysis O 0 5.835269689669076e-07
of O 0 3.6554755666884375e-08
coproporphyrinogen O 0 0.00010604319686535746
oxidase O 0 4.7535366320516914e-05
gene O 0 0.0005664603668265045
defects O 1 0.9550854563713074
in O 0 3.746019388017885e-07
hereditary B-Disease 1 0.9285902976989746
coproporphyria I-Disease 0 0.03884468600153923
and O 0 1.2287987374293152e-06
mutation O 0 3.166338728988194e-06
update O 0 8.622547284176107e-06
. O 0 4.509142570441327e-07

Hereditary B-Disease 1 0.9998863935470581
coproporphyria I-Disease 1 0.7409260272979736
( O 0 1.534788498247508e-05
HC B-Disease 0 0.40605828166007996
) O 0 4.799335329153109e-07
is O 0 2.887486338920553e-08
an O 0 6.092706144045223e-07
acute O 0 0.07833892852067947
hepatic B-Disease 1 0.9999958276748657
porphyria I-Disease 1 0.9999984502792358
with O 0 7.165286660892889e-06
autosomal O 1 0.9995940327644348
dominant O 0 0.14425207674503326
inheritance O 0 0.0041648754850029945
caused O 0 4.3842981540365145e-05
by O 0 4.956983445936203e-08
deficient B-Disease 0 5.4111100325826555e-05
activity I-Disease 0 1.604036015123711e-07
of I-Disease 0 1.344712785567026e-08
coproporphyrinogen I-Disease 0 0.00023448927095159888
III I-Disease 0 0.0002158024290110916
oxidase I-Disease 0 7.189044936239952e-06
( O 0 1.2446579944480618e-07
CPO O 0 0.00015423727745655924
) O 0 4.3979056840726116e-08
. O 0 1.448633781819808e-07

Clinical O 0 0.00017791995196603239
manifestations O 0 9.797739949135575e-06
of O 0 2.3601165466402563e-08
the O 0 2.3098817791833426e-07
disease O 0 0.00032147756428457797
are O 0 9.054618388404378e-09
characterized O 0 4.817829903913662e-07
by O 0 7.481103381223875e-08
acute O 0 3.61463098670356e-05
attacks O 0 4.35738438682165e-05
of O 0 1.2085672551620519e-06
neurological B-Disease 1 0.9995459914207458
dysfunction I-Disease 0 0.10882167518138885
often O 0 8.954405075201066e-07
precipitated O 0 9.7269344223605e-07
by O 0 3.983182672584462e-09
drugs O 0 1.0088259472240679e-07
, O 0 4.2976981973197326e-09
fasting O 0 3.652730242720281e-07
, O 0 3.743940624190145e-08
cyclical O 0 5.2372397476574406e-05
hormonal O 0 5.984048584650736e-06
changes O 0 2.07570440835525e-08
, O 0 1.7199335289319606e-08
or O 0 1.7586617104825564e-06
infectious B-Disease 0 4.043732405989431e-05
diseases I-Disease 0 0.0001374974672216922
. O 0 7.843402158869139e-07

Skin O 1 0.9999961853027344
photosensitivity O 1 0.999855637550354
may O 0 0.0004346344212535769
also O 0 1.8484853114841826e-07
be O 0 1.9380934190849075e-08
present O 0 5.86459805163031e-08
. O 0 1.6873948993634258e-07

The O 0 6.335000648505229e-07
seven O 0 1.0611902467871914e-07
exons O 0 1.7203917650476797e-06
, O 0 7.81929188065078e-09
the O 0 1.497099111347211e-09
exon O 0 1.6531313349332777e-06
/ O 0 3.231407390558161e-05
intron O 0 1.8163789718528278e-05
boundaries O 0 1.3132861909070925e-07
and O 0 2.2798806398327542e-08
part O 0 2.9187701144905986e-09
of O 0 4.291437760706174e-10
3 O 0 1.0645307746415256e-08
noncoding O 0 5.200931951776511e-08
sequence O 0 7.745518892932068e-09
of O 0 6.073034852782655e-10
the O 0 2.4116189933920396e-08
CPO O 0 4.170115789747797e-05
gene O 0 8.637080384232831e-08
were O 0 8.90779716655743e-09
systematically O 0 9.707824801807874e-07
analyzed O 0 7.203485807849574e-08
by O 0 5.275438419438672e-10
an O 0 1.8332944051735467e-09
exon O 0 7.128571724024368e-07
- O 0 9.602460977475857e-07
by O 0 2.5678554393948616e-08
- O 0 9.619026059226599e-06
exon O 0 5.04820272908546e-05
denaturing O 0 7.937800546642393e-05
gradient O 0 1.4517648196488153e-05
gel O 0 0.0001309473445871845
electrophoresis O 0 4.606628408510005e-06
( O 0 1.7461456280898346e-08
DGGE O 0 3.4884933484136127e-06
) O 0 2.935396370418175e-09
strategy O 0 1.976409258475087e-08
followed O 0 1.7057247836405054e-09
by O 0 9.864312144891585e-11
direct O 0 3.63843177808576e-09
sequencing O 0 1.0799099925407063e-07
in O 0 9.015447943738764e-09
seven O 0 3.863426911721035e-08
unrelated O 0 9.539155598758953e-08
heterozygous O 0 6.283513585003675e-07
HC B-Disease 0 0.0002768765843939036
patients O 0 1.079129106074106e-06
from O 0 4.271685227763555e-09
France O 0 3.0829339721094584e-06
, O 0 4.030975375712842e-08
Holland O 0 6.8732470026589e-06
, O 0 3.544725402093718e-08
and O 0 2.8119925943315138e-08
Czech O 0 2.3952891297085444e-06
Republic O 0 2.7730797569347487e-07
. O 0 2.665141209945432e-07

Seven O 0 3.118063887086464e-06
novel O 0 1.1335964700265322e-06
mutations O 0 5.478882485476788e-06
and O 0 1.4411865478791697e-08
two O 0 6.211816394596781e-09
new O 0 1.5052809487769991e-07
polymorphisms O 0 5.213947588345036e-05
were O 0 3.8500539289998414e-07
detected O 0 4.170826741756173e-06
. O 0 2.1195897659254115e-07

Among O 0 3.651929034731438e-07
these O 0 3.117428093446506e-08
mutations O 0 1.0027692951553036e-06
two O 0 2.6898680616227466e-08
are O 0 1.4048107566111412e-08
missense O 0 6.663433396170149e-06
( O 0 1.91153581852177e-08
G197W O 0 2.568414458892221e-07
, O 0 9.610008788740743e-09
W427R O 0 8.955705510516054e-08
) O 0 2.7635731481012726e-09
, O 0 1.0171505859801755e-09
two O 0 1.2591033105024962e-08
are O 0 1.919236858327622e-08
nonsense O 0 1.7321890481980518e-06
( O 0 3.475764565052941e-09
Q306X O 0 4.3252320836018043e-08
, O 0 4.004061526785563e-09
Q385X O 0 5.4946514893572385e-08
) O 0 1.941859339993357e-09
, O 0 9.683677193450535e-10
two O 0 1.543208671961338e-09
are O 0 1.676115246596055e-09
small O 0 1.1455130177751016e-08
deletions O 0 2.7031583158532158e-06
( O 0 8.616032332042778e-09
662de14bp O 0 9.348302398848318e-08
; O 0 4.3989101250474505e-09
1168del3bp O 0 1.942814691346939e-07
removing O 0 2.1920966375432727e-08
a O 0 2.5334651709840728e-08
glycine O 0 1.879521960290731e-06
at O 0 1.928668353912144e-07
position O 0 1.7392096651747124e-07
390 O 0 2.6782316808748874e-08
) O 0 2.5890949384432815e-09
, O 0 2.148065281204481e-09
and O 0 3.934870651534084e-09
one O 0 3.065655285183766e-09
is O 0 1.1307316194475447e-09
a O 0 3.111664259591862e-09
splicing O 0 2.0759277958859457e-06
mutation O 0 3.5118119967592065e-07
( O 0 4.821407717514603e-09
IVS1 O 0 5.1822348723362666e-06
- O 0 2.1875621314393356e-06
15c O 0 4.788897172147699e-07
- O 0 5.580196102528134e-06
- O 0 1.1673838343995158e-05
> O 0 2.2606856475704262e-07
g O 0 2.1733055746153696e-06
) O 0 2.204893378987549e-09
which O 0 2.4090800465614848e-09
creates O 0 3.795223246783053e-09
a O 0 3.3901494944643673e-09
new O 0 2.020093425869618e-08
acceptor O 0 2.2060540061374923e-07
splice O 0 3.293178815511055e-05
site O 0 3.45746889252041e-06
. O 0 4.4425217993193655e-07

The O 0 8.365502139895398e-07
pathological O 0 9.3172347988002e-06
significance O 0 4.869040637345279e-08
of O 0 2.74881672979177e-09
the O 0 6.62887345015406e-09
point O 0 7.747139534330927e-07
mutations O 0 6.278889372879348e-07
G197W O 0 6.339050173664873e-08
, O 0 2.0775214881751936e-09
W427R O 0 3.185651564763248e-08
, O 0 2.2671824417841435e-09
and O 0 6.64101884595425e-10
the O 0 7.259908230139445e-10
in O 0 5.513587364447403e-09
- O 0 4.855875431530876e-06
frame O 0 0.0003824792802333832
deletion O 0 1.122585581470048e-05
390delGly O 0 1.1122170917587937e-06
were O 0 1.0994921417761816e-08
assessed O 0 3.038842422142807e-08
by O 0 8.857136135631549e-10
their O 0 7.013206904105118e-09
respective O 0 1.0560047059016142e-08
expression O 0 2.1711661801759874e-08
in O 0 1.1622695028634666e-09
a O 0 3.409701188061831e-09
prokaryotic O 0 7.879868313409588e-09
system O 0 5.737665009775128e-09
using O 0 3.179350471782527e-08
site O 0 1.5332932434830582e-06
- O 0 6.199099061632296e-06
directed O 0 2.3079968514139182e-07
mutagenesis O 0 9.72055750025902e-06
. O 0 5.849460649187677e-07

These O 0 2.6217858817290107e-07
mutations O 0 9.130134458246175e-06
resulted O 0 1.2571541674333275e-07
in O 0 7.852561267895908e-09
the O 0 1.1458364035377144e-08
absence O 0 3.8422847126184934e-08
or O 0 1.3340496707314742e-08
a O 0 5.674273850786449e-08
dramatic O 0 2.0953484636265785e-06
decrease O 0 4.504218395595672e-06
of O 0 1.1810191047345597e-08
CPO O 0 0.00039446770097129047
activity O 0 4.7660753921263677e-07
. O 0 1.7893627557441505e-07

The O 0 3.056374282550678e-07
two O 0 4.9732530982282697e-08
polymorphisms O 0 9.120613867708016e-06
were O 0 7.484214847863768e-08
localized O 0 4.737240999475034e-07
in O 0 1.4748737342529239e-08
noncoding O 0 1.1542801985342521e-06
part O 0 2.3097314283404558e-08
of O 0 2.2074758687651297e-10
the O 0 1.1343520567308474e-09
gene O 0 2.9139100021779996e-08
1 O 0 6.167791610778295e-09
) O 0 1.018330753055352e-09
a O 0 1.836406404720492e-08
C O 0 5.08100310980808e-06
/ O 0 7.46447858546162e-06
G O 0 9.166576091956813e-06
polymorphism O 0 5.4924505832332216e-08
in O 0 2.5836093264786086e-09
the O 0 6.109914796326166e-09
promotor O 0 9.866742402664386e-06
region O 0 5.296818699207506e-07
, O 0 1.165335650199495e-08
142 O 0 3.2168401276067016e-08
bp O 0 3.7334764328988967e-06
upstream O 0 1.1698635660195578e-07
from O 0 8.866196665735515e-10
the O 0 3.4384681213417423e-10
transcriptional O 0 1.3198813597625758e-08
initiation O 0 3.4237448431895245e-09
site O 0 1.6782249190328002e-07
( O 0 9.210531892733798e-09
- O 0 1.3526971542887622e-06
142C O 0 1.2101587572033168e-06
/ O 0 2.831356823662645e-06
G O 0 4.672051090892637e-06
) O 0 2.2029933433032056e-09
, O 0 2.0949222356847486e-09
and O 0 4.2442431791300805e-09
2 O 0 1.9636189563243533e-08
) O 0 1.1750080908257132e-09
a O 0 1.1729062165954929e-08
6 O 0 9.910037590543652e-08
bp O 0 1.7460264643887058e-05
deletion O 0 1.4519282842684333e-07
polymorphism O 0 3.9520440253681954e-08
in O 0 2.6591069346437735e-09
the O 0 7.903033782952207e-09
3 O 0 4.4449283365111114e-08
noncoding O 0 8.542628648910977e-08
part O 0 3.856217567488329e-09
of O 0 6.092246707112281e-10
the O 0 1.4491250865944494e-08
CPO O 0 4.934880053042434e-05
gene O 0 9.799907729757251e-08
, O 0 3.5608309634227453e-09
574 O 0 4.4144954358671384e-08
bp O 0 4.578903372021159e-06
downstream O 0 1.641764555415648e-07
of O 0 5.168391825627339e-10
the O 0 3.0393045857834977e-09
last O 0 2.5777220002964896e-07
base O 0 7.3346533291385185e-09
of O 0 1.7395321294522148e-10
the O 0 2.882708294293934e-09
normal O 0 1.825272732958183e-07
termination O 0 7.152433312285211e-08
codon O 0 1.7359715798193065e-07
( O 0 7.694102244215628e-09
+ O 0 2.564307806096622e-07
574 O 0 2.2957651424349024e-07
delATTCTT O 0 1.6264685882561025e-06
) O 0 3.326089270672128e-08
. O 0 1.1647294684280496e-07

Five O 0 3.2825009839143604e-06
intragenic O 0 7.075994653860107e-05
dimorphisms O 0 8.230120147345588e-05
are O 0 8.112703397955556e-08
now O 0 4.349844928697166e-08
well O 0 1.0284463058951587e-08
characterized O 0 1.2229003232278046e-07
and O 0 1.950327011002173e-08
the O 0 2.2894488527214207e-09
high O 0 5.4458222820130686e-08
degree O 0 1.254362036462453e-08
of O 0 1.47246692616676e-09
allelic O 0 4.216810509660718e-07
heterogeneity O 0 1.2966625035915058e-06
in O 0 1.1670999811030924e-07
HC B-Disease 0 0.0022265934385359287
is O 0 4.382197360541795e-08
demonstrated O 0 5.612358577877785e-09
with O 0 1.8323600969871734e-10
seven O 0 1.7903104554406468e-09
new O 0 1.5481498305547348e-09
different O 0 5.804531855169159e-10
mutations O 0 3.046305252496495e-08
making O 0 2.1138431005596203e-09
a O 0 3.881432064645196e-09
total O 0 5.958460835842061e-09
of O 0 2.8432283194490537e-09
nineteen O 0 1.5846785572648514e-06
CPO O 0 0.05143364146351814
gene B-Disease 0 0.0001863818906713277
defects I-Disease 1 0.9719521403312683
reported O 0 1.179819355456857e-05
so O 0 2.0269014910923033e-08
far O 0 2.2439349933733865e-08
. O 0 2.365587725705609e-08
. O 0 1.4405193837774277e-07

Coincidence O 0 1.1440387424954679e-05
of O 0 2.430691381505312e-08
two O 0 2.2644954356110247e-08
novel O 0 1.3967265033443255e-07
arylsulfatase O 0 5.148884611116955e-06
A O 0 1.4010517190854443e-07
alleles O 0 1.2909555380247184e-07
and O 0 2.379775132510531e-08
mutation O 0 2.489425980911619e-07
459 O 0 1.4805650039306784e-07
+ O 0 1.5555375512121827e-06
1G O 0 2.788835990941152e-05
> O 0 6.652802397866253e-08
A O 0 4.435113254430689e-08
within O 0 3.0037579090702593e-09
a O 0 1.1069941763253155e-07
family O 0 5.644938596560678e-07
with O 0 1.7296897567575797e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 0.9999996423721313
: O 0 1.8607275720228245e-08
molecular O 0 4.929978913992272e-08
basis O 0 2.837173163072748e-08
of O 0 1.2910805757826438e-08
phenotypic O 0 1.2089800293324515e-05
heterogeneity O 0 6.0926471633138135e-05
. O 0 1.9247597720095655e-06

In O 0 1.0516921520320466e-06
a O 0 8.246529148436821e-08
family O 0 6.216204440079309e-08
with O 0 1.4236031020686823e-08
three O 0 2.1844797970516083e-07
siblings O 0 8.419077062171709e-07
, O 0 1.2500955826055815e-09
one O 0 1.380439873521766e-09
developed O 0 3.895072353543583e-08
classical O 0 2.201327475859216e-07
late O 0 6.963124906178564e-05
infantile O 1 0.9990348815917969
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 5.3754218242829666e-05
MLD B-Disease 1 0.9999990463256836
) O 0 1.2959316109117935e-07
, O 0 2.517165675897104e-08
fatal O 0 1.4713058590132277e-05
at O 0 7.131977781682508e-07
age O 0 2.1147556594769412e-08
5 O 0 2.1441449504777665e-08
years O 0 6.644810923717159e-09
, O 0 1.2048588793334147e-09
with O 0 1.6623461718268118e-08
deficient O 0 3.558952812454663e-05
arylsulfatase O 0 1.0514339919609483e-05
A O 0 1.4291471188698779e-06
( O 0 8.34422948514657e-08
ARSA O 0 8.706254448043182e-05
) O 0 6.077197411968882e-09
activity O 0 1.2121711634449639e-08
and O 0 1.882815681142347e-08
increased O 0 1.6405608960212703e-07
galactosylsulfatide O 0 0.00010429385292809457
( O 0 4.1349113644173485e-07
GS O 1 0.9999970197677612
) O 0 1.6037515138123126e-07
excretion O 0 8.961068829194119e-07
. O 0 1.31233974798306e-07

The O 0 3.243715980261186e-07
two O 0 7.521320810610632e-08
other O 0 1.5436599554163877e-08
siblings O 0 8.853359645399905e-07
, O 0 1.9516702920441276e-08
apparently O 0 1.8936134438263252e-07
healthy O 0 4.3747562017415476e-08
at O 0 2.629848694368775e-08
12 O 0 1.617423883715219e-08
( O 0 1.6153636206439614e-09
1 O 0 3.694095696005206e-08
/ O 0 2.4979472073027864e-06
2 O 0 1.0083912371783299e-07
) O 0 3.26602589417746e-09
and O 0 2.024289891267017e-08
15 O 0 2.7866631668871378e-08
years O 0 7.939399360168409e-09
, O 0 6.5529817128151535e-09
respectively O 0 5.425387783475344e-08
, O 0 2.5279034421288316e-09
and O 0 4.2688590440320695e-09
their O 0 3.7681047615478747e-08
father O 0 2.704416885990213e-07
, O 0 1.0831318064674633e-08
apparently O 0 1.017636535038946e-07
healthy O 0 8.117606142832301e-09
as O 0 1.6208232533898581e-09
well O 0 7.484510788913212e-09
, O 0 8.36009306226515e-09
presented O 0 1.0902310521032632e-07
ARSA O 0 0.00015056323900353163
and O 0 1.173131977338926e-06
GS O 1 0.9999972581863403
values O 0 3.810871618270539e-08
within O 0 7.898342535561653e-10
the O 0 2.5807331827110147e-09
range O 0 1.7812111252624163e-07
of O 0 1.5263516672803235e-07
MLD B-Disease 1 0.999998927116394
patients O 0 2.0213641619193368e-05
. O 0 2.6403236574878974e-07

Mutation O 0 1.757619065756444e-05
screening O 0 1.56610758494935e-06
and O 0 5.504406530576489e-08
sequence O 0 7.914289312793699e-08
analysis O 0 1.3187595016006526e-07
disclosed O 0 5.704191153199645e-06
the O 0 1.0208905720787698e-08
involvement O 0 2.0230238817475765e-08
of O 0 3.1932950728119636e-10
three O 0 3.647770530079697e-09
different O 0 1.1668213062421273e-08
ARSA O 0 0.0002509521727915853
mutations O 0 1.0975749091812759e-06
being O 0 8.574947862882709e-09
the O 0 8.441630727773486e-10
molecular O 0 2.7431040550141006e-08
basis O 0 3.172263518536056e-08
of O 0 1.0678026463040169e-08
intrafamilial O 0 6.17474433965981e-05
phenotypic O 0 7.499269941035891e-06
heterogeneity O 0 1.625791446713265e-05
. O 0 7.043902314762818e-07

The O 0 7.076092174429505e-07
late O 0 9.146841875917744e-06
infantile O 0 0.10301685333251953
patient O 0 0.0003425425093155354
inherited O 0 0.000139859679620713
from O 0 3.831165713563678e-07
his O 0 1.3369608495850116e-06
mother O 0 1.5838445506233256e-06
the O 0 2.24754059807708e-09
frequent O 0 9.312957161000668e-08
0 O 0 1.1667105326296223e-07
- O 0 3.7499048630706966e-06
type O 0 1.0753701644716784e-06
mutation O 0 8.118428240777575e-07
459 O 0 9.37058075578534e-08
+ O 0 2.812165007526346e-07
1G O 0 3.7283634810592048e-06
> O 0 3.2668122429413415e-08
A O 0 2.923235342677799e-07
, O 0 1.9692825148354132e-08
and O 0 4.047763013659278e-08
from O 0 9.567286518574747e-09
his O 0 1.950130439354325e-07
father O 0 2.0513736842531216e-07
a O 0 2.1105407199684123e-08
novel O 0 8.185194388943273e-08
, O 0 2.923093544993094e-09
single O 0 2.8399615104035547e-08
basepair O 0 1.5369957964139758e-06
microdeletion O 0 1.7847411015736725e-07
of O 0 3.5200223291731447e-10
guanine O 0 8.79995543101586e-09
at O 0 2.2312669489821246e-09
nucleotide O 0 2.6184370227610998e-08
7 O 0 1.6020662130245e-08
in O 0 1.4063569198086157e-09
exon O 0 4.633093624306639e-07
1 O 0 1.5624540594671998e-07
( O 0 1.2454102638059794e-08
7delG O 0 8.979101266959333e-07
) O 0 3.636435152998274e-08
. O 0 1.467595183157755e-07

The O 0 6.059398742763733e-07
two O 0 5.384757741921931e-07
clinically O 0 0.0007010564440861344
unaffected O 0 1.0704346095735673e-05
siblings O 0 8.910790256777545e-07
carried O 0 1.0729539923204356e-07
the O 0 1.416193384784492e-08
maternal O 0 8.197300758183701e-07
mutation O 0 7.182392209870159e-07
459 O 0 2.0036779346810363e-07
+ O 0 1.3192052392696496e-06
1G O 0 2.7690319257089868e-05
> O 0 2.0481483886669594e-07
A O 0 4.298368594390922e-07
and O 0 1.0471978839632357e-07
, O 0 9.471274431405163e-09
on O 0 8.215522484533722e-08
their O 0 2.803600729350819e-08
paternal O 0 1.5854328694331343e-07
allele O 0 2.9637527632075944e-07
, O 0 1.9236521264787143e-09
a O 0 2.4140061061217466e-09
novel O 0 1.8550434077724276e-08
cytosine O 0 8.523749528421831e-08
to O 0 4.409982601316642e-09
thymidine O 0 7.064959390845615e-07
transition O 0 6.739419688983617e-08
at O 0 1.3114696884031218e-08
nucleotide O 0 1.0139534367681335e-07
2435 O 0 3.617398078858969e-07
in O 0 5.697457172715303e-09
exon O 0 3.551602105744678e-07
8 O 0 5.6424465100235466e-08
, O 0 1.2067999932696694e-09
resulting O 0 1.1244729591908253e-09
in O 0 2.0576330916899366e-10
substitution O 0 3.0452229626831695e-09
of O 0 1.6644742251159528e-09
alanine O 0 8.750466804485768e-06
464 O 0 4.5180357233221e-07
by O 0 9.28636936237126e-08
valine O 0 0.00214936351403594
( O 0 1.1277280975718895e-07
A464V O 0 1.9784363303188e-06
) O 0 7.566905679823321e-08
. O 0 1.8784865574161813e-07

The O 0 1.4511422250507167e-06
fathers O 0 5.582335234066704e-06
genotype O 0 2.2104853997007012e-05
thus O 0 3.646388506695075e-07
was O 0 8.298248417304421e-07
7delG O 0 2.583754940133076e-05
/ O 0 6.648647831752896e-05
A464V O 0 1.2014802450721618e-05
. O 0 8.351678957296826e-07

Mutation O 0 0.0001467008696636185
A464V O 0 3.0433018764597364e-05
was O 0 2.8102906526328297e-06
not O 0 8.926267724973513e-09
found O 0 1.022515849768979e-08
in O 0 7.764897169693086e-09
18 O 0 3.523711313846434e-07
unrelated O 0 7.858146091166418e-06
MLD B-Disease 1 0.9999998807907104
patients O 0 6.237656634766608e-05
and O 0 1.9329213785113097e-08
50 O 0 4.4046295499811094e-08
controls O 0 1.4618384739151224e-05
. O 0 1.1183625474586734e-06

A464V O 0 7.768382783979177e-05
, O 0 3.0614762636105297e-07
although O 0 3.033468232160885e-08
clearly O 0 9.624559282883638e-08
modifying O 0 7.77524292061571e-07
ARSA O 0 0.001112257014028728
and O 0 9.550481991027482e-06
GS O 1 0.9999998807907104
levels O 0 4.3657387323037256e-06
, O 0 1.0337424249939886e-08
apparently O 0 4.6715111778894425e-08
bears O 0 2.168190782469992e-08
little O 0 2.1482824408280976e-09
significance O 0 4.2206789174770165e-09
for O 0 1.0569517705505405e-08
clinical O 0 1.2814932404126012e-07
manifestation O 0 3.050602686016646e-07
of O 0 1.0970122588105369e-07
MLD B-Disease 1 0.9999994039535522
, O 0 1.3065739778994612e-07
mimicking O 0 3.776105586439371e-06
the O 0 6.292911081118291e-08
frequent O 0 1.2653029443754349e-05
ARSA O 0 0.013693244196474552
pseudodeficiency O 0 0.00017322243365924805
allele O 0 3.543202910805121e-05
. O 0 1.092005732061807e-06

Our O 0 1.0523268429096788e-05
results O 0 2.908329861384118e-06
demonstrate O 0 4.6457696356583256e-08
that O 0 7.110288469114323e-10
in O 0 5.5786086861076e-10
certain O 0 3.4359655121107835e-09
genetic O 0 4.459842784854118e-06
conditions O 0 3.064305201405659e-05
MLD B-Disease 1 0.9999997615814209
- O 0 0.0006248608697205782
like O 0 8.774815682954795e-07
ARSA O 0 0.005501770414412022
and O 0 4.477237325772876e-06
GS O 1 0.9999980926513672
values O 0 1.7932886464677722e-07
need O 0 4.351543569924843e-09
not O 0 1.1469618588222374e-09
be O 0 7.422297221282292e-10
paralleled O 0 1.1590914539283403e-07
by O 0 1.594797893744726e-08
clinical O 0 2.240513140350231e-06
disease O 0 8.11022528068861e-06
, O 0 1.8745123231411753e-09
a O 0 1.245441172414985e-08
finding O 0 2.552269329214596e-08
with O 0 3.198973885787382e-08
serious O 0 1.6990260292004677e-06
diagnostic O 0 1.434182468074141e-05
and O 0 2.2861256354644865e-07
prognostic O 0 0.0003373993095010519
implications O 0 6.706677595502697e-06
. O 0 1.2044606592098717e-06

Moreover O 0 1.8526819985709153e-05
, O 0 2.1994345900111512e-07
further O 0 1.9594180855619925e-07
ARSA O 0 0.0004361447936389595
alleles O 0 1.720992372611363e-06
functionally O 0 2.0483878415689105e-06
similar O 0 3.6270215275635564e-08
to O 0 3.2723125542588605e-08
A464V O 0 1.0792670082082623e-06
might O 0 1.2403353366607917e-07
exist O 0 1.7781282224405004e-08
which O 0 7.534498358552355e-09
, O 0 1.8888468567013206e-09
together O 0 1.5183679868968625e-09
with O 0 1.4430286965350092e-09
0 O 0 8.531947059964295e-08
- O 0 6.98837220625137e-06
type O 0 4.9050950110540725e-06
mutations O 0 2.9883936804253608e-05
, O 0 9.874565876089036e-08
may O 0 1.3694361769012176e-06
cause O 0 2.81122623846386e-07
pathological O 0 1.6596459317952394e-05
ARSA O 0 0.01615985482931137
and O 0 1.2382129170873668e-05
GS O 1 1.0
levels O 0 1.6064531109805102e-06
, O 0 5.717466056154308e-09
but O 0 4.454177027213291e-09
not O 0 9.019712976510164e-09
clinical O 0 1.7637390214986226e-08
outbreak O 0 9.057709249304935e-09
of O 0 5.16512999038099e-10
the O 0 1.3669814791228418e-07
disease O 0 2.6594168957672082e-05
. O 0 2.3927192671635567e-08
. O 0 2.0111288279167638e-07

Human O 0 0.0006180203054100275
MLH1 O 1 0.9978805780410767
deficiency O 1 0.9874544143676758
predisposes O 0 0.0001734442193992436
to O 0 3.648138545031543e-06
hematological B-Disease 1 0.6181387901306152
malignancy I-Disease 1 0.8420865535736084
and O 0 8.106590939860325e-06
neurofibromatosis B-Disease 0 0.057119082659482956
type I-Disease 0 3.628517333709169e-06
1 I-Disease 0 1.6652043086651247e-06
. O 0 5.878462161490461e-07

Heterozygous O 0 0.0008364114910364151
germ O 0 0.008510824292898178
- O 0 0.0007651472114957869
line O 0 9.292076720157638e-05
mutations O 0 4.970103873347398e-06
in O 0 3.5972365086678337e-09
the O 0 5.7866937908102045e-09
DNA O 0 6.564464001712622e-06
mismatch O 0 1.2433246411092114e-05
repair O 0 2.2902528144186363e-05
genes O 0 1.1768601098083309e-06
lead O 0 3.900830506609054e-06
to O 0 1.4918863598722965e-05
hereditary B-Disease 1 0.9999984502792358
nonpolyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.785213604918681e-06

The O 0 5.644949851557612e-06
disease O 0 0.00039336795452982187
susceptibility O 0 9.344776117359288e-06
of O 0 2.0375688691842697e-08
individuals O 0 8.841026044592581e-08
who O 0 6.142925940366695e-06
constitutionally O 0 9.465159564570058e-06
lack O 0 1.2371782709408308e-08
both O 0 2.2490243001271892e-09
wild O 0 9.054863170376848e-08
- O 0 2.3603975932928734e-05
type O 0 2.79117170975951e-06
alleles O 0 3.7445158795890165e-07
is O 0 4.315458923542792e-08
unknown O 0 5.704125101146929e-07
. O 0 3.9267760598704626e-07

We O 0 6.066399237170117e-06
have O 0 2.5952964222142327e-08
identified O 0 2.4522284647332526e-08
three O 0 4.592728419794412e-09
offspring O 0 8.115875971270725e-08
in O 0 8.93406859603374e-09
a O 0 6.648833277722588e-06
hereditary B-Disease 1 0.9999992847442627
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 9.693109859654214e-06
who O 0 1.3396896747508436e-06
developed O 0 5.737634864999563e-07
hematological B-Disease 0 0.0006607563118450344
malignancy I-Disease 0 0.00016800461162347347
at O 0 3.464105589046085e-07
a O 0 4.1516088344906166e-08
very O 0 2.1502307490095518e-08
early O 0 1.3463994719131733e-07
age O 0 2.7325503637598558e-08
, O 0 8.346836999351126e-09
and O 0 1.739394583921694e-08
at O 0 5.514337075851472e-08
least O 0 1.221544865259716e-09
two O 0 7.507468535727924e-10
of O 0 2.9653943189877907e-10
them O 0 2.2520334486131333e-09
displayed O 0 1.0878900269517544e-07
signs O 0 1.5427393407208e-07
of O 0 5.530787383634106e-09
neurofibromatosis B-Disease 0 0.00045770080760121346
type I-Disease 0 1.4557039094142965e-06
1 I-Disease 0 9.868631423159968e-07
( O 0 1.3762321771082497e-07
NF1 B-Disease 0 2.736302667472046e-05
) O 0 6.359297799463093e-08
. O 0 2.671513072982634e-07

DNA O 0 4.311647444410482e-06
sequence O 0 2.5514569301776646e-07
analysis O 0 3.048292995799784e-08
and O 0 7.926235667810033e-09
allele O 0 2.6360515903434134e-07
- O 0 1.2105950872864923e-06
specific O 0 2.334133419878981e-08
amplification O 0 2.4105756324388494e-07
in O 0 4.407821219132302e-09
two O 0 2.1953937334728835e-08
siblings O 0 8.964838116298779e-07
revealed O 0 9.469704309594817e-07
a O 0 7.483701125465814e-08
homozygous O 0 3.746444917851477e-06
MLH1 O 0 9.477778075961396e-05
mutation O 0 1.919444002851378e-06
( O 0 1.0876282097171952e-08
C676T O 0 7.995056421350455e-07
- O 0 1.9043187421630137e-05
- O 0 0.00010265164019074291
> O 0 2.006373279073159e-06
Arg226Stop O 0 1.8587077647680417e-05
) O 0 6.430480681274275e-08
. O 0 1.5530962116372393e-07

Thus O 0 2.5142494450847153e-06
, O 0 3.8097162757821934e-08
a O 0 5.910899147920645e-08
homozygous O 0 3.4494987630750984e-06
germ O 0 0.00023708830121904612
- O 0 0.00013745947217103094
line O 0 0.000482043280499056
MLH1 O 0 0.0008280759793706238
mutation O 0 7.53919039198081e-06
and O 0 9.588114835423767e-08
consequent O 0 1.924224488902837e-05
mismatch O 0 0.03290068358182907
repair O 1 0.9998064637184143
deficiency O 1 0.9880601763725281
results O 0 2.804534005917958e-06
in O 0 7.190346540397741e-09
a O 0 5.637272124658921e-07
mutator O 0 0.008011849597096443
phenotype O 0 0.00017778428446035832
characterized O 0 9.646296348364558e-07
by O 0 9.725202687604906e-08
leukemia B-Disease 0 0.05939329043030739
and O 0 6.833021416241536e-06
/ O 1 0.9997758269309998
or O 1 0.9798097610473633
lymphoma B-Disease 1 1.0
associated O 0 9.37251479626866e-06
with O 0 6.333780788736476e-08
neurofibromatosis B-Disease 0 0.22902047634124756
type I-Disease 0 1.3240451153251342e-06
1 I-Disease 0 1.5999353308870923e-07
. O 0 3.4697123396654206e-08
. O 0 1.874460195949723e-07

Missense O 0 0.002140833530575037
mutations O 0 0.0006274244515225291
in O 0 5.5205880755693215e-08
the O 0 3.5034064538308485e-09
most O 0 1.095232127212853e-09
ancient O 0 3.231665601788336e-09
residues O 0 2.74520118637156e-07
of O 0 7.404113433473469e-10
the O 0 4.789401319982289e-09
PAX6 O 0 1.1246685971855186e-05
paired O 0 4.481025541736017e-07
domain O 0 2.8050376954524836e-07
underlie O 0 1.5826473145352793e-06
a O 0 4.66877665417087e-08
spectrum O 0 6.666018634859938e-07
of O 0 7.997155648808985e-08
human O 0 0.001859823940321803
congenital B-Disease 1 1.0
eye I-Disease 1 0.9999983310699463
malformations I-Disease 1 0.9999915361404419
. O 0 1.4300852853921242e-05

Mutations O 0 0.00023972298367880285
of O 0 4.876085313298972e-08
the O 0 4.710252454742658e-08
human O 0 3.099026741892885e-07
PAX6 O 0 0.00098911311943084
gene O 0 0.0010528899729251862
underlie O 1 0.6604545712471008
aniridia B-Disease 1 1.0
( O 0 0.00028772014775313437
congenital B-Disease 1 0.9999984502792358
absence I-Disease 0 1.646318992243323e-06
of I-Disease 0 5.0409609819723755e-09
the I-Disease 0 2.2951346068111889e-07
iris I-Disease 0 0.46741488575935364
) O 0 8.127634032462083e-08
, O 0 2.1647392767221163e-09
a O 0 1.8380255539796053e-08
rare O 0 4.4843943669548025e-07
dominant O 0 0.01246070209890604
malformation B-Disease 1 0.6984272003173828
of I-Disease 0 1.6667845770257372e-08
the I-Disease 0 4.487872331537801e-07
eye I-Disease 0 0.34486597776412964
. O 0 3.5537434541765833e-06

The O 0 3.5301320622238563e-07
spectrum O 0 7.362667133747891e-07
of O 0 2.3312148655918463e-08
PAX6 O 0 9.075149137061089e-05
mutations O 0 9.229835995938629e-05
in O 0 3.4916877211799147e-07
aniridia B-Disease 1 1.0
patients O 0 3.9652499253861606e-05
is O 0 8.490482095169227e-09
highly O 0 2.505898955007524e-08
biased O 0 2.2633548724115826e-06
, O 0 3.856769126286963e-09
with O 0 3.425284778035831e-10
92 O 0 9.210882723209579e-09
% O 0 7.69859009874807e-10
of O 0 1.613087441398875e-10
all O 0 1.0349399559572703e-08
reported O 0 2.9600363632198423e-05
mutations O 0 1.5186764130703523e-06
leading O 0 2.425125558147556e-07
to O 0 1.8798917267304205e-07
premature O 0 7.927763476800465e-07
truncation O 0 3.953469729367498e-07
of O 0 1.343573807766063e-09
the O 0 1.0041166120799971e-08
protein O 0 9.342666089651175e-07
( O 0 1.5324799207405704e-08
nonsense O 0 2.8474991609073186e-07
, O 0 8.277171170689712e-10
splicing O 0 9.219868246646001e-08
, O 0 2.377909202877504e-09
insertions O 0 5.464248786779535e-08
and O 0 4.210420812000848e-08
deletions O 0 3.548690301613533e-07
) O 0 1.0257466875884802e-08
and O 0 2.3467398690968366e-08
just O 0 2.8392847184477432e-08
2 O 0 2.652983432938072e-08
% O 0 8.676716567457277e-10
leading O 0 2.7529145629756613e-09
to O 0 3.4006522597884725e-10
substitution O 0 8.66586746806064e-10
of O 0 1.0382962545296692e-10
one O 0 2.5564919070575343e-09
amino O 0 2.637836260532822e-08
acid O 0 3.567202355725385e-08
by O 0 9.080018958940173e-10
another O 0 1.5092446403741633e-08
( O 0 1.705019769815408e-08
missense O 0 1.909934098875965e-06
) O 0 4.065264747055153e-08
. O 0 2.512147148081567e-07

The O 0 6.762442126273527e-07
extraordinary O 0 1.278791472714147e-07
conservation O 0 1.1881317263373603e-08
of O 0 1.0720938581343376e-09
the O 0 3.0439051279529394e-09
PAX6 O 0 1.198446284433885e-06
protein O 0 7.63558389849095e-08
at O 0 6.3014602424971145e-09
the O 0 1.1639200714341769e-09
amino O 0 4.387507956948866e-08
acid O 0 1.6043480854932568e-07
level O 0 4.518041940571038e-09
amongst O 0 2.716185720785802e-09
vertebrates O 0 3.007589199910399e-08
predicts O 0 1.5599439393554348e-06
that O 0 6.133103358507697e-09
pathological O 0 8.939133522289922e-07
missense O 0 1.3565400877268985e-05
mutations O 0 1.2384467481751926e-05
should O 0 4.881035309267645e-08
in O 0 3.972810969088414e-09
fact O 0 9.861311767167535e-09
be O 0 1.379250935684695e-08
common O 0 1.7587536760288458e-08
even O 0 2.864742754127292e-08
though O 0 2.0512596066168953e-08
they O 0 6.332244062434711e-09
are O 0 8.965269082672478e-10
hardly O 0 2.060667192438359e-08
ever O 0 1.3460035752643762e-08
seen O 0 2.0292077351768967e-07
in O 0 9.75457297158755e-08
aniridia B-Disease 1 0.9999998807907104
patients O 0 4.1658895497675985e-06
. O 0 9.855843785544494e-08

This O 0 3.0134177109175653e-07
indicates O 0 2.454573575505492e-07
that O 0 5.191117313785298e-09
there O 0 1.9868782175080923e-09
is O 0 2.255713393850556e-09
a O 0 4.6715467050262305e-08
heavy O 0 3.530847607180476e-05
ascertainment O 0 4.4833108404418454e-05
bias O 0 1.9501505903463112e-06
in O 0 1.487943990241547e-09
the O 0 1.0812796213954812e-09
selection O 0 4.882187543131522e-09
of O 0 1.1847050007673943e-09
patients O 0 2.2433873425597994e-08
for O 0 1.5228635019681747e-09
PAX6 O 0 3.2352556900150375e-06
mutation O 0 8.284450245810149e-07
analysis O 0 4.160058608704276e-08
and O 0 1.0034043818052396e-08
that O 0 2.8333808632652335e-09
the O 0 1.0153367924203849e-08
missing O 0 1.3351464076549746e-06
PAX6 O 0 0.0001458820333937183
missense O 0 0.0001416652085026726
mutations O 0 4.362873005447909e-05
frequently O 0 1.909821321532945e-06
may O 0 2.9308607736311387e-06
underlie O 0 1.1358928531990387e-05
phenotypes O 0 1.1675174391712062e-05
distinct O 0 9.971029157895828e-07
from O 0 3.475939251984528e-07
textbook O 0 0.00016404180496465415
aniridia B-Disease 1 0.9999994039535522
. O 0 4.88757495986647e-06

Here O 0 1.4296597328211647e-06
we O 0 1.0180034593076925e-07
present O 0 8.559375430650107e-09
four O 0 6.054809986721921e-09
novel O 0 1.3154823363947798e-07
PAX6 O 0 3.729498712345958e-05
missense O 0 4.812920815311372e-05
mutations O 0 2.3185000827652402e-05
, O 0 1.9641545279114325e-08
two O 0 9.505987108582303e-09
in O 0 1.3869328796545233e-08
association O 0 4.216084370511908e-09
with O 0 2.669723109249844e-09
atypical O 0 2.9978157272125827e-06
phenotypes O 0 4.685276053351117e-06
ectopia B-Disease 0 0.00014364630624186248
pupillae I-Disease 0 0.0002744779922068119
( O 0 6.875594493749304e-08
displaced B-Disease 0 2.704339578940562e-07
pupils I-Disease 0 5.925527943873021e-07
) O 0 2.8305689170338155e-07
and O 0 7.475350139429793e-05
congenital B-Disease 1 0.9999994039535522
nystagmus I-Disease 0 0.057993143796920776
( O 0 1.2733626419958455e-07
searching B-Disease 0 1.5090770375536522e-06
gaze I-Disease 0 0.00014123656728770584
) O 0 4.994880242747968e-08
, O 0 2.4285037980575908e-08
and O 0 2.0970341907400325e-08
two O 0 2.3018150940856685e-08
in O 0 2.0916653298286292e-08
association O 0 1.8526805645180389e-09
with O 0 5.780336764793503e-10
more O 0 1.1588059400935435e-08
recognizable O 0 0.00013638507516589016
aniridia B-Disease 1 0.9999939203262329
phenotypes O 0 5.2253762987675145e-05
. O 0 5.139456789038377e-07

Strikingly O 0 0.00015502610767725855
, O 0 3.29037590063308e-07
all O 0 3.150049554534462e-09
four O 0 9.07389452464713e-09
mutations O 0 2.186393146530463e-07
are O 0 1.0875736977666861e-09
located O 0 1.21509700079514e-08
within O 0 2.4729738257178724e-09
the O 0 9.021158042799016e-09
PAX6 O 0 3.110532134087407e-06
paired O 0 1.3930788611560274e-07
domain O 0 3.820966298917483e-08
and O 0 1.6705241634440426e-08
affect O 0 1.4108283430402935e-08
amino O 0 2.186355274602647e-08
acids O 0 4.883736082206269e-08
which O 0 2.7691713366806425e-09
are O 0 1.906887148184211e-10
highly O 0 1.4143192172966224e-09
conserved O 0 8.614406077356307e-09
in O 0 1.9968089404187594e-09
all O 0 8.806600448885149e-10
known O 0 1.0088505142391568e-08
paired O 0 9.285997037977722e-08
domain O 0 9.96762850036248e-08
proteins O 0 1.2301384799684456e-07
. O 0 2.3821192485229403e-07

Our O 0 6.406390639313031e-06
results O 0 7.157195227591728e-07
support O 0 1.883845524019989e-09
the O 0 1.9331969358660217e-09
hypothesis O 0 1.9931267303263667e-08
that O 0 6.332276369924728e-10
the O 0 6.476448266568013e-10
under O 0 1.343830158262449e-09
- O 0 1.1814859846026593e-07
representation O 0 3.16180717163661e-08
of O 0 6.791096573977029e-09
missense O 0 3.318592644063756e-05
mutations O 0 1.5081624042068142e-05
is O 0 3.449790142440179e-08
caused O 0 9.559902025557676e-08
by O 0 8.832696352101266e-09
ascertainment O 0 2.539984961913433e-05
bias O 0 1.3533910532714799e-05
and O 0 4.426915367616857e-08
suggest O 0 1.4569294215505124e-08
that O 0 8.169729892593125e-10
a O 0 5.738923558595843e-09
substantial O 0 2.2587496317783007e-08
burden O 0 1.531650610786528e-07
of O 0 6.450390888090851e-09
PAX6 B-Disease 0 0.0012725263368338346
- I-Disease 0 0.11758727580308914
related I-Disease 0 0.00020928237063344568
disease I-Disease 0 0.005422947462648153
remains O 0 7.037778004814754e-07
to O 0 5.8757386511842924e-08
be O 0 8.627975489616801e-08
uncovered O 0 5.571815108851297e-06
. O 0 6.371693928031164e-08
. O 0 1.554773803036369e-07

The O 0 5.253914991953934e-07
chromosomal O 0 0.0002518500841688365
order O 0 4.4323140713231624e-08
of O 0 4.07533162771756e-09
genes O 0 1.8679358504414267e-07
controlling O 0 6.312190180324251e-06
the O 0 2.8901972370931617e-08
major O 0 6.21852862536798e-08
histocompatibility O 0 3.739690725979017e-07
complex O 0 6.094320781357965e-08
, O 0 7.468796248133458e-09
properdin O 0 7.337433203247201e-07
factor O 0 1.4713447349379294e-08
B O 0 7.780747068864002e-07
, O 0 4.262051334080752e-08
and O 0 2.2749647996533895e-06
deficiency B-Disease 0 3.7848410556762246e-06
of I-Disease 0 1.7277110297975184e-10
the I-Disease 0 2.020686062920163e-09
second I-Disease 0 2.8047944056197593e-07
component I-Disease 0 7.374481469923921e-08
of I-Disease 0 2.6030535504872887e-09
complement I-Disease 0 3.650550013389875e-07
. O 0 3.099257241956366e-07

The O 0 2.458096730606485e-07
relationship O 0 1.7686902253899461e-07
of O 0 2.0263981603818593e-09
the O 0 2.534420895372591e-09
genes O 0 1.6544099423754233e-08
coding O 0 6.817528515057347e-07
for O 0 1.7359907289460352e-08
HLA O 0 5.185892405279446e-06
to O 0 1.0665570648882294e-08
those O 0 1.6636552135906868e-09
coding O 0 8.938436479866141e-08
for O 0 2.3954718209040493e-09
properdin O 0 5.722345122194383e-07
Factor O 0 7.665655665789473e-09
B O 0 1.5575135137169127e-07
allotypes O 0 1.1431488928792533e-06
and O 0 8.401978135452737e-08
for O 0 9.128822853199381e-08
deficiency B-Disease 0 1.7775554397303495e-06
of I-Disease 0 2.5151572491388663e-10
the I-Disease 0 2.7721043238670973e-09
second I-Disease 0 2.9993003636263893e-07
component I-Disease 0 3.6768870614878324e-08
of I-Disease 0 5.114164092212548e-10
complement I-Disease 0 3.809759618889075e-08
( O 0 1.4153076932643671e-08
C2 O 0 6.3511433836538345e-06
) O 0 7.57269269513472e-09
was O 0 4.586813062701367e-08
studied O 0 3.805298742776131e-09
in O 0 1.4046627194730377e-09
families O 0 1.4456182917399474e-09
of O 0 3.5386438224094263e-09
patients O 0 3.789139100263128e-07
with O 0 8.001016027492369e-08
connective O 0 0.39423540234565735
tissue O 1 0.9991068243980408
disorders O 1 0.7731176018714905
. O 0 8.79643323514756e-07

Patients O 0 0.005468771327286959
were O 0 2.4776568352535833e-07
selected O 0 3.813191185031428e-08
because O 0 9.083660934550153e-09
they O 0 6.844333544364645e-09
were O 0 6.03490946105012e-09
heterozygous O 0 3.273198956321721e-08
or O 0 6.452423662040019e-08
homozygous O 0 8.051901204453316e-06
for O 0 1.677929685683921e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
. O 0 1.4138501001070836e-06

12 O 0 3.3377177715010475e-06
families O 0 7.818385938662686e-08
with O 0 9.797344269202313e-09
15 O 0 4.6964999000920216e-08
matings O 0 2.963042334158672e-06
informative O 0 7.445163191732718e-06
for O 0 0.00011767657269956544
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 3.3101474627983407e-07
found O 0 1.702203320519402e-07
. O 0 2.371144489643484e-07

Of O 0 2.0881898876723426e-07
57 O 0 7.122618512767076e-07
informative O 0 5.113428187542013e-07
meioses O 0 1.2955405509273987e-05
, O 0 1.123680259951243e-08
two O 0 2.781606278645654e-09
crossovers O 0 3.9865295775598497e-07
were O 0 2.3650914116046806e-08
noted O 0 2.2862035820025994e-08
between O 0 2.2822561618340842e-08
the O 0 1.00620454759337e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999991655349731
gene O 0 1.2412299099651136e-07
and O 0 3.4065226195423293e-09
the O 0 4.022310040596722e-09
HLA O 0 1.1825060028058942e-05
- O 0 4.00011231249664e-06
B O 0 1.6341508057848841e-07
gene O 0 7.497870768702342e-09
, O 0 1.1778775177440082e-10
with O 0 3.354998223681349e-11
a O 0 6.995354850936053e-10
recombinant O 0 6.07530825647018e-09
fraction O 0 6.248844997003289e-09
of O 0 1.498436152935767e-09
0 O 0 2.92373727006634e-07
. O 0 3.0087485924923385e-07

035 O 0 0.025539211928844452
. O 0 8.557476394344121e-05

A O 0 1.2818009963666555e-05
lod O 0 0.0021109823137521744
score O 0 5.982212201161019e-07
of O 0 3.670733050853414e-09
13 O 0 3.371913948058136e-08
was O 0 3.3603317461938786e-08
calculated O 0 6.634517291104203e-08
for O 0 6.527185014704173e-09
linkage O 0 2.1670741261914372e-05
between O 0 8.621776214567944e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.9891965052920568e-07
HLA O 0 1.289859847020125e-05
- O 0 1.9634542240964947e-06
B O 0 8.307528105433448e-07
at O 0 1.0364966662734787e-08
a O 0 1.9118993055400324e-09
maximum O 0 1.9665264971990837e-09
likelihood O 0 2.1227397617451516e-09
value O 0 7.444088678809635e-10
of O 0 7.901381632313687e-11
the O 0 3.0650457172320955e-10
recombinant O 0 4.588683211181888e-09
fraction O 0 4.561735877928186e-09
of O 0 8.71552940928666e-10
0 O 0 9.254664945501645e-08
. O 0 2.045688631824305e-07

04 O 0 0.0012478092685341835
. O 0 1.7191245206049643e-05

18 O 0 7.854174327803776e-06
families O 0 6.088291115702305e-08
with O 0 6.099970306649993e-09
21 O 0 3.383426516734289e-08
informative O 0 6.99497419986983e-08
matings O 0 1.0236260550300358e-06
for O 0 1.1533704658006627e-08
both O 0 7.745608598952458e-09
properdin O 0 1.1099305083916988e-06
Factor O 0 7.936522550267e-09
B O 0 1.256757258261132e-07
allotype O 0 6.965537409087119e-07
and O 0 5.4615497901977506e-08
HLA O 0 1.1904421626240946e-05
- O 0 7.630002073710784e-06
B O 0 2.991612291225465e-06
were O 0 3.3347156147556234e-08
found O 0 7.282493186266947e-08
. O 0 8.030048803675527e-08

Of O 0 3.164456359172618e-07
72 O 0 1.2612000546141644e-06
informative O 0 6.677955184386519e-07
meioses O 0 1.3821030734106898e-05
, O 0 1.5478848425232172e-08
three O 0 7.683059521923497e-09
recombinants O 0 6.366522484313464e-06
were O 0 4.3737550470268616e-08
found O 0 8.274522400597562e-09
, O 0 6.038360367277562e-10
giving O 0 3.1485403173547866e-10
a O 0 1.0870220279457499e-09
recombinant O 0 7.598953466469993e-09
fraction O 0 9.203700024329464e-09
of O 0 1.688732709226315e-09
0 O 0 2.174210607108762e-07
. O 0 3.7690395515710406e-07

042 O 0 0.0019582672975957394
. O 0 3.481018211459741e-05

A O 0 1.7880571249406785e-05
lod O 0 0.0007035931921564043
score O 0 1.8734343143478327e-07
of O 0 1.5498574645889107e-09
16 O 0 7.077439967417831e-09
between O 0 2.138882848612411e-09
HLA O 0 1.2460665857361164e-05
- O 0 1.593039883118763e-06
B O 0 3.511068200623413e-07
and O 0 4.077182147455005e-09
Factor O 0 2.325591053065068e-09
B O 0 7.537520474443227e-08
allotypes O 0 4.009887959455227e-07
was O 0 1.108576768160674e-07
calculated O 0 5.534631597470252e-08
at O 0 3.74271769132406e-09
a O 0 3.0810958229210428e-09
maximum O 0 2.9403948165196425e-09
likelihood O 0 3.275083537701562e-09
value O 0 1.5008302378660687e-09
of O 0 1.1294098295477895e-10
the O 0 1.4546016613437018e-09
recombinant O 0 1.3679381183351325e-08
fraction O 0 2.37871784491972e-08
of O 0 3.476653187561851e-09
0 O 0 1.6883960540781118e-07
. O 0 4.1829338215393363e-07

04 O 0 0.003246449399739504
. O 0 3.452882083365694e-05

A O 0 1.0832256975845667e-06
crossover O 0 9.684412134447484e-07
was O 0 1.5799886341483216e-06
shown O 0 3.623391364726558e-08
to O 0 4.7999182406499585e-09
have O 0 2.523379949437299e-09
occurred O 0 3.5063143499769467e-09
between O 0 5.353202880975516e-10
genes O 0 5.0864517042725765e-09
for O 0 9.774120401928599e-10
Factor O 0 3.443575868899984e-09
B O 0 8.932216388757297e-08
and O 0 1.8412183777627433e-08
HLA O 0 5.298422365740407e-06
- O 0 7.279059900611173e-06
D O 0 3.3733202144503593e-05
, O 0 4.301576872478563e-09
in O 0 7.163621917882779e-10
which O 0 1.0621496571161515e-08
HLA O 0 4.166640792391263e-06
- O 0 3.476825440884568e-06
D O 0 8.311368219438009e-06
segregared O 0 5.828222811032902e-07
with O 0 2.5914170809215875e-09
HLA O 0 1.8386044757789932e-06
- O 0 1.5527082553035143e-07
A O 0 3.7494720572794904e-07
and O 0 1.1622750406559135e-07
B O 0 7.515304787375499e-07
. O 0 1.5569729328035464e-07

These O 0 3.426246166782221e-07
studies O 0 8.881149682338219e-08
suggest O 0 2.7106597855208747e-08
that O 0 5.049590745542787e-10
the O 0 3.660195202481731e-10
genes O 0 5.71351943534637e-09
for O 0 1.918979641857277e-09
Factor O 0 2.8169418797574508e-08
B O 0 2.507451245037373e-05
and O 0 0.0022092461585998535
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 2.8236755156285653e-09
located O 0 4.279456788935931e-09
outside O 0 9.46177713956331e-09
those O 0 3.3157629975022473e-09
for O 0 4.244161910804678e-09
HLA O 0 1.985009703275864e-06
, O 0 7.354012510063512e-09
that O 0 3.778060919668036e-10
the O 0 3.5579983403977167e-10
order O 0 1.135770144600201e-09
of O 0 2.632043749617452e-10
genese O 0 6.868011723781819e-07
is O 0 7.76823050330222e-09
HLA O 0 5.620764795821742e-07
- O 0 5.488806209541508e-08
A O 0 2.5636720124566637e-07
, O 0 8.27073609599438e-09
- O 0 2.362646114306699e-07
B O 0 2.273294086307942e-07
, O 0 2.670848875396814e-09
- O 0 8.970183102974261e-07
D O 0 3.448607458267361e-06
, O 0 9.85483916693397e-10
Factor O 0 1.7576060606927513e-09
B O 0 1.239528870655704e-07
allotype O 0 7.025920695014065e-06
, O 0 6.382912033586763e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
, O 0 1.2925164272203915e-09
that O 0 1.4790386970719993e-10
the O 0 2.852189040503106e-10
genes O 0 2.102248330970724e-08
coding O 0 1.7145317542599514e-05
for O 0 4.072338197147474e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
and O 0 1.9885359137106207e-08
Factor O 0 3.399758918831708e-09
B O 0 5.4959194528692024e-08
allotypes O 0 1.3848780611169786e-07
are O 0 3.498109579780362e-10
approximately O 0 1.0361719260387758e-09
3 O 0 7.78016673308457e-09
- O 0 2.6432158506395353e-07
- O 0 1.156384655587317e-06
5 O 0 4.6883730675517654e-08
centimorgans O 0 1.8204433160917688e-07
from O 0 5.227759336534632e-10
the O 0 1.6129498847661239e-09
HLA O 0 1.2844166121794842e-06
- O 0 2.149433697695713e-07
A O 0 3.1230973718265886e-07
and O 0 1.6335619079654862e-07
HLA O 0 8.475003596686292e-06
- O 0 1.5206460375338793e-06
B O 0 1.304126584500409e-07
loci O 0 9.874882245242134e-09
, O 0 1.0670997419026662e-09
and O 0 1.0137823913680677e-09
that O 0 9.239541354233438e-10
the O 0 3.615016064273391e-09
apparent O 0 1.3193809422773484e-07
lack O 0 3.5247136320748496e-09
of O 0 3.2526084603468064e-10
recombinants O 0 3.806114250437531e-07
between O 0 5.861953145114285e-10
the O 0 1.3273585564022028e-09
Factor O 0 5.341211473108842e-09
B O 0 3.959159755595465e-07
gene O 0 7.105508075255784e-07
and O 0 0.00021073510288260877
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
gene O 0 6.051245122762339e-07
suggests O 0 2.0722787041904667e-08
that O 0 3.778565516032728e-10
these O 0 7.678144231526574e-11
two O 0 2.4477924132071394e-09
genes O 0 1.18747969679589e-07
lie O 0 2.9436982913466636e-06
in O 0 1.4867022279929643e-08
close O 0 2.1994912913214648e-07
proximity O 0 4.668313380307154e-08
to O 0 8.110305316222366e-08
one O 0 3.036889850704938e-08
another O 0 2.1999129273808649e-07
. O 0 4.940912958772969e-07

Distribution O 0 2.4328724066435825e-06
of O 0 5.349757614681039e-08
emerin O 0 4.377125878818333e-05
and O 0 2.661163875927741e-07
lamins O 0 9.808632057684008e-06
in O 0 1.8963994818932406e-08
the O 0 3.672352733019579e-08
heart O 0 1.564457852509804e-05
and O 0 8.083679858827963e-08
implications O 0 4.441953649347852e-08
for O 0 8.964336473127332e-08
Emery B-Disease 1 0.8982892632484436
- I-Disease 1 0.9924046397209167
Dreifuss I-Disease 1 0.9999521970748901
muscular I-Disease 1 0.9443307518959045
dystrophy I-Disease 1 0.7608140707015991
. O 0 1.3404603578237584e-06

Emerin O 0 0.0003002637531608343
is O 0 1.1156530632661088e-07
a O 0 1.686573547488024e-08
nuclear O 0 2.9247689781186637e-07
membrane O 0 1.3056647674147825e-07
protein O 0 5.180942252991372e-07
which O 0 2.3075648059034393e-08
is O 0 1.093792256767756e-08
missing O 0 1.3250148356291902e-07
or O 0 8.433173803723548e-08
defective O 0 7.097203706507571e-06
in O 0 4.322123103861486e-08
Emery B-Disease 1 0.9928287863731384
- I-Disease 1 0.9999580383300781
Dreifuss I-Disease 1 0.9999982118606567
muscular I-Disease 1 0.9998874664306641
dystrophy I-Disease 1 0.9998247027397156
( O 0 2.676266376511194e-06
EDMD B-Disease 1 0.9999994039535522
) O 0 3.571522881884448e-07
. O 0 2.575154383066547e-07

It O 0 2.1212936189840548e-06
is O 0 2.6804086061815724e-08
one O 0 4.7259081092931865e-09
member O 0 5.569361860580102e-09
of O 0 2.557309919382078e-10
a O 0 2.60987089717446e-08
family O 0 1.1109177933121828e-07
of O 0 3.2096814095439186e-08
lamina O 0 1.960092231456656e-05
- O 0 7.783546607242897e-06
associated O 0 1.484586107380892e-07
proteins O 0 7.661883572041006e-09
which O 0 6.452335110651575e-09
includes O 0 4.085683347199165e-09
LAP1 O 0 9.730267265695147e-06
, O 0 1.949646488696999e-08
LAP2 O 0 6.709152785333572e-06
and O 0 1.137026117703499e-07
lamin O 0 1.0335302249586675e-05
B O 0 1.5918765257083578e-06
receptor O 0 2.2569113866666157e-07
( O 0 1.165129432934009e-07
LBR O 0 1.3502893125405535e-05
) O 0 7.76426389847984e-08
. O 0 3.527083265453257e-07

A O 0 6.078283149690833e-06
panel O 0 1.1902045571332565e-06
of O 0 4.351809135272333e-09
16 O 0 2.367483453724617e-08
monoclonal O 0 9.524484312350978e-08
antibodies O 0 1.5418038401548984e-07
( O 0 2.929692577424703e-08
mAbs O 0 4.068282919433841e-07
) O 0 1.6565634197718282e-08
has O 0 2.9403178558595755e-08
been O 0 4.545557530377664e-08
mapped O 0 1.9400390556256752e-06
to O 0 7.001632162939586e-09
six O 0 2.773775875652973e-09
specific O 0 6.355387882628349e-10
sites O 0 2.3868576448649037e-08
throughout O 0 3.828573458264373e-09
the O 0 8.779045823636977e-10
emerin O 0 8.818593499881899e-08
molecule O 0 4.09837408454905e-09
using O 0 6.171287036949025e-09
phage O 0 2.0936610667376954e-08
- O 0 6.18275279862246e-08
displayed O 0 1.1431252389115798e-08
peptide O 0 4.232569406070752e-09
libraries O 0 9.917082710586556e-10
and O 0 3.7780480965921015e-09
has O 0 1.3789405173270097e-08
been O 0 5.2416400109223105e-09
used O 0 1.64100288913005e-08
to O 0 1.961979201325903e-08
localize O 0 1.084262657968793e-05
emerin O 0 2.3031183445709758e-05
in O 0 1.9916141624776174e-08
human O 0 4.2978967940143775e-08
and O 0 1.5829462540750683e-07
rabbit O 0 0.004844038747251034
heart O 0 0.0002754736633505672
. O 0 8.036864755922579e-07

Several O 0 3.9289372466555506e-07
mAbs O 0 5.8880846154352184e-06
against O 0 1.2609707056299158e-08
different O 0 7.934146672994302e-09
emerin O 0 2.5545737116772216e-06
epitopes O 0 1.7292807115154574e-06
did O 0 1.9854665822549578e-07
not O 0 4.197693748153597e-09
recognize O 0 7.809365598632212e-09
intercalated O 0 2.4874129422869373e-08
discs O 0 1.2790072105417494e-05
in O 0 3.324300479334852e-08
the O 0 3.6658093449659646e-08
heart O 0 1.1670765161397867e-05
, O 0 1.8829414472065764e-08
though O 0 6.214992964714838e-09
they O 0 3.9232102011510506e-09
recognized O 0 5.0413073715560586e-09
cardiomyocyte O 0 7.022230761322135e-07
nuclei O 0 2.0039109926983656e-07
strongly O 0 4.796498132009219e-08
, O 0 2.3177531005558194e-09
both O 0 2.3949051630722806e-09
at O 0 1.0393161176125432e-07
the O 0 1.5192814117881426e-08
rim O 0 3.5541704619390657e-06
and O 0 6.635415417122204e-08
in O 0 7.54642126565841e-09
intranuclear O 0 2.948525207102648e-06
spots O 0 5.730788075197779e-07
or O 0 1.1333430904869601e-07
channels O 0 3.4228112326673e-06
. O 0 3.9848418964538723e-07

A O 0 1.3976680747873615e-05
polyclonal O 0 0.0001059267669916153
rabbit O 0 7.628099410794675e-05
antiserum O 0 2.9764085411443375e-05
against O 0 3.204534664291714e-07
emerin O 0 5.539244011742994e-05
did O 0 1.341285042144591e-06
recognize O 0 5.51917729296747e-08
both O 0 7.363345932986931e-09
nuclear O 0 3.895429472322576e-07
membrane O 0 7.301687077188035e-08
and O 0 1.875460853284494e-08
intercalated O 0 4.2791896248672856e-08
discs O 0 7.635767360625323e-06
but O 0 2.1421543650035346e-08
, O 0 6.010759112662356e-10
after O 0 1.0783941517544804e-09
affinity O 0 6.184622258764705e-10
purification O 0 3.088603817147373e-09
against O 0 3.190817055021e-10
a O 0 4.299829825527013e-09
pure O 0 5.7754714788416095e-08
- O 0 6.569774996023625e-06
emerin O 0 4.741331395052839e-06
band O 0 8.853463384639326e-08
on O 0 1.1657312448676294e-08
a O 0 7.494396214724475e-09
western O 0 1.9180261290330236e-07
blot O 0 0.0005280423210933805
, O 0 2.392961384600767e-08
it O 0 1.873008592667702e-08
stained O 0 2.5373690277774585e-06
only O 0 3.887981936401275e-09
the O 0 5.447325701624095e-09
nuclear O 0 1.2589252946781926e-06
membrane O 0 6.479185117314046e-07
. O 0 2.3140181326652964e-07

These O 0 3.7132468833078747e-07
results O 0 2.497797140676994e-06
would O 0 2.9693762115812206e-08
not O 0 4.034619305315346e-09
be O 0 4.309008705405404e-09
expected O 0 5.6725419028680335e-08
if O 0 1.1838157121246695e-08
immunostaining O 0 8.217205049732001e-07
at O 0 2.3452230379916728e-08
intercalated O 0 3.463127029590396e-08
discs O 0 1.1567063666007016e-05
were O 0 2.7656890111416033e-08
due O 0 6.1206342216735266e-09
to O 0 2.4904451834117936e-09
a O 0 4.72592631695079e-09
product O 0 1.0252620796791234e-07
of O 0 1.9177566479289254e-10
the O 0 3.5774618822870252e-09
emerin O 0 1.1553528338481556e-06
gene O 0 1.2905320545542054e-07
and O 0 2.634839191273386e-08
, O 0 1.1663785492999068e-08
therefore O 0 3.68768748870707e-09
, O 0 2.4851354307742213e-09
cast O 0 2.4074875426549625e-08
some O 0 7.627090625739186e-10
doubt O 0 1.3509436902481298e-09
upon O 0 3.73796438246643e-10
the O 0 2.4850690394373487e-09
hypothesis O 0 2.5983530349549255e-07
that O 0 3.122201235328248e-07
cardiac B-Disease 0 0.021192768588662148
defects I-Disease 0 0.4959910809993744
in O 0 1.0774549537018174e-06
EDMD B-Disease 1 1.0
are O 0 7.451594683516305e-07
caused O 0 2.5418395921406045e-07
by O 0 2.31730679089992e-09
absence O 0 2.3633552004298508e-08
of O 0 3.3376155172959443e-09
emerin O 0 1.684194830886554e-05
from O 0 3.0904200087888967e-08
intercalated O 0 7.262427743626176e-07
discs O 0 0.00011856196942972019
. O 0 9.376469165545132e-07

Although O 0 2.1248024495434947e-06
emerin O 0 2.3652377421967685e-05
was O 0 1.994907279367908e-07
abundant O 0 4.1395722405468405e-09
in O 0 8.320287792074055e-10
the O 0 9.650634735791641e-10
membranes O 0 4.900073946600969e-08
of O 0 1.1852927528366308e-09
cardiomyocyte O 0 3.7069244172016624e-06
nuclei O 0 2.5369573108946497e-07
, O 0 1.2950883920836986e-08
it O 0 4.113467255706382e-08
was O 0 1.1265499466617257e-07
absent O 0 1.983055142318335e-08
from O 0 4.630637262525994e-10
many O 0 4.623664784375592e-10
non O 0 7.265330737027398e-08
- O 0 5.805019100080244e-06
myocyte O 0 2.5067625756491907e-05
cells O 0 9.102697049456765e-07
in O 0 4.112735485506391e-09
the O 0 2.4533933995485313e-08
heart O 0 2.9933655241620727e-05
. O 0 6.956773859201348e-07

This O 0 9.031646186485887e-08
distribution O 0 1.1183310988371886e-07
of O 0 5.661956681279889e-09
emerin O 0 1.0767076673801057e-05
was O 0 4.521052971995232e-07
similar O 0 2.4241062490659715e-09
to O 0 4.889325833090652e-09
that O 0 2.007991772856599e-09
of O 0 6.185165157823747e-10
lamin O 0 2.1452081000461476e-06
A O 0 2.7197080498808646e-07
, O 0 5.3583333325946114e-09
a O 0 9.85392301089405e-09
candidate O 0 2.8518766015395158e-08
gene O 0 1.4516313484591592e-08
for O 0 1.188589004996743e-09
an O 0 1.4368363387973204e-08
autosomal O 0 0.00026791670825332403
form O 0 7.631899165971845e-07
of O 0 5.617286547021649e-07
EDMD B-Disease 1 0.9999998807907104
. O 0 9.039123142429162e-06

In O 0 4.3654128489833965e-07
contrast O 0 3.9899833836898324e-07
, O 0 1.526849473520997e-07
lamin O 0 0.00030004195286892354
B1 O 0 0.0003149677941109985
was O 0 6.068906373002392e-07
absent O 0 7.477479613271498e-08
from O 0 5.673058467436931e-09
cardiomyocyte O 0 1.3750477592111565e-06
nuclei O 0 5.369527684706554e-07
, O 0 2.3472994215012477e-08
showing O 0 3.186995058968023e-07
that O 0 2.511410990280183e-08
lamin O 0 3.993392601842061e-05
B1 O 0 2.604118526505772e-05
is O 0 9.564585568000439e-09
not O 0 1.010278860569258e-09
essential O 0 2.2406152488940734e-09
for O 0 9.330854977562808e-10
localization O 0 8.71251231160386e-08
of O 0 1.2289741446736002e-09
emerin O 0 3.4508643693698104e-06
to O 0 2.2120511644629914e-08
the O 0 4.9558206427491314e-08
nuclear O 0 3.189092967659235e-05
lamina O 0 3.5418277548160404e-05
. O 0 6.729349024681142e-07

Lamin O 1 0.7667655348777771
B1 O 0 0.32152342796325684
is O 0 5.826705660183507e-07
also O 0 5.9142600150607905e-08
almost O 0 7.565635939954518e-08
completely O 0 2.1557411855610553e-06
absent O 0 4.347182596120547e-07
from O 0 2.5605437770082062e-08
skeletal O 0 0.00011298500612610951
muscle O 0 2.604650035209488e-05
nuclei O 0 1.7821295841713436e-05
. O 0 6.751636192348087e-07

In O 0 1.366927881463198e-05
EDMD B-Disease 1 0.9999973773956299
, O 0 1.6904327537758945e-07
the O 0 2.3942838822677004e-09
additional O 0 5.096463251419436e-09
absence O 0 9.494480757155088e-09
of O 0 5.093946597867216e-09
lamin O 0 9.536606376059353e-05
B1 O 0 0.00016495215822942555
from O 0 1.1557370527270905e-07
heart O 0 1.538958531455137e-05
and O 0 1.4672078805233468e-06
skeletal O 0 0.009705579839646816
muscle O 0 2.6944364435621537e-05
nuclei O 0 4.067509507876821e-06
which O 0 2.933988128006604e-07
already O 0 4.074499315720459e-07
lack O 0 1.57975144077227e-08
emerin O 0 8.480080396111589e-06
may O 0 9.883987672765215e-08
offer O 0 1.7202279600780912e-09
an O 0 9.485406904374827e-10
alternative O 0 1.4702563611024289e-08
explanation O 0 9.503195563809186e-09
of O 0 8.129253936672853e-10
why O 0 1.1784584863505643e-08
these O 0 1.4115004720594015e-09
tissues O 0 4.4749313587999495e-07
are O 0 4.702090716790508e-09
particularly O 0 1.1055020010530825e-08
affected O 0 3.5291147781890686e-08
. O 0 1.149489836649309e-08
. O 0 1.365615958093258e-07

Genetic O 0 0.00011569890921236947
mapping O 0 9.517239959677681e-06
of O 0 2.3230875001445384e-08
the O 0 2.844391246981104e-07
copper B-Disease 0 0.0005625956691801548
toxicosis I-Disease 0 0.0006354791112244129
locus O 0 2.2605524918617448e-06
in O 0 4.071907611091774e-08
Bedlington O 0 2.7231515559833497e-05
terriers O 0 0.00017557840328663588
to O 0 5.130006002218579e-07
dog O 0 4.8926605813903734e-05
chromosome O 0 0.00020743897766806185
10 O 0 1.281412664866366e-07
, O 0 2.517390296219446e-09
in O 0 8.035004883666375e-10
a O 0 6.327356771862469e-08
region O 0 5.284706730890321e-06
syntenic O 0 5.585210237768479e-05
to O 0 1.7240316196875938e-07
human O 0 1.5265582931078825e-07
chromosome O 0 6.409092020476237e-05
region O 0 5.275678176985821e-06
2p13 O 0 8.712612725503277e-06
- O 0 1.1064195859944448e-05
p16 O 0 7.939695933600888e-06
. O 0 5.890123020435567e-07

Abnormal O 1 0.9922764897346497
hepatic B-Disease 1 0.9998096823692322
copper I-Disease 0 0.03306391090154648
accumulation I-Disease 0 3.3478390832897276e-05
is O 0 5.593808438675296e-08
recognized O 0 2.7704302851816465e-08
as O 0 7.51656017428104e-08
an O 0 9.861925718723796e-06
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 1.9382530069833592e-07
man O 0 1.9500947018968873e-05
, O 0 7.592538509015867e-08
mouse O 0 7.535747045039898e-06
, O 0 1.2441239505278645e-07
rat O 0 0.0017722811317071319
and O 0 9.213291036758164e-07
dog O 0 0.00016750238137319684
. O 0 6.795374360990536e-07

The O 0 6.132918883849925e-07
major O 0 2.709068667172687e-07
cause O 0 5.239569418336032e-07
of O 0 2.4376927143521243e-08
hepatic B-Disease 1 0.9734784364700317
copper I-Disease 0 0.1626841127872467
accumulation I-Disease 0 7.743025889794808e-06
in O 0 9.917979326701243e-08
man O 0 4.392751179693732e-06
is O 0 1.9136589202162213e-08
a O 0 5.995342178266583e-08
dysfunctional O 0 5.049806532042567e-06
ATP7B O 0 5.2384581067599356e-05
gene O 0 3.879379619320389e-06
, O 0 4.9009432956381715e-08
causing O 0 8.342393812199589e-06
Wilson B-Disease 0 3.8423630030592903e-05
disease I-Disease 0 0.0001948690478457138
( O 0 1.9596012634792714e-07
WD B-Disease 0 0.004780279938131571
) O 0 2.140182004950475e-07
. O 0 3.2426828511233907e-07

Mutations O 0 0.00011694967543007806
in O 0 6.043907774255786e-08
the O 0 1.88503985754096e-08
ATP7B O 0 8.849967707647011e-05
genes O 0 1.4657100564363645e-06
have O 0 4.681912102455499e-08
also O 0 3.367948053778491e-08
been O 0 1.4059178710112974e-08
demonstrated O 0 1.0315188703202693e-08
in O 0 2.214874506023534e-09
mouse O 0 5.7950187510869e-06
and O 0 9.649903631725465e-07
rat O 0 0.0013105233665555716
. O 0 1.0952725233437377e-06

The O 0 5.256190434010932e-07
ATP7B O 0 8.200334559660405e-05
gene O 0 2.3814702672098065e-06
has O 0 8.271591411812551e-08
been O 0 2.4440987900220534e-08
excluded O 0 2.86404340243962e-08
in O 0 6.563022902916771e-10
the O 0 6.757124304535012e-10
much O 0 1.4652255408975634e-08
rarer O 0 2.6167626856477e-06
human O 0 8.652924634588999e-07
copper B-Disease 0 0.004585356451570988
overload I-Disease 0 0.000504798605106771
disease O 0 8.214594708988443e-05
non B-Disease 0 5.043435749030323e-07
- I-Disease 0 3.901507079717703e-05
Indian I-Disease 0 2.9046941563137807e-07
childhood I-Disease 0 1.47031696542399e-05
cirrhosis I-Disease 0 0.0010442869970574975
, O 0 3.8476603236858864e-08
indicating O 0 5.907506874791579e-07
genetic O 0 3.017961034856853e-06
heterogeneity O 0 3.6681423807749525e-05
. O 0 2.357879111514194e-06

By O 0 2.581380158517277e-07
investigating O 0 4.2114172060792043e-07
the O 0 2.1772290637045444e-08
common O 0 2.0573681922542164e-06
autosomal O 1 0.961772084236145
recessive O 1 0.9983876943588257
copper B-Disease 1 0.883313000202179
toxicosis I-Disease 1 0.9855383634567261
( O 0 1.2820021311199525e-06
CT B-Disease 1 0.9948399662971497
) O 0 3.4359146638962557e-08
in O 0 1.955157813426922e-08
Bedlington O 0 0.00011606721818679944
terriers O 0 0.007513165473937988
, O 0 2.703566224226961e-07
we O 0 1.717619113605906e-08
have O 0 2.455864178685374e-09
identified O 0 9.645892085075047e-09
a O 0 1.63976621170292e-09
new O 0 2.1833006513816144e-08
locus O 0 4.4038824853487313e-07
involved O 0 8.831537456899241e-08
in O 0 1.520744604022184e-06
progressive O 1 0.9994733929634094
liver B-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 2.9977038593642646e-06

We O 0 5.028565738030011e-06
examined O 0 1.4853071661491413e-06
whether O 0 3.61153773553724e-08
the O 0 2.2066110716423282e-08
WD B-Disease 0 0.00048434120253659785
gene O 0 3.83002543458133e-06
ATP7B O 0 3.540402394719422e-05
was O 0 1.2665199733419286e-07
also O 0 3.139037696442415e-09
causative O 0 2.0758429641887233e-08
for O 0 6.345385994421804e-09
CT B-Disease 1 0.8773045539855957
by O 0 1.5906358896700112e-08
investigating O 0 8.903487014322309e-08
the O 0 3.5337624382236754e-08
chromosomal O 0 0.0002882725966628641
co O 0 2.9243077733553946e-05
- O 0 5.267187134450069e-06
localization O 0 5.013482677895809e-07
of O 0 2.012078725854849e-09
ATP7B O 0 1.3954026144347154e-05
and O 0 7.534441515133494e-09
C04107 O 0 1.8187821027026985e-08
, O 0 2.4209492743842986e-10
using O 0 1.8122089384675633e-09
fluorescence O 0 1.1669659905066965e-08
in O 0 7.320034356439464e-09
situ O 0 6.382616675182362e-07
hybridization O 0 1.0995281485293162e-07
( O 0 7.880348817934646e-09
FISH O 0 4.847403829444374e-07
) O 0 5.883712361764992e-08
. O 0 2.130421847823527e-07

C04107 O 0 6.715921335853636e-05
is O 0 1.5886431015132985e-07
an O 0 1.1576505087873556e-08
anonymous O 0 1.891765037953519e-07
microsatellite O 0 6.8023259700567e-06
marker O 0 1.8394253856968135e-05
closely O 0 7.104828455339884e-06
linked O 0 0.00012710677401628345
to O 0 1.5629877907485934e-06
CT B-Disease 1 0.9996713399887085
. O 0 1.5645133544239798e-06

However O 0 8.25677125249058e-06
, O 0 3.251077487220755e-07
BAC O 0 4.52167478215415e-05
clones O 0 1.429594249202637e-05
containing O 0 7.801478574265275e-08
ATP7B O 0 2.723971920204349e-05
and O 0 1.4979510964963083e-08
C04107 O 0 2.243054240125275e-07
mapped O 0 1.238932441083307e-06
to O 0 9.28581567194442e-09
the O 0 9.743319928645633e-09
canine O 0 1.9662909835460596e-05
chromosome O 0 0.00023847530246712267
regions O 0 1.6306215684380732e-06
CFA22q11 O 0 2.2601716409553774e-05
and O 0 9.561561142845676e-08
CFA10q26 O 0 3.886904778482858e-06
, O 0 1.2355156897569941e-08
respectively O 0 2.6528670815650912e-08
, O 0 1.7110458605529288e-09
demonstrating O 0 8.943378482229036e-09
that O 0 7.562112713799252e-09
WD B-Disease 0 0.0002882044645957649
cannot O 0 1.652702792398486e-07
be O 0 4.422921140445624e-09
homologous O 0 6.038665389951348e-08
to O 0 3.6520611956802895e-07
CT B-Disease 1 0.9979210495948792
. O 0 1.5448019894392928e-06

The O 0 9.548883781462791e-07
copper O 0 1.0024442417488899e-05
transport O 0 3.4757670164253796e-07
genes O 0 3.3904299812093086e-07
CTR1 O 0 3.5620632843347266e-05
and O 0 2.064074351437739e-07
CTR2 O 0 9.673072781879455e-05
were O 0 7.648060318388161e-08
also O 0 2.2964211865428297e-08
excluded O 0 2.4414616106582798e-08
as O 0 2.604255255889143e-09
candidate O 0 1.196493837340995e-08
genes O 0 1.4968430050998904e-08
for O 0 2.183242386877282e-08
CT B-Disease 1 0.9991212487220764
since O 0 5.675723286913126e-07
they O 0 1.1144339673307968e-08
both O 0 3.0242350845810506e-09
mapped O 0 2.6766442715597805e-06
to O 0 7.633705934040336e-08
canine O 0 2.9771863410132937e-05
chromosome O 0 0.0005339701310731471
region O 0 2.2360187358572148e-05
CFA11q22 O 0 0.0003306188737042248
. O 0 1.0542004247326986e-06

2 O 0 3.130670665996149e-05
- O 0 8.86674242792651e-05
22 O 0 2.2358663045451976e-06
. O 0 4.384203862173308e-07

5 O 0 1.5245130271068774e-05
. O 0 3.7375018564489437e-06

A O 0 2.1890441530558746e-06
transcribed O 0 8.574936146032996e-06
sequence O 0 2.3819782768441655e-07
identified O 0 2.8117440820096817e-07
from O 0 3.894974121010364e-09
the O 0 3.761869482588054e-09
C04107 O 0 4.2540358435871894e-07
- O 0 3.277508767496329e-06
containing O 0 3.2710744335417985e-07
BAC O 0 1.844188773247879e-05
was O 0 3.983223564318905e-07
found O 0 9.27930088323592e-09
to O 0 2.5645503498594735e-09
be O 0 1.3107888108265797e-09
homologous O 0 4.1668064554301054e-09
to O 0 4.253303043100232e-09
a O 0 7.286102388093241e-09
gene O 0 1.6340013075932802e-07
expressed O 0 5.321169282979099e-09
from O 0 3.128046488498626e-09
human O 0 2.3120188430425515e-08
chromosome O 0 1.6564532415941358e-05
2p13 O 0 1.4283594964581425e-06
- O 0 4.915265890303999e-06
p16 O 0 4.760152023663977e-07
, O 0 7.305612115260374e-09
a O 0 2.0230238817475765e-08
region O 0 5.29320288933377e-07
devoid O 0 1.991200804241089e-07
of O 0 1.9431671827163655e-09
any O 0 1.9963149355817222e-08
positional O 0 2.7717469492927194e-06
candidate O 0 1.1745235042326385e-06
genes O 0 1.9322228581586387e-06
. O 0 4.3989459186377644e-07

Molecular O 0 7.323232694034232e-06
analysis O 0 4.426759403486358e-07
of O 0 3.637640411113807e-09
the O 0 8.825741026896594e-09
APC B-Disease 0 6.28088969278906e-07
gene O 0 6.621419856855937e-08
in O 0 1.7858223788635996e-09
205 O 0 7.107606947442946e-09
families O 0 3.2120193171891742e-09
: O 0 1.2522720638230567e-09
extended O 0 6.34529158105579e-08
genotype O 0 1.6918607798288576e-05
- O 0 3.419898348511197e-05
phenotype O 0 4.060711580677889e-05
correlations O 0 9.335381037089974e-07
in O 0 2.8782707772734284e-08
FAP B-Disease 0 1.7730474155541742e-07
and O 0 4.33766587093487e-08
evidence O 0 4.905729156234884e-09
for O 0 4.829781019566326e-10
the O 0 8.942179774429349e-10
role O 0 6.5387233405544976e-09
of O 0 4.722923163669179e-10
APC B-Disease 0 1.286113899823249e-07
amino O 0 2.089145390016256e-08
acid O 0 1.7155539921986929e-07
changes O 0 1.1003903921391611e-07
in O 0 0.00010145756823476404
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.0011446238495409489
. O 0 1.9691940451593837e-06

BACKGROUND O 0 6.424145249184221e-05
/ O 0 0.00019174021144863218
AIMS O 0 7.023248826953932e-07
The O 0 1.662422199899538e-08
development O 0 1.0801427663409413e-07
of O 0 0.0001372144470224157
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.1467857063962583e-07
a O 0 2.4317390767691904e-08
variable O 0 3.534255199610925e-07
range O 0 1.0807383432620554e-07
of O 0 1.9831157160865587e-08
extracolonic O 0 0.001074555329978466
manifestations O 0 0.0001197747842525132
in O 0 2.2169644580571912e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 1.0
( O 0 3.270887827966362e-05
FAP B-Disease 0 7.183994057413656e-06
) O 0 8.36759426192657e-08
is O 0 6.178376921184281e-09
the O 0 2.8953603958825624e-09
result O 0 1.4276547055658284e-08
of O 0 2.8098237625506783e-10
the O 0 1.540779948072668e-08
dominant O 0 4.3160365748917684e-05
inheritance O 0 0.00015621230704709888
of O 0 2.602584208943881e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999984502792358
coli I-Disease 1 0.9999998807907104
( O 0 1.520663317933213e-06
APC B-Disease 0 1.2419997801771387e-05
) O 0 9.153372104719892e-08
gene O 0 2.962372946058167e-06
mutations O 0 3.2026095141191036e-05
. O 0 4.2083578932761156e-07

In O 0 4.026365445497504e-07
this O 0 1.168560714859268e-08
study O 0 8.128948181251872e-09
, O 0 1.507339475459446e-09
direct O 0 8.974135212724832e-09
mutation O 0 9.598636552254902e-08
analysis O 0 5.983538997611504e-09
of O 0 3.4371827606349825e-10
the O 0 8.600057554986051e-09
APC B-Disease 0 4.078009681052208e-07
gene O 0 7.357705555932625e-08
was O 0 5.189595952970194e-08
performed O 0 1.8444346494561614e-08
to O 0 3.3993243775398696e-09
determine O 0 2.2743559924265355e-08
genotype O 0 5.214985321799759e-06
- O 0 6.627865514019504e-05
phenotype O 0 2.0604096789611503e-05
correlations O 0 4.3789430037577404e-07
for O 0 5.420544013645667e-09
nine O 0 8.956166652751563e-08
extracolonic O 0 1.2001437426079065e-05
manifestations O 0 3.245197888190887e-07
and O 0 1.0193963007054663e-08
to O 0 7.519238565123487e-09
investigate O 0 3.002304538313183e-08
the O 0 4.979590961795566e-09
incidence O 0 9.891782610793598e-07
of O 0 2.6156503629692907e-09
APC B-Disease 0 1.6830987306093448e-06
mutations O 0 2.9307832960512314e-07
in O 0 4.652258134285603e-09
non O 0 2.9158421966712922e-05
- O 1 0.9998823404312134
FAP O 1 0.9999512434005737
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 2.30871978601499e-06

METHODS O 0 6.5598642322584055e-06
The O 0 1.3645691865349363e-07
APC B-Disease 0 2.6475147478777217e-06
gene O 0 7.405476480926154e-07
was O 0 1.3147361244136846e-07
analysed O 0 1.0017487284130766e-07
in O 0 1.6690202553348854e-09
190 O 0 1.1955470391455947e-08
unrelated O 0 3.756837685386927e-08
FAP B-Disease 0 1.0291334717749123e-07
and O 0 6.315080902652426e-09
15 O 0 3.0077497825686805e-08
non O 0 9.301982572651468e-06
- O 1 0.9997202754020691
FAP O 1 0.9999376535415649
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 6.2024937506066635e-06
using O 0 9.007509760294852e-08
denaturing O 0 7.255496893776581e-05
gradient O 0 5.735739614465274e-05
gel O 0 0.00016910264093894511
electrophoresis O 0 1.6119930705826846e-06
, O 0 6.492022919246665e-09
the O 0 1.1547720557558705e-09
protein O 0 5.0014769215067645e-08
truncation O 0 1.1949380223086337e-06
test O 0 6.827750809179634e-08
, O 0 1.1772491870232216e-09
and O 0 2.515139208014716e-09
direct O 0 5.387142110180321e-08
sequencing O 0 1.8805313857228612e-06
. O 0 3.010040074968856e-07

RESULTS O 0 0.0002924217260442674
Chain O 0 7.700028800172731e-05
terminating O 0 6.993011993472464e-06
signals O 0 2.5745946459210245e-06
were O 0 1.103113422828983e-08
only O 0 1.6936615443441383e-09
identified O 0 8.522805927668742e-08
in O 0 7.203772245389928e-09
patients O 0 2.2157797374688926e-08
belonging O 0 1.0205400968743561e-08
to O 0 9.101594145022318e-09
the O 0 1.1302297764359537e-08
FAP B-Disease 0 4.894002927358088e-07
group O 0 7.149581620069512e-07
( O 0 9.080403984285113e-09
105 O 0 4.5443005802781045e-08
patients O 0 5.792118074054997e-08
) O 0 8.937716344803448e-09
. O 0 1.2076057487320213e-07

Amino O 0 9.038864845933858e-06
acid O 0 5.6661574490135536e-06
changes O 0 6.714041944633209e-08
were O 0 1.2068190891056929e-08
identified O 0 2.126988363215787e-08
in O 0 2.1635091496108316e-09
four O 0 9.174819126656075e-08
patients O 0 1.2220469614021567e-07
, O 0 8.624314595806482e-10
three O 0 2.4595203651500697e-09
of O 0 1.4546767124201665e-09
whom O 0 4.001658737706748e-08
belonged O 0 4.1652988613805064e-08
to O 0 2.9183135907828728e-09
the O 0 4.417407328816125e-09
non O 0 4.3889855305678793e-07
- O 0 1.4260498574003577e-05
FAP O 0 2.3215475266624708e-06
group O 0 4.6933044359320775e-05
of O 0 6.5859108872246e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 4.198967508273199e-05
. O 0 3.135700694656407e-07

Genotype O 0 0.06841099262237549
- O 0 0.006081993691623211
phenotype O 0 0.0006218537455424666
correlations O 0 2.3338976461673155e-05
identified O 0 5.260038960841484e-06
significant O 0 7.019151837539539e-08
differences O 0 1.4228871236809937e-07
in O 0 1.3039072932485851e-08
the O 0 8.794016181923325e-09
nature O 0 6.465149482437482e-08
of O 0 1.1859710991046768e-09
certain O 0 3.920464397566548e-09
extracolonic O 0 1.3061012396065053e-05
manifestations O 0 5.303227794684062e-07
in O 0 9.457356675568462e-09
FAP B-Disease 0 8.656027148390422e-07
patients O 0 1.5562839905669534e-07
belonging O 0 7.46630313130936e-09
to O 0 7.63708118967088e-09
three O 0 3.5093268735408856e-08
mutation O 0 2.705314500417444e-06
subgroups O 0 6.18508101979387e-06
. O 0 5.658509962813696e-07

CONCLUSIONS O 0 5.984499875921756e-05
Extended O 0 2.3512750431109453e-06
genotype O 0 0.00011494915816001594
- O 0 0.0001329513906966895
phenotype O 0 4.258074113749899e-05
correlations O 0 2.8803167424484855e-06
made O 0 1.7043247169112874e-07
in O 0 1.5018132515365323e-08
this O 0 1.2429778095679467e-08
study O 0 3.6290767724267425e-08
may O 0 5.846293333888752e-07
have O 0 4.263772890311657e-09
the O 0 1.3961872769030492e-09
potential O 0 6.5912395541545266e-09
to O 0 9.932363376208286e-09
determine O 0 6.977928013185419e-09
the O 0 7.124705270200593e-10
most O 0 6.747195024914276e-10
appropriate O 0 6.804278251948404e-10
surveillance O 0 3.106477208802971e-08
and O 0 9.637378006743802e-09
prophylactic O 0 2.7308630023981095e-07
treatment O 0 6.631455562455812e-08
regimens O 0 1.8749995334133018e-08
for O 0 2.1102497527181185e-09
those O 0 6.115266515394069e-09
patients O 0 2.6682076992301518e-08
with O 0 2.844454227712845e-09
mutations O 0 2.703137852222426e-06
associated O 0 4.177918100367606e-08
with O 0 2.6150530629820423e-08
life O 0 8.342227374669164e-06
threatening O 0 0.010293643921613693
conditions O 0 2.1142121113371104e-05
. O 0 5.44682393410767e-07

This O 0 8.545054583919409e-07
study O 0 1.2079755151717109e-07
also O 0 2.7441819483442487e-08
provided O 0 5.085704302132399e-09
evidence O 0 6.000499208624888e-09
for O 0 2.0043797732682833e-09
the O 0 8.656257044492577e-09
pathological O 0 9.7507108876016e-07
nature O 0 7.793697243130282e-09
of O 0 4.031632527823348e-10
amino O 0 3.64168961652922e-08
acid O 0 1.1709596492437413e-07
changes O 0 2.821597400171072e-09
in O 0 1.4208192400388953e-09
APC O 0 1.698366816071939e-07
associated O 0 4.608049053445029e-09
with O 0 4.94397633943322e-10
both O 0 6.144202924218689e-09
FAP B-Disease 0 1.837041025964936e-07
and O 0 4.7689489690583287e-08
non O 0 3.393262886675075e-05
- O 1 0.9999375343322754
FAP O 1 0.9999682903289795
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 3.8718553696526214e-05
. O 0 1.4721700303255147e-08
. O 0 2.166017054605618e-07

Inherited B-Disease 1 0.9999914169311523
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999938011169434
and O 0 0.366176575422287
cancer B-Disease 1 0.9169562458992004
risk O 0 8.63014065544121e-06
of O 0 8.234249726513099e-09
the O 0 1.581215656187851e-07
APC O 0 2.9400338462437503e-05
I1307K O 0 2.499927632015897e-06
polymorphism O 0 4.078665369888768e-06
. O 0 4.881240442955459e-07

Germ O 0 0.005103860050439835
- O 0 0.00021311966702342033
line O 0 2.055462209682446e-05
and O 0 4.4951455890895886e-08
somatic O 0 5.329292775968497e-07
truncating O 0 2.851169483619742e-06
mutations O 0 2.637774286995409e-06
of O 0 2.5573598794181862e-09
the O 0 5.177293704861086e-09
APC B-Disease 0 1.0491605735296616e-06
gene O 0 1.232254192018445e-07
are O 0 1.5307030087896578e-09
thought O 0 1.2537545224233781e-08
to O 0 2.08210096275252e-07
initiate O 0 0.00020596811373252422
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.06098902225494385
formation O 0 1.0970895345963072e-05
in O 0 4.199319664621726e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.00010838783055078238
sporadic O 1 0.6559736728668213
colorectal O 1 1.0
carcinogenesis O 1 0.9481416940689087
, O 0 1.4558052043867065e-06
respectively O 0 8.873351362126414e-06
. O 0 4.977742378287076e-07

Recently O 0 6.697986100334674e-05
, O 0 1.1536844368720267e-07
an O 0 2.6006778952591958e-08
isoleucine O 0 0.03045998327434063
- O 0 0.0012401626445353031
- O 0 0.0002883228880818933
> O 0 6.977018642828625e-07
lysine O 0 1.4102402019489091e-05
polymorphism O 0 6.513644166261656e-07
at O 0 1.4934570913283096e-07
codon O 0 1.0902098210863187e-06
1307 O 0 9.75211492004746e-07
( O 0 6.543140251835666e-09
I1307K O 0 4.353853810812325e-08
) O 0 9.57261159229006e-10
of O 0 1.97426741621598e-10
the O 0 6.871081925652334e-09
APC B-Disease 0 6.863565999992716e-07
gene O 0 1.0108792736218675e-07
has O 0 6.2419598378937735e-09
been O 0 3.123461711496134e-09
identified O 0 9.435321857154122e-09
in O 0 3.4640218471437834e-10
6 O 0 5.382343015725155e-09
% O 0 8.747805813058562e-10
- O 0 1.2981828945157758e-07
7 O 0 1.7788769923754444e-07
% O 0 9.77425029802248e-10
of O 0 2.0575545434109443e-10
the O 0 1.0517954507349714e-08
Ashkenazi O 0 1.2659752428589854e-05
Jewish O 0 2.1430906826935825e-07
population O 0 8.334907874996134e-08
. O 0 1.716254303119058e-07

To O 0 1.494508524046978e-06
assess O 0 3.1103272704058327e-06
the O 0 2.808283383615162e-08
risk O 0 1.0473377187736332e-07
of O 0 6.242885652874008e-10
this O 0 3.0024633890235464e-09
common O 0 6.269465302466415e-08
APC B-Disease 0 1.827545588639623e-06
allelic O 0 8.951305972004775e-07
variant O 0 3.367377576068975e-05
in O 0 1.9025108485948294e-05
colorectal O 1 1.0
carcinogenesis O 0 0.3554723560810089
, O 0 7.40703001156362e-07
we O 0 4.938195274917234e-08
have O 0 4.02498079310476e-09
analyzed O 0 2.4349370519871627e-08
a O 0 2.161405721068377e-09
large O 0 6.850263023494563e-09
cohort O 0 4.4721410574766196e-08
of O 0 1.388101966703914e-09
unselected O 0 3.6457247460930375e-06
Ashkenazi O 0 1.8239208657178096e-05
Jewish O 0 6.264803431577093e-08
subjects O 0 3.271676263238987e-08
with O 0 1.8241044230649095e-08
adenomatous B-Disease 0 0.0003555488947313279
polyps I-Disease 0 0.004044664558023214
and O 0 5.317438080965076e-07
. O 0 7.114404070307501e-07
or O 1 0.9995531439781189
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 3.312982954639665e-08
for O 0 4.293666755472714e-09
the O 0 1.7396100560063132e-08
APC O 0 1.2366434020805173e-05
I1307K O 0 2.5603080757719e-06
polymorphism O 0 3.6832859677815577e-06
. O 0 4.047964807796234e-07

The O 0 1.5224829894577852e-06
APC O 0 7.343205197685165e-06
I1307K O 0 1.4315206726678298e-06
allele O 0 1.4119233355813776e-06
was O 0 2.95803516792148e-07
identified O 0 5.221665944077358e-08
in O 0 3.1934244137943324e-09
48 O 0 4.526359020928794e-08
( O 0 1.4298068284901433e-09
10 O 0 2.461510328899408e-09
. O 0 4.75373240771404e-10
1 O 0 5.677962544581305e-09
% O 0 1.2689053141556883e-09
) O 0 5.948169734537601e-10
of O 0 1.4831582628715978e-09
476 O 0 5.222263439463859e-07
patients O 0 7.169355171754432e-07
. O 0 2.144190460739992e-07

Compared O 0 1.8918941350420937e-05
with O 0 6.521784001733977e-09
the O 0 3.6000780134770594e-09
frequency O 0 1.5997889590835257e-07
in O 0 4.4009240696141205e-09
two O 0 3.809532689302841e-09
separate O 0 9.616081086960548e-08
population O 0 6.4851914949315415e-09
control O 0 1.8882426289223986e-08
groups O 0 1.2120779935287374e-09
, O 0 1.660307891171442e-09
the O 0 2.1362407398584082e-09
APC O 0 1.7594909706986073e-07
I1307K O 0 3.1762958485614945e-08
allele O 0 7.451609462805209e-08
is O 0 3.1758213836496907e-09
associated O 0 2.68489985799647e-09
with O 0 8.551505614740051e-10
an O 0 8.219688041322115e-09
estimated O 0 2.6696540089687915e-07
relative O 0 5.0557350306235094e-08
risk O 0 6.590185819277394e-08
of O 0 1.400932814199507e-09
1 O 0 7.453144235114451e-07
. O 0 5.273140004646848e-07

5 O 0 7.797686521371361e-06
- O 0 3.5229564673500136e-05
1 O 0 1.0050786158899427e-06
. O 0 4.599402245730744e-07

7 O 0 0.0002734868903644383
for O 0 3.543131970218383e-05
colorectal B-Disease 1 1.0
neoplasia I-Disease 0 0.07598389685153961
( O 0 1.139891764978529e-06
both O 0 2.101318727909529e-07
P O 0 0.01617865078151226
= O 0 3.7457305097632343e-06
. O 0 7.189663620010833e-08
01 O 0 5.931091209276929e-07
) O 0 3.076217680586524e-08
. O 0 1.7930321405401628e-07

Furthermore O 0 1.08912936411798e-05
, O 0 9.240906706509122e-08
compared O 0 5.4998519516402666e-08
with O 0 3.926421410227476e-09
noncarriers O 0 1.7229336663149297e-05
, O 0 4.420536470206571e-08
APC O 0 4.1840829112516076e-07
I1307K O 0 1.435319347820041e-07
carriers O 0 2.98839886170299e-08
had O 0 9.113892751599906e-09
increased O 0 3.709506923854633e-09
numbers O 0 1.0691620921932099e-08
of O 0 7.3100170361328765e-09
adenomas B-Disease 0 0.22371727228164673
and O 0 0.22745203971862793
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9922758936882019
per O 0 1.0777688657981344e-05
patient O 0 7.504621407861123e-06
( O 0 4.354377125537212e-08
P O 0 0.002650713548064232
= O 0 3.172214064761647e-06
. O 0 9.899609665353637e-08
03 O 0 9.251223787032359e-08
) O 0 1.983303965502614e-09
, O 0 1.3670038434554499e-09
as O 0 2.1843489239614655e-09
well O 0 1.5950253340335507e-09
as O 0 1.5746786097281529e-09
a O 0 1.0312040110704856e-08
younger O 0 5.0068315715634526e-08
age O 0 4.905635453411605e-09
at O 0 3.8324987627902374e-08
diagnosis O 0 1.0958921848214231e-05
. O 0 1.7685569275727175e-07

We O 0 4.888964213023428e-06
conclude O 0 4.4523278575070435e-07
that O 0 4.506552464533797e-09
the O 0 3.487784727695953e-09
APC O 0 6.213169854163425e-07
I1307K O 0 1.3102500417971896e-07
variant O 0 3.2823118090163916e-07
leads O 0 1.201022570285204e-07
to O 0 3.144600313476076e-08
increased O 0 9.005763672575995e-07
adenoma B-Disease 1 0.9999995231628418
formation O 0 1.0405732382423594e-06
and O 0 3.599791398301022e-08
directly O 0 1.4874396825348413e-08
contributes O 0 2.4931647857329153e-08
to O 0 1.1364851282280597e-09
3 O 0 5.3619730877585425e-09
% O 0 1.0363893077069974e-09
- O 0 5.4067413657321595e-08
4 O 0 1.578167285742893e-08
% O 0 3.044838270405137e-10
of O 0 3.599623099592719e-10
all O 0 8.233232762222542e-08
Ashkenazi O 0 0.10245437920093536
Jewish O 1 0.969570517539978
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 1.1932231700484408e-06

The O 0 2.392480382695794e-07
estimated O 0 5.200793111725943e-07
relative O 0 1.7466861379489274e-07
risk O 0 1.649772229939117e-07
for O 0 6.683706477161877e-09
carriers O 0 1.2005632754608087e-07
may O 0 1.4457243935339648e-07
justify O 0 4.048998647476765e-08
specific O 0 3.1463927019359517e-09
clinical O 0 1.6006854508532342e-08
screening O 0 5.68280533741472e-09
for O 0 1.3124574760325913e-09
the O 0 1.7213175329544583e-09
360 O 0 1.1385670006802684e-07
, O 0 2.157673817393402e-09
000 O 0 1.5841740141908645e-09
Americans O 0 1.9654016192305335e-09
expected O 0 1.5286612864429117e-08
to O 0 4.02077571237669e-09
harbor O 0 1.7407826646831381e-07
this O 0 9.673449818947688e-10
allele O 0 6.005218722293648e-08
, O 0 4.651086626950018e-09
and O 0 3.2558442608632276e-09
genetic O 0 1.646517944209336e-08
testing O 0 5.654693602252792e-09
in O 0 6.394979545909507e-10
the O 0 7.255879785894592e-10
setting O 0 3.010194760122431e-08
of O 0 1.7158302556552485e-09
long O 0 1.8518129252242943e-07
- O 0 2.6805251764017157e-05
term O 0 2.5837100565695437e-06
- O 0 6.020018190611154e-06
outcome O 0 7.802295272085757e-07
studies O 0 1.450145248327317e-08
may O 0 1.0389732096882653e-07
impact O 0 4.645477602593928e-08
significantly O 0 3.2413085136795416e-05
on O 1 0.9999285936355591
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 1.343953385912755e-06
in O 0 1.93608995502359e-09
this O 0 3.5815037602304756e-09
population O 0 3.950363591798123e-08
. O 0 2.82175022903175e-07

Localization O 0 2.3229264115798287e-05
of O 0 1.1908433350527048e-07
human O 0 1.8959842407184624e-07
BRCA1 O 0 2.4987810320453718e-05
and O 0 1.8839656945601746e-07
its O 0 2.3632657075722818e-07
loss O 0 5.078771891930955e-07
in O 0 4.825823740617352e-09
high O 0 3.7804291252996336e-08
- O 0 2.7670089366438333e-06
grade O 0 2.9339817047002725e-06
, O 0 2.9463247841476914e-08
non B-Disease 0 3.071632136197877e-06
- I-Disease 0 0.38384783267974854
inherited I-Disease 1 0.9911388754844666
breast I-Disease 1 0.9999575614929199
carcinomas I-Disease 1 1.0
. O 0 4.787906618730631e-06

Although O 0 3.293282873073622e-07
the O 0 9.71305702535119e-09
link O 0 1.737760442210856e-07
between O 0 7.89467158313073e-09
the O 0 1.6909453393054719e-07
BRCA1 O 0 0.3842926621437073
tumour B-Disease 1 1.0
- O 0 9.45772699196823e-05
suppressor O 0 5.0827024097088724e-05
gene O 0 1.942927519849036e-05
and O 0 3.211058583474369e-06
hereditary B-Disease 1 0.9999706745147705
breast I-Disease 1 0.9999998807907104
and I-Disease 1 0.9999984502792358
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 7.582089978086515e-08
established O 0 5.560806481952341e-09
, O 0 4.580830381684109e-09
the O 0 1.6983328077202486e-09
role O 0 3.2442226682860564e-08
, O 0 1.159219298330072e-08
if O 0 1.834130292088787e-09
any O 0 6.751044168140652e-10
, O 0 6.529323748338811e-10
of O 0 1.3370900220355253e-10
BRCA1 O 0 9.982285291698645e-07
in O 0 9.094444308743732e-09
non B-Disease 0 6.734005182806868e-06
- I-Disease 0 0.36329934000968933
familial I-Disease 1 0.8296855688095093
cancers I-Disease 1 0.999466598033905
is O 0 2.463456780787965e-07
unclear O 0 1.3414155546342954e-06
. O 0 3.225023590402998e-07

BRCA1 O 0 0.022843971848487854
mutations O 0 0.00023381235951092094
are O 0 2.805221299695404e-08
rare O 0 3.074540089187394e-08
in O 0 3.9061802681317204e-08
sporadic B-Disease 0 8.883213013177738e-05
cancers I-Disease 1 0.8328006863594055
, O 0 1.4539568837790284e-07
but O 0 8.789056238356352e-08
loss O 0 5.996394634166791e-07
of O 0 5.868925789798141e-09
BRCA1 O 0 6.603067595278844e-05
resulting O 0 3.5500443118507974e-07
from O 0 8.403641338361467e-09
reduced O 0 2.1365826796682086e-07
expression O 0 7.243096433739993e-08
or O 0 5.121021473541987e-08
incorrect O 0 9.065660719898005e-07
subcellular O 0 6.036148079147097e-06
localization O 0 2.6486259230296127e-06
is O 0 1.8231862242146235e-08
postulated O 0 7.37053014177036e-08
to O 0 5.81668180288375e-09
be O 0 1.2768686108444172e-09
important O 0 6.70881350472996e-10
in O 0 3.5459002400983763e-09
non B-Disease 0 4.053449174534762e-06
- I-Disease 1 0.565801203250885
familial I-Disease 1 0.9977536797523499
breast I-Disease 1 0.9999995231628418
and I-Disease 1 0.9998942613601685
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 2.8755055154761067e-06

Epigenetic O 0 0.0011310590198263526
loss O 0 0.00433369493111968
, O 0 2.2979993730132264e-07
however O 0 3.78485900398573e-08
, O 0 1.2375345193049725e-08
has O 0 5.3098062835488236e-08
not O 0 1.294885976221849e-08
received O 0 4.62303262338537e-09
general O 0 3.856379215960715e-09
acceptance O 0 3.479308219311861e-08
due O 0 1.4252712787765631e-08
to O 0 6.57233334422358e-09
controversy O 0 3.56822149605307e-09
regarding O 0 4.369591799502359e-09
the O 0 1.3841916501888818e-09
subcellular O 0 7.423747661050584e-07
localization O 0 3.0546434004463663e-07
of O 0 3.4176383945094813e-09
BRCA1 O 0 2.614121285660076e-06
proteins O 0 1.0696131624854388e-07
, O 0 1.7588543954616398e-08
reports O 0 9.233612985326545e-08
of O 0 5.107788081382125e-10
which O 0 5.18797271809035e-08
have O 0 2.883842675771575e-08
ranged O 0 3.614390564621317e-08
from O 0 1.171590824355917e-09
exclusively O 0 1.7234340177196827e-08
nuclear O 0 1.2011557828373043e-06
, O 0 4.807963360775602e-09
to O 0 3.829873307381604e-09
conditionally O 0 2.05840638045629e-06
nuclear O 0 2.1511583270239498e-07
, O 0 9.790016575195182e-10
to O 0 1.5270052999838413e-09
the O 0 4.605817061076323e-09
ER O 0 0.0003156029852107167
/ O 0 2.4189257601392455e-05
golgi O 0 3.941320755984634e-06
, O 0 1.063759391684016e-08
to O 0 2.620953898357925e-09
cytoplasmic O 0 3.186028720847389e-07
invaginations O 0 2.437391685816692e-06
into O 0 2.2605769700589917e-08
the O 0 1.995435638946219e-08
nucleus O 0 9.448179980608984e-07
. O 0 3.495789258067816e-07

In O 0 4.15624469951581e-07
an O 0 1.892778733747491e-08
attempt O 0 5.836755576638097e-07
to O 0 3.3350596595482784e-07
resolve O 0 6.544228199345525e-07
this O 0 1.723966747135819e-08
issue O 0 4.2850867743027266e-08
, O 0 1.12733831159062e-08
we O 0 1.131454929748088e-08
have O 0 2.5466708741817e-09
comprehensively O 0 4.6723498599021696e-06
characterized O 0 8.284854402518249e-08
19 O 0 3.1745635453717114e-08
anti O 0 1.8451248706696788e-07
- O 0 2.1924302927800454e-05
BRCA1 O 0 0.00013749694335274398
antibodies O 0 1.3439777148960275e-06
. O 0 2.3206833077438205e-07

These O 0 1.6083708942460362e-07
reagents O 0 4.988425530427776e-07
detect O 0 1.5995751709851902e-06
a O 0 2.2928411169687024e-08
220 O 0 6.462967405695963e-08
- O 0 3.124159775325097e-06
kD O 0 2.6132936454814626e-06
protein O 0 1.3708654478250537e-07
localized O 0 1.5346172688168735e-07
in O 0 3.483875188337038e-09
discrete O 0 2.058314976238762e-07
nuclear O 0 3.1343990940513322e-06
foci O 0 2.011423475778429e-06
in O 0 6.882572289867994e-09
all O 0 4.455536384284642e-09
epithelial O 0 1.0792011835292215e-06
cell O 0 9.183234942611307e-05
lines O 0 2.9263443138916045e-05
, O 0 1.2470146693033257e-08
including O 0 1.255055392945792e-09
those O 0 1.2249629088856295e-09
derived O 0 2.9012547031470604e-08
from O 0 1.715264374979597e-07
breast B-Disease 0 0.0005429653683677316
malignancies I-Disease 0 8.745027298573405e-05
. O 0 1.422129003003647e-06

Immunohistochemical O 0 0.0006226801197044551
staining O 0 0.00039117716369219124
of O 0 4.0627887187838496e-07
human O 0 3.7862525914533762e-06
breast O 0 0.0023707083892077208
specimens O 0 1.6267911178147187e-06
also O 0 5.747349973717064e-07
revealed O 0 2.5756555714906426e-06
BRCA1 O 0 1.1387506674509495e-05
nuclear O 0 1.6168213505807216e-06
foci O 0 5.845774467161391e-06
in O 0 6.56274110610866e-08
benign O 0 0.02023298479616642
breast O 0 0.008750536479055882
, O 0 5.810779839521274e-07
invasive B-Disease 0 0.0011422362877056003
lobular I-Disease 1 0.9960616230964661
cancers I-Disease 1 0.9993970394134521
and O 0 9.012370583150187e-07
low B-Disease 0 8.475779395666905e-06
- I-Disease 0 0.33987683057785034
grade I-Disease 0 0.03455602750182152
ductal I-Disease 1 0.9998010993003845
carcinomas I-Disease 1 1.0
. O 0 7.273105893546017e-06

Conversely O 0 4.748861101688817e-05
, O 0 2.2615868999764643e-07
BRCA1 O 0 7.515422112192027e-06
expression O 0 2.926948354797787e-07
was O 0 4.945486011820321e-07
reduced O 0 5.15721083615972e-08
or O 0 3.5680869814314065e-08
undetectable O 0 4.834661808672536e-07
in O 0 9.9135455400301e-10
the O 0 6.903841387462251e-10
majority O 0 7.760835862846704e-10
of O 0 2.741720184218366e-10
high O 0 8.795445438636307e-08
- O 0 1.5348632587119937e-05
grade O 0 2.1630170522257686e-05
, O 0 3.473659546671115e-07
ductal B-Disease 0 0.07339988648891449
carcinomas I-Disease 1 1.0
, O 0 1.4093362210587657e-07
suggesting O 0 8.343577206915143e-08
that O 0 2.804096288500091e-09
absence O 0 5.491903376508844e-09
of O 0 2.0866115502116145e-09
BRCA1 O 0 5.80093364987988e-05
may O 0 1.8664914023247547e-06
contribute O 0 6.3981548947822375e-09
to O 0 6.809293573439845e-09
the O 0 3.997971731450889e-09
pathogenesis O 0 5.172914825379848e-07
of O 0 2.0078375073673271e-10
a O 0 1.3325238690242713e-08
significant O 0 1.5075329429237172e-08
percentage O 0 6.265436240937561e-07
of O 0 7.277935587524098e-09
sporadic B-Disease 0 0.0005401538801379502
breast I-Disease 1 0.9920895099639893
cancers I-Disease 0 0.48297935724258423
. O 0 9.836556102982286e-08
. O 0 4.2559915414130955e-07

